PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2550427-7	1989	This apparent reduction in the affinity of VDR for 1,25-(OH)2D3 was due to degradation of free 1,25-(OH)2[3H]D3 which occurred during whole cell saturation assay.	Cholecalciferol	61-63	vitamin D receptor	Homo sapiens	43-46
2509030-2	1989	In idiopathic hypoparathyroidism (IHP), 100 Units of human PTH (1-34) increased urinary excretion of NAG from 0.029 +/- 0.027 to 0.173 +/- 0.035 U/lGF (p less than 0.05) in two patients before treatment and from 0.025 +/- 0.004 to 0.189 +/- 0.092U/lGF (p less than 0.02) in four patients during treatment with active vitamin D3 (1,25(OH)2D3 or 1 alpha OHD3).	Cholecalciferol	317-327	parathyroid hormone	Homo sapiens	59-62
2509030-2	1989	In idiopathic hypoparathyroidism (IHP), 100 Units of human PTH (1-34) increased urinary excretion of NAG from 0.029 +/- 0.027 to 0.173 +/- 0.035 U/lGF (p less than 0.05) in two patients before treatment and from 0.025 +/- 0.004 to 0.189 +/- 0.092U/lGF (p less than 0.02) in four patients during treatment with active vitamin D3 (1,25(OH)2D3 or 1 alpha OHD3).	Cholecalciferol	317-327	O-GlcNAcase	Homo sapiens	101-104
2559250-0	1989	Effect of vitamin D3 administration on serum 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and osteocalcin in vitamin D-deficient elderly people.	Cholecalciferol	10-20	bone gamma-carboxyglutamate protein	Homo sapiens	96-107
2546501-3	1989	In cells treated with both 1,25-[3H]D3 and ketoconazole, up-regulation of VDR was increased by 40% over that observed with cells receiving 1,25-[3H]D3 alone.	Cholecalciferol	36-38	vitamin D receptor	Rattus norvegicus	74-77
2804448-5	1989	After vitamin D3 treatment, increased immunoreactivity of 28K calbindin was observed in the cytoplasm and, even more pronounced, in the nuclei.	Cholecalciferol	6-16	hippocalcin	Rattus norvegicus	62-71
2548278-0	1989	Inhibition of human natural killer cell and lymphokine-activated killer cell cytotoxicity and differentiation by vitamin D3.	Cholecalciferol	113-123	interleukin 2	Homo sapiens	44-54
2548278-2	1989	The effect of vitamin D3 and 1,25(OH)2D3 on human natural killer (NK) cells and their activation by interferon (IFN) and interleukin 2 (IL-2) was investigated.	Cholecalciferol	14-24	interleukin 2	Homo sapiens	121-134
2548278-7	1989	Vitamin D3 inhibited both IFN and IL-2 activation of NK activity.	Cholecalciferol	0-10	interferon alpha 1	Homo sapiens	26-29
2548278-7	1989	Vitamin D3 inhibited both IFN and IL-2 activation of NK activity.	Cholecalciferol	0-10	interleukin 2	Homo sapiens	34-38
2548278-8	1989	However, increasing doses of IL-2 were able to abrogate the inhibition caused by vitamin D3.	Cholecalciferol	81-91	interleukin 2	Homo sapiens	29-33
2548278-9	1989	Vitamin D3 was able to inhibit NK activity of phytohaemagglutinin and IL-2-activated cells, and also inhibit the proliferation and lymphokine-activated killer activity induced by IL-2.	Cholecalciferol	0-10	interleukin 2	Homo sapiens	70-74
2548278-9	1989	Vitamin D3 was able to inhibit NK activity of phytohaemagglutinin and IL-2-activated cells, and also inhibit the proliferation and lymphokine-activated killer activity induced by IL-2.	Cholecalciferol	0-10	interleukin 2	Homo sapiens	131-141
2548278-9	1989	Vitamin D3 was able to inhibit NK activity of phytohaemagglutinin and IL-2-activated cells, and also inhibit the proliferation and lymphokine-activated killer activity induced by IL-2.	Cholecalciferol	0-10	interleukin 2	Homo sapiens	179-183
2548278-11	1989	NA cells pretreated with low doses of IL-2 were sensitive to inhibition by vitamin D3 while those pretreated with high doses of IL-2 were not.	Cholecalciferol	75-85	interleukin 2	Homo sapiens	38-42
2548278-12	1989	The data presented suggest that vitamin D3 and 1,25(OH)2D3 inhibit NK activity and LAK cellular differentiation.	Cholecalciferol	32-42	alpha kinase 1	Homo sapiens	83-86
2786759-7	1989	Vitamin D3 inhibited TdR and IL-2 production in a dose-dependent manner but had no significant (P greater than 0.1) effect on IL-2R expression.	Cholecalciferol	0-10	interleukin 2	Mus musculus	29-33
2786759-8	1989	Recombinant IL-2 had no effect on CsA-induced inhibition of TdR, whereas rIL-2 completely reversed the vitamin D3-induced inhibition of TdR.	Cholecalciferol	103-113	interleukin 2	Rattus norvegicus	73-78
2786759-10	1989	A consistent synergism was observed between all concentrations of CsA used and vitamin D3 (10(-8) and 10(-7) M).	Cholecalciferol	79-89	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	66-69
2786759-11	1989	This study shows that the potentiation of immunosuppressive effects of CsA by vitamin D3 could be used as an approach to reduce the dosage of CsA in clinical use without compromising immunosuppression, thus preventing or minimizing the dose-related toxic effects of CsA.	Cholecalciferol	78-88	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	71-74
2786759-11	1989	This study shows that the potentiation of immunosuppressive effects of CsA by vitamin D3 could be used as an approach to reduce the dosage of CsA in clinical use without compromising immunosuppression, thus preventing or minimizing the dose-related toxic effects of CsA.	Cholecalciferol	78-88	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	142-145
2786759-11	1989	This study shows that the potentiation of immunosuppressive effects of CsA by vitamin D3 could be used as an approach to reduce the dosage of CsA in clinical use without compromising immunosuppression, thus preventing or minimizing the dose-related toxic effects of CsA.	Cholecalciferol	78-88	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	142-145
2575735-1	1989	The present study was undertaken to investigate the in vitro effects of two cholecalciferol metabolites 1,25(OH)2CC and 24,25(OH)2CC on the renal cortex alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT) and acid phosphatase (ACP) activities in hypophysectomized rats.	Cholecalciferol	76-91	gamma-glutamyltransferase 1	Rattus norvegicus	181-206
2786632-0	1989	Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3.	Cholecalciferol	107-117	bone gamma-carboxyglutamate protein	Homo sapiens	31-42
2656246-7	1989	Taken together, these results indicate that 1,25-(OH)2D3, the most physiologically active form of vitamin D3, is the predominant regulator of PKI, but serum calcium, indirectly through the regulation of PTH secretion, is also involved.	Cholecalciferol	98-108	tyrosine kinase 2	Gallus gallus	142-145
2542952-1	1989	The influence of chronic vitamin D3 application on the concentration of the four calcium-binding proteins parvalbumin, the 28-kDa calbindin-D, calmodulin, and S-100 was studied in various brain regions and in the kidney.	Cholecalciferol	25-35	parvalbumin	Rattus norvegicus	106-117
2752207-4	1989	Although the mean intestinal level of calbindin-D28K was as low as 118.23 +/- 20.08 (SD) ng/mg protein in vitamin D-deficient mice (-D), the level of this protein was markedly increased to the control level (198.68 +/- 9.98 vs. 198.49 +/- 14.29 ng/mg protein of control) (P less than 0.001) in response to the administration of vitamin D3 (1000 I.U.	Cholecalciferol	328-338	calbindin 1	Mus musculus	38-42
2521453-5	1989	Thus, in the presence of the vitamin D3 metabolite, only one-hundredth the concentration of CsA was required to produce the same effect on IL-2 production as that produced by CsA alone.	Cholecalciferol	29-39	interleukin 2	Homo sapiens	139-143
2492049-6	1989	IL-4 also stimulated C2 production by HL-60 cells that had been pre-treated with vitamin D3 to induce monocytic differentiation.	Cholecalciferol	81-91	interleukin 4	Homo sapiens	0-4
2572101-1	1989	Skin biopsies from 5 patients with chronic plaque psoriasis were examined to test the effect of topical treatment with a new synthetic vitamin D3 analogue, MC 903, on epidermal interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF alpha).	Cholecalciferol	135-145	interleukin 6	Homo sapiens	177-190
2612149-4	1989	Messenger RNAs for osteonectin and osteopontin were present in RCT-3 cells and osteopontin mRNA was enhanced by 1,25 (OH)2 vitamin D3 treatment.	Cholecalciferol	123-133	secreted phosphoprotein 1	Rattus norvegicus	79-90
2553083-0	1989	The glyoxylate cycle in rat epiphyseal cartilage: the effect of vitamin-D3 on the activity of the enzymes isocitrate lyase and malate synthase.	Cholecalciferol	64-74	citramalyl-CoA lyase	Rattus norvegicus	127-142
2843573-0	1988	Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism.	Cholecalciferol	18-28	bone gamma-carboxyglutamate protein	Homo sapiens	66-77
2466090-4	1988	The presence of vitamin D3 reduced IFN-gamma titers when PHA and IL-2 were used to induce IFN, but not when ionomycin was used as the inducer.	Cholecalciferol	16-26	interferon gamma	Homo sapiens	35-44
2466090-4	1988	The presence of vitamin D3 reduced IFN-gamma titers when PHA and IL-2 were used to induce IFN, but not when ionomycin was used as the inducer.	Cholecalciferol	16-26	interleukin 2	Homo sapiens	65-69
3196340-3	1988	The preparation also catalyzed 25-hydroxylation of vitamin D3 at a rate of 350 pmol/nmol of cytochrome P-450 x min-1.	Cholecalciferol	51-61	cytochrome P-450	Oryctolagus cuniculus	92-108
3196340-8	1988	The results indicate that there are different species of cytochrome P-450 in rabbit liver mitochondria catalyzing 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol and 25-hydroxylation of vitamin D3.	Cholecalciferol	209-219	cytochrome P-450	Oryctolagus cuniculus	57-73
2844763-8	1988	The liver mitochondrial cytochrome P-450 hydroxylates vitamin D3 and 1 alpha-hydroxyvitamin D3 at position 25, but did not show any activity toward xenobiotics such as benzphetamine, 7-ethoxycoumarin, and benzo[a]pyrene.	Cholecalciferol	54-64	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	24-40
2843573-7	1988	In idiopathic hypoparathyroidism, the active vitamin D3 increased serum osteocalcin without PTH.	Cholecalciferol	45-55	bone gamma-carboxyglutamate protein	Homo sapiens	72-83
2843573-8	1988	In pseudohypoparathyroidism, PTH may increase serum osteocalcin or modulate the effect of active vitamin D3 on serum osteocalcin.	Cholecalciferol	97-107	parathyroid hormone	Homo sapiens	29-32
2843573-8	1988	In pseudohypoparathyroidism, PTH may increase serum osteocalcin or modulate the effect of active vitamin D3 on serum osteocalcin.	Cholecalciferol	97-107	bone gamma-carboxyglutamate protein	Homo sapiens	117-128
2837492-10	1988	Furthermore, P-450mt1, P-450mt2, as well as partially purified P-450 from control liver, but not P-450c, showed varying activities for 25- and 26-hydroxylation of cholesterol and 25-hydroxylation of vitamin D3.	Cholecalciferol	199-209	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	23-31
2851923-1	1988	The response to vitamin D3 (D3) was studied in a model of micronodular cirrhosis induced by CCl4.	Cholecalciferol	16-26	C-C motif chemokine ligand 4	Rattus norvegicus	92-96
2845922-0	1988	Purification of a cytochrome P-450 from pig kidney microsomes catalysing the 25-hydroxylation of vitamin D3.	Cholecalciferol	97-107	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	18-34
2845922-1	1988	Cytochrome P-450 catalysing 25-hydroxylation of vitamin D3 was purified from pig kidney microsomes.	Cholecalciferol	48-58	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	0-16
2845922-3	1988	The purified cytochrome P-450 catalysed 25-hydroxylation of vitamin D3 up to 1,000 times more efficiently, and 25-hydroxylation of 1 alpha-hydroxyvitamin D3 up to 4000 times more efficiently, than the microsomes.	Cholecalciferol	60-70	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	13-29
2845922-9	1988	The possible role of the kidney microsomal cytochrome P-450 in the metabolism of vitamin D3 is discussed.	Cholecalciferol	81-91	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	43-59
3259542-2	1988	Since its production is dependent upon interleukin 1 (IL-1) produced by antigen-presenting cells, we tested five vitamin D3 analogues for effects on the production and function of human natural and recombinant IL-1.	Cholecalciferol	113-123	interleukin 1 alpha	Homo sapiens	54-58
2836517-1	1988	We found an increased amount of immunoreactive tyrosinase in human melanocytes after 6-d culturing with vitamin D3 (cholecalciferol).	Cholecalciferol	104-114	tyrosinase	Homo sapiens	47-57
2836517-1	1988	We found an increased amount of immunoreactive tyrosinase in human melanocytes after 6-d culturing with vitamin D3 (cholecalciferol).	Cholecalciferol	116-131	tyrosinase	Homo sapiens	47-57
2844144-0	1988	25-Hydroxylation of vitamin D3 by a cytochrome P-450 from rabbit liver mitochondria.	Cholecalciferol	20-30	cytochrome P-450	Oryctolagus cuniculus	36-52
2844144-1	1988	A cytochrome P-450 catalysing 25-hydroxylation of vitamin D3 was purified from liver mitochondria of untreated rabbits.	Cholecalciferol	50-60	cytochrome P-450	Oryctolagus cuniculus	2-18
2844144-5	1988	The purified cytochrome P-450 catalysed 25-hydroxylation of vitamin D3 up to 5000 times more efficiently than did the mitochondria.	Cholecalciferol	60-70	cytochrome P-450	Oryctolagus cuniculus	13-29
2844144-8	1988	The cytochrome P-450 catalysed, in addition to 25-hydroxylation of vitamin D3, the 25-hydroxylation of 1 alpha-hydroxyvitamin D3 and the 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol.	Cholecalciferol	67-77	cytochrome P-450	Oryctolagus cuniculus	4-20
2844144-10	1988	The results raise the possibility that the 25-hydroxylation of vitamin D3 and the 26-hydroxylation of C27 steroids are catalysed by the same species of cytochrome P-450 in liver mitochondria.	Cholecalciferol	63-73	cytochrome P-450	Oryctolagus cuniculus	152-168
2844144-11	1988	The possible role of the liver mitochondrial cytochrome P-450 in the metabolism of vitamin D3 is discussed.	Cholecalciferol	83-93	cytochrome P-450	Oryctolagus cuniculus	45-61
2838261-6	1988	After iv administration of tracer amounts of vitamin D3 to fasting rats, gradient gel electrophoretic analyses of plasma revealed most of the [3H] associated with the vitamin D-binding protein, and smaller amounts associated with LDL and high density lipoprotein.	Cholecalciferol	45-55	GC, vitamin D binding protein	Rattus norvegicus	167-192
2460437-0	1988	Immunochemical evidence for the catalysis of vitamin D3 25-hydroxylation and testosterone 16 alpha-hydroxylation by homologous forms of cytochrome P-450 in rat liver microsomes.	Cholecalciferol	45-55	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	136-152
2834451-7	1988	Pretreatment with vitamin D3 followed by IFN-gamma stimulation resulted in a 147% increase in C2 mRNA content compared with IFN-gamma stimulation alone.	Cholecalciferol	18-28	interferon gamma	Homo sapiens	124-133
2840181-0	1988	Suppression of rat hepatic vitamin D-25-hydroxylase by cholecalciferol, but not by 25-hydroxy- or 1,25-dihydroxymetabolites.	Cholecalciferol	55-70	cytochrome P450, family 2, subfamily r, polypeptide 1	Rattus norvegicus	27-51
2829737-0	1988	Differential effects of 1,25-dihydroxyvitamin D3 upon intestinal vitamin D3-dependent calbindin (a 28,000-dalton calcium binding protein) and its mRNA in D-replete and D-deficient chickens.	Cholecalciferol	38-48	calbindin 1	Gallus gallus	86-95
2829737-13	1988	Dietary withdrawal of vitamin D3 led to a gradual decline in ambient intestinal calbindin levels, while intestinal sensitivity to 1,25(OH)2D3 was restored.	Cholecalciferol	22-32	calbindin 1	Gallus gallus	80-89
2850724-1	1988	With the development of a sensitive bioassay for the skeletal effects of parathyroid hormone (PTH), it has become possible to investigate the possible interaction between PTH and vitamin D3 metabolites.	Cholecalciferol	179-189	parathyroid hormone	Rattus norvegicus	73-92
2845200-0	1988	Effect of prostaglandin E2 on gamma-interferon and 1,25(OH)2D3 vitamin D3-induced c-myc reduction during HL-60 cell differentiation.	Cholecalciferol	63-73	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	82-87
3339128-1	1988	The hypophosphatemic (Hyp) mouse, a murine homologue of human X-linked hypophosphatemic rickets, is characterized by renal defects in brush border membrane phosphate transport and vitamin D3 metabolism.	Cholecalciferol	180-190	phosphate regulating endopeptidase homolog, X-linked	Mus musculus	22-25
3257676-0	1988	Biological activity of 26,26,26,27,27,27-hexafluorinated analogs of vitamin D3 in inhibiting interleukin-2 production by peripheral blood mononuclear cells stimulated by phytohemagglutinin.	Cholecalciferol	68-78	interleukin 2	Homo sapiens	93-106
2844707-0	1988	Pyloric gastrin-producing cells and pyloric sphincter muscle cells are nuclear targets for 3H 1,25(OH)2 vitamin D3.	Cholecalciferol	104-114	gastrin	Rattus norvegicus	8-15
2831435-1	1988	Biological assays were performed to evaluate 10-oxo-19-nor-vitamin D3 (10-oxo-D3) and 5(E) 25-hydroxy-10-oxo-19-nor-vitamin D3 (25-OH-10-oxo-D3) two bacterial products of vitamin D3 (D3) and 25-hydroxyvitamin D3 (25-OHD3) metabolism, respectively.	Cholecalciferol	59-69	iodothyronine deiodinase 3	Homo sapiens	78-80
2831435-1	1988	Biological assays were performed to evaluate 10-oxo-19-nor-vitamin D3 (10-oxo-D3) and 5(E) 25-hydroxy-10-oxo-19-nor-vitamin D3 (25-OH-10-oxo-D3) two bacterial products of vitamin D3 (D3) and 25-hydroxyvitamin D3 (25-OHD3) metabolism, respectively.	Cholecalciferol	59-69	iodothyronine deiodinase 3	Homo sapiens	78-80
3257676-6	1988	Suppression of PBMC proliferation by vitamin D3 analogs seemed to be a secondary effect of their inhibition of IL-2 production.	Cholecalciferol	37-47	interleukin 2	Homo sapiens	111-115
3266311-4	1988	This fact suggests that 1 alpha-OHD3 therapy may be useful for the restoration of IL-2 production in hemodialysis patients, and that the vitamin D3 deficiency may be responsible for the impairment of cellular immunity associated with IL-2 production disorder in hemodialysis patients.	Cholecalciferol	137-147	interleukin 2	Homo sapiens	234-238
3119653-2	1987	The sarcoid cells, all collected from patients with normal calcium metabolism, synthesized 1,25-(OH)2-[3H]D3 from the substrate 25-hydroxyvitamin [3H]D3 (25OH-[3H]D3), whereas in vitro incubation with recombinant human interferon-gamma (IFN gamma) or lipopolysaccharide (LPS) was required for induction of synthesis of the hormone by normal PAM.	Cholecalciferol	106-108	interferon gamma	Homo sapiens	219-235
3119653-2	1987	The sarcoid cells, all collected from patients with normal calcium metabolism, synthesized 1,25-(OH)2-[3H]D3 from the substrate 25-hydroxyvitamin [3H]D3 (25OH-[3H]D3), whereas in vitro incubation with recombinant human interferon-gamma (IFN gamma) or lipopolysaccharide (LPS) was required for induction of synthesis of the hormone by normal PAM.	Cholecalciferol	106-108	interferon gamma	Homo sapiens	237-246
3621189-1	1987	Topical application of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3], an active form of vitamin D3, was previously shown to inhibit the induction of ornithine decarboxylase (ODC) and tumor promotion by tumor promoters in mouse skin.	Cholecalciferol	43-53	ornithine decarboxylase, structural 1	Mus musculus	154-177
3621189-1	1987	Topical application of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3], an active form of vitamin D3, was previously shown to inhibit the induction of ornithine decarboxylase (ODC) and tumor promotion by tumor promoters in mouse skin.	Cholecalciferol	43-53	ornithine decarboxylase, structural 1	Mus musculus	179-182
3621189-7	1987	These results suggest that an active form of vitamin D3 has a systemic inhibitory effect on induction of ODC activity by tumor promoters.	Cholecalciferol	45-55	ornithine decarboxylase, structural 1	Mus musculus	105-108
3117462-11	1987	These data suggest that vitamin D3 inhibits Ig production by inhibiting IL-2 receptor expression on B cells and via its effect on adherent macrophages.	Cholecalciferol	24-34	interleukin 2 receptor subunit beta	Homo sapiens	72-85
2820580-0	1987	The involvement of intracellular calcium ion concentration and calmodulin in the 25-hydroxylation of cholecalciferol in ovine and rat liver.	Cholecalciferol	101-116	calmodulin 1	Rattus norvegicus	63-73
2820580-7	1987	The calmodulin antagonists; W7, compound 48/80, trifluoperazine (TFP) and calmidazolium (R24571) were all found to effect a dose response inhibition of the 25 hydroxylation of cholecalciferol by homogenates of ovine liver.	Cholecalciferol	176-191	calmodulin 1	Rattus norvegicus	4-14
3034980-2	1987	We show that 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), the most hormonally active metabolite of vitamin D3, modulates sensitively and specifically both the protein and messenger RNA accumulation of the multilineage growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF).	Cholecalciferol	27-37	colony stimulating factor 2	Homo sapiens	227-275
3033646-1	1987	1 alpha,25-Dihydroxyvitamin D3 [1,25-(OH)2D3], the biologically active metabolite of vitamin D3, inhibited synthesis of gamma-interferon (IFN-gamma) by phytohemagglutinin-activated peripheral blood lymphocytes (PBLs).	Cholecalciferol	20-30	interferon gamma	Homo sapiens	138-147
3034980-2	1987	We show that 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), the most hormonally active metabolite of vitamin D3, modulates sensitively and specifically both the protein and messenger RNA accumulation of the multilineage growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF).	Cholecalciferol	27-37	colony stimulating factor 2	Homo sapiens	277-283
3491621-6	1986	Induction of CSF response appeared linked to differentiation, since KG1 cells differentiated with TPA and developed CSF-induced proliferative responses, but showed no differentiation or CSF induced proliferation after treatment with vitamin D3.	Cholecalciferol	233-243	colony stimulating factor 2	Homo sapiens	13-16
3026790-8	1987	25-Hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 were effective but somewhat less potent inducers of CaBP, whereas vitamin D3 was without significant effect.	Cholecalciferol	10-20	calcium-binding protein	Gallus gallus	103-107
3827911-1	1987	A mitochondrial cytochrome P-450 fraction, which catalyzed 25-hydroxylation of vitamin D3 much more efficiently than intact mitochondria was isolated from livers of male and female rats.	Cholecalciferol	79-89	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	16-32
3828767-1	1986	The 28,000-Da vitamin D-dependent calcium-binding protein, CaBP, which is induced by one hormonally active form of vitamin D3, 1,25-dihydroxyvitamin D3, was localized by immunocytochemistry in the human brainstem, cerebellum and cervical segment of the spinal cord.	Cholecalciferol	115-125	S100 calcium binding protein G	Homo sapiens	59-63
3018359-0	1986	Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration.	Cholecalciferol	85-95	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	42-47
3787230-4	1986	HL60 cells induced to differentiate by DMSO or vitamin D3 decreased TfR but increased Fer.	Cholecalciferol	47-57	transferrin receptor	Homo sapiens	68-71
3787230-5	1986	Expression of TfR with fresh leukemia and normal marrow cells was less clear than in HL60 cells; DMSO or vitamin D3 induced differentiation was associated with a 10-fold Fer increase in leukemia cells and greater than 100-fold increase in marrow cells.	Cholecalciferol	105-115	transferrin receptor	Homo sapiens	14-17
3018359-0	1986	Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration.	Cholecalciferol	85-95	colony stimulating factor 1 receptor	Homo sapiens	52-57
3018359-0	1986	Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration.	Cholecalciferol	85-95	calmodulin 1	Homo sapiens	160-170
3028082-16	1986	Bradykinin (0.02 microgram/kg/min) also caused to kallikrein-like changes of vitamin D3.	Cholecalciferol	77-87	kininogen 1	Canis lupus familiaris	0-10
3022423-1	1986	An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase.	Cholecalciferol	117-132	tyrosinase	Homo sapiens	29-39
3022423-1	1986	An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase.	Cholecalciferol	117-132	tyrosinase	Homo sapiens	237-247
3022423-1	1986	An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase.	Cholecalciferol	134-144	tyrosinase	Homo sapiens	29-39
3022423-1	1986	An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase.	Cholecalciferol	134-144	tyrosinase	Homo sapiens	237-247
3091093-1	1986	Cholecalciferol (calcitriol) the active hormonal form of vitamin D induces the synthesis of at least two intracellular calcium-binding proteins (Ka = 10(6) M-1), the cholecalcins (CaBP) in mammals.	Cholecalciferol	0-15	S100 calcium binding protein G	Rattus norvegicus	180-184
2821660-11	1986	22-Fluorovitamin D3 7 bound to the rat plasma vitamin D binding protein less avidly than vitamin D3.	Cholecalciferol	9-19	GC, vitamin D binding protein	Rattus norvegicus	46-71
3745145-0	1986	Isolation of a cytochrome P-450 that catalyzes the 25-hydroxylation of vitamin D3 from rat liver microsomes.	Cholecalciferol	71-81	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	15-31
3745145-1	1986	A molecular species of cytochrome P-450 that catalyzes the 25-hydroxylation of cholecalciferol (P-450cc25) was purified from rat liver microsomes on the basis of its catalytic activity.	Cholecalciferol	79-94	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	23-39
3745145-10	1986	The antibody elicited against the purified enzyme in a rabbit inhibited the cholecalciferol 25-hydroxylation activity by more than 90% with a concentration of 2 mg of immunoglobulin per nmol of cytochrome P-450.	Cholecalciferol	76-91	cytochrome P-450	Oryctolagus cuniculus	194-210
3002968-4	1986	Because dihydroxy vitamin D3 (1,25-(OH)2 D3) can cause phenotypic differentiation of immature leukemic lines into macrophage-like cells, we have explored the possibility that exposure to cholecalciferol metabolites in vitro might increase the ability of monocytes to control proliferation of M. tuberculosis, or cause monocytes to mature into cells able to respond appropriately to IFN-gamma.	Cholecalciferol	187-202	interferon gamma	Homo sapiens	382-391
2998336-4	1985	The relative potencies of other vitamin D3 compounds correlated closely with their relative affinities for the 1,25-dihydroxyvitamin D3 receptor and their biological activities in other systems.	Cholecalciferol	32-42	vitamin D receptor	Rattus norvegicus	111-144
2999689-11	1985	When the amount of [3H]-25-hydroxyvitamin D3 formed was expressed in relation to the amount of enzyme present in the reaction medium, a constant C-25 hydroxylation capacity in all age groups was observed suggesting that the cytochrome P-450 isoenzyme responsible for the C-25 hydroxylation of vitamin D3 may be constitutionally determined and that its appearance originates during fetal life.	Cholecalciferol	34-44	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	224-240
3002965-0	1985	Influence of vitamin D3 metabolites on the production of interleukins 1,2 and 3.	Cholecalciferol	13-23	interleukin 2	Mus musculus	57-79
3002965-1	1985	We investigated the effect of vitamin D3 metabolites on the release of the three interleukins (IL) IL 1, IL 2 and IL 3 by mononuclear cells.	Cholecalciferol	30-40	interleukin 1 complex	Mus musculus	99-103
3002965-1	1985	We investigated the effect of vitamin D3 metabolites on the release of the three interleukins (IL) IL 1, IL 2 and IL 3 by mononuclear cells.	Cholecalciferol	30-40	interleukin 2	Mus musculus	105-109
3002965-1	1985	We investigated the effect of vitamin D3 metabolites on the release of the three interleukins (IL) IL 1, IL 2 and IL 3 by mononuclear cells.	Cholecalciferol	30-40	interleukin 3	Mus musculus	114-118
3838511-2	1985	The rat possesses two cholecalciferol-induced calcium-binding proteins, the cholecalcins (CaBP).	Cholecalciferol	22-37	S100 calcium binding protein G	Rattus norvegicus	90-94
2990230-14	1985	The radioactive vitamin D3 recovered in the lymph fraction with d greater than 1.006 (free of chylomicrons) coeluted with purified rat serum binding protein for vitamin D and its metabolites (DBP) from an antirat DBP column.	Cholecalciferol	16-26	D-box binding PAR bZIP transcription factor	Rattus norvegicus	192-195
2990230-14	1985	The radioactive vitamin D3 recovered in the lymph fraction with d greater than 1.006 (free of chylomicrons) coeluted with purified rat serum binding protein for vitamin D and its metabolites (DBP) from an antirat DBP column.	Cholecalciferol	16-26	D-box binding PAR bZIP transcription factor	Rattus norvegicus	213-216
3887031-7	1985	Elevation of the serum calcium concentration following vitamin D3 treatment resulted in reduced release of parathyroid hormone by exocytosis and enhanced retrieval of plasma membranes by endocytosis.	Cholecalciferol	55-65	parathyroid hormone	Rattus norvegicus	107-126
3933491-0	1985	Purification, immunological and biochemical characterization of rat 28 kDa cholecalcin (cholecalciferol-induced calcium-binding proteins).	Cholecalciferol	88-103	S100 calcium binding protein G	Rattus norvegicus	75-86
2990344-0	1985	Changes of intestinal alkaline phosphatase produced by cholecalciferol or 1,25-dihydroxyvitamin D3 in vitamin D-deficient chicks.	Cholecalciferol	55-70	alkaline phosphatase, intestinal	Homo sapiens	11-42
2987615-6	1985	With regard to in vitro activity in displacing radiolabeled 25-hydroxyvitamin D3 from vitamin D binding protein and radiolabelled 1,25-dihydroxyvitamin D3 from a chick intestinal cytosol receptor, 3 beta-fluorovitamin D3 and 3 beta-deoxyvitamin D3 both showed very poor binding efficiencies when compared with vitamin D3.	Cholecalciferol	70-80	GC vitamin D binding protein	Gallus gallus	86-111
3874829-1	1985	The pharmacological effects of prolonged administration of a corticosteroid, betamethasone, and active vitamin D3 [1,24R-(OH)2D3] on lymphoproliferation and autoimmune disease of MRL/MP-lpr/lpr (MRL/1) mice were examined.	Cholecalciferol	103-115	Fas (TNF receptor superfamily member 6)	Mus musculus	179-193
6089793-1	1984	The amount of skin calcium-binding protein, evaluated using a sensitive radioimmunoassay and indirect immunofluorescence, was decreased in vitamin-D deficient rats and increased after one week vitamin D3 or 1 alpha-hydroxyvitamin D3 treatment.	Cholecalciferol	193-203	hippocalcin	Rattus norvegicus	19-42
6489266-4	1984	By transferring proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to nitrocellulose blots electrophoretically, CaBP was immunologically detected in brush borders from vitamin D3-treated chicks, but not in those from vitamin D3-deficient chicks.	Cholecalciferol	197-207	centrin 1	Homo sapiens	141-145
6489266-4	1984	By transferring proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to nitrocellulose blots electrophoretically, CaBP was immunologically detected in brush borders from vitamin D3-treated chicks, but not in those from vitamin D3-deficient chicks.	Cholecalciferol	246-256	centrin 1	Homo sapiens	141-145
3001619-3	1985	vitamin D3-drops for 18 days) of vitamin D-deficiency rickets (VDR).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	63-66
6689055-10	1983	In addition, we demonstrate that removal of vitamin D3, after the onset of maturational change, results in the reappearance of elevated myc mRNA levels.	Cholecalciferol	44-54	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	136-139
6331517-3	1984	Microsomal cytochrome P-450 catalyzed an efficient 25-hydroxylation of vitamin D3, but no 25-hydroxylation of vitamin D2 could be detected.	Cholecalciferol	71-81	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	11-27
6546486-6	1984	These results indicate that when the lactonization at C-23 and C-26 positions of various vitamin D3 derivatives occurred the stereochemical configuration at their C-23 and/or C-25 positions was not changed and the difference of the stereochemical configurations determined the rate of lactonization.	Cholecalciferol	89-99	nucleolin	Homo sapiens	54-58
6546486-6	1984	These results indicate that when the lactonization at C-23 and C-26 positions of various vitamin D3 derivatives occurred the stereochemical configuration at their C-23 and/or C-25 positions was not changed and the difference of the stereochemical configurations determined the rate of lactonization.	Cholecalciferol	89-99	nucleolin	Homo sapiens	163-167
6427926-1	1984	The hormonal form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], at picomolar concentrations, inhibited the growth-promoting lymphokine interleukin-2, which is produced by human T lymphocytes activated in vitro by the mitogen phytohemagglutinin.	Cholecalciferol	21-31	interleukin 2	Homo sapiens	144-157
6427926-2	1984	Other metabolites of vitamin D3 were less effective than 1,25(OH)2D3 in suppressing interleukin-2; their order of potency corresponded to their respective affinity for the 1,25(OH)2D3 receptor, suggesting that the effect on interleukin-2 was mediated by this specific receptor.	Cholecalciferol	21-31	interleukin 2	Homo sapiens	84-97
6427926-2	1984	Other metabolites of vitamin D3 were less effective than 1,25(OH)2D3 in suppressing interleukin-2; their order of potency corresponded to their respective affinity for the 1,25(OH)2D3 receptor, suggesting that the effect on interleukin-2 was mediated by this specific receptor.	Cholecalciferol	21-31	interleukin 2	Homo sapiens	224-237
6325646-5	1984	Low dietary intake of phosphorus resulted in an increase in 47Ca and 203Pb absorption and in CaBP synthesis when the animals were treated with cholecalciferol.	Cholecalciferol	143-158	centrin 1	Homo sapiens	93-97
6363517-1	1984	Vitamin D-dependent calcium-binding protein (CaBP) was localized in intestinal tissue sections obtained from rats raised under three different nutritional conditions: a normal vitamin D-replete diet, a vitamin D-free diet followed by supplementation with vitamin D3, or a vitamin D-free diet without additional supplementation.	Cholecalciferol	255-265	hippocalcin	Rattus norvegicus	20-43
6363517-1	1984	Vitamin D-dependent calcium-binding protein (CaBP) was localized in intestinal tissue sections obtained from rats raised under three different nutritional conditions: a normal vitamin D-replete diet, a vitamin D-free diet followed by supplementation with vitamin D3, or a vitamin D-free diet without additional supplementation.	Cholecalciferol	255-265	hippocalcin	Rattus norvegicus	45-49
6363517-6	1984	In rats raised on a vitamin D-deficient diet then supplemented with vitamin D3, CaBP was present in cells at the full depth of the crypts and in absorptive cells along the total villus length in the duodenum.	Cholecalciferol	68-78	hippocalcin	Rattus norvegicus	80-84
6315669-8	1983	Treatment with 500 mg of vitamin D3, but not 50 mg of dihydrotachysterol, significantly increased serum Ca and CaBP concentrations in Holstein heifers after a lag period of 7 to 10 d. Serum Ca and CaBP concentrations began to increase in serum at approximately the same time and both exhibited parallel responses to treatment with vitamin D3.	Cholecalciferol	25-35	S100 calcium binding protein G	Bos taurus	111-115
6687257-1	1983	The effects of cholecalciferol (vitamin D3)-binding proteins and anti-cytochrome b5 immunoglobulin were studied on vitamin D3 25-hydroxylase activities of microsomes and mitochondria under various experimental conditions.	Cholecalciferol	15-30	sterol 26-hydroxylase, mitochondrial	Oryctolagus cuniculus	115-140
6687257-1	1983	The effects of cholecalciferol (vitamin D3)-binding proteins and anti-cytochrome b5 immunoglobulin were studied on vitamin D3 25-hydroxylase activities of microsomes and mitochondria under various experimental conditions.	Cholecalciferol	32-42	sterol 26-hydroxylase, mitochondrial	Oryctolagus cuniculus	115-140
6687257-2	1983	The vitamin D3-binding protein in serum as well as in the liver postmicrosomal supernatant (cellular vitamin D3-binding protein), but not serum albumin and ovalbumin, stimulated vitamin D3 25-hydroxylase activities of microsomes and mitochondria.	Cholecalciferol	4-14	sterol 26-hydroxylase, mitochondrial	Oryctolagus cuniculus	178-203
6315669-8	1983	Treatment with 500 mg of vitamin D3, but not 50 mg of dihydrotachysterol, significantly increased serum Ca and CaBP concentrations in Holstein heifers after a lag period of 7 to 10 d. Serum Ca and CaBP concentrations began to increase in serum at approximately the same time and both exhibited parallel responses to treatment with vitamin D3.	Cholecalciferol	25-35	S100 calcium binding protein G	Bos taurus	197-201
6315669-10	1983	Serum Ca and CaBP concentrations were still elevated in heifers 75 d after initial treatment with vitamin D3.	Cholecalciferol	98-108	S100 calcium binding protein G	Bos taurus	13-17
6311881-2	1983	Milk from cows kept indoors contained barely detectable vitamin (less than 2 IU/100 ml) predominantly in the form of vitamin D3.	Cholecalciferol	117-127	Weaning weight-maternal milk	Bos taurus	0-4
6688877-1	1983	Previous studies from this laboratory have demonstrated that the acute infusion of the vitamin D3 derivative, 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) is antiphosphaturic when administered with small "permissive" amounts of parathyroid hormone (PTH).	Cholecalciferol	87-97	parathyroid hormone	Rattus norvegicus	223-242
6688877-1	1983	Previous studies from this laboratory have demonstrated that the acute infusion of the vitamin D3 derivative, 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) is antiphosphaturic when administered with small "permissive" amounts of parathyroid hormone (PTH).	Cholecalciferol	87-97	parathyroid hormone	Rattus norvegicus	244-247
6311881-3	1983	When cows were given 5 or 10 million IU vitamin D3, maximums were in milk 3 to 7 days after oral doses and up to 10 days after intravenous injections.	Cholecalciferol	40-50	Weaning weight-maternal milk	Bos taurus	69-73
6847206-2	1983	Addition of papain to brush borders isolated from vitamin D3-treated and deficient chicks resulted in a differential solubilization of leucine aminopeptidase, maltase, and sucrase activities (114, 195, and 79%, respectively, of appropriate control levels) but not alkaline phosphatase activity.	Cholecalciferol	50-60	carboxypeptidase Q	Homo sapiens	143-157
6308609-1	1983	We have constructed a recombinant cDNA library to facilitate study of the genomic actions of vitamin D3 and its hormonally active metabolite 1,25-dihydroxyvitamin D3 in initiation of the de novo biosynthesis of a 28,000-dalton vitamin D-dependent calcium binding protein (CaBP) present in chick intestine.	Cholecalciferol	93-103	calcium-binding protein	Gallus gallus	247-270
6308609-1	1983	We have constructed a recombinant cDNA library to facilitate study of the genomic actions of vitamin D3 and its hormonally active metabolite 1,25-dihydroxyvitamin D3 in initiation of the de novo biosynthesis of a 28,000-dalton vitamin D-dependent calcium binding protein (CaBP) present in chick intestine.	Cholecalciferol	93-103	calcium-binding protein	Gallus gallus	272-276
6304056-0	1983	25-hydroxylation of C27-steroids and vitamin D3 by a constitutive cytochrome P-450 from rat liver microsomes.	Cholecalciferol	37-47	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	66-82
6304056-1	1983	A constitutive cytochrome P-450 catalyzing 25-hydroxylation of C27-steroids and vitamin D3 was purified from rat liver microsomes.	Cholecalciferol	80-90	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	15-31
6304056-3	1983	The purified cytochrome P-450 catalyzed 25-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha-diol, 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol, and 1 alpha-hydroxyvitamin D3 up to 50 times more efficiently, and 25-hydroxylation of vitamin D3 about 150 times more efficiently than the microsomes.	Cholecalciferol	172-182	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	13-29
6304056-6	1983	The 25-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol and vitamin D3 with the purified cytochrome P-450 was not stimulated by addition of phospholipid or cytochrome b5 to the reconstituted system.	Cholecalciferol	79-89	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	108-124
6304056-8	1983	The possibility that 25-hydroxylation of C27-steroids and vitamin D3 is catalyzed by the same species of cytochrome P-450 is discussed.	Cholecalciferol	58-68	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	105-121
6290291-0	1982	Effects of vitamin D3 metabolites on production of prolactin and growth hormone in rat pituitary cells.	Cholecalciferol	11-21	prolactin	Rattus norvegicus	51-60
6299329-2	1983	The plasma disappearance of 3H-labelled 25-hydroxyvitamin D3 (25(OH)D3) was studied in healthy volunteers on normal and high-fibre diets, using 3H-labelled tracer doses given intravenously.	Cholecalciferol	68-70	iodothyronine deiodinase 3	Homo sapiens	58-60
6297543-6	1983	This new vitamin D3 metabolite, however, had greater affinity than 25-hydroxyvitamin D3 to both the rat plasma vitamin D binding protein and the 1,25-dihydroxyvitamin D specific cytosol receptor.	Cholecalciferol	9-19	GC, vitamin D binding protein	Rattus norvegicus	111-136
6884003-1	1983	Cholecalciferol (vitamin D3) 25-hydroxylase activity and its tissue and subcellular distributions were studied using rabbit, rat, bovine, chick, duck, guinea-pig and yellowtail.	Cholecalciferol	0-15	sterol 26-hydroxylase, mitochondrial	Oryctolagus cuniculus	17-43
6897035-9	1982	Daily administration of vitamin D3 or 1 alpha,25-(OH)2D3 for 2 weeks resulted in a marked increase in CaBP levels mainly in the mid- and upper villus regions.	Cholecalciferol	24-34	centrin 1	Homo sapiens	102-106
6981502-1	1982	In young rats, PTH markedly stimulates the renal conversion of 25-hydroxyvitamin D3 (25OHD3) to 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], the biologically active form of vitamin D3.	Cholecalciferol	73-83	parathyroid hormone	Rattus norvegicus	15-18
6830145-4	1983	The results indicate that CaBP is not biosynthesised in response to raising the extracellular calcium ion concentration, and only appears if the chickens had received cholecalciferol.	Cholecalciferol	167-182	calcium-binding protein	Gallus gallus	26-30
6278948-8	1982	Vitamin D3, in a single dose of 250 micrograms, partially restored serum calcium of vitamin D-deficient birds toward normal by 72 h and also partly restored renal cyclic AMP responsiveness to PTH and the PTH receptor number toward control values.	Cholecalciferol	0-10	parathyroid hormone	Gallus gallus	192-195
6291527-0	1982	23-keto-25-hydroxyvitamin D3 and 23-keto-1,25-dihydroxyvitamin D3: two new vitamin D3 metabolites with high affinity for the 1,25-dihydroxyvitamin D3 receptor.	Cholecalciferol	18-28	vitamin D receptor	Homo sapiens	125-158
6278948-8	1982	Vitamin D3, in a single dose of 250 micrograms, partially restored serum calcium of vitamin D-deficient birds toward normal by 72 h and also partly restored renal cyclic AMP responsiveness to PTH and the PTH receptor number toward control values.	Cholecalciferol	0-10	parathyroid hormone	Gallus gallus	204-207
6895593-1	1981	The effect of cholecalciferol and its metabolites on ornithine decarboxylase activity was investigated in the duodenal mucosa of vitamin D-deficient chicks.	Cholecalciferol	14-29	ornithine decarboxylase	Gallus gallus	53-76
6141291-0	1982	Calcitonin secretion during postnatal development in the rat: beta-adrenergic agents and vitamin D3 metabolites.	Cholecalciferol	89-99	calcitonin-related polypeptide alpha	Rattus norvegicus	0-10
6141291-2	1982	So, in vivo and in vitro (using a perifusion system) effects of beta-adrenergic agents and vitamin D3 metabolites on CT release were studied in the rat during the postnatal development.	Cholecalciferol	91-101	calcitonin-related polypeptide alpha	Rattus norvegicus	117-119
6274987-0	1981	Side chain hydroxylation of C27-steroids and vitamin D3 by a cytochrome P-450 enzyme system isolated from human liver mitochondria.	Cholecalciferol	45-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-77
6274987-7	1981	The cytochrome P-450 preparation catalyzed 26-hydroxylation of C27-steroids and 25-hydroxylation of vitamin D3 when reconstructed with NADPH, the ferredoxin and the ferredoxin reductase.	Cholecalciferol	100-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	4-20
6274987-7	1981	The cytochrome P-450 preparation catalyzed 26-hydroxylation of C27-steroids and 25-hydroxylation of vitamin D3 when reconstructed with NADPH, the ferredoxin and the ferredoxin reductase.	Cholecalciferol	100-110	ferredoxin reductase	Homo sapiens	165-185
6274987-11	1981	It is concluded that human liver mitochondria contain cytochrome P-450 involved in the oxidation of the side chain of C27-steroids and vitamin D3.	Cholecalciferol	135-145	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-70
6265564-4	1981	The plasma vitamin-D binding protein preferentially translocates vitamin D3 from the skin into the circulation.	Cholecalciferol	65-75	GC vitamin D binding protein	Homo sapiens	11-36
6895593-2	1981	The duodenal ornithine decarboxylase activity decreased in animals fed a vitamin D-deficient diet and its retarded activity was increased dose-dependently by a single injection of cholecalciferol.	Cholecalciferol	180-195	ornithine decarboxylase	Gallus gallus	13-36
734693-1	1978	Since intestinal calcium-binding protein (CaBP) can be regarded as an expression of the hormone-like action of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on the duodenal enterocyte we have investigated the potential biological activity of 25R and 25S,26-(OH)2D3 (two recently synthesized epimers of vitamin D3 metabolite) to promote intestinal CaBP production as compared to bone calcium mobilization in vitamin D and calcium-deficient rats.	Cholecalciferol	125-135	S100 calcium binding protein G	Rattus norvegicus	42-46
443376-2	1979	The relation between CaBP and calcium absorption was dependent on a) source of vitamin D activity (either vitamin D3 or 1,25-dihydroxycholecalciferol); b) dosage of vitamin D3; c) time after administration of vitamin D3 to rachitic animals.	Cholecalciferol	106-116	centrin 1	Homo sapiens	21-25
443376-2	1979	The relation between CaBP and calcium absorption was dependent on a) source of vitamin D activity (either vitamin D3 or 1,25-dihydroxycholecalciferol); b) dosage of vitamin D3; c) time after administration of vitamin D3 to rachitic animals.	Cholecalciferol	165-175	centrin 1	Homo sapiens	21-25
443376-2	1979	The relation between CaBP and calcium absorption was dependent on a) source of vitamin D activity (either vitamin D3 or 1,25-dihydroxycholecalciferol); b) dosage of vitamin D3; c) time after administration of vitamin D3 to rachitic animals.	Cholecalciferol	165-175	centrin 1	Homo sapiens	21-25
6263587-12	1981	It app]ears that 1 alpha-hydroxylase activities of the fetoplacental unit (placenta and fetal kidney) are blunted in TPTX animals and that CaBP synthesis in the fetus depends on the presence of 1 alpha-hydroxylated vitamin D3 metabolites in the mother.	Cholecalciferol	215-225	hippocalcin	Rattus norvegicus	139-143
7453803-2	1980	However, it has long been known that a soluble, calcium-binding protein (CaBP), is produced in large amounts in the cytoplasm of the intestinal cells of animals after in vivo administration of vitamin D3 or 1,25-(OH)2D3 (refs 1,2).	Cholecalciferol	193-203	calcium-binding protein	Gallus gallus	48-71
7453803-2	1980	However, it has long been known that a soluble, calcium-binding protein (CaBP), is produced in large amounts in the cytoplasm of the intestinal cells of animals after in vivo administration of vitamin D3 or 1,25-(OH)2D3 (refs 1,2).	Cholecalciferol	193-203	calcium-binding protein	Gallus gallus	73-77
90502-0	1979	Quantitative studies of the interaction of cholecalciferol ((vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols.	Cholecalciferol	43-58	growth hormone receptor	Homo sapiens	132-153
90502-0	1979	Quantitative studies of the interaction of cholecalciferol ((vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols.	Cholecalciferol	61-71	growth hormone receptor	Homo sapiens	132-153
90502-1	1979	Cholecalciferol (vitamin D3) and its 25-hydroxy metabolite are transported in plasma bound to a specific protein, the binding protein for cholecalciferol and its metabolites (DBP).	Cholecalciferol	0-15	D-box binding PAR bZIP transcription factor	Homo sapiens	175-178
90502-1	1979	Cholecalciferol (vitamin D3) and its 25-hydroxy metabolite are transported in plasma bound to a specific protein, the binding protein for cholecalciferol and its metabolites (DBP).	Cholecalciferol	17-27	D-box binding PAR bZIP transcription factor	Homo sapiens	175-178
90502-1	1979	Cholecalciferol (vitamin D3) and its 25-hydroxy metabolite are transported in plasma bound to a specific protein, the binding protein for cholecalciferol and its metabolites (DBP).	Cholecalciferol	138-153	D-box binding PAR bZIP transcription factor	Homo sapiens	175-178
90502-8	1979	More extensive studies were then conducted to compare the binding of four cholecalciferol-related sterols to each of three genetic variants of DBP, by using sera from homozygous persons with the Gc 1-1, Gc 2-2 and Gc Ab-Ab phenotypes.	Cholecalciferol	74-89	D-box binding PAR bZIP transcription factor	Homo sapiens	143-146
90502-10	1979	The affinities of the three genetic types of DBP/Gc protein were found to be similar for each of the four cholecalciferol-related sterols.	Cholecalciferol	106-121	GC vitamin D binding protein	Homo sapiens	45-51
90502-15	1979	Thus the common genetic variants of DBP/Gc protein, and the uncommon genetic variants studied here, all appear to have similar binding properties for cholecalciferol and its several metabolites.	Cholecalciferol	150-165	GC vitamin D binding protein	Homo sapiens	36-42
221183-1	1979	Vitamin D3 in rachitic chicks stimulates calcium absorption and induces the synthesis of two pools of intestinal calcium-binding protein (CaBP), one soluble and the other membrane bound.	Cholecalciferol	0-10	S100 calcium binding protein G	Homo sapiens	138-142
221183-5	1979	It was further observed that the slope of the Ca absorption vs. soluble CaBP regression line was greater in chicks given 1,25-dihyroxyvitamin D3 compared to those given vitamin D3, and this is interpreted to mean that another factor or condition, in addition to assayed concentrations of soluble CaBP, determines the degree of calcium absorption.	Cholecalciferol	134-144	S100 calcium binding protein G	Homo sapiens	72-76
211584-0	1978	Vitamin D3-induced calcium binding protein in bone tissue.	Cholecalciferol	0-10	calcium-binding protein	Gallus gallus	19-42
211584-1	1978	As detected by radioimmunoassay with antiserums against chick intestinal calcium binding protein (CaBP), administration of vitamin D3 to rachitic chicks causes a 25- to 100-fold increase in immunoreactive CaBP in chick bone.	Cholecalciferol	123-133	calcium-binding protein	Gallus gallus	73-96
211584-1	1978	As detected by radioimmunoassay with antiserums against chick intestinal calcium binding protein (CaBP), administration of vitamin D3 to rachitic chicks causes a 25- to 100-fold increase in immunoreactive CaBP in chick bone.	Cholecalciferol	123-133	calcium-binding protein	Gallus gallus	98-102
211584-1	1978	As detected by radioimmunoassay with antiserums against chick intestinal calcium binding protein (CaBP), administration of vitamin D3 to rachitic chicks causes a 25- to 100-fold increase in immunoreactive CaBP in chick bone.	Cholecalciferol	123-133	calcium-binding protein	Gallus gallus	205-209
357647-1	1978	Calcium binding protein (CaBP) was localized by the indirect peroxidase-labeled antibody method in chick duodenum 72 hr after administering 32.5 nmol of cholecalciferol to vitamin D-deficient chicks.	Cholecalciferol	153-168	calcium-binding protein	Gallus gallus	0-23
357647-1	1978	Calcium binding protein (CaBP) was localized by the indirect peroxidase-labeled antibody method in chick duodenum 72 hr after administering 32.5 nmol of cholecalciferol to vitamin D-deficient chicks.	Cholecalciferol	153-168	calcium-binding protein	Gallus gallus	25-29
233823-11	1977	These studies in both the chick and rat indicate that dietary vitamin D3 excess enhances circulating 25-OHD3, probably because the vitamin D3-25-hydroxylase enzyme is not strigently controlled.	Cholecalciferol	62-72	cytochrome P450, family 27, subfamily a, polypeptide 1	Rattus norvegicus	131-156
204303-11	1978	Rachitic chicks require the presence of dietary calcium for maximum stimulation of calcium-binding protein production by cholecalciferol.	Cholecalciferol	121-136	calcium-binding protein	Gallus gallus	83-106
201067-3	1977	In the group of rabbits which were fed on the mixture of carbostimulin and vitamin D3 the phosphofructokinase activity is 7-2 times as high.	Cholecalciferol	75-85	ATP-dependent 6-phosphofructokinase, muscle type	Oryctolagus cuniculus	90-109
204359-3	1978	The accumulation of cholecalciferol metabolites in the parotid gland was shown to be functional, as a calcium-binding protein was found to be present in the gland, possessing similar properties to the renal vitamin D-dependent calcium-binding protein.	Cholecalciferol	20-35	hippocalcin	Rattus norvegicus	102-125
204359-3	1978	The accumulation of cholecalciferol metabolites in the parotid gland was shown to be functional, as a calcium-binding protein was found to be present in the gland, possessing similar properties to the renal vitamin D-dependent calcium-binding protein.	Cholecalciferol	20-35	hippocalcin	Rattus norvegicus	227-250
564862-2	1978	PTH potentiated CaBP synthesis in the presence of vitamin D3, 25-OH-D3, 1 alpha-OH-D3, DHT, and 1,25(OH)2D3.	Cholecalciferol	50-60	parathyroid hormone	Gallus gallus	0-3
195023-0	1977	Characterization of sterol carrier protein binding with 7-dehydrocholesterol and vitamin D3.	Cholecalciferol	81-91	fatty acid binding protein 1	Rattus norvegicus	20-42
195023-9	1977	From these results, it was clearly demonstrated that SCP was involved in the transformation of 7-dehydrocholesterol to cholesterol and could also bind vitamin D3.	Cholecalciferol	151-161	fatty acid binding protein 1	Rattus norvegicus	53-56
402471-10	1977	Since EHDP inhibits formation of 1,25-(OH)2D3 the effect of PTH on Ca absorption is likely to be mediated through this vitamin D3 metabolite.	Cholecalciferol	119-129	parathyroid hormone	Rattus norvegicus	60-63
821943-6	1976	Sucrose gradient ultracentrifugation of Cal-BP and ligand incubations indicated that there was apparently one binding site for either cholecalciferol, calcifidiol or 1,25-dihydroxycholecalciferol per molecule of human Cal-BP.	Cholecalciferol	134-149	calreticulin	Rattus norvegicus	40-46
821943-9	1976	Specific binding of vitamin D3,25-OH-D3, and 1,25-(OH)2D3 by human serum was completely neutralized after immunoprecipitation of the serum with the gamma globulin fraction of anti-Cal-BP antiserum, indicating a common transport protein for these sterols in human plasma.	Cholecalciferol	20-30	calreticulin	Rattus norvegicus	180-186
180950-0	1975	The role of calcium binding protein in the mechanism of action of cholecalciferol (vitamin D3).	Cholecalciferol	66-81	centrin 1	Homo sapiens	12-35
180950-0	1975	The role of calcium binding protein in the mechanism of action of cholecalciferol (vitamin D3).	Cholecalciferol	83-93	centrin 1	Homo sapiens	12-35
180950-1	1975	A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks.	Cholecalciferol	104-119	centrin 1	Homo sapiens	31-54
180950-1	1975	A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks.	Cholecalciferol	104-119	centrin 1	Homo sapiens	56-60
180950-1	1975	A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks.	Cholecalciferol	125-135	centrin 1	Homo sapiens	31-54
180950-1	1975	A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks.	Cholecalciferol	125-135	centrin 1	Homo sapiens	56-60
31842709-2	2021	We aimed to investigate the effect of the calcitriol or active form of Vitamin D3 (1, 25(OH) 2D3) on serum Cholesteryl ester transfer protein (CETP) levels in a rabbit model of atherosclerosis.	Cholecalciferol	71-81	cholesteryl ester transfer protein	Oryctolagus cuniculus	107-141
165031-17	1975	The data suggest that the production of 1,25-(OH)2D3 from a pulse dose of cholecalciferol is normally regulated, directly or indirectly, by the parathyroid hormone.	Cholecalciferol	74-89	parathyroid hormone	Homo sapiens	144-163
189757-9	1976	It is postulated that cholecalciferol forms part of a complex with its specific binding protein, Ca2+ and the yolk phosphoprotein, phosvitin.	Cholecalciferol	22-37	carbonic anhydrase 2	Gallus gallus	97-100
189757-9	1976	It is postulated that cholecalciferol forms part of a complex with its specific binding protein, Ca2+ and the yolk phosphoprotein, phosvitin.	Cholecalciferol	22-37	Casein kinase II subunit beta	Gallus gallus	131-140
178845-1	1975	It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP).	Cholecalciferol	84-99	fatty acid binding protein 1	Rattus norvegicus	162-184
178845-1	1975	It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP).	Cholecalciferol	84-99	fatty acid binding protein 1	Rattus norvegicus	186-189
178845-1	1975	It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP).	Cholecalciferol	101-111	fatty acid binding protein 1	Rattus norvegicus	162-184
178845-1	1975	It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP).	Cholecalciferol	101-111	fatty acid binding protein 1	Rattus norvegicus	186-189
178845-2	1975	The enzyme activity was significantly decreased in the combination with microsomes obtained from either vitamin D-deficient or vitamin D3-treated rat liver and with SCP obtained from vitamin D3-treated rat.	Cholecalciferol	127-137	fatty acid binding protein 1	Rattus norvegicus	165-168
178845-2	1975	The enzyme activity was significantly decreased in the combination with microsomes obtained from either vitamin D-deficient or vitamin D3-treated rat liver and with SCP obtained from vitamin D3-treated rat.	Cholecalciferol	183-193	fatty acid binding protein 1	Rattus norvegicus	165-168
178845-3	1975	It was also demonstrated by the binding assay of the dextran-charcoal technique that 7-dehydrocholesterol binding to SCP could be specifically displaced by vitamin D3.	Cholecalciferol	156-166	fatty acid binding protein 1	Rattus norvegicus	117-120
178845-4	1975	The inhibition of cholecalciferol on 7-dehydrocholesterol binding to liver SCP was confirmed to be non-competitive inhibition.	Cholecalciferol	18-33	fatty acid binding protein 1	Rattus norvegicus	75-78
33043722-6	2021	Vitamin D3 (700-800IU/d) plus calcium showed statistical significance in reducing the incidence of total, hip and non-vertebral fractures in the pairwise meta-analysis.	Cholecalciferol	0-10	hedgehog interacting protein	Homo sapiens	106-109
31842709-2	2021	We aimed to investigate the effect of the calcitriol or active form of Vitamin D3 (1, 25(OH) 2D3) on serum Cholesteryl ester transfer protein (CETP) levels in a rabbit model of atherosclerosis.	Cholecalciferol	71-81	cholesteryl ester transfer protein	Oryctolagus cuniculus	143-147
34051273-0	2021	Vitamin D3 protects against lead-induced testicular toxicity by modulating Nrf2 and NF-kappaB genes expression in rat.	Cholecalciferol	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	75-79
33592299-12	2021	CONCLUSION: Vitamin D3 efficiently protected allografts from memory T-cell allo-responses when combined with anti-CD40L/anti-LFA-1 antibodies therapy.	Cholecalciferol	12-22	CD40 ligand	Mus musculus	114-119
33400182-0	2021	Protective Effect of Vitamin D3 Against Pb-Induced Neurotoxicity by Regulating the Nrf2 and NF-kappaB Pathways.	Cholecalciferol	21-31	NFE2 like bZIP transcription factor 2	Rattus norvegicus	83-87
34051273-3	2021	This study was conducted to evaluate the effects of vitamin D3 (VD) on the prevention of testicular damages of Pb and its association with Nrf2 and NF-kappaB gene expression levels and their downstream molecules.	Cholecalciferol	52-62	NFE2 like bZIP transcription factor 2	Rattus norvegicus	139-143
34032540-0	2022	Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors.	Cholecalciferol	71-81	vitamin D receptor	Homo sapiens	0-18
34032540-0	2022	Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors.	Cholecalciferol	71-81	vitamin D receptor	Homo sapiens	20-23
34032540-1	2022	We investigated how vitamin D receptor (VDR) allelic variants affect breast cancer survivors" responses to vitamin D3 supplementation to increase circulating 25-hydroxy vitamin D (25(OH)D) levels.	Cholecalciferol	107-117	vitamin D receptor	Homo sapiens	20-38
34032540-4	2022	The TaqI and BsmI VDR sequence variants modified the effect of vitamin D3 treatment on the plasma 25(OH)D changes (P value = 0.008 for TaqI and P value = 0.0005 for BsmI).	Cholecalciferol	63-73	vitamin D receptor	Homo sapiens	18-21
34032540-7	2022	VDR allelic variants modulate vitamin D3 supplementation to increase plasma 25(OH) levels in breast cancer survivors.	Cholecalciferol	30-40	vitamin D receptor	Homo sapiens	0-3
33985576-6	2021	Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice.	Cholecalciferol	195-205	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	31-90
34020532-11	2021	In diabetic hearts, the mRNA expression level of parp-1 gene was 2.8-fold higher compared to control rats and partially decreased by vitamin D3 treatment.	Cholecalciferol	133-143	poly (ADP-ribose) polymerase 1	Rattus norvegicus	49-55
34011380-0	2021	Association of vitamin D-binding protein and vitamin D3 with insulin and homeostatic model assessment (HOMA-IR) in overweight and obese females.	Cholecalciferol	45-55	insulin	Homo sapiens	61-68
33985576-6	2021	Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice.	Cholecalciferol	195-205	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	92-96
33985576-6	2021	Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice.	Cholecalciferol	195-205	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	126-130
33985576-6	2021	Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice.	Cholecalciferol	195-205	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	126-130
33985576-8	2021	Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids.	Cholecalciferol	169-179	DNA-damage inducible transcript 3	Mus musculus	71-95
33985576-8	2021	Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids.	Cholecalciferol	169-179	DNA-damage inducible transcript 3	Mus musculus	97-101
33985576-8	2021	Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids.	Cholecalciferol	169-179	activating transcription factor 6	Mus musculus	108-141
33985576-8	2021	Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids.	Cholecalciferol	169-179	activating transcription factor 6	Mus musculus	143-147
32804345-9	2021	CONCLUSION: One-year cholecalciferol supplementation, able to restore D status, significantly improves FG, HbA1c, SBP and HDL-cholesterol levels in patients with poor-controlled type 2 diabetes mellitus and D deficiency.	Cholecalciferol	21-36	selenium binding protein 1	Homo sapiens	114-117
33548476-11	2021	Ki67-positive cells, a marker of placental proliferation, were reduced in mice administered with high-dose cholecalciferol.	Cholecalciferol	107-122	antigen identified by monoclonal antibody Ki 67	Mus musculus	0-4
33548476-12	2021	N-cadherin and vimentin, two mesenchymal markers, were decreased in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells.	Cholecalciferol	68-83	cadherin 2	Mus musculus	0-10
33548476-12	2021	N-cadherin and vimentin, two mesenchymal markers, were decreased in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells.	Cholecalciferol	68-83	vimentin	Mus musculus	15-23
33718825-5	2021	Using genetic and pharmacological inhibition, we show that the induction of mature IL-1beta is through a non-classical pathway dependent upon caspase-1, caspase-8, the NLRP3 inflammasome, potassium efflux, and autophagy while being independent of TRIF (TICAM1), vitamin D3, and pyroptosis.	Cholecalciferol	262-272	interleukin 1 alpha	Homo sapiens	83-91
33877707-10	2021	Compared to the control group, high-dose vitamin D3 supplementation resulted in a decreased trabecular number (regression coefficient B: -0.22; p < 0.01) and lower compression stiffness (B: -3.63; p < 0.05, together with an increase in the bone resorption marker CTX (B: 0.062; p < 0.05).	Cholecalciferol	41-51	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	263-266
33899473-1	2021	Vitamin D3 metabolites inhibit the expression of lipogenic genes by impairing sterol regulatory element-binding protein (SREBP), a master transcription factor of lipogenesis, independent of their canonical activity through a vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	225-243
33899473-1	2021	Vitamin D3 metabolites inhibit the expression of lipogenic genes by impairing sterol regulatory element-binding protein (SREBP), a master transcription factor of lipogenesis, independent of their canonical activity through a vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	245-248
33964955-0	2021	Combined effect of vitamin C and vitamin D3 on intestinal epithelial barrier by regulating Notch signaling pathway.	Cholecalciferol	33-43	notch receptor 1	Homo sapiens	91-96
33964955-3	2021	This study was performed to investigate whether vitamin C combined with vitamin D3 affects intestinal mucosal barrier stability via the Notch signaling pathway.	Cholecalciferol	72-82	notch receptor 1	Homo sapiens	136-141
33964955-11	2021	In SW480 cell experiments, compared with the control group, cell migration and repair following treatment with different concentrations of vitamin C combined with vitamin D3 were significantly improved and the protein expression of Notch-1 was increased, whereas the protein expression of claudin-2 was significantly decreased.	Cholecalciferol	163-173	claudin 2	Homo sapiens	289-298
33964955-12	2021	Thus, our results demonstrate that an appropriate amount of vitamin C combined with vitamin D3 can regulate the expression of claudin-2 by regulating Notch-1, relieve destruction of the intestinal mucosal barrier, and promote the repair of damage to the cell mucosal barrier.	Cholecalciferol	84-94	claudin 2	Homo sapiens	126-135
33964955-12	2021	Thus, our results demonstrate that an appropriate amount of vitamin C combined with vitamin D3 can regulate the expression of claudin-2 by regulating Notch-1, relieve destruction of the intestinal mucosal barrier, and promote the repair of damage to the cell mucosal barrier.	Cholecalciferol	84-94	notch receptor 1	Homo sapiens	150-157
33541129-0	2021	Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice.	Cholecalciferol	10-20	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	105-109
33541129-0	2021	Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice.	Cholecalciferol	10-20	thymoma viral proto-oncogene 1	Mus musculus	110-113
33541129-0	2021	Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice.	Cholecalciferol	10-20	mechanistic target of rapamycin kinase	Mus musculus	114-118
33541129-8	2021	Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice.	Cholecalciferol	13-23	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	66-94
33541129-8	2021	Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice.	Cholecalciferol	13-23	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	96-100
33541129-8	2021	Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice.	Cholecalciferol	13-23	AKT serine/threonine kinase 1	Homo sapiens	116-119
33541129-8	2021	Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice.	Cholecalciferol	13-23	mechanistic target of rapamycin kinase	Homo sapiens	144-173
33541129-8	2021	Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice.	Cholecalciferol	13-23	mechanistic target of rapamycin kinase	Homo sapiens	175-179
33541129-10	2021	The results suggested that vitamin D3 may ameliorate hepatic lipid dysregulation by activating autophagy regulatory AMPK/Akt-mTOR signaling in T2DM, providing insights into its beneficial effects on NAFLD in type 2 diabetic patients.	Cholecalciferol	27-37	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	116-120
33541129-10	2021	The results suggested that vitamin D3 may ameliorate hepatic lipid dysregulation by activating autophagy regulatory AMPK/Akt-mTOR signaling in T2DM, providing insights into its beneficial effects on NAFLD in type 2 diabetic patients.	Cholecalciferol	27-37	AKT serine/threonine kinase 1	Homo sapiens	121-124
33541129-10	2021	The results suggested that vitamin D3 may ameliorate hepatic lipid dysregulation by activating autophagy regulatory AMPK/Akt-mTOR signaling in T2DM, providing insights into its beneficial effects on NAFLD in type 2 diabetic patients.	Cholecalciferol	27-37	mechanistic target of rapamycin kinase	Homo sapiens	125-129
33548476-13	2021	MMP-2 and MMP-9, two matrix metalloproteinases, were downregulated in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells.	Cholecalciferol	70-85	matrix metallopeptidase 2	Mus musculus	0-5
33548476-13	2021	MMP-2 and MMP-9, two matrix metalloproteinases, were downregulated in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells.	Cholecalciferol	70-85	matrix metallopeptidase 9	Mus musculus	10-15
33838712-4	2021	This study aims to investigate the effect of CPS on expression of CYP27A1, CYP27B1 and CYP24A1, the enzymes involved in synthesis and metabolism of vitamin D3, in human keratinocytes HaCaT and human fibroblasts BJ.	Cholecalciferol	148-158	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	66-73
33838712-4	2021	This study aims to investigate the effect of CPS on expression of CYP27A1, CYP27B1 and CYP24A1, the enzymes involved in synthesis and metabolism of vitamin D3, in human keratinocytes HaCaT and human fibroblasts BJ.	Cholecalciferol	148-158	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	75-82
33838712-4	2021	This study aims to investigate the effect of CPS on expression of CYP27A1, CYP27B1 and CYP24A1, the enzymes involved in synthesis and metabolism of vitamin D3, in human keratinocytes HaCaT and human fibroblasts BJ.	Cholecalciferol	148-158	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	87-94
33933463-7	2021	Here we investigated the caspase-9 and 3/7 activity during 1,25-dihydroxycholecalciferol (D3)-mediated differentiation of SH-SY5Y cells and took advantage of the inducible caspase-9 system in putting out the differentiation of the neuroblastoma cells.	Cholecalciferol	90-92	caspase 9	Homo sapiens	25-42
33933463-7	2021	Here we investigated the caspase-9 and 3/7 activity during 1,25-dihydroxycholecalciferol (D3)-mediated differentiation of SH-SY5Y cells and took advantage of the inducible caspase-9 system in putting out the differentiation of the neuroblastoma cells.	Cholecalciferol	90-92	caspase 9	Homo sapiens	25-34
33981701-5	2021	Sirtuin 3 upregulation was detected in high-fat diet-fed mice receiving vitamin D3 compared with that in high-fat diet-fed mice.	Cholecalciferol	72-82	sirtuin 3	Mus musculus	0-9
33878208-8	2021	RESULTS: Treatment with vitamin D3 increased serum 25OHD and upregulated VDR in lung tissues with or without hyperoxia.	Cholecalciferol	24-34	vitamin D receptor	Rattus norvegicus	73-76
33878208-9	2021	In addition, treatment with vitamin D3 attenuated alveolar simplification, increased VEGF and VEGFR2, and protected alveolar simplification induced by hyperoxia.	Cholecalciferol	28-38	vascular endothelial growth factor A	Rattus norvegicus	85-89
33878208-9	2021	In addition, treatment with vitamin D3 attenuated alveolar simplification, increased VEGF and VEGFR2, and protected alveolar simplification induced by hyperoxia.	Cholecalciferol	28-38	kinase insert domain receptor	Rattus norvegicus	94-100
33878208-10	2021	Furthermore, treatment with vitamin D3 resulted in a decrease of IL-1beta and IFN-gamma and an increase of HIF-1alpha in lung tissues under hyperoxia conditions.	Cholecalciferol	28-38	interleukin 1 alpha	Rattus norvegicus	65-73
33878208-10	2021	Furthermore, treatment with vitamin D3 resulted in a decrease of IL-1beta and IFN-gamma and an increase of HIF-1alpha in lung tissues under hyperoxia conditions.	Cholecalciferol	28-38	interferon gamma	Rattus norvegicus	78-87
33878208-10	2021	Furthermore, treatment with vitamin D3 resulted in a decrease of IL-1beta and IFN-gamma and an increase of HIF-1alpha in lung tissues under hyperoxia conditions.	Cholecalciferol	28-38	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	107-117
33848909-8	2021	In addition to the mentioned formulations, the combination of protein with Vitamin D3 also resulted in significantly higher serum IgA and IFN-gamma levels as compared to the fusion protein alone.	Cholecalciferol	75-85	interferon gamma	Mus musculus	138-147
33516786-0	2021	Analysis of vitamin D3 metabolites in survivors of infantile idiopathic hypercalcemia caused by CYP24A1 mutation or SLC34A1 mutation.	Cholecalciferol	12-22	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	96-103
33516786-0	2021	Analysis of vitamin D3 metabolites in survivors of infantile idiopathic hypercalcemia caused by CYP24A1 mutation or SLC34A1 mutation.	Cholecalciferol	12-22	solute carrier family 34 member 1	Homo sapiens	116-123
33749990-7	2021	The changes in duodenal calcium and phosphate absorption in the iron deficient animals were associated with increased claudin 2 and 3 mRNA and protein levels, while levels of parathyroid hormone, fibroblast growth factor-23 and 1,25-dihydroxy vitamin D3 were unchanged.	Cholecalciferol	243-253	fibroblast growth factor 23	Rattus norvegicus	196-229
33618332-0	2021	Cholecalciferol (vitamin D3) has a direct protective activity against interleukin 6-induced atrophy in C2C12 myotubes.	Cholecalciferol	0-15	interleukin 6	Mus musculus	70-83
33753848-1	2021	The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3).	Cholecalciferol	121-131	vitamin D receptor	Homo sapiens	25-43
33753848-1	2021	The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3).	Cholecalciferol	121-131	vitamin D receptor	Homo sapiens	45-48
33618332-0	2021	Cholecalciferol (vitamin D3) has a direct protective activity against interleukin 6-induced atrophy in C2C12 myotubes.	Cholecalciferol	17-27	interleukin 6	Mus musculus	70-83
33572224-8	2021	Moreover, we found that the extent of CNP uptake by hCMEC/D3 was +43% higher in the presence of Abeta.	Cholecalciferol	58-60	amyloid beta precursor protein	Homo sapiens	96-101
32243494-9	2021	In vivo, AAV-mediated overexpression of uromodulin ameliorated vascular calcification in mice with cholecalciferol overload.	Cholecalciferol	99-114	uromodulin	Homo sapiens	40-50
32243494-10	2021	Conversely, cholecalciferol overload-induced vascular calcification was aggravated in uromodulin-deficient mice.	Cholecalciferol	12-27	uromodulin	Mus musculus	86-96
32243494-18	2021	Uromodulin ameliorated vascular calcification in vitro and in mice with cholecalciferol overload, but not during renal failure in mice.	Cholecalciferol	72-87	uromodulin	Homo sapiens	0-10
33565715-6	2021	Changes in eGFR were 1.2 mL/min/1.73 m2 (95% CI; -0.7 to 3.1) in the cholecalciferol group and 1.8 mL/min/1.73 m2 (95% CI; -0.02 to 3.7) in the placebo group, with no significant between-group difference (-0.7 mL/min/1.73 m2 [95% CI; -3.3 to 2.0], P = 0.63).	Cholecalciferol	69-84	epidermal growth factor receptor	Homo sapiens	11-15
33565715-7	2021	Subgroup analyses showed detrimental effects of cholecalciferol in patients with eGFR <45 mL/min/1.73m2 (Pinteraction <0.05, between-group difference; -4.3 mL/min/1.73 m2 [95% CI; -7.3 to -1.3]).	Cholecalciferol	48-63	epidermal growth factor receptor	Homo sapiens	81-85
33594986-9	2021	Cholecalciferol significantly increased serum levels of 25(OH)D and fetuin-A in the treatment group (p-value < 0.001), while no significant difference was observed in the placebo group.	Cholecalciferol	0-15	alpha 2-HS glycoprotein	Homo sapiens	68-76
33594986-12	2021	CONCLUSION: Cholecalciferol was shown to be an effective, tolerable, inexpensive pharmacotherapeutic option to overcome vitamin D deficiency, with a possible modulating effect on fetuin-A, among hemodialysis patients.	Cholecalciferol	12-27	alpha 2-HS glycoprotein	Homo sapiens	179-187
33191899-5	2021	Increased FGF23 secretion leads to hypophosphatemia by (1) reduced phosphate reabsorption via activation of the proximal renal tubular epithelial cells to internalize sodium phosphate cotransporters and (2) reduced activation of vitamin D3 via inhibition of the renal enzyme 1-alpha hydroxylase.	Cholecalciferol	229-239	fibroblast growth factor 23	Homo sapiens	10-15
33443066-0	2021	Vitamin D3-Induced Promotor Dissociation of PU.1 and YY1 Results in FcepsilonRI Reduction on Dendritic Cells in Atopic Dermatitis.	Cholecalciferol	0-10	YY1 transcription factor	Homo sapiens	53-56
30905309-9	2021	Functional DAF-16 proved to be crucial for the effects of cholecalciferol and DAF-16 nuclear translocation was increased by cholecalciferol and also RNAi versus nhr-8, daf-36, daf-9 or daf-12 with no additive or synergistic effects.	Cholecalciferol	58-73	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	11-17
30905309-9	2021	Functional DAF-16 proved to be crucial for the effects of cholecalciferol and DAF-16 nuclear translocation was increased by cholecalciferol and also RNAi versus nhr-8, daf-36, daf-9 or daf-12 with no additive or synergistic effects.	Cholecalciferol	124-139	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	11-17
30905309-9	2021	Functional DAF-16 proved to be crucial for the effects of cholecalciferol and DAF-16 nuclear translocation was increased by cholecalciferol and also RNAi versus nhr-8, daf-36, daf-9 or daf-12 with no additive or synergistic effects.	Cholecalciferol	124-139	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	78-84
30905309-10	2021	CONCLUSIONS: Our results suggest, that cholecalciferol inhibits Abeta-induced paralysis in C. elegans through inhibition of steroid-signaling and the concomitant nuclear translocation of DAF-16.	Cholecalciferol	39-54	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	187-193
33552054-0	2020	Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness.	Cholecalciferol	0-10	CD4 molecule	Homo sapiens	88-91
33107570-1	2021	Previous studies showed that non-calcemic 20(OH)D3, a product of CYP11A1 action on vitamin D3, has antifibrotic activity in human dermal fibroblasts and in a bleomycin mouse model of scleroderma.	Cholecalciferol	83-93	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	65-72
33540416-0	2021	Vitamin D3 Controls TLR4- and TLR2-Mediated Inflammatory Responses of Endometrial Cells.	Cholecalciferol	0-10	toll like receptor 4	Homo sapiens	20-24
33540416-0	2021	Vitamin D3 Controls TLR4- and TLR2-Mediated Inflammatory Responses of Endometrial Cells.	Cholecalciferol	0-10	toll like receptor 2	Homo sapiens	30-34
33162070-1	2021	Objectives of the experiment were to determine the length of exposure to an acidogenic diet that would elicit changes in acid-base balance, mineral digestion, and response to parathyroid hormone (PTH)-induced changes in blood Ca and vitamin D3 in prepartum dairy cows.	Cholecalciferol	233-243	parathyroid hormone	Bos taurus	175-194
33162070-1	2021	Objectives of the experiment were to determine the length of exposure to an acidogenic diet that would elicit changes in acid-base balance, mineral digestion, and response to parathyroid hormone (PTH)-induced changes in blood Ca and vitamin D3 in prepartum dairy cows.	Cholecalciferol	233-243	parathyroid hormone	Bos taurus	196-199
32474936-8	2021	RESULTS: The vitamin D3 -induced increase of osteocalcin and osteopontin expression was significantly decreased in the presence of standard PgLPS and Pam3CSK4, which was not observed by ultrapure PgLPS.	Cholecalciferol	13-23	bone gamma-carboxyglutamate protein	Homo sapiens	45-56
32474936-8	2021	RESULTS: The vitamin D3 -induced increase of osteocalcin and osteopontin expression was significantly decreased in the presence of standard PgLPS and Pam3CSK4, which was not observed by ultrapure PgLPS.	Cholecalciferol	13-23	secreted phosphoprotein 1	Homo sapiens	61-72
32474936-11	2021	Standard PgLPS and Pam3CSK4 increased VDR expression in the presence of vitamin D3 .	Cholecalciferol	72-82	vitamin D receptor	Homo sapiens	38-41
32474936-13	2021	CONCLUSIONS: This study indicates that the transcriptional activity of VDR is diminished under inflammatory conditions, which might mitigate the effectiveness of vitamin D3 supplementation during periodontal treatment.	Cholecalciferol	162-172	vitamin D receptor	Homo sapiens	71-74
33626316-4	2021	Overall, CYP2R1 structure adopts a closed conformation with the B" helix serving as a gate covering the substrate access channel, with the substrate vitamin D3 occupying a position with the side chain pointing toward the heme group.	Cholecalciferol	149-159	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	9-15
33368331-0	2021	Vitamin D3-elicited CD14+ human skin dendritic cells promote thymic stromal lymphopoietin-independent type 2 T-helper responses.	Cholecalciferol	0-10	CD14 molecule	Homo sapiens	20-24
33368331-0	2021	Vitamin D3-elicited CD14+ human skin dendritic cells promote thymic stromal lymphopoietin-independent type 2 T-helper responses.	Cholecalciferol	0-10	thymic stromal lymphopoietin	Mus musculus	61-89
33368331-8	2021	RESULTS: Vitamin D3 induced skin DCs to differentiate Th2 cells producing IL-4 and IL-13.	Cholecalciferol	9-19	interleukin 4	Homo sapiens	74-78
33368331-8	2021	RESULTS: Vitamin D3 induced skin DCs to differentiate Th2 cells producing IL-4 and IL-13.	Cholecalciferol	9-19	interleukin 13	Homo sapiens	83-88
33368331-9	2021	Vitamin D3 triggered TSLP release in ~30% of skin explants, correlating with IL-13 detection in Th2 cells.	Cholecalciferol	0-10	thymic stromal lymphopoietin	Homo sapiens	21-25
33368331-9	2021	Vitamin D3 triggered TSLP release in ~30% of skin explants, correlating with IL-13 detection in Th2 cells.	Cholecalciferol	0-10	interleukin 13	Homo sapiens	77-82
33368331-11	2021	Among skin DCs emerged CD14+ cells that had responded directly to vitamin D3 and differed from classical CD14+ dermal emigrants.	Cholecalciferol	66-76	CD14 molecule	Homo sapiens	23-27
33368331-12	2021	Vitamin D3-elicited CD14+ DCs sufficed to promote IL-4+ Th2 cells in a TSLP-independent manner.	Cholecalciferol	0-10	CD14 molecule	Homo sapiens	20-24
33368331-12	2021	Vitamin D3-elicited CD14+ DCs sufficed to promote IL-4+ Th2 cells in a TSLP-independent manner.	Cholecalciferol	0-10	interleukin 4	Homo sapiens	50-54
33368331-12	2021	Vitamin D3-elicited CD14+ DCs sufficed to promote IL-4+ Th2 cells in a TSLP-independent manner.	Cholecalciferol	0-10	thymic stromal lymphopoietin	Homo sapiens	71-75
33368331-13	2021	CONCLUSION: Vitamin D3, despite inducing TSLP in some donors, had a direct influence on skin DCs, affecting their phenotype and ability to drive Th2 responses independently of TSLP.	Cholecalciferol	12-22	thymic stromal lymphopoietin	Homo sapiens	41-45
33457118-0	2020	Effect of Vitamin D3 Supplementation on Insulin Sensitivity in Prediabetes With Hypovitaminosis D: A Randomized Placebo-Controlled Trial.	Cholecalciferol	10-20	insulin	Homo sapiens	40-47
33288743-1	2020	The bioactive vitamin D3, 1alpha,25(OH)2D3, plays a central role in calcium homeostasis by controlling the activity of the vitamin D receptor (VDR) in various tissues.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	123-141
33288743-1	2020	The bioactive vitamin D3, 1alpha,25(OH)2D3, plays a central role in calcium homeostasis by controlling the activity of the vitamin D receptor (VDR) in various tissues.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	143-146
33262439-3	2020	We investigated the effects of vitamin D3 (Vit D) and erythropoietin (EPO) on microRNA-21(miR-21) expression in renal IR.	Cholecalciferol	31-41	microRNA 21	Rattus norvegicus	78-89
33262439-9	2020	Treatment with vitamin D3 and EPO significantly decreased the BUN-Cr levels and hsp70 and caspase-3 expression.	Cholecalciferol	15-25	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	80-85
33262439-9	2020	Treatment with vitamin D3 and EPO significantly decreased the BUN-Cr levels and hsp70 and caspase-3 expression.	Cholecalciferol	15-25	caspase 3	Rattus norvegicus	90-99
33246442-5	2020	It has also been reported that vitamin D3 treatment enhances dysferlin expression.	Cholecalciferol	31-41	dysferlin	Mus musculus	61-70
33198232-1	2020	Background and objective: The aim of the present study was to establish a new differentiation protocol using cannabidiol (CBD) and vitamin D3 (Vit.	Cholecalciferol	131-141	vitrin	Homo sapiens	143-146
33184146-14	2022	Fibrinogen levels significantly decreased with cholecalciferol supplementation (intergroup difference 0.70 ng/ml; P=0.007) unlike other inflammatory biomarkers.	Cholecalciferol	47-62	fibrinogen beta chain	Homo sapiens	0-10
33184146-15	2022	CONCLUSION: Greater proportion of vitamin D-deficient individuals with SARS-CoV-2 infection turned SARS-CoV-2 RNA negative with a significant decrease in fibrinogen on high-dose cholecalciferol supplementation.	Cholecalciferol	178-193	fibrinogen beta chain	Homo sapiens	154-164
33305262-11	2020	In contrast, altered transcription of genes from cholinergic, monoaminergic, and peptidergic neurotransmission, steroid sulfation and production as well as vitamin D3 activation was the main CYP46A1-independent efavirenz effect.	Cholecalciferol	156-166	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	191-198
33108744-0	2021	Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: Role of AMPK/SIRT1 activation and DPP-4 inhibition.	Cholecalciferol	0-10	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	111-115
33108744-0	2021	Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: Role of AMPK/SIRT1 activation and DPP-4 inhibition.	Cholecalciferol	0-10	sirtuin 1	Rattus norvegicus	116-121
33107041-9	2021	RESULTS: Vitamin D3 significantly enhanced the generation of hCAP-18/LL-37.	Cholecalciferol	9-19	cathelicidin antimicrobial peptide	Homo sapiens	61-68
33107041-9	2021	RESULTS: Vitamin D3 significantly enhanced the generation of hCAP-18/LL-37.	Cholecalciferol	9-19	cathelicidin antimicrobial peptide	Homo sapiens	69-74
33107041-10	2021	A combination of Pg-LPS and vitamin D3 significantly promoted hCAP-18/LL-37 expression.	Cholecalciferol	28-38	cathelicidin antimicrobial peptide	Homo sapiens	62-69
33107041-10	2021	A combination of Pg-LPS and vitamin D3 significantly promoted hCAP-18/LL-37 expression.	Cholecalciferol	28-38	cathelicidin antimicrobial peptide	Homo sapiens	70-75
33107041-13	2021	CONCLUSION: The vitamin D pathway from vitamin D3 to hCAP-18/LL-37 exists in hPDLCs, and CYP27A1 might be involved in periodontal immune defense.	Cholecalciferol	39-49	cathelicidin antimicrobial peptide	Homo sapiens	53-60
33107041-13	2021	CONCLUSION: The vitamin D pathway from vitamin D3 to hCAP-18/LL-37 exists in hPDLCs, and CYP27A1 might be involved in periodontal immune defense.	Cholecalciferol	39-49	cathelicidin antimicrobial peptide	Homo sapiens	61-66
32564464-0	2020	Intestinal epithelial ablation of Pit-2/Slc20a2 in mice leads to sustained elevation of vitamin D3 upon dietary restriction of phosphate.	Cholecalciferol	88-98	solute carrier family 20, member 2	Mus musculus	34-39
32564464-0	2020	Intestinal epithelial ablation of Pit-2/Slc20a2 in mice leads to sustained elevation of vitamin D3 upon dietary restriction of phosphate.	Cholecalciferol	88-98	solute carrier family 20, member 2	Mus musculus	40-47
32564464-11	2020	However, in response to dietary phosphate restriction, Pit-2 deficient mice showed exacerbated hypercalciuria and sustained elevation of 1,25(OH)2 vitamin D3 .	Cholecalciferol	147-157	solute carrier family 20, member 2	Mus musculus	55-60
32784046-4	2020	Cyp27b1+/- mice were generated to develop a model of active vitamin D3 deficiency.	Cholecalciferol	60-70	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	0-7
32593863-7	2020	The concentrations of pro-inflammatory cytokines (i.e., IL-1beta, IL-6, and TNF-alpha) and the chemokine (IL-8) showed a significant decrease in the treatment group while the concentration of IL-10 increased in the treatment groups following the vitamin D3 injection (P = .001).	Cholecalciferol	246-256	interleukin-10	Bos taurus	192-197
32593863-8	2020	The evidence from the current study suggests that vitamin D3 exert the immunomodulatory effects in infectious diseases through the regulation of cytokines and activation of VDR pathways to produce antimicrobial peptides.	Cholecalciferol	50-60	vitamin D receptor	Bos taurus	173-176
32468622-7	2020	Instrumental limits of detection are 30 ng L-1 for testosterone using ESI and 1 mug L-1 for vitamin D3 using APCI.	Cholecalciferol	92-102	L1 cell adhesion molecule	Homo sapiens	84-87
32768933-0	2020	Ziziphora clinopodioides flavonoids based on network pharmacology attenuates atherosclerosis in rats induced by high-fat emulsion combined with vitamin D3 by down-regulating VEGF/AKT/NF-kappaB signaling pathway.	Cholecalciferol	144-154	vascular endothelial growth factor A	Rattus norvegicus	174-178
32768933-0	2020	Ziziphora clinopodioides flavonoids based on network pharmacology attenuates atherosclerosis in rats induced by high-fat emulsion combined with vitamin D3 by down-regulating VEGF/AKT/NF-kappaB signaling pathway.	Cholecalciferol	144-154	AKT serine/threonine kinase 1	Rattus norvegicus	179-182
32740169-3	2020	Linear regression was used to analyze whether the effect of vitamin D3 supplementation on response variables was associated with the selected VDR single nucleotide polymorphisms executing by "association" function in the R package "SNPassoc".	Cholecalciferol	60-70	vitamin D receptor	Homo sapiens	142-145
32936063-1	2020	Background: Significant inverse correlations between circulating vitamin D3 and the presence and strength of common clinical entities influenced by insulin resistance (IR) have been reported.	Cholecalciferol	65-75	insulin	Homo sapiens	148-155
32585162-0	2020	Cholecalciferol abolishes depressive-like behavior and hippocampal glucocorticoid receptor impairment induced by chronic corticosterone administration in mice.	Cholecalciferol	0-15	nuclear receptor subfamily 3, group C, member 1	Mus musculus	67-90
32585162-10	2020	Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice.	Cholecalciferol	14-29	NLR family, pyrin domain containing 3	Mus musculus	76-81
32585162-10	2020	Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice.	Cholecalciferol	14-29	steroid sulfatase	Mus musculus	112-115
32585162-10	2020	Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice.	Cholecalciferol	14-29	caspase 1	Mus musculus	117-126
32585162-10	2020	Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice.	Cholecalciferol	14-29	thioredoxin interacting protein	Mus musculus	132-137
32831908-0	2020	Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial.	Cholecalciferol	40-42	bone gamma-carboxyglutamate protein	Homo sapiens	71-82
32831908-0	2020	Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial.	Cholecalciferol	40-42	insulin	Homo sapiens	87-94
32831908-2	2020	The objective of this study was to evaluate the effect of vitamin D3 and vitamin K2 supplements alone or in combination on osteocalcin levels and metabolic parameters in patients with T2DM.	Cholecalciferol	58-68	bone gamma-carboxyglutamate protein	Homo sapiens	123-134
32831908-10	2020	Only in the group with vitamin D3 supplementation, it was observed a reduction in undercarboxylated osteocalcin while vitamin K2 increased the carboxylated osteocalcin levels.Trial registration NCT04041492.	Cholecalciferol	23-33	bone gamma-carboxyglutamate protein	Homo sapiens	100-111
32831908-10	2020	Only in the group with vitamin D3 supplementation, it was observed a reduction in undercarboxylated osteocalcin while vitamin K2 increased the carboxylated osteocalcin levels.Trial registration NCT04041492.	Cholecalciferol	23-33	bone gamma-carboxyglutamate protein	Homo sapiens	156-167
32742408-0	2020	Vitamin D3 protects articular cartilage by inhibiting the Wnt/beta-catenin signaling pathway.	Cholecalciferol	0-10	Wnt family member 3A	Homo sapiens	58-61
32742408-0	2020	Vitamin D3 protects articular cartilage by inhibiting the Wnt/beta-catenin signaling pathway.	Cholecalciferol	0-10	catenin beta 1	Homo sapiens	62-74
32742408-7	2020	Furthermore, vitamin D3 and PNU-74654 were observed to partially attenuate the effects induced by TNF-alpha.	Cholecalciferol	13-23	tumor necrosis factor	Homo sapiens	98-107
32742408-9	2020	Western blotting data revealed that TNF-alpha increased Wnt-3a and beta-catenin protein levels in chondrocytes, while Vitamin D3 and PNU-74654 decreased the expression levels of Wnt-3a and nuclear beta-catenin.	Cholecalciferol	118-128	Wnt family member 3A	Homo sapiens	178-184
32742408-9	2020	Western blotting data revealed that TNF-alpha increased Wnt-3a and beta-catenin protein levels in chondrocytes, while Vitamin D3 and PNU-74654 decreased the expression levels of Wnt-3a and nuclear beta-catenin.	Cholecalciferol	118-128	catenin beta 1	Homo sapiens	197-209
32742408-10	2020	In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway.	Cholecalciferol	83-93	matrix metallopeptidase 3	Homo sapiens	217-222
32583974-9	2020	CONCLUSION: In conclusion, SR-B1 plays a critical role in vitamin D3 biology, paving the way for novel therapeutic interventions.	Cholecalciferol	58-68	scavenger receptor class B member 1	Homo sapiens	27-32
33709028-12	2021	Pathway enrichment analysis showed that the DEGs were significantly enriched in the retinoate biosynthesis II, signaling pathways regulating pluripotency of stem cells, ALK2 signaling events, vitamin D3 biosynthesis, cell cycle and aurora B signaling.	Cholecalciferol	192-202	delta 4-desaturase, sphingolipid 1	Homo sapiens	44-48
33709028-12	2021	Pathway enrichment analysis showed that the DEGs were significantly enriched in the retinoate biosynthesis II, signaling pathways regulating pluripotency of stem cells, ALK2 signaling events, vitamin D3 biosynthesis, cell cycle and aurora B signaling.	Cholecalciferol	192-202	aurora kinase B	Homo sapiens	232-240
33634989-0	2021	Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway.	Cholecalciferol	0-10	NLR family, pyrin domain containing 3	Mus musculus	91-96
33634989-0	2021	Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway.	Cholecalciferol	0-10	sirtuin 3	Mus musculus	122-127
33634989-0	2021	Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway.	Cholecalciferol	0-10	superoxide dismutase 2, mitochondrial	Mus musculus	128-132
33597896-11	2021	The evidence of vitamin D3 metabolite retention was assessed by measuring CYP24A1 expression.	Cholecalciferol	16-26	cytochrome P450 family 24 subfamily A member 1	Gallus gallus	74-81
33200827-4	2021	However, it is remains unknown whether NaPi-IIb is the only target for hormonal regulation by 1,25(OH)2 vitamin D3 .	Cholecalciferol	104-114	solute carrier family 34 (sodium phosphate), member 2	Mus musculus	39-47
33200827-8	2021	In both groups, 1,25(OH)2 vitamin D3 elicited the expected increase of plasma FGF23 and reduction of PTH.	Cholecalciferol	26-36	fibroblast growth factor 23	Mus musculus	78-83
33200827-8	2021	In both groups, 1,25(OH)2 vitamin D3 elicited the expected increase of plasma FGF23 and reduction of PTH.	Cholecalciferol	26-36	parathyroid hormone	Mus musculus	101-104
33200827-16	2021	In both genotypes, 1,25(OH)2 vitamin D3 induced similar hyperphosphaturic responses and changes in FGF23 and PTH.	Cholecalciferol	29-39	fibroblast growth factor 23	Mus musculus	99-104
33200827-16	2021	In both genotypes, 1,25(OH)2 vitamin D3 induced similar hyperphosphaturic responses and changes in FGF23 and PTH.	Cholecalciferol	29-39	parathyroid hormone	Mus musculus	109-112
32844292-10	2021	CONCLUSION: Alfacalcidol and native vitamin D3 were equally effective in decreasing PTH levels and increasing serum 25(OH)D3 in pre-dialysis CKD patients.	Cholecalciferol	36-46	parathyroid hormone	Homo sapiens	84-87
33721248-6	2021	Median of photoconversion to vitamin D3 through the year was higher in LAT3 S [median (IQR): LAT 3 S 4.1% (6.0); LAT 23 S 2.9% (4.5); p value = 0.020].	Cholecalciferol	29-39	solute carrier family 43 member 1	Homo sapiens	71-75
33721248-7	2021	Vitamin D3 production strongly correlated with UV-B (LAT3  S, r = 0.917; p < 0.0001 and at LAT23  S, r = 0.879; p < 0.0001) and SZA (LAT3  S, r = - 0.924; p < 0.0001 and in LAT23 S, r = - 0.808; p < 0.0001).	Cholecalciferol	0-10	solute carrier family 43 member 1	Homo sapiens	53-57
33721248-7	2021	Vitamin D3 production strongly correlated with UV-B (LAT3  S, r = 0.917; p < 0.0001 and at LAT23  S, r = 0.879; p < 0.0001) and SZA (LAT3  S, r = - 0.924; p < 0.0001 and in LAT23 S, r = - 0.808; p < 0.0001).	Cholecalciferol	0-10	solute carrier family 43 member 1	Homo sapiens	133-137
33188595-9	2021	In fully adjusted models, each 1% higher VDBP was associated with a 0.92%[95% CI(0.37,1.49%)], 0.76% (0.39, 1.13%), and 0.57% (0.29, 0.85%), higher 24,25(OH)2D3, 25(OH)D3, and 1,25(OH)2D3.	Cholecalciferol	158-160	GC vitamin D binding protein	Homo sapiens	41-45
32475360-7	2021	In conclusion, vitamin D3 intervention with a treatment dose of 50,000 IU per week for at least 2 months may help in lowering homocysteine and CRP levels and may improve liver function tests, which in turn might help in minimizing the risk of CVD and liver diseases among overweight women but negatively affect kidney function.	Cholecalciferol	15-25	C-reactive protein	Homo sapiens	143-146
32195696-0	2021	CCL20 mediates the anti-tumor effect of vitamin D3 in p38MAPK/NF-kappaB signaling in colitis-associated carcinogenesis.	Cholecalciferol	40-50	chemokine (C-C motif) ligand 20	Mus musculus	0-5
32195696-0	2021	CCL20 mediates the anti-tumor effect of vitamin D3 in p38MAPK/NF-kappaB signaling in colitis-associated carcinogenesis.	Cholecalciferol	40-50	mitogen-activated protein kinase 14	Mus musculus	54-61
32195696-3	2021	Here we aim to evaluate whether vitamin D3 plays a protective role in colitis-associated colorectal cancer (CAC) by affecting CCL20 and the molecular mechanism.	Cholecalciferol	32-42	chemokine (C-C motif) ligand 20	Mus musculus	126-131
32195696-7	2021	In-vivo and -vitro, vitamin D3 reduced the levels of CCL20, phospho-p38 MAPK (p-p38) and phospho-NF-kappaB p65 (p-p65), and the transcriptional activity of NF-kappaB.	Cholecalciferol	20-30	chemokine (C-C motif) ligand 20	Mus musculus	53-58
32195696-7	2021	In-vivo and -vitro, vitamin D3 reduced the levels of CCL20, phospho-p38 MAPK (p-p38) and phospho-NF-kappaB p65 (p-p65), and the transcriptional activity of NF-kappaB.	Cholecalciferol	20-30	lymphocyte cytosolic protein 1	Mus musculus	89-110
32195696-7	2021	In-vivo and -vitro, vitamin D3 reduced the levels of CCL20, phospho-p38 MAPK (p-p38) and phospho-NF-kappaB p65 (p-p65), and the transcriptional activity of NF-kappaB.	Cholecalciferol	20-30	lymphocyte cytosolic protein 1	Mus musculus	112-117
32195696-8	2021	Further studies showed that CCL20 mediated the inhibition of vitamin D3 in p38MAPK-mediated NF-kappaB signaling in vitro.	Cholecalciferol	61-71	chemokine (C-C motif) ligand 20	Mus musculus	28-33
32195696-8	2021	Further studies showed that CCL20 mediated the inhibition of vitamin D3 in p38MAPK-mediated NF-kappaB signaling in vitro.	Cholecalciferol	61-71	mitogen-activated protein kinase 14	Mus musculus	75-82
32195696-10	2021	Downregulation of CCL20 may contribute to the preventive effect of vitamin D3 on NF-kappaB activity.	Cholecalciferol	67-77	chemokine (C-C motif) ligand 20	Mus musculus	18-23
33210462-6	2021	Compared with wild-type mice, miR155-/- mice showed significant resistance to vitamin D3 induced vascular calcification.	Cholecalciferol	78-88	microRNA 155	Mus musculus	30-36
33210462-7	2021	Protein analysis showed that miR155 deficiency alleviated the reduction of Rictor, increased phosphorylation of Akt at S473 and accelerated phosphorylation and degradation of FOXO3a in cultured VSMCs and in the aortas of vitamin D3-treated mice.	Cholecalciferol	221-231	microRNA 155	Mus musculus	29-35
33210462-7	2021	Protein analysis showed that miR155 deficiency alleviated the reduction of Rictor, increased phosphorylation of Akt at S473 and accelerated phosphorylation and degradation of FOXO3a in cultured VSMCs and in the aortas of vitamin D3-treated mice.	Cholecalciferol	221-231	forkhead box O3	Mus musculus	175-181
32965596-14	2021	Low serum vitamin D3 level negatively associated with increased IL-9 and TLR2 expression and disease severity in RA patients.	Cholecalciferol	10-20	interleukin 9	Homo sapiens	64-68
32965596-14	2021	Low serum vitamin D3 level negatively associated with increased IL-9 and TLR2 expression and disease severity in RA patients.	Cholecalciferol	10-20	toll like receptor 2	Homo sapiens	73-77
32906066-7	2021	Moreover, both MUB and UB exhibited improved encapsulation functionality to protect cholecalciferol (vitamin D3) from UV degradation compared to the original pectin.	Cholecalciferol	84-99	ubiquitin like 3	Homo sapiens	15-18
32906066-7	2021	Moreover, both MUB and UB exhibited improved encapsulation functionality to protect cholecalciferol (vitamin D3) from UV degradation compared to the original pectin.	Cholecalciferol	101-111	ubiquitin like 3	Homo sapiens	15-18
33069738-9	2020	Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA.	Cholecalciferol	29-39	insulin-like growth factor 1	Mus musculus	114-137
33069738-9	2020	Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA.	Cholecalciferol	29-39	insulin-like growth factor 1	Mus musculus	139-144
33069738-9	2020	Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA.	Cholecalciferol	53-63	insulin-like growth factor 1	Mus musculus	114-137
33069738-9	2020	Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA.	Cholecalciferol	53-63	insulin-like growth factor 1	Mus musculus	139-144
33341312-0	2021	A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease.	Cholecalciferol	67-82	insulin	Homo sapiens	109-116
32829183-1	2020	Vitamin D3 is the precursor of the steroid hormone calcitriol (1alpha,25-dihydroxyvitamin D3), a potent agonist of the transcription factor vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	140-158
32829183-1	2020	Vitamin D3 is the precursor of the steroid hormone calcitriol (1alpha,25-dihydroxyvitamin D3), a potent agonist of the transcription factor vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	160-163
33262439-0	2020	Vitamin D3 and erythropoietin protect against renal ischemia-reperfusion injury via heat shock protein 70 and microRNA-21 expression.	Cholecalciferol	0-10	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	84-105
33262439-0	2020	Vitamin D3 and erythropoietin protect against renal ischemia-reperfusion injury via heat shock protein 70 and microRNA-21 expression.	Cholecalciferol	0-10	microRNA 21	Rattus norvegicus	110-121
33238436-1	2020	The compound 1alpha,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is the active form of vitamin D3 and a representative ligand of the vitamin D receptor (VDR).	Cholecalciferol	32-42	vitamin D receptor	Rattus norvegicus	125-143
33238436-1	2020	The compound 1alpha,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is the active form of vitamin D3 and a representative ligand of the vitamin D receptor (VDR).	Cholecalciferol	32-42	vitamin D receptor	Rattus norvegicus	145-148
33147594-1	2021	INTRODUCTION: This study was conducted to evaluate the effect of short-term sunlight exposure on blood pressure (BP) and pulse rate (PR) in vitamin D3-insufficient, prehypertensive patients.	Cholecalciferol	140-150	transmembrane protein 37	Homo sapiens	133-135
32883565-0	2020	Immunomodulatory effects of vitamin D3 on gene expression of MDGF, EGF and PDGFB in endometriosis.	Cholecalciferol	28-38	pro-platelet basic protein	Homo sapiens	61-65
32883565-0	2020	Immunomodulatory effects of vitamin D3 on gene expression of MDGF, EGF and PDGFB in endometriosis.	Cholecalciferol	28-38	epidermal growth factor	Homo sapiens	67-70
32883565-0	2020	Immunomodulatory effects of vitamin D3 on gene expression of MDGF, EGF and PDGFB in endometriosis.	Cholecalciferol	28-38	platelet derived growth factor subunit B	Homo sapiens	75-80
32883565-2	2020	Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis.	Cholecalciferol	47-57	platelet derived growth factor subunit B	Homo sapiens	188-220
32883565-2	2020	Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis.	Cholecalciferol	47-57	platelet derived growth factor subunit B	Homo sapiens	222-227
32883565-2	2020	Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis.	Cholecalciferol	47-57	pro-platelet basic protein	Homo sapiens	230-271
32883565-2	2020	Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis.	Cholecalciferol	47-57	pro-platelet basic protein	Homo sapiens	273-277
32883565-2	2020	Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis.	Cholecalciferol	47-57	pro-platelet basic protein	Homo sapiens	293-297
32883565-2	2020	Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis.	Cholecalciferol	47-57	epidermal growth factor	Homo sapiens	303-326
32883565-2	2020	Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis.	Cholecalciferol	47-57	epidermal growth factor	Homo sapiens	328-331
32883565-6	2020	Vitamin D3 significantly decreased EGF expression at 6, 24 and 48 h (P < 0.001, P < 0.001 and P = 0.007, respectively), MDGF at 24 and 48 h (P < 0.001 and P = 0.009, respectively) and PDGFB at 6 h (P = 0.047) in the endometriosis group.	Cholecalciferol	0-10	epidermal growth factor	Homo sapiens	35-38
32883565-6	2020	Vitamin D3 significantly decreased EGF expression at 6, 24 and 48 h (P < 0.001, P < 0.001 and P = 0.007, respectively), MDGF at 24 and 48 h (P < 0.001 and P = 0.009, respectively) and PDGFB at 6 h (P = 0.047) in the endometriosis group.	Cholecalciferol	0-10	pro-platelet basic protein	Homo sapiens	120-124
32883565-6	2020	Vitamin D3 significantly decreased EGF expression at 6, 24 and 48 h (P < 0.001, P < 0.001 and P = 0.007, respectively), MDGF at 24 and 48 h (P < 0.001 and P = 0.009, respectively) and PDGFB at 6 h (P = 0.047) in the endometriosis group.	Cholecalciferol	0-10	platelet derived growth factor subunit B	Homo sapiens	184-189
33126474-6	2020	We demonstrated that 1alpha,25(OH)2 vitamin D3 acts via vitamin D receptor in GL15 cells and via neutral sphingomyelinase1, with an enrichment of ceramide pool, in U251 and LN18 cells.	Cholecalciferol	36-46	vitamin D receptor	Homo sapiens	56-74
33194806-0	2020	Vitamin D3 Inhibits Helicobacter pylori Infection by Activating the VitD3/VDR-CAMP Pathway in Mice.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	74-77
33009959-7	2020	Oral over-the-counter (OTC) vitamin D3 and calcium citrate were prescribed to increase subjects" serum 25(OH)D to levels between 40 and 50 ng/ml, serum calcium levels above 9.2 mg/dl, and PTH levels below 60 pg/ml, which were confirmed at 6 and 12 weeks.	Cholecalciferol	28-38	parathyroid hormone	Homo sapiens	188-191
31971486-3	2020	We found that the major enzyme responsible for 1,25-Vitamin D3 synthesis, the 1-hydoxylase CYP27B1 (3,6-fold for OVA IP and 2,7-fold for OVA IP + EC), the vitamin D receptor (not altered) and the sensitive Vitamin D-mediated signalling target gene CYP24A1 (65-fold in OVA IP and 726-fold in OVA IP + EC) are upregulated after systemic and systemic plus topical allergic sensitization (OVA IP + EC).	Cholecalciferol	47-62	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	91-98
31971486-3	2020	We found that the major enzyme responsible for 1,25-Vitamin D3 synthesis, the 1-hydoxylase CYP27B1 (3,6-fold for OVA IP and 2,7-fold for OVA IP + EC), the vitamin D receptor (not altered) and the sensitive Vitamin D-mediated signalling target gene CYP24A1 (65-fold in OVA IP and 726-fold in OVA IP + EC) are upregulated after systemic and systemic plus topical allergic sensitization (OVA IP + EC).	Cholecalciferol	47-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	155-173
33585324-8	2020	However, serum PTH was high with slightly decreased Vitamin D3.	Cholecalciferol	52-62	parathyroid hormone	Homo sapiens	15-18
32936248-2	2020	The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model.	Cholecalciferol	124-139	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	195-209
32936248-2	2020	The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model.	Cholecalciferol	124-139	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	211-216
32936248-2	2020	The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model.	Cholecalciferol	141-144	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	195-209
32936248-2	2020	The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model.	Cholecalciferol	141-144	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	211-216
32968158-0	2020	Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial.	Cholecalciferol	10-25	hepcidin antimicrobial peptide	Homo sapiens	35-43
32968158-1	2020	In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients.	Cholecalciferol	96-111	hepcidin antimicrobial peptide	Homo sapiens	137-145
32968158-5	2020	After adjustment for baseline values, serum hepcidin levels were higher at Day 3 in the combined cholecalciferol (vs. placebo) group, but were lower at Month 6 with increased erythropoietin resistance.	Cholecalciferol	97-112	hepcidin antimicrobial peptide	Homo sapiens	44-52
32968158-7	2020	Cholecalciferol also suppressed intact PTH only among patients with severe vitamin D deficiency.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	39-42
32968158-8	2020	In conclusion, cholecalciferol supplementation increases serum hepcidin-25 levels in the short term and may increase erythropoietin resistance in the long term among haemodialysis patients.	Cholecalciferol	15-30	erythropoietin	Homo sapiens	117-131
32622071-12	2020	In conclusion, twelve months supplementation of vitamin D3 increased serum DLK1.	Cholecalciferol	48-58	delta like non-canonical Notch ligand 1	Homo sapiens	75-79
33066859-8	2020	CONCLUSION: The intake of vitamin D3 did not change the quality and quantity of spermograms and serum levels of LH, FSH, TT, and FAI but affected FT and SHBG.	Cholecalciferol	26-36	sex hormone binding globulin	Homo sapiens	153-157
32344004-1	2020	Mutations in CYP2R1 and CYP27A1 involved in the conversion of Cholecalciferol into Calcidiol were associated with the impaired 25-hydroxylase activity therefore affecting the Vitamin D metabolism.	Cholecalciferol	62-77	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	13-19
32344004-1	2020	Mutations in CYP2R1 and CYP27A1 involved in the conversion of Cholecalciferol into Calcidiol were associated with the impaired 25-hydroxylase activity therefore affecting the Vitamin D metabolism.	Cholecalciferol	62-77	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	24-31
32048305-4	2020	Vitamin D3 applies its effect via the mitogen-activated pathway kinase-extracellular signal-regulated kinases (MAPK-ERK1/2) pathway.	Cholecalciferol	0-10	mitogen-activated protein kinase 3	Mus musculus	116-122
33000618-0	2020	Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes.	Cholecalciferol	0-10	insulin	Homo sapiens	53-60
33000618-1	2020	BACKGROUND: Vitamin D3 (vit.	Cholecalciferol	12-22	vitrin	Homo sapiens	24-27
32702412-5	2020	RESULTS: Hdac9 expression was significantly down-regulated during high phosphate-induced vascular smooth muscle cell (VSMC) calcification and MAC in mice administered with vitamin D3 (vD).	Cholecalciferol	172-182	histone deacetylase 9	Mus musculus	9-14
32878208-2	2020	To investigate the role of mast cells (MCs) and MC-specific proteases on the immunopathogenesis of AD, a vitamin D3-analog (MC903) was used to induce clinical AD-like symptoms in c-kit-dependent MC-deficient Wsh-/- and the MC protease-deficient mMCP-4-/-, mMCP-6-/-, and CPA3-/- mouse strains.	Cholecalciferol	105-115	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	179-184
32809289-3	2020	We herein report our experience on the impact of cholecalciferol supplementation on PTH and 25(OH)D levels in a group of RTRs with 25(OH)D <30 ng/mL and SHPT.	Cholecalciferol	49-64	parathyroid hormone	Homo sapiens	84-87
32905226-0	2020	Erratum to: Pharmaceutic application of vitamin D3 on particle-induced fibrotic effects through induction of Nrf2 signals.	Cholecalciferol	40-50	NFE2 like bZIP transcription factor 2	Homo sapiens	109-113
32742408-10	2020	In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway.	Cholecalciferol	83-93	matrix metallopeptidase 13	Homo sapiens	224-230
32742408-10	2020	In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway.	Cholecalciferol	83-93	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	232-240
32742408-10	2020	In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway.	Cholecalciferol	83-93	ADAM metallopeptidase with thrombospondin type 1 motif 5	Homo sapiens	245-253
32742408-10	2020	In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway.	Cholecalciferol	83-93	Wnt family member 3A	Homo sapiens	278-281
32742408-10	2020	In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway.	Cholecalciferol	83-93	catenin beta 1	Homo sapiens	282-294
32447000-0	2020	CYP11A1-derived vitamin D3 products protect against UVB-induced inflammation and promote keratinocytes differentiation.	Cholecalciferol	16-26	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	0-7
32447000-4	2020	Since the protective effect of 1,25(OH)2D3 against UVB-induced skin damage and inflammation is recognized, CYP11A1-derived vitamin D3-hydroxyderivatives including 20(OH)D3, 1,20(OH)2D3, 20,23(OH)2D3 and 1,20,23(OH)3D3 were tested for their anti-inflammatory and skin protection properties in UVB-irradiated human epidermal keratinocytes (HEKn).	Cholecalciferol	123-133	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	107-114
32334010-9	2020	In addition, vitamin D3 decreased IL-6 and MDA levels, whereas the activities of CAT, SOD, and total thiol content in the hippocampus tissue were significantly increased.	Cholecalciferol	13-23	interleukin 6	Rattus norvegicus	34-38
32722164-9	2020	Therefore, this hypothesis paper describes the use of flavonoid supplements combined with vitamin D3 to activate Nrf2, which may be a potential target to prevent and/or decrease SARS-CoV-2 infection severity, reducing oxidative stress and inflammation, enhancing innate immunity, and downregulating ACE2 receptors.	Cholecalciferol	90-100	NFE2 like bZIP transcription factor 2	Homo sapiens	113-117
32722164-9	2020	Therefore, this hypothesis paper describes the use of flavonoid supplements combined with vitamin D3 to activate Nrf2, which may be a potential target to prevent and/or decrease SARS-CoV-2 infection severity, reducing oxidative stress and inflammation, enhancing innate immunity, and downregulating ACE2 receptors.	Cholecalciferol	90-100	angiotensin converting enzyme 2	Homo sapiens	299-303
32360127-13	2020	SIGNIFICANCE: Overall, the present study shows that vitamin D3 had an impact on resistance to different chemotherapeutic agents which could be due to the inhibition of ALDH-1, suggesting its use as an adjuvant therapy to cancer patients receiving chemotherapy.	Cholecalciferol	52-62	aldehyde dehydrogenase 1 family member A1	Homo sapiens	168-174
32434409-8	2020	Significantly, in response to hyperphosphatemia induced by vitamin D3, medial VC was attenuated in TDAG51-/- mice.	Cholecalciferol	59-69	pleckstrin homology like domain, family A, member 1	Mus musculus	99-105
32043288-0	2020	Adding Vitamin D3 to the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin Has the Potential to Protect beta-Cell Function in LADA Patients: A One-Year Pilot Study.	Cholecalciferol	7-17	ladinin 1	Homo sapiens	121-125
32043288-1	2020	AIMS: This trial was conducted to explore the protective effect on beta-cell function of adding vitamin D3 to DPP-4 inhibitors to treat patients with LADA.	Cholecalciferol	96-106	ladinin 1	Homo sapiens	150-154
32043288-7	2020	CONCLUSIONS: The data suggested that adding 2000 IU per day vitamin D3 to saxagliptin might preserve beta-cell function in patients with LADA.	Cholecalciferol	60-70	ladinin 1	Homo sapiens	137-141
32542627-3	2020	In addition 65 patients receiving either cholecalciferol or placebo were analyzed during 6 months intervention and 6 months follow-up.T2D risk alleles are VDR rs7975232 "G" (pc=0.031), rs1544410 "G" (pc=0.027) and CYP2R1 rs10741657 "A" (pc=0.016).	Cholecalciferol	41-56	vitamin D receptor	Homo sapiens	155-158
32542627-8	2020	The response to cholecalciferol supplementation can be measured as 25(OH)D3 increment and PTH suppression.	Cholecalciferol	16-31	parathyroid hormone	Homo sapiens	90-93
32663289-7	2020	We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs).	Cholecalciferol	34-49	C-C motif chemokine ligand 2	Homo sapiens	73-78
32663289-7	2020	We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs).	Cholecalciferol	34-49	vitamin D receptor	Homo sapiens	163-182
32663289-7	2020	We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs).	Cholecalciferol	34-49	vitamin D receptor	Homo sapiens	184-187
32663289-7	2020	We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs).	Cholecalciferol	51-61	C-C motif chemokine ligand 2	Homo sapiens	73-78
32663289-7	2020	We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs).	Cholecalciferol	51-61	vitamin D receptor	Homo sapiens	163-182
32663289-7	2020	We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs).	Cholecalciferol	51-61	vitamin D receptor	Homo sapiens	184-187
32154933-1	2020	FGF-23 has arisen as an early biomarker of renal dysfunction, but at the onset of chronic kidney disease (CKD) data suggest that FGF-23 may be produced independently of the parathyroid hormone (PTH), 1,25(OH)2 -Vitamin D3 signaling axis.	Cholecalciferol	211-221	fibroblast growth factor 23	Mus musculus	129-135
32565955-0	2020	Vitamin D3 mediates miR-15a-5p inhibition of liver cancer cell proliferation via targeting E2F3.	Cholecalciferol	0-10	E2F transcription factor 3 S homeolog	Xenopus laevis	91-95
32565955-8	2020	Therefore, Vitamin D3 suppressed cell proliferation by miR-15a-5p-mediated silencing of E2F3 gene expression.	Cholecalciferol	11-21	E2F transcription factor 3 S homeolog	Xenopus laevis	88-92
32530156-2	2020	We herein report our experience on the impact of cholecalciferol supplementation on PTH levels in a group of HD patients.	Cholecalciferol	49-64	parathyroid hormone	Homo sapiens	84-87
32530156-12	2020	Cholecalciferol treatment significantly increased serum 25(OH)D levels, significantly decreased PTH levels and paricalcitol doses, concurrently entailing a better control of anemia.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	96-99
32498437-1	2020	20(S)-Hydroxyvitamin D3 (20(OH)D3) is an endogenous metabolite produced by the action of CYP11A1 on the side chain of vitamin D3 (D3).	Cholecalciferol	13-23	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	89-96
32498437-1	2020	20(S)-Hydroxyvitamin D3 (20(OH)D3) is an endogenous metabolite produced by the action of CYP11A1 on the side chain of vitamin D3 (D3).	Cholecalciferol	21-23	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	89-96
32441029-1	2020	We have previously described new pathways of vitamin D3 activation by CYP11A1 to produce a variety of metabolites including 20(OH)D3 and 20,23(OH)2D3.	Cholecalciferol	45-55	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	70-77
32348877-3	2020	Recently, for a clinical application, a few potent (highly cell-permeable and water-soluble) PAK1 blockers have been developed from natural or synthetic PAK1 blockers (triptolide, vitamin D3 and ketorolac) via a series of "chemical evolutions" that boost pharmacological activities >500 times.	Cholecalciferol	180-190	p21 (RAC1) activated kinase 1	Homo sapiens	93-97
32348877-3	2020	Recently, for a clinical application, a few potent (highly cell-permeable and water-soluble) PAK1 blockers have been developed from natural or synthetic PAK1 blockers (triptolide, vitamin D3 and ketorolac) via a series of "chemical evolutions" that boost pharmacological activities >500 times.	Cholecalciferol	180-190	p21 (RAC1) activated kinase 1	Homo sapiens	153-157
31868234-0	2020	Switches in histone modifications epigenetically control vitamin D3-dependent transcriptional upregulation of the CYP24A1 gene in osteoblastic cells.	Cholecalciferol	57-67	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	114-121
31907922-0	2020	Ezh2-dependent H3K27me3 modification dynamically regulates vitamin D3-dependent epigenetic control of CYP24A1 gene expression in osteoblastic cells.	Cholecalciferol	59-69	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
31907922-0	2020	Ezh2-dependent H3K27me3 modification dynamically regulates vitamin D3-dependent epigenetic control of CYP24A1 gene expression in osteoblastic cells.	Cholecalciferol	59-69	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	102-109
31907922-4	2020	Treatment of cells with the active vitamin D metabolite 1,25(OH)2 D3 , results in transcriptional activation of the CYP24A1 gene, which encodes a 24-hydroxylase enzyme, that is, essential for physiological control of vitamin D3 levels.	Cholecalciferol	217-227	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	116-123
32160330-0	2020	Pleiotropic effects of vitamin D3 on CD4+ T lymphocytes mediated by human periodontal ligament cells and inflammatory environment.	Cholecalciferol	23-33	CD4 molecule	Homo sapiens	37-40
32160330-2	2020	Here we analyzed the impact of vitamin D3 on the immunosuppressive properties of hPDLCs towards CD4+ T-lymphocytes.	Cholecalciferol	31-41	CD4 molecule	Homo sapiens	96-99
32160330-10	2020	CONCLUSION: Effects of vitamin D3 on CD4+ T-lymphocyte are modified by hPDLCs depending on the microenvironment.	Cholecalciferol	23-33	CD4 molecule	Homo sapiens	37-40
32119872-0	2020	Differential effects of the 1,25D3-MARRS receptor (ERp57/PDIA3) on murine mammary gland development depend on the vitamin D3 dose.	Cholecalciferol	114-124	protein disulfide isomerase associated 3	Mus musculus	51-56
32119872-0	2020	Differential effects of the 1,25D3-MARRS receptor (ERp57/PDIA3) on murine mammary gland development depend on the vitamin D3 dose.	Cholecalciferol	114-124	protein disulfide isomerase associated 3	Mus musculus	57-62
32234325-7	2020	Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism.	Cholecalciferol	0-10	syntaxin 17	Homo sapiens	91-102
32234325-7	2020	Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism.	Cholecalciferol	0-10	syntaxin 17	Homo sapiens	104-109
32234325-7	2020	Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism.	Cholecalciferol	0-10	ATPase H+ transporting V0 subunit a2	Homo sapiens	145-153
32234325-7	2020	Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	222-241
32234325-7	2020	Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	243-246
32528227-11	2020	Both enzymatic (GST, catalase, and SOD) and nonenzymatic antioxidants (reduced GSH) were raised significantly in the presence of vitamin D3 and curcumin, which resulted in the better recovery of neuronal cells from Abeta1-42 treatment.	Cholecalciferol	129-139	glutathione S-transferase kappa 1	Homo sapiens	16-19
32528227-11	2020	Both enzymatic (GST, catalase, and SOD) and nonenzymatic antioxidants (reduced GSH) were raised significantly in the presence of vitamin D3 and curcumin, which resulted in the better recovery of neuronal cells from Abeta1-42 treatment.	Cholecalciferol	129-139	catalase	Homo sapiens	21-29
32528227-11	2020	Both enzymatic (GST, catalase, and SOD) and nonenzymatic antioxidants (reduced GSH) were raised significantly in the presence of vitamin D3 and curcumin, which resulted in the better recovery of neuronal cells from Abeta1-42 treatment.	Cholecalciferol	129-139	superoxide dismutase 1	Homo sapiens	35-38
32508805-8	2020	Some nTreg variation could be attributed to vitamin D status where normal linear regression estimated that an absolute increase in nTreg/CD4+ by 0.11% could be expected with 10 nmol increase in serum 25 (OH) vitamin D3 (p = 0.005, 95% CI: 0.03-0.19).	Cholecalciferol	208-218	CD4 molecule	Homo sapiens	137-140
32508805-13	2020	Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status.	Cholecalciferol	150-160	immunoglobulin kappa variable 2D-24 (non-functional)	Homo sapiens	86-91
32508805-13	2020	Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status.	Cholecalciferol	150-160	CD4 molecule	Homo sapiens	92-95
32508805-13	2020	Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status.	Cholecalciferol	150-160	interleukin 2 receptor subunit alpha	Homo sapiens	96-100
32508805-13	2020	Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status.	Cholecalciferol	150-160	forkhead box P3	Homo sapiens	101-106
32374278-0	2020	Efficacy of weekly administration of cholecalciferol on parathyroid hormone in stable kidney-transplanted patients with CKD stage 1-3.	Cholecalciferol	37-52	parathyroid hormone	Homo sapiens	56-75
32374278-3	2020	We evaluated the efficacy of weekly cholecalciferol administration on parathyroid hormone (PTH) levels in stable KTx patients with chronic kidney disease stage 1-3.	Cholecalciferol	36-51	parathyroid hormone	Homo sapiens	70-89
32374278-3	2020	We evaluated the efficacy of weekly cholecalciferol administration on parathyroid hormone (PTH) levels in stable KTx patients with chronic kidney disease stage 1-3.	Cholecalciferol	36-51	parathyroid hormone	Homo sapiens	91-94
32374278-10	2020	Conclusions Weekly administration of cholecalciferol can significantly and stably reduce PTH levels, without any adverse effects on serum calcium and renal function.	Cholecalciferol	37-52	parathyroid hormone	Homo sapiens	89-92
32375246-3	2020	Restriction Fragment Length Polymorphism was completed for the detection of vitamin D receptor (VDR) gene polymorphism; Results: Serum 25-hydroxy vitamin D3 (vitamin D) levels were found to be 1.6 times elevated in severe dengue cases as compared to healthy controls.	Cholecalciferol	76-85	vitamin D receptor	Homo sapiens	96-99
31593637-0	2020	The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial.	Cholecalciferol	28-38	insulin	Homo sapiens	61-68
31593637-0	2020	The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial.	Cholecalciferol	28-38	tumor necrosis factor	Homo sapiens	84-111
31593637-8	2020	It seems that chromium and vitamin D3 co-supplementation are probably effective in controlling HOMA-IR by decreasing TNF-alpha in T2DM.	Cholecalciferol	27-37	tumor necrosis factor	Homo sapiens	117-126
31593637-10	2020	Chromium and vitamin D3 alone and/or in simultaneous pretreatment decrease TNF-alpha in T2DM.	Cholecalciferol	13-23	tumor necrosis factor	Homo sapiens	75-84
31897949-6	2020	Also, the patients receiving vitamin D3 yielded a marginally significant lower IL-6 serum concentration (76.43 ng/L) compared to placebo (93.10 ng/L) (P value:0.055).	Cholecalciferol	29-39	interleukin 6	Homo sapiens	79-83
32154912-1	2020	BACKGROUND AND PURPOSE: The synthetic vitamin D3 analog paricalcitol acts as a selective activator of vitamin D receptor (VDR).	Cholecalciferol	38-48	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	102-120
32154912-1	2020	BACKGROUND AND PURPOSE: The synthetic vitamin D3 analog paricalcitol acts as a selective activator of vitamin D receptor (VDR).	Cholecalciferol	38-48	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	122-125
32268148-8	2020	Smooth muscle-specific deletion of LGL1 increased HMGB1 level and aggravated vitamin D3-induced vascular calcification, which was attenuated by an HMGB1 inhibitor.	Cholecalciferol	77-87	LLGL1 scribble cell polarity complex component	Mus musculus	35-39
32268148-8	2020	Smooth muscle-specific deletion of LGL1 increased HMGB1 level and aggravated vitamin D3-induced vascular calcification, which was attenuated by an HMGB1 inhibitor.	Cholecalciferol	77-87	high mobility group box 1	Mus musculus	147-152
32760818-7	2020	Combination of Vitamin D3 and MitoQ10 significantly reduced levels of estradiol, progesterone, FSH, LH, LH/FSH, SOD and MDA.	Cholecalciferol	15-25	follicle stimulating hormone beta	Mus musculus	95-98
32760818-7	2020	Combination of Vitamin D3 and MitoQ10 significantly reduced levels of estradiol, progesterone, FSH, LH, LH/FSH, SOD and MDA.	Cholecalciferol	15-25	follicle stimulating hormone beta	Mus musculus	107-110
31899206-7	2020	Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3.	Cholecalciferol	248-258	interleukin 17 receptor A	Mus musculus	10-17
31899206-7	2020	Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3.	Cholecalciferol	248-258	tumor necrosis factor	Mus musculus	127-130
31899206-7	2020	Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3.	Cholecalciferol	248-258	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	131-136
31899206-7	2020	Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3.	Cholecalciferol	248-258	caspase 2	Mus musculus	147-156
32483423-0	2020	Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D3 in colorectal cancer.	Cholecalciferol	112-122	sirtuin 6	Homo sapiens	26-31
32344650-0	2020	The Effect of Vitamin D3 Supplementation on Hepcidin, Iron, and IL-6 Responses after a 100 km Ultra-Marathon.	Cholecalciferol	14-24	hepcidin antimicrobial peptide	Homo sapiens	44-52
32344650-0	2020	The Effect of Vitamin D3 Supplementation on Hepcidin, Iron, and IL-6 Responses after a 100 km Ultra-Marathon.	Cholecalciferol	14-24	interleukin 6	Homo sapiens	64-68
31783155-6	2020	There is a key impact of the lower vitamin D3 in NWD1 and its signaling through the Vdr.	Cholecalciferol	35-45	NACHT and WD repeat domain containing 1	Mus musculus	49-53
32357579-0	2020	Are Vitamin D3 Tablets and Oil Drops Equally Effective in Raising S-25-Hydroxyvitamin D Concentrations?	Cholecalciferol	4-14	ribosomal protein S25	Homo sapiens	66-70
32325790-1	2020	The biologically active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), modulates innate and adaptive immunity via genes regulated by the transcription factor vitamin D receptor (VDR).	Cholecalciferol	32-42	vitamin D receptor	Homo sapiens	176-194
32325790-1	2020	The biologically active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), modulates innate and adaptive immunity via genes regulated by the transcription factor vitamin D receptor (VDR).	Cholecalciferol	32-42	vitamin D receptor	Homo sapiens	196-199
32227012-6	2020	When three achiral fluorescent molecules, pyrene-1-carboxylic acid (D2), rhodamine 110 (D3) and rhodamine B (D4), were incorporated into the helical structures formed by bola-1, the nanohelix could be retained and the CPL from the dye molecules could be induced.	Cholecalciferol	88-90	bolA family member 1	Homo sapiens	170-176
32251441-1	2020	BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3.	Cholecalciferol	170-180	interleukin 10	Homo sapiens	108-113
32251441-1	2020	BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3.	Cholecalciferol	170-180	interleukin 6	Homo sapiens	137-141
32251441-1	2020	BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3.	Cholecalciferol	170-180	interleukin 17A	Homo sapiens	144-150
32251441-7	2020	In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3.	Cholecalciferol	130-140	interleukin 27	Homo sapiens	34-39
32251441-7	2020	In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3.	Cholecalciferol	130-140	transforming growth factor beta 1	Homo sapiens	41-50
32251441-7	2020	In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3.	Cholecalciferol	130-140	interleukin 10	Homo sapiens	52-57
32251441-7	2020	In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3.	Cholecalciferol	130-140	interleukin 17A	Homo sapiens	59-65
32251441-7	2020	In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3.	Cholecalciferol	130-140	interleukin 6	Homo sapiens	71-75
32052217-2	2020	As suppression of parathyroid hormone (PTH) is one indicator of vitamin D efficacy, we examined to what extent doses of vitamin D3 supplementation suppress PTH levels in individuals with and without obesity.	Cholecalciferol	120-130	parathyroid hormone	Homo sapiens	156-159
32052217-5	2020	Obese individuals (n = 141) experienced a steep reduction of 3-month PTH from placebo to 1,000 IU/day of vitamin D3 supplementation, but no further reduction at 2,000 or 4,000 IU/day.	Cholecalciferol	105-115	parathyroid hormone	Homo sapiens	69-72
32052217-6	2020	For non-obese individuals (n = 109), the reduction of 3-month PTH was approximately linear for increasing vitamin D3 doses.	Cholecalciferol	106-116	parathyroid hormone	Homo sapiens	62-65
31986066-8	2020	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.	Cholecalciferol	13-23	TNF superfamily member 11	Homo sapiens	50-55
32237947-5	2022	Significant increase in LL37 intensity of expression was observed after intralesional injection of vitamin D3 (p = 0.003) and in verrucae showing complete clinical response (p = 0.022).Conclusions: Intralesional injection of vitamin D is effective and safe treatment for verruca vulgaris and causes increase in LL37 expression.	Cholecalciferol	99-109	cathelicidin antimicrobial peptide	Homo sapiens	24-28
32316365-19	2020	In the immune tolerance phase of HBeAg-negative chronic HBV infection, vitamin D3 may be a modulator of immune function via CD8, CD19, and HBV DNA.	Cholecalciferol	71-81	CD8a molecule	Homo sapiens	124-127
31809868-14	2020	Furthermore, co-treatment with leptin and vitamin D3 metabolites promoted ALP activity compared with either alone.	Cholecalciferol	42-52	ATHS	Homo sapiens	74-77
31783155-6	2020	There is a key impact of the lower vitamin D3 in NWD1 and its signaling through the Vdr.	Cholecalciferol	35-45	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	84-87
31901710-6	2020	For premenopausal women, cholecalciferol supplementation resulted in a significant decrease in serum levels of Ang-2 and VEGF-A after 8 wk of treatment (P < 0.05).	Cholecalciferol	25-40	angiopoietin 2	Homo sapiens	111-116
31901710-6	2020	For premenopausal women, cholecalciferol supplementation resulted in a significant decrease in serum levels of Ang-2 and VEGF-A after 8 wk of treatment (P < 0.05).	Cholecalciferol	25-40	vascular endothelial growth factor A	Homo sapiens	121-127
31544572-5	2020	Vitamin D3 supplementation with HFD significantly increased the exploration of the novel object and the discrimination index and attenuated the alterations in the prefrontal cortex CAT and Achase expression.Conclusions: The present findings support the potential effect of vitamin D on recognition memory and cholinergic transmission in the prefrontal cortex and add to the pathophysiology of HFD consumption.	Cholecalciferol	0-10	choline O-acetyltransferase	Rattus norvegicus	181-184
32122449-10	2020	Results: The median level of serum IgE was increased in patients with vitamin D3 deficiency compared with other groups.	Cholecalciferol	70-80	immunoglobulin heavy constant epsilon	Homo sapiens	35-38
32122449-13	2020	Conclusion: Vitamin D3 deficiency is associated with exacerbation severity and serum IgE levels in patients with pediatric asthma; hence, it can have an important role in pediatric asthma pathogenesis, possibly through IgE.	Cholecalciferol	12-22	immunoglobulin heavy constant epsilon	Homo sapiens	85-88
32122449-13	2020	Conclusion: Vitamin D3 deficiency is associated with exacerbation severity and serum IgE levels in patients with pediatric asthma; hence, it can have an important role in pediatric asthma pathogenesis, possibly through IgE.	Cholecalciferol	12-22	immunoglobulin heavy constant epsilon	Homo sapiens	219-222
32742635-0	2020	Pharmaceutic application of vitamin D3 on particle-induced fibrotic effects through induction of Nrf2 signals.	Cholecalciferol	28-38	NFE2 like bZIP transcription factor 2	Homo sapiens	97-101
32742635-6	2020	In vivo studies showed that vitamin D3 significantly attenuated fibrosis effects by decreasing alpha-smooth muscle actin-regulated extracellular matrix deposition and restoring expressions of E-cadherin and N-cadherin.	Cholecalciferol	28-38	cadherin 1	Homo sapiens	192-202
32742635-6	2020	In vivo studies showed that vitamin D3 significantly attenuated fibrosis effects by decreasing alpha-smooth muscle actin-regulated extracellular matrix deposition and restoring expressions of E-cadherin and N-cadherin.	Cholecalciferol	28-38	cadherin 2	Homo sapiens	207-217
32742635-9	2020	In addition, our results indicated that the therapeutic effects of vitamin D3 were through Nrf2 signals.	Cholecalciferol	67-77	NFE2 like bZIP transcription factor 2	Homo sapiens	91-95
32127613-2	2020	Reabsorption of vitamin D3 occurs in the proximal tubule after being endocytosed in combination with DBP (vitamin D binding protein) by the megalin/cubilin receptor.	Cholecalciferol	16-26	GC vitamin D binding protein	Homo sapiens	106-131
32127613-2	2020	Reabsorption of vitamin D3 occurs in the proximal tubule after being endocytosed in combination with DBP (vitamin D binding protein) by the megalin/cubilin receptor.	Cholecalciferol	16-26	LDL receptor related protein 2	Homo sapiens	140-147
31053513-9	2020	CONCLUSION: In the DALI vitamin D trial, supplementation with 1600 IU vitamin D3/day achieved vitamin D sufficiency in virtually all pregnant women and a small effect in FPG at 35-37 weeks.	Cholecalciferol	70-80	DNMT1-associated long intergenic non-coding RNA	Homo sapiens	19-23
31544572-0	2020	Vitamin D3 favorable outcome on recognition memory and prefrontal cortex expression of choline acetyltransferase and acetylcholinesterase in experimental model of chronic high-fat feeding.	Cholecalciferol	0-10	choline O-acetyltransferase	Rattus norvegicus	87-112
31544572-0	2020	Vitamin D3 favorable outcome on recognition memory and prefrontal cortex expression of choline acetyltransferase and acetylcholinesterase in experimental model of chronic high-fat feeding.	Cholecalciferol	0-10	acetylcholinesterase	Rattus norvegicus	117-137
31544572-5	2020	Vitamin D3 supplementation with HFD significantly increased the exploration of the novel object and the discrimination index and attenuated the alterations in the prefrontal cortex CAT and Achase expression.Conclusions: The present findings support the potential effect of vitamin D on recognition memory and cholinergic transmission in the prefrontal cortex and add to the pathophysiology of HFD consumption.	Cholecalciferol	0-10	acetylcholinesterase	Rattus norvegicus	189-195
31701851-0	2020	A single injection of vitamin D3 improves insulin sensitivity and beta-cell function but not muscle damage or the inflammatory and cardiovascular responses to an acute bout of resistance exercise in vitamin D-deficient resistance-trained males.	Cholecalciferol	22-32	insulin	Homo sapiens	42-49
31701851-9	2020	A single injection of vitamin D3 improved insulin resistance and beta-cell function following RE in previously vitamin D-deficient resistance-trained males.	Cholecalciferol	22-32	insulin	Homo sapiens	42-49
31978964-6	2020	Results: While we found no differences in Th17 cells between vitamin D3 groups, vitamin D3 restriction specifically promoted memory B cell development, accompanied by elevated levels of serum IgM, IgG1, IgG3, and anti-dsDNA IgG.	Cholecalciferol	80-90	immunoglobulin heavy constant mu	Mus musculus	192-195
31879032-6	2020	The results showed that vitamin D3 treatment increases PR mRNA and protein level and phospho-Ser294 PR protein level in the isolated eSC of both RIF patients and the control group.	Cholecalciferol	24-34	progesterone receptor	Homo sapiens	55-57
31879032-6	2020	The results showed that vitamin D3 treatment increases PR mRNA and protein level and phospho-Ser294 PR protein level in the isolated eSC of both RIF patients and the control group.	Cholecalciferol	24-34	progesterone receptor	Homo sapiens	100-102
31879032-7	2020	These results suggest that vitamin D3 may possibly play a key role during the embryo implantation process by affecting the expression pattern and regulatory modifications of the PR in the eSC.	Cholecalciferol	27-37	progesterone receptor	Homo sapiens	178-180
31820026-11	2020	Exposure of human intestinal Caco-2 cells to 10-100 nM PCB 126 in the presence of vitamin D3 resulted in inhibition of mRNAs for the calcium transporters TRPV6 and PMCA1b (P < 0.05).	Cholecalciferol	82-92	transient receptor potential cation channel subfamily V member 6	Homo sapiens	154-159
32031576-2	2020	Cholecalciferol (VIT-D) is a known modulator of oxidative stress and angiogenesis.	Cholecalciferol	0-15	vitrin	Homo sapiens	17-20
31820026-7	2020	Hyperparathyroidism was accompanied by increased expression of mRNAs of vitamin D3 metabolizing cytochrome P450 enzymes CYP27B1 and CYP24 in the kidney (P < 0.05).	Cholecalciferol	72-82	cytochrome P450, family 27, subfamily b, polypeptide 1	Rattus norvegicus	120-127
31820026-7	2020	Hyperparathyroidism was accompanied by increased expression of mRNAs of vitamin D3 metabolizing cytochrome P450 enzymes CYP27B1 and CYP24 in the kidney (P < 0.05).	Cholecalciferol	72-82	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	132-137
31410630-0	2020	Oxytetracycline reduces inflammation and treponeme burden whereas vitamin D3 promotes beta-defensin expression in bovine infectious digital dermatitis.	Cholecalciferol	66-76	LOC100296173	Bos taurus	86-99
31410630-9	2020	Vitamin D3 did not modify expression of cytokines or Tlrs, or bacterial loads, but enhanced transcription of tracheal antimicrobial peptide (Tap), a key bovine beta-defensin.	Cholecalciferol	0-10	tracheal antimicrobial peptide	Bos taurus	109-139
31410630-9	2020	Vitamin D3 did not modify expression of cytokines or Tlrs, or bacterial loads, but enhanced transcription of tracheal antimicrobial peptide (Tap), a key bovine beta-defensin.	Cholecalciferol	0-10	tracheal antimicrobial peptide	Bos taurus	141-144
31410630-9	2020	Vitamin D3 did not modify expression of cytokines or Tlrs, or bacterial loads, but enhanced transcription of tracheal antimicrobial peptide (Tap), a key bovine beta-defensin.	Cholecalciferol	0-10	LOC100296173	Bos taurus	160-173
31978964-6	2020	Results: While we found no differences in Th17 cells between vitamin D3 groups, vitamin D3 restriction specifically promoted memory B cell development, accompanied by elevated levels of serum IgM, IgG1, IgG3, and anti-dsDNA IgG.	Cholecalciferol	80-90	LOC105243590	Mus musculus	197-201
31978964-6	2020	Results: While we found no differences in Th17 cells between vitamin D3 groups, vitamin D3 restriction specifically promoted memory B cell development, accompanied by elevated levels of serum IgM, IgG1, IgG3, and anti-dsDNA IgG.	Cholecalciferol	80-90	Immunoglobulin heavy constant gamma 3	Mus musculus	203-207
31731231-0	2020	Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4+ T cell CTLA-4 expression.	Cholecalciferol	0-10	CD4 molecule	Homo sapiens	158-161
31731231-0	2020	Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4+ T cell CTLA-4 expression.	Cholecalciferol	0-10	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	170-176
31731231-6	2020	These new data provide solid support for the view that vitamin D3 reduces MS risk in part through a mechanism involving myeloid cell 1,25-(OH)2D3 production and CTLA-4 upregulation in CNS-infiltrating CD4+ T cells.	Cholecalciferol	55-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-167
31731231-6	2020	These new data provide solid support for the view that vitamin D3 reduces MS risk in part through a mechanism involving myeloid cell 1,25-(OH)2D3 production and CTLA-4 upregulation in CNS-infiltrating CD4+ T cells.	Cholecalciferol	55-65	CD4 molecule	Homo sapiens	201-204
31731231-7	2020	We suggest that CTLA-4 serves as a vitamin D3-regulated immunological checkpoint in multiple sclerosis prevention.	Cholecalciferol	35-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	16-22
32918226-2	2020	The active form of vitamin D, vitamin D3 or calcitriol, binds to the ligand-activated transcription factor vitamin D receptor (VDR) for genomic and non-genomic effects.	Cholecalciferol	30-40	vitamin D receptor	Homo sapiens	107-125
31657006-4	2020	We explored whether 48-week high-dose vitamin D3 supplements were associated with lower circulating NfL levels.	Cholecalciferol	38-48	neurofilament light chain	Homo sapiens	100-103
32918223-5	2020	Vitamin D3 itself and its canonical (1,25(OH)2D3) and noncanonical (CYP11A1-intitated) D3 hydroxyderivatives show photoprotective functions in the skin.	Cholecalciferol	0-10	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	68-75
32918226-2	2020	The active form of vitamin D, vitamin D3 or calcitriol, binds to the ligand-activated transcription factor vitamin D receptor (VDR) for genomic and non-genomic effects.	Cholecalciferol	30-40	vitamin D receptor	Homo sapiens	127-130
32863311-1	2020	The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 and also for the secondary bile acid lithocholic acid (LCA).	Cholecalciferol	74-84	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-22
32013343-7	2020	Most of the negative changes were negligible but PTH level dramatically decreased after 48 hours in 2 - 8 C. In addition, although a clear increase in the concentration of triglycerides, Cr, Urea, T4, and 25-OH vitamin D3 was observed, it was not significant.	Cholecalciferol	211-221	parathyroid hormone	Homo sapiens	49-52
32009088-6	2020	Results In a multivariable linear regression analysis, FGF19 was associated with ALT, a history of cardiovascular disease, and medication with active vitamin D3.	Cholecalciferol	150-160	fibroblast growth factor 19	Homo sapiens	55-60
31628941-0	2020	Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer.	Cholecalciferol	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	43-57
31628941-4	2020	The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo.	Cholecalciferol	91-101	ATP binding cassette subfamily B member 1	Homo sapiens	110-115
31628941-4	2020	The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo.	Cholecalciferol	91-101	aldehyde dehydrogenase 1 family member A1	Homo sapiens	120-126
31628941-4	2020	The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo.	Cholecalciferol	99-101	ATP binding cassette subfamily B member 1	Homo sapiens	110-115
31628941-4	2020	The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo.	Cholecalciferol	99-101	aldehyde dehydrogenase 1 family member A1	Homo sapiens	120-126
32203968-0	2020	Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial.	Cholecalciferol	0-10	corticotropin releasing hormone	Homo sapiens	129-160
32203968-0	2020	Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial.	Cholecalciferol	0-10	interleukin 6	Homo sapiens	166-179
32203968-12	2020	CONCLUSION: Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients.	Cholecalciferol	39-49	corticotropin releasing hormone	Homo sapiens	98-101
32203968-12	2020	CONCLUSION: Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients.	Cholecalciferol	39-49	interleukin 6	Homo sapiens	106-110
31106659-4	2020	After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha.	Cholecalciferol	62-72	C-reactive protein	Homo sapiens	191-194
31106659-4	2020	After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha.	Cholecalciferol	62-72	tumor necrosis factor	Homo sapiens	199-208
31106659-4	2020	After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha.	Cholecalciferol	132-142	C-reactive protein	Homo sapiens	191-194
31106659-4	2020	After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha.	Cholecalciferol	132-142	tumor necrosis factor	Homo sapiens	199-208
31106659-5	2020	In addition, serum level of IL-6 was decreased significantly in omega-3, vitamin D3, and cosupplementation groups compared with baseline.	Cholecalciferol	73-83	interleukin 6	Homo sapiens	28-32
31124381-11	2020	However, treatment initiation significantly improved plasma IL-10 levels after 2 months in both placebo and cholecalciferol groups.	Cholecalciferol	108-123	interleukin 10	Homo sapiens	60-65
32863311-1	2020	The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 and also for the secondary bile acid lithocholic acid (LCA).	Cholecalciferol	74-84	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	24-27
32877827-1	2020	Vitamin D3 is a fat-soluble essential nutrient that affects multiple biologic functions in the organism through calcitriol and the vitamin D3 receptor.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	131-150
31667917-9	2020	In addition, the hypermethylation of cg07873128 at the baseline, which is located in the imprinted gene OSBPL5, might reduce the serum 25(OH)D response to vitamin D3 supplementation.	Cholecalciferol	155-165	oxysterol binding protein like 5	Homo sapiens	104-110
31668442-10	2020	Abundance of mRNA transcripts for interleukin-1beta (IL1B) and inducible nitric oxide synthase (iNOS) in milk somatic cells before S. uberis challenge were increased in cows fed 25(OH)D3 compared with cows fed vitamin D3.	Cholecalciferol	210-220	nitric oxide synthase 2	Bos taurus	96-100
32877827-3	2020	The mechanisms of vitamin D3 action involve, among others, polymorphism of vitamin D3 receptor, cell cycle, caspases, and cancer stem cells.	Cholecalciferol	18-28	vitamin D receptor	Homo sapiens	75-94
32597823-8	2020	Although therapies selectively down-regulating both AhR and IDO1 are currently lacking, medications in clinical use such as dexamethasone may down-regulate both AhR and IDO1 genes, as calcitriol/vitamin D3 may down-regulate the AhR gene, and tocopherol/vitamin E may down-regulate the IDO1 gene.	Cholecalciferol	195-205	aryl hydrocarbon receptor	Homo sapiens	161-164
33271562-0	2020	Correlation of Vitamin D3 with the Expression of RORgammat and Foxp3 mRNAs in the Peripheral Blood of Myasthenia Gravis Patients.	Cholecalciferol	15-25	forkhead box P3	Homo sapiens	63-68
32597823-8	2020	Although therapies selectively down-regulating both AhR and IDO1 are currently lacking, medications in clinical use such as dexamethasone may down-regulate both AhR and IDO1 genes, as calcitriol/vitamin D3 may down-regulate the AhR gene, and tocopherol/vitamin E may down-regulate the IDO1 gene.	Cholecalciferol	195-205	aryl hydrocarbon receptor	Homo sapiens	161-164
31769776-0	2019	Synthesis and vitamin D receptor affinity of 16-oxa vitamin D3 analogues.	Cholecalciferol	45-62	vitamin D receptor	Homo sapiens	14-32
31847491-8	2019	The additional gene network analysis revealed 43 new genes and 127 new interactions, so in the whole 222 out of 281 (79%) high scored genes from SFARI Gene database were connected with mTOR signaling activity and/or dependent on vitamin D3 availability directly or indirectly.	Cholecalciferol	229-239	mechanistic target of rapamycin kinase	Homo sapiens	185-189
31618573-2	2019	In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity.	Cholecalciferol	101-111	vitamin D receptor	Homo sapiens	133-136
31618573-2	2019	In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity.	Cholecalciferol	101-111	CCHC-type zinc finger nucleic acid binding protein	Homo sapiens	140-145
31618573-2	2019	In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity.	Cholecalciferol	101-111	vitamin D receptor	Homo sapiens	163-166
31618573-2	2019	In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity.	Cholecalciferol	101-111	vitamin D receptor	Homo sapiens	163-166
31618573-1	2019	Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	119-137
31618573-1	2019	Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	139-142
31618573-1	2019	Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways.	Cholecalciferol	0-10	CCHC-type zinc finger nucleic acid binding protein	Homo sapiens	148-189
31618573-1	2019	Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways.	Cholecalciferol	0-10	CCHC-type zinc finger nucleic acid binding protein	Homo sapiens	191-196
31787743-0	2019	Vitamin D3 Is Transformed into 1,25(OH)2D3 by Triggering CYP3A11(CYP3A4) Activity and Hydrolyzing Midazolam.	Cholecalciferol	0-10	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	57-64
31822280-1	2019	BACKGROUND: The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases.	Cholecalciferol	70-80	vitamin D receptor	Homo sapiens	30-48
31822280-1	2019	BACKGROUND: The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases.	Cholecalciferol	70-80	vitamin D receptor	Homo sapiens	50-53
31787743-3	2019	This study aimed to investigate effects of vitamin D3 (VD3) on CYP3A11 activity.	Cholecalciferol	43-53	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	63-70
31787743-10	2019	Expressions of hepatic CYP3A11 were more than 10-fold higher in rats treated with vitamin D3 compared to Control rats (p<0.05).	Cholecalciferol	82-92	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	23-30
31787743-12	2019	CYP3A11 expressions in vitamin D3-treated groups were significantly higher compared to the Control group (p<0.05).	Cholecalciferol	23-33	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	0-7
31787743-15	2019	CONCLUSIONS Vitamin D3 was transformed into 1,25(OH)2D3 by triggering CYP3A11 and CYP3A11 activity and by hydrolyzing MDZ.	Cholecalciferol	12-22	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	70-77
31787743-15	2019	CONCLUSIONS Vitamin D3 was transformed into 1,25(OH)2D3 by triggering CYP3A11 and CYP3A11 activity and by hydrolyzing MDZ.	Cholecalciferol	12-22	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	82-89
31805709-2	2019	The aim of this study was to determine whether omega-3 FA and cholecalciferol have effects on vitamin D metabolism related to CYP27B1 and 24-hydroxylase (CYP24) activities in the kidney and liver of 5/6 nephrectomy (Nx) rats.	Cholecalciferol	62-77	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	126-152
31794287-5	2022	After vitamin D3 supplementation with HFD, cardiac apoptotic, inflammatory and oxidative markers were mitigated and expression of UCP3 was downregulated and UCP2 was upregulated.	Cholecalciferol	6-16	uncoupling protein 3	Rattus norvegicus	130-134
31794287-5	2022	After vitamin D3 supplementation with HFD, cardiac apoptotic, inflammatory and oxidative markers were mitigated and expression of UCP3 was downregulated and UCP2 was upregulated.	Cholecalciferol	6-16	uncoupling protein 2	Rattus norvegicus	157-161
31794287-6	2022	This work highlights the novel cardioprotective effect of vitamin D3 in the experimental model of HFD feeding through the downregulation of UCP3.	Cholecalciferol	58-68	uncoupling protein 3	Rattus norvegicus	140-144
31675485-7	2019	These data demonstrate that the GR cooperates with D3 and PTH signaling, causing massive osteoclastogenesis, which may explain the rapid bone loss observed with high dosages of GC treatment.-Conaway, H. H., Henning, P., Lie, A., Tuckermann, J., Lerner, U. H. Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormone-induced osteoclastogenesis.	Cholecalciferol	334-344	nuclear receptor subfamily 3, group C, member 1	Mus musculus	32-34
31541729-1	2019	During our ongoing studies of vitamin D, we focused on the vitamin D3 side-chain 24-position, which is the major metabolic site of human CYP24A1.	Cholecalciferol	59-69	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	137-144
31100998-1	2019	OBJECTIVE: Investigate Vitamin D3 (VD3) effect on the Acetylcholinesterase (AChE), oxidative damage and behavioral tests in animals subjected to Intracerebroventicular injection of Streptozotocin (ICV-STZ) simulating a Sporadic Dementia of Alzheimer"s Type (SDAT) and treated with VD3 (21 days).	Cholecalciferol	23-33	acetylcholinesterase	Rattus norvegicus	54-74
31100998-1	2019	OBJECTIVE: Investigate Vitamin D3 (VD3) effect on the Acetylcholinesterase (AChE), oxidative damage and behavioral tests in animals subjected to Intracerebroventicular injection of Streptozotocin (ICV-STZ) simulating a Sporadic Dementia of Alzheimer"s Type (SDAT) and treated with VD3 (21 days).	Cholecalciferol	23-33	acetylcholinesterase	Rattus norvegicus	76-80
31675485-0	2019	Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormone-induced osteoclastogenesis.	Cholecalciferol	75-85	nuclear receptor subfamily 3, group C, member 1	Mus musculus	37-60
31566824-5	2019	The treatment of vitamin D3 at lower doses to aged rats showed increased expression of BAX and active caspase-3 in the sperm, this finding suggests that increased apoptosis may be responsible for removal of poor quality sperm during aging.	Cholecalciferol	17-27	BCL2 associated X, apoptosis regulator	Rattus norvegicus	87-90
31566824-5	2019	The treatment of vitamin D3 at lower doses to aged rats showed increased expression of BAX and active caspase-3 in the sperm, this finding suggests that increased apoptosis may be responsible for removal of poor quality sperm during aging.	Cholecalciferol	17-27	caspase 3	Rattus norvegicus	102-111
31566824-8	2019	It has been found that expression of AGER, visfatin, and HSPA1A increased in the sperm aged rats and vitamin D3 treatments at both doses decreased its expression.	Cholecalciferol	101-111	advanced glycosylation end product-specific receptor	Rattus norvegicus	37-41
31566824-9	2019	Thus, it might be suggested that during aging vitamin D3 treatment would be important for managing the sperm quality by regulating the apoptosis, antioxidant system and DNA integrity via modulation of visfatin and HSPA1A.	Cholecalciferol	46-56	nicotinamide phosphoribosyltransferase	Rattus norvegicus	201-209
31566824-9	2019	Thus, it might be suggested that during aging vitamin D3 treatment would be important for managing the sperm quality by regulating the apoptosis, antioxidant system and DNA integrity via modulation of visfatin and HSPA1A.	Cholecalciferol	46-56	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	214-220
31805709-2	2019	The aim of this study was to determine whether omega-3 FA and cholecalciferol have effects on vitamin D metabolism related to CYP27B1 and 24-hydroxylase (CYP24) activities in the kidney and liver of 5/6 nephrectomy (Nx) rats.	Cholecalciferol	62-77	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	154-159
31805709-7	2019	CYP24 expression was increased in the kidney of the 5/6 Nx rat model, which was found to be reversed by omega-3 FA or cholecalciferol/omega-3 FA supplementation.	Cholecalciferol	118-133	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	0-5
31805709-8	2019	Decreased CYP27B1 expression was observed in the liver of the 5/6 Nx rats and its expression was recovered by supplementation with cholecalciferol/omega-3 FA.	Cholecalciferol	131-146	cytochrome P450, family 27, subfamily b, polypeptide 1	Rattus norvegicus	10-17
31805709-9	2019	In conclusion, omega-3 FA and cholecalciferol may synergistically increase 1,25(OH)2D levels by inhibiting CYP24 expression in the kidney and liver and activating CYP27B1 expression in the liver of 5/6 Nx rats.	Cholecalciferol	30-45	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	107-112
31805709-9	2019	In conclusion, omega-3 FA and cholecalciferol may synergistically increase 1,25(OH)2D levels by inhibiting CYP24 expression in the kidney and liver and activating CYP27B1 expression in the liver of 5/6 Nx rats.	Cholecalciferol	30-45	cytochrome P450, family 27, subfamily b, polypeptide 1	Rattus norvegicus	163-170
31775746-18	2019	Additional experiment showed that Cyp27b1 gene knockout, leading to active vitamin D3 deficiency, exacerbated BLM-induced pulmonary fibrosis.	Cholecalciferol	75-85	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	34-41
31798578-2	2019	Although there are only a few reports on interdependency of their actions, the interplay between IFN-gamma and vit D3 has been clearly demonstrated in certain aspects of immune reactivity.	Cholecalciferol	111-117	interferon gamma	Homo sapiens	97-106
31703120-10	2019	Mean change in eGFR from baseline to year 5 was -12.3 (95% CI, -13.4 to -11.2) mL/min/1.73 m2 with vitamin D3 vs -13.1 (95% CI, -14.2 to -11.9) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.5] mL/min/1.73 m2).	Cholecalciferol	99-109	epidermal growth factor receptor	Homo sapiens	15-19
31619537-3	2019	We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway.	Cholecalciferol	138-148	toll-like receptor 2	Mus musculus	196-200
31619537-3	2019	We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway.	Cholecalciferol	138-148	mitogen-activated protein kinase 14	Mus musculus	211-219
31619537-3	2019	We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway.	Cholecalciferol	138-148	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	220-227
31619537-3	2019	We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway.	Cholecalciferol	138-148	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	228-231
31798578-4	2019	Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone.	Cholecalciferol	24-30	leukocyte immunoglobulin like receptor B4	Homo sapiens	79-117
31798578-4	2019	Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone.	Cholecalciferol	24-30	CD274 molecule	Homo sapiens	133-153
31798578-4	2019	Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone.	Cholecalciferol	212-218	interferon gamma	Homo sapiens	35-44
31798578-4	2019	Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone.	Cholecalciferol	212-218	leukocyte immunoglobulin like receptor B4	Homo sapiens	79-117
31798578-10	2019	The percentage of FoxP3-positive cells in co-cultures with naive CD4+ T cells was significantly higher where gamma/D3DCs were used as stimulators compared to DCs treated with vit D3 alone and it could be partially reversed by PDL-1 blockade.	Cholecalciferol	175-181	forkhead box P3	Homo sapiens	18-23
31798578-10	2019	The percentage of FoxP3-positive cells in co-cultures with naive CD4+ T cells was significantly higher where gamma/D3DCs were used as stimulators compared to DCs treated with vit D3 alone and it could be partially reversed by PDL-1 blockade.	Cholecalciferol	175-181	CD274 molecule	Homo sapiens	226-231
31737787-2	2019	The present study investigated vitamin D3 on over-expression of CXCR3 and CXCL10 in mice induced by cigarette smoking.	Cholecalciferol	31-41	chemokine (C-X-C motif) receptor 3	Mus musculus	64-69
31737787-2	2019	The present study investigated vitamin D3 on over-expression of CXCR3 and CXCL10 in mice induced by cigarette smoking.	Cholecalciferol	31-41	chemokine (C-X-C motif) ligand 10	Mus musculus	74-80
31559433-0	2019	Effect of vitamin D3 supplementation on insulin resistance and beta-cell function in prediabetes: a double-blind, randomized, placebo-controlled trial.	Cholecalciferol	10-20	insulin	Homo sapiens	40-47
31614338-11	2019	CONCLUSIONS: In severe vitamin D deficiency, a high-dose cholecalciferol supplementation was associated with a reduction in thrombin generation and an average decreased number of fibrin protofibrils per fibers and fibrin fiber size measured by turbidimetry.	Cholecalciferol	57-72	coagulation factor II, thrombin	Homo sapiens	124-132
31867158-3	2019	VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4.	Cholecalciferol	0-3	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	81-100
31867158-3	2019	VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4.	Cholecalciferol	0-3	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	102-108
31867158-3	2019	VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4.	Cholecalciferol	0-3	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	110-117
31867158-3	2019	VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4.	Cholecalciferol	0-3	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	122-129
31867158-3	2019	VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4.	Cholecalciferol	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	190-196
31559433-3	2019	OBJECTIVE: The purpose of this double-blind randomized placebo-controlled trial was to investigate the effect of vitamin D3 supplementation on insulin resistance (IR) and beta-cell function in people with prediabetes and suboptimal vitamin D status (&lt;50 nmol/L).	Cholecalciferol	113-123	insulin	Homo sapiens	143-150
31361973-12	2019	In the organoids and colitis IL-10-/- mice, vitamin D3 treatment increased VDR and ATG16L1 protein expression levels, which activated autophagic responses.	Cholecalciferol	44-54	interleukin 10	Mus musculus	29-34
31361973-12	2019	In the organoids and colitis IL-10-/- mice, vitamin D3 treatment increased VDR and ATG16L1 protein expression levels, which activated autophagic responses.	Cholecalciferol	44-54	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	75-78
31361973-12	2019	In the organoids and colitis IL-10-/- mice, vitamin D3 treatment increased VDR and ATG16L1 protein expression levels, which activated autophagic responses.	Cholecalciferol	44-54	autophagy related 16-like 1 (S. cerevisiae)	Mus musculus	83-90
31372708-0	2019	Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis.	Cholecalciferol	5-15	fibroblast growth factor 23	Homo sapiens	48-75
31365099-10	2019	CONCLUSIONS: In infants, vitamin D binding protein genotype affects 25OHD concentration and efficiency of high-dose vitamin D3 supplementation.	Cholecalciferol	116-126	GC vitamin D binding protein	Homo sapiens	25-50
31372708-8	2019	The meta-analyses found that serum intact FGF23 increased significantly after oral vitamin D3 supplementation in vitamin D-deficient participants with the pooled SMD of 0.36 (95%CI, 0.14, 0.57; p = 0.001; I2 of 36%).	Cholecalciferol	83-93	fibroblast growth factor 23	Homo sapiens	42-47
31372708-9	2019	Serum C-terminal FGF23 also increased after vitamin D3 supplementation in vitamin D-deficient participants with the pooled SMD of 0.28 although without reaching statistical significance (95%CI, - 0.08, 0.65; p = 0.13; I2 of 0%).	Cholecalciferol	44-54	fibroblast growth factor 23	Homo sapiens	17-22
31372708-13	2019	The present systematic review and meta-analysis revealed that serum intact FGF23 concentration increased significantly after oral vitamin D3 supplementation in vitamin D-deficient participants.	Cholecalciferol	130-140	fibroblast growth factor 23	Homo sapiens	75-80
31352041-0	2019	Effects of glucocorticoids on vitamin D3-metabolizing 24-hydroxylase (CYP24A1) in Saos-2 cells and primary human osteoblasts.	Cholecalciferol	30-40	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	70-77
31616008-3	2019	Mechanistically, we also found a gender-specific correlation of the CYP2C9rs1799853T/T genotype with serum vitamin D3 levels (P = 0.00085) and a modest effect on IL1beta levels after stimulation of PBMCs or blood with LPS and PHA (P = 0.0057 and P = 0.0058).	Cholecalciferol	107-117	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	68-74
31465769-9	2019	Vitamin D3 effects on epithelial intracellular Ca++ (Ca++i) were determined using the dye Cal-520.	Cholecalciferol	0-10	carbonic anhydrase 1	Mus musculus	53-58
31561249-14	2019	Thus, vitamin D3 is involved in desmosome and hemidesmosome junction formation/regulation, and their decreased expression likely contributes to the loosely adherent corneal epithelium in VDR KO mice.	Cholecalciferol	6-16	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	187-190
31250540-10	2019	Supplementation with 2,000-IU/d vitamin D3 is more effective than 1,000 IU/d in pregnant women in terms of increasing circulating 25(OH)D, ameliorating pro-inflammatory markers notably TNF-alpha in mother and IL-6 in cord blood, and improving neonatal outcomes including the birth sizes.	Cholecalciferol	32-42	tumor necrosis factor	Homo sapiens	185-194
31250540-10	2019	Supplementation with 2,000-IU/d vitamin D3 is more effective than 1,000 IU/d in pregnant women in terms of increasing circulating 25(OH)D, ameliorating pro-inflammatory markers notably TNF-alpha in mother and IL-6 in cord blood, and improving neonatal outcomes including the birth sizes.	Cholecalciferol	32-42	interleukin 6	Homo sapiens	209-213
31582399-1	2019	OBJECTIVE: To determine the effect of vitamin D3 on interferon-beta (IFN-beta) response and immune regulation in MS mononuclear cells (MNCs).	Cholecalciferol	38-48	interferon beta 1	Homo sapiens	52-67
31582399-1	2019	OBJECTIVE: To determine the effect of vitamin D3 on interferon-beta (IFN-beta) response and immune regulation in MS mononuclear cells (MNCs).	Cholecalciferol	38-48	interferon beta 1	Homo sapiens	69-77
31325498-1	2019	A phase inversion based cold water dilution method was developed to encapsulate Vitamin D3 (Vit D) in nano-structured lipid carrier (NLC) by blending caprylic-/capric triglyceride, Leciva S70 and Kolliphor HS 15, Vit D and sodium chloride.	Cholecalciferol	80-90	vitrin	Homo sapiens	92-95
31326626-2	2019	Calcitriol (1,25D3), the most active form of vitamin D3, acts mainly through the vitamin D receptor, regulating the expression of target genes.	Cholecalciferol	45-55	vitamin D receptor	Homo sapiens	81-99
31001801-9	2019	Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation.	Cholecalciferol	164-174	oxytocin/neurophysin I prepropeptide	Rattus norvegicus	23-26
31001801-9	2019	Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation.	Cholecalciferol	164-174	prodynorphin	Rattus norvegicus	28-32
31001801-9	2019	Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation.	Cholecalciferol	164-174	proenkephalin	Rattus norvegicus	34-38
31001801-9	2019	Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation.	Cholecalciferol	164-174	proopiomelanocortin	Rattus norvegicus	40-44
31001801-9	2019	Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation.	Cholecalciferol	164-174	parathyroid hormone	Rattus norvegicus	46-49
31001801-9	2019	Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation.	Cholecalciferol	164-174	tachykinin, precursor 1	Rattus norvegicus	51-55
31001801-9	2019	Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation.	Cholecalciferol	164-174	transforming growth factor, beta 1	Rattus norvegicus	61-66
31352041-4	2019	In the current study, human osteosarcoma Saos-2 cells and primary human osteoblasts were found to express mRNA for the vitamin D receptor as well as activating and deactivating enzymes in vitamin D3 metabolism.	Cholecalciferol	188-198	vitamin D receptor	Homo sapiens	119-137
31527804-10	2019	Moreover, the expression levels of hsa-miR146b-5p in CD14+ monocytes were significantly increased after achieving SVR and 1(OH)Vitamin D3 treatment.	Cholecalciferol	127-137	CD14 molecule	Homo sapiens	53-57
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	interleukin 4	Mus musculus	135-139
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	interleukin 10	Mus musculus	141-146
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	transforming growth factor, beta 1	Mus musculus	152-160
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	interferon gamma	Mus musculus	213-222
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	interleukin 6	Mus musculus	224-228
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	tumor necrosis factor	Mus musculus	230-239
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	interleukin 17A	Mus musculus	245-250
31402771-10	2019	Real-time PCR results indicated that middle and high dose vitamin D3 treatment reduced T-bet and ROR-gammat expression, but enhanced GATA3 and Foxp3 expression.	Cholecalciferol	58-68	GATA binding protein 3	Mus musculus	133-138
31402771-10	2019	Real-time PCR results indicated that middle and high dose vitamin D3 treatment reduced T-bet and ROR-gammat expression, but enhanced GATA3 and Foxp3 expression.	Cholecalciferol	58-68	forkhead box P3	Mus musculus	143-148
31402771-12	2019	This study indicated that middle and high doses of vitamin D3 deviate the balance between Th1/Th2 and Th17/Treg to Th2 and Treg.	Cholecalciferol	51-61	negative elongation factor complex member C/D, Th1l	Mus musculus	90-93
31402771-12	2019	This study indicated that middle and high doses of vitamin D3 deviate the balance between Th1/Th2 and Th17/Treg to Th2 and Treg.	Cholecalciferol	51-61	heart and neural crest derivatives expressed 2	Mus musculus	94-97
31402771-12	2019	This study indicated that middle and high doses of vitamin D3 deviate the balance between Th1/Th2 and Th17/Treg to Th2 and Treg.	Cholecalciferol	51-61	heart and neural crest derivatives expressed 2	Mus musculus	115-118
31575929-8	2019	The expression of AGER was down-regulated by vitamin D3 treatment in aged testis.	Cholecalciferol	45-55	advanced glycosylation end product-specific receptor	Rattus norvegicus	18-22
31575929-10	2019	The immunolocalization of VDR showed increased immunostaining in the testis by vitamin D3 treatment.	Cholecalciferol	79-89	vitamin D receptor	Rattus norvegicus	26-29
31521173-0	2019	Correction to: Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3.	Cholecalciferol	171-181	vitamin D receptor	Homo sapiens	15-33
31539353-4	2019	Materials and methods We evaluated the effect of in vitro treatment with a precursor of VitD, cholecalciferol, on the activation/maturation phenotype of differentiated monocyte-derived DCs and their ability to transfer HIV-1 to autologous CD4+ T cells.	Cholecalciferol	94-109	CD4 molecule	Homo sapiens	239-242
31427443-13	2019	In vitro experiments showed that active vitamin D3 inhibits TGF-beta-induced Smad2/3 phosphorylation in MRC-5 cells.	Cholecalciferol	40-50	transforming growth factor alpha	Homo sapiens	60-68
31427443-13	2019	In vitro experiments showed that active vitamin D3 inhibits TGF-beta-induced Smad2/3 phosphorylation in MRC-5 cells.	Cholecalciferol	40-50	SMAD family member 2	Homo sapiens	77-84
31572402-1	2019	The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) activates at sub-nanomolar concentrations the transcription factor vitamin D receptor (VDR).	Cholecalciferol	4-14	vitamin D receptor	Homo sapiens	137-155
31572402-1	2019	The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) activates at sub-nanomolar concentrations the transcription factor vitamin D receptor (VDR).	Cholecalciferol	4-14	vitamin D receptor	Homo sapiens	157-160
31508781-3	2019	Immunomodulation mediated by vitamin D3, especially the production of antimicrobial peptides such as cathelicidin LL-37, might be related to the severity and symptoms of CD.	Cholecalciferol	29-39	cathelicidin antimicrobial peptide	Homo sapiens	114-119
31344685-1	2019	OBJECTIVE: To determine whether vitamin D3 supplementation improves insulin sensitivity, using the hyperinsulinemic-euglycemic clamp.	Cholecalciferol	32-42	insulin	Homo sapiens	68-75
31519581-6	2019	CONCLUSION: Antioxidant regulation via TXNIP is an important cell death mechanism in human endometrial cancer, and occurs via induction by vitamin D3.	Cholecalciferol	139-149	thioredoxin interacting protein	Homo sapiens	39-44
31583252-10	2019	Conclusion: The serum 25(OH)D level in patients with diabetes mellitus after long-term vitamin D3 supplementation is associated with CYP27B1 polymorphism.	Cholecalciferol	87-97	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	133-140
31313056-11	2019	The rs10766197 variant, near the CYP2R1 gene locus, significantly modified the efficacy of high-dose vitamin D3 supplementation for its effects on improving cognitive abilities indicate that some subjects might require a higher dose to benefit from in terms of cognitive performance.	Cholecalciferol	101-111	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	33-39
30696977-12	2019	CONCLUSIONS: In this novel preliminary clinical trial study, supplementation with cholecalciferol in HT patients for 3 months changed the balance of CD4+ T-cell subsets to improve the disease control.	Cholecalciferol	82-97	CD4 molecule	Homo sapiens	149-152
31265936-5	2019	In this work, best binding modes of vitamin D3 and E on insulin obtained from AutoDock Vina were selected for Molecular Dynamic, MD, study.	Cholecalciferol	36-46	insulin	Homo sapiens	56-63
30696977-8	2019	RESULTS: Results of this study showed that cholecalciferol supplementation caused a significant decrease in Th17/Tr1 ratio.	Cholecalciferol	43-58	thioredoxin reductase 1	Homo sapiens	113-116
31169292-6	2019	Furthermore, the DNA mismatch repair pathway is elevated in Lgr5hi cells by lower vitamin D3 and/or calcium in NWD1, paralleled by reduced accumulation of relevant somatic mutations detected by single-cell exome sequencing.	Cholecalciferol	82-92	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	60-64
30712064-0	2019	Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats.	Cholecalciferol	86-96	FYN binding protein 1	Rattus norvegicus	30-33
31395070-0	2019	Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3.	Cholecalciferol	156-166	vitamin D receptor	Homo sapiens	0-18
31176774-0	2019	Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome.	Cholecalciferol	0-10	caspase 3	Mus musculus	25-34
31176774-0	2019	Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome.	Cholecalciferol	0-10	CDK2 (cyclin-dependent kinase 2)-associated protein 1	Mus musculus	35-38
31176774-0	2019	Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome.	Cholecalciferol	0-10	methylenetetrahydrofolate reductase	Mus musculus	40-45
31176774-0	2019	Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome.	Cholecalciferol	0-10	phosphoglycolate phosphatase	Mus musculus	51-65
31460469-1	2019	The multimolecular complexes formed between 2,4,6,8,10,12-hexanitro-2,4,6,6,8,10,12-hexaazaisowurtzitane (CL-20) and nitropyrazole compounds were investigated using B3LYP-D3/6-311G(d,p) and B97-3c methods.	Cholecalciferol	170-173	epithelial membrane protein 1	Homo sapiens	106-111
31496777-4	2019	As an affordable natural agent, vitamin D3 can be used to counteract obesity-induced inflammation, block early adipogenesis, enhance glucose uptake, counteract hyperleptinemia, ameliorate insulin resistance, and reduce hypertension.	Cholecalciferol	32-42	insulin	Homo sapiens	188-195
30916559-2	2019	Vitamin D3 acts via its metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] as potent agonist of the transcription factor vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	125-143
30916559-2	2019	Vitamin D3 acts via its metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] as potent agonist of the transcription factor vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	145-148
31387633-0	2019	Regulation of somatostatin expression by vitamin D3 and valproic acid in human adipose-derived mesenchymal stem cells.	Cholecalciferol	41-51	somatostatin	Homo sapiens	14-26
31387633-6	2019	Furthermore, the reprogramming effect of vitamin D3 and VPA was evaluated on somatostatin expression in pancreatic lineage differentiation.	Cholecalciferol	41-51	somatostatin	Homo sapiens	77-89
31387633-12	2019	Upon stimulation with vitamin D3, nuclear translocation of vitamin D receptor (VDR) was observed.	Cholecalciferol	22-32	vitamin D receptor	Homo sapiens	59-77
31387633-12	2019	Upon stimulation with vitamin D3, nuclear translocation of vitamin D receptor (VDR) was observed.	Cholecalciferol	22-32	vitamin D receptor	Homo sapiens	79-82
31387633-13	2019	Interestingly, the presence of vitamin D3 reduced the transcription of the somatostatin gene.	Cholecalciferol	31-41	somatostatin	Homo sapiens	75-87
31387633-18	2019	Moreover, our results demonstrate that somatostatin expression in ADMSC is constitutive, partially secreted and regulated by vitamin D3 and VPA.	Cholecalciferol	125-135	somatostatin	Homo sapiens	39-51
31395070-5	2019	Multivariate multiple linear regression analyses were used to determine the association between the VDR single-nucleotide polymorphisms (SNPs) and changes in metabolic and anthropometric measures in response to vitamin D3 supplementation.	Cholecalciferol	211-221	vitamin D receptor	Homo sapiens	100-103
31395070-8	2019	In addition, the heterozygous genotype (Bb) of the BsmI VDR was associated with higher increase in WC following vitamin D3 supplementation, compared to BB [2.7(0.1,5.3)].	Cholecalciferol	112-122	vitamin D receptor	Homo sapiens	56-59
31395070-10	2019	CONCLUSIONS: Findings of this study showed that genetic variation in the VDR gene was associated with changes in cardio-metabolic parameters in breast cancer survivors, supplemented with vitamin D3, results could provide a novel insight into better understanding of which subset of individuals benefit most from normalization of vitamin D status.	Cholecalciferol	187-197	vitamin D receptor	Homo sapiens	73-76
31450894-0	2019	IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer.	Cholecalciferol	29-39	interleukin 6	Homo sapiens	0-4
31450894-12	2019	Conclusion: The presence of IL-6 in the breast tumor microenvironment may impair theactivity of vitamin D3 signaling, limiting its anti-tumor effects in TNBC.	Cholecalciferol	96-106	interleukin 6	Homo sapiens	28-32
30802957-11	2019	Topical application of both vitamin D3 and 1,25(OH)2 D3 to the gingiva of mice led to rapid inhibition of IL-1alpha expression, a prominent pro-inflammatory cytokine associated with inflammation, which also exhibited more than a 2-fold decrease from basal levels in OKF6/TERT1 cells upon 1,25(OH)2 D3 treatment, as determined by RNA-seq.	Cholecalciferol	28-38	interleukin 1 alpha	Mus musculus	106-115
30597013-9	2019	Moreover, ChemR23-deficient mice were protected against vitamin D3-induced vascular calcification.	Cholecalciferol	56-66	chemokine-like receptor 1	Mus musculus	10-17
31043390-1	2019	PURPOSE: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D), has immunoregulatory properties via binding vitamin D receptor (VDR).	Cholecalciferol	47-57	vitamin D receptor	Homo sapiens	137-155
31043390-1	2019	PURPOSE: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D), has immunoregulatory properties via binding vitamin D receptor (VDR).	Cholecalciferol	47-57	vitamin D receptor	Homo sapiens	157-160
31044263-9	2019	Furthermore, using a multiple linear regression model, we confirmed FGF23 as a predictor for reduced trabecular parameters even when adjusting for confounding factors such as age, BMI, phosphate, bone-specific alkaline phosphatase, vitamin D3, and PTH.	Cholecalciferol	232-242	fibroblast growth factor 23	Homo sapiens	68-73
30825201-3	2019	In this study, we show that 1,25-dihydroxyvitamin D3 (the active form of vitamin D3) induces senescence of glioma cells and increases the expression of senescence markers, INK4A and cyclin-dependent kinase inhibitor 1A (CDKN1A).	Cholecalciferol	42-52	cyclin dependent kinase inhibitor 2A	Homo sapiens	172-177
30825201-3	2019	In this study, we show that 1,25-dihydroxyvitamin D3 (the active form of vitamin D3) induces senescence of glioma cells and increases the expression of senescence markers, INK4A and cyclin-dependent kinase inhibitor 1A (CDKN1A).	Cholecalciferol	42-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	182-218
30825201-3	2019	In this study, we show that 1,25-dihydroxyvitamin D3 (the active form of vitamin D3) induces senescence of glioma cells and increases the expression of senescence markers, INK4A and cyclin-dependent kinase inhibitor 1A (CDKN1A).	Cholecalciferol	42-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	220-226
31357443-5	2019	Thus, a high dose of vitamin D3 (5.0 mg/kg sc) could improve the depression-like profile in long-term OVX adult female rats subjected to the CUMS procedure, which might be mediated by the regulation of BDNF and the NT-3/NT-4 signaling pathways in the hippocampus, as well as the corticosterone/ACTH levels of the blood serum.	Cholecalciferol	21-31	brain-derived neurotrophic factor	Rattus norvegicus	202-206
31592277-24	2019	Vitamin D3 level (1,25(OH)2D) was negatively associated with serum TNF-alpha concentration and airway obstruction level and severity of COPD.	Cholecalciferol	0-10	tumor necrosis factor	Homo sapiens	67-76
31357443-4	2019	The results showed that vitamin D3 (5.0 mg/kg), as well as fluoxetine treatment, considerably reversed the depression-like state in the SPT and FST, decreased serum corticosterone/ACTH levels, and increased BDNF and NT-3/NT-4 levels in the hippocampus of long-term OVX rats compared to OVX rats with CUMS (p < 0.05).	Cholecalciferol	24-34	brain-derived neurotrophic factor	Rattus norvegicus	207-211
31357443-5	2019	Thus, a high dose of vitamin D3 (5.0 mg/kg sc) could improve the depression-like profile in long-term OVX adult female rats subjected to the CUMS procedure, which might be mediated by the regulation of BDNF and the NT-3/NT-4 signaling pathways in the hippocampus, as well as the corticosterone/ACTH levels of the blood serum.	Cholecalciferol	21-31	neurotrophin 3	Rattus norvegicus	215-219
31357443-4	2019	The results showed that vitamin D3 (5.0 mg/kg), as well as fluoxetine treatment, considerably reversed the depression-like state in the SPT and FST, decreased serum corticosterone/ACTH levels, and increased BDNF and NT-3/NT-4 levels in the hippocampus of long-term OVX rats compared to OVX rats with CUMS (p < 0.05).	Cholecalciferol	24-34	neurotrophin 3	Rattus norvegicus	216-220
31357443-4	2019	The results showed that vitamin D3 (5.0 mg/kg), as well as fluoxetine treatment, considerably reversed the depression-like state in the SPT and FST, decreased serum corticosterone/ACTH levels, and increased BDNF and NT-3/NT-4 levels in the hippocampus of long-term OVX rats compared to OVX rats with CUMS (p < 0.05).	Cholecalciferol	24-34	neurotrophin 4	Rattus norvegicus	221-225
31357443-5	2019	Thus, a high dose of vitamin D3 (5.0 mg/kg sc) could improve the depression-like profile in long-term OVX adult female rats subjected to the CUMS procedure, which might be mediated by the regulation of BDNF and the NT-3/NT-4 signaling pathways in the hippocampus, as well as the corticosterone/ACTH levels of the blood serum.	Cholecalciferol	21-31	neurotrophin 4	Rattus norvegicus	220-224
31287793-0	2019	miR-99b-3p is induced by vitamin D3 and contributes to its antiproliferative effects in gastric cancer cells by targeting HoxD3.	Cholecalciferol	25-35	microRNA 99b	Homo sapiens	0-7
30827608-2	2019	In this study, the interactions of beta-casein with curcumin and vitamin D3 under the same physico-chemical conditions were investigated.	Cholecalciferol	65-75	casein beta	Bos taurus	35-46
30827608-5	2019	Conversely, the SPR responses obtained for vitamin D3 show that the interactions between this hydrophobic compound and the beta-casein immobilized on the sensor chip were below the sensitivity of the SPR apparatus.	Cholecalciferol	43-53	casein beta	Bos taurus	123-134
31287793-0	2019	miR-99b-3p is induced by vitamin D3 and contributes to its antiproliferative effects in gastric cancer cells by targeting HoxD3.	Cholecalciferol	25-35	homeobox D3	Homo sapiens	122-127
31287793-2	2019	miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b.	Cholecalciferol	99-109	microRNA 99b	Homo sapiens	0-7
31287793-2	2019	miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b.	Cholecalciferol	99-109	vitamin D receptor	Homo sapiens	122-140
31287793-2	2019	miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b.	Cholecalciferol	99-109	vitamin D receptor	Homo sapiens	142-145
31287793-2	2019	miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b.	Cholecalciferol	99-109	microRNA 99b	Homo sapiens	181-188
31287793-4	2019	Overall, our results show that miR-99b-3p mediates the antiproliferative of vitamin D3 in GC cells and might hold promise for prognosis and therapeutic strategies for GC treatment.	Cholecalciferol	76-86	microRNA 99b	Homo sapiens	31-38
30856341-8	2019	Vitamin D3 treatment significantly decreased ovariectomy-induced cardiac Fas and FasL apoptosis-related proteins, whole heart mass, body mass, C-reactive protein, and malondialdehyde accompanied by decreased inflammation and reduced collagen deposition between cardiac muscle fibres.	Cholecalciferol	0-10	Fas ligand	Rattus norvegicus	81-85
30478352-10	2019	Treatment of UF cells with Vitamin D3 (100 nM) significantly decreased DNA damage and restored DDR concomitant with VDR induction.	Cholecalciferol	27-37	vitamin D receptor	Homo sapiens	116-119
30478352-11	2019	Notably, the PCR array demonstrated that among 75 downregulated genes after VDR KD, 67 (89.3%) were upregulated after vitamin D3 treatment.	Cholecalciferol	118-128	vitamin D receptor	Homo sapiens	76-79
31350967-0	2019	Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial.	Cholecalciferol	57-67	vitamin D receptor	Homo sapiens	22-25
31350967-4	2019	This study was aimed to assess the impact of vitamin D3 supplementation onthe serum concentration of inflammatory markers and antioxidant capacity with regard to VDR polymorphism in theVDR gene in breast cancer women.	Cholecalciferol	45-55	vitamin D receptor	Homo sapiens	162-165
30856341-8	2019	Vitamin D3 treatment significantly decreased ovariectomy-induced cardiac Fas and FasL apoptosis-related proteins, whole heart mass, body mass, C-reactive protein, and malondialdehyde accompanied by decreased inflammation and reduced collagen deposition between cardiac muscle fibres.	Cholecalciferol	0-10	C-reactive protein	Rattus norvegicus	143-161
31460236-0	2019	Synthesis and CYP24A1-Dependent Metabolism of 23-Fluorinated Vitamin D3 Analogues.	Cholecalciferol	61-71	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	14-21
31278070-2	2019	Deficiency in vitamin D3 (VD3), which regulates gene expression through binding to vitamin D receptor (VDR), is associated with high risks of COPD susceptibility.	Cholecalciferol	14-24	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	83-101
31278070-2	2019	Deficiency in vitamin D3 (VD3), which regulates gene expression through binding to vitamin D receptor (VDR), is associated with high risks of COPD susceptibility.	Cholecalciferol	14-24	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	103-106
30959372-8	2019	RESULTS: Vitamin D3 significantly increased the expression of mPR alpha and mPR beta on the surface of CD4+ T cells (p &lt;= 0.05).	Cholecalciferol	9-19	S100 calcium binding protein A6 (calcyclin)	Mus musculus	62-71
30959372-8	2019	RESULTS: Vitamin D3 significantly increased the expression of mPR alpha and mPR beta on the surface of CD4+ T cells (p &lt;= 0.05).	Cholecalciferol	9-19	progesterone receptor	Mus musculus	76-84
31293564-0	2019	MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.	Cholecalciferol	33-43	microtubule associated protein 7	Homo sapiens	0-4
31233568-7	2019	In young healthy mice acute or chronic treatment with D3 induces hyperactivation of TrkA-mediated signals in hippocampus, and causes a deficit in hippocampal-dependent memory consolidation proximal to drug exposure, without affecting learning or memory retrieval.	Cholecalciferol	54-56	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	84-88
31293564-0	2019	MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.	Cholecalciferol	33-43	mucin like 1	Homo sapiens	9-14
31174403-0	2019	The Influence of Different Cholecalciferol Supplementation Regimes on 25(OH) Cholecalciferol, Calcium and Parathyroid Hormone after Bariatric Surgery.	Cholecalciferol	27-42	parathyroid hormone	Homo sapiens	106-125
31140795-5	2019	Advantages of the stereodivergent nature of this reaction are seen in the synthesis of anti- and syn-1,3 amino alcohol vitamin D3 analogue intermediates in half the steps and higher overall yield relative to previous routes.	Cholecalciferol	119-129	synapsin I	Homo sapiens	97-102
31167402-0	2019	Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial.	Cholecalciferol	106-116	vitamin D receptor	Homo sapiens	0-18
31167402-5	2019	In addition, carriers of BsmI bb showed greater decrease in circulating TNFalpha levels after vitamin D3 supplementation [recessive model (bb compared to BB & Bb].	Cholecalciferol	94-104	tumor necrosis factor	Homo sapiens	72-80
31167402-8	2019	Overall, our findings suggest that changes in certain inflammatory biomarkers in breast cancer survivors with low plasma 25(OH)D levels, supplemented with vitamin D3, may depend on VDR SNPs and haplotypes.	Cholecalciferol	155-165	vitamin D receptor	Homo sapiens	181-184
31281852-0	2019	Vitamin D3 Activates Phosphatidylinositol-3-Kinase/Protein Kinase B via Insulin-Like Growth Factor-1 to Improve Testicular Function in Diabetic Rats.	Cholecalciferol	0-10	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	21-50
31281852-0	2019	Vitamin D3 Activates Phosphatidylinositol-3-Kinase/Protein Kinase B via Insulin-Like Growth Factor-1 to Improve Testicular Function in Diabetic Rats.	Cholecalciferol	0-10	insulin-like growth factor 1	Rattus norvegicus	72-100
31281852-7	2019	Results: Twelve weeks of vitamin D3 supplementation improved the testosterone levels, as shown by the increase in the level of serum IGF-1 in diabetic rats.	Cholecalciferol	25-35	insulin-like growth factor 1	Rattus norvegicus	133-138
31281852-8	2019	Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), which was a downstream of the signaling pathway of IGF-1, was significantly increased after vitamin D3 treatment.	Cholecalciferol	153-163	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	0-29
31281852-8	2019	Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), which was a downstream of the signaling pathway of IGF-1, was significantly increased after vitamin D3 treatment.	Cholecalciferol	153-163	AKT serine/threonine kinase 1	Rattus norvegicus	55-58
30790351-8	2019	Using linear regression we determined a curve with 25(OH)D3/cholecalciferol versus normalized Cyp2R1 mRNA abundance with an R2 value of 0.85.	Cholecalciferol	60-75	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	94-100
31281852-8	2019	Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), which was a downstream of the signaling pathway of IGF-1, was significantly increased after vitamin D3 treatment.	Cholecalciferol	153-163	insulin-like growth factor 1	Rattus norvegicus	112-117
31281852-9	2019	Conclusions: The study shows that vitamin D3 may promote the expression of testosterone and improve testicular function in diabetic rats by activating PI3K/AKT via IGF-1.	Cholecalciferol	34-44	AKT serine/threonine kinase 1	Rattus norvegicus	156-159
31281852-9	2019	Conclusions: The study shows that vitamin D3 may promote the expression of testosterone and improve testicular function in diabetic rats by activating PI3K/AKT via IGF-1.	Cholecalciferol	34-44	insulin-like growth factor 1	Rattus norvegicus	164-169
30923019-6	2019	Vitamin D3 treatment also increased CYP19A1 and decreased AR expression in the testes of d-gal-induced aged and normal rats.	Cholecalciferol	0-10	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	36-43
30923019-6	2019	Vitamin D3 treatment also increased CYP19A1 and decreased AR expression in the testes of d-gal-induced aged and normal rats.	Cholecalciferol	0-10	ferredoxin reductase	Rattus norvegicus	58-60
30930221-3	2019	Hence, we assessed the role of sodium butyrate (NaB), sodium octanoate (NaO) and cholecalciferol on S. aureus adhesin expression and its internalization into bMECs.	Cholecalciferol	81-96	AT695_RS03940	Staphylococcus aureus	110-117
30765133-4	2019	Tolerogenic DC (tolDC) obtained by vitamin D3 treatment were studied in parallel.	Cholecalciferol	35-45	chemokine (C-C motif) ligand 22	Mus musculus	12-14
30961641-1	2019	OBJECTIVE: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs.	Cholecalciferol	137-147	vitamin D receptor	Homo sapiens	11-29
30961641-1	2019	OBJECTIVE: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs.	Cholecalciferol	137-147	vitamin D receptor	Homo sapiens	31-34
30477283-4	2019	Vitamin D3 was administered in patients with either vitamin D deficiency or insufficiency and CRP serum vitamin D levels and PMS were re-examined at 6 months of administration.	Cholecalciferol	0-10	C-reactive protein	Homo sapiens	94-97
30070012-8	2019	CONCLUSIONS: Deficiency of vitamin D3 accompanied with higher IL-17 in an inverse pattern may have a possible role in active acne vulgaris.	Cholecalciferol	27-37	interleukin 17A	Homo sapiens	62-67
30678899-4	2019	The simultaneous presence of nHA and vitamin D3 led to the increased activity of ALP in the early stages (on the 14th day) and increased mineralization in the late stages (on the 21st day) in differentiated hADSCs.	Cholecalciferol	37-47	ATHS	Homo sapiens	81-84
30678899-5	2019	Further, it was found that the use of nHA and vitamin D3 resulted in increased expression of BGLAP and COLL I and reduced expression of ALP and RUNX2 in hADSCs for 21 days.	Cholecalciferol	46-56	bone gamma-carboxyglutamate protein	Homo sapiens	93-98
30678899-5	2019	Further, it was found that the use of nHA and vitamin D3 resulted in increased expression of BGLAP and COLL I and reduced expression of ALP and RUNX2 in hADSCs for 21 days.	Cholecalciferol	46-56	ATHS	Homo sapiens	136-139
30678899-5	2019	Further, it was found that the use of nHA and vitamin D3 resulted in increased expression of BGLAP and COLL I and reduced expression of ALP and RUNX2 in hADSCs for 21 days.	Cholecalciferol	46-56	RUNX family transcription factor 2	Homo sapiens	144-149
30922377-10	2019	RESULTS: The level of Il-17A in EBC significantly decreased in calcitriol group from 0,475 pg/mL (+- SD 0,515 pg/mL) to 0,384 pg/mL (+- SD 0,429 pg/mL) (p = 0,008); there was no change in cholecalciferol group (p = 0,074).	Cholecalciferol	188-203	interleukin 17A	Homo sapiens	22-28
31019650-8	2019	Additional experiment showed that I/R-induced upregulation of renal GRP78 and CHOP was inhibited by cholecalciferol.	Cholecalciferol	100-115	heat shock protein 5	Mus musculus	68-73
31019650-8	2019	Additional experiment showed that I/R-induced upregulation of renal GRP78 and CHOP was inhibited by cholecalciferol.	Cholecalciferol	100-115	DNA-damage inducible transcript 3	Mus musculus	78-82
31019650-11	2019	I/R-induced upregulation of renal NADPH oxidases, such as p47phox, gp91phox, and nox4, was inhibited by cholecalciferol.	Cholecalciferol	104-119	neutrophil cytosolic factor 1	Mus musculus	58-65
30888584-0	2019	Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial.	Cholecalciferol	0-15	fibroblast growth factor 23	Homo sapiens	42-47
30927227-4	2019	The proteins of FGF19 subfamily influence the enterohepatic circulation of bile, participate in glucose and lipid metabolism regulation, and maintenance of phosphorus and vitamin D3 homeostasis.	Cholecalciferol	171-181	fibroblast growth factor 19	Homo sapiens	16-21
31002352-7	2019	Furthermore, vitamin D3 delayed the onset of tumor formation derived from injection of ovarian CSCs to nude mice, by reducing CD44 and enhancing beta-catenin expressions in vivo.	Cholecalciferol	13-23	CD44 antigen	Mus musculus	126-130
31002352-7	2019	Furthermore, vitamin D3 delayed the onset of tumor formation derived from injection of ovarian CSCs to nude mice, by reducing CD44 and enhancing beta-catenin expressions in vivo.	Cholecalciferol	13-23	catenin (cadherin associated protein), beta 1	Mus musculus	145-157
31039479-0	2019	Protective effects of novel derivatives of vitamin D3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms.	Cholecalciferol	43-53	NFE2 like bZIP transcription factor 2	Homo sapiens	141-145
31039479-0	2019	Protective effects of novel derivatives of vitamin D3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms.	Cholecalciferol	43-53	tumor protein p53	Homo sapiens	150-153
31039479-12	2019	In conclusion, pretreatment of keratinocytes with 1,25(OH)2D3 or CYP11A1-derived vitamin D3- or lumisterol hydroxy-derivatives, protected them against UVB-induced damage via activation of the Nrf2-dependent antioxidant response and p53-phosphorylation, as well as by the induction of the DNA repair system.	Cholecalciferol	81-91	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	65-72
31039479-12	2019	In conclusion, pretreatment of keratinocytes with 1,25(OH)2D3 or CYP11A1-derived vitamin D3- or lumisterol hydroxy-derivatives, protected them against UVB-induced damage via activation of the Nrf2-dependent antioxidant response and p53-phosphorylation, as well as by the induction of the DNA repair system.	Cholecalciferol	81-91	NFE2 like bZIP transcription factor 2	Homo sapiens	192-196
31039479-12	2019	In conclusion, pretreatment of keratinocytes with 1,25(OH)2D3 or CYP11A1-derived vitamin D3- or lumisterol hydroxy-derivatives, protected them against UVB-induced damage via activation of the Nrf2-dependent antioxidant response and p53-phosphorylation, as well as by the induction of the DNA repair system.	Cholecalciferol	81-91	tumor protein p53	Homo sapiens	232-235
31092845-1	2019	Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)2D3), affect multiple tissue types by interacting with the vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	126-144
31092845-1	2019	Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)2D3), affect multiple tissue types by interacting with the vitamin D receptor (VDR).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	146-149
31086078-6	2019	Using the CRISPR-Cas9 editing technology to knockout the vitamin D receptor, we found that the antiviral activity of vitamin D3 and 25(OH)D3 was not impaired in the vitamin D receptor knockout cells.	Cholecalciferol	117-127	vitamin D receptor	Homo sapiens	57-75
31086078-9	2019	Taken together, this study proposes a novel mode of action for the anti-hepatitis C virus activity of vitamin D3 that is mediated by 25(OH)D3 in a vitamin D receptor-independent mechanism.	Cholecalciferol	102-112	vitamin D receptor	Homo sapiens	147-165
30972950-0	2019	Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	72-75
30729713-1	2019	AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6).	Cholecalciferol	5-15	interleukin 6	Homo sapiens	165-178
30729713-1	2019	AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6).	Cholecalciferol	5-15	interleukin 6	Homo sapiens	180-184
31060176-14	2019	(2) At PIH 6 and 24, expressions of ZO-1 and occludin of intestinal tissue of mice in vitamin D3 vehicle+ burn injury group were significantly lower than those of mice in vitamin D3 vehicle+ sham injury group, and expressions of ZO-1 and occludin of intestinal tissue of mice in vitamin D3+ burn injury group were close to those of mice in vitamin D3+ sham injury group.	Cholecalciferol	86-96	occludin	Mus musculus	45-53
31060176-15	2019	At PIH 6 and 24, expressions of ZO-1 and occludin of intestinal tissue of mice in vitamin D3+ burn injury group were significantly higher than those of mice in vitamin D3 vehicle+ burn injury group.	Cholecalciferol	82-92	occludin	Mus musculus	41-49
31060176-18	2019	(4) At PIH 6 and 24, expressions of occludin of intestinal tissue of mice in vitamin D3 vehicle+ burn injury group were 0.720+-0.003, 0.638+-0.052 respectively, significantly lower than 0.918+-0.003 of mice in vitamin D3 vehicle+ sham injury group (t=57.33, 5.36, P&lt;0.05).	Cholecalciferol	77-87	occludin	Mus musculus	36-44
31060176-19	2019	At PIH 6 and 24, expressions of occludin of intestinal tissue of mice in vitamin D3+ burn injury group were 0.994+-0.058, 1.064+-0.060, close to 0.938+-0.023 of mice in vitamin D3+ sham injury group (t=0.91, 1.96, P&gt;0.05).	Cholecalciferol	73-83	occludin	Mus musculus	32-40
31060176-20	2019	At PIH 6 and 24, expressions of occludin of intestinal tissue of mice in vitamin D3 vehicle+ burn injury group were significantly lower than those of mice in vitamin D3+ burn injury group (t=4.75, 5.35, P&lt;0.05).	Cholecalciferol	73-83	occludin	Mus musculus	32-40
30978243-0	2019	25(OH)D3 and 1.25(OH)2D3 inhibits TNF-alpha expression in human monocyte derived macrophages.	Cholecalciferol	6-8	tumor necrosis factor	Homo sapiens	34-43
30612517-7	2019	Vitamin D3 treatment caused a restored lysosomal degradation function by activating the PDIA3 receptor, thereby promoting the nuclear translocation of PDIA3-STAT3 protein complex and the subsequent upregulation of MCOLN3 channels, resulting in an enhanced Ca2+ release from lysosomes and normalized lysosomal acidification.	Cholecalciferol	0-10	protein disulfide isomerase family A member 3	Homo sapiens	88-93
30612517-7	2019	Vitamin D3 treatment caused a restored lysosomal degradation function by activating the PDIA3 receptor, thereby promoting the nuclear translocation of PDIA3-STAT3 protein complex and the subsequent upregulation of MCOLN3 channels, resulting in an enhanced Ca2+ release from lysosomes and normalized lysosomal acidification.	Cholecalciferol	0-10	signal transducer and activator of transcription 3	Homo sapiens	157-162
30612517-7	2019	Vitamin D3 treatment caused a restored lysosomal degradation function by activating the PDIA3 receptor, thereby promoting the nuclear translocation of PDIA3-STAT3 protein complex and the subsequent upregulation of MCOLN3 channels, resulting in an enhanced Ca2+ release from lysosomes and normalized lysosomal acidification.	Cholecalciferol	0-10	mucolipin TRP cation channel 3	Homo sapiens	214-220
30430362-8	2019	Taken together, our findings provided novel experimental evidences supporting that vitamin D3 could reduce the predominantly oxidative stress-mediated inflammation induced by PM2.5via the p38/NF-kappaB/NLRP3 signaling pathway.	Cholecalciferol	83-93	mitogen-activated protein kinase 14	Homo sapiens	188-191
30430362-8	2019	Taken together, our findings provided novel experimental evidences supporting that vitamin D3 could reduce the predominantly oxidative stress-mediated inflammation induced by PM2.5via the p38/NF-kappaB/NLRP3 signaling pathway.	Cholecalciferol	83-93	nuclear factor kappa B subunit 1	Homo sapiens	192-201
30430362-8	2019	Taken together, our findings provided novel experimental evidences supporting that vitamin D3 could reduce the predominantly oxidative stress-mediated inflammation induced by PM2.5via the p38/NF-kappaB/NLRP3 signaling pathway.	Cholecalciferol	83-93	NLR family pyrin domain containing 3	Homo sapiens	202-207
31019650-11	2019	I/R-induced upregulation of renal NADPH oxidases, such as p47phox, gp91phox, and nox4, was inhibited by cholecalciferol.	Cholecalciferol	104-119	cytochrome b-245, beta polypeptide	Mus musculus	67-75
31019650-11	2019	I/R-induced upregulation of renal NADPH oxidases, such as p47phox, gp91phox, and nox4, was inhibited by cholecalciferol.	Cholecalciferol	104-119	NADPH oxidase 4	Mus musculus	81-85
31019650-12	2019	I/R-induced upregulation of heme oxygenase- (HO-) 1, gshpx and gshrd, was attenuated in mice pretreated with cholecalciferol.	Cholecalciferol	109-124	heme oxygenase 1	Mus musculus	28-51
30901909-2	2019	Vitamin D3 represents a master example of nutrigenomics, since via its metabolite 1alpha,25-dihydroxyvitamin D3, which binds with high-affinity to the vitamin D receptor, the secosteroid directly affects the epigenome and transcriptome at thousands of loci within the human genome.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	151-169
30792149-0	2019	Impact of high-fat diet and vitamin D3 supplementation on aortic stenosis establishment in waved-2 epidermal growth factor receptor mutant mice.	Cholecalciferol	28-38	epidermal growth factor receptor	Mus musculus	91-98
29602956-2	2019	Considering the high prevalence of vitamin D deficiency and the association of FGF23 with adverse outcomes, we investigated effects of vitamin D3 supplementation on FGF23 concentrations.	Cholecalciferol	135-145	fibroblast growth factor 23	Homo sapiens	165-170
30890957-1	2019	The molecular basis of vitamin D signaling implies that the metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) of the secosteroid vitamin D3 activates the transcription factor vitamin D receptor (VDR), which in turn modulates the expression of hundreds of primary vitamin D target genes.	Cholecalciferol	90-100	vitamin D receptor	Homo sapiens	180-198
30890957-1	2019	The molecular basis of vitamin D signaling implies that the metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) of the secosteroid vitamin D3 activates the transcription factor vitamin D receptor (VDR), which in turn modulates the expression of hundreds of primary vitamin D target genes.	Cholecalciferol	90-100	vitamin D receptor	Homo sapiens	200-203
30792149-0	2019	Impact of high-fat diet and vitamin D3 supplementation on aortic stenosis establishment in waved-2 epidermal growth factor receptor mutant mice.	Cholecalciferol	28-38	epidermal growth factor receptor	Mus musculus	99-131
30792149-9	2019	HFD and vitamin D3 supplementation did result in improvements to the model, since AS was only detected in 6 (15.3%) mice (2 in the 3 groups) and AR was developed in the remaining animals.	Cholecalciferol	8-18	ferredoxin reductase	Mus musculus	145-147
30222077-3	2019	Both cholecalciferol (D3) and 25-hydroxycholecalciferol [25(OH)D3] apical effluxes were decreased by chemical inhibition of ABCB1 in Caco-2 cells and increased by ABCB1 overexpression in Griptites or Madin-Darby canine kidney type II cells.	Cholecalciferol	5-20	ATP binding cassette subfamily B member 1	Homo sapiens	124-129
30389627-2	2019	An alternative pathway of vitamin D3 metabolism by cytochrome P450scc CYP11A1 was reported to afford 20-hydroxyvitamin D3 (3), functions of which remain to be explored.	Cholecalciferol	26-36	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	70-77
30387163-12	2019	Using a Cox regression model, the hazard ratio for hypocalcaemia in the cholecalciferol group was 0.56 (95%CI 0.32-0.98, P = 0.04) after stratification for Day 1 PTH.	Cholecalciferol	72-87	parathyroid hormone	Homo sapiens	162-165
30222077-3	2019	Both cholecalciferol (D3) and 25-hydroxycholecalciferol [25(OH)D3] apical effluxes were decreased by chemical inhibition of ABCB1 in Caco-2 cells and increased by ABCB1 overexpression in Griptites or Madin-Darby canine kidney type II cells.	Cholecalciferol	5-20	ATP binding cassette subfamily B member 1	Homo sapiens	163-168
28825325-1	2019	The role of vitamin D3 (VitD3) in the upregulation of osteopontin (OPN) and eNOS in the endothelium of cerebral arteries after subarachnoid hemorrhage (SAH) is investigated.	Cholecalciferol	12-22	secreted phosphoprotein 1	Rattus norvegicus	54-65
28825325-1	2019	The role of vitamin D3 (VitD3) in the upregulation of osteopontin (OPN) and eNOS in the endothelium of cerebral arteries after subarachnoid hemorrhage (SAH) is investigated.	Cholecalciferol	12-22	secreted phosphoprotein 1	Rattus norvegicus	67-70
28825325-1	2019	The role of vitamin D3 (VitD3) in the upregulation of osteopontin (OPN) and eNOS in the endothelium of cerebral arteries after subarachnoid hemorrhage (SAH) is investigated.	Cholecalciferol	12-22	nitric oxide synthase 3	Rattus norvegicus	76-80
30367940-1	2019	Three 23-hydroxylated vitamin D3 derivatives, which are metabolites of 25-hydroxyvitamin D3 produced by CYP24A1 and a related diastereomer, were efficiently synthesized.	Cholecalciferol	22-32	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	104-111
30967742-5	2019	VDDR2A is a rare autosomal recessive disorder caused by mutation in the Vitamin D receptor gene, leading to end-organ resistance to 1,25(OH)2 Vitamin D3.	Cholecalciferol	142-152	vitamin D receptor	Homo sapiens	72-90
30399506-1	2019	Vitamin D3 acting via its nuclear receptor (VDR) was shown to target many reproductive tissues and regulate their function.	Cholecalciferol	0-10	vitamin D receptor	Sus scrofa	44-47
30382318-0	2019	Mutation update and long-term outcome after treatment with active vitamin D3 in Chinese patients with pseudovitamin D-deficiency rickets (PDDR).	Cholecalciferol	66-76	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	138-142
30382318-14	2019	Our findings revealed after 1-year treatment of active vitamin D3, PTH and ALP significantly decreased.	Cholecalciferol	55-65	ATHS	Homo sapiens	75-78
30669280-2	2019	Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation.	Cholecalciferol	42-52	hepcidin antimicrobial peptide	Homo sapiens	94-102
31269890-5	2019	Therefore, this study aimed to investigate the effect of vitamin D3 supplementation on serum levels of brain-derived neurotrophic factor (BDNF), dopamine and serotonin in school-aged children with ADHD.	Cholecalciferol	57-67	brain derived neurotrophic factor	Homo sapiens	103-136
30253183-1	2019	Vitamin D3 (1,25-dihydroxyvitamin D3, VD3) in vitro attenuates the effect of the pro-inflammatory advanced glycation end products (AGEs) on steroidogenesis in human granulosa cells (GCs) by downregulating the receptor for AGEs (RAGE).	Cholecalciferol	0-10	advanced glycosylation end-product specific receptor	Homo sapiens	228-232
30662354-4	2019	Therefore, in this research, we aimed to explore the roles and mechanisms of FGF21 in VC induced by vitamin D3 plus nicotine (VDN) treatment rats.	Cholecalciferol	100-110	fibroblast growth factor 21	Rattus norvegicus	77-82
31602990-6	2019	Moreover, there was a significant inverse association between vitamin D3 levels and megalin levels in urine (OR=0.281, p=0.047).	Cholecalciferol	62-72	LDL receptor related protein 2	Homo sapiens	84-91
31269890-0	2019	The Effect of Vitamin D3 Supplementation on Serum BDNF, Dopamine and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder.	Cholecalciferol	14-24	brain derived neurotrophic factor	Homo sapiens	50-54
31269890-5	2019	Therefore, this study aimed to investigate the effect of vitamin D3 supplementation on serum levels of brain-derived neurotrophic factor (BDNF), dopamine and serotonin in school-aged children with ADHD.	Cholecalciferol	57-67	brain derived neurotrophic factor	Homo sapiens	138-142
31298160-2	2019	The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 acts as a nuclear hormone activating the transcription factor vitamin D receptor (VDR).	Cholecalciferol	4-14	vitamin D receptor	Homo sapiens	118-136
31298160-2	2019	The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 acts as a nuclear hormone activating the transcription factor vitamin D receptor (VDR).	Cholecalciferol	4-14	vitamin D receptor	Homo sapiens	138-141
30367913-0	2019	Vitamin D3 deficiency in puberty rats causes presynaptic malfunctioning through alterations in exocytotic release and uptake of glutamate/GABA and expression of EAAC-1/GAT-3 transporters.	Cholecalciferol	0-10	solute carrier family 1 member 1	Rattus norvegicus	161-167
30067874-10	2019	CONCLUSIONS: Asian compared with Caucasian males had a larger increment in measured free 25OHD following 150 000 units vitamin D3, possibly reflecting differences in DBP affinity for 25OHD.	Cholecalciferol	119-129	D-box binding PAR bZIP transcription factor	Homo sapiens	166-169
30367913-0	2019	Vitamin D3 deficiency in puberty rats causes presynaptic malfunctioning through alterations in exocytotic release and uptake of glutamate/GABA and expression of EAAC-1/GAT-3 transporters.	Cholecalciferol	0-10	solute carrier family 6 member 11	Rattus norvegicus	168-173
31061279-0	2019	Effect of Cholecalciferol in Food Allergy Mouse Model Is Associated with Decrease of CD69+ CD4+ T Cells.	Cholecalciferol	10-25	CD69 antigen	Mus musculus	85-89
31061279-0	2019	Effect of Cholecalciferol in Food Allergy Mouse Model Is Associated with Decrease of CD69+ CD4+ T Cells.	Cholecalciferol	10-25	CD4 antigen	Mus musculus	91-94
31061279-8	2019	Taken together, we suggest that administration of cholecalciferol might be useful to suppress symptomatic food allergy in association with the decrease of CD69+ CD4+ T cells.	Cholecalciferol	50-65	CD4 antigen	Mus musculus	161-164
31061279-6	2019	Treatment of cholecalciferol reduced the allergic diarrhea (p&lt;0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol.	Cholecalciferol	13-28	CD69 antigen	Mus musculus	103-107
31061279-6	2019	Treatment of cholecalciferol reduced the allergic diarrhea (p&lt;0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol.	Cholecalciferol	13-28	CD4 antigen	Mus musculus	109-112
31061279-6	2019	Treatment of cholecalciferol reduced the allergic diarrhea (p&lt;0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol.	Cholecalciferol	210-225	CD4 antigen	Mus musculus	109-112
31061279-6	2019	Treatment of cholecalciferol reduced the allergic diarrhea (p&lt;0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol.	Cholecalciferol	210-225	CD4 antigen	Mus musculus	109-112
31061279-8	2019	Taken together, we suggest that administration of cholecalciferol might be useful to suppress symptomatic food allergy in association with the decrease of CD69+ CD4+ T cells.	Cholecalciferol	50-65	CD69 antigen	Mus musculus	155-159
30618630-0	2018	1, 25-D3 Protects From Cerebral Ischemia by Maintaining BBB Permeability via PPAR-gamma Activation.	Cholecalciferol	6-8	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	77-87
29990544-7	2019	We also quantified an increase of 25(OH)D in adipose tissue that was inversely correlated to the free 25(OH)D. Interestingly, this accumulation of 25(OH)D in adipose tissue was highly correlated to the induction of Cyp2r1, which could actively participate in vitamin D3 trapping and subsequent conversion to 25(OH)D in adipose tissue.	Cholecalciferol	259-269	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	215-221
30930376-4	2019	We found that activated vitamin D3 may be a candidate agent for modulating the Abeta clearance across the BBB.	Cholecalciferol	24-34	amyloid beta precursor protein	Homo sapiens	79-84
31804923-1	2019	PURPOSE: The purpose of this retrospective cohort study was to measure the difference between cholecalciferol and ergocalciferol in their ability to effect vitamin D, parathyroid hormone (PTH), calcium, and phosphorous serum concentrations in patients with stage 3 or 4 chronic kidney disease.	Cholecalciferol	94-109	parathyroid hormone	Homo sapiens	167-186
31804923-1	2019	PURPOSE: The purpose of this retrospective cohort study was to measure the difference between cholecalciferol and ergocalciferol in their ability to effect vitamin D, parathyroid hormone (PTH), calcium, and phosphorous serum concentrations in patients with stage 3 or 4 chronic kidney disease.	Cholecalciferol	94-109	parathyroid hormone	Homo sapiens	188-191
30232176-3	2018	We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP.	Cholecalciferol	40-50	ATP binding cassette subfamily C member 1	Homo sapiens	121-125
30545134-13	2018	CONCLUSION: Oral supplementation with 3000 IU/day of vitamin D3 during eight weeks showed to be sufficient to prevent a decline in hematological levels of hemoglobin and hematocrit, and improve transferrin of 25(OH)D levels.	Cholecalciferol	53-63	transferrin	Homo sapiens	194-205
30232176-3	2018	We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP.	Cholecalciferol	40-50	phosphoglycolate phosphatase	Homo sapiens	189-193
30232176-3	2018	We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP.	Cholecalciferol	40-50	ATP binding cassette subfamily C member 1	Homo sapiens	195-199
30232176-3	2018	We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP.	Cholecalciferol	40-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	205-209
30232176-6	2018	Such collateral sensitivity, however, was not observed in HEK293/P-gp and HEK293/BCRP cells, although the vitamin D3 analogs inhibited calcein efflux in P-gp-overexpressing cells, and mitoxantrone efflux in BCRP-overexpressing cells.	Cholecalciferol	106-116	phosphoglycolate phosphatase	Homo sapiens	153-157
30232176-6	2018	Such collateral sensitivity, however, was not observed in HEK293/P-gp and HEK293/BCRP cells, although the vitamin D3 analogs inhibited calcein efflux in P-gp-overexpressing cells, and mitoxantrone efflux in BCRP-overexpressing cells.	Cholecalciferol	106-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	207-211
30453584-4	2018	The mRNA levels of TG2 and TNF-alpha were higher in PBMC of subjects having hypovitaminosis D, namely plasma 25(OH)vitamin D3 levels lower than 50 nmol/L, than in those with normal vitamin D levels.	Cholecalciferol	115-125	transglutaminase 2	Homo sapiens	19-22
30568875-1	2019	Objective: Through its receptor (VDR), vitamin D3 plays an important role in a wide variety of cellular processes.	Cholecalciferol	39-49	vitamin D receptor	Homo sapiens	33-36
30453584-4	2018	The mRNA levels of TG2 and TNF-alpha were higher in PBMC of subjects having hypovitaminosis D, namely plasma 25(OH)vitamin D3 levels lower than 50 nmol/L, than in those with normal vitamin D levels.	Cholecalciferol	115-125	tumor necrosis factor	Homo sapiens	27-36
30532541-3	2018	Patients were randomly assigned to 8-week oral treatment with 100,000 IU/week cholecalciferol (Vit D group) or a matching placebo (control group).	Cholecalciferol	78-93	vitrin	Homo sapiens	95-98
30356853-8	2018	The results of our study showed that vitamin D3 supplementation in patients with T1DM and T2DM reduced the concentrations of the inflammatory Th1-type cytokines and increased the levels of Th2-type cytokines.	Cholecalciferol	37-47	negative elongation factor complex member C/D	Homo sapiens	142-145
29733445-0	2018	Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial.	Cholecalciferol	67-77	parathyroid hormone	Homo sapiens	81-100
29733445-9	2018	Vitamin D3 supplementation reduced PTH by 3.4% (25th, 75th -9.0 to 8.7) compared to a 7.1% increase (25th, 75th -2.4 to 30.9) in the placebo group (P = .01), but did not affect blood pressure, cardiac conduction or concentrations of renin and aldosterone.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	35-38
29733445-9	2018	Vitamin D3 supplementation reduced PTH by 3.4% (25th, 75th -9.0 to 8.7) compared to a 7.1% increase (25th, 75th -2.4 to 30.9) in the placebo group (P = .01), but did not affect blood pressure, cardiac conduction or concentrations of renin and aldosterone.	Cholecalciferol	0-10	renin	Homo sapiens	233-238
29733445-11	2018	Vitamin D3 reduced PTH but did not affect blood pressure, cardiac conduction or the RAAS.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	19-22
30533524-5	2018	Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p &lt; 0.001 for all).	Cholecalciferol	9-19	interleukin 17A	Homo sapiens	43-49
30533524-5	2018	Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p &lt; 0.001 for all).	Cholecalciferol	9-19	interleukin 10	Homo sapiens	51-56
30533524-5	2018	Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p &lt; 0.001 for all).	Cholecalciferol	9-19	interleukin 6	Homo sapiens	62-66
30533524-8	2018	Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups.	Cholecalciferol	43-53	interleukin 17A	Homo sapiens	92-98
30533524-8	2018	Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups.	Cholecalciferol	43-53	interleukin 6	Homo sapiens	103-107
30533524-8	2018	Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups.	Cholecalciferol	43-53	interleukin 10	Homo sapiens	151-156
30533524-10	2018	Of interest, in a deficiency state of serum vitamin D3, IL-17A expression had a positive feedback effect on the expression of IL-6.	Cholecalciferol	44-54	interleukin 17A	Homo sapiens	56-62
30533524-10	2018	Of interest, in a deficiency state of serum vitamin D3, IL-17A expression had a positive feedback effect on the expression of IL-6.	Cholecalciferol	44-54	interleukin 6	Homo sapiens	126-130
29931459-2	2018	In a double-blinded, randomized placebo-controlled trial, we aimed to investigate effects of vitamin D3 supplementation on above-mentioned outcomes in healthy community-dwelling postmenopausal women with plasma levels of 25-hydroxyvitamin D (25(OH)D) below &lt; 50 nmol/l and high parathyroid hormone (PTH) levels.	Cholecalciferol	93-103	parathyroid hormone	Homo sapiens	281-300
29931459-2	2018	In a double-blinded, randomized placebo-controlled trial, we aimed to investigate effects of vitamin D3 supplementation on above-mentioned outcomes in healthy community-dwelling postmenopausal women with plasma levels of 25-hydroxyvitamin D (25(OH)D) below &lt; 50 nmol/l and high parathyroid hormone (PTH) levels.	Cholecalciferol	93-103	parathyroid hormone	Homo sapiens	302-305
29931459-4	2018	Vitamin D3 supplementation increased levels of 25(OH)D and 1,25(OH)2D by 230% (95% CI 189 to 272)%, p &lt; 0.001 and 58% (190 to 271%), p &lt; 0.001, respectively, and reduced PTH by 17% (- 23 to - 11%), p &lt; 0.001.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	176-179
30243072-2	2018	Vitamin D (Vit.D; cholecalciferol) has regulatory functions associated with both innate and adaptive immune responses.	Cholecalciferol	18-33	vitrin	Mus musculus	0-3
30166055-0	2018	The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production.	Cholecalciferol	4-14	interleukin 23, alpha subunit p19	Mus musculus	126-131
30166055-0	2018	The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production.	Cholecalciferol	4-14	interleukin 17A	Mus musculus	136-141
30166055-1	2018	BACKGROUND: Psoriasis is a Th1/Th17-mediated inflammatory dermatosis treated with topical corticosteroids and vitamin D3 analogs (VD3 As).	Cholecalciferol	110-120	negative elongation factor complex member C/D, Th1l	Mus musculus	27-30
30043092-7	2018	Vitamin D3 treatment reduced PTH by 17% (11-23%), but did not reduce RAAS activity.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	29-32
30297679-14	2018	Thus, our microarray, qPCR, functional studies and molecular modeling indicate that AhR is the major receptor target for 20,23(OH)2D3, opening an exciting area of investigation on the interaction of different vitamin D3-hydroxyderivatives with AhR and the subsequent downstream activation of signal transduction pathways in a cell-type-dependent manner.	Cholecalciferol	209-219	aryl hydrocarbon receptor	Homo sapiens	84-87
30043092-9	2018	CONCLUSIONS: Vitamin D3 supplementation normalized vitamin D levels and reduced PTH.	Cholecalciferol	13-23	parathyroid hormone	Homo sapiens	80-83
30184235-5	2018	Treatment of WT-TE671 cells with vitamin D3 alone and cotreatment with U0126 also promoted dysferlin expression.	Cholecalciferol	33-43	dysferlin	Homo sapiens	91-100
28913556-0	2018	High-dose vitamin D3 supplementation decreases the number of colonic CD103+ dendritic cells in healthy subjects.	Cholecalciferol	10-20	integrin subunit alpha E	Homo sapiens	69-74
30402875-0	2018	Vitamin D3 promotes cerebral angiogenesis after cerebral infarction in rats by activating Shh signaling pathway.	Cholecalciferol	0-10	sonic hedgehog signaling molecule	Rattus norvegicus	90-93
30233662-0	2018	CYP24A1 depletion facilitates the antitumor effect of vitamin D3 on thyroid cancer cells.	Cholecalciferol	54-64	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
30445888-18	2018	CONCLUSION: The proposed protocol of cholecalciferol and dietary calcium supplementation is safe and valid for correcting vitamin D abnormalities in almost all patients as well as reducing PTH levels in a high percentage of patients; however, it is not sufficient for normalization, particularly in patients exposed to tenofovir or efavirenz.	Cholecalciferol	37-52	parathyroid hormone	Homo sapiens	189-192
29310423-8	2018	To investigate the in vivo effects of Phloxine O, we induced TSLP expression in mouse ear skin by topically applying MC903, a vitamin D3 analogue that is a well-known inducer of atopic dermatitis-like symptoms.	Cholecalciferol	126-136	thymic stromal lymphopoietin	Mus musculus	61-65
29869004-9	2018	CONCLUSIONS: In BPD/DS patients, having hypovitaminosis D despite full oral supplementation, a single injection of 600,000 IU of cholecalciferol was effective in elevating vitamin D levels and normalizing levels of intact PTH.	Cholecalciferol	129-144	parathyroid hormone	Homo sapiens	222-225
29961920-11	2018	Our data demonstrate stimulation of FGF23 levels in mice which impacts mostly on 1,25 (OH)2 vitamin D3 levels and metabolism.	Cholecalciferol	92-102	fibroblast growth factor 23	Mus musculus	36-41
30119888-0	2018	Role of PKB/SGK-dependent phosphorylation of GSK-3alpha/beta in vascular calcification during cholecalciferol overload in mice.	Cholecalciferol	94-109	thymoma viral proto-oncogene 1	Mus musculus	8-11
30119888-0	2018	Role of PKB/SGK-dependent phosphorylation of GSK-3alpha/beta in vascular calcification during cholecalciferol overload in mice.	Cholecalciferol	94-109	serum/glucocorticoid regulated kinase 1	Mus musculus	12-15
30119888-0	2018	Role of PKB/SGK-dependent phosphorylation of GSK-3alpha/beta in vascular calcification during cholecalciferol overload in mice.	Cholecalciferol	94-109	glycogen synthase kinase 3 alpha	Mus musculus	45-55
30119888-5	2018	In gsk-3WT mice, high-dosed cholecalciferol induced vascular calcification and aortic osteo-/chondrogenic signaling, shown by increased expression of osteogenic markers Msx2, Cbfa1 and tissue-nonspecific alkaline phosphatase (Alpl).	Cholecalciferol	28-43	msh homeobox 2	Mus musculus	169-173
30119888-5	2018	In gsk-3WT mice, high-dosed cholecalciferol induced vascular calcification and aortic osteo-/chondrogenic signaling, shown by increased expression of osteogenic markers Msx2, Cbfa1 and tissue-nonspecific alkaline phosphatase (Alpl).	Cholecalciferol	28-43	runt related transcription factor 2	Mus musculus	175-180
30119888-5	2018	In gsk-3WT mice, high-dosed cholecalciferol induced vascular calcification and aortic osteo-/chondrogenic signaling, shown by increased expression of osteogenic markers Msx2, Cbfa1 and tissue-nonspecific alkaline phosphatase (Alpl).	Cholecalciferol	28-43	alkaline phosphatase, liver/bone/kidney	Mus musculus	226-230
30119888-7	2018	Cholecalciferol decreased aortic Gsk-3alpha/beta phosphorylation (Ser21/9) in gsk-3WT mice, while no phosphorylation was observed in gsk-3KI mice.	Cholecalciferol	0-15	glycogen synthase kinase 3 alpha	Mus musculus	33-43
30119888-8	2018	Moreover, the mRNA expression of type III sodium-dependent phosphate transporter (Pit1) and plasminogen activator inhibitor 1 (Pai1) was increased following cholecalciferol treatment in aortic tissue of gsk-3WT mice, effects again blunted in gsk-3KI mice.	Cholecalciferol	157-172	solute carrier family 20, member 1	Mus musculus	82-86
30119888-8	2018	Moreover, the mRNA expression of type III sodium-dependent phosphate transporter (Pit1) and plasminogen activator inhibitor 1 (Pai1) was increased following cholecalciferol treatment in aortic tissue of gsk-3WT mice, effects again blunted in gsk-3KI mice.	Cholecalciferol	157-172	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	92-125
30119888-8	2018	Moreover, the mRNA expression of type III sodium-dependent phosphate transporter (Pit1) and plasminogen activator inhibitor 1 (Pai1) was increased following cholecalciferol treatment in aortic tissue of gsk-3WT mice, effects again blunted in gsk-3KI mice.	Cholecalciferol	157-172	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	127-131
29775620-7	2018	Levels of VDBP along with total 25OH vitamin D3 can be used to calculate free 25OH vitamin D3 levels and these compare well with consensus values determined independently.	Cholecalciferol	83-93	GC vitamin D binding protein	Homo sapiens	10-14
29981295-3	2018	The present study aimed to investigate the cholecalciferol capability to revert depressive-like behavior induced by chronic corticosterone (CORT) treatment in mice and its implication on the oxidative stress modulation.	Cholecalciferol	43-58	cortistatin	Mus musculus	140-144
30246694-0	2018	Vitamin D3 Induced Decrease in IL-17 and Malondialdehyde, and Increase in IL-10 and Total Antioxidant Capacity Levels in Patients with Irritable Bowel Syndrome.	Cholecalciferol	0-10	interleukin 17A	Homo sapiens	31-36
30246694-0	2018	Vitamin D3 Induced Decrease in IL-17 and Malondialdehyde, and Increase in IL-10 and Total Antioxidant Capacity Levels in Patients with Irritable Bowel Syndrome.	Cholecalciferol	0-10	interleukin 10	Homo sapiens	74-79
30246694-8	2018	CONCLUSION: Vitamin D3 supplementation reduces the serum IL-17 and MDA levels, and augments the serum IL-10 and TAC levels in IBS patients, particularly in IBS-D subtype.	Cholecalciferol	12-22	interleukin 17A	Homo sapiens	57-62
30246694-8	2018	CONCLUSION: Vitamin D3 supplementation reduces the serum IL-17 and MDA levels, and augments the serum IL-10 and TAC levels in IBS patients, particularly in IBS-D subtype.	Cholecalciferol	12-22	interleukin 10	Homo sapiens	102-107
29981295-8	2018	It was observed that corticosterone treatment resulted in depressive-like behavior with established oxidative stress in mice, while cholecalciferol ameliorated both, behavioral (immobility time and grooming latency) and biochemical (protein carbonyl and nitrite levels) changes induced by CORT model, suggesting that cholecalciferol has antidepressant-like effect with the involvement of the oxidative stress modulation.	Cholecalciferol	132-147	cortistatin	Mus musculus	289-293
29655559-7	2018	The combination of negative DCAD and cholecalciferol reduced IGF1 concentrations prepartum.	Cholecalciferol	37-52	insulin like growth factor 1	Bos taurus	61-65
29955863-6	2018	A significant positive correlation was found between Cyp2r1 mRNA and 25(OH)D, and a stronger correlation was found between Cyp2r1 mRNA and the ratio of 25(OH)D3 to cholecalciferol.	Cholecalciferol	164-179	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	123-129
29889103-7	2018	Aortic calcification, stiffness, and osteo-/chondrogenic transdifferentiation in mice following cholecalciferol overload were strongly reduced by genetic knockout or pharmacological inhibition of Sgk1 by EMD638683.	Cholecalciferol	96-111	serum/glucocorticoid regulated kinase 1	Mus musculus	196-200
29436118-6	2018	RESULTS: In aorta from a rat vitamin D3 calcification model, CST abrogated calcium deposition and pathological damage, decreased the protein expression of OCN and beta-catenin and increased SM-alpha-actin expression.	Cholecalciferol	29-39	cortistatin	Rattus norvegicus	61-64
29527916-8	2018	These results suggest that androgens regulate the response of follicular cells to vitamin D3 in pigs ovary via regulation of VDR transcriptional activity.	Cholecalciferol	82-92	vitamin D receptor	Sus scrofa	125-128
29655559-11	2018	We found evidence of a feedback mechanism between vitamin D3 and IGF1, with positive effect size (ES) on the same day and 3 d later, and negative ES 9 d later, that was more evident in cholecalciferol-fed cows.	Cholecalciferol	50-60	insulin like growth factor 1	Bos taurus	65-69
29655559-11	2018	We found evidence of a feedback mechanism between vitamin D3 and IGF1, with positive effect size (ES) on the same day and 3 d later, and negative ES 9 d later, that was more evident in cholecalciferol-fed cows.	Cholecalciferol	185-200	insulin like growth factor 1	Bos taurus	65-69
29930537-12	2018	Cholecalciferol prevented prednisolone-elicited disturbances of the RANKL/RANK/OPG, which correlated with improved bioavailability and vitamin D signaling through VDR.	Cholecalciferol	0-15	TNF superfamily member 11	Rattus norvegicus	68-73
29452159-0	2018	CYP27A1 acts on the pre-vitamin D3 photoproduct, lumisterol, producing biologically active hydroxy-metabolites.	Cholecalciferol	24-34	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-7
29452159-3	2018	Recently, we reported that L3 is present in serum and that CYP11A1 can act on L3 producing monohydroxy- and dihydroxy-metabolites which inhibit skin cell proliferation similarly to 1alpha,25-dihydroxyvitamin D3.	Cholecalciferol	208-210	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	59-66
29452159-8	2018	CYP27A1 displayed a high kcat for the metabolism of L3 (76 mol product/min/mol CYP27A1) and a catalytic efficiency (kcat/Km) that was 260-fold higher than that for vitamin D3.	Cholecalciferol	164-174	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-7
29719203-1	2018	The metabolites of vitamin D3 (VD3) mediated by different cytochrome P450 (CYP) enzymes, play fundamental roles in many physiological processes in relation to human health.	Cholecalciferol	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
29719203-1	2018	The metabolites of vitamin D3 (VD3) mediated by different cytochrome P450 (CYP) enzymes, play fundamental roles in many physiological processes in relation to human health.	Cholecalciferol	19-29	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
29930537-12	2018	Cholecalciferol prevented prednisolone-elicited disturbances of the RANKL/RANK/OPG, which correlated with improved bioavailability and vitamin D signaling through VDR.	Cholecalciferol	0-15	TNF receptor superfamily member 11B	Rattus norvegicus	79-82
29930537-12	2018	Cholecalciferol prevented prednisolone-elicited disturbances of the RANKL/RANK/OPG, which correlated with improved bioavailability and vitamin D signaling through VDR.	Cholecalciferol	0-15	vitamin D receptor	Rattus norvegicus	163-166
29930537-14	2018	Our findings suggest that prednisolone-induced abnormalities in GR and RANKL/RANK/OPG signaling pathways are associated with the impairments of vitamin D auto/paracrine system in BM cells and can be ameliorated by cholecalciferol supplementation.	Cholecalciferol	214-229	TNF superfamily member 11	Rattus norvegicus	71-76
29930537-14	2018	Our findings suggest that prednisolone-induced abnormalities in GR and RANKL/RANK/OPG signaling pathways are associated with the impairments of vitamin D auto/paracrine system in BM cells and can be ameliorated by cholecalciferol supplementation.	Cholecalciferol	214-229	TNF receptor superfamily member 11B	Rattus norvegicus	82-85
29751936-14	2018	We found a significant correlation of cholecalciferol with the variability of SBP during the day.	Cholecalciferol	38-53	selenium binding protein 1	Homo sapiens	78-81
29676471-7	2018	Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay.	Cholecalciferol	0-10	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	149-156
29844206-4	2018	Activation of Vdr signaling by the vitamin D3 agonist calcitriol increased the outgrowth of EryD colonies from fetal liver and adult bone marrow, maintained progenitor potential, and delayed erythroid maturation, as revealed by clonogenic assays, suspension culture, cell surface phenotype, and gene expression analyses.	Cholecalciferol	35-45	vitamin D receptor	Homo sapiens	14-17
29726119-9	2018	Vitamin D3 levels appeared to be modulated by genetic variation in CYP24A1 and VDR genes.	Cholecalciferol	0-10	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	67-74
29726119-9	2018	Vitamin D3 levels appeared to be modulated by genetic variation in CYP24A1 and VDR genes.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	79-82
29676471-7	2018	Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay.	Cholecalciferol	0-10	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	160-167
29676471-7	2018	Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay.	Cholecalciferol	0-10	steroidogenic acute regulatory protein	Mus musculus	169-173
29676471-7	2018	Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay.	Cholecalciferol	0-10	cytochrome P450, family 19, subfamily a, polypeptide 1	Mus musculus	175-193
28918929-4	2018	However, increased VDR following vitamin D3 (VD3) treatment improved insulin release of early-passage MIN6 and insulin index of db/- (heterozygous) islets to levels seen in normal functional islets.	Cholecalciferol	33-43	vitamin D receptor	Rattus norvegicus	19-22
29522785-0	2018	Vitamin D3 inhibits the proliferation of T helper cells, downregulate CD4+ T cell cytokines and upregulate inhibitory markers.	Cholecalciferol	0-10	CD4 molecule	Homo sapiens	70-73
29392742-0	2018	The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells.	Cholecalciferol	4-14	toll-like receptor 9	Mus musculus	62-66
29392742-0	2018	The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells.	Cholecalciferol	4-14	myeloid differentiation primary response gene 88	Mus musculus	67-72
29431349-3	2018	The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes.	Cholecalciferol	58-68	interleukin 6	Homo sapiens	145-149
29431349-3	2018	The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes.	Cholecalciferol	58-68	C-X-C motif chemokine ligand 8	Homo sapiens	151-155
29431349-3	2018	The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes.	Cholecalciferol	58-68	interleukin 10	Homo sapiens	157-162
29431349-3	2018	The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes.	Cholecalciferol	58-68	hepatocyte growth factor	Homo sapiens	205-208
29875733-1	2018	The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the exclusive high-affinity ligand of the vitamin D receptor (VDR), a transcription factor with direct effects on gene expression.	Cholecalciferol	4-14	vitamin D receptor	Homo sapiens	115-133
29875733-1	2018	The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the exclusive high-affinity ligand of the vitamin D receptor (VDR), a transcription factor with direct effects on gene expression.	Cholecalciferol	4-14	vitamin D receptor	Homo sapiens	135-138
29467214-2	2018	25-Hydroxyvitamin D3 (25OHD3), the most abundant circulating metabolite of vitamin D3, is further transformed to the biologically active metabolite 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) by CYP27B1 in the kidney and extrarenal tissues, and to nonactive metabolites by other cytochrome P450 enzymes.	Cholecalciferol	10-20	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	201-208
29677904-0	2018	Re: Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.	Cholecalciferol	4-14	transient receptor potential cation channel subfamily C member 6	Homo sapiens	100-105
29528271-0	2018	Genetic polymorphisms of vitamin D3 metabolizing CYP24A1 and CYP2R1 enzymes in Turkish patients with ischemic stroke.	Cholecalciferol	25-35	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	49-56
29528271-0	2018	Genetic polymorphisms of vitamin D3 metabolizing CYP24A1 and CYP2R1 enzymes in Turkish patients with ischemic stroke.	Cholecalciferol	25-35	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	61-67
29504254-7	2018	CONCLUSIONS: Cholecalciferol supplementation, combined with a weight loss program, significantly improves insulin sensitivity in healthy subjects with obesity and might represent a personalized approach for insulin-resistant subjects with obesity.	Cholecalciferol	13-28	insulin	Homo sapiens	106-113
29849881-0	2018	Effects of Vitamin D3 on the NADPH Oxidase and Matrix Metalloproteinase 9 in an Animal Model of Global Cerebral Ischemia.	Cholecalciferol	11-21	matrix metallopeptidase 9	Mus musculus	47-73
29849881-8	2018	Pretreatment with vitamin D3 was especially effective on NOX2 subunits, MMP9, and the level of malondialdehyde and superoxide anion.	Cholecalciferol	18-28	cytochrome b-245, beta polypeptide	Mus musculus	57-61
29849881-8	2018	Pretreatment with vitamin D3 was especially effective on NOX2 subunits, MMP9, and the level of malondialdehyde and superoxide anion.	Cholecalciferol	18-28	matrix metallopeptidase 9	Mus musculus	72-76
29438722-3	2018	Mouse mammary glands express the critical enzymes responsible for 1,25(OH)2D synthesis (Cyp2r1 and Cyp27b1), degradation (Cyp24a1), as well as the vitamin D3 receptor (Vdr), and genetically modified mouse models have revealed a great deal about the role of vitamin D3 in cancer initiation and progression.	Cholecalciferol	147-157	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	168-171
29438722-4	2018	Ablation of Vdr or Cyp27b1 in murine models of mammary cancer reduces the anti-tumor effects of vitamin D3, while elevation of Cyp24a1 levels increases degradation of 1,25(OH)2D, leading to diminished anti-tumor effects.	Cholecalciferol	96-106	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	12-15
29438722-4	2018	Ablation of Vdr or Cyp27b1 in murine models of mammary cancer reduces the anti-tumor effects of vitamin D3, while elevation of Cyp24a1 levels increases degradation of 1,25(OH)2D, leading to diminished anti-tumor effects.	Cholecalciferol	96-106	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	19-26
29504254-7	2018	CONCLUSIONS: Cholecalciferol supplementation, combined with a weight loss program, significantly improves insulin sensitivity in healthy subjects with obesity and might represent a personalized approach for insulin-resistant subjects with obesity.	Cholecalciferol	13-28	insulin	Homo sapiens	207-214
29534438-0	2018	Expression of TXNIP in Cancer Cells and Regulation by 1,25(OH)2D3: Is It Really the Vitamin D3 Upregulated Protein?	Cholecalciferol	84-94	thioredoxin interacting protein	Homo sapiens	14-19
29633734-2	2018	Currently available treatments for HPT include high dose vitamin D (ergocalciferol, D2 and cholecalciferol, D3) or, the active metabolite dihydroxy vitamin D (calcitriol), in addition to calcium supplements.This regimen, if not well monitored, can lead to hypercalciuria, as PTH deficiency impairs renal calcium reabsorption.	Cholecalciferol	91-106	HPT	Homo sapiens	35-38
29632537-4	2018	In contrast, pharmacological agents, such as vitamin D3 and adalimumab, were reported to induce the expansion of Tregs by promoting the interaction of transmembrane TNF (tmTNF) with TNFR2.	Cholecalciferol	45-55	TNF receptor superfamily member 1B	Homo sapiens	182-187
29766000-2	2018	This study aimed to elucidate the effect of vitamin D3 on gene expression of lectin-like oxidized LDL receptor-1 (LOX-1), scavenger receptor-A (SR-A), Cluster of Differentiation 36 (CD36), and Cluster of Differentiation 68 (CD68) as the main Ox-LDL receptors in streptozotocin (STZ)-induced diabetic rat aortas.	Cholecalciferol	44-54	oxidized low density lipoprotein receptor 1	Rattus norvegicus	114-119
29766000-9	2018	CD68 and LOX-1 expression were greater in the vitamin D3/diabetic rats than in the diabetic control and healthy control rats, respectively.	Cholecalciferol	46-56	oxidized low density lipoprotein receptor 1	Rattus norvegicus	9-14
29462197-9	2018	The level of Let-7 in thymic B progenitors was up regulated by in vitro co-culture with IL15, Vitamin-D3, and retinoic acid, thus down-regulating Arid3a to promote B cell differentiation.	Cholecalciferol	94-104	AT rich interactive domain 3A (BRIGHT-like)	Mus musculus	146-152
29349624-2	2018	RESULTS: Compared to the untreated control or individual drug, the combinations of aspirin and vitamin D3 significantly decreased the rates of cell proliferation by CCK-8 assay, and caused higher rates of cell apoptosis in both CAL-27 and SCC-15 cells by Annexin V-FITC apoptosis assay and flow cytometry.	Cholecalciferol	95-105	annexin A5	Homo sapiens	255-264
29349624-3	2018	Remarkably, the combined treatment with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 protein and p-Erk1/2 protein, examined by western blot analysis.	Cholecalciferol	52-62	BCL2 apoptosis regulator	Homo sapiens	106-111
29349624-3	2018	Remarkably, the combined treatment with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 protein and p-Erk1/2 protein, examined by western blot analysis.	Cholecalciferol	52-62	mitogen-activated protein kinase 3	Homo sapiens	126-132
29331461-0	2018	Stabilizing vitamin D3 using the molten globule state of alpha-lactalbumin.	Cholecalciferol	12-22	lactalbumin alpha	Bos taurus	57-74
29331461-3	2018	The MG state of alpha-LA exposes a significant number of hydrophobic patches that could be used to bind and stabilize small hydrophobic molecules such as vitamin D3 (vitD).	Cholecalciferol	154-164	lactalbumin alpha	Bos taurus	16-24
29273827-12	2018	CONCLUSION: These findings suggest that oral administration of vitamin D3 analogues (ALF and ELD) stimulates FCA but plain vitamin D3 does not.	Cholecalciferol	63-73	general transcription factor IIA subunit 1 like	Homo sapiens	85-88
29273827-12	2018	CONCLUSION: These findings suggest that oral administration of vitamin D3 analogues (ALF and ELD) stimulates FCA but plain vitamin D3 does not.	Cholecalciferol	123-133	general transcription factor IIA subunit 1 like	Homo sapiens	85-88
29273827-13	2018	Those effects of vitamin D3 compounds on FCA were independent of serum calcitriol concentration, suggesting that ALF and ELD may directly stimulate intestinal vitamin D receptors.	Cholecalciferol	17-27	general transcription factor IIA subunit 1 like	Homo sapiens	113-116
27988847-0	2018	Calcium and vitamin D3 combinations improve fatty liver disease through AMPK-independent mechanisms.	Cholecalciferol	12-22	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	72-76
28795342-0	2018	Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial.	Cholecalciferol	10-25	fibroblast growth factor 23	Homo sapiens	43-48
28795342-2	2018	However, the effect of Cholecalciferol therapy on FGF23 serum level in patients with vitamin D deficiency has not been studied, yet.	Cholecalciferol	23-38	fibroblast growth factor 23	Homo sapiens	50-55
28795342-5	2018	RESULTS: After Cholecalciferol therapy, delta of serum PTH in treatment group was less than the controls (P &lt; 0.001).	Cholecalciferol	15-30	parathyroid hormone	Homo sapiens	55-58
30511526-10	2018	mRNA expression of Arg-1 in vitamin D3 group was higher than that in AS-serum group (t=6.219, P&lt;0.05), while mRNA expression of iNOS was lower than that in AS-serum group (t=5.876, P&lt;0.05).	Cholecalciferol	28-38	arginase 1	Homo sapiens	19-24
29682582-0	2018	Vitamin D3 Protects against Diabetic Retinopathy by Inhibiting High-Glucose-Induced Activation of the ROS/TXNIP/NLRP3 Inflammasome Pathway.	Cholecalciferol	0-10	thioredoxin interacting protein	Homo sapiens	106-111
29682582-0	2018	Vitamin D3 Protects against Diabetic Retinopathy by Inhibiting High-Glucose-Induced Activation of the ROS/TXNIP/NLRP3 Inflammasome Pathway.	Cholecalciferol	0-10	NLR family pyrin domain containing 3	Homo sapiens	112-117
29682582-7	2018	Results: Vitamin D3 significantly downregulated intracellular ROS and inhibited TRX-interacting protein (TXNIP)/NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome pathway activation.	Cholecalciferol	9-19	thioredoxin interacting protein	Homo sapiens	80-103
29682582-7	2018	Results: Vitamin D3 significantly downregulated intracellular ROS and inhibited TRX-interacting protein (TXNIP)/NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome pathway activation.	Cholecalciferol	9-19	thioredoxin interacting protein	Homo sapiens	105-110
29682582-7	2018	Results: Vitamin D3 significantly downregulated intracellular ROS and inhibited TRX-interacting protein (TXNIP)/NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome pathway activation.	Cholecalciferol	9-19	NLR family pyrin domain containing 3	Homo sapiens	165-170
29682582-8	2018	Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio.	Cholecalciferol	14-24	vascular endothelial growth factor A	Homo sapiens	33-67
29682582-8	2018	Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio.	Cholecalciferol	14-24	vascular endothelial growth factor A	Homo sapiens	69-73
29682582-8	2018	Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio.	Cholecalciferol	14-24	BCL2 associated X, apoptosis regulator	Homo sapiens	94-97
29682582-8	2018	Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio.	Cholecalciferol	14-24	BCL2 apoptosis regulator	Homo sapiens	98-103
29682582-10	2018	Conclusions: Vitamin D3 decreases diabetes-induced ROS and exerts protective effects against retinal vascular damage and cell apoptosis in association with inhibition of the ROS/TXNIP/NLRP3 inflammasome pathway.	Cholecalciferol	13-23	thioredoxin interacting protein	Homo sapiens	178-183
29682582-10	2018	Conclusions: Vitamin D3 decreases diabetes-induced ROS and exerts protective effects against retinal vascular damage and cell apoptosis in association with inhibition of the ROS/TXNIP/NLRP3 inflammasome pathway.	Cholecalciferol	13-23	NLR family pyrin domain containing 3	Homo sapiens	184-189
29243851-5	2018	Cholecalciferol treatment partially restored renal Oat3 mRNA/protein expression back to that of vitamin D-sufficient mice.	Cholecalciferol	0-15	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	51-55
29483908-12	2018	Expression of the tissue homing-associated markers alpha4beta7 and CCR9 or CCR10 on lymphocytes can be influenced by vitamin A and vitamin D3, respectively.	Cholecalciferol	131-141	C-C motif chemokine receptor 9	Bos taurus	67-71
29483908-12	2018	Expression of the tissue homing-associated markers alpha4beta7 and CCR9 or CCR10 on lymphocytes can be influenced by vitamin A and vitamin D3, respectively.	Cholecalciferol	131-141	C-C motif chemokine receptor 10	Bos taurus	75-80
29439405-0	2018	Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	41-60
29186386-0	2018	Gene Expression Pattern in Response to Cholecalciferol Supplementation Highlights Cubilin as a Major Protein of 25(OH)D Uptake in Adipocytes and Male Mice White Adipose Tissue.	Cholecalciferol	39-54	cubilin (intrinsic factor-cobalamin receptor)	Mus musculus	82-89
29186386-4	2018	Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT.	Cholecalciferol	23-38	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	185-192
29186386-4	2018	Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT.	Cholecalciferol	23-38	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	194-201
29186386-4	2018	Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT.	Cholecalciferol	23-38	cubilin (intrinsic factor-cobalamin receptor)	Mus musculus	217-224
29186386-4	2018	Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT.	Cholecalciferol	157-172	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	185-192
29186386-4	2018	Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT.	Cholecalciferol	157-172	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	194-201
29403473-5	2017	Only a minority of in vitro generated vitamin D3 (vitD3)-treated tolDCs expressed the inflammatory chemokine receptor CCR5.	Cholecalciferol	38-48	C-C motif chemokine receptor 5	Homo sapiens	118-122
30856079-0	2018	Vitamin D3 supplementation improves serum SFRP5 and Wnt5a levels in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.	Cholecalciferol	0-10	secreted frizzled related protein 5	Homo sapiens	42-47
30856079-0	2018	Vitamin D3 supplementation improves serum SFRP5 and Wnt5a levels in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.	Cholecalciferol	0-10	Wnt family member 5A	Homo sapiens	52-57
30856079-1	2018	Objective: To explore the effect of vitamin D3 on novel serum adipokines, secreted frizzled-related protein 5 (SFRP5) and Wingless-Type MMTV Integration Site Family Member 5a (Wnt5a) levels in Type 2 Diabetes Mellitus (T2DM) patients.	Cholecalciferol	36-46	Wnt family member 5A	Homo sapiens	176-181
30856079-9	2018	Conclusion: 8 weeks of vitamin D3 supplementation for patients with type 2 diabetes may increase serum anti-inflammatory adipokine SFRP5 but decrease serum pro-inflammatory Wnt5a and TNF-alpha.	Cholecalciferol	23-33	secreted frizzled related protein 5	Homo sapiens	131-136
30856079-9	2018	Conclusion: 8 weeks of vitamin D3 supplementation for patients with type 2 diabetes may increase serum anti-inflammatory adipokine SFRP5 but decrease serum pro-inflammatory Wnt5a and TNF-alpha.	Cholecalciferol	23-33	Wnt family member 5A	Homo sapiens	173-178
30856079-9	2018	Conclusion: 8 weeks of vitamin D3 supplementation for patients with type 2 diabetes may increase serum anti-inflammatory adipokine SFRP5 but decrease serum pro-inflammatory Wnt5a and TNF-alpha.	Cholecalciferol	23-33	tumor necrosis factor	Homo sapiens	183-192
29153546-1	2018	Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro.	Cholecalciferol	0-10	interleukin 2 receptor subunit alpha	Homo sapiens	23-42
29273504-0	2018	Fibroblast growth factor 21 ameliorates vascular calcification by inhibiting osteogenic transition in vitamin D3 plus nicotine-treated rats.	Cholecalciferol	102-112	fibroblast growth factor 21	Rattus norvegicus	0-27
29273504-4	2018	Thus, in this study, we observed the effect and mechanism of FGF21 on VC induced by vitamin D3 plus nicotine (VDN) treated rats.	Cholecalciferol	84-94	fibroblast growth factor 21	Rattus norvegicus	61-66
29370073-3	2018	Studies with vitamin D3 plus phorbol ester transformed THP-1 macrophages demonstrated that functionalization, regardless of amount, corresponded with profoundly decreased NLRP3 inflammasome activation.	Cholecalciferol	13-23	NLR family, pyrin domain containing 3	Mus musculus	171-176
29153546-5	2018	We speculate that vitamin D3 may promote the maintenance of CD25-related immune homeostasis in MS.	Cholecalciferol	18-28	interleukin 2 receptor subunit alpha	Homo sapiens	60-64
29153546-1	2018	Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro.	Cholecalciferol	0-10	interleukin 2 receptor subunit alpha	Homo sapiens	44-49
29153546-1	2018	Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro.	Cholecalciferol	0-10	interleukin 2 receptor subunit alpha	Homo sapiens	51-55
29153546-2	2018	We investigated effects of 48-weeks vitamin D3 supplements on CD25-expression by CD4+ T cells of patients with multiple sclerosis (MS).	Cholecalciferol	36-46	interleukin 2 receptor subunit alpha	Homo sapiens	62-66
29257234-3	2018	The aim of the present study was to investigate the therapeutic effects and the underlying primary mechanism of FGF-21 on atherosclerosis in a rat model induced by vitamin D3 and a high fat diet.	Cholecalciferol	164-174	fibroblast growth factor 21	Rattus norvegicus	112-118
29416330-8	2018	Vitamin D3 restored uncoupled eNOS and endothelial function by increasing cytoprotective NO and decreasing the cytotoxic ONOO-.	Cholecalciferol	0-10	nitric oxide synthase 3	Homo sapiens	30-34
29416330-9	2018	The beneficial effect of vitamin D3 is associated with a favorable rate of NO and ONOO- release, restoration of the [NO]/[ONOO-] and the overall decrease in the overexpression of eNOS, inducible nitric oxide synthase and NADPH oxidase.	Cholecalciferol	25-35	nitric oxide synthase 3	Homo sapiens	179-183
30269120-3	2018	A combination of oral active vitamin D3 and phosphate salt is the current standard therapy for patients with FGF23-related hypophosphatemic rickets and osteomalacia.	Cholecalciferol	29-39	fibroblast growth factor 23	Homo sapiens	109-114
28034764-4	2018	The concept is based on the fact that vitamin D3 activates via its metabolite 1alpha,25-dihydroxyvitamin D3 the transcription factor vitamin D receptor and thus has a direct effect on the epigenome and transcriptome of many human tissues and cell types.	Cholecalciferol	38-48	vitamin D receptor	Homo sapiens	133-151
29115640-9	2018	In conclusion, IMA and NIL interfere with the vitamin D3 cascade due to their metabolism by CYP27B1.	Cholecalciferol	46-56	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	92-99
29021285-5	2017	Notably, in vitro experiments with trophoblasts showed increased production and secretion of 25(OH)D3 and higher CYP24A1 gene transcript abundance in response to cholecalciferol treatment.Conclusions: The numerous associations of many of the placental biomarkers of vitamin D metabolism with circulating vitamin D metabolites among pregnant women [including a CYP27B1-associated increase in 1,25(OH)2D3] and the evidence of trophoblast production and secretion of vitamin D metabolites, especially 25(OH)D3, suggest that the placenta may play an active role in modulating the vitamin D metabolite profile in maternal circulation in human pregnancy.	Cholecalciferol	162-177	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	113-120
30412176-0	2018	[The influence of the vitamin D3 level in the blood serum of lactase gene polymorphism on the development of chronic polypous rhinosinusitis].	Cholecalciferol	22-32	lactase	Homo sapiens	61-68
30412176-1	2018	The objective of the present study was to elucidate the possible correlations between the vitamin D3 level in the blood serum and lactase gene polymorphism (LCT-13910 T&gt;C) in the patients presenting with chronic polypous rhinosinusitis (CPRS).	Cholecalciferol	90-100	lactase	Homo sapiens	130-137
29021285-5	2017	Notably, in vitro experiments with trophoblasts showed increased production and secretion of 25(OH)D3 and higher CYP24A1 gene transcript abundance in response to cholecalciferol treatment.Conclusions: The numerous associations of many of the placental biomarkers of vitamin D metabolism with circulating vitamin D metabolites among pregnant women [including a CYP27B1-associated increase in 1,25(OH)2D3] and the evidence of trophoblast production and secretion of vitamin D metabolites, especially 25(OH)D3, suggest that the placenta may play an active role in modulating the vitamin D metabolite profile in maternal circulation in human pregnancy.	Cholecalciferol	162-177	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	360-367
28484266-4	2017	Upon phorbol-myristate acetate or Vitamin D3/granulocyte macrophage colony-stimulating factor (GM-CSF)-driven differentiation, both ADAR1 and ADAR2 enzymes are upregulated, with a concomitant global increase of A-to-I RNA editing.	Cholecalciferol	34-44	colony stimulating factor 2	Homo sapiens	95-101
28747359-5	2017	The model predicts that large perturbations in PTH or vitamin D3 synthesis have a greater impact on the plasma concentration of Ca2+ ([Ca2+]p) than on that of PO4 ([PO4]p); due to negative feedback loops, [PO4]p does not consistently increase when the production rate of PTH or vitamin D3 is decreased.	Cholecalciferol	54-64	parathyroid hormone	Rattus norvegicus	271-274
29271617-0	2017	Effects of Single Vitamin D3 Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency.	Cholecalciferol	18-28	fibroblast growth factor 23	Homo sapiens	64-91
29271617-0	2017	Effects of Single Vitamin D3 Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency.	Cholecalciferol	18-28	sclerostin	Homo sapiens	96-106
29271617-4	2017	The aim of this study was to evaluate the effects of vitamin D3 intramuscular injection therapy on serum fibroblast growth factor 23 concentrations, and several other parameters associated with bone metabolism such as sclerostin, dickkopf-1, and parathyroid hormone.	Cholecalciferol	53-63	fibroblast growth factor 23	Homo sapiens	105-132
28747359-5	2017	The model predicts that large perturbations in PTH or vitamin D3 synthesis have a greater impact on the plasma concentration of Ca2+ ([Ca2+]p) than on that of PO4 ([PO4]p); due to negative feedback loops, [PO4]p does not consistently increase when the production rate of PTH or vitamin D3 is decreased.	Cholecalciferol	278-288	parathyroid hormone	Rattus norvegicus	47-50
29165303-1	2017	In mouse skin models, mast cells have been shown to express vitamin D receptor (VDR) that can mediate the immunosuppressive effects of ultraviolet B radiation and vitamin D3.	Cholecalciferol	163-173	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	60-78
29165303-1	2017	In mouse skin models, mast cells have been shown to express vitamin D receptor (VDR) that can mediate the immunosuppressive effects of ultraviolet B radiation and vitamin D3.	Cholecalciferol	163-173	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	80-83
29165303-2	2017	However, VDR activation leads to the expression of CYP24A1, a hydroxylase that can inactivate vitamin D3 metabolites.	Cholecalciferol	94-104	vitamin D receptor	Homo sapiens	9-12
29165303-2	2017	However, VDR activation leads to the expression of CYP24A1, a hydroxylase that can inactivate vitamin D3 metabolites.	Cholecalciferol	94-104	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	51-58
28544067-4	2017	The present study investigated the effects of vitamin D3 on the expression of TLR3, TLR7, and TLR9 in SLE patients.	Cholecalciferol	46-56	toll like receptor 3	Homo sapiens	78-82
28544067-4	2017	The present study investigated the effects of vitamin D3 on the expression of TLR3, TLR7, and TLR9 in SLE patients.	Cholecalciferol	46-56	toll like receptor 7	Homo sapiens	84-88
28544067-4	2017	The present study investigated the effects of vitamin D3 on the expression of TLR3, TLR7, and TLR9 in SLE patients.	Cholecalciferol	46-56	toll like receptor 9	Homo sapiens	94-98
28484266-4	2017	Upon phorbol-myristate acetate or Vitamin D3/granulocyte macrophage colony-stimulating factor (GM-CSF)-driven differentiation, both ADAR1 and ADAR2 enzymes are upregulated, with a concomitant global increase of A-to-I RNA editing.	Cholecalciferol	34-44	adenosine deaminase RNA specific	Homo sapiens	132-137
28484266-4	2017	Upon phorbol-myristate acetate or Vitamin D3/granulocyte macrophage colony-stimulating factor (GM-CSF)-driven differentiation, both ADAR1 and ADAR2 enzymes are upregulated, with a concomitant global increase of A-to-I RNA editing.	Cholecalciferol	34-44	adenosine deaminase RNA specific B1	Homo sapiens	142-147
29171448-11	2017	RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively).	Cholecalciferol	28-38	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	81-100
28808057-0	2017	A kidney-specific genetic control module in mice governs endocrine regulation of the cytochrome P450 gene Cyp27b1 essential for vitamin D3 activation.	Cholecalciferol	128-138	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	106-113
28808057-2	2017	Terminal activation of vitamin D3 to its hormonal form, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), occurs in the kidney via the cytochrome P450 enzyme CYP27B1.	Cholecalciferol	23-33	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	153-160
29061804-4	2017	We aimed to investigate the effect of MART-10 [19-nor-2alpha-(3-hydroxypropyl)-1alpha,25(OH)2D3], a 1alpha,25-dihydroxy-vitamin D3 (1alpha,25(OH)2D3) analog, on PanNET cell metastasis after VEGF-A stimulation.	Cholecalciferol	119-130	vascular endothelial growth factor A	Homo sapiens	190-196
29084522-3	2017	The objective of this study was to determine if vitamin D3 at a comparatively high dose would replete 25-hydroxyvitamin D (25(OH)D) stores, improve BNP, PTH, cardiopulmonary function, reduce inflammatory markers, and improve quality of life (QOL) in HF patients.	Cholecalciferol	48-58	natriuretic peptide B	Homo sapiens	148-151
29084522-3	2017	The objective of this study was to determine if vitamin D3 at a comparatively high dose would replete 25-hydroxyvitamin D (25(OH)D) stores, improve BNP, PTH, cardiopulmonary function, reduce inflammatory markers, and improve quality of life (QOL) in HF patients.	Cholecalciferol	48-58	parathyroid hormone	Homo sapiens	153-156
28605609-4	2017	Therefore, we investigated the effects of postexercise supplementation with protein and carbohydrate (CHO) and vitamins D3 and K2 on the postexercise hepcidin response.	Cholecalciferol	111-122	hepcidin antimicrobial peptide	Homo sapiens	150-158
29171448-11	2017	RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively).	Cholecalciferol	28-38	cathelicidin antimicrobial peptide	Mus musculus	102-107
29171448-11	2017	RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively).	Cholecalciferol	28-38	microtubule-associated protein 1 light chain 3 beta	Mus musculus	109-113
29171448-11	2017	RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively).	Cholecalciferol	28-38	caspase 3	Mus musculus	115-124
29171448-11	2017	RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively).	Cholecalciferol	28-38	matrix metallopeptidase 13	Mus musculus	167-171
28130182-0	2017	Induction of CFTR gene expression by 1,25(OH)2 vitamin D3, 25OH vitamin D3, and vitamin D3 in cultured human airway epithelial cells and in mouse airways.	Cholecalciferol	47-57	CF transmembrane conductance regulator	Homo sapiens	13-17
28576736-5	2017	A blinded, unsupervised hierarchical clustering of participants based on global gene expression profiles revealed that participants with significantly higher serum vitamin D3 levels after treatment (P = 0.007) demonstrated increased skin expression of the anti-inflammatory mediator arginase-1 (P = 0.005), and a sustained reduction in skin redness (P = 0.02), correlating with significant expression of genes related to skin barrier repair.	Cholecalciferol	164-174	arginase 1	Homo sapiens	283-293
28664547-0	2017	Vitamin D3 ameliorates podocyte injury through the nephrin signalling pathway.	Cholecalciferol	0-10	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	51-58
28664547-4	2017	Vitamin D3 through its receptor, VDR, provides renal protection in DN but limited data exist about its effect on podocytes.	Cholecalciferol	0-10	vitamin D receptor	Rattus norvegicus	33-36
28130182-8	2017	Treatment of BEC with 10muM cholecalciferol led to increases in both CYP24A1 and CFTR mRNA levels, even when added to the apical surface of cells grown in an air-liquid interface, suggesting that topical administration of vitamin D could be used therapeutically.	Cholecalciferol	28-43	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	69-76
27923594-2	2017	Although CYP24A1 catalyzes multi-step oxidations toward the CD-ring side chain of the active vitamin D3 [1alpha,25(OH)2D3], the CYP24A1-dependent metabolism of AH-1 tended to stop at the first step hydroxylation at the C24-position of AH-1.	Cholecalciferol	93-103	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	9-16
28130182-8	2017	Treatment of BEC with 10muM cholecalciferol led to increases in both CYP24A1 and CFTR mRNA levels, even when added to the apical surface of cells grown in an air-liquid interface, suggesting that topical administration of vitamin D could be used therapeutically.	Cholecalciferol	28-43	cystic fibrosis transmembrane conductance regulator	Mus musculus	81-85
28257826-5	2017	This review will present the structural information on recognition of the vitamin D3 and metabolites by CYP proteins and DBP as well as the structural basis of VDR activation by 1,25(OH)2D3 and metabolites.	Cholecalciferol	74-84	D-box binding PAR bZIP transcription factor	Homo sapiens	121-124
28931466-7	2017	After treatment with 1-alpha,25-dihydroxyvitamin D3, the biologically active form of vitamin D3, there were significant increases in the ALP activities of Caco-2 cells.	Cholecalciferol	41-51	alkaline phosphatase, placental	Homo sapiens	137-140
28315703-1	2017	The molecular endocrinology of vitamin D is based on the facts that i) its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) is the high affinity ligand of the nuclear receptor vitamin D receptor (VDR) and ii) the transcription factor VDR is the unique target of 1,25(OH)2D3 in the nucleus.	Cholecalciferol	113-115	vitamin D receptor	Homo sapiens	202-205
28315703-1	2017	The molecular endocrinology of vitamin D is based on the facts that i) its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) is the high affinity ligand of the nuclear receptor vitamin D receptor (VDR) and ii) the transcription factor VDR is the unique target of 1,25(OH)2D3 in the nucleus.	Cholecalciferol	113-115	vitamin D receptor	Homo sapiens	240-243
28891930-3	2017	The active metabolite of vitamin D3 has an immunoregulatory role mediated by binding to the vitamin D receptor (VDR) in monocyte, macrophages, and lymphocytes.	Cholecalciferol	25-35	vitamin D receptor	Homo sapiens	92-110
28891930-3	2017	The active metabolite of vitamin D3 has an immunoregulatory role mediated by binding to the vitamin D receptor (VDR) in monocyte, macrophages, and lymphocytes.	Cholecalciferol	25-35	vitamin D receptor	Homo sapiens	112-115
28891930-9	2017	CONCLUSION: Genetic polymorphism in two SNP in VDR may be correlated with development of ASD symptoms by influencing functionality of vitamin D3 metabolism, while vitamin D3 levels were not significantly different between ASD and non-ASD children.	Cholecalciferol	134-144	vitamin D receptor	Homo sapiens	47-50
28746983-4	2017	Among the 13 human SULTs, SULT2A1 shows sulfating activity toward all vitamin D3 -related compounds, whereas SULT1A1 and SULT2B1a/SULT2B1b show sulfating activity exclusively for, respectively, calcitriol and 7-dehydrocholesterol.	Cholecalciferol	70-80	sulfotransferase family 2A member 1	Homo sapiens	26-33
28795969-0	2017	E-cadherin Mediates the Preventive Effect of Vitamin D3 in Colitis-associated Carcinogenesis.	Cholecalciferol	45-55	cadherin 1	Mus musculus	0-10
28795969-7	2017	Cell proliferation decreased in vitamin D3 groups compared with the control group after inhibition of expression of beta-catenin and its downstream target gene cyclin D1 in the colon.	Cholecalciferol	32-42	catenin (cadherin associated protein), beta 1	Mus musculus	116-128
28795969-7	2017	Cell proliferation decreased in vitamin D3 groups compared with the control group after inhibition of expression of beta-catenin and its downstream target gene cyclin D1 in the colon.	Cholecalciferol	32-42	cyclin D1	Mus musculus	160-169
28795969-8	2017	In vitro, vitamin D3 reduced the transcriptional activity and nuclear level of beta-catenin, and it also increased E-cadherin expression and its binding affinity for beta-catenin.	Cholecalciferol	10-20	catenin (cadherin associated protein), beta 1	Mus musculus	79-91
28795969-8	2017	In vitro, vitamin D3 reduced the transcriptional activity and nuclear level of beta-catenin, and it also increased E-cadherin expression and its binding affinity for beta-catenin.	Cholecalciferol	10-20	cadherin 1	Mus musculus	115-125
28795969-8	2017	In vitro, vitamin D3 reduced the transcriptional activity and nuclear level of beta-catenin, and it also increased E-cadherin expression and its binding affinity for beta-catenin.	Cholecalciferol	10-20	catenin (cadherin associated protein), beta 1	Mus musculus	166-178
28795969-9	2017	Moreover, repression of E-cadherin was rescued by supplemental vitamin D3 in mouse colons.	Cholecalciferol	63-73	cadherin 1	Mus musculus	24-34
28795969-11	2017	Our findings further suggest that upregulation of E-cadherin contributes to the preventive effect of vitamin D3 on beta-catenin activity.	Cholecalciferol	101-111	cadherin 1	Mus musculus	50-60
28795969-11	2017	Our findings further suggest that upregulation of E-cadherin contributes to the preventive effect of vitamin D3 on beta-catenin activity.	Cholecalciferol	101-111	catenin (cadherin associated protein), beta 1	Mus musculus	115-127
28692301-7	2017	Adjunctive vitamin D3 accelerated sputum culture conversion in patients with one or more minor alleles for SNPs in genes encoding the vitamin D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio &gt;= 1.47; P for interaction &lt;= 0.02).	Cholecalciferol	11-21	vitamin D receptor	Homo sapiens	134-152
28692301-7	2017	Adjunctive vitamin D3 accelerated sputum culture conversion in patients with one or more minor alleles for SNPs in genes encoding the vitamin D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio &gt;= 1.47; P for interaction &lt;= 0.02).	Cholecalciferol	11-21	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	221-228
28780161-0	2017	Synthesis and evaluation of vitamin D3 analogues with C-11 modifications as inhibitors of Hedgehog signaling.	Cholecalciferol	28-38	RNA polymerase III subunit K	Homo sapiens	54-58
28662432-7	2017	RESULTS: Low vitamin D3 levels were accompanied with decreased expression of cathelicidin and VDR in PKDL-BT patients.	Cholecalciferol	13-23	vitamin D receptor	Homo sapiens	94-97
27402475-0	2017	High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults.	Cholecalciferol	10-20	hepcidin antimicrobial peptide	Homo sapiens	41-49
27402475-3	2017	We aimed to examine the effect of high-dose vitamin D3 on plasma hepcidin, inflammatory cytokine, and ferritin concentrations in healthy adults.	Cholecalciferol	44-54	hepcidin antimicrobial peptide	Homo sapiens	65-73
27402475-7	2017	After 1 week, plasma hepcidin concentrations decreased by 73% from baseline in those who received vitamin D3 (geometric mean ratio [GMR] = 0.27 (95% CI: 0.11-0.62); P = 0.005); there was no significant change in the placebo group (GMR = 0.73 (95% CI: 0.49-1.09); P = 0.11).	Cholecalciferol	98-108	hepcidin antimicrobial peptide	Homo sapiens	21-29
27402475-9	2017	CONCLUSIONS: High-dose vitamin D3 significantly reduced plasma hepcidin concentrations in healthy adults 1 week post-dosing, without a change in plasma pro-inflammatory cytokine or ferritin concentrations.	Cholecalciferol	23-33	hepcidin antimicrobial peptide	Homo sapiens	63-71
28575224-2	2017	Objective: To determine whether SNPs in DHCR7, CYP2R1, CYP24A1, and GC are associated with the response to gestational cholecalciferol supplementation.	Cholecalciferol	119-134	7-dehydrocholesterol reductase	Homo sapiens	40-45
28532201-11	2017	Interestingly, vitamin D3 inhibits ex vivo NO production, iNOS and NF-kappaB expression in BD patients.	Cholecalciferol	15-25	nitric oxide synthase 2	Homo sapiens	58-62
29041890-0	2017	[Effect of Cholecalciferol and Diuretics as Components of Combination Antihypertensive Therapy on Plasma Renin Activity and Endothelial Function in Patients With Arterial Hypertension].	Cholecalciferol	11-26	renin	Homo sapiens	105-110
29041890-1	2017	AIM: To evaluate the effect of cholecalciferol and diuretics as components of combination antihypertensive therapy (CAHT) on plasma renin activity (PRA) and endothelial function in patients with arterial hypertension (AH).	Cholecalciferol	31-46	renin	Homo sapiens	132-137
28575224-2	2017	Objective: To determine whether SNPs in DHCR7, CYP2R1, CYP24A1, and GC are associated with the response to gestational cholecalciferol supplementation.	Cholecalciferol	119-134	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	47-53
28575224-2	2017	Objective: To determine whether SNPs in DHCR7, CYP2R1, CYP24A1, and GC are associated with the response to gestational cholecalciferol supplementation.	Cholecalciferol	119-134	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	55-62
28575224-12	2017	Conclusions: Genetic variation in DHCR7, which encodes 7-dehyrocholesterol reductase in the epidermal vitamin D biosynthesis pathway, appears to modify baseline 25(OH)D. In contrast, the response to antenatal cholecalciferol supplementation was associated with SNPs in CYP2R1, which may alter 25-hydroxylase activity, and GC, which may affect vitamin D binding protein synthesis or metabolite affinity.	Cholecalciferol	209-224	7-dehydrocholesterol reductase	Homo sapiens	34-39
27671249-1	2017	In this study, we investigated the role of vitamin D3 (VitD3) on endogenous osteopontin (OPN), a neuroprotective glycoprotein, after subarachnoid hemorrhage (SAH).	Cholecalciferol	43-53	secreted phosphoprotein 1	Rattus norvegicus	76-87
28686246-1	2017	DMY combined with the dietary vitamin D3 at lower concentrations exhibited a synergistic effect on the inhibition of tyrosinase.	Cholecalciferol	30-40	tyrosinase	Homo sapiens	117-127
27671249-1	2017	In this study, we investigated the role of vitamin D3 (VitD3) on endogenous osteopontin (OPN), a neuroprotective glycoprotein, after subarachnoid hemorrhage (SAH).	Cholecalciferol	43-53	secreted phosphoprotein 1	Rattus norvegicus	89-92
27671249-3	2017	Vitamin D3 (30, 60, 120 ng/kg/day) increased more than one fold endogenous OPN expression in astrocytes and endothelial cells of rat brain.	Cholecalciferol	0-10	secreted phosphoprotein 1	Rattus norvegicus	75-78
27671249-6	2017	These protective effects of vitamin D3 were completely attenuated by intracerebroventricular injection of transcription inhibitor Actinomycin D and significantly inhibited by small interfering ribonucleic acid (siRNA) for vitamin D receptor and OPN in Pre-SAH + VitD3 rats.	Cholecalciferol	28-38	vitamin D receptor	Rattus norvegicus	222-240
27671249-6	2017	These protective effects of vitamin D3 were completely attenuated by intracerebroventricular injection of transcription inhibitor Actinomycin D and significantly inhibited by small interfering ribonucleic acid (siRNA) for vitamin D receptor and OPN in Pre-SAH + VitD3 rats.	Cholecalciferol	28-38	secreted phosphoprotein 1	Rattus norvegicus	245-248
27671249-8	2017	The results show that intranasal vitamin D3 attenuates blood-brain barrier (BBB) disruption through endogenous upregulation of OPN and subsequent CD44 and P-gp glycosylation signals in brain endothelial cells.	Cholecalciferol	33-43	secreted phosphoprotein 1	Rattus norvegicus	127-130
27671249-8	2017	The results show that intranasal vitamin D3 attenuates blood-brain barrier (BBB) disruption through endogenous upregulation of OPN and subsequent CD44 and P-gp glycosylation signals in brain endothelial cells.	Cholecalciferol	33-43	CD44 molecule (Indian blood group)	Rattus norvegicus	146-150
27671249-8	2017	The results show that intranasal vitamin D3 attenuates blood-brain barrier (BBB) disruption through endogenous upregulation of OPN and subsequent CD44 and P-gp glycosylation signals in brain endothelial cells.	Cholecalciferol	33-43	phosphoglycolate phosphatase	Rattus norvegicus	155-159
29145536-5	2017	RESULTS: Significant positive effects on DID, FCP, and SCP levels were observed after supplementation with alphacalcidole and cholecalciferol, whereas supplementation with calcitriol showed no effect.	Cholecalciferol	126-141	solute carrier family 50 member 1	Homo sapiens	55-58
28474500-0	2017	Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR-/- and LDLR+/+ mice.	Cholecalciferol	0-10	low density lipoprotein receptor	Mus musculus	101-105
28665937-6	2017	We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group.	Cholecalciferol	166-181	toll like receptor 7	Homo sapiens	45-49
28665937-6	2017	We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group.	Cholecalciferol	166-181	toll like receptor 9	Homo sapiens	51-55
28665937-6	2017	We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group.	Cholecalciferol	166-181	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	71-78
28665937-6	2017	We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group.	Cholecalciferol	166-181	vitamin D receptor	Homo sapiens	98-101
28665937-6	2017	We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group.	Cholecalciferol	166-181	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	106-113
28978056-3	2017	The 1alpha-Hydroxylase ["1alpha(OH)ase"] is a key enzyme for activate vitamin D3 synthesis.	Cholecalciferol	70-80	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	25-38
28978056-4	2017	Here, we show that 1alpha(OH)ase stable knockdown by targeted shRNA led to vitamin D3 depletion in L02 hepatocytes.	Cholecalciferol	75-85	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	19-32
28430709-4	2017	Here, we found that lipopolysaccharide stimulation in astrocytes could enhance the expression of vitamin D receptor and Cyp27B1, which encodes the enzyme for converting vitamin D3 into its active form.	Cholecalciferol	169-179	vitamin D receptor	Rattus norvegicus	97-115
28430709-4	2017	Here, we found that lipopolysaccharide stimulation in astrocytes could enhance the expression of vitamin D receptor and Cyp27B1, which encodes the enzyme for converting vitamin D3 into its active form.	Cholecalciferol	169-179	cytochrome P450, family 27, subfamily b, polypeptide 1	Rattus norvegicus	120-127
28430709-5	2017	Vitamin D3 suppressed the expression of proinflammatory cytokines tumour necrosis factor-alpha, interleukin-1beta, vascular endothelial growth factor, and also TLR4 in activated astrocytes.	Cholecalciferol	0-10	interleukin 1 beta	Rattus norvegicus	96-113
28430709-5	2017	Vitamin D3 suppressed the expression of proinflammatory cytokines tumour necrosis factor-alpha, interleukin-1beta, vascular endothelial growth factor, and also TLR4 in activated astrocytes.	Cholecalciferol	0-10	toll-like receptor 4	Rattus norvegicus	160-164
28592257-2	2017	Ointment containing 1,25-dihydroxy-22-oxavitamin D3 (maxacalcitol), a noncalcemic analog of the active form of vitamin D3, is applied for the treatment of hyperkeratotic cutaneous conditions such as psoriasis and ichtyosis because it suppresses the proliferation and promotes the differentiation of keratinocytes through interaction with the vitamin D receptor.	Cholecalciferol	41-51	vitamin D receptor	Homo sapiens	342-360
28474500-0	2017	Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR-/- and LDLR+/+ mice.	Cholecalciferol	0-10	low density lipoprotein receptor	Mus musculus	113-117
28474500-5	2017	Levels of non-esterified fatty acids and lipid peroxidation products were significantly lower in the group supplemented with additional Vitamin D3 , as were systemic markers of inflammation (serum endotoxin and IL-6).	Cholecalciferol	136-146	interleukin 6	Mus musculus	211-215
28474500-8	2017	CONCLUSION: In summary, Vitamin D3 was a significantly beneficial dietary additive to blunt a prediabetic phenotype in diet-induced obesity of female LDLR-/- and LDLR+/+ mice.	Cholecalciferol	24-34	low density lipoprotein receptor	Mus musculus	150-154
28474500-8	2017	CONCLUSION: In summary, Vitamin D3 was a significantly beneficial dietary additive to blunt a prediabetic phenotype in diet-induced obesity of female LDLR-/- and LDLR+/+ mice.	Cholecalciferol	24-34	low density lipoprotein receptor	Mus musculus	162-166
28332200-3	2017	The direct actions of vitamin D3 on naive T cells result in the proliferation of more regulatory T cells and inhibitory cytokines such as IL-4, IL-10 and IL-5.	Cholecalciferol	22-32	interleukin 4	Homo sapiens	138-142
28218743-2	2017	Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1alpha-hydroxylase (CYP27B1) to produce 1,25(OH)2D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1.	Cholecalciferol	208-211	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	65-71
28218743-2	2017	Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1alpha-hydroxylase (CYP27B1) to produce 1,25(OH)2D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1.	Cholecalciferol	208-211	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	108-115
28332200-3	2017	The direct actions of vitamin D3 on naive T cells result in the proliferation of more regulatory T cells and inhibitory cytokines such as IL-4, IL-10 and IL-5.	Cholecalciferol	22-32	interleukin 10	Homo sapiens	144-149
28332200-3	2017	The direct actions of vitamin D3 on naive T cells result in the proliferation of more regulatory T cells and inhibitory cytokines such as IL-4, IL-10 and IL-5.	Cholecalciferol	22-32	interleukin 5	Homo sapiens	154-158
28421904-11	2017	which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL.	Cholecalciferol	33-43	caspase 3	Homo sapiens	145-161
28938596-0	2017	Vitamin D3 induces vitamin D receptor and HDAC11 binding to relieve the promoter of the tight junction proteins.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	19-37
28938596-0	2017	Vitamin D3 induces vitamin D receptor and HDAC11 binding to relieve the promoter of the tight junction proteins.	Cholecalciferol	0-10	histone deacetylase 11	Homo sapiens	42-48
28475159-5	2017	Compared to the PL group, cholecalciferol administration increased 25(OH)Vit D levels (p &lt; 0.001) and promoted a significant increase of HMW-A expression analyzed by WIB (p = 0.02).	Cholecalciferol	26-41	cilia and flagella associated protein 97	Homo sapiens	140-143
28475159-9	2017	Current findings suggest that acute cholecalciferol administration selectively modifies HMW-A and the leptin/HMW-A ratio.	Cholecalciferol	36-51	cilia and flagella associated protein 97	Homo sapiens	88-91
28475159-9	2017	Current findings suggest that acute cholecalciferol administration selectively modifies HMW-A and the leptin/HMW-A ratio.	Cholecalciferol	36-51	leptin	Homo sapiens	102-108
28475159-9	2017	Current findings suggest that acute cholecalciferol administration selectively modifies HMW-A and the leptin/HMW-A ratio.	Cholecalciferol	36-51	cilia and flagella associated protein 97	Homo sapiens	109-112
28095044-2	2017	Vitamin D3 undergoes conversion through a multitude of enzymatic reactions described within the paper, and vitamin D levels are dependent on many factors including the vitamin D binding protein (DBP).	Cholecalciferol	0-10	D-box binding PAR bZIP transcription factor	Homo sapiens	195-198
28476406-0	2017	Influence of Cdx2 and TaqI Gene Variants on Vitamin D3 Modulated Intracellular Chemokine Positive T-Cell Subsets in Pulmonary Tuberculosis.	Cholecalciferol	44-54	caudal type homeobox 2	Homo sapiens	13-17
28476406-4	2017	FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment.	Cholecalciferol	10-20	C-C motif chemokine ligand 2	Homo sapiens	46-80
28476406-4	2017	FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment.	Cholecalciferol	10-20	C-C motif chemokine ligand 3	Homo sapiens	82-124
28476406-4	2017	FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment.	Cholecalciferol	10-20	C-C motif chemokine ligand 4	Homo sapiens	126-135
28476406-4	2017	FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment.	Cholecalciferol	10-20	C-C motif chemokine ligand 5	Homo sapiens	200-206
28476406-4	2017	FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment.	Cholecalciferol	10-20	C-X-C motif chemokine ligand 10	Homo sapiens	213-250
28476406-4	2017	FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment.	Cholecalciferol	10-20	C-X-C motif chemokine ligand 10	Homo sapiens	252-257
28476406-6	2017	Whereas in the TaqI tt genotype, decreased MIP-1beta and RANTES and increased IP-10-positive T cells were observed compared with the TT genotype in vitamin D3 treated cells (p &lt; 0.05).	Cholecalciferol	148-158	C-C motif chemokine ligand 4	Homo sapiens	43-52
28476406-6	2017	Whereas in the TaqI tt genotype, decreased MIP-1beta and RANTES and increased IP-10-positive T cells were observed compared with the TT genotype in vitamin D3 treated cells (p &lt; 0.05).	Cholecalciferol	148-158	C-C motif chemokine ligand 5	Homo sapiens	57-63
28476406-6	2017	Whereas in the TaqI tt genotype, decreased MIP-1beta and RANTES and increased IP-10-positive T cells were observed compared with the TT genotype in vitamin D3 treated cells (p &lt; 0.05).	Cholecalciferol	148-158	C-X-C motif chemokine ligand 10	Homo sapiens	78-83
28476406-7	2017	IMPLICATIONS: This study suggests that vitamin D3 may regulate the chemokine-positive T cells through the Cdx2 AA and TaqI tt genotypes.	Cholecalciferol	39-49	caudal type homeobox 2	Homo sapiens	106-110
28421904-11	2017	which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL.	Cholecalciferol	33-43	BCL2 apoptosis regulator	Homo sapiens	187-192
28421904-11	2017	which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL.	Cholecalciferol	33-43	BCL2 like 1	Homo sapiens	197-203
28013381-0	2017	Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.	Cholecalciferol	29-44	hepcidin antimicrobial peptide	Homo sapiens	64-72
27978548-15	2017	Conclusions and Relevance: Our findings suggest that benefits from vitamin D3 supplementation for the prevention of advanced colorectal adenomas may vary according to vitamin D receptor genotype.	Cholecalciferol	67-77	vitamin D receptor	Homo sapiens	167-185
27978548-2	2017	Objective: To investigate whether common variants in 7 vitamin D and calcium pathway genes (VDR, GC, DHCR7, CYP2R1, CYP27B1, CYP24A1, and CASR) modify the effects of vitamin D3 or calcium supplementation on colorectal adenoma recurrence.	Cholecalciferol	166-176	7-dehydrocholesterol reductase	Homo sapiens	101-106
27978548-2	2017	Objective: To investigate whether common variants in 7 vitamin D and calcium pathway genes (VDR, GC, DHCR7, CYP2R1, CYP27B1, CYP24A1, and CASR) modify the effects of vitamin D3 or calcium supplementation on colorectal adenoma recurrence.	Cholecalciferol	166-176	calcium sensing receptor	Homo sapiens	138-142
28013381-3	2017	METHODS: A randomized controlled trial of daily vitamin D supplementation for 12 weeks was performed with the aim to test the effects of 4000 versus 400 IU of cholecalciferol on serum hepcidin levels in children with non-dialysis CKD recruited at a tertiary care children"s hospital.	Cholecalciferol	159-174	hepcidin antimicrobial peptide	Homo sapiens	184-192
28116494-1	2017	Vitamin D3 and its metabolites are lipophilic molecules with low aqueous solubility and must be transported bound to plasma carrier proteins, primarily to vitamin D binding protein (DBP).	Cholecalciferol	0-10	GC vitamin D binding protein	Homo sapiens	155-180
28004974-0	2017	Vitamin D3 protects against prednisolone-induced liver injury associated with the impairment of the hepatic NF-kappaB/iNOS/NO pathway.	Cholecalciferol	0-10	nitric oxide synthase 2	Rattus norvegicus	118-122
28004974-8	2017	In conclusion, prednisolone-induced liver disturbances were associated with the impairment of NF-kappaB/iNOS/NO responses that can be ameliorated by vitamin D3 treatment through VDR-mediated mechanisms.	Cholecalciferol	149-159	nitric oxide synthase 2	Rattus norvegicus	104-111
28004974-8	2017	In conclusion, prednisolone-induced liver disturbances were associated with the impairment of NF-kappaB/iNOS/NO responses that can be ameliorated by vitamin D3 treatment through VDR-mediated mechanisms.	Cholecalciferol	149-159	vitamin D receptor	Rattus norvegicus	178-181
28383552-2	2017	Here we report that MyD88 signaling is crucial in the pathogenesis of experimental AD induced by vitamin D3 analog MC903.	Cholecalciferol	97-107	myeloid differentiation primary response gene 88	Mus musculus	20-25
28116494-1	2017	Vitamin D3 and its metabolites are lipophilic molecules with low aqueous solubility and must be transported bound to plasma carrier proteins, primarily to vitamin D binding protein (DBP).	Cholecalciferol	0-10	D-box binding PAR bZIP transcription factor	Homo sapiens	182-185
28116494-2	2017	The biological functions of vitamin D3 metabolites are intimately dependent on the protein, hence the importance of determining their affinity for DBP.	Cholecalciferol	28-38	D-box binding PAR bZIP transcription factor	Homo sapiens	147-150
28116494-3	2017	In this study, we developed a novel procedure for measuring the kinetic and equilibrium constants of human-DBP with vitamin D3 and three metabolites: 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], 25-hydroxyvitamin D3 (25OHD3) and 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] by surface plasmon resonance (SPR).	Cholecalciferol	116-126	D-box binding PAR bZIP transcription factor	Homo sapiens	107-110
28077289-0	2017	Vitamin D3 protects against Abeta peptide cytotoxicity in differentiated human neuroblastoma SH- SY5Y cells: A role for S1P1/p38MAPK/ATF4 axis.	Cholecalciferol	0-10	sphingosine-1-phosphate receptor 1	Homo sapiens	120-124
28338939-4	2017	Based on these observations, we have proposed that this latitude-dependent gradient of FLG mutations across Europe, Asia and Africa could have provided an evolutionary advantage for heterozygous FLG mutation carriers, residing at northern latitudes, depletion of the FLG downstream product, trans-urocanic acid, would facilitate the intracutaneous synthesis of vitamin D3 by allowing increased transcutaneous absorption of UVB photons.	Cholecalciferol	361-371	filaggrin	Homo sapiens	87-90
28338939-4	2017	Based on these observations, we have proposed that this latitude-dependent gradient of FLG mutations across Europe, Asia and Africa could have provided an evolutionary advantage for heterozygous FLG mutation carriers, residing at northern latitudes, depletion of the FLG downstream product, trans-urocanic acid, would facilitate the intracutaneous synthesis of vitamin D3 by allowing increased transcutaneous absorption of UVB photons.	Cholecalciferol	361-371	filaggrin	Homo sapiens	195-198
28338939-4	2017	Based on these observations, we have proposed that this latitude-dependent gradient of FLG mutations across Europe, Asia and Africa could have provided an evolutionary advantage for heterozygous FLG mutation carriers, residing at northern latitudes, depletion of the FLG downstream product, trans-urocanic acid, would facilitate the intracutaneous synthesis of vitamin D3 by allowing increased transcutaneous absorption of UVB photons.	Cholecalciferol	361-371	filaggrin	Homo sapiens	195-198
28077289-0	2017	Vitamin D3 protects against Abeta peptide cytotoxicity in differentiated human neuroblastoma SH- SY5Y cells: A role for S1P1/p38MAPK/ATF4 axis.	Cholecalciferol	0-10	activating transcription factor 4	Homo sapiens	133-137
28001444-4	2017	We demonstrated VDR protein expression in primary plasmablastic tumor cells and confirmed in cell lines expression of both VDR and the metabolic enzyme CYP27B1, which catalyzes active vitamin D3 production.	Cholecalciferol	184-194	vitamin D receptor	Homo sapiens	123-126
28054069-4	2017	Human keratinocytes contain the enzymatic machinery (CYP27B1) for the synthesis of the biologically most active natural vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), representing an autonomous vitamin D3 pathway.	Cholecalciferol	155-165	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	53-60
28001444-4	2017	We demonstrated VDR protein expression in primary plasmablastic tumor cells and confirmed in cell lines expression of both VDR and the metabolic enzyme CYP27B1, which catalyzes active vitamin D3 production.	Cholecalciferol	184-194	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	152-159
28001444-6	2017	Positive autoregulation evidenced intact VDR function in all plasmablastic lines, and inhibition of growth by active vitamin D3 was both dependent on MYC protein inhibition and could be enhanced by cotreatment with a synthetic ROR ligand SR-1078.	Cholecalciferol	117-127	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	150-153
28001444-6	2017	Positive autoregulation evidenced intact VDR function in all plasmablastic lines, and inhibition of growth by active vitamin D3 was both dependent on MYC protein inhibition and could be enhanced by cotreatment with a synthetic ROR ligand SR-1078.	Cholecalciferol	117-127	RAR related orphan receptor A	Homo sapiens	227-230
28001444-7	2017	Furthermore, a VDR polymorphism, FOK1, was associated with greater vitamin D3-dependent growth inhibition.	Cholecalciferol	67-77	vitamin D receptor	Homo sapiens	15-18
28222027-4	2017	RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells.	Cholecalciferol	9-24	CD4 molecule	Homo sapiens	62-65
28222027-4	2017	RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells.	Cholecalciferol	9-24	CD38 molecule	Homo sapiens	67-71
28222027-4	2017	RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells.	Cholecalciferol	9-24	CD8a molecule	Homo sapiens	77-80
28222027-4	2017	RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells.	Cholecalciferol	9-24	CD38 molecule	Homo sapiens	82-86
28222027-4	2017	RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells.	Cholecalciferol	9-24	CD8a molecule	Homo sapiens	109-112
28392936-9	2017	CONCLUSIONS: Following supplementation with 5,000 IU of vitamin D3, all subjects" 25(OH)D levels rose to a sufficient level (&gt;=30 ng mL-1).	Cholecalciferol	56-66	L1 cell adhesion molecule	Mus musculus	136-140
28383629-4	2017	Short-acting beta2-adrenoreceptor agonists, budesonide and formoterol (all important relievers in asthma exacerbation), such as vitamin D3, vitamin C, have been shown to inhibit airway cells inflammatory responses by modulating these chemokines.	Cholecalciferol	128-138	adrenoceptor beta 2	Homo sapiens	13-33
27984337-9	2017	High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2.	Cholecalciferol	11-26	msh homeobox 2	Mus musculus	110-114
27984337-9	2017	High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2.	Cholecalciferol	11-26	runt related transcription factor 2	Mus musculus	116-121
27984337-9	2017	High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2.	Cholecalciferol	11-26	alkaline phosphatase, liver/bone/kidney	Mus musculus	126-130
27984337-9	2017	High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2.	Cholecalciferol	11-26	collagen, type I, alpha 1	Mus musculus	152-158
27984337-9	2017	High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2.	Cholecalciferol	11-26	collagen, type III, alpha 1	Mus musculus	180-186
27984337-9	2017	High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2.	Cholecalciferol	11-26	fibronectin 1	Mus musculus	192-203
27984337-9	2017	High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2.	Cholecalciferol	11-26	fibronectin 1	Mus musculus	205-208
27984337-10	2017	These effects were paralleled by increased aortic Casr mRNA expression in cholecalciferol-treated mice, which was further augmented by MgCl2.	Cholecalciferol	74-89	calcium-sensing receptor	Mus musculus	50-54
26826259-7	2017	Glutamine, arginine, and vitamin D3, but not ALA, significantly attenuated IL-8 production.	Cholecalciferol	25-35	C-X-C motif chemokine ligand 8	Homo sapiens	75-79
27966575-8	2017	The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P&lt;0.05).	Cholecalciferol	37-39	C-X-C motif chemokine ligand 8	Homo sapiens	74-78
26054653-2	2017	In fact, it has been demonstrated that topical administration of vitamin D3 inhibits Langerhans cells migration from the central cornea, corneal neovascularization, and production of cytokines (i.e., interleukin-1-6-8) in experimental animals.	Cholecalciferol	65-75	LOW QUALITY PROTEIN: pro-interleukin-16	Cavia porcellus	200-217
28063949-7	2017	In addition, cholecalciferol supplementation significantly upregulated pAMPK, SIRT-1 and GLUT-4 levels in adipose tissue of mice fed with HFD.	Cholecalciferol	13-28	sirtuin 1	Mus musculus	78-84
28063949-7	2017	In addition, cholecalciferol supplementation significantly upregulated pAMPK, SIRT-1 and GLUT-4 levels in adipose tissue of mice fed with HFD.	Cholecalciferol	13-28	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	89-95
28039464-1	2017	A novel pathway of vitamin D3 (D3) metabolism, initiated by C20-hydroxylation of D3 by CYP11A1, has been confirmed to operate in vivo.	Cholecalciferol	19-29	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	87-94
28056993-0	2017	Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment.	Cholecalciferol	17-27	vascular endothelial growth factor A	Homo sapiens	31-35
27852823-2	2017	We previously showed that hRXRalpha phosphorylation at serine 260 through the Ras-Raf-MAPK ERK1/2 activation is responsible for resistance to the growth inhibitory effects of 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the biologically active metabolite of vitamin D3 To further investigate the mechanism of this resistance, we studied intranuclear dynamics of hVDR and hRXRalpha-tagged constructs in living cells together with endogenous and tagged protein in fixed cells.	Cholecalciferol	202-204	retinoid X receptor alpha	Homo sapiens	26-35
27852823-2	2017	We previously showed that hRXRalpha phosphorylation at serine 260 through the Ras-Raf-MAPK ERK1/2 activation is responsible for resistance to the growth inhibitory effects of 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the biologically active metabolite of vitamin D3 To further investigate the mechanism of this resistance, we studied intranuclear dynamics of hVDR and hRXRalpha-tagged constructs in living cells together with endogenous and tagged protein in fixed cells.	Cholecalciferol	194-204	retinoid X receptor alpha	Homo sapiens	26-35
27879271-0	2017	Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.	Cholecalciferol	0-10	transient receptor potential cation channel subfamily C member 6	Homo sapiens	96-101
28079136-0	2017	SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial.	Cholecalciferol	75-85	retinoid X receptor alpha	Homo sapiens	18-22
28056993-0	2017	Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment.	Cholecalciferol	17-27	ADAM metallopeptidase domain 33	Homo sapiens	44-50
27930980-0	2017	Vitamin D3 intake as regulator of insulin degrading enzyme and insulin receptor phosphorylation in diabetic rats.	Cholecalciferol	0-10	insulin receptor	Rattus norvegicus	63-79
27816791-7	2017	METHODS: M1- and M2-like Mphis were generated in vitro from the THP-1 monocyte cell line by differentiation with PMA and Vitamin D3, respectively.	Cholecalciferol	121-131	GLI family zinc finger 2	Homo sapiens	64-69
27930980-11	2017	We concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation.	Cholecalciferol	18-28	insulin degrading enzyme	Rattus norvegicus	137-140
29179169-4	2017	FGF23 inhibits Cyp27b1, an enzyme to produce an active vitamin D3, 1,25(OH)2D3, through FGF receptor/Klotho complex.	Cholecalciferol	55-65	fibroblast growth factor 23	Homo sapiens	0-5
27930980-11	2017	We concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation.	Cholecalciferol	18-28	insulin receptor	Rattus norvegicus	159-175
28637951-9	2017	Maxacalcitol (22-oxacalcitriol: OCT) is a biologically active metabolite of vitamin D3 analog, and OCT increases hCAP-18/LL-37 production by human gingival epithelial cells.	Cholecalciferol	76-86	plexin A2	Homo sapiens	32-35
27697285-0	2017	Vitamin D3 regulates LAMP3 expression in monocyte derived dendritic cells.	Cholecalciferol	0-10	lysosomal associated membrane protein 3	Homo sapiens	21-26
27697285-4	2017	Here, we investigated the capacity of Vitamin D3 to modulate the expression of LAMP3 during the dendritic cells differentiation and maturation.	Cholecalciferol	38-48	lysosomal associated membrane protein 3	Homo sapiens	79-84
28164126-7	2017	Western blotting showed that MMP2 expression was significantly increased in rats treated with cholecalciferol.	Cholecalciferol	94-109	matrix metallopeptidase 2	Rattus norvegicus	29-33
29179169-4	2017	FGF23 inhibits Cyp27b1, an enzyme to produce an active vitamin D3, 1,25(OH)2D3, through FGF receptor/Klotho complex.	Cholecalciferol	55-65	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	15-22
27697285-5	2017	Our results demonstrated that the Vitamin D3 reduce the LAMP3 mRNA/protein expression during the dendritic cells differentiation and maturation, via NFkappaB pathways.	Cholecalciferol	34-44	lysosomal associated membrane protein 3	Homo sapiens	56-61
27697285-6	2017	Furthermore, we demonstrated that the Vitamin D3 was able to modulate the expression of LAMP3 likewise to in vitro tolerogenic dendritic cells.	Cholecalciferol	38-48	lysosomal associated membrane protein 3	Homo sapiens	88-93
29179169-4	2017	FGF23 inhibits Cyp27b1, an enzyme to produce an active vitamin D3, 1,25(OH)2D3, through FGF receptor/Klotho complex.	Cholecalciferol	55-65	klotho	Homo sapiens	101-107
27473187-3	2017	INTRODUCTION: This study evaluated the association between polymorphisms in four single nucleotide polymorphisms (SNPs) of the CYP2R1 gene and 25(OH)D levels before and 1 year after supplementation with two different doses of vitamin D3 (600 IU daily or a dose equivalent to 3750 IU daily), in a cohort of 218 (96 men and 122 women) Lebanese elderly overweight subjects.	Cholecalciferol	226-236	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	127-133
27667787-0	2017	Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-beta1.	Cholecalciferol	61-71	transforming growth factor beta 1	Homo sapiens	126-158
29074830-3	2017	An active form of vitamin D3, 1alpha,25(OH)2D3, binds to vitamin D nuclear receptor(VDR, vitamin D receptor), and regulates expression of specific target genes.	Cholecalciferol	18-28	vitamin D receptor	Homo sapiens	84-87
29074830-3	2017	An active form of vitamin D3, 1alpha,25(OH)2D3, binds to vitamin D nuclear receptor(VDR, vitamin D receptor), and regulates expression of specific target genes.	Cholecalciferol	18-28	vitamin D receptor	Homo sapiens	89-107
28477201-3	2017	When treated in vitro with cholecalciferol or 1,25(OH)2 vitamin D3, cells polarized under Th9 conditions significantly downregulate production of IL-9.	Cholecalciferol	27-42	interleukin 9	Homo sapiens	146-150
27998432-8	2016	Conclusions: Flushing dose of vitamin D3 and nicotine can induce the change of pathology and function of the kidney.Meanwhile, the expression of FGF21 in kidney up-regulated significantly, suggesting that FGF21 may be involved in the occurrence and development of vascular calcification and subsequent kidney injury.	Cholecalciferol	30-40	fibroblast growth factor 21	Rattus norvegicus	145-150
28003019-12	2016	Transcriptome and pathway analyses revealed that ERbeta knockdown led to activation of TGFbeta signalling and induced expression of a network of genes with functions in extracellular matrix, tumor cell invasion and vitamin D3 metabolism.	Cholecalciferol	215-225	estrogen receptor 2	Homo sapiens	49-55
27509245-4	2016	RESULTS: Cholecalciferol decreased the frequency of HIV-1-infected p24CD4 T cells and levels of p24 in supernatants in a dose-dependent manner.	Cholecalciferol	9-24	transmembrane p24 trafficking protein 2	Homo sapiens	67-70
27942020-12	2016	We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3.	Cholecalciferol	229-239	vitamin D receptor	Homo sapiens	24-42
27942020-12	2016	We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3.	Cholecalciferol	229-239	vitamin D receptor	Homo sapiens	164-182
27942020-12	2016	We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3.	Cholecalciferol	229-239	vitamin D receptor	Homo sapiens	198-201
27998432-8	2016	Conclusions: Flushing dose of vitamin D3 and nicotine can induce the change of pathology and function of the kidney.Meanwhile, the expression of FGF21 in kidney up-regulated significantly, suggesting that FGF21 may be involved in the occurrence and development of vascular calcification and subsequent kidney injury.	Cholecalciferol	30-40	fibroblast growth factor 21	Rattus norvegicus	205-210
27827962-0	2016	Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	41-60
27897272-1	2016	Calcitriol, the active form of vitamin D3, can regulate the gene expression through the binding to the nuclear receptor VDR, but it can also display nongenomic actions, acting through a membrane-associated receptor, which has been discovered as the disulfide isomerase ERp57.	Cholecalciferol	31-41	vitamin D receptor	Homo sapiens	120-123
27897272-1	2016	Calcitriol, the active form of vitamin D3, can regulate the gene expression through the binding to the nuclear receptor VDR, but it can also display nongenomic actions, acting through a membrane-associated receptor, which has been discovered as the disulfide isomerase ERp57.	Cholecalciferol	31-41	protein disulfide isomerase family A member 3	Homo sapiens	269-274
27820818-0	2016	Increased Serum Levels of IL-17A and IL-23 Are Associated with Decreased Vitamin D3 and Increased Pain in Osteoarthritis.	Cholecalciferol	73-83	interleukin 17A	Homo sapiens	26-32
27820818-0	2016	Increased Serum Levels of IL-17A and IL-23 Are Associated with Decreased Vitamin D3 and Increased Pain in Osteoarthritis.	Cholecalciferol	73-83	interleukin 23 subunit alpha	Homo sapiens	37-42
27820818-5	2016	A significant positive correlation was found between the serum levels of IL-17A and IL-23 using WOMAC pain scores and vitamin D3 serum levels.	Cholecalciferol	118-128	interleukin 17A	Homo sapiens	73-79
27820818-5	2016	A significant positive correlation was found between the serum levels of IL-17A and IL-23 using WOMAC pain scores and vitamin D3 serum levels.	Cholecalciferol	118-128	interleukin 23 subunit alpha	Homo sapiens	84-89
27161894-9	2016	In monocytes, while CYP27B1 expression and VDR expression increased in the cholecalciferol group (p &lt; 0.05), CYP27B1 expression did not change, and VDR expression decreased in the control group (p &lt; 0.05).	Cholecalciferol	75-90	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	20-27
27161894-9	2016	In monocytes, while CYP27B1 expression and VDR expression increased in the cholecalciferol group (p &lt; 0.05), CYP27B1 expression did not change, and VDR expression decreased in the control group (p &lt; 0.05).	Cholecalciferol	75-90	vitamin D receptor	Homo sapiens	43-46
27161894-11	2016	Serum concentration of IL-6 and CRP decreased from 8.1 +- 6.6 pg/mL to 4.6 +- 4.1 pg/mL (p &lt; 0.05) and from 0.50 (0.10-1.27) mg/dL to 0.28 (0.09-0.62) mg/dL (p &lt; 0.05), respectively only in the cholecalciferol group.	Cholecalciferol	200-215	interleukin 6	Homo sapiens	23-27
27161894-11	2016	Serum concentration of IL-6 and CRP decreased from 8.1 +- 6.6 pg/mL to 4.6 +- 4.1 pg/mL (p &lt; 0.05) and from 0.50 (0.10-1.27) mg/dL to 0.28 (0.09-0.62) mg/dL (p &lt; 0.05), respectively only in the cholecalciferol group.	Cholecalciferol	200-215	C-reactive protein	Homo sapiens	32-35
27642128-8	2016	Molecular dynamic simulation results indicated that vitamin D3 decreases the helical and strand structural contents of human insulin, but vitamin E stabilizes more regular secondary structures such as helical and strand structural contents as shown by experimental results.	Cholecalciferol	52-62	insulin	Homo sapiens	125-132
26592177-4	2016	An increased intake of vitamin D3 in a high fat diet-induced obesity mouse model is associated with a decreased weight of white adipose tissue due to induction of apoptosis and the improved blood markers related to adiposity, diabetes, and vitamin D status (plasma concentrations of glucose, insulin, adiponectin, 25-hydroxyvitamin D, and 1,25(OH)2D3).	Cholecalciferol	23-33	adiponectin, C1Q and collagen domain containing	Mus musculus	301-312
27454349-1	2016	INTRODUCTION: Vitamin D3 activates via its hormonal form 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the transcription factor vitamin D receptor (VDR).	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	132-150
27454349-1	2016	INTRODUCTION: Vitamin D3 activates via its hormonal form 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the transcription factor vitamin D receptor (VDR).	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	152-155
27018098-9	2016	Interestingly, both myoblasts and myotubes expressed CYP27B1 and CYP24 mRNA which are required for vitamin D3 metabolism.	Cholecalciferol	99-109	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	53-60
27018098-9	2016	Interestingly, both myoblasts and myotubes expressed CYP27B1 and CYP24 mRNA which are required for vitamin D3 metabolism.	Cholecalciferol	99-109	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	65-70
26232635-1	2016	Recently, we found that 2alpha-[2-(tetrazol-2-yl)ethyl]-1alpha,25-dihydroxyvitamin D3 showed higher osteocalcin promoter transactivation activity in human osteosarcoma (HOS) cells and a greater therapeutic effect in ovariectomized (OVX) rats in vivo than those of active vitamin D3, 1alpha,25(OH)2D3.	Cholecalciferol	75-85	bone gamma-carboxyglutamate protein	Homo sapiens	100-111
27648718-0	2016	Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D. BACKGROUND: Vitamin D deficiency is related to an increased prevalence of cardiovascular disease.	Cholecalciferol	0-15	renin	Homo sapiens	40-45
27648718-11	2016	CONCLUSION: The restoration of normal vitamin D levels after 8-week cholecalciferol treatment is able to inhibit peripheral renin-angiotensin system and improve FMD in essential hypertensive patients with hypovitaminosis D.	Cholecalciferol	68-83	renin	Homo sapiens	124-129
27542236-4	2016	The main objective was to investigate if intake of vitamin D3 enriched salmon or vitamin D3 tablets decreased bone biomarkers (urinary N-telopeptides, deoxypyridinoline, serum bone-specific alkaline phosphatase, and osteocalcin) compared to a low vitamin D3 intake.	Cholecalciferol	51-61	bone gamma-carboxyglutamate protein	Homo sapiens	216-227
27554639-0	2016	TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma.	Cholecalciferol	52-62	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	0-3
27554639-6	2016	Vitamin D3 can also inhibit cell proliferation by promoting p53 expression in ICC cells.	Cholecalciferol	0-10	tumor protein p53	Homo sapiens	60-63
27705794-7	2016	Finally, gene expression and epistasis analysis indicated that CXCL8(IL-8) was a functional target of vitamin D3-mediated HSPC regulation.	Cholecalciferol	102-112	C-X-C motif chemokine ligand 8	Homo sapiens	63-68
27830027-9	2016	Cyp27a1 prevented Cca cell apoptosis induced by vitamin D3.	Cholecalciferol	48-58	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-7
27783938-4	2016	We found that vitamin-D3-induced lifespan extension requires the stress response pathway genes skn-1, ire-1, and xbp-1.	Cholecalciferol	14-24	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	102-107
27783938-4	2016	We found that vitamin-D3-induced lifespan extension requires the stress response pathway genes skn-1, ire-1, and xbp-1.	Cholecalciferol	14-24	X-box binding protein 1	Homo sapiens	113-118
27705794-7	2016	Finally, gene expression and epistasis analysis indicated that CXCL8(IL-8) was a functional target of vitamin D3-mediated HSPC regulation.	Cholecalciferol	102-112	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
27616756-2	2016	The purpose of this study was to examine whether 25(OH)D levels and supplementation with oral cholecalciferol (Vitamin D3 (Vit D3)) are associated with morbidity and mortality among patients with significant CKD.	Cholecalciferol	94-109	vitrin	Homo sapiens	111-114
27259383-6	2016	CYP27A1 is involved in the metabolism of vitamin D3, which plays important roles in modulating immune function.	Cholecalciferol	41-51	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-7
27107558-0	2016	Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.	Cholecalciferol	0-10	solute carrier family 30 member 10	Homo sapiens	61-69
27107558-0	2016	Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	78-96
27107558-9	2016	In addition to increasing gene expression of SLC30A10 and the positive control TRPV6, vitamin D3 also increased ZnT10 protein expression, as indicated by Western blot and cytofluorescence.	Cholecalciferol	86-96	solute carrier family 30 member 10	Homo sapiens	45-53
27107558-9	2016	In addition to increasing gene expression of SLC30A10 and the positive control TRPV6, vitamin D3 also increased ZnT10 protein expression, as indicated by Western blot and cytofluorescence.	Cholecalciferol	86-96	transient receptor potential cation channel subfamily V member 6	Homo sapiens	79-84
27174720-7	2016	5000 IU/kg dietary vitamin D3 supplementation greatly up-regulated LC3-II/LC3-I ratios and PR-39 mRNA expression under the condition of RV challenged.	Cholecalciferol	19-29	antibacterial protein PR-39	Sus scrofa	91-96
27107558-9	2016	In addition to increasing gene expression of SLC30A10 and the positive control TRPV6, vitamin D3 also increased ZnT10 protein expression, as indicated by Western blot and cytofluorescence.	Cholecalciferol	86-96	solute carrier family 30 member 10	Homo sapiens	112-117
27107558-12	2016	In conclusion, we have shown that vitamin D3 transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression.	Cholecalciferol	34-44	solute carrier family 30 member 10	Homo sapiens	64-72
27107558-12	2016	In conclusion, we have shown that vitamin D3 transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression.	Cholecalciferol	34-44	vitamin D receptor	Homo sapiens	83-86
27107558-12	2016	In conclusion, we have shown that vitamin D3 transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression.	Cholecalciferol	34-44	solute carrier family 30 member 10	Homo sapiens	128-133
27107558-13	2016	Because SLC30A10 is highly expressed in the small intestine, it is possible that the control of zinc and manganese systemic levels is regulated by vitamin D3 in the intestine.	Cholecalciferol	147-157	solute carrier family 30 member 10	Homo sapiens	8-16
27174721-2	2016	Previous studies showed that stress-activated protein kinase JNKs (c-Jun NH2-terminal kinases) and p38 cooperated to activate VDR and increase vitamin D3-dependent growth inhibition in breast cancer cells.	Cholecalciferol	143-153	mitogen-activated protein kinase 14	Homo sapiens	99-102
27595605-1	2016	BACKGROUND: The vitamin D receptor (VDR) mediates the immunological function of vitamin D3, which activates macrophages, and vitamin D deficiency has been linked to tuberculosis risk.	Cholecalciferol	80-90	vitamin D receptor	Homo sapiens	16-34
27798898-0	2016	Vitamin D3 Treatment Influences PGE2 and TGFbeta in Normal and Increased Breast Cancer Risk Women.	Cholecalciferol	0-10	transforming growth factor beta 1	Homo sapiens	41-48
27798898-9	2016	CONCLUSION: Vitamin D3 influenced TGFbeta1 and -beta2 expression.	Cholecalciferol	12-22	transforming growth factor beta 1	Homo sapiens	34-53
27595605-1	2016	BACKGROUND: The vitamin D receptor (VDR) mediates the immunological function of vitamin D3, which activates macrophages, and vitamin D deficiency has been linked to tuberculosis risk.	Cholecalciferol	80-90	vitamin D receptor	Homo sapiens	36-39
27506667-3	2016	PURPOSE: We aimed to investigate whether 16 weeks of daily vitamin D3 supplementation had an effect on serum ferritin, haemoglobin, serum iron and transferrin saturation.	Cholecalciferol	59-69	transferrin	Homo sapiens	147-158
27369077-2	2016	The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores.	Cholecalciferol	35-45	vitamin D receptor	Homo sapiens	4-22
27369077-2	2016	The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores.	Cholecalciferol	35-45	vitamin D receptor	Homo sapiens	24-27
27369077-2	2016	The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores.	Cholecalciferol	97-107	vitamin D receptor	Homo sapiens	4-22
27369077-2	2016	The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores.	Cholecalciferol	97-107	vitamin D receptor	Homo sapiens	24-27
27369077-2	2016	The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores.	Cholecalciferol	97-107	importin 4	Homo sapiens	69-79
27369077-2	2016	The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores.	Cholecalciferol	97-107	vitamin D receptor	Homo sapiens	93-96
27369077-8	2016	The PoreWalker algorithm indicates that, of the 427 residues in each VDR monomer, 91 line the largest channel, including two vitamin D3 binding sites and residues from both the TM helix and "half-helix".	Cholecalciferol	125-135	vitamin D receptor	Homo sapiens	69-72
27369077-10	2016	Programmed changes in bound cholesterol may regulate both membrane Ca(2+) response systems and vitamin D3 uptake as well as receptor internalization by the endomembrane system culminating in uptake of the vitamin D3-VDR-importin-4 complex into the nucleus.	Cholecalciferol	205-215	vitamin D receptor	Homo sapiens	216-219
27369077-10	2016	Programmed changes in bound cholesterol may regulate both membrane Ca(2+) response systems and vitamin D3 uptake as well as receptor internalization by the endomembrane system culminating in uptake of the vitamin D3-VDR-importin-4 complex into the nucleus.	Cholecalciferol	205-215	importin 4	Homo sapiens	220-230
29767113-0	2016	Vitamin D3 increased intestinal Na/Pi-IIb and CYP27B1 mRNA level in rats fed low-phosphorus diets.	Cholecalciferol	0-10	cytochrome P450, family 27, subfamily b, polypeptide 1	Rattus norvegicus	46-53
26375627-1	2016	Through experimental and theoretical approaches, it has been shown that bovine beta-lactoglobulin (betalg) uses its hydrophobic cavity or calyx as the primary binding site for hydrophobic molecules, whereas the existence of a second ligand binding site at the dimeric interface has only been structurally identified for vitamin D3 (VD3).	Cholecalciferol	320-330	beta-lactoglobulin	Bos taurus	79-97
27575987-3	2016	In that first study the active vitamin D3 metabolite, 1,25-dihydroxycholecalciferol (1,25D), stimulated YKL-40 expression, thereby indicating that a vital factor for skeletal health promoted YKL-40 synthesis by bone forming cells.	Cholecalciferol	31-41	chitinase 3 like 1	Homo sapiens	104-110
27575987-3	2016	In that first study the active vitamin D3 metabolite, 1,25-dihydroxycholecalciferol (1,25D), stimulated YKL-40 expression, thereby indicating that a vital factor for skeletal health promoted YKL-40 synthesis by bone forming cells.	Cholecalciferol	31-41	chitinase 3 like 1	Homo sapiens	191-197
27500498-1	2016	The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression.	Cholecalciferol	25-35	vitamin D receptor	Homo sapiens	95-113
27500498-1	2016	The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression.	Cholecalciferol	25-35	vitamin D receptor	Homo sapiens	115-118
27500498-1	2016	The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression.	Cholecalciferol	25-35	vitamin D receptor	Homo sapiens	134-137
27500498-2	2016	Recently, we characterized 1alpha,25-dihydroxyvitamin D3 -26,23-lactams (DLAMs), which mimic vitamin D3 metabolites, as noncalcemic VDR ligands that barely activate the receptor.	Cholecalciferol	46-56	vitamin D receptor	Homo sapiens	132-135
27484042-0	2016	The protective role of vitamin D3 in a murine model of asthma via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway.	Cholecalciferol	23-33	nuclear factor, erythroid derived 2, like 2	Mus musculus	131-135
27484042-0	2016	The protective role of vitamin D3 in a murine model of asthma via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway.	Cholecalciferol	23-33	heme oxygenase 1	Mus musculus	136-140
27484042-6	2016	In addition, treatment with vitamin D3 decreased alpha-SMA expression, collagen deposition and goblet cell hyperplasia, and inhibited TGF-beta/Smad signaling in the asthmatic airway.	Cholecalciferol	28-38	actin alpha 2, smooth muscle, aorta	Mus musculus	49-58
27484042-8	2016	Furthermore, treatment with vitamin D3 enhanced activation of the Nrf2/HO-1 pathway in the airways of asthmatic mice.	Cholecalciferol	28-38	nuclear factor, erythroid derived 2, like 2	Mus musculus	66-70
27484042-8	2016	Furthermore, treatment with vitamin D3 enhanced activation of the Nrf2/HO-1 pathway in the airways of asthmatic mice.	Cholecalciferol	28-38	heme oxygenase 1	Mus musculus	71-75
27484042-9	2016	In conclusion, these findings suggest that vitamin D3 may protect airways from asthmatic damage via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway; however, these protective effects were shown to be accompanied by hypercalcemia.	Cholecalciferol	43-53	nuclear factor, erythroid derived 2, like 2	Mus musculus	165-169
27484042-9	2016	In conclusion, these findings suggest that vitamin D3 may protect airways from asthmatic damage via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway; however, these protective effects were shown to be accompanied by hypercalcemia.	Cholecalciferol	43-53	heme oxygenase 1	Mus musculus	170-174
27447175-4	2016	It was shown that human keratinocytes possess the enzymatic machinery (CYP27B1) for the synthesis of the biologically most active natural vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), representing an autonomous vitamin D3 pathway.	Cholecalciferol	173-183	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	71-78
27506771-0	2016	Prenatal high-dose vitamin D3 supplementation has balanced effects on cord blood Th1 and Th2 responses.	Cholecalciferol	19-29	negative elongation factor complex member C/D	Homo sapiens	81-84
27642554-2	2016	In the present study, we examined the molecular mechanism of Npnt gene expression and found that vitamin D3 (1alpha,25-dihydroxyvitamin D3,VD 3) strongly enhanced Npnt mRNA expression in MC3T3-E1 cells from a mouse osteoblastic cell line.	Cholecalciferol	97-107	nephronectin	Mus musculus	61-65
27345382-10	2016	However, when the genetic variants of the VDR gene were analyzed after adjusting for the serum 25-OH vitamin D3 level, the TaqI and BsmI minor allele increased the risk of PD.	Cholecalciferol	101-111	vitamin D receptor	Homo sapiens	42-45
27221206-9	2016	Vitamin D3 and calcium supplementation increased the concentrations of calcium, phosphorous and decreased the concentrations of parathyroid hormone and alkaline phosphatase.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	128-147
27473111-0	2016	Vitamin D3/VDR resists diet-induced obesity by modulating UCP3 expression in muscles.	Cholecalciferol	0-10	uncoupling protein 3 (mitochondrial, proton carrier)	Mus musculus	58-62
27473111-8	2016	RESULTS: Mice consuming a high-fat diet treated with cholecalciferol had lower body weight and adipose tissue weight and higher expression of UCP3 compared to the other treatment groups.	Cholecalciferol	53-68	uncoupling protein 3 (mitochondrial, proton carrier)	Mus musculus	142-146
27642554-2	2016	In the present study, we examined the molecular mechanism of Npnt gene expression and found that vitamin D3 (1alpha,25-dihydroxyvitamin D3,VD 3) strongly enhanced Npnt mRNA expression in MC3T3-E1 cells from a mouse osteoblastic cell line.	Cholecalciferol	97-107	interferon activated gene 205	Mus musculus	136-143
27642554-2	2016	In the present study, we examined the molecular mechanism of Npnt gene expression and found that vitamin D3 (1alpha,25-dihydroxyvitamin D3,VD 3) strongly enhanced Npnt mRNA expression in MC3T3-E1 cells from a mouse osteoblastic cell line.	Cholecalciferol	97-107	nephronectin	Mus musculus	163-167
27314336-7	2016	Furthermore, our study confirms a deregulation of the vitamin D system: among the transcription factors that potentially regulate the deregulated genes, we find TCF3 and SP1 that are both involved in vitamin D3-induced p27Kip1 expression.	Cholecalciferol	200-210	transcription factor 3	Homo sapiens	161-165
27424994-0	2016	Role of vitamin D3 in regulation of interleukin-6 and osteopontin expression in liver of diabetic mice.	Cholecalciferol	8-18	interleukin 6	Mus musculus	36-49
27424994-0	2016	Role of vitamin D3 in regulation of interleukin-6 and osteopontin expression in liver of diabetic mice.	Cholecalciferol	8-18	secreted phosphoprotein 1	Mus musculus	54-65
27424994-1	2016	OBJECTIVE: To study the link between hepatic interleukin-6 (IL-6) and osteopontin (OPN) gene expression and vitamin D3 status associated with type 1 diabetes in mice; and to evaluate the effects of vitamin D3 treatment (800 IU/kg of body weight for 6 weeks) on diabetes-induced impairments.	Cholecalciferol	108-118	interleukin 6	Mus musculus	45-58
27424994-1	2016	OBJECTIVE: To study the link between hepatic interleukin-6 (IL-6) and osteopontin (OPN) gene expression and vitamin D3 status associated with type 1 diabetes in mice; and to evaluate the effects of vitamin D3 treatment (800 IU/kg of body weight for 6 weeks) on diabetes-induced impairments.	Cholecalciferol	108-118	interleukin 6	Mus musculus	60-64
27424994-6	2016	Vitamin D3 treatment restored 25OHD3 that led to a substantial reduction of OPN and IL-6 mRNA levels.	Cholecalciferol	0-10	secreted phosphoprotein 1	Mus musculus	76-79
27424994-6	2016	Vitamin D3 treatment restored 25OHD3 that led to a substantial reduction of OPN and IL-6 mRNA levels.	Cholecalciferol	0-10	interleukin 6	Mus musculus	84-88
27424994-7	2016	CONCLUSIONS: Diabetes-induced vitamin D3 deficiency was associated with increased hepatic levels of IL-6 and OPN mRNA and these changes were countered by vitamin D3 administration.	Cholecalciferol	30-40	interleukin 6	Mus musculus	100-104
27424994-7	2016	CONCLUSIONS: Diabetes-induced vitamin D3 deficiency was associated with increased hepatic levels of IL-6 and OPN mRNA and these changes were countered by vitamin D3 administration.	Cholecalciferol	30-40	secreted phosphoprotein 1	Mus musculus	109-112
27655488-7	2016	Ex vivo human osteoblasts cultured, for 3 weeks, with vitamin D3 and vitamin K2 were exposed to PENT, a well-known advanced glycoxidation end product for the last 72 hours.	Cholecalciferol	54-64	phenylethanolamine N-methyltransferase	Homo sapiens	96-100
27154546-1	2016	The active form of vitamin D3 (1alpha,25(OH)2D3, also known as calcitriol) controls the expression of target genes via the vitamin D receptor (VDR).	Cholecalciferol	19-29	vitamin D receptor	Homo sapiens	123-141
27154546-1	2016	The active form of vitamin D3 (1alpha,25(OH)2D3, also known as calcitriol) controls the expression of target genes via the vitamin D receptor (VDR).	Cholecalciferol	19-29	vitamin D receptor	Homo sapiens	143-146
27295094-0	2016	Vitamin D3 inhibits TNFalpha-induced latent HIV reactivation in J-LAT cells.	Cholecalciferol	0-10	tumor necrosis factor	Homo sapiens	20-28
27295094-0	2016	Vitamin D3 inhibits TNFalpha-induced latent HIV reactivation in J-LAT cells.	Cholecalciferol	0-10	linker for activation of T cells	Homo sapiens	66-69
26939683-1	2016	BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences.	Cholecalciferol	27-37	fibroblast growth factor 23	Homo sapiens	46-73
26939683-1	2016	BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences.	Cholecalciferol	27-37	fibroblast growth factor 23	Homo sapiens	75-81
26939683-1	2016	BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences.	Cholecalciferol	27-37	renin	Homo sapiens	113-118
26939683-1	2016	BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences.	Cholecalciferol	27-37	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	173-216
25601896-0	2016	The Effect of High-Dose Vitamin D3 on Soluble P-Selectin and hs-CRP Level in Patients With Venous Thromboembolism: A Randomized Clinical Trial.	Cholecalciferol	24-34	selectin P	Homo sapiens	46-56
30480416-7	2016	Prolonged vitamin D3 treatment (within 2 months) in a dose of 20 IU/animal leads to normalization of the proliferative activity and the ratio of T-cell subpopulations, reduces the formation of phosphorylated subunit of NF-kappaB - p65 and contributes to a balanced secretion of IgG against artificial antigen.	Cholecalciferol	10-20	RELA proto-oncogene, NF-kB subunit	Homo sapiens	231-234
27314336-7	2016	Furthermore, our study confirms a deregulation of the vitamin D system: among the transcription factors that potentially regulate the deregulated genes, we find TCF3 and SP1 that are both involved in vitamin D3-induced p27Kip1 expression.	Cholecalciferol	200-210	cyclin dependent kinase inhibitor 1B	Homo sapiens	219-226
27296673-9	2016	RESULTS: Cholecalciferol supplementation was associated with higher absolute numbers of Helios(+), CTLA-4(+), and total Tregs than calcitriol (p &lt; 0.001, p = 0.004, p = 0.001 respectively).	Cholecalciferol	9-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	99-105
27622485-0	2016	Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells.	Cholecalciferol	45-55	C-X-C motif chemokine ligand 8	Homo sapiens	103-107
27317433-8	2016	In addition a novel finding is represented by the demonstration that pre-treatment with vitamin D3 is also able to significantly counteract tumoral biomarkers activation, such as p53, pan-Ras, Ki67 and c-Myc, and consequently the catalytic iron-induced cellular injury.	Cholecalciferol	88-98	tumor protein p53	Homo sapiens	179-182
27317433-8	2016	In addition a novel finding is represented by the demonstration that pre-treatment with vitamin D3 is also able to significantly counteract tumoral biomarkers activation, such as p53, pan-Ras, Ki67 and c-Myc, and consequently the catalytic iron-induced cellular injury.	Cholecalciferol	88-98	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	202-207
27622485-0	2016	Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells.	Cholecalciferol	45-55	interleukin 1 beta	Homo sapiens	109-117
27622485-0	2016	Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells.	Cholecalciferol	45-55	interleukin 10	Homo sapiens	119-124
27622485-0	2016	Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells.	Cholecalciferol	45-55	CD4 molecule	Homo sapiens	161-164
26970587-1	2016	20S-Hydroxyvitamin D3 [20(OH)D3] is the biologically active major product of the action of CYP11A1 on vitamin D3 and is present in human plasma.	Cholecalciferol	11-21	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	91-98
27199286-6	2016	Focusing on the phosphatidylinositol 3-kinase (PI3K) signalling pathway, we found that the reduced expression of Pik3r1 mRNA was reversed by cholecalciferol supplementation in skeletal muscle, and that insulin-stimulated glucose uptake into C2C12 myotube was inhibited in the presence of quetiapine, which was reversed by concomitant calcitriol in a PI3K-dependent manner.	Cholecalciferol	141-156	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	16-45
27199286-6	2016	Focusing on the phosphatidylinositol 3-kinase (PI3K) signalling pathway, we found that the reduced expression of Pik3r1 mRNA was reversed by cholecalciferol supplementation in skeletal muscle, and that insulin-stimulated glucose uptake into C2C12 myotube was inhibited in the presence of quetiapine, which was reversed by concomitant calcitriol in a PI3K-dependent manner.	Cholecalciferol	141-156	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	113-119
27333923-9	2016	Cholecalciferol supplementation (mean dose of 3384 +- 1211 IU) was followed by a significant increase in 25-OH-D3 concentration (from 17.3 +- 5.8 to 41.4 +- 17.5 ng/ml; p&lt;0.05) and decrease in PTH (p&lt;0.05).	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	196-199
27143932-10	2016	Moreover, we found the vitamin D3 increased the expression of E-cadherin and vitamin D receptor while it decreased the expression of beta-catenin.	Cholecalciferol	23-33	cadherin 1	Mus musculus	62-72
27143932-10	2016	Moreover, we found the vitamin D3 increased the expression of E-cadherin and vitamin D receptor while it decreased the expression of beta-catenin.	Cholecalciferol	23-33	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	77-95
27143932-10	2016	Moreover, we found the vitamin D3 increased the expression of E-cadherin and vitamin D receptor while it decreased the expression of beta-catenin.	Cholecalciferol	23-33	catenin (cadherin associated protein), beta 1	Mus musculus	133-145
27058533-1	2016	Ultraviolet (UV) radiation is involved in almost all skin cancer cases, but on the other hand, it stimulates the production of pre-vitamin D3, whose active metabolite, 1,25-dihydroxyvitamin D3 (1,25VD3), plays important physiological functions on binding with its receptor (vitamin D receptor, VDR).	Cholecalciferol	131-141	vitamin D receptor	Homo sapiens	294-297
27091127-7	2016	CONCLUSIONS: We found that however all normal and malignant germ-line derived cells express functional VDR, Vitamin D3 differently affects their proliferation and migration.	Cholecalciferol	108-118	vitamin D receptor	Homo sapiens	103-106
26893158-9	2016	These observations were supported in vivo whereby Cftr(-/-) mice fed large amounts of vitamin D3 for 2 mo led to a reduction in the number of eosinophils and apoptotic cells in the duodenal mucosa of females but not males.	Cholecalciferol	86-96	cystic fibrosis transmembrane conductance regulator	Mus musculus	50-54
27103796-8	2016	The plasma vitamin D3 level was lower in patients with the GC2 variant (estimated =-3.73 ng/mL) and higher in those with genotype 1F-1S (estimated =4.08 ng/mL).	Cholecalciferol	11-21	solute carrier family 25 member 18	Homo sapiens	59-62
26691009-6	2016	In addition, vitamin D3 treatment reduced VEGF-A gene expression by EESCs (P = 0.046-0.009).	Cholecalciferol	13-23	vascular endothelial growth factor A	Homo sapiens	42-48
26694996-7	2016	Vitamin D3 was protective against vitamin D deficiency-induced cholesterol increase by maintaining the transcriptional activity of VDR and Insig-2 expression.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	131-134
27279980-4	2016	In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE.	Cholecalciferol	41-51	interleukin 17A	Mus musculus	73-78
27279980-4	2016	In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE.	Cholecalciferol	41-51	interleukin 23, alpha subunit p19	Mus musculus	80-85
27279980-4	2016	In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE.	Cholecalciferol	41-51	interleukin 4	Mus musculus	87-91
27279980-4	2016	In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE.	Cholecalciferol	41-51	interferon gamma	Mus musculus	96-105
27279980-8	2016	RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction.	Cholecalciferol	171-181	interleukin 17A	Mus musculus	33-38
27279980-8	2016	RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction.	Cholecalciferol	171-181	interleukin 23, alpha subunit p19	Mus musculus	40-45
27279980-8	2016	RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction.	Cholecalciferol	171-181	interferon gamma	Mus musculus	51-60
27279980-8	2016	RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction.	Cholecalciferol	171-181	interleukin 17A	Mus musculus	82-87
27279980-8	2016	RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction.	Cholecalciferol	171-181	interleukin 4	Mus musculus	133-137
26820714-0	2016	Vitamin D3 Inhibits Wnt/beta-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells.	Cholecalciferol	0-10	Wnt family member 4	Homo sapiens	20-23
26820714-0	2016	Vitamin D3 Inhibits Wnt/beta-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells.	Cholecalciferol	0-10	catenin beta 1	Homo sapiens	24-36
26820714-0	2016	Vitamin D3 Inhibits Wnt/beta-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells.	Cholecalciferol	0-10	mechanistic target of rapamycin kinase	Homo sapiens	41-45
26820714-2	2016	OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells.	Cholecalciferol	65-75	Wnt family member 4	Homo sapiens	97-100
26820714-2	2016	OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells.	Cholecalciferol	65-75	catenin beta 1	Homo sapiens	101-113
26820714-2	2016	OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells.	Cholecalciferol	65-75	mechanistic target of rapamycin kinase	Homo sapiens	118-147
26820714-2	2016	OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells.	Cholecalciferol	65-75	mechanistic target of rapamycin kinase	Homo sapiens	149-153
26820714-6	2016	Vitamin D3 administration reduced the levels of Wnt4 and beta-catenin in both HuLM and PUF cells.	Cholecalciferol	0-10	Wnt family member 4	Homo sapiens	48-52
26820714-6	2016	Vitamin D3 administration reduced the levels of Wnt4 and beta-catenin in both HuLM and PUF cells.	Cholecalciferol	0-10	catenin beta 1	Homo sapiens	57-69
26820714-7	2016	Vitamin D3 also reduced the expression/activation of mTOR signaling in both cell types.	Cholecalciferol	0-10	mechanistic target of rapamycin kinase	Homo sapiens	53-57
26820714-8	2016	In contrast, vitamin D3 induced the expression of DNA damaged-induced transcription 4 (an inhibitor of mTOR) and tuberous sclerosis genes (TSC1/2) in a concentration-dependent manner in HuLM cells.	Cholecalciferol	13-23	mechanistic target of rapamycin kinase	Homo sapiens	103-107
26820714-8	2016	In contrast, vitamin D3 induced the expression of DNA damaged-induced transcription 4 (an inhibitor of mTOR) and tuberous sclerosis genes (TSC1/2) in a concentration-dependent manner in HuLM cells.	Cholecalciferol	13-23	TSC complex subunit 1	Homo sapiens	139-145
26820714-11	2016	Together these results suggest that vitamin D3 functions as an inhibitor of Wnt4/beta-catenin and mTOR signaling pathways, which may play major roles in fibroid pathogenesis.	Cholecalciferol	36-46	Wnt family member 4	Homo sapiens	76-80
26820714-11	2016	Together these results suggest that vitamin D3 functions as an inhibitor of Wnt4/beta-catenin and mTOR signaling pathways, which may play major roles in fibroid pathogenesis.	Cholecalciferol	36-46	catenin beta 1	Homo sapiens	81-93
26820714-11	2016	Together these results suggest that vitamin D3 functions as an inhibitor of Wnt4/beta-catenin and mTOR signaling pathways, which may play major roles in fibroid pathogenesis.	Cholecalciferol	36-46	mechanistic target of rapamycin kinase	Homo sapiens	98-102
26694996-7	2016	Vitamin D3 was protective against vitamin D deficiency-induced cholesterol increase by maintaining the transcriptional activity of VDR and Insig-2 expression.	Cholecalciferol	0-10	insulin induced gene 2	Homo sapiens	139-146
26762804-3	2016	We recently described the therapeutic activity of the association between myelin oligodendrocyte glycoprotein peptide (MOG) and active vitamin D3 (VitD) against experimental autoimmune encephalomyelitis (EAE).	Cholecalciferol	135-145	myelin oligodendrocyte glycoprotein	Mus musculus	74-117
26943970-0	2016	Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism.	Cholecalciferol	0-10	interleukin 10	Homo sapiens	52-57
26943970-0	2016	Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism.	Cholecalciferol	0-10	suppressor of cytokine signaling 3	Homo sapiens	68-73
26943970-7	2016	In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3.	Cholecalciferol	139-149	vitamin D receptor	Homo sapiens	67-85
26943970-7	2016	In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3.	Cholecalciferol	139-149	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	90-97
26943970-7	2016	In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3.	Cholecalciferol	214-224	vitamin D receptor	Homo sapiens	67-85
26943970-7	2016	In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3.	Cholecalciferol	214-224	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	90-97
26943970-8	2016	Most importantly, the activated microglia exposed to vitamin D3 had reduced expression of pro-inflammatory cytokines, IL-6, IL-12, and TNFalpha, and increased expression of IL-10.	Cholecalciferol	53-63	interleukin 6	Homo sapiens	118-122
26943970-8	2016	Most importantly, the activated microglia exposed to vitamin D3 had reduced expression of pro-inflammatory cytokines, IL-6, IL-12, and TNFalpha, and increased expression of IL-10.	Cholecalciferol	53-63	tumor necrosis factor	Homo sapiens	135-143
26943970-8	2016	Most importantly, the activated microglia exposed to vitamin D3 had reduced expression of pro-inflammatory cytokines, IL-6, IL-12, and TNFalpha, and increased expression of IL-10.	Cholecalciferol	53-63	interleukin 10	Homo sapiens	173-178
26943970-10	2016	Therefore, vitamin D3 increases the expression of IL-10 creating a feedback loop via SOCS3 that downregulates the pro-inflammatory immune response by activated microglia which would likewise prevent immune mediated damage in the CNS.	Cholecalciferol	11-21	interleukin 10	Homo sapiens	50-55
26943970-10	2016	Therefore, vitamin D3 increases the expression of IL-10 creating a feedback loop via SOCS3 that downregulates the pro-inflammatory immune response by activated microglia which would likewise prevent immune mediated damage in the CNS.	Cholecalciferol	11-21	suppressor of cytokine signaling 3	Homo sapiens	85-90
26977043-1	2016	BACKGROUND: Vitamin D3 can be metabolized in the skin to 25(OH)D and 1,25(OH)2D because the skin expresses vitamin D-25-hydroxylase, 25(OH)D-1-alpha-hydroxylase, and the vitamin D receptor.	Cholecalciferol	12-22	vitamin D receptor	Homo sapiens	170-188
26976974-1	2016	Vitamin D3 (D3) can be metabolized by cytochrome P450scc (CYP11A1) into 20S-hydroxyvitamin D3 (20D3) as a major metabolite.	Cholecalciferol	0-10	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	58-65
26813503-2	2016	A combination of oral active vitamin D3 and phosphate is the current standard therapy for FGF23-related hypophosphatemia.	Cholecalciferol	29-39	fibroblast growth factor 23	Homo sapiens	90-95
26902087-2	2016	The VDR binds to active vitamin D3 metabolites, which stimulates downstream transduction signaling involved in various physiological activities such as calcium homeostasis, bone mineralization, and cell differentiation.	Cholecalciferol	24-34	vitamin D receptor	Homo sapiens	4-7
26786573-2	2016	This study was designed to investigate the effect of high-dose vitamin D3 treatment on beta-cell function, insulin sensitivity, and glucose tolerance in subjects with prediabetes or diet-treated type 2 diabetes.	Cholecalciferol	63-73	insulin	Homo sapiens	107-114
26744303-0	2016	Inhibition of alpha-glucosidase by vitamin D3 and the effect of vitamins B1 and B2.	Cholecalciferol	35-45	sucrase-isomaltase	Homo sapiens	14-31
26744303-3	2016	The inhibitory effect of vitamin D3 on alpha-glucosidase as well as its mechanism of action was investigated in this work.	Cholecalciferol	25-35	sucrase-isomaltase	Homo sapiens	39-56
26744303-4	2016	The results showed that vitamin D3 exhibited stronger inhibition on alpha-glucosidase than acarbose with the IC50 value of 1.28 x 10(-4) mol L(-1), and the inhibition was a mixed-type mechanism through a multiphase kinetic process.	Cholecalciferol	24-34	sucrase-isomaltase	Homo sapiens	68-85
26744303-6	2016	Vitamin D3 interacted with alpha-glucosidase by hydrophobic interactions, and molecular docking further verified that the inhibitor inserted into the active site pocket of alpha-glucosidase and interacted with the amino residues, which induced the rearrangement and conformational changes of alpha-glucosidase, and might move to cover the active pocket, hindering the binding of the substrate leading to the inhibition of the enzyme activity.	Cholecalciferol	0-10	sucrase-isomaltase	Homo sapiens	27-44
26744303-6	2016	Vitamin D3 interacted with alpha-glucosidase by hydrophobic interactions, and molecular docking further verified that the inhibitor inserted into the active site pocket of alpha-glucosidase and interacted with the amino residues, which induced the rearrangement and conformational changes of alpha-glucosidase, and might move to cover the active pocket, hindering the binding of the substrate leading to the inhibition of the enzyme activity.	Cholecalciferol	0-10	sucrase-isomaltase	Homo sapiens	172-189
26744303-6	2016	Vitamin D3 interacted with alpha-glucosidase by hydrophobic interactions, and molecular docking further verified that the inhibitor inserted into the active site pocket of alpha-glucosidase and interacted with the amino residues, which induced the rearrangement and conformational changes of alpha-glucosidase, and might move to cover the active pocket, hindering the binding of the substrate leading to the inhibition of the enzyme activity.	Cholecalciferol	0-10	sucrase-isomaltase	Homo sapiens	172-189
26744303-7	2016	Moreover, it was found that vitamin D3 combined with vitamin B1 or vitamin B2 exhibited significant synergistic effects on inhibition of alpha-glucosidase.	Cholecalciferol	28-38	sucrase-isomaltase	Homo sapiens	137-154
26744303-8	2016	This study has provided new insights into the role of vitamin D3 in inhibiting alpha-glucosidase catalysis and offered useful information on the dietary recommendation of vitamin D3 for the treatment of type 2 diabetes.	Cholecalciferol	54-64	sucrase-isomaltase	Homo sapiens	79-96
26718578-9	2016	CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells.	Cholecalciferol	13-28	CD4 molecule	Homo sapiens	229-232
26499096-9	2016	Plasma samples collected from patients after the administration of activated vitamin D3 caused significantly increased ALP activity in SMC compared to the samples drawn prior to activated vitamin D3 and here, again induction of ferritin diminished the osteoblastic transformation.	Cholecalciferol	77-87	alkaline phosphatase, placental	Homo sapiens	119-122
26358366-6	2016	Furthermore, pre-treatment with Dex inhibits vitamin D3 induced cathelicidin expression in THP-1 monocytes, primary monocytes and in the human bronchial epithelial cell line BCi NS 1.1.	Cholecalciferol	45-55	GLI family zinc finger 2	Homo sapiens	91-96
26358366-7	2016	We also demonstrate that treatment with the glucocorticoid receptor (GR) inhibitor RU486 counteracts Dex mediated down-regulation of basal and vitamin D3 induced cathelicidin expression in THP-1 monocytes.	Cholecalciferol	143-153	nuclear receptor subfamily 3 group C member 1	Homo sapiens	44-67
26358366-7	2016	We also demonstrate that treatment with the glucocorticoid receptor (GR) inhibitor RU486 counteracts Dex mediated down-regulation of basal and vitamin D3 induced cathelicidin expression in THP-1 monocytes.	Cholecalciferol	143-153	nuclear receptor subfamily 3 group C member 1	Homo sapiens	69-71
26358366-7	2016	We also demonstrate that treatment with the glucocorticoid receptor (GR) inhibitor RU486 counteracts Dex mediated down-regulation of basal and vitamin D3 induced cathelicidin expression in THP-1 monocytes.	Cholecalciferol	143-153	GLI family zinc finger 2	Homo sapiens	189-194
26653112-9	2016	RESULTS: Treatment with 4000 IU of vitamin D3 decreased intracellular CD4+ ATP release by 95.5 ng/ml (interquartile range, -219.5 to 105.8).	Cholecalciferol	35-45	CD4 molecule	Homo sapiens	70-73
26653112-10	2016	In contrast, 400 IU of vitamin D3 decreased intracellular CD4+ ATP release by 0.5 ng/ml (interquartile range, -69.2 to 148.5).	Cholecalciferol	23-33	CD4 molecule	Homo sapiens	58-61
26653112-11	2016	In a proportional odds model, high-dose vitamin D3 was more likely than low-dose vitamin D3 to decrease CD4+ ATP release (odds ratio, 3.43; 95% confidence interval, 1.06-1.11).	Cholecalciferol	40-50	CD4 molecule	Homo sapiens	104-107
26653112-11	2016	In a proportional odds model, high-dose vitamin D3 was more likely than low-dose vitamin D3 to decrease CD4+ ATP release (odds ratio, 3.43; 95% confidence interval, 1.06-1.11).	Cholecalciferol	81-91	CD4 molecule	Homo sapiens	104-107
26653112-12	2016	CONCLUSIONS: In this ancillary study of a randomized controlled trial, we found that high-dose vitamin D3 significantly reduced CD4+ T-cell activation compared to low-dose vitamin D3, providing human evidence that vitamin D can influence cell-mediated immunity.	Cholecalciferol	95-105	CD4 molecule	Homo sapiens	128-131
26828994-3	2016	Although agents such as omega-3 (omega3) and vitamin D3 (Vit D3) are known to contribute to the success of islet allo-transplantation (ITX), in this study we aimed to experimentally determine their effects on glycemia and TNF-alpha production.	Cholecalciferol	45-55	tumor necrosis factor	Rattus norvegicus	222-231
26718578-9	2016	CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells.	Cholecalciferol	13-28	CD4 molecule	Homo sapiens	288-291
26718578-9	2016	CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells.	Cholecalciferol	13-28	CD4 molecule	Homo sapiens	288-291
26718578-9	2016	CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells.	Cholecalciferol	13-28	CD4 molecule	Homo sapiens	288-291
26638999-0	2016	Expression of human CYP27A1 in B. megaterium for the efficient hydroxylation of cholesterol, vitamin D3 and 7-dehydrocholesterol.	Cholecalciferol	93-103	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	20-27
26238339-11	2016	Irrespective of the dietary vitamin D3, dietary soy is able to increase tumour volume when tumours overexpress CYP24A1, suggesting that combination of vitamin D3 and soy could have an anti-tumourigenic effect only if CYP24A1 levels are normal.	Cholecalciferol	151-161	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	111-118
26238339-11	2016	Irrespective of the dietary vitamin D3, dietary soy is able to increase tumour volume when tumours overexpress CYP24A1, suggesting that combination of vitamin D3 and soy could have an anti-tumourigenic effect only if CYP24A1 levels are normal.	Cholecalciferol	151-161	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	217-224
26638999-4	2016	The resulting whole cell system allowed the efficient biotechnological conversion of the CYP27A1 substrates cholesterol, 7-dehydrocholesterol (7-DHC) and vitamin D3.	Cholecalciferol	154-164	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	89-96
26750596-3	2016	Here, we show that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevents IL-4-induced conversion to IL-13-producers.	Cholecalciferol	58-68	CD8a molecule	Homo sapiens	77-80
27356607-0	2016	Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells.	Cholecalciferol	0-10	plexin A2	Homo sapiens	32-35
27356607-0	2016	Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells.	Cholecalciferol	0-10	cathelicidin antimicrobial peptide	Homo sapiens	45-52
27356607-0	2016	Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells.	Cholecalciferol	0-10	cathelicidin antimicrobial peptide	Homo sapiens	53-58
27356607-1	2016	Maxacalcitol (22-oxacalcitriol: OCT) is a synthetic vitamin D3 analog with a limited calcemic effect.	Cholecalciferol	52-62	plexin A2	Homo sapiens	32-35
27336154-0	2016	Vitamin D3-Supplemented Yogurt Drink Improves Insulin Resistance and Lipid Profiles in Women with Gestational Diabetes Mellitus: A Randomized Double Blinded Clinical Trial.	Cholecalciferol	0-10	insulin	Homo sapiens	46-53
27336154-1	2016	BACKGROUND: Our study aimed to examine the effects of daily consumption of vitamin D3-supplemented yogurt (VDY) drink on insulin resistance and lipid profiles in pregnant gestational diabetes mellitus (GDM) patients.	Cholecalciferol	75-85	insulin	Homo sapiens	121-128
26750596-3	2016	Here, we show that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevents IL-4-induced conversion to IL-13-producers.	Cholecalciferol	58-68	interleukin 4	Homo sapiens	116-120
26750596-3	2016	Here, we show that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevents IL-4-induced conversion to IL-13-producers.	Cholecalciferol	58-68	interleukin 13	Homo sapiens	143-148
26607259-11	2016	CONCLUSION: Although exploratory, this study indicates rs8176345 in CYP27B1 gene as significantly correlated with erlotinib-induced SR in aNSCLC patients probably through a mechanism mediated by vitamin D3 and inflammation at skin level.	Cholecalciferol	195-205	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	68-75
27764518-0	2016	Administration of vitamin D3 induces CNPase and myelin oligodendrocyte glycoprotein expression in the cerebral cortex of the murine model of cuprizone-induced demyelination.	Cholecalciferol	18-28	2',3'-cyclic nucleotide 3' phosphodiesterase	Mus musculus	37-43
27252860-2	2016	Herein, we report a case of a young male, diagnosed with LADA based on both clinical presentation and positive anti-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) (sitagliptin) and cholecalciferol.	Cholecalciferol	279-294	dipeptidyl peptidase 4	Homo sapiens	220-242
27777388-2	2016	Active vitamin D3 and its derivatives have their own feature of pharmacokinetics, due to differences in binding affinity for carrier protein such as vitamin D binding protein and in metabolism.	Cholecalciferol	7-17	GC vitamin D binding protein	Homo sapiens	149-174
28035286-11	2016	Vitamin D3 also activates CD4+CD25+FoxP3+ regulatory T-cells, and these medications combined can improve the immune response in patients with new-onset T1DM and probably promote sustained clinical remission.	Cholecalciferol	0-10	forkhead box P3	Homo sapiens	35-40
28035286-12	2016	LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission.	Cholecalciferol	44-54	insulin	Homo sapiens	142-149
28035286-12	2016	LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission.	Cholecalciferol	44-54	insulin	Homo sapiens	214-221
28035286-12	2016	LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission.	Cholecalciferol	44-54	glutamate decarboxylase 1	Homo sapiens	530-533
26433491-0	2016	Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production.	Cholecalciferol	0-10	cathelicidin antimicrobial peptide	Homo sapiens	74-81
26433491-0	2016	Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production.	Cholecalciferol	0-10	cathelicidin antimicrobial peptide	Homo sapiens	82-87
27764518-0	2016	Administration of vitamin D3 induces CNPase and myelin oligodendrocyte glycoprotein expression in the cerebral cortex of the murine model of cuprizone-induced demyelination.	Cholecalciferol	18-28	myelin oligodendrocyte glycoprotein	Mus musculus	48-83
26385608-2	2016	In this study, we examined the potencies of other vitamin D3 and D2 analogs to stimulate the ectodomain shedding of TNFR1 in HASMCs.	Cholecalciferol	50-60	TNF receptor superfamily member 1A	Homo sapiens	116-121
27096068-10	2016	Also, results indicated that vitamin D3 caused a decrease in lipid peroxidation levels and an increase in CAT activities.	Cholecalciferol	29-39	catalase	Homo sapiens	106-109
27313879-0	2016	Vitamin D3 Suppresses Class II Invariant Chain Peptide Expression on Activated B-Lymphocytes: A Plausible Mechanism for Downregulation of Acute Inflammatory Conditions.	Cholecalciferol	0-10	proopiomelanocortin	Homo sapiens	22-54
27313879-3	2016	We hypothesized that activated vitamin D3 suppresses CLIP expression on activated B-cells after nonspecific activation or priming of C57BL/6 mice with CpG.	Cholecalciferol	31-41	CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	Mus musculus	53-57
27313879-4	2016	This study showed activated vitamin D3 actively reduced CLIP expression and decreased the number of CLIP(+) B-lymphocytes in a dose and formulation dependent fashion.	Cholecalciferol	28-38	proopiomelanocortin	Homo sapiens	56-60
27313879-4	2016	This study showed activated vitamin D3 actively reduced CLIP expression and decreased the number of CLIP(+) B-lymphocytes in a dose and formulation dependent fashion.	Cholecalciferol	28-38	proopiomelanocortin	Homo sapiens	100-104
27313879-5	2016	Flow cytometry was used to analyze changes in mean fluorescent intensity (MFI) based on changes in concentration of CLIP on activated B-lymphocytes after treatment with the various formulations of vitamin D3.	Cholecalciferol	197-207	proopiomelanocortin	Homo sapiens	116-120
25777538-5	2016	We hypothesized that 1,25-dihydroyvitamin D3 (1,25-D3), the active form of vitamin D3, promotes differentiation by modulating beta-catenin/T-cell factor (TCF) 4-mediated gene transcription.	Cholecalciferol	34-44	catenin (cadherin associated protein), beta 1	Mus musculus	126-138
27505422-0	2016	Vitamin D3 Partly Antagonizes Advanced-Glycation Endproducts-Induced NFkappaB Activation in Mouse Podocytes.	Cholecalciferol	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-77
27701167-7	2016	Patients with mGFR below the median shown significantly higher PTH and lower vitamin D3.	Cholecalciferol	77-87	Rap guanine nucleotide exchange factor (GEF) 5	Mus musculus	14-18
27505422-13	2016	CONCLUSION: Vitamin D3 or its analog paricalcitol partly prevented AGE-mediated NFkappaB activation, an important feature of diabetic nephropathy (DN).	Cholecalciferol	12-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	80-88
26314252-2	2015	Herein, we presented evidence indicating that DDX5 is transcriptionally upregulated by calcitriol, the hormonal form of vitamin D3.	Cholecalciferol	120-130	DEAD-box helicase 5	Homo sapiens	46-50
26827949-1	2016	The vitamin D nuclear receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 hormone (1,25(OH)2D3, or calcitriol), classically regulate mineral homeostasis and metabolism but also much broader range of biological functions, such as cell growth, differentiation, antiproliferation, apoptosis, adaptive/innate immune responses.	Cholecalciferol	88-90	vitamin D receptor	Homo sapiens	4-30
26827949-1	2016	The vitamin D nuclear receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 hormone (1,25(OH)2D3, or calcitriol), classically regulate mineral homeostasis and metabolism but also much broader range of biological functions, such as cell growth, differentiation, antiproliferation, apoptosis, adaptive/innate immune responses.	Cholecalciferol	88-90	vitamin D receptor	Homo sapiens	32-35
26206289-7	2015	In contrast, peptide delivered intradermally on the surface of vitamin D3-modulated (tolerogenic) dendritic cells, controls autoimmunity in association with proinsulin-specific IL-10 production, but no change in regulatory CD4 T cells.	Cholecalciferol	63-73	insulin II	Mus musculus	157-167
26440923-9	2016	Compared with the control group, patients treated with vitamin D3 also had greater decreases in high sensitivity C-reactive protein and renin-angiotensin system activity (p &lt; 0.05).	Cholecalciferol	55-65	C-reactive protein	Homo sapiens	113-131
26440923-9	2016	Compared with the control group, patients treated with vitamin D3 also had greater decreases in high sensitivity C-reactive protein and renin-angiotensin system activity (p &lt; 0.05).	Cholecalciferol	55-65	renin	Homo sapiens	136-141
26827960-1	2016	The Arg274 residue of the ligand binding domain of human vitamin D receptor (hVDR) is important for 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) binding as a specific ligand through forming a hydrogen bond with the 1alpha-OH group of the active vitamin D3, 1alpha,25(OH)2D3.	Cholecalciferol	119-129	vitamin D receptor	Homo sapiens	57-75
26827960-1	2016	The Arg274 residue of the ligand binding domain of human vitamin D receptor (hVDR) is important for 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) binding as a specific ligand through forming a hydrogen bond with the 1alpha-OH group of the active vitamin D3, 1alpha,25(OH)2D3.	Cholecalciferol	119-129	vitamin D receptor	Homo sapiens	77-81
26664810-4	2015	We show that treatment of VA10 cells with vitamin D3 and/or 4-phenyl butyric acid counteracted cyclic stretch mediated down-regulation of CAMP mRNA and protein expression (LL-37).	Cholecalciferol	42-52	cathelicidin antimicrobial peptide	Homo sapiens	138-142
29391997-6	2015	There was a positive correlation between IFN-gamma and vitamin D levels (p&lt;0.05) in the study group, whereas IgE, IL-4, and IL-10 levels showed a negative correlation with vitamin D3 levels (p&lt;0.05).	Cholecalciferol	175-185	immunoglobulin heavy constant epsilon	Homo sapiens	112-115
29391997-6	2015	There was a positive correlation between IFN-gamma and vitamin D levels (p&lt;0.05) in the study group, whereas IgE, IL-4, and IL-10 levels showed a negative correlation with vitamin D3 levels (p&lt;0.05).	Cholecalciferol	175-185	interleukin 10	Homo sapiens	127-132
26640388-9	2015	Twelve-month oral cholecalciferol administration increased 25-hydroxyvitamin D and reduced PTH serum levels.	Cholecalciferol	18-33	parathyroid hormone	Homo sapiens	91-94
26640388-12	2015	Oral cholecalciferol administration increased 25-hydroxyvitamin D and mildly reduced PTH serum levels.	Cholecalciferol	5-20	parathyroid hormone	Homo sapiens	85-88
26399683-6	2015	Bropirimine partially suppressed the expression of RANKL mRNA in UAMS-32 cells induced by activated vitamin D3.	Cholecalciferol	100-110	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	51-56
26501255-1	2015	Vitamin D3 shows tumoristatic and anticancer effects by acting through the vitamin D receptor (VDR), while hydroxylation of 25-hydroxyvitamin D3 at position 1alpha by CYP27B1 is an essential step in its activation.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	75-93
26560812-3	2015	Both genetic and pharmacological inhibition of PDK4 ameliorated the calcification in phosphate-treated VSMCs and aortic rings and in vitamin D3-treated mice.	Cholecalciferol	133-143	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	47-51
26463745-3	2015	OBJECTIVES: To study vitamin D3 metabolizing enzymes, CYP27A1 and CYP27B1, in mast cells in epithelial skin cancers and psoriasis.	Cholecalciferol	21-31	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	54-61
26397033-0	2015	Evaluation of the lipopolysaccharide-induced transcription of the human TREM-1 gene in vitamin D3-matured THP-1 macrophage-like cells.	Cholecalciferol	87-97	triggering receptor expressed on myeloid cells 1	Homo sapiens	72-78
26397033-4	2015	Reverse transcription-polymerase chain reaction (RT-PCR) revealed that TREM-1 mRNA was constitutively expressed at a low level in resting cells, and that its expression was upregulated by treatment with vitamin D3 (VitD3), but not by LPS.	Cholecalciferol	203-213	triggering receptor expressed on myeloid cells 1	Homo sapiens	71-77
26770399-0	2015	Vitamin D3 alters Toll-like receptor 4 signaling in monocytes of pregnant women at risk for preeclampsia.	Cholecalciferol	0-10	toll like receptor 4	Homo sapiens	18-38
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	tumor necrosis factor	Mus musculus	188-197
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	interleukin 1 beta	Mus musculus	199-207
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	interleukin 6	Mus musculus	209-213
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	interleukin 17A	Mus musculus	225-231
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	interleukin 17F	Mus musculus	237-243
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	regenerating islet-derived 3 gamma	Mus musculus	281-290
25938886-10	2015	Totally, the administration of cholecalciferol supplements among pregnant women at risk for pre-eclampsia for 12 weeks had favorable effects on insulin metabolism parameters, serum HDL-cholesterol, and plasma TAC concentrations.	Cholecalciferol	31-46	insulin	Homo sapiens	144-151
26770399-4	2015	Because vitamin D3 supplementation can induce anti-inflammatory cytokine signaling, peripheral blood monocytes were investigated by flow cytometry for expression of toll-like receptor 4 (TLR4), an important mediator of innate immune response.	Cholecalciferol	8-18	toll like receptor 4	Homo sapiens	187-191
26770399-9	2015	Based on these results, we conclude that vitamin D3 supplementation for patients at risk of preeclampsia leads to a decrease in the expression of peripheral blood monocytes TLR4 and a subsequent decrease in pro-inflammatory cytokine secretion.	Cholecalciferol	41-51	toll like receptor 4	Homo sapiens	173-177
26501255-1	2015	Vitamin D3 shows tumoristatic and anticancer effects by acting through the vitamin D receptor (VDR), while hydroxylation of 25-hydroxyvitamin D3 at position 1alpha by CYP27B1 is an essential step in its activation.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	95-98
26770399-10	2015	Therefore, inhibiting the expression of monocytes TLR4 through vitamin D3 supplement may be a new approach to preeclampsia prevention.	Cholecalciferol	63-73	toll like receptor 4	Homo sapiens	50-54
26054778-8	2015	Vitamin D3 supplementation restored the alteration in vitamin D receptor expression, AMPA receptor density and AMPA and IP3 receptor expression in the pancreatic islets that helps to restore the calcium-mediated insulin secretion.	Cholecalciferol	0-10	inositol 1,4,5-trisphosphate receptor, type 3	Rattus norvegicus	120-132
26408720-9	2015	CONCLUSION: This observation indicates that a combination of high-dose vitamin D3 and ketogenic diet leads to changes in some biological markers of breast cancer, i.e. negativization of HER2 expression and increased expression of PgR.	Cholecalciferol	71-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	186-190
26408720-9	2015	CONCLUSION: This observation indicates that a combination of high-dose vitamin D3 and ketogenic diet leads to changes in some biological markers of breast cancer, i.e. negativization of HER2 expression and increased expression of PgR.	Cholecalciferol	71-81	progesterone receptor	Homo sapiens	230-233
26445902-1	2015	To investigate whether novel pathways of vitamin D3 (D3) and 7-dehydrocholesterol (7DHC) metabolism initiated by CYP11A1 and previously characterized in vitro, occur in vivo, we analyzed samples of human serum and epidermis, and pig adrenals for the presence of intermediates and products of these pathways.	Cholecalciferol	41-51	cytochrome P450 family 11 subfamily A member 1	Sus scrofa	113-120
25495336-5	2015	RESULTS: Treatment with 30 ng/mL of vitamin D3, corresponding to an optimal plasma concentration of vitamin D, for 24 h had no effect on PDL cell number and morphology but increased PDL cell osteopontin and osteocalcin mRNA expression by about 70 and 40%, respectively, and, moreover, treatment with vitamin D3 for 48 h enhanced PDL cell alkaline phosphatase activity by about two times showing that vitamin D3 exerts pro-osteogenic effects in human PDL cells.	Cholecalciferol	36-46	secreted phosphoprotein 1	Homo sapiens	191-202
25495336-10	2015	CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue.	Cholecalciferol	13-23	interleukin 6	Homo sapiens	113-117
25495336-5	2015	RESULTS: Treatment with 30 ng/mL of vitamin D3, corresponding to an optimal plasma concentration of vitamin D, for 24 h had no effect on PDL cell number and morphology but increased PDL cell osteopontin and osteocalcin mRNA expression by about 70 and 40%, respectively, and, moreover, treatment with vitamin D3 for 48 h enhanced PDL cell alkaline phosphatase activity by about two times showing that vitamin D3 exerts pro-osteogenic effects in human PDL cells.	Cholecalciferol	36-46	bone gamma-carboxyglutamate protein	Homo sapiens	207-218
26904855-3	2015	Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR).	Cholecalciferol	58-68	vitamin D receptor	Homo sapiens	193-196
25495336-7	2015	The LPS-induced increase in IL-6 and CXCL1 transcripts was attenuated by vitamin D3 (30 ng/mL).	Cholecalciferol	73-83	interleukin 6	Homo sapiens	28-32
25495336-7	2015	The LPS-induced increase in IL-6 and CXCL1 transcripts was attenuated by vitamin D3 (30 ng/mL).	Cholecalciferol	73-83	C-X-C motif chemokine ligand 1	Homo sapiens	37-42
25495336-8	2015	Treatment with vitamin D3 (3-300 ng/mL) for 24 h reduced the LPS-evoked increase in PDL cell IL-6 protein by about 50%.	Cholecalciferol	15-25	interleukin 6	Homo sapiens	93-97
26007153-2	2015	The aim of this study was to investigate the effects of vitamin D3 treatment on serum sclerostin levels in young adult females with severe vitamin D deficiency.	Cholecalciferol	56-66	sclerostin	Homo sapiens	86-96
26007153-7	2015	We conclude that serum sclerostin level is decreased following vitamin D3 treatment in patients with vitamin D deficiency.	Cholecalciferol	63-73	sclerostin	Homo sapiens	23-33
25495336-10	2015	CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue.	Cholecalciferol	13-23	C-X-C motif chemokine ligand 1	Homo sapiens	131-136
25495336-10	2015	CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue.	Cholecalciferol	194-204	interleukin 6	Homo sapiens	113-117
25495336-10	2015	CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue.	Cholecalciferol	194-204	C-X-C motif chemokine ligand 1	Homo sapiens	131-136
26904855-3	2015	Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR).	Cholecalciferol	113-123	vitamin D receptor	Homo sapiens	173-191
26904855-3	2015	Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR).	Cholecalciferol	113-123	vitamin D receptor	Homo sapiens	193-196
26904855-4	2015	VDR and vitamin D metabolic enzymes expressed in male reproductive system, it suggest that vitamin D3 plays a pivotal role in male reproductive biology.	Cholecalciferol	91-101	vitamin D receptor	Homo sapiens	0-3
26562280-3	2015	The advent of new treatment options for NF1 such as topical vitamin D3 analogues, lovastatin, rapamycin (or sirolimus), and imatinib mesylate has added new dimensions that require further investigation to provide the greatest benefit to patients.	Cholecalciferol	60-70	neurofibromin 1	Homo sapiens	40-43
26394045-2	2015	Previous results have shown that vitamin D3 (vitD3) and 4-phenyl butyrate (PBA) are potent inducers of the host defense peptide LL-37 that possess anti-mycobacterial effects.	Cholecalciferol	33-43	cathelicidin antimicrobial peptide	Homo sapiens	128-133
26350811-3	2015	OBJECTIVE: To examine the effect of sunlight exposure and serum DHCR7 levels on cholecalciferol and cholesterol levels and studying any interrelationship.	Cholecalciferol	80-95	7-dehydrocholesterol reductase	Homo sapiens	64-69
25931412-1	2015	Several compounds are produced along the complex pathways of vitamin D3 metabolism, and synthetic analogs have been generated to improve kinetics and/or vitamin D receptor activation.	Cholecalciferol	61-71	vitamin D receptor	Homo sapiens	153-171
26184408-3	2015	The discovery that almost all tissues and cells in the body express the VDR and that several tissues possess the enzymatic capability to convert 25-hydroxyvitamin D (25(OH)-D3; cholecalciferol) to the active form, suggests that vitamin D fulfills various extra-osseous functions (Bouillon et al., Endocr Rev 29(6):726-776, 2008; Holick, N Engl J Med 357(3):266-281, 2007).	Cholecalciferol	177-192	vitamin D receptor	Homo sapiens	72-75
26232426-4	2015	RegDC generated from monocyte-derived DC treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secrete lower amounts of IFN-gamma than NK cells exposed to mDC.	Cholecalciferol	84-94	chemokine (C-C motif) ligand 22	Mus musculus	3-5
26232426-4	2015	RegDC generated from monocyte-derived DC treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secrete lower amounts of IFN-gamma than NK cells exposed to mDC.	Cholecalciferol	99-109	chemokine (C-C motif) ligand 22	Mus musculus	3-5
26232426-4	2015	RegDC generated from monocyte-derived DC treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secrete lower amounts of IFN-gamma than NK cells exposed to mDC.	Cholecalciferol	99-109	interferon gamma	Homo sapiens	176-185
26126827-3	2015	Here, we demonstrate that calcitriol, the hormonally active form of vitamin D3, is an excellent candidate for transmission of Ptch/Smo interaction.	Cholecalciferol	68-78	patched 1	Homo sapiens	126-130
26198928-12	2015	The multiple linear regression analysis indicated that the consumption of vitamin D3 was positively and significantly associated with the logarithm of IL-17 measures (beta=1.719; p=0.002 and R2=0.91), adjusted by EDSS scores.	Cholecalciferol	74-84	interleukin 17A	Homo sapiens	151-156
26198928-13	2015	CONCLUSION: IL-17 levels showed significant change in RRMS patients after receiving high dose vitamin D3 for 12weeks.	Cholecalciferol	94-104	interleukin 17A	Homo sapiens	12-17
26126827-3	2015	Here, we demonstrate that calcitriol, the hormonally active form of vitamin D3, is an excellent candidate for transmission of Ptch/Smo interaction.	Cholecalciferol	68-78	smoothened, frizzled class receptor	Homo sapiens	131-134
25576857-2	2015	In this randomized controlled double blind trial, we examined whether vitamin D3 supplementation at 2500 IU/d (D) or placebo has differential effects on markers of insulin sensitivity and bone turnover in overweight/obese postmenopausal women during 6 weeks of caloric restriction (weight loss; WL, n = 39) compared to weight maintenance (WM, n = 37).	Cholecalciferol	70-80	insulin	Homo sapiens	164-171
26205949-12	2015	CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90.	Cholecalciferol	13-23	catenin beta 1	Rattus norvegicus	108-120
26205949-12	2015	CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90.	Cholecalciferol	13-23	transforming growth factor, beta 1	Rattus norvegicus	130-139
26205949-12	2015	CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90.	Cholecalciferol	13-23	nitric oxide synthase 2	Rattus norvegicus	149-153
26205949-12	2015	CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90.	Cholecalciferol	13-23	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	155-160
26205949-12	2015	CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90.	Cholecalciferol	13-23	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	165-171
26205949-11	2015	Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P &lt; 0.05), in comparison with their corresponding monotherapy groups.	Cholecalciferol	17-27	catenin beta 1	Rattus norvegicus	91-103
26205949-11	2015	Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P &lt; 0.05), in comparison with their corresponding monotherapy groups.	Cholecalciferol	17-27	nitric oxide synthase 2	Rattus norvegicus	105-109
26205949-11	2015	Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P &lt; 0.05), in comparison with their corresponding monotherapy groups.	Cholecalciferol	17-27	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	111-116
26205949-11	2015	Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P &lt; 0.05), in comparison with their corresponding monotherapy groups.	Cholecalciferol	17-27	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	121-127
26205949-11	2015	Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P &lt; 0.05), in comparison with their corresponding monotherapy groups.	Cholecalciferol	17-27	dickkopf WNT signaling pathway inhibitor 1	Rattus norvegicus	174-179
26205949-11	2015	Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P &lt; 0.05), in comparison with their corresponding monotherapy groups.	Cholecalciferol	17-27	transforming growth factor, beta 1	Rattus norvegicus	181-190
26205949-11	2015	Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P &lt; 0.05), in comparison with their corresponding monotherapy groups.	Cholecalciferol	17-27	SMAD family member 4	Rattus norvegicus	204-209
25707738-6	2015	The protocol was evaluated in anti-CD3/CD28-stimulated peripheral blood mononuclear cells (PBMCs) from vitamin D3- (n = 9) and placebo-treated (n = 9) CD patients.	Cholecalciferol	103-113	CD28 molecule	Homo sapiens	39-43
25998127-4	2015	We found that de-differentiated Schwann cells could be re-differentiated in vitro into mature cells by treatment with an aldose reductase inhibitor, to reduce sorbitol levels, or with vitamin D3, to elevate Igf1 expression.	Cholecalciferol	184-194	insulin like growth factor 1	Homo sapiens	207-211
25777546-0	2015	Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.	Cholecalciferol	68-78	interferon alpha 1	Homo sapiens	86-96
26002980-3	2015	In this study, we show that the CCR8-inducing factors are heat stable and protease resistant and include the vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 and PGE2.	Cholecalciferol	109-119	C-C motif chemokine receptor 8	Homo sapiens	32-36
25908506-7	2015	In stratified analyses, participants randomized to vitamin D3 who lost 5% to 10% of baseline weight, versus participants who gained weight/had no weight-loss, had significantly greater decreases in levels of IL6 compared with those randomized to placebo: absolute change -0.75 pg/mL (-17.2%), placebo versus -1.77 pg/mL (-37.3%), vitamin D, P = 0.004.	Cholecalciferol	51-61	interleukin 6	Homo sapiens	208-211
25908506-9	2015	Effects of vitamin D3 supplementation on levels of IL1beta were inconsistent when stratified by weight loss.	Cholecalciferol	11-21	interleukin 1 beta	Homo sapiens	51-58
25908506-11	2015	In conclusion, vitamin D3 supplementation in combination with weight-loss of at least 5% of baseline weight was associated with significant reductions in levels of IL6.	Cholecalciferol	15-25	interleukin 6	Homo sapiens	164-167
26002980-8	2015	Epidermal-derived vitamin D3 metabolites and PGs provide an essential cue for the localization of CCR8(+) immune surveillance T cells within healthy human skin.	Cholecalciferol	18-28	C-C motif chemokine receptor 8	Homo sapiens	98-102
26158294-0	2015	p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3.	Cholecalciferol	125-135	tumor protein p53	Homo sapiens	0-3
26158294-0	2015	p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3.	Cholecalciferol	125-135	cystatin D	Homo sapiens	23-33
26158294-11	2015	In addition, treatment with calcitriol, the active vitamin D3 metabolite, and simultaneous activation of p53 resulted in enhanced CST5 induction and increased repression of SNAIL, an epithelial-mesenchymal transition (EMT) inducing transcription factor.	Cholecalciferol	51-61	cystatin D	Homo sapiens	130-134
26158294-0	2015	p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3.	Cholecalciferol	125-135	cystatin D	Homo sapiens	34-38
26158294-11	2015	In addition, treatment with calcitriol, the active vitamin D3 metabolite, and simultaneous activation of p53 resulted in enhanced CST5 induction and increased repression of SNAIL, an epithelial-mesenchymal transition (EMT) inducing transcription factor.	Cholecalciferol	51-61	snail family transcriptional repressor 1	Homo sapiens	173-178
26158294-15	2015	In addition, they suggest that a combined treatment activating p53 and the vitamin D3 pathway may function via induction of CST5.	Cholecalciferol	75-85	cystatin D	Homo sapiens	124-128
25639477-0	2015	Vitamin D3 metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells.	Cholecalciferol	0-10	NLR family pyrin domain containing 3	Homo sapiens	35-40
25903858-0	2015	Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway.	Cholecalciferol	0-10	mechanistic target of rapamycin kinase	Homo sapiens	120-124
25762594-7	2015	Vitamin D3 significantly promoted RANKL expression in ABCs and OPG in DPCs.	Cholecalciferol	0-10	TNF superfamily member 11	Rattus norvegicus	34-39
25762594-7	2015	Vitamin D3 significantly promoted RANKL expression in ABCs and OPG in DPCs.	Cholecalciferol	0-10	TNF receptor superfamily member 11B	Rattus norvegicus	63-66
25929726-11	2015	Based on these findings, it was concluded that the administration of cholecalciferol markedly attenuated the development of ISO-induced cardiac hypertrophy likely through downregulation of TNF-alpha /NF-kb/p65 signaling pathways.	Cholecalciferol	69-84	tumor necrosis factor	Rattus norvegicus	189-198
25929726-11	2015	Based on these findings, it was concluded that the administration of cholecalciferol markedly attenuated the development of ISO-induced cardiac hypertrophy likely through downregulation of TNF-alpha /NF-kb/p65 signaling pathways.	Cholecalciferol	69-84	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	200-205
25929726-11	2015	Based on these findings, it was concluded that the administration of cholecalciferol markedly attenuated the development of ISO-induced cardiac hypertrophy likely through downregulation of TNF-alpha /NF-kb/p65 signaling pathways.	Cholecalciferol	69-84	synaptotagmin 1	Rattus norvegicus	206-209
25814176-7	2015	Treatment of cells with 1,25(OH)2D3 increased the ability of macrophages to respond to stimuli and produce NO, but vitamin D3 alone did not activate macrophages and resulted in the down-regulation of CD86, MHC-II, CXCL8 and IL-1beta.	Cholecalciferol	115-125	interleukin 8-like 2	Gallus gallus	214-219
25869067-7	2015	Our results suggest that orally ingested dietary vitamin D3 in aged mice improves glucose metabolism as a GLP-1 enhancer.	Cholecalciferol	49-59	glucagon	Mus musculus	106-111
25788584-14	2015	In line with the in vivo data, in vitro functional studies showed that cells treated with 25(OH)D3 for 24 h had increased VDR expression, and activated the mechanistic target of rapamycin (mTOR)/S6 kinase (S6K) pathway, enhanced Ki67 protein concentrations, and induced QM7 cell proliferation compared with untreated or cholecalciferol-treated cells.	Cholecalciferol	320-335	serine/threonine-protein kinase mTOR	Coturnix japonica	189-193
25727742-1	2015	CYP11A1 hydroxylates vitamin D3 producing 20S-hydroxyvitamin D3 [20(OH)D3] and 20S,23-dihydroxyvitamin D3 [20,23(OH)2D3] as the major and most characterized metabolites.	Cholecalciferol	21-31	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	0-7
26098102-2	2015	In this study, 7-dehydrocholesterol (7-DHC, a crucial precursor of vitamin D3) biosynthesis pathway was constructed in Saccharomyces cerevisiae BY4742 with endogenous ergosterol synthesis pathway blocked by knocking out the erg5 gene (encoding C-22 desaturase).	Cholecalciferol	67-77	C-22 sterol desaturase	Saccharomyces cerevisiae S288C	224-228
26065916-0	2015	Vitamin D3 inhibits lipopolysaccharide-induced placental inflammation through reinforcing interaction between vitamin D receptor and nuclear factor kappa B p65 subunit.	Cholecalciferol	0-10	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	110-128
26065916-0	2015	Vitamin D3 inhibits lipopolysaccharide-induced placental inflammation through reinforcing interaction between vitamin D receptor and nuclear factor kappa B p65 subunit.	Cholecalciferol	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	133-155
26068234-4	2015	As placental cytochrome P450scc pleiotropic activity is implicated in the metabolism of free radical mediated arachidonic acid derivatives as well as multiple Vitamin D3 hydroxylations and progesterone synthesis, we propose that Vitamin D3 might act as a competitive inhibitor of placental cytochrome P450scc preventing the production of lipid peroxides or excess progesterone synthesis, both of which may contribute to the etiopathogenesis of preeclampsia.	Cholecalciferol	159-169	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	13-31
25835512-3	2015	We conducted a clinical study to determine whether oral cholecalciferol supplementation would exert direct bioactivity in human skin through modulation of the VD receptor (VDR).	Cholecalciferol	56-71	vitamin D receptor	Homo sapiens	159-170
25835512-3	2015	We conducted a clinical study to determine whether oral cholecalciferol supplementation would exert direct bioactivity in human skin through modulation of the VD receptor (VDR).	Cholecalciferol	56-71	vitamin D receptor	Homo sapiens	172-175
25835512-11	2015	High-dose cholecalciferol supplementation raised serum VD metabolite levels concurrently with CYP24 mRNA and caspase-14 levels in the skin.	Cholecalciferol	10-25	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	94-99
25835512-11	2015	High-dose cholecalciferol supplementation raised serum VD metabolite levels concurrently with CYP24 mRNA and caspase-14 levels in the skin.	Cholecalciferol	10-25	caspase 14	Homo sapiens	109-119
25827670-0	2015	Effect of vitamin D3 supplementation and influence of BsmI polymorphism of the VDR gene of the inflammatory profile and oxidative stress in elderly women with vitamin D insufficiency: Vitamin D3 megadose reduces inflammatory markers.	Cholecalciferol	184-194	vitamin D receptor	Homo sapiens	79-82
25814176-7	2015	Treatment of cells with 1,25(OH)2D3 increased the ability of macrophages to respond to stimuli and produce NO, but vitamin D3 alone did not activate macrophages and resulted in the down-regulation of CD86, MHC-II, CXCL8 and IL-1beta.	Cholecalciferol	115-125	CD86 molecule	Gallus gallus	200-204
28377958-0	2015	Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway.	Cholecalciferol	10-20	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	60-72
28377958-12	2015	The plasma PTH had decreased by a mean of - 1.97 pmol/L (95% CI: - 2.7, - 1.3, P &lt; 0.0001) in the vitamin D3 group compared to placebo.	Cholecalciferol	101-111	parathyroid hormone	Homo sapiens	11-14
25741777-1	2015	Vitamin D3 is one of the few natural compounds that has, via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	149-167
25741777-1	2015	Vitamin D3 is one of the few natural compounds that has, via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	169-172
25569194-2	2015	This study evaluates the effects of vitamin D3 and vitamin K2 supplementation in conjunction with conventional periodontal therapy (scaling and root planing [SRP]) on gingival interleukin (IL)-1beta and IL-10, serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRAP-5b), and calcium and alveolar bone levels in rats with experimentally induced periodontitis.	Cholecalciferol	36-46	interleukin 10	Rattus norvegicus	203-208
25639477-0	2015	Vitamin D3 metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells.	Cholecalciferol	0-10	interleukin 1 beta	Homo sapiens	64-72
25639477-0	2015	Vitamin D3 metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells.	Cholecalciferol	0-10	GLI family zinc finger 2	Homo sapiens	84-89
25639477-2	2015	With metabolic enzymes for vitamin D3 activation and vitamin D receptors (VDR) now identified in a variety of immune cells, the active vitamin D3 metabolite 1,25(OH)2D3, is thought to possess immunomodulatory properties.	Cholecalciferol	135-145	vitamin D receptor	Homo sapiens	53-72
25639477-2	2015	With metabolic enzymes for vitamin D3 activation and vitamin D receptors (VDR) now identified in a variety of immune cells, the active vitamin D3 metabolite 1,25(OH)2D3, is thought to possess immunomodulatory properties.	Cholecalciferol	135-145	vitamin D receptor	Homo sapiens	74-77
25849854-11	2015	These novel findings demonstrate for the first time that p63 variants are differentially expressed in naive hMSC (TAp63alpha,beta), are important during the osteoblastic differentiation of hMSC (TAp63gamma and DeltaNp63beta), and are differentially regulated by the vitamin D3 metabolites, 1alpha,25(OH)2D3 and 24R,25(OH)2D3.	Cholecalciferol	266-276	tumor protein p63	Homo sapiens	57-60
25875760-1	2015	Vitamin D3 has transcriptome- and genome-wide effects and activates, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D3 to the transcription factor vitamin D receptor (VDR), several hundred target genes.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	161-179
25875760-1	2015	Vitamin D3 has transcriptome- and genome-wide effects and activates, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D3 to the transcription factor vitamin D receptor (VDR), several hundred target genes.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	181-184
25875760-2	2015	Using samples from a 5-month vitamin D3 intervention study (VitDmet), we recently reported that the expression of 12 VDR target genes in peripheral blood mononuclear cells (PBMCs) as well as 12 biochemical and clinical parameters of the study participants are significantly triggered by vitamin D3.	Cholecalciferol	29-39	vitamin D receptor	Homo sapiens	117-120
25762621-0	2015	miR-145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells.	Cholecalciferol	70-80	E2F transcription factor 3 S homeolog	Xenopus laevis	103-107
25466013-6	2015	Vitamin D3, used as a model nutraceutical, was successfully entrapped in the betalg/Lyso microspheres with an encapsulation efficiency of 90.8+-4.8%.	Cholecalciferol	0-10	lysozyme	Homo sapiens	84-88
25875760-2	2015	Using samples from a 5-month vitamin D3 intervention study (VitDmet), we recently reported that the expression of 12 VDR target genes in peripheral blood mononuclear cells (PBMCs) as well as 12 biochemical and clinical parameters of the study participants are significantly triggered by vitamin D3.	Cholecalciferol	287-297	vitamin D receptor	Homo sapiens	117-120
25849854-11	2015	These novel findings demonstrate for the first time that p63 variants are differentially expressed in naive hMSC (TAp63alpha,beta), are important during the osteoblastic differentiation of hMSC (TAp63gamma and DeltaNp63beta), and are differentially regulated by the vitamin D3 metabolites, 1alpha,25(OH)2D3 and 24R,25(OH)2D3.	Cholecalciferol	266-276	musculin	Homo sapiens	108-112
25849854-11	2015	These novel findings demonstrate for the first time that p63 variants are differentially expressed in naive hMSC (TAp63alpha,beta), are important during the osteoblastic differentiation of hMSC (TAp63gamma and DeltaNp63beta), and are differentially regulated by the vitamin D3 metabolites, 1alpha,25(OH)2D3 and 24R,25(OH)2D3.	Cholecalciferol	266-276	musculin	Homo sapiens	189-193
25448738-1	2015	Vitamin D3 is a pleiotropic signaling molecule that has via activation of the transcription factor vitamin D receptor (VDR) a direct effect on the expression of more than 100 genes.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	99-117
25835492-1	2015	PURPOSE: To investigate the effect of vitamin D3 on hepatic Cytochrome P450 enzyme (CYP) 3A4 in patients with abnormal glucose regulation using the endogenous marker 4beta-hydroxycholesterol (4beta-OHC):cholesterol ratio.	Cholecalciferol	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-92
25500068-0	2015	Synthesis and biological activities of vitamin D3 derivatives with cyanoalkyl side chain at C-2 position.	Cholecalciferol	39-49	complement C2	Homo sapiens	92-95
25500068-1	2015	We synthesized and evaluated novel vitamin D3 derivatives with cyanoalkyl side chain at C-2 position on the basis of our previous research for 2alpha side chain which bears nitrogen atom-containing functional group.	Cholecalciferol	35-45	complement C2	Homo sapiens	88-91
25448743-4	2015	The cholesterol side chain cleavage enzyme CYP11A1 is expressed in skin and produces 20-hydroxyvitamin D3 (20OHD) as a major product of vitamin D3.	Cholecalciferol	95-105	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	43-50
25448738-1	2015	Vitamin D3 is a pleiotropic signaling molecule that has via activation of the transcription factor vitamin D receptor (VDR) a direct effect on the expression of more than 100 genes.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	119-122
25500071-3	2015	Treatment of adult human epidermal keratinocytes (HEKa) with 10muM cholecalciferol resulted in a rapid decrease in DHCR7 activity (19% of control activity at 2h).	Cholecalciferol	67-82	7-dehydrocholesterol reductase	Homo sapiens	115-120
25617667-1	2015	CYP11A1 hydroxylates the side chain of vitamin D3 (D3) in a sequential fashion [D3 20S(OH)D3 20,23(OH)2D3 17,20,23(OH)3D3], in an alternative to the classical pathway of activation [D3 25(OH)D3 1,25(OH)2D3].	Cholecalciferol	39-49	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	0-7
25716812-2	2015	To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1.	Cholecalciferol	41-51	GC vitamin D binding protein	Homo sapiens	116-141
25501030-6	2015	Based on interaction studies of imatinib with the cytochrome P450 (CYP450) inhibitors VID400 and ketoconazole, it is proposed that imatinib may interfere with the vitamin D3 cascade due to its metabolism by CYP27B1, which is involved in vitamin D3 metabolism.	Cholecalciferol	163-173	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	207-214
24166893-6	2015	These preliminary results, although not statistically significant, suggest that supplemental calcium and vitamin D3 may increase TGFbeta1 expression and shift TGFalpha expression downward from the differentiation to the proliferation zone in the crypts in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients, and support further investigation in a larger clinical trial.	Cholecalciferol	105-115	transforming growth factor beta 1	Homo sapiens	129-137
24166893-6	2015	These preliminary results, although not statistically significant, suggest that supplemental calcium and vitamin D3 may increase TGFbeta1 expression and shift TGFalpha expression downward from the differentiation to the proliferation zone in the crypts in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients, and support further investigation in a larger clinical trial.	Cholecalciferol	105-115	transforming growth factor alpha	Homo sapiens	159-167
25799416-1	2015	BACKGROUND: Vitamin D3 is a secoster oid that exerts its effect by binding to its nuclear receptor called vitamin D receptor (VDR), inducing apoptosis and thereby inhibiting cell proliferation in cancer cells.	Cholecalciferol	12-22	vitamin D receptor	Homo sapiens	106-124
25799416-1	2015	BACKGROUND: Vitamin D3 is a secoster oid that exerts its effect by binding to its nuclear receptor called vitamin D receptor (VDR), inducing apoptosis and thereby inhibiting cell proliferation in cancer cells.	Cholecalciferol	12-22	vitamin D receptor	Homo sapiens	126-129
25773149-0	2015	Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.	Cholecalciferol	0-10	LAP	Homo sapiens	103-106
25773149-0	2015	Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.	Cholecalciferol	0-10	transforming growth factor beta 1	Homo sapiens	111-119
25773149-9	2015	CONCLUSIONS: We showed increased serum latency activated peptide (LAP) of TGF-beta levels in MS patients treated with vitamin D3.	Cholecalciferol	118-128	LAP	Homo sapiens	66-69
25773149-9	2015	CONCLUSIONS: We showed increased serum latency activated peptide (LAP) of TGF-beta levels in MS patients treated with vitamin D3.	Cholecalciferol	118-128	transforming growth factor beta 1	Homo sapiens	74-82
25716812-2	2015	To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1.	Cholecalciferol	41-51	D-box binding PAR bZIP transcription factor	Homo sapiens	143-146
25716812-2	2015	To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1.	Cholecalciferol	41-51	vitamin D receptor	Homo sapiens	149-167
25716812-2	2015	To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1.	Cholecalciferol	41-51	vitamin D receptor	Homo sapiens	169-172
25716812-2	2015	To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1.	Cholecalciferol	41-51	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	179-186
25716813-3	2015	Meanwhile, the active form of vitamin D3, 1alpha, 25-dihydroxyvitamin D3 [1alpha, 25 (OH) 2D3], upregulates expression of receptor activator of nuclear factor-kappaB ligand (RANKL) in osteoblastic cells.	Cholecalciferol	30-40	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	122-172
25716813-3	2015	Meanwhile, the active form of vitamin D3, 1alpha, 25-dihydroxyvitamin D3 [1alpha, 25 (OH) 2D3], upregulates expression of receptor activator of nuclear factor-kappaB ligand (RANKL) in osteoblastic cells.	Cholecalciferol	30-40	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	174-179
25716813-8	2015	However, daily administration of an active vitamin D3 analog (eldecalcitol, an osteoporotic therapeutic drug) for a month suppressed RANKL expression in osteoblasts, resulting in suppression of bone resorption.	Cholecalciferol	43-53	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	133-138
25201000-9	2015	CONCLUSIONS: A definite alteration was seen in vitamin D3-inactivating CYP24A1 gene activity in PTC compared to their normal tissues on a relatively large patient population.	Cholecalciferol	47-57	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	71-78
25479835-0	2015	Effects of 1,25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin d receptor in human skeletal muscle cells.	Cholecalciferol	25-35	vitamin D receptor	Homo sapiens	76-94
25479835-2	2015	We conducted a series of studies to examine the (1) effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on VDR gene expression in human primary myoblasts, (2) effect of 16-week supplementation with vitamin D3 on intramuscular VDR gene expression in older women, and (3) association between serum 25-hydroxyvitamin D (25OHD) and intramuscular VDR protein concentration in older adults.	Cholecalciferol	76-86	vitamin D receptor	Homo sapiens	104-107
25479835-5	2015	Intramuscular VDR mRNA was significantly different from placebo after 16 weeks of vitamin D3 (1.2+-0.99; -3.2+-1.7, respectively; P=0.04).	Cholecalciferol	82-92	vitamin D receptor	Homo sapiens	14-17
25479835-9	2015	25OHD is associated with VDR protein and 16 weeks of supplementation with vitamin D3 resulted in a persistent increase in VDR gene expression of vitamin D3 in muscle tissue biopsies.	Cholecalciferol	74-84	vitamin D receptor	Homo sapiens	122-125
25479835-9	2015	25OHD is associated with VDR protein and 16 weeks of supplementation with vitamin D3 resulted in a persistent increase in VDR gene expression of vitamin D3 in muscle tissue biopsies.	Cholecalciferol	145-155	vitamin D receptor	Homo sapiens	122-125
25866638-0	2015	TSLP is differentially regulated by vitamin D3 and cytokines in human skin.	Cholecalciferol	36-46	thymic stromal lymphopoietin	Homo sapiens	0-4
25561293-0	2015	Vitamin D3 as a novel regulator of basic fibroblast growth factor in chronic rhinosinusitis with nasal polyposis.	Cholecalciferol	0-10	fibroblast growth factor 2	Homo sapiens	35-65
25187428-1	2015	BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats.	Cholecalciferol	20-30	vitamin D receptor	Rattus norvegicus	91-109
25187428-1	2015	BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats.	Cholecalciferol	20-30	vitamin D receptor	Rattus norvegicus	111-114
25187428-1	2015	BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats.	Cholecalciferol	20-30	calcium-sensing receptor	Rattus norvegicus	120-144
25187428-1	2015	BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats.	Cholecalciferol	20-30	calcium-sensing receptor	Rattus norvegicus	146-150
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	renin	Rattus norvegicus	78-83
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	angiotensinogen	Rattus norvegicus	153-167
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	angiotensinogen	Rattus norvegicus	169-174
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	calcium-sensing receptor	Rattus norvegicus	188-192
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	angiotensinogen	Rattus norvegicus	202-207
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	angiotensinogen	Rattus norvegicus	202-207
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	vitamin D receptor	Rattus norvegicus	358-361
25187428-8	2015	In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions.	Cholecalciferol	19-29	calcium-sensing receptor	Rattus norvegicus	363-367
26005829-13	2015	A cholecalciferol load was administered, with significant descent of PTH.	Cholecalciferol	2-17	parathyroid hormone	Homo sapiens	69-72
25441291-5	2015	Atopic dermatitis and increased serum TSLP concentrations were induced by topical application of the vitamin D3 analog MC903.	Cholecalciferol	101-111	thymic stromal lymphopoietin	Homo sapiens	38-42
25416412-6	2015	Furthermore, our results showed that enhancement of metformin"s chemopreventive effects by vitamin D3 was associated with downregulation of S6P expression, via the AMPK (IGFI)/mTOR pathway.	Cholecalciferol	91-101	mechanistic target of rapamycin kinase	Rattus norvegicus	176-180
26038696-8	2015	Furthermore, we evaluated the metabolism of ED-71 by recombinant CYP24A1, which plays an important role in the metabolism of the active form of vitamin D3 (1alpha,25(OH)2D3) and its analogs.	Cholecalciferol	144-154	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	65-72
26413188-6	2015	Moreover, we uncovered yet another paradox; the increasing CMM incidences significantly correlate with decreasing personal annual UV dose, a proxy for low vitamin D3 levels.	Cholecalciferol	155-165	dysplastic nevus syndrome	Homo sapiens	59-62
26413188-9	2015	Thus, we propose the 2 major risk factors for getting CMM are intermittent UV exposures that result in low cutaneous levels of vitamin D3 and possibly viral infection.	Cholecalciferol	127-137	dysplastic nevus syndrome	Homo sapiens	54-57
25667505-2	2015	This important medical problem leads to the question, whether an insight into the genome-wide actions of the transcription factor vitamin D receptor (VDR) and its high affinity ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) can help in a more global appreciation of the physiological impact of vitamin D3.	Cholecalciferol	203-213	vitamin D receptor	Homo sapiens	130-148
25667505-2	2015	This important medical problem leads to the question, whether an insight into the genome-wide actions of the transcription factor vitamin D receptor (VDR) and its high affinity ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) can help in a more global appreciation of the physiological impact of vitamin D3.	Cholecalciferol	203-213	vitamin D receptor	Homo sapiens	150-153
25416412-7	2015	In addition, enhancement of vitamin D3"s chemopreventive effects by metformin was associated with inhibition of the protein expressions of c-Myc and Cyclin D1, via the vitamin D receptor/beta-catenin pathway.	Cholecalciferol	28-38	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	139-144
25416412-7	2015	In addition, enhancement of vitamin D3"s chemopreventive effects by metformin was associated with inhibition of the protein expressions of c-Myc and Cyclin D1, via the vitamin D receptor/beta-catenin pathway.	Cholecalciferol	28-38	cyclin D1	Rattus norvegicus	149-158
25271011-2	2015	This study investigated whether high-dose vitamin D3 given once to healthy adults before winter will (1) prevent the wintertime decline in vitamin D status, (2) promote vitamin D sufficiency 1 year following the dose and (3) prevent the rise of parathyroid hormone (PTH) concentrations.	Cholecalciferol	42-52	parathyroid hormone	Homo sapiens	245-264
25458314-6	2015	PBA also increases mRNA expression of the vitamin D3 regulated genes CYP24A1 and CD14.	Cholecalciferol	42-52	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	69-76
25644349-2	2015	OBJECTIVE: The objective of the study was to determine the effect of 2 doses of cholecalciferol (vitamin D3) supplementation on insulin action (Si) and pancreatic beta-cell function in obese adolescents.	Cholecalciferol	80-95	insulin	Homo sapiens	128-135
25644349-2	2015	OBJECTIVE: The objective of the study was to determine the effect of 2 doses of cholecalciferol (vitamin D3) supplementation on insulin action (Si) and pancreatic beta-cell function in obese adolescents.	Cholecalciferol	97-107	insulin	Homo sapiens	128-135
25458314-6	2015	PBA also increases mRNA expression of the vitamin D3 regulated genes CYP24A1 and CD14.	Cholecalciferol	42-52	CD14 molecule	Homo sapiens	81-85
25530010-10	2015	High vitamin D3 and calcium intakes significantly increased bone Ca and P content and relative bone weight in DIO mice, which was accompanied by an increase in 1,25(OH)2D3 and a decrease in PTH and osteocalcin concentrations in blood.	Cholecalciferol	5-15	parathyroid hormone	Mus musculus	190-193
25530010-10	2015	High vitamin D3 and calcium intakes significantly increased bone Ca and P content and relative bone weight in DIO mice, which was accompanied by an increase in 1,25(OH)2D3 and a decrease in PTH and osteocalcin concentrations in blood.	Cholecalciferol	5-15	bone gamma-carboxyglutamate protein 2	Mus musculus	198-209
25563481-8	2015	The release of proinflammatory interleukin (IL)-6 was decreased and the release of anti-inflammatory IL-10 was increased in mice fed a diet with high vitamin D3 supplementation.	Cholecalciferol	150-160	interleukin 10	Mus musculus	101-106
25997252-0	2015	Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways.	Cholecalciferol	34-44	RAR related orphan receptor C	Homo sapiens	123-126
25527766-0	2015	Common variants in CYP2R1 and GC genes are both determinants of serum 25-hydroxyvitamin D concentrations after UVB irradiation and after consumption of vitamin D3-fortified bread and milk during winter in Denmark.	Cholecalciferol	152-162	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	19-25
25527766-2	2015	In the Food with vitamin D (VitmaD) study, we showed that common genetic variants rs10741657 and rs10766197 in 25-hydroxylase (CYP2R1) and rs842999 and rs4588 in vitamin D binding protein (GC) predict 25(OH)D concentrations at late summer and after 6-mo consumption of cholecalciferol (vitamin D3)-fortified bread and milk.	Cholecalciferol	269-284	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	127-133
25527766-2	2015	In the Food with vitamin D (VitmaD) study, we showed that common genetic variants rs10741657 and rs10766197 in 25-hydroxylase (CYP2R1) and rs842999 and rs4588 in vitamin D binding protein (GC) predict 25(OH)D concentrations at late summer and after 6-mo consumption of cholecalciferol (vitamin D3)-fortified bread and milk.	Cholecalciferol	286-296	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	127-133
25527766-9	2015	CONCLUSION: Common genetic variants in the CYP2R1 and GC genes modify 25(OH)D concentrations in the same manner after artificial UVB-induced vitamin D and consumption of vitamin D3-fortified bread and milk.	Cholecalciferol	170-180	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	43-49
26064953-7	2015	Vitamin D3 supplementation decreased the calcium entry through calcium release activated calcium (CRAC) channels and purinergic P2X7 channels.	Cholecalciferol	0-10	purinergic receptor P2X 7	Homo sapiens	128-132
25538061-0	2015	Identification of two populations of osteoarthritic osteoblasts according to the 1,25[OH]2 vitamin D3 potency to stimulate osteocalcin.	Cholecalciferol	91-101	bone gamma-carboxyglutamate protein	Homo sapiens	123-134
26064953-10	2015	Vitamin D3 supplementation had a beneficial effect on [Ca(2+)]i decreasing calcium entry via CRAC and P2X7 channels and reducing P2X7 receptors expression.	Cholecalciferol	0-10	purinergic receptor P2X 7	Homo sapiens	102-106
26064953-10	2015	Vitamin D3 supplementation had a beneficial effect on [Ca(2+)]i decreasing calcium entry via CRAC and P2X7 channels and reducing P2X7 receptors expression.	Cholecalciferol	0-10	purinergic receptor P2X 7	Homo sapiens	129-133
25429711-5	2015	Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer.	Cholecalciferol	0-15	sonic hedgehog signaling molecule	Homo sapiens	78-81
26218841-6	2015	PBA and the active form of vitamin D3 (1,25[OH]2D3), separately or particularly in combination, were able to overcome Mtb-induced suppression of LL-37 expression.	Cholecalciferol	27-37	cathelicidin antimicrobial peptide	Homo sapiens	145-150
25429711-5	2015	Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer.	Cholecalciferol	0-15	GLI family zinc finger 1	Homo sapiens	82-85
25429711-5	2015	Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer.	Cholecalciferol	41-51	sonic hedgehog signaling molecule	Homo sapiens	78-81
25429711-5	2015	Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer.	Cholecalciferol	41-51	GLI family zinc finger 1	Homo sapiens	82-85
25584176-0	2015	Effect of vitamin D3 supplementation on TNF-alpha serum level and disease activity index in Iranian IBD patients.	Cholecalciferol	10-20	tumor necrosis factor	Homo sapiens	40-49
25584176-1	2015	AIM: The aim of the study was to assess the effectiveness of vitamin D3 [1, 25(OH)2D3] treatment in IBD with regard to tumor necrosis factor-alpha (TNF-alpha) serum level and clinical disease activity index (CDAI).	Cholecalciferol	61-71	tumor necrosis factor	Homo sapiens	119-146
25584176-1	2015	AIM: The aim of the study was to assess the effectiveness of vitamin D3 [1, 25(OH)2D3] treatment in IBD with regard to tumor necrosis factor-alpha (TNF-alpha) serum level and clinical disease activity index (CDAI).	Cholecalciferol	61-71	tumor necrosis factor	Homo sapiens	148-157
25584176-12	2015	CONCLUSION: Oral supplementation vitamin D3 significantly increased serum vitamin D levels and insignificantly reduced serum TNF-alpha level.	Cholecalciferol	33-43	tumor necrosis factor	Homo sapiens	125-134
25628655-0	2015	The Associations of Novel Vitamin D3 Metabolic Gene CYP27A1 Polymorphism, Adiponectin/Leptin Ratio, and Metabolic Syndrome in Middle-Aged Taiwanese Males.	Cholecalciferol	26-36	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	52-59
25872112-0	2015	Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF-alpha-Secreting Monocytes in Asthmatic Patients.	Cholecalciferol	0-10	Fc gamma receptor IIIa	Homo sapiens	46-50
25872112-0	2015	Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF-alpha-Secreting Monocytes in Asthmatic Patients.	Cholecalciferol	0-10	tumor necrosis factor	Homo sapiens	64-73
25872112-2	2015	Here, we wished to analyze whether the active form of vitamin D, i.e. vitamin D3, referred to as 1alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] can exert GC-like proapoptotic effects on CD16-positive monocytes and thus decrease the proinflammatory potential of these cells.	Cholecalciferol	70-80	Fc gamma receptor IIIa	Homo sapiens	184-188
25628655-2	2015	Both vitamin D3 and adipocytokines (especially adiponectin and leptin) have a great impact on CVD and MetS.	Cholecalciferol	5-15	adiponectin, C1Q and collagen domain containing	Homo sapiens	47-58
25628655-2	2015	Both vitamin D3 and adipocytokines (especially adiponectin and leptin) have a great impact on CVD and MetS.	Cholecalciferol	5-15	leptin	Homo sapiens	63-69
25628655-3	2015	In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes.	Cholecalciferol	3-13	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	30-55
25628655-3	2015	In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes.	Cholecalciferol	3-13	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	57-64
25628655-3	2015	In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes.	Cholecalciferol	3-13	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	70-110
25628655-3	2015	In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes.	Cholecalciferol	3-13	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	112-119
25460500-9	2014	Thus, BRCA1 expression is critical for mediating the biological impact of vitamin D3 in breast tumor cells.	Cholecalciferol	74-84	BRCA1 DNA repair associated	Homo sapiens	6-11
25236689-4	2015	Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice.	Cholecalciferol	91-101	galactosylceramidase	Mus musculus	53-57
25236689-4	2015	Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice.	Cholecalciferol	91-101	galactosylceramidase	Mus musculus	58-61
25236689-4	2015	Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice.	Cholecalciferol	149-159	galactosylceramidase	Mus musculus	53-57
25236689-4	2015	Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice.	Cholecalciferol	149-159	galactosylceramidase	Mus musculus	246-249
26401986-11	2015	CONCLUSION: IL-10 levels increased significantly in RRMS patients after taking high-dose vitamin D3 for 3 months.	Cholecalciferol	89-99	interleukin 10	Homo sapiens	12-17
24451003-0	2014	Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma.	Cholecalciferol	11-21	thioredoxin interacting protein	Homo sapiens	37-68
24451003-4	2014	In addition, we wanted to determine the effects of vitamin D3-induced TXNIP stimulation in HCC-derived cell lines.	Cholecalciferol	51-61	thioredoxin interacting protein	Homo sapiens	70-75
24451003-8	2014	RESULTS: TXNIP expression levels were low in HCC cell lines, and vitamin D3 stimulated TXNIP expression in vitro.	Cholecalciferol	65-75	thioredoxin interacting protein	Homo sapiens	87-92
24451003-9	2014	In HCC cells transfected with a TXNIP expression vector or treated with exogenous vitamin D3, there was a reduction in cell proliferation and an increase in apoptosis.	Cholecalciferol	82-92	thioredoxin interacting protein	Homo sapiens	32-37
24451003-13	2014	Vitamin D3 stimulates TXNIP expression, resulting in diminished proliferation and enhanced apoptosis.	Cholecalciferol	0-10	thioredoxin interacting protein	Homo sapiens	22-27
24451003-15	2014	These findings suggest that stimulation of TXNIP expression, by factors such as vitamin D3, may attenuate carcinogenesis in patients with chronic liver disease.	Cholecalciferol	80-90	thioredoxin interacting protein	Homo sapiens	43-48
24777663-0	2014	The paracrine feedback loop between vitamin D3 (1,25(OH)2D3) and PTHrP in prehypertrophic chondrocytes.	Cholecalciferol	36-46	parathyroid hormone-like peptide	Mus musculus	65-70
24777663-1	2014	The endocrine feedback loop between vitamin D3(1,25(OH)2D3) and parathyroid hormone (PTH) plays a central role in skeletal development.	Cholecalciferol	36-46	parathyroid hormone	Mus musculus	64-83
24777663-1	2014	The endocrine feedback loop between vitamin D3(1,25(OH)2D3) and parathyroid hormone (PTH) plays a central role in skeletal development.	Cholecalciferol	36-46	parathyroid hormone	Mus musculus	85-88
25376735-8	2014	DISCUSSION: We previously reported that the intensive cholecalciferol treatment (100 000 IU every 2 weeks for 2 months) was safe in RTR.	Cholecalciferol	54-69	nuclear receptor subfamily 6 group A member 1	Homo sapiens	132-135
25380286-8	2014	Vitamin D3 inhibited LPS-induced ROS and DNA damage and were associated with a decline in TNF-alpha and NFkappaB in epithelial cells.	Cholecalciferol	0-10	tumor necrosis factor	Homo sapiens	90-99
25380286-8	2014	Vitamin D3 inhibited LPS-induced ROS and DNA damage and were associated with a decline in TNF-alpha and NFkappaB in epithelial cells.	Cholecalciferol	0-10	nuclear factor kappa B subunit 1	Homo sapiens	104-112
25139050-8	2014	In examining cellular cross-talk ex vivo, we show that ligand-dependent VDR signaling in adipocytes significantly inhibits mammary epithelial cell growth in part through the vitamin D3-dependent production of the cytokine IL-6.	Cholecalciferol	174-184	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	72-75
25236584-0	2014	Vitamin D3 metabolite calcidiol primes human dendritic cells to promote the development of immunomodulatory IL-10-producing T cells.	Cholecalciferol	0-10	interleukin 10	Homo sapiens	108-113
25139050-8	2014	In examining cellular cross-talk ex vivo, we show that ligand-dependent VDR signaling in adipocytes significantly inhibits mammary epithelial cell growth in part through the vitamin D3-dependent production of the cytokine IL-6.	Cholecalciferol	174-184	interleukin 6	Mus musculus	222-226
25139050-9	2014	Collectively, these studies delineate independent roles for vitamin D3-dependent VDR signaling in mammary adipocytes and epithelial cells in controlling pubertal mammary gland development.	Cholecalciferol	60-70	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	81-84
25297969-8	2014	A vitamin D3-deficient diet normalized the serum 1,25 (OH)2 vitamin D3 level in kl/kl mice and enhanced UUO-induced RTF and TGF-beta/Smad3 signaling.	Cholecalciferol	2-12	transforming growth factor, beta 1	Mus musculus	124-132
25297969-8	2014	A vitamin D3-deficient diet normalized the serum 1,25 (OH)2 vitamin D3 level in kl/kl mice and enhanced UUO-induced RTF and TGF-beta/Smad3 signaling.	Cholecalciferol	2-12	SMAD family member 3	Mus musculus	133-138
24176765-1	2014	Research over the last decade has revealed that CYP11A1 can hydroxylate the side chain of vitamin D3 at carbons 17, 20, 22 and 23 to produce at least 10 metabolites, with 20(OH)D3, 20,23(OH)2D3, 20,22(OH)2D3, 17,20(OH)2D3 and 17,20,23(OH)3D3 being the main products.	Cholecalciferol	90-100	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	48-55
25729548-0	2014	Vitamin D3 influence the Th1/Th2 ratio in C57BL/6 induced model of experimental autoimmune encephalomyelitis.	Cholecalciferol	0-10	negative elongation factor complex member C/D	Homo sapiens	25-28
25729548-12	2014	The level of TNF-alpha but not IL-10 significantly decreased following vitamin D3 administration.	Cholecalciferol	71-81	tumor necrosis factor	Homo sapiens	13-22
24960544-0	2014	Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol.	Cholecalciferol	64-79	fibroblast growth factor 23	Homo sapiens	14-20
24960544-2	2014	OBJECTIVE: The aim was to investigate if FGF-23 and 24,25(OH)2D can guide cholecalciferol replacement.	Cholecalciferol	74-89	fibroblast growth factor 23	Homo sapiens	41-47
24960544-3	2014	DESIGN: Oral cholecalciferol (10,000 IU weekly) administered to subjects with 25(OH)D levels &lt; 20 etag/mL and eGFR &gt; 60 mL/min/1.73 m(2) (n = 25), chronic kidney disease (CKD) (n = 27), or end stage renal disease (ESRD) (n = 14).	Cholecalciferol	13-28	CD59 molecule (CD59 blood group)	Homo sapiens	129-134
24960544-7	2014	Cholecalciferol increased serum FGF-23 levels only in normal subjects (44 +- 57 etag/mL, P = .01).	Cholecalciferol	0-15	fibroblast growth factor 23	Homo sapiens	32-38
24960544-11	2014	In addition, catabolism of 25(OH)D may also contribute to the low circulating vitamin D levels in CKD, since elevations of FGF-23 in CKD are associated with increased 24,25(OH)2D after cholecalciferol administration.	Cholecalciferol	185-200	fibroblast growth factor 23	Homo sapiens	123-129
25130438-6	2014	The catalytic efficiency of bovine CYP11A1 for metabolism of L3 dissolved in 2-hydroxypropyl-beta-cyclodextrin was approximately 20% of that reported for vitamin D3 and cholesterol.	Cholecalciferol	154-164	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	35-42
25070320-0	2014	Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial.	Cholecalciferol	68-78	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	20-26
25070320-0	2014	Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial.	Cholecalciferol	68-78	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	28-35
25070320-0	2014	Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial.	Cholecalciferol	68-78	vitamin D receptor	Homo sapiens	41-44
25070320-10	2014	The increase in [25(OH)D] due to vitamin D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, rs6013897 near CYP24A1, and rs7968585 near VDR.	Cholecalciferol	33-43	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	105-111
25070320-10	2014	The increase in [25(OH)D] due to vitamin D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, rs6013897 near CYP24A1, and rs7968585 near VDR.	Cholecalciferol	33-43	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	128-135
25070320-10	2014	The increase in [25(OH)D] due to vitamin D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, rs6013897 near CYP24A1, and rs7968585 near VDR.	Cholecalciferol	33-43	vitamin D receptor	Homo sapiens	156-159
25070320-11	2014	CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes.	Cholecalciferol	55-65	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	134-158
25070320-11	2014	CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes.	Cholecalciferol	55-65	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	160-166
25070320-11	2014	CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes.	Cholecalciferol	55-65	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	185-192
25070320-11	2014	CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes.	Cholecalciferol	55-65	vitamin D receptor	Homo sapiens	203-221
25070320-11	2014	CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes.	Cholecalciferol	55-65	vitamin D receptor	Homo sapiens	223-226
24269662-10	2014	In summary, our results suggest that abiraterone inhibits the CYP3A4-mediated inactivation of active vitamin D3 in human liver and intestine, potentially providing additional anti-cancer benefits to prostate cancer patients.	Cholecalciferol	101-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
25138634-1	2014	20-Hydroxyvitamin D3 [20(OH)D3], the major product of CYP11A1 action on vitamin D3, is biologically active and like 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] can inhibit proliferation and promote differentiation of a range of cells, and has anti-inflammatory properties.	Cholecalciferol	10-20	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	54-61
24176765-3	2014	The placenta, adrenal glands and epidermal keratinocytes have been shown to metabolize vitamin D3 via this CYP11A1-mediated pathway that is modified by the activity of CYP27B1, with 20(OH)D3 (the major metabolite), 20,23(OH)2D3, 1,20(OH)2D3, 1,20,23(OH)3D3 and 17,20,23(OH)3D3 being detected, defining these secosteroids as endogenous regulators/natural products.	Cholecalciferol	87-97	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	107-114
24176765-3	2014	The placenta, adrenal glands and epidermal keratinocytes have been shown to metabolize vitamin D3 via this CYP11A1-mediated pathway that is modified by the activity of CYP27B1, with 20(OH)D3 (the major metabolite), 20,23(OH)2D3, 1,20(OH)2D3, 1,20,23(OH)3D3 and 17,20,23(OH)3D3 being detected, defining these secosteroids as endogenous regulators/natural products.	Cholecalciferol	87-97	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	168-175
25109309-3	2014	The present study investigated the effect of derivatives of vitamin D3 on GGT activity in LLC-PK1 porcine renal tubular epithelial cells in order to analyze the biochemical basis of bone metabolism-associated alterations in GGT activity in the kidney.	Cholecalciferol	60-70	glutathione hydrolase 1 proenzyme	Sus scrofa	74-77
24975273-4	2014	Using adipose tissue biopsy samples from 47 participants of a 5-month vitamin D3 intervention study, we demonstrated that all four primary VDR target genes can serve as biomarkers for the vitamin D3 responsiveness of human individuals.	Cholecalciferol	70-80	vitamin D receptor	Homo sapiens	139-142
24975273-4	2014	Using adipose tissue biopsy samples from 47 participants of a 5-month vitamin D3 intervention study, we demonstrated that all four primary VDR target genes can serve as biomarkers for the vitamin D3 responsiveness of human individuals.	Cholecalciferol	188-198	vitamin D receptor	Homo sapiens	139-142
24975273-7	2014	Using human adipocytes as examples, we show that such ubiquitous VDR target genes can be used as markers for the individual"s response to a supplementation with vitamin D3.	Cholecalciferol	161-171	vitamin D receptor	Homo sapiens	65-68
25247786-8	2014	Male offspring exposed to continuous 25 IU vitamin D3/kg diet had lower (p &lt; 0.001) colonic VDR expression and those exposed only to low vitamin D3 until weaning had higher serum IL-6.	Cholecalciferol	43-53	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	95-98
25089537-0	2014	Prenatal vitamin D3 supplementation suppresses LL-37 peptide expression in ex vivo activated neonatal macrophages but not their killing capacity.	Cholecalciferol	9-19	cathelicidin antimicrobial peptide	Homo sapiens	47-52
25135648-7	2014	In conclusion, our data support that DMF stimulates Nrf2 activity to attenuate hyperphosphatamia in vitro or Vitamin D3-induced in vivo vascular calcification, which would be a beneficial effect on vascular diseases induced by oxidative stress such as vascular calcification.	Cholecalciferol	109-119	nuclear factor, erythroid derived 2, like 2	Mus musculus	52-56
25247786-8	2014	Male offspring exposed to continuous 25 IU vitamin D3/kg diet had lower (p &lt; 0.001) colonic VDR expression and those exposed only to low vitamin D3 until weaning had higher serum IL-6.	Cholecalciferol	140-150	interleukin 6	Mus musculus	182-186
25015343-5	2014	METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration.	Cholecalciferol	63-73	protein tyrosine phosphatase, receptor type, C	Mus musculus	144-148
25015343-5	2014	METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration.	Cholecalciferol	63-73	kinase insert domain protein receptor	Mus musculus	160-164
25015343-5	2014	METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration.	Cholecalciferol	83-98	protein tyrosine phosphatase, receptor type, C	Mus musculus	144-148
25015343-5	2014	METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration.	Cholecalciferol	83-98	kinase insert domain protein receptor	Mus musculus	160-164
25015343-15	2014	CONCLUSIONS: By inducing SDF1, vitamin D3 is a novel approach to promote vascular repair.	Cholecalciferol	31-41	chemokine (C-X-C motif) ligand 12	Mus musculus	25-29
25506102-0	2014	Evidence That Loss-of-Function Filaggrin Gene Mutations Evolved in Northern Europeans to Favor Intracutaneous Vitamin D3 Production.	Cholecalciferol	110-120	filaggrin	Homo sapiens	31-40
25230725-1	2014	BACKGROUND: In vitro studies have shown that the active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation.	Cholecalciferol	64-74	negative elongation factor complex member C/D	Homo sapiens	180-183
25356124-1	2014	OBJECTIVES: To measure the effect of vitamin D3 (VitD) supplementation on erythrocyte indices, serum and kidney erythropoietin (EPO) in normal rats treated with Pegylated interferon-alpha (Peg-INF-alpha) and ribavirin (RBV).	Cholecalciferol	37-47	erythropoietin	Rattus norvegicus	112-126
25386886-5	2014	This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3.	Cholecalciferol	150-165	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	52-77
25386886-5	2014	This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3.	Cholecalciferol	150-165	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	88-95
25386886-5	2014	This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3.	Cholecalciferol	150-165	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	100-106
25386886-5	2014	This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3.	Cholecalciferol	52-62	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	88-95
25386886-5	2014	This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3.	Cholecalciferol	52-62	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	100-106
24974387-2	2014	There are few data about the effect of vitamin D3 (cholecalciferol) supplementation on prostate-specific antigen (PSA) in healthy Black men.	Cholecalciferol	51-66	kallikrein related peptidase 3	Homo sapiens	87-118
25165875-0	2014	Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.	Cholecalciferol	33-43	BCL2 interacting killer	Homo sapiens	107-110
25317290-2	2014	This study was conducted to represent the effect of supplemental vitamin D3 on serum leptin, TNF-alpha and adiposity in type 2 diabetic patients.	Cholecalciferol	65-75	leptin	Homo sapiens	85-91
25317290-2	2014	This study was conducted to represent the effect of supplemental vitamin D3 on serum leptin, TNF-alpha and adiposity in type 2 diabetic patients.	Cholecalciferol	65-75	tumor necrosis factor	Homo sapiens	93-102
25044176-0	2014	Effects of 12 weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency - a double-blind, randomized, placebo-controlled trial.	Cholecalciferol	30-40	insulin	Homo sapiens	54-61
24854954-0	2014	Primary vitamin D receptor target genes as biomarkers for the vitamin D3 status in the hematopoietic system.	Cholecalciferol	62-72	vitamin D receptor	Homo sapiens	8-26
24931970-7	2014	Birds fed 25-hydroxycholecalciferol at 25 and 50 microg/kg and injected with LPS had approximately 7-fold and 3-fold less (P = 0.010) IL-1beta mRNA in the liver compared with those birds fed 6.25 microg/kg of 25-hydroxycholecalciferol and the cholecalciferol (250 IU/kg) group.	Cholecalciferol	20-35	interleukin 1, beta	Gallus gallus	134-142
24931970-9	2014	At 28 d of age, birds were fed 25-hydroxycholecalciferol and injected with LPS had 1.1-fold less (P &lt; 0.01) IL-1beta mRNA in the liver than the cholecalciferol-fed group.	Cholecalciferol	41-56	interleukin 1, beta	Gallus gallus	111-119
24911063-7	2014	These cells responded to treatment with activated vitamin D3 by upregulating OCN.	Cholecalciferol	50-60	bone gamma-carboxyglutamate protein	Homo sapiens	77-80
24332699-9	2014	In those with CD, a lower p:t Akt ratio (&lt;0.97) was associated with lower serum vitamin D3, lower physical activity indices (49 vs 64 mmol/L, 1.7 vs 2.2x10(6) accelerometer counts respectively, each p&lt;0.05) and a trend towards lower serum ferritin levels (128 vs 322mg/L, p=0.07), compared with CD subjects with normal/high p:t Akt ratios.	Cholecalciferol	83-93	AKT serine/threonine kinase 1	Homo sapiens	30-33
24657655-5	2014	Finally, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration.	Cholecalciferol	25-40	RUNX family transcription factor 2	Homo sapiens	49-54
24657655-5	2014	Finally, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration.	Cholecalciferol	25-40	RUNX family transcription factor 2	Homo sapiens	152-157
24892558-12	2014	VDR- or VEGF blockade reduced tubule formation, partially restorable by vitamin D3.	Cholecalciferol	72-82	vitamin D receptor	Homo sapiens	0-3
24550187-6	2014	Moreover, vitamin D3 treatment decreased interferon-gamma-positive CD8(+) T cells and increased CD4(+)(CD25(+))FoxP3(+) T cells in pancreatic draining lymph nodes.	Cholecalciferol	10-20	CD4 antigen	Mus musculus	96-99
24727236-11	2014	Cholecalciferol supplementation decreased the latency period of passively avoiding tasks in rats with hepatosteatosis, and also significantly reduced brain TNF-alpha and plasma MDA levels.	Cholecalciferol	0-15	tumor necrosis factor	Rattus norvegicus	156-165
24246341-11	2014	Vitamin D3 doses &gt;=300,000 IU provided optimal changes in serum/plasma 25(OH)D and parathyroid hormone (PTH) concentrations.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	86-105
24374976-9	2014	RESULTS: Compared with baseline values, LPS-matured mo-DC exhibited reduced expression of CD80 and reduced production of the cytokines IL-10, IL-1beta, and IL-6 following 26 weeks of oral vitamin D3 supplementation.	Cholecalciferol	188-198	interleukin 10	Homo sapiens	135-140
24374976-9	2014	RESULTS: Compared with baseline values, LPS-matured mo-DC exhibited reduced expression of CD80 and reduced production of the cytokines IL-10, IL-1beta, and IL-6 following 26 weeks of oral vitamin D3 supplementation.	Cholecalciferol	188-198	interleukin 6	Homo sapiens	156-160
24670704-2	2014	CXCL10 gene expression is downregulated in monocytes by metabolically active vitamin D3 (1,25dihydroxy vitamin D).	Cholecalciferol	77-87	C-X-C motif chemokine ligand 10	Homo sapiens	0-6
24922634-1	2014	BACKGROUND: Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects.	Cholecalciferol	12-22	vitamin D receptor	Homo sapiens	35-53
24922634-1	2014	BACKGROUND: Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects.	Cholecalciferol	12-22	vitamin D receptor	Homo sapiens	55-58
24646031-3	2014	In many cases, downregulation of CDK activity by ATRA and vitamin D3 is a result of elevated p21- and p27-bound CDKs.	Cholecalciferol	58-68	H3 histone pseudogene 16	Homo sapiens	93-96
24646031-3	2014	In many cases, downregulation of CDK activity by ATRA and vitamin D3 is a result of elevated p21- and p27-bound CDKs.	Cholecalciferol	58-68	interferon alpha inducible protein 27	Homo sapiens	102-105
24646031-3	2014	In many cases, downregulation of CDK activity by ATRA and vitamin D3 is a result of elevated p21- and p27-bound CDKs.	Cholecalciferol	58-68	cyclin dependent kinase 2	Homo sapiens	112-116
24646031-6	2014	ATRA and vitamin D3 can also downregulate expression of G1 CDKs, especially CDK2 and CDK6.	Cholecalciferol	9-19	cyclin dependent kinase 2	Homo sapiens	59-63
24646031-6	2014	ATRA and vitamin D3 can also downregulate expression of G1 CDKs, especially CDK2 and CDK6.	Cholecalciferol	9-19	cyclin dependent kinase 2	Homo sapiens	76-80
24646031-6	2014	ATRA and vitamin D3 can also downregulate expression of G1 CDKs, especially CDK2 and CDK6.	Cholecalciferol	9-19	cyclin dependent kinase 6	Homo sapiens	85-89
24646031-8	2014	In vitro, not only dephosphorylation of pRb but also elevation of total pRb is required for ATRA and vitamin D3 to suppress growth and trigger their differentiation.	Cholecalciferol	101-111	RB transcriptional corepressor 1	Homo sapiens	40-43
24646031-8	2014	In vitro, not only dephosphorylation of pRb but also elevation of total pRb is required for ATRA and vitamin D3 to suppress growth and trigger their differentiation.	Cholecalciferol	101-111	RB transcriptional corepressor 1	Homo sapiens	72-75
25505940-5	2014	METHOD: In a double blind randomized placebo controlled study we evaluated the effect of a monthly dose of 100,000IU of vitamin D3 for three months on the level of serum 25(OH)D, intact parathyroid hormone (PTH), urinary isoprostane, adipocyte cytokine expression and arterial stiffness among 130 overweight and obese (BMI &gt; 25) African Americans with elevated blood pressure (130 - 150/85 - 100 mmHg) and low serum vitamin D level (10 - 25 ng/ml).	Cholecalciferol	120-130	parathyroid hormone	Homo sapiens	186-205
24792400-1	2014	The active form of vitamin D3, 1,25(OH)2D3, has significant immunomodulatory properties and is an important determinant in the differentiation of CD4+ effector T cells.	Cholecalciferol	19-29	CD4 molecule	Homo sapiens	146-149
24622804-2	2014	OBJECTIVE: We compared 12 mo of vitamin D3 supplementation with placebo on weight, body composition, insulin, and C-reactive protein (CRP) in postmenopausal women in a weight-loss intervention.	Cholecalciferol	32-42	C-reactive protein	Homo sapiens	114-132
24613576-3	2014	We investigated 25-hydroxyvitamin D3 levels in children and adults with neurofibromatosis type 1 in winter and summer and compared them to healthy controls to get more pathogenic insights in vitamin D3 metabolism in NF1 patients.	Cholecalciferol	26-36	neurofibromin 1	Homo sapiens	72-96
24619107-9	2014	After vitamin D3, exclusively in women a reduction in the area under the postprandial curve for monocytes CD11b and CD35 by 10.5% (P=0.016) and 12.5% (P=0.04) and neutrophil CD11b by 17.0% (P=0.014) was observed.	Cholecalciferol	6-16	integrin subunit alpha M	Homo sapiens	106-111
24619107-9	2014	After vitamin D3, exclusively in women a reduction in the area under the postprandial curve for monocytes CD11b and CD35 by 10.5% (P=0.016) and 12.5% (P=0.04) and neutrophil CD11b by 17.0% (P=0.014) was observed.	Cholecalciferol	6-16	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	116-120
24619107-9	2014	After vitamin D3, exclusively in women a reduction in the area under the postprandial curve for monocytes CD11b and CD35 by 10.5% (P=0.016) and 12.5% (P=0.04) and neutrophil CD11b by 17.0% (P=0.014) was observed.	Cholecalciferol	6-16	integrin subunit alpha M	Homo sapiens	174-179
24461581-3	2014	OBJECTIVE: We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can repress IgE-dependent mast cell activation through mast cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast cell-VDR activity.	Cholecalciferol	43-53	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	199-206
24461581-3	2014	OBJECTIVE: We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can repress IgE-dependent mast cell activation through mast cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast cell-VDR activity.	Cholecalciferol	43-53	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	222-225
24461581-5	2014	RESULTS: Here we show that mouse and human mast cells can convert 25OHD3 to 1alpha,25(OH)2D3 through CYP27B1 activity and that both of these vitamin D3 metabolites suppressed IgE-induced mast cell-derived proinflammatory and vasodilatory mediator production in a VDR-dependent manner in vitro.	Cholecalciferol	141-151	vitamin D receptor	Homo sapiens	263-266
24461581-6	2014	Furthermore, epicutaneously applied vitamin D3 metabolites significantly reduced the magnitude of skin swelling associated with IgE-mediated PCA reactions in vivo; a response that required functional mast cell-VDRs and mast cell-CYP27B1.	Cholecalciferol	36-46	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	229-236
24486455-13	2014	In summary, our results suggest that ginsenosides, specifically aPPD and aPPT, inhibit the CYP3A4-mediated catabolism of active vitamin D3 in human liver and intestine, potentially providing additional vitamin D-related benefits to patients with cancer, neurodegenerative and metabolic diseases.	Cholecalciferol	128-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
24597546-9	2014	Upon inhibition of the vitamin D3-metabolizing enzymes (cytochrome P450s), 25(OH)D3 increased ROS production, potentially due to its known (low) affinity for VDR.	Cholecalciferol	23-33	vitamin D receptor	Homo sapiens	158-161
24855833-4	2014	On postnatal day (PND) 21, plasma IL-4 levels were elevated by 10.43% (p &lt; 0.01) in the offspring from the high dose vitamin D3 group compared with the control group.	Cholecalciferol	120-130	interleukin 4	Rattus norvegicus	34-38
23612780-0	2014	The in vitro treatment with vitamin D3 is ineffective on the expression of PKC isoenzymes, but decreases further the impaired production of IL-2 in the T lymphocytes of SLE patients.	Cholecalciferol	28-38	interleukin 2	Homo sapiens	140-144
23612780-1	2014	The objective of the study was to investigate the possibility whether the in vitro treatment with vitamin D3 can restore the impaired expression of protein kinase C (PKC) isoenzymes and IL-2 production in the lymphocytes of patients with systemic lupus erythematosus (SLE).	Cholecalciferol	98-108	interleukin 2	Homo sapiens	186-190
23612780-5	2014	However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups.	Cholecalciferol	19-29	interleukin 10	Homo sapiens	69-74
23612780-5	2014	However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups.	Cholecalciferol	19-29	interleukin 2	Homo sapiens	109-113
23612780-5	2014	However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups.	Cholecalciferol	19-29	interleukin 6	Homo sapiens	115-119
23612780-5	2014	However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups.	Cholecalciferol	19-29	interferon gamma	Homo sapiens	121-137
23612780-5	2014	However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups.	Cholecalciferol	19-29	tumor necrosis factor	Homo sapiens	142-151
23612780-6	2014	As the low production of IL-2 is one of the main pathologic features of SLE, we recommend to avoid the use of high doses of vitamin D3 for treatment of lupus patients with vitamin D3 deficiency.	Cholecalciferol	124-134	interleukin 2	Homo sapiens	25-29
23612780-6	2014	As the low production of IL-2 is one of the main pathologic features of SLE, we recommend to avoid the use of high doses of vitamin D3 for treatment of lupus patients with vitamin D3 deficiency.	Cholecalciferol	172-182	interleukin 2	Homo sapiens	25-29
24576880-5	2014	RESULTS: The HSF, HCEC-12, ODM-2, and ARPE-19 express mRNA and protein for all vitamin D3 synthesizing and metabolizing components.	Cholecalciferol	79-89	interleukin 6	Homo sapiens	13-16
23999998-0	2014	High-dose cholecalciferol supplementation significantly increases peripheral CD4+ Tregs in healthy adults without negatively affecting the frequency of other immune cells.	Cholecalciferol	10-25	CD4 molecule	Homo sapiens	77-80
23999998-3	2014	METHODS: In a double-blind, placebo controlled study in 60 healthy volunteers, we assessed the effect of a 12-week high-dose oral cholecalciferol supplementation (140,000 IU/month) on the number and function of CD4(pos)CD25(high)FoxP3(pos)CD127(dim) Tregs.	Cholecalciferol	130-145	CD4 molecule	Homo sapiens	211-214
24892558-12	2014	VDR- or VEGF blockade reduced tubule formation, partially restorable by vitamin D3.	Cholecalciferol	72-82	vascular endothelial growth factor A	Homo sapiens	8-12
24868917-1	2014	The study was devoted to identifying the relation between vitamin D3 availability (assessed by the level of circulatory 25OHD3), content of vitamin D3 25-hydroxylase isozymes CYP27A1 and CYP2R1 in hepatic tissue and functional activity of peripheral blood phagocytes in mice with experimental type 1 diabetes.	Cholecalciferol	58-68	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	140-165
27122781-0	2014	Effect of Vitamin D3 on Monocyte Chemoattractant Protein 1 Production in Monocytes and Macrophages.	Cholecalciferol	10-20	C-C motif chemokine ligand 2	Homo sapiens	24-58
24398649-1	2014	OBJECTIVES: We assessed the effect of cholecalciferol and calcium supplementation on mRNA expression of cathelicidin (LL-37), Th1 and Th2 cytokines and their transcription factors in the peripheral blood mononuclear cells (PBMCs) in healthy females with vitamin D deficiency (VDD).	Cholecalciferol	38-53	cathelicidin antimicrobial peptide	Homo sapiens	118-123
24398649-1	2014	OBJECTIVES: We assessed the effect of cholecalciferol and calcium supplementation on mRNA expression of cathelicidin (LL-37), Th1 and Th2 cytokines and their transcription factors in the peripheral blood mononuclear cells (PBMCs) in healthy females with vitamin D deficiency (VDD).	Cholecalciferol	38-53	negative elongation factor complex member C/D	Homo sapiens	126-129
24398649-6	2014	Despite significant increase in mean serum 25(OH)D in the cholecalciferol-supplemented groups, their mean mRNA transcripts of LL-37, IFN-gamma, IL-4, transcription factors and their IFN-gamma/IL-4 and T-bet/GATA-3 ratios were similar to that of calcium and placebo groups.	Cholecalciferol	58-73	cathelicidin antimicrobial peptide	Homo sapiens	126-131
24423366-12	2014	Postoperatively, PTH remained lower in the cholecalciferol group compared with the placebo group (P = .04).	Cholecalciferol	43-58	parathyroid hormone	Homo sapiens	17-20
23283825-0	2014	Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. INTRODUCTION: Vitamin D plasma levels are negatively associated with blood pressure and cardiovascular mortality, and vitamin D supplementation reduces cardiovascular events.	Cholecalciferol	0-15	renin	Homo sapiens	51-56
24868917-1	2014	The study was devoted to identifying the relation between vitamin D3 availability (assessed by the level of circulatory 25OHD3), content of vitamin D3 25-hydroxylase isozymes CYP27A1 and CYP2R1 in hepatic tissue and functional activity of peripheral blood phagocytes in mice with experimental type 1 diabetes.	Cholecalciferol	58-68	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	175-182
24868917-1	2014	The study was devoted to identifying the relation between vitamin D3 availability (assessed by the level of circulatory 25OHD3), content of vitamin D3 25-hydroxylase isozymes CYP27A1 and CYP2R1 in hepatic tissue and functional activity of peripheral blood phagocytes in mice with experimental type 1 diabetes.	Cholecalciferol	58-68	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	187-193
24868917-4	2014	Cholecalciferol administration resulted in normalization of tissue levels of both isoforms of vitamin D3 25-hydroxylase and blood serum 25OHD3 content.	Cholecalciferol	0-15	cytochrome P450, family 27, subfamily a, polypeptide 1	Mus musculus	94-119
24393028-14	2014	The change of the electronic configuration of the metal atom from d(3) (Tc(IV)) to d(5) (Tc(II)) is accompanied by the formation of metal-metal bonds in the coordination polyhedra.	Cholecalciferol	66-70	transcobalamin 2	Homo sapiens	89-95
25568836-0	2014	Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis.	Cholecalciferol	47-57	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	78-85
25568836-12	2014	INTERPRETATION: The known MS risk allele rs2248359-C increases CYP24A1 expression in human brain providing a genetic link between MS and vitamin D metabolism, and predicting that the physiologically active form of vitamin D3 is protective.	Cholecalciferol	214-224	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	63-70
24277747-14	2014	TNF-alpha/IL-10 expressing CD3(+)/4(+) cell ratios were significantly decreased with 100 nM of vitamin D3 (31.3 +- 9.4, P &lt; 0.05) when compared with controls (40.4 +- 11.3) in vitro.	Cholecalciferol	95-105	tumor necrosis factor	Homo sapiens	0-9
24327720-10	2014	Future studies of longer supplemental vitamin D3 duration are necessary to examine the complex influence of vitamin D3 on CRP and other chronic inflammatory cytokines for possible reduction of cancer health disparities in African Americans.	Cholecalciferol	108-118	C-reactive protein	Homo sapiens	122-125
24277747-14	2014	TNF-alpha/IL-10 expressing CD3(+)/4(+) cell ratios were significantly decreased with 100 nM of vitamin D3 (31.3 +- 9.4, P &lt; 0.05) when compared with controls (40.4 +- 11.3) in vitro.	Cholecalciferol	95-105	interleukin 10	Homo sapiens	10-15
24277747-15	2014	Additionally, INF-gamma/IL-10 expressing CD3(+)/4(+) cell ratio was significantly decreased with 100 nM of vitamin D3 (12.1 +- 4.0, P &lt; 0.05) when compared with controls (14.8 +- 4.6).	Cholecalciferol	107-117	interleukin 10	Homo sapiens	24-29
24277747-16	2014	IFN-gamma and TNF-alpha secretion from NK cells were significantly decreased (P &lt; 0.01 each), and IL-10, IL-1beta, vascular endothelial growth factor and granulocyte colony stimulating factor levels were significantly increased (P &lt; 0.01 each) with vitamin D3 100 nM when compared with those of controls.	Cholecalciferol	255-265	tumor necrosis factor	Homo sapiens	14-23
24466013-1	2014	Renal alpha-Klotho (alpha-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)2 vitamin D3 (1,25VitD3).	Cholecalciferol	163-173	fibroblast growth factor 23	Homo sapiens	76-103
24445291-17	2014	CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH.	Cholecalciferol	18-28	kallikrein related peptidase 3	Homo sapiens	108-111
24445291-17	2014	CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH.	Cholecalciferol	18-28	parathyroid hormone	Homo sapiens	116-119
24466411-2	2014	A full vitamin D (refers to vitamin D2 and D3) endocrine system, characterized by a specific VDR (vitamin D receptor, member of the nuclear receptor family), specific vitamin D metabolizing CYP450 enzymes regulated by calciotropic hormones and a dedicated plasma transport-protein is only found in vertebrates.	Cholecalciferol	43-45	vitamin D receptor	Homo sapiens	93-96
24466411-2	2014	A full vitamin D (refers to vitamin D2 and D3) endocrine system, characterized by a specific VDR (vitamin D receptor, member of the nuclear receptor family), specific vitamin D metabolizing CYP450 enzymes regulated by calciotropic hormones and a dedicated plasma transport-protein is only found in vertebrates.	Cholecalciferol	43-45	vitamin D receptor	Homo sapiens	98-116
24404137-8	2014	Western Immunoblot (WIB) analyses of 2D-gels demonstrated a downregulation of adiponectin in VDD subjects, which was confirmed in the plasma from VDD with respect to NVD subjects (p&lt;0.035) and increased following 12mo vitamin D3 supplementation in VDD subjects (p&lt;0.02).	Cholecalciferol	221-231	adiponectin, C1Q and collagen domain containing	Homo sapiens	78-89
24404137-9	2014	High molecular weight (HMW) adiponectin, a surrogate indicator of insulin sensitivity, was significantly lower in VDD subjects (p&lt;0.02) and improved with vitamin D3 supplementation (p&lt;0.042).	Cholecalciferol	157-167	adiponectin, C1Q and collagen domain containing	Homo sapiens	28-39
24466013-1	2014	Renal alpha-Klotho (alpha-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)2 vitamin D3 (1,25VitD3).	Cholecalciferol	163-173	fibroblast growth factor 23	Homo sapiens	105-110
25207374-4	2014	This has been demonstrated in BCC-bearing Ptch mutant mice and BCC cell lines, in which both vitamin D3 and its active metabolite calcitriol (1alpha-25(OH)2D3) exert antitumor effects.	Cholecalciferol	93-103	patched 1	Mus musculus	42-46
25034315-0	2014	Effect of vitamin D3 supplementation on serum 25(OH)D, lipids and markers of insulin resistance in obese adolescents: a prospective, randomized, placebo-controlled pilot trial.	Cholecalciferol	10-20	insulin	Homo sapiens	77-84
24356952-8	2014	Vitamin D3 supplementation significantly increased serum leptin and OPG levels.	Cholecalciferol	0-10	leptin	Homo sapiens	57-63
24356952-8	2014	Vitamin D3 supplementation significantly increased serum leptin and OPG levels.	Cholecalciferol	0-10	TNF receptor superfamily member 11b	Homo sapiens	68-71
24313624-7	2014	Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased.	Cholecalciferol	10-25	CD38 molecule	Homo sapiens	65-69
24313624-7	2014	Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased.	Cholecalciferol	10-25	interferon gamma	Homo sapiens	122-131
24313624-7	2014	Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased.	Cholecalciferol	10-25	interleukin 17A	Homo sapiens	142-147
24313624-7	2014	Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased.	Cholecalciferol	10-25	CD4 molecule	Homo sapiens	149-152
25486939-1	2014	The hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR).	Cholecalciferol	30-40	vitamin D receptor	Homo sapiens	177-195
25486939-1	2014	The hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR).	Cholecalciferol	30-40	vitamin D receptor	Homo sapiens	197-200
24081904-0	2014	Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies.	Cholecalciferol	111-121	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	24-31
24081904-6	2014	The use of CYP24A1 RNAi enhanced the cytostatic effects of vitamin D3 in human prostate cancer cells.	Cholecalciferol	59-69	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	11-18
24081904-7	2014	Remarkably, subcutaneous and orthotopic xenografts of prostate cancer cells harboring CYP24A1 shRNA resulted in a drastic reduction in tumor volume when mice were subjected to vitamin D3 supplementation.	Cholecalciferol	176-186	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	86-93
24081904-8	2014	CYP24A1 may be a predictive marker of vitamin D3 clinical efficacy in patients with advanced prostate cancer.	Cholecalciferol	38-48	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
24081904-9	2014	For those with up-regulated CYP24A1, combination therapy with RNAi targeting CYP24A1 could be considered to improve clinical responsiveness to vitamin D3.	Cholecalciferol	143-153	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	28-35
24081904-9	2014	For those with up-regulated CYP24A1, combination therapy with RNAi targeting CYP24A1 could be considered to improve clinical responsiveness to vitamin D3.	Cholecalciferol	143-153	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	77-84
23775785-9	2014	Administration of vitamin D3 compounds to these mice resulted in substantial levels of CAMP in the systemic circulation.	Cholecalciferol	18-28	cathelicidin antimicrobial peptide	Mus musculus	87-91
23761326-2	2014	The main objective of this trial was to measure the effect of different doses of vitamin D3 on serum 25OHD and serum parathyroid hormone (PTH) in young women with vitamin D insufficiency (serum 25OHD &lt;= 20 ng/mL (50 nmol/L).	Cholecalciferol	81-91	parathyroid hormone	Homo sapiens	117-136
23761326-2	2014	The main objective of this trial was to measure the effect of different doses of vitamin D3 on serum 25OHD and serum parathyroid hormone (PTH) in young women with vitamin D insufficiency (serum 25OHD &lt;= 20 ng/mL (50 nmol/L).	Cholecalciferol	81-91	parathyroid hormone	Homo sapiens	138-141
25034315-7	2014	CONCLUSIONS: 12 weeks of vitamin D3 supplementation in obese adolescents with 2,000 IU once daily resulted in a modest increase in 25(OH)D concentration in obese adolescents, but did not affect the lipid profile and markers of insulin resistance and inflammation.	Cholecalciferol	25-35	insulin	Homo sapiens	227-234
25034315-8	2014	Further studies with higher doses of vitamin D3 and/or longer duration of supplementation are needed to understand if vitamin D3 supplementation can impact lipid profiles and markers of insulin resistance and inflammation in obese children.	Cholecalciferol	118-128	insulin	Homo sapiens	186-193
24304609-9	2013	PTH levels correlate negatively with serum 25-OH-Vitamin D3 levels, and neither calcium nor vitamin D intake exert a strong influence on either of the two parameters.	Cholecalciferol	49-59	parathyroid hormone	Homo sapiens	0-3
24918275-3	2014	Nowadays, growing attention is focused on the study of the interactions of the active form of vitamin D3 with its receptor and inhibitory effect of vitamin D3 receptor polymorphisms on multiple signaling pathways involved in proliferative and metastatic processes.	Cholecalciferol	94-104	vitamin D receptor	Homo sapiens	148-167
24918275-5	2014	It summarizes current knowledge of malignant melanoma in regard to the role of the active form of vitamin D3 binding to vitamin D3 receptor (VDR), as well as it describes the influence of polymorphisms of VDR on the inhibition of HH.	Cholecalciferol	98-108	vitamin D receptor	Homo sapiens	120-139
24918275-5	2014	It summarizes current knowledge of malignant melanoma in regard to the role of the active form of vitamin D3 binding to vitamin D3 receptor (VDR), as well as it describes the influence of polymorphisms of VDR on the inhibition of HH.	Cholecalciferol	98-108	vitamin D receptor	Homo sapiens	141-144
23564710-1	2014	The vitamin D signal transduction system involves a series of cytochrome P450-containing sterol hydroxylases to generate and degrade the active hormone, 1alpha,25-dihydroxyvitamin D3, which serves as a ligand for the vitamin D receptor-mediated transcriptional gene expression described in companion articles in this review series.	Cholecalciferol	180-182	vitamin D receptor	Homo sapiens	217-235
24192346-3	2014	The aim of our study is to elucidate the impact of 25(OH) vitamin D3 on amyloid precursor protein processing in mice and N2A cells utilizing very moderate and physiological vitamin D hypovitaminosis in the range of 20-30% compared to wild-type mice.	Cholecalciferol	58-68	amyloid beta (A4) precursor protein	Mus musculus	72-97
25669690-0	2014	The effect of vitamin D3 supplementation on intracellular calcium and plasma membrane calcium ATPase activity in early stages of chronic kidney disease.	Cholecalciferol	14-24	ATPase plasma membrane Ca2+ transporting 3	Homo sapiens	70-100
25669690-2	2014	The aim of our study was to investigate the impact of 6 months vitamin D(3) supplementation (14 000 IU/week) on free cytosolic calcium concentration ([Ca(2+)](i)) and on the plasma membrane calcium ATPase (PMCA) activity of patients with CKD stage 2-3.	Cholecalciferol	63-75	ATPase plasma membrane Ca2+ transporting 3	Homo sapiens	206-210
24379907-3	2013	The principal aim of this study was to investigate if the phosphodiesterase inhibitor Ibudilast (Ibu) and 1alpha,25-dihydroxyvitamin D3 (Vit D3) could interfere with NO release from trigeminal SGCs.	Cholecalciferol	133-135	vitrin	Rattus norvegicus	137-140
24349534-2	2013	We investigated the roles of vitamin D receptor (Vdr) and runt-related transcription factor 2 (Runx2) in the osteoblastic differentiation of VSMCs in response to vitamin D3 using in vitro VSMCs cultures and in vivo in Vdr knockout (Vdr(-/-)) and Runx2 carboxy-terminus truncated heterozygous (Runx2(+/DeltaC)) mice.	Cholecalciferol	162-172	runt related transcription factor 2	Mus musculus	58-93
24349534-2	2013	We investigated the roles of vitamin D receptor (Vdr) and runt-related transcription factor 2 (Runx2) in the osteoblastic differentiation of VSMCs in response to vitamin D3 using in vitro VSMCs cultures and in vivo in Vdr knockout (Vdr(-/-)) and Runx2 carboxy-terminus truncated heterozygous (Runx2(+/DeltaC)) mice.	Cholecalciferol	162-172	runt related transcription factor 2	Mus musculus	95-100
24349534-3	2013	Treatment of VSMCs with active vitamin D3 promoted matrix mineral deposition, and increased the expressions of Vdr, Runx2, and of osteoblastic genes but decreased the expression of smooth muscle myosin heavy chain in primary VSMCs cultures.	Cholecalciferol	31-41	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	111-114
24349534-3	2013	Treatment of VSMCs with active vitamin D3 promoted matrix mineral deposition, and increased the expressions of Vdr, Runx2, and of osteoblastic genes but decreased the expression of smooth muscle myosin heavy chain in primary VSMCs cultures.	Cholecalciferol	31-41	runt related transcription factor 2	Mus musculus	116-121
24349534-5	2013	Furthermore, silencing Vdr or Runx2 attenuated the procalcific effects of vitamin D3.	Cholecalciferol	74-84	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	23-26
24349534-5	2013	Furthermore, silencing Vdr or Runx2 attenuated the procalcific effects of vitamin D3.	Cholecalciferol	74-84	runt related transcription factor 2	Mus musculus	30-35
24349534-7	2013	Vascular calcification induced by high-dose vitamin D3 was completely inhibited in Vdr(-/-) or Runx2(+/DeltaC) mice, despite elevated levels of serum calcium or alkaline phosphatase.	Cholecalciferol	44-54	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	83-86
24349534-7	2013	Vascular calcification induced by high-dose vitamin D3 was completely inhibited in Vdr(-/-) or Runx2(+/DeltaC) mice, despite elevated levels of serum calcium or alkaline phosphatase.	Cholecalciferol	44-54	runt related transcription factor 2	Mus musculus	95-100
24349534-8	2013	Collectively, these findings suggest that functional cooperation between Vdr and Runx2 is necessary for vascular calcification in response to vitamin D3.	Cholecalciferol	142-152	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	73-76
24349534-8	2013	Collectively, these findings suggest that functional cooperation between Vdr and Runx2 is necessary for vascular calcification in response to vitamin D3.	Cholecalciferol	142-152	runt related transcription factor 2	Mus musculus	81-86
23973664-2	2013	The present study was designed to identify a possible correlation between ORM1 and Vitamin D3 (1,25(OH)2D3), a hormone exerting a widespread effect on cell proliferation, differentiation and regulation of the immune system.	Cholecalciferol	83-93	orosomucoid 1	Homo sapiens	74-78
24060240-0	2013	Vitamin D3 derivatives increase soluble CD14 release through ERK1/2 activation and decrease IL-8 production in intestinal epithelial cells.	Cholecalciferol	0-10	CD14 molecule	Homo sapiens	40-44
24060240-0	2013	Vitamin D3 derivatives increase soluble CD14 release through ERK1/2 activation and decrease IL-8 production in intestinal epithelial cells.	Cholecalciferol	0-10	mitogen-activated protein kinase 3	Homo sapiens	61-67
24060240-0	2013	Vitamin D3 derivatives increase soluble CD14 release through ERK1/2 activation and decrease IL-8 production in intestinal epithelial cells.	Cholecalciferol	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	92-96
24060240-4	2013	Among the innate immune-related receptors such as Toll-like receptor (TLR) 1, 2, 4, 6, and CD14 examined by flow cytometry, only CD14 was up-regulated by vitamin D3 derivatives.	Cholecalciferol	154-164	CD14 molecule	Homo sapiens	91-95
24060240-4	2013	Among the innate immune-related receptors such as Toll-like receptor (TLR) 1, 2, 4, 6, and CD14 examined by flow cytometry, only CD14 was up-regulated by vitamin D3 derivatives.	Cholecalciferol	154-164	CD14 molecule	Homo sapiens	129-133
24060240-5	2013	Release of soluble form CD14 (sCD14) was also increased by vitamin D3 derivatives.	Cholecalciferol	59-69	CD14 molecule	Homo sapiens	24-28
24060240-8	2013	IL-8 production stimulated with LPS was diminished by vitamin D3 derivatives.	Cholecalciferol	54-64	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
24060240-10	2013	The anti-inflammatory effect of vitamin D3 derivatives was thus associated with diminution of IL-8 production due to increased release of sCD14.	Cholecalciferol	32-42	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
24304198-5	2013	It was hypothesized that vitamin D3 supplementation would increase the lifespan of C. elegans in a DAF-12-dependent manner.	Cholecalciferol	25-35	Nuclear hormone receptor family member daf-12	Caenorhabditis elegans	99-105
24304198-7	2013	The daf-12 mutants exposed to 1,000 microg/ml vitamin D3 lived significantly longer than daf-12 controls exposed to 0 microg/ml (p&lt;0.001), but among worms exposed to 1,000 microg/ml vitamin D3, wild type lived significantly longer than daf-12 (p&lt;0.01).	Cholecalciferol	46-56	Nuclear hormone receptor family member daf-12	Caenorhabditis elegans	4-10
24304198-7	2013	The daf-12 mutants exposed to 1,000 microg/ml vitamin D3 lived significantly longer than daf-12 controls exposed to 0 microg/ml (p&lt;0.001), but among worms exposed to 1,000 microg/ml vitamin D3, wild type lived significantly longer than daf-12 (p&lt;0.01).	Cholecalciferol	185-195	Nuclear hormone receptor family member daf-12	Caenorhabditis elegans	4-10
24304198-8	2013	The data suggest that vitamin D3 can interact with multiple receptors, possibly implicating the NHR family of nuclear hormone receptors related to DAF-12.	Cholecalciferol	22-32	Nuclear hormone receptor family member daf-12	Caenorhabditis elegans	147-153
24183235-4	2013	U937 subclones expressing the NPM-RAR mutants showed significantly less inhibition of vitamin D3/TGFbeta-induced differentiation, compared with NPM-RAR.	Cholecalciferol	86-96	retinoic acid receptor alpha	Homo sapiens	34-37
24183235-4	2013	U937 subclones expressing the NPM-RAR mutants showed significantly less inhibition of vitamin D3/TGFbeta-induced differentiation, compared with NPM-RAR.	Cholecalciferol	86-96	nucleophosmin 1	Homo sapiens	30-33
24392366-5	2013	In this study, we tried to find out the probable association of Vitamin D3, calcium and magnesium with reference to insulin resistance in type 2 diabetes mellitus (T2DM) cases.	Cholecalciferol	64-74	insulin	Homo sapiens	116-123
24108316-0	2013	A randomized study on the effect of vitamin D3 supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women.	Cholecalciferol	36-46	vitamin D receptor	Homo sapiens	97-115
24108316-10	2013	CONCLUSION: Vitamin D3 supplementation increased intramyonuclear VDR concentration by 30% and increased muscle fiber size by 10% in older, mobility-limited, vitamin D-insufficient women.	Cholecalciferol	12-22	vitamin D receptor	Homo sapiens	65-68
24169587-2	2013	Our results indicate that 1,25(OH)2D3, the biologically active metabolite of vitamin D3, calcipotriol and FTY720 augment IL-2-activated NK cell lysis of K562 and RAJI tumor cell lines as well as immature (i) and mature (m) DCs, with variable efficacies.	Cholecalciferol	77-87	interleukin 2	Homo sapiens	121-125
24169587-5	2013	The three drugs down-regulate the expression of CCR6 on the surface of iDCs, whereas vitamin D3 and calcipotriol tend to up-regulate the expression of CCR7 on mDCs, suggesting that they may influence the migration of DCs into the lymph nodes.	Cholecalciferol	85-95	C-C motif chemokine receptor 7	Homo sapiens	151-155
23792937-1	2013	We previously showed that oral cholecalciferol and ergocalciferol have comparable effects in decreasing circulating parathyroid hormone (PTH), despite a greater increase in total serum 25-hydroxyvitamin D (25OHD) concentration with cholecalciferol supplementation.	Cholecalciferol	31-46	parathyroid hormone	Homo sapiens	116-135
23792937-1	2013	We previously showed that oral cholecalciferol and ergocalciferol have comparable effects in decreasing circulating parathyroid hormone (PTH), despite a greater increase in total serum 25-hydroxyvitamin D (25OHD) concentration with cholecalciferol supplementation.	Cholecalciferol	31-46	parathyroid hormone	Homo sapiens	137-140
24183235-4	2013	U937 subclones expressing the NPM-RAR mutants showed significantly less inhibition of vitamin D3/TGFbeta-induced differentiation, compared with NPM-RAR.	Cholecalciferol	86-96	transforming growth factor beta 1	Homo sapiens	97-104
23961975-0	2013	Narrowband ultraviolet B irradiation increases the serum level of vitamin D3 in patients with neurofibromatosis 1.	Cholecalciferol	66-76	neurofibromin 1	Homo sapiens	94-113
23792937-14	2013	These findings may explain why cholecalciferol and ergocalciferol supplementation result in similar magnitudes of PTH reduction, but implicate potential differences in other vitamin D metabolites, such as 24,25(OH)2D, that could explain their different effects on ionized calcium.	Cholecalciferol	31-46	parathyroid hormone	Homo sapiens	114-117
23961975-1	2013	The serum vitamin D3 levels in patients with neurofibromatosis 1 has been reported to be significantly lower than that in control subjects, and the level of vitamin D3 reversely correlates with the severity of neurofibroma formation.	Cholecalciferol	10-20	neurofibromin 1	Homo sapiens	45-64
23961975-1	2013	The serum vitamin D3 levels in patients with neurofibromatosis 1 has been reported to be significantly lower than that in control subjects, and the level of vitamin D3 reversely correlates with the severity of neurofibroma formation.	Cholecalciferol	157-167	neurofibromin 1	Homo sapiens	45-64
23961975-2	2013	We found that narrowband ultraviolet B (NB-UVB) irradiation increased the serum level of 1,25(OH)2 vitamin D3 in patients with neurofibromatosis 1.	Cholecalciferol	99-109	neurofibromin 1	Homo sapiens	127-146
23961975-5	2013	It is suggested that NB-UVB irradiation is effective for increasing the serum level of vitamin D3 in patients with neurofibromatosis 1, which may be of benefit for skin symptoms such as pigmented macules or neurofibromas.	Cholecalciferol	87-97	neurofibromin 1	Homo sapiens	115-134
23899497-3	2013	The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 that regulates numerous physiological processes.	Cholecalciferol	74-84	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-22
23899497-3	2013	The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 that regulates numerous physiological processes.	Cholecalciferol	74-84	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	24-27
23966631-0	2013	Human CD1c+ myeloid dendritic cells acquire a high level of retinoic acid-producing capacity in response to vitamin D3.	Cholecalciferol	108-118	CD1c molecule	Homo sapiens	6-10
24023320-9	2013	CONCLUSION: Vitamin D-3 reduces the PG cascade and increases TGFbeta2 in a dose-dependent fashion.	Cholecalciferol	12-23	transforming growth factor beta 2	Homo sapiens	61-69
23974111-0	2013	EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.	Cholecalciferol	94-104	epidermal growth factor receptor	Homo sapiens	0-4
23869208-7	2013	CD14(hi) and CD14(lo) M1- and M2-like MPhis were generated in vitro from the THP-1 monocyte cell line by differentiation with PMA and vitamin D3, respectively.	Cholecalciferol	134-144	CD14 molecule	Homo sapiens	0-4
24009820-9	2013	Additionally, cell culture experiments proved that Vitamin D3 could prevent the degradation of mutant LXR-alpha and restore its functional activity to some extent.	Cholecalciferol	51-61	nuclear receptor subfamily 1 group H member 3	Homo sapiens	102-111
24009820-10	2013	CONCLUSION: Mutant LXR-alpha protein in CHD subjects is degraded by BARD1/BRCA1 complex and Vitamin D3 can rescue and restore its function.	Cholecalciferol	92-102	nuclear receptor subfamily 1 group H member 3	Homo sapiens	19-28
23814095-0	2013	Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells.	Cholecalciferol	0-10	matrix metallopeptidase 2	Homo sapiens	49-82
23924389-2	2013	The objective of this study was to determine the effect of vitamin D3 supplementation in a cohort of Saudi DMT2 population on diet, insulin and/or different oral hypoglycemic agents and compare them with a non-DMT2 control cohort.	Cholecalciferol	59-69	insulin	Homo sapiens	132-139
23895820-0	2013	Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial).	Cholecalciferol	11-21	renin	Homo sapiens	52-57
23456391-6	2013	In the 50 patients receiving D(3) supplementation, serum levels of 25(OH)D(3) increased (p = 0.008), PTH decreased (p = 0.036) and 24,25(OH)(2)D(3), 1,25(OH)(2)D(3), VDBP levels and PBMC 24-OHase activity were unchanged.	Cholecalciferol	29-33	parathyroid hormone	Homo sapiens	101-104
23456391-6	2013	In the 50 patients receiving D(3) supplementation, serum levels of 25(OH)D(3) increased (p = 0.008), PTH decreased (p = 0.036) and 24,25(OH)(2)D(3), 1,25(OH)(2)D(3), VDBP levels and PBMC 24-OHase activity were unchanged.	Cholecalciferol	29-33	GC vitamin D binding protein	Homo sapiens	166-170
23456391-6	2013	In the 50 patients receiving D(3) supplementation, serum levels of 25(OH)D(3) increased (p = 0.008), PTH decreased (p = 0.036) and 24,25(OH)(2)D(3), 1,25(OH)(2)D(3), VDBP levels and PBMC 24-OHase activity were unchanged.	Cholecalciferol	29-33	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	187-195
23837623-6	2013	RESULTS: We find evidence of positive selection for DHCR7, which governs availability of 7-dehydrocholesterol for conversion to vitamin D3 by the action of sunlight on the skin.	Cholecalciferol	128-138	7-dehydrocholesterol reductase	Homo sapiens	52-57
23639807-10	2013	Bone vitamin D receptor expression was increased in mice with chronic colitis, especially in the high vitamin D3 group.	Cholecalciferol	102-112	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	5-23
23591713-8	2013	The bone resorption marker C-terminal telopetide of type 1 collagen (CTX) decreased borderline significantly in the cholecalciferol group compared with the placebo group (p = 0.07).	Cholecalciferol	116-131	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	52-73
23220095-4	2013	The active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3], is known to be a hormone which enhances RANKL expression in vitro.	Cholecalciferol	19-29	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	121-126
23853726-1	2013	The hormonally active form of vitamin D3, 1,25(OH)2D3 (calcitriol), exerts actions through VDR receptor, which acts as a transcriptional factor.	Cholecalciferol	30-40	vitamin D receptor	Homo sapiens	91-94
23026510-1	2013	We previously demonstrated that non-small cell lung cancer (NSCLC) cells and primary human lung tumors aberrantly express the vitamin D3-catabolizing enzyme, CYP24, and that CYP24 restricts transcriptional regulation and growth control by 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) in NSCLC cells.	Cholecalciferol	126-136	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	158-163
23026510-1	2013	We previously demonstrated that non-small cell lung cancer (NSCLC) cells and primary human lung tumors aberrantly express the vitamin D3-catabolizing enzyme, CYP24, and that CYP24 restricts transcriptional regulation and growth control by 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) in NSCLC cells.	Cholecalciferol	126-136	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	174-179
22939886-5	2013	We found elevations in circulating calcitriol as well as increased CYP27B1 expression in the tumor and the intestine in tumor-bearing mice ingesting a vitamin D3-supplemented diet.	Cholecalciferol	151-161	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	67-74
23378417-10	2013	The PTH levels tended to increase over the study period under placebo and to decrease in the cholecalciferol group.	Cholecalciferol	93-108	parathyroid hormone	Homo sapiens	4-7
23500833-3	2013	The present study was aimed to evaluate in vitro differences in VEGF production and expression of cultured human osteoblastic cells derived from healthy donors and from subjects affected by osteoarthritis and osteoporosis, under basal conditions than after vitamin D3, and to investigate the angiogenic activity of culture media obtained by these cells in chick embryo chorioallantoic membrane (CAM) assay.	Cholecalciferol	257-267	vascular endothelial growth factor A	Homo sapiens	64-68
23467424-5	2013	Moreover, CIDHPs lacking VDR displayed enhanced ANG II production, and treatment of HIV/CIDHPs with EB1089 (vitamin D3; VD) attenuated ANG II production.	Cholecalciferol	108-118	angiogenin	Homo sapiens	135-138
23339019-14	2013	When DBP was upregulated, however, the benefits from the vitamin D3 supplements were lost.	Cholecalciferol	57-67	D-box binding PAR bZIP transcription factor	Homo sapiens	5-8
23065434-9	2013	CONCLUSIONS: Cholecalciferol replacement therapy significantly decreases PTH levels and insulin resistance.	Cholecalciferol	13-28	insulin	Homo sapiens	88-95
23548573-4	2013	When vitamin D3 or vitamin D2 was added to the cell suspension of CYP2R1-expressing yeast cells in a buffer containing glucose and beta-cyclodextrin, the vitamins were converted into their 25-hydroxylated products.	Cholecalciferol	5-15	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	66-72
23737310-0	2013	Comparison of vitamin D3 serum levels in new diagnosed patients with multiple sclerosis versus their healthy relatives.	Cholecalciferol	14-24	MS	Homo sapiens	69-87
23717463-10	2013	RESULTS: 1(OH) vitamin D3/Peg-IFN/RBV treatment could induce rapid viral reduction, especially in IL28B T/T polymorphism.	Cholecalciferol	15-25	interferon lambda 3	Homo sapiens	98-103
23717463-11	2013	Several kinds of cytokines including IP-10 were significantly decreased after 4 weeks of 1(OH) vitamin D3 treatment (p&lt;0.05).	Cholecalciferol	95-105	C-X-C motif chemokine ligand 10	Homo sapiens	37-42
23674869-0	2013	CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells.	Cholecalciferol	56-66	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
23674869-2	2013	25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), the enzyme that inactivates the active vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25-D3), is considered to be the main enzyme determining the biological half-life of 1,25-D3.	Cholecalciferol	86-96	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	37-44
23674869-4	2013	The aim of this study was to investigate the anti-tumor effects of vitamin D3 on the human CRC cell line Caco-2 after inhibition of the cytochrome P450 component of CYP24A1 activity.	Cholecalciferol	67-77	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	165-172
23485413-6	2013	Interaction analyses showed that VDR FokI genotypes modified the effect of vitamin D3 on changes in the HY stage (P-interaction = 0.045), UPDRS total (P-interaction = 0.039), and UPDRS part II (P-interaction = 0.021).	Cholecalciferol	75-85	vitamin D receptor	Homo sapiens	33-36
23457386-6	2013	Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels.	Cholecalciferol	15-25	TNF superfamily member 11	Homo sapiens	40-45
23971693-9	2013	We predict that cholecalciferol will attenuate hypertension, proteinuria and reduce the urinary excretion of a biomarker, monocyte chemoattractant protein-1 (MCP-1, a surrogate inflammatory marker of progression in ADPKD).	Cholecalciferol	16-31	C-C motif chemokine ligand 2	Homo sapiens	122-156
23971693-9	2013	We predict that cholecalciferol will attenuate hypertension, proteinuria and reduce the urinary excretion of a biomarker, monocyte chemoattractant protein-1 (MCP-1, a surrogate inflammatory marker of progression in ADPKD).	Cholecalciferol	16-31	C-C motif chemokine ligand 2	Homo sapiens	158-163
23454830-0	2013	Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1.	Cholecalciferol	45-55	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	17-24
23454830-0	2013	Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1.	Cholecalciferol	45-55	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	86-93
23454830-1	2013	CYP11A1 can hydroxylate vitamin D3 at carbons 17, 20, 22, and 23, producing a range of secosteroids which are biologically active with respect to their ability to inhibit proliferation and stimulate differentiation of various cell types, including cancer cells.	Cholecalciferol	24-34	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	0-7
23021159-0	2013	Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study.	Cholecalciferol	10-20	neurofibromin 1	Homo sapiens	50-69
23457386-6	2013	Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels.	Cholecalciferol	15-25	TNF receptor superfamily member 11b	Homo sapiens	46-49
23021159-3	2013	This study investigates the therapeutic potential of oral vitamin D3 on bone mineral density (BMD) in NF1 patients with vitamin D3 deficiency.	Cholecalciferol	58-68	neurofibromin 1	Homo sapiens	102-105
23457386-6	2013	Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels.	Cholecalciferol	15-25	dickkopf WNT signaling pathway inhibitor 2	Homo sapiens	60-65
23021159-3	2013	This study investigates the therapeutic potential of oral vitamin D3 on bone mineral density (BMD) in NF1 patients with vitamin D3 deficiency.	Cholecalciferol	120-130	neurofibromin 1	Homo sapiens	102-105
23021159-10	2013	CONCLUSIONS: Vitamin D3 supplementation improves BMD in adult NF1 patients.	Cholecalciferol	13-23	neurofibromin 1	Homo sapiens	62-65
23457386-6	2013	Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels.	Cholecalciferol	15-25	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	89-94
24327998-6	2013	After one-year use, the median % changes of BMD at three sites were similar among the three groups; however, the median values were highest in alendronate + cholecalciferol group (L1-4: 4.48%, 6.74%, and 4.50%; FT: 2.09%, 3.70%, and 2.31%; FN: 3.05%, 3.79%, and 2.03%).	Cholecalciferol	157-172	immunoglobulin kappa variable 1D-17	Homo sapiens	180-184
23940873-4	2013	The study has shown that prednisolone action causes impairment of cholecalciferol metabolism in hepatocytes due to inhibiting vitamin D3 25-hydroxylase activity.	Cholecalciferol	66-81	cytochrome P450, family 27, subfamily a, polypeptide 1	Rattus norvegicus	126-151
23593176-3	2013	Recent studies implicate that hormones including glucocorticoids (ligand for glucocorticoid receptor) and vitamin D3 (ligand for vitamin D receptor) protect or promote repair of podocytes from injury.	Cholecalciferol	106-116	vitamin D receptor	Homo sapiens	129-147
23521914-0	2013	Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE.	Cholecalciferol	0-10	indoleamine 2,3-dioxygenase 1	Rattus norvegicus	19-22
23521914-4	2013	RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE.	Cholecalciferol	73-83	Cd4 molecule	Rattus norvegicus	239-242
23521914-4	2013	RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE.	Cholecalciferol	73-83	forkhead box P3	Rattus norvegicus	254-259
23521914-4	2013	RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE.	Cholecalciferol	121-131	indoleamine 2,3-dioxygenase 1	Rattus norvegicus	141-144
23521914-4	2013	RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE.	Cholecalciferol	121-131	Cd4 molecule	Rattus norvegicus	239-242
23521914-4	2013	RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE.	Cholecalciferol	121-131	forkhead box P3	Rattus norvegicus	254-259
23521914-6	2013	Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression.	Cholecalciferol	54-64	interleukin 10	Rattus norvegicus	105-110
23521914-6	2013	Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression.	Cholecalciferol	54-64	tumor necrosis factor	Rattus norvegicus	112-120
23521914-6	2013	Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression.	Cholecalciferol	54-64	indoleamine 2,3-dioxygenase 1	Rattus norvegicus	126-129
23521914-6	2013	Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression.	Cholecalciferol	54-64	Cd80 molecule	Rattus norvegicus	166-170
23521914-7	2013	The adoptive transfer of IDO (+) DCs induces a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) T cells in the lymph nodes, comparable with vitamin D3 treatment.	Cholecalciferol	157-167	indoleamine 2,3-dioxygenase 1	Rattus norvegicus	25-28
23375797-10	2013	Vitamin D3 receptor, CYP24A1 and CYP27B1 expression was measured in cholangiocarcinoma cells stimulated with vehicle or vitamin D3.	Cholecalciferol	120-130	vitamin D receptor	Homo sapiens	0-19
23375797-10	2013	Vitamin D3 receptor, CYP24A1 and CYP27B1 expression was measured in cholangiocarcinoma cells stimulated with vehicle or vitamin D3.	Cholecalciferol	120-130	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	33-40
23375797-12	2013	Vitamin D3 induced nuclear translocation of vitamin D3 receptor in cholangiocarcinoma and decreased cholangiocarcinoma growth.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	44-63
23375797-13	2013	CONCLUSION: Treatment with vitamin D3 decreased CYP24A1, whereas CYP27B1 expression increased.	Cholecalciferol	27-37	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	48-55
23556437-0	2013	Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2supplementation.	Cholecalciferol	98-108	GC vitamin D binding protein	Homo sapiens	56-81
23556437-13	2013	CONCLUSION: Genetic variation in DBP (rs4588 SNP) influences responsiveness to vitamin D3 but not vitamin D2.	Cholecalciferol	79-89	D-box binding PAR bZIP transcription factor	Homo sapiens	33-36
23199009-9	2013	In patients receiving calcitriol and cholecalciferol, the mean levels of P1NP (p&lt;0.001) and CTx (p= 0.002) declined significantly compared to our placebo group.	Cholecalciferol	37-52	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	95-98
23375797-3	2013	Vitamin D3 is synthesized by the enzyme, CYP27B1, and signals via the nuclear vitamin D3 receptor.	Cholecalciferol	0-10	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	41-48
23375797-3	2013	Vitamin D3 is synthesized by the enzyme, CYP27B1, and signals via the nuclear vitamin D3 receptor.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	78-97
23375797-4	2013	The enzyme, CYP24A1, degrades vitamin D3.	Cholecalciferol	30-40	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	12-19
23463655-15	2013	CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH.	Cholecalciferol	18-28	kallikrein related peptidase 3	Homo sapiens	108-111
22661288-0	2013	Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies.	Cholecalciferol	103-113	CEA cell adhesion molecule 1	Homo sapiens	58-61
22661288-0	2013	Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies.	Cholecalciferol	103-113	CEA cell adhesion molecule 1	Homo sapiens	69-72
23458303-6	2013	To our knowledge, this is the first time, albeit using a simple model, a description of the complete passage of D(3) through the cell membrane, the cytoplasm, into the cell nucleus, and finally the production of RANKL with its passage to the exterior of the cell, has been modeled.	Cholecalciferol	112-116	TNF superfamily member 11	Homo sapiens	212-217
23386641-3	2013	OBJECTIVES: The objective of the study was to measure the effect of vitamin D3 on serum 25OHD and serum PTH in older African American women with vitamin D insufficiency and the serum 25OHD 20 ng/mL or less (&lt;50 nmol/L).	Cholecalciferol	68-78	parathyroid hormone	Homo sapiens	104-107
25382938-2	2013	Presented here is a study on the effects of the local delivery of cholecalciferol (D3) using nanoparticulate carriers composed of hydroxyapatite (HAp) and poly(D,L-lactide-co-glycolide) (PLGA).	Cholecalciferol	66-81	scaffold attachment factor B	Mus musculus	146-149
25382938-3	2013	Multifunctional nanoparticulate HAp-based powders were prepared for the purpose of: (a) either fast or sustained, local delivery of cholecalciferol, and (b) the secondary, osteoconductive and defect-filling effect of the carrier itself.	Cholecalciferol	132-147	scaffold attachment factor B	Mus musculus	32-35
25382938-6	2013	In contrast, an extensively fast release of cholecalciferol from the system comprising HAp nanoparticles coated with cholecalciferol (HAp/D3) triggered necrosis of the osteoblastic cells in vitro.	Cholecalciferol	44-59	scaffold attachment factor B	Mus musculus	87-90
25382938-6	2013	In contrast, an extensively fast release of cholecalciferol from the system comprising HAp nanoparticles coated with cholecalciferol (HAp/D3) triggered necrosis of the osteoblastic cells in vitro.	Cholecalciferol	44-59	scaffold attachment factor B	Mus musculus	134-137
25382938-6	2013	In contrast, an extensively fast release of cholecalciferol from the system comprising HAp nanoparticles coated with cholecalciferol (HAp/D3) triggered necrosis of the osteoblastic cells in vitro.	Cholecalciferol	117-132	scaffold attachment factor B	Mus musculus	134-137
25382938-7	2013	Artificial defects induced in the osteoporotic bone of the rat mandible were successfully reconstructed following implantation of cholecalciferol-coated HAp nanoparticles as well as those comprising HAp nanoparticles coated with cholecalciferol-loaded PLGA (HAp/D3/PLGA).	Cholecalciferol	130-145	scaffold attachment factor B	Mus musculus	153-156
22720723-7	2013	High-dose cholecalciferol supplementation differentially influenced skin-homing markers on Treg with an increased level of CCR10 expression and while a reduction in CCR4 expression level was observed together with a lower percentage of Treg expressing CCR4.	Cholecalciferol	10-25	C-C motif chemokine receptor 10	Homo sapiens	123-128
22720723-7	2013	High-dose cholecalciferol supplementation differentially influenced skin-homing markers on Treg with an increased level of CCR10 expression and while a reduction in CCR4 expression level was observed together with a lower percentage of Treg expressing CCR4.	Cholecalciferol	10-25	C-C motif chemokine receptor 4	Homo sapiens	165-169
22720723-7	2013	High-dose cholecalciferol supplementation differentially influenced skin-homing markers on Treg with an increased level of CCR10 expression and while a reduction in CCR4 expression level was observed together with a lower percentage of Treg expressing CCR4.	Cholecalciferol	10-25	C-C motif chemokine receptor 4	Homo sapiens	252-256
23142162-7	2013	RESULTS: Vitamin D3 therapy significantly raised 25(OH)D and 1,25(OH)2D concentrations, and lowered parathyroid hormone, but had no effect on concentrations of adiponectin, resistin, leptin, IL-6, PAI-1, urinary TGFbeta1, or HOMA-IR.	Cholecalciferol	9-19	serpin family E member 1	Homo sapiens	197-202
23142162-7	2013	RESULTS: Vitamin D3 therapy significantly raised 25(OH)D and 1,25(OH)2D concentrations, and lowered parathyroid hormone, but had no effect on concentrations of adiponectin, resistin, leptin, IL-6, PAI-1, urinary TGFbeta1, or HOMA-IR.	Cholecalciferol	9-19	transforming growth factor beta 1	Homo sapiens	212-220
23361158-7	2013	RESULTS: By 12 weeks, serum MCP-1 decreased in the cholecalciferol group (66.2+-2.5 to 60.8+-2.6 pg/ml, group-by-time interaction P=0.02) but was not different from baseline at 1 year.	Cholecalciferol	51-66	C-C motif chemokine ligand 2	Homo sapiens	28-33
23361158-10	2013	CONCLUSIONS: High-dose cholecalciferol decreased serum MCP-1 concentrations by 12 weeks in patients with early CKD, although the decrease was not maintained for the remainder of the year.	Cholecalciferol	23-38	C-C motif chemokine ligand 2	Homo sapiens	55-60
23489420-5	2013	Based on the induction of a transcriptional activator consisting of the vitamin D receptor fused to the Gal4 DNA-binding domain, the vitamin D3-responsive sensor facilitates non-invasive and rapid assessment of permeability and functional properties of vitamin D3 analogues.	Cholecalciferol	133-143	vitamin D receptor	Homo sapiens	72-90
23489420-5	2013	Based on the induction of a transcriptional activator consisting of the vitamin D receptor fused to the Gal4 DNA-binding domain, the vitamin D3-responsive sensor facilitates non-invasive and rapid assessment of permeability and functional properties of vitamin D3 analogues.	Cholecalciferol	253-263	vitamin D receptor	Homo sapiens	72-90
23611825-6	2013	Cholecalciferol supplementation produced an early (3 months) decrease in PTH, a concomitant increase in 25(OH)D, and a later (6 months) increase in 1,25(OH)2D levels, all persisting at 12 months.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	73-76
23611825-9	2013	CONCLUSIONS: In our cohort of HIV-infected youth, a 12-month cholecalciferol supplementation increased 25(OH)D and 1-25(OH)2D and decreased PTH levels but had no effect on CD4+ T-cells.	Cholecalciferol	61-76	parathyroid hormone	Homo sapiens	140-143
23465499-5	2013	Klotho participates in mineral homeostasis via interplay with other calciophosphoregulatory hormones (parathyroid hormone, fibroblast growth factor-23, and 1,25-[OH]2 vitamin D3) in kidney, bone, intestine, and parathyroid gland.	Cholecalciferol	167-177	klotho	Homo sapiens	0-6
22124604-5	2013	Osteoarthritic osteoblasts showed a significantly higher VEGF expression compared to the normal and OP osteoblasts, both under basal conditions than in the presence of vitamin D3, whereas no difference was found between osteoporotic and normal osteoblast.	Cholecalciferol	168-178	vascular endothelial growth factor A	Homo sapiens	57-61
22124604-6	2013	Vitamin D3 significantly enhanced VEGF expression in normal and pathological osteoblasts.	Cholecalciferol	0-10	vascular endothelial growth factor A	Homo sapiens	34-38
22124604-7	2013	This preliminary study supports the hypothesis that VEGF is involved in the pathogenic mechanisms underlying the bone alterations typical of osteoarthritis and confirms the crucial role of vitamin D3 supplementation in metabolic bone diseases.	Cholecalciferol	189-199	vascular endothelial growth factor A	Homo sapiens	52-56
23291929-0	2013	Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells.	Cholecalciferol	27-37	CD14 molecule	Homo sapiens	61-65
23291929-0	2013	Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells.	Cholecalciferol	27-37	forkhead box P3	Homo sapiens	122-127
23295467-0	2013	20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo.	Cholecalciferol	11-21	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	46-53
23463655-15	2013	CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH.	Cholecalciferol	18-28	parathyroid hormone	Homo sapiens	116-119
23348932-4	2013	Thanks, in fact, to its considerable functional versatility, MLT can exert both direct and indirect anticancer effects in factorial synergy with other differentiating, antiproliferative, immunomodulating and trophic molecules that form part of the anticancer treatment formulated by Luigi Di Bella (Di Bella Method, DBM: somatostatin, retinoids, ascorbic acid, vitamin D3, prolactin inhibitors, chondroitin-sulfate).	Cholecalciferol	361-371	MALT1 paracaspase	Homo sapiens	61-64
23042025-2	2013	Vitamin D3 and dexamethasone-modulated dendritic cells (Combi-DCs) loaded with islet antigens inducing islet-specific regulatory CD4(+)  T cells may offer a tissue-specific intervention therapy.	Cholecalciferol	0-10	CD4 molecule	Homo sapiens	129-132
23710204-2	2013	Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86.	Cholecalciferol	0-10	CD14 molecule	Homo sapiens	100-104
23710204-2	2013	Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86.	Cholecalciferol	0-10	CD40 molecule	Homo sapiens	106-110
23710204-2	2013	Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86.	Cholecalciferol	0-10	CD80 molecule	Homo sapiens	112-116
23710204-2	2013	Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86.	Cholecalciferol	0-10	CD83 molecule	Homo sapiens	118-122
23710204-2	2013	Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86.	Cholecalciferol	0-10	CD86 molecule	Homo sapiens	128-132
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	0-10	CD40 molecule	Homo sapiens	59-63
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	0-10	CD80 molecule	Homo sapiens	65-69
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	0-10	CD83 molecule	Homo sapiens	71-75
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	0-10	CD86 molecule	Homo sapiens	81-85
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	0-10	CD14 molecule	Homo sapiens	120-124
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	166-176	CD40 molecule	Homo sapiens	59-63
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	166-176	CD80 molecule	Homo sapiens	65-69
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	166-176	CD83 molecule	Homo sapiens	71-75
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	166-176	CD86 molecule	Homo sapiens	81-85
23710204-5	2013	Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation.	Cholecalciferol	166-176	CD14 molecule	Homo sapiens	120-124
23710204-6	2013	Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12.	Cholecalciferol	0-10	interleukin 6	Homo sapiens	90-94
23710204-6	2013	Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12.	Cholecalciferol	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	96-100
23710204-6	2013	Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12.	Cholecalciferol	0-10	interleukin 10	Homo sapiens	106-111
24494038-4	2013	Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type.	Cholecalciferol	21-31	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	10-17
24494038-4	2013	Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type.	Cholecalciferol	21-31	cytokine like 1	Homo sapiens	100-103
24494038-4	2013	Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type.	Cholecalciferol	21-31	nucleolin	Homo sapiens	115-118
24494038-4	2013	Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type.	Cholecalciferol	21-31	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	165-172
24494038-4	2013	Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type.	Cholecalciferol	21-31	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	183-190
24494038-4	2013	Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type.	Cholecalciferol	21-31	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	202-209
22832486-5	2013	Furthermore, using TSLP(over) mice in which overexpression of keratinocytic TSLP is induced by skin topical application of MC903 (a vitamin D3 analog) in a dose-dependent manner, we show that keratinocytic TSLP levels are correlated with skin sensitization strength and asthma severity.	Cholecalciferol	132-142	thymic stromal lymphopoietin	Mus musculus	19-23
23159604-0	2013	A vitamin D3 analog augmented interleukin-8 production by human monocytic cells in response to various microbe-related synthetic ligands, especially NOD2 agonistic muramyldipeptide.	Cholecalciferol	2-12	C-X-C motif chemokine ligand 8	Homo sapiens	30-43
23159604-0	2013	A vitamin D3 analog augmented interleukin-8 production by human monocytic cells in response to various microbe-related synthetic ligands, especially NOD2 agonistic muramyldipeptide.	Cholecalciferol	2-12	nucleotide binding oligomerization domain containing 2	Homo sapiens	149-153
22832486-5	2013	Furthermore, using TSLP(over) mice in which overexpression of keratinocytic TSLP is induced by skin topical application of MC903 (a vitamin D3 analog) in a dose-dependent manner, we show that keratinocytic TSLP levels are correlated with skin sensitization strength and asthma severity.	Cholecalciferol	132-142	thymic stromal lymphopoietin	Mus musculus	76-80
22832486-5	2013	Furthermore, using TSLP(over) mice in which overexpression of keratinocytic TSLP is induced by skin topical application of MC903 (a vitamin D3 analog) in a dose-dependent manner, we show that keratinocytic TSLP levels are correlated with skin sensitization strength and asthma severity.	Cholecalciferol	132-142	thymic stromal lymphopoietin	Mus musculus	76-80
23673970-0	2013	Cholecalciferol supplementation reduces soluble Klotho concentration in hemodialysis patients.	Cholecalciferol	0-15	klotho	Homo sapiens	48-54
22858193-6	2013	SIE treatment was more effective than vitamin D3 or 17beta-estradiol in inhibiting increases in serum tumor necrosis factor-alpha levels and osteoblast osteoprotegerin expression.	Cholecalciferol	38-48	tumor necrosis factor	Rattus norvegicus	102-129
22858193-7	2013	SIE plus vitamin D3 was more effective in increasing osterix expression than each alone.	Cholecalciferol	9-19	Sp7 transcription factor	Rattus norvegicus	53-60
22858193-12	2013	In addition, there are further effects on increasing transcription factor osterix expression and preosteoblast proliferation when these were combined with vitamin D3.	Cholecalciferol	155-165	Sp7 transcription factor	Rattus norvegicus	74-81
23424670-11	2013	Furthermore, either the TLR2 or TLR6 antibody reduced vitamin D3 signaling and tumor cell progression in vitro.	Cholecalciferol	54-64	toll like receptor 2	Homo sapiens	24-28
23424670-11	2013	Furthermore, either the TLR2 or TLR6 antibody reduced vitamin D3 signaling and tumor cell progression in vitro.	Cholecalciferol	54-64	toll like receptor 6	Homo sapiens	32-36
23043683-1	2013	AIM: To assess the impact of vitamin D supplementation (cholecalciferol) on the insulin sensitivity and metabolic health of patients with chronic kidney disease (CKD).	Cholecalciferol	56-71	insulin	Homo sapiens	80-87
23673970-3	2013	OBJECTIVES: The aim of the study was to evaluate the effect of cholecalciferol supplementation on soluble Klotho levels in HD patients.	Cholecalciferol	63-78	klotho	Homo sapiens	106-112
23673970-8	2013	Cholecalciferol treatment reduced the median concentration of soluble Klotho (from 438.73 pg/ml; interquartile range, 257.99-865.51 pg/ml; to 370.94 pg/ml; 181.72-710.91 pg/ml; P &lt;0.05).	Cholecalciferol	0-15	klotho	Homo sapiens	70-76
23673970-10	2013	CONCLUSIONS: Supplementation with cholecalciferol in HD patients decreases soluble Klotho levels without affecting the FGF-23 concentration.	Cholecalciferol	34-49	klotho	Homo sapiens	83-89
22317756-12	2012	The findings showed that supplementation with vitamin D3 can significantly improve HDL-cholesterol, apoA-I concentrations and LDL-cholesterol:apoB-100 ratio, which remained significant in the multivariate model including anthropometric, dietary and physical activity measures.	Cholecalciferol	46-56	apolipoprotein A1	Homo sapiens	100-106
22925537-0	2012	Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects.	Cholecalciferol	41-56	interleukin 6	Homo sapiens	60-73
22925537-0	2012	Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects.	Cholecalciferol	41-56	tumor necrosis factor	Homo sapiens	75-102
22925537-0	2012	Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects.	Cholecalciferol	41-56	insulin	Homo sapiens	107-114
22925537-6	2012	We also proposed that the intervention with high dose of cholecalciferol may have effect on the cytokine levels and result in corresponding changes in the measures of insulin resistance (HOMA-IR and QUICKI).	Cholecalciferol	57-72	insulin	Homo sapiens	167-174
22753133-0	2012	Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus.	Cholecalciferol	96-106	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	38-45
22317756-12	2012	The findings showed that supplementation with vitamin D3 can significantly improve HDL-cholesterol, apoA-I concentrations and LDL-cholesterol:apoB-100 ratio, which remained significant in the multivariate model including anthropometric, dietary and physical activity measures.	Cholecalciferol	46-56	apolipoprotein B	Homo sapiens	142-150
22655972-5	2012	Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus.	Cholecalciferol	0-15	beta-defensin 5	Bos taurus	100-140
22655972-5	2012	Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus.	Cholecalciferol	0-15	lingual antimicrobial peptide	Bos taurus	196-225
22655972-5	2012	Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus.	Cholecalciferol	0-15	lingual antimicrobial peptide	Bos taurus	227-230
22655972-5	2012	Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus.	Cholecalciferol	0-15	beta-defensin 1	Bos taurus	240-255
22655972-5	2012	Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus.	Cholecalciferol	0-15	beta-defensin 1	Bos taurus	257-262
22843547-3	2012	Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling.	Cholecalciferol	39-49	sonic hedgehog signaling molecule	Homo sapiens	124-127
22843547-3	2012	Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling.	Cholecalciferol	39-49	GLI family zinc finger 1	Homo sapiens	128-131
22843547-3	2012	Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling.	Cholecalciferol	57-72	sonic hedgehog signaling molecule	Homo sapiens	124-127
22843547-3	2012	Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling.	Cholecalciferol	57-72	GLI family zinc finger 1	Homo sapiens	128-131
22843547-8	2012	Cholecalciferol decreases cell proliferation and increases cell death by inhibition of the SHH-Gli pathway.	Cholecalciferol	0-15	sonic hedgehog signaling molecule	Homo sapiens	91-94
22843547-8	2012	Cholecalciferol decreases cell proliferation and increases cell death by inhibition of the SHH-Gli pathway.	Cholecalciferol	0-15	GLI family zinc finger 1	Homo sapiens	95-98
22843547-11	2012	These findings establish that, although VD3 receptors and metabolizing enzymes are absent in CCC, cholecalciferol supplementation is a strong tool to block the reactivation of SHH-Gli pathway in this pathology, leading ultimately to tumor regression.	Cholecalciferol	98-113	sonic hedgehog signaling molecule	Homo sapiens	176-179
22843547-11	2012	These findings establish that, although VD3 receptors and metabolizing enzymes are absent in CCC, cholecalciferol supplementation is a strong tool to block the reactivation of SHH-Gli pathway in this pathology, leading ultimately to tumor regression.	Cholecalciferol	98-113	GLI family zinc finger 1	Homo sapiens	180-183
22871591-7	2012	In vivo overexpression of miR-204 by injection of miR-204 agomirs in Kunming mice attenuated vitamin D3-induced medial artery calcification.	Cholecalciferol	93-103	microRNA 204	Mus musculus	26-33
22871591-7	2012	In vivo overexpression of miR-204 by injection of miR-204 agomirs in Kunming mice attenuated vitamin D3-induced medial artery calcification.	Cholecalciferol	93-103	microRNA 204	Mus musculus	50-57
23246829-1	2012	Vitamin-D3 upregulated protein-1 (VDUP1) is a stress response protein.	Cholecalciferol	0-10	thioredoxin interacting protein	Mus musculus	34-39
23076256-1	2012	Vitamin D(3) is a neurosteroid that mediates its effects via the vitamin D receptor (VDR).	Cholecalciferol	0-12	vitamin D receptor	Homo sapiens	65-83
23076256-1	2012	Vitamin D(3) is a neurosteroid that mediates its effects via the vitamin D receptor (VDR).	Cholecalciferol	0-12	vitamin D receptor	Homo sapiens	85-88
22989379-5	2012	All new vitamin D3 analogues bound less strongly to the VDR than 1alpha,25-dihydroxyvitamin D3 but had similar antiproliferative, pro-differentiating, and transcriptional activity as the native hormone.	Cholecalciferol	8-18	vitamin D receptor	Homo sapiens	56-59
22930071-0	2012	Synthesis of vitamin D3 derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity.	Cholecalciferol	13-23	complement C2	Homo sapiens	80-83
22930071-0	2012	Synthesis of vitamin D3 derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity.	Cholecalciferol	13-23	vitamin D receptor	Homo sapiens	108-126
22964475-0	2012	A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/beta-catenin pathway in the normal mucosa of colorectal adenoma patients.	Cholecalciferol	71-81	catenin beta 1	Homo sapiens	93-105
22862690-1	2012	CYP27B1 is a mitochondrial cytochrome P450 that catalyses the hydroxylation of 25-hydroxyvitamin D3 at the C1alpha-position to give the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3.	Cholecalciferol	89-99	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	0-7
22862690-1	2012	CYP27B1 is a mitochondrial cytochrome P450 that catalyses the hydroxylation of 25-hydroxyvitamin D3 at the C1alpha-position to give the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3.	Cholecalciferol	89-99	endogenous retrovirus group K member 1	Homo sapiens	107-114
22896638-0	2012	The Ifng gene is essential for Vdr gene expression and vitamin D3-mediated reduction of the pathogenic T cell burden in the central nervous system in experimental autoimmune encephalomyelitis, a multiple sclerosis model.	Cholecalciferol	55-65	interferon gamma	Mus musculus	4-8
22910291-4	2012	We analyzed the effect of vitamin D3 on dysferlin expression in vitro using HL60 cells, monocytes and myotubes from controls and carriers of a single mutation in DYSF.	Cholecalciferol	26-36	dysferlin	Homo sapiens	40-49
22910291-7	2012	Treatment with vitamin D3 increased expression of dysferlin in vitro.	Cholecalciferol	15-25	dysferlin	Homo sapiens	50-59
22910291-8	2012	The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter.	Cholecalciferol	14-24	mitogen-activated protein kinase kinase 7	Homo sapiens	75-78
22910291-8	2012	The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter.	Cholecalciferol	14-24	mitogen-activated protein kinase 1	Homo sapiens	79-82
22910291-8	2012	The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	126-145
22910291-8	2012	The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter.	Cholecalciferol	14-24	dysferlin	Homo sapiens	153-162
22910291-9	2012	Carriers treated with vitamin D3 had significantly increased expression of dysferlin in monocytes compared with nontreated carriers (P &lt; 0.05).	Cholecalciferol	22-32	dysferlin	Homo sapiens	75-84
22910291-10	2012	These findings will have important therapeutic implications since a combination of different molecular strategies together with vitamin D3 uptake could increase dysferlin expression to nonpathological protein levels.	Cholecalciferol	128-138	dysferlin	Homo sapiens	161-170
23097629-9	2012	During NTera2 tumor formation, down-regulation of VDR was observed, resulting in limited responsiveness to cholecalciferol and 1,25(OH)(2)D(3) treatment in vivo.	Cholecalciferol	107-122	vitamin D receptor	Homo sapiens	50-53
22212646-9	2012	We conclude that both 1500 mug and two doses of 3000 mug vitamin D3 had a beneficial effect on infant anthropometry, the larger dose also improving CB ALP and maternal 25(OH)D.	Cholecalciferol	57-67	alkaline phosphatase, placental	Homo sapiens	151-154
22896638-5	2012	Sardinian MS patients frequently carry a low Ifng expresser allele, suggesting that inadequate IFN-gamma may undermine vitamin D3-mediated inhibition of demyelinating disease.	Cholecalciferol	119-129	interferon gamma	Homo sapiens	45-49
22896638-5	2012	Sardinian MS patients frequently carry a low Ifng expresser allele, suggesting that inadequate IFN-gamma may undermine vitamin D3-mediated inhibition of demyelinating disease.	Cholecalciferol	119-129	interferon gamma	Homo sapiens	95-104
22896638-12	2012	Thus, the Ifng gene was needed for CNS Vdr gene expression and vitamin D3-dependent mechanisms that inhibit EAE.	Cholecalciferol	63-73	interferon gamma	Mus musculus	10-14
22854402-0	2012	High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.	Cholecalciferol	10-25	parathyroid hormone	Homo sapiens	34-53
22854402-11	2012	Furthermore, serum PTH improved after cholecalciferol treatment, particularly in patients who had secondary hyperparathyroidism.	Cholecalciferol	38-53	parathyroid hormone	Homo sapiens	19-22
22683847-0	2012	In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1.	Cholecalciferol	40-50	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	75-82
22683847-0	2012	In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1.	Cholecalciferol	40-50	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	99-106
21477267-4	2012	Vitamin D3 exerts its actions through the vitamin D receptor, which is known to be an important regulator of P-glycoprotein (P-gp).	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	42-60
22822092-8	2012	Cholecalciferol supplementation led to a significant increase to a median of 155 nmol/L 25-OHD (interquartile range 137-173 nmol/L) in treated patients (n = 25, P &lt; 0.001).	Cholecalciferol	0-15	immunoglobulin kappa variable 3D-7	Homo sapiens	86-94
22822092-11	2012	Cholecalciferol supplementation caused a significant increase in serum calcium and FGF-23.	Cholecalciferol	0-15	fibroblast growth factor 23	Homo sapiens	83-89
22770938-6	2012	However, the activity of these enzymes returned to near control values with hexokinase activity reaching 0.717 +- 0.003 mug/mg/ml on vitamin D3 supplementation.	Cholecalciferol	133-143	hexokinase 1	Homo sapiens	76-86
22572998-9	2012	Estrous cycles were restored when vitamin D(3)-deficient Cyp27b1 null young adult females were transferred to a vitamin D(3)-replete diet.	Cholecalciferol	34-46	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	57-64
21477267-4	2012	Vitamin D3 exerts its actions through the vitamin D receptor, which is known to be an important regulator of P-glycoprotein (P-gp).	Cholecalciferol	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	109-123
21477267-4	2012	Vitamin D3 exerts its actions through the vitamin D receptor, which is known to be an important regulator of P-glycoprotein (P-gp).	Cholecalciferol	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
21477267-5	2012	As P-gp plays a significant role in limiting drug bioavailability, we undertook a study to compare single-dose digoxin (a P-gp substrate) pharmacokinetics in eight healthy male subjects before and after vitamin D3 supplementation (1000 IU per day).	Cholecalciferol	203-213	ATP binding cassette subfamily B member 1	Homo sapiens	3-7
22579915-0	2012	beta2-adrenoceptor and insulin receptor expression in the skeletal muscle of streptozotocin induced diabetic rats: antagonism by vitamin D3 and curcumin.	Cholecalciferol	129-139	adrenoceptor beta 2	Rattus norvegicus	0-18
22579915-0	2012	beta2-adrenoceptor and insulin receptor expression in the skeletal muscle of streptozotocin induced diabetic rats: antagonism by vitamin D3 and curcumin.	Cholecalciferol	129-139	insulin receptor	Rattus norvegicus	23-39
22486751-2	2012	Vitamin D3 enhances LL-37 production in keratinocytes.	Cholecalciferol	0-10	cathelicidin antimicrobial peptide	Homo sapiens	20-25
22751874-5	2012	RESULTS: Mean (SD) chemokine ligand 2 (monocyte chemoattractant protein 1) levels were significantly higher (184.6 [101.1] vs 121.4 [55.8] pg/mL) at 12 months, as well as the increase in regulatory T-cell percentage (4.55% [1.5%] vs 3.34% [1.8%]) with cholecalciferol vs placebo.	Cholecalciferol	252-267	C-C motif chemokine ligand 2	Homo sapiens	39-73
22751874-8	2012	CONCLUSIONS: Cholecalciferol used as adjunctive therapy with insulin is safe and associated with a protective immunologic effect and slow decline of residual beta-cell function in patients with new-onset T1DM.	Cholecalciferol	13-28	insulin	Homo sapiens	61-68
22508710-2	2012	OBJECTIVES: The objective of the study was to determine whether vitamin D(3) supplementation at 4000 IU/d for 1 yr is safe and would result in a decrease in serum levels of prostate-specific antigen (PSA) or in the rate of progression.	Cholecalciferol	64-76	kallikrein related peptidase 3	Homo sapiens	200-203
22508713-12	2012	Cholecalciferol supplementation prevented seasonal AMH change.	Cholecalciferol	0-15	anti-Mullerian hormone	Homo sapiens	51-54
22677528-0	2012	Systematic SAR study of the side chain of nonsecosteroidal vitamin D3 analogs.	Cholecalciferol	59-69	sarcosine dehydrogenase	Homo sapiens	11-14
22539586-0	2012	Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study.	Cholecalciferol	0-10	angiotensinogen	Homo sapiens	54-68
22539586-2	2012	OBJECTIVE: The objective of the study was to evaluate whether vitamin D(3) therapy in obesity reduces tissue-RAS activity, as indicated by an increase in tissue sensitivity to angiotensin II (AngII).	Cholecalciferol	62-74	angiotensinogen	Homo sapiens	176-190
22539586-2	2012	OBJECTIVE: The objective of the study was to evaluate whether vitamin D(3) therapy in obesity reduces tissue-RAS activity, as indicated by an increase in tissue sensitivity to angiotensin II (AngII).	Cholecalciferol	62-74	angiotensinogen	Homo sapiens	192-197
22211698-0	2012	Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes.	Cholecalciferol	118-128	F2R like trypsin receptor 1	Homo sapiens	0-49
22211698-0	2012	Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes.	Cholecalciferol	118-128	C-X-C motif chemokine ligand 1	Homo sapiens	73-78
22211698-0	2012	Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes.	Cholecalciferol	118-128	C-X-C motif chemokine ligand 8	Homo sapiens	83-88
26105278-15	2012	mRNA expression analysis showed a 1.8 times higher expression of VEGF-A mRNA in ECFCs treated with 10nM vitamin D3 compared to controls (1.82+-0.43, p&lt;0.0001, n=18).	Cholecalciferol	104-114	vascular endothelial growth factor A	Homo sapiens	65-71
26105278-17	2012	This effect is mediated by an up-regulation of VEGF-mRNA in ECFCs by Vitamin D3.	Cholecalciferol	69-79	vascular endothelial growth factor A	Homo sapiens	47-51
22486751-12	2012	CONCLUSIONS: Systemic vitamin D3 levels are reduced in patients with AD, which may contribute to decreased systemic LL-37 levels.	Cholecalciferol	22-32	cathelicidin antimicrobial peptide	Homo sapiens	116-121
22387385-6	2012	Moreover, vitamin D3 significantly reduced the levels of proinflammatory cytokines (TNF-alpha, IL-6, IL-12p70 and IL-1beta) produced by infected U937 cells.	Cholecalciferol	10-20	tumor necrosis factor	Homo sapiens	84-93
25386318-3	2012	Vitamin D3 analog is also reported to suppress T-cell mediated immunity, T-cell skin recruitment, and skin infiltration via down-regulating cutaneous lymphocyte antigen expression.	Cholecalciferol	0-10	major histocompatibility complex, class II, DO alpha	Homo sapiens	150-168
22419730-4	2012	RESULTS: Only vigorous treatment with im cholecalciferol led to a significant improvement of serum calcium, a decrease in PTH levels, and histological improvement of osteomalacic bone disease.	Cholecalciferol	41-56	parathyroid hormone	Homo sapiens	122-125
26105278-6	2012	OBJECTIVES: Therefore we investigated the influence of vitamin D3 on the differentiation of endothelial progenitor cells (ECFCs) in a placental angiogenesis model and hypothesized that vitamin D3 stimulates the expression of vascular endothelial growth factor (VEGF) in ECFCs.	Cholecalciferol	55-65	vascular endothelial growth factor A	Homo sapiens	225-259
26105278-6	2012	OBJECTIVES: Therefore we investigated the influence of vitamin D3 on the differentiation of endothelial progenitor cells (ECFCs) in a placental angiogenesis model and hypothesized that vitamin D3 stimulates the expression of vascular endothelial growth factor (VEGF) in ECFCs.	Cholecalciferol	185-195	vascular endothelial growth factor A	Homo sapiens	225-259
26105278-6	2012	OBJECTIVES: Therefore we investigated the influence of vitamin D3 on the differentiation of endothelial progenitor cells (ECFCs) in a placental angiogenesis model and hypothesized that vitamin D3 stimulates the expression of vascular endothelial growth factor (VEGF) in ECFCs.	Cholecalciferol	185-195	vascular endothelial growth factor A	Homo sapiens	261-265
22387385-6	2012	Moreover, vitamin D3 significantly reduced the levels of proinflammatory cytokines (TNF-alpha, IL-6, IL-12p70 and IL-1beta) produced by infected U937 cells.	Cholecalciferol	10-20	interleukin 6	Homo sapiens	95-99
22387385-6	2012	Moreover, vitamin D3 significantly reduced the levels of proinflammatory cytokines (TNF-alpha, IL-6, IL-12p70 and IL-1beta) produced by infected U937 cells.	Cholecalciferol	10-20	interleukin 1 beta	Homo sapiens	114-122
22889840-0	2012	Cholecalciferol supplementation in chronic kidney disease: restoration of vitamin D status and impact on parathyroid hormone.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	105-124
22350110-3	2012	The aim of this prospective study was to test the effect of vitamin D (cholecalciferol) on the incidence of APR and intensity of pain in women undergoing infusion of zoledronic acid for postmenopausal osteoporosis.	Cholecalciferol	71-86	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	108-111
22492477-2	2012	Calcitriol, the biologically active form of vitamin D3, affects not only bone metabolism but also acts on the renal renin secretion, the pancreatic insulin production in the beta cells, growth and proliferation of smooth and cardiac muscle cells and the function of lymphocytes and macrophages.	Cholecalciferol	44-54	renin	Homo sapiens	116-121
22210453-0	2012	Metabolism of cholesterol, vitamin D3 and 20-hydroxyvitamin D3 incorporated into phospholipid vesicles by human CYP27A1.	Cholecalciferol	27-37	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	112-119
22210453-1	2012	CYP27A1 is a mitochondrial cytochrome P450 which can hydroxylate vitamin D3 and cholesterol at carbons 25 and 26, respectively.	Cholecalciferol	65-75	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-7
22210453-5	2012	We also examined the ability of CYP27A1 to metabolize 20-hydroxyvitamin D3 (20(OH)D3), a novel non-calcemic form of vitamin D derived from CYP11A1 action on vitamin D3 which has anti-proliferative activity on keratinocytes, leukemic and myeloid cells.	Cholecalciferol	64-74	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	32-39
22210453-5	2012	We also examined the ability of CYP27A1 to metabolize 20-hydroxyvitamin D3 (20(OH)D3), a novel non-calcemic form of vitamin D derived from CYP11A1 action on vitamin D3 which has anti-proliferative activity on keratinocytes, leukemic and myeloid cells.	Cholecalciferol	64-74	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	139-146
22210453-8	2012	20(OH)D3 was metabolized by CYP27A1 to two major products with a k(cat)/K(m) that was 2.5-fold higher than that for vitamin D3, suggesting that 20(OH)D3 could effectively compete with vitamin D3 for catalysis.	Cholecalciferol	116-126	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	28-35
22210453-8	2012	20(OH)D3 was metabolized by CYP27A1 to two major products with a k(cat)/K(m) that was 2.5-fold higher than that for vitamin D3, suggesting that 20(OH)D3 could effectively compete with vitamin D3 for catalysis.	Cholecalciferol	184-194	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	28-35
22210453-11	2012	Our study reports the highest k(cat) for the 25-hydroxylation of vitamin D3 by any human cytochrome P450 suggesting that CYP27A1 might be an important contributor to the synthesis of 25-hydroxyvitamin D3, particularly in tissues where it is highly expressed.	Cholecalciferol	65-75	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	121-128
21801466-3	2012	The present results showed that in non-invasive MCF-7 cells, ATRA, vitamin D3 and resveratrol possess high efficacy in the reduction of PTEN promoter methylation.	Cholecalciferol	67-77	phosphatase and tensin homolog	Homo sapiens	136-140
21801466-4	2012	It was associated with PTEN induction as well as DNA methyltransferase down-regulation and p21 up-regulation after treatments with vitamin D3 and resveratrol, suggesting a complex regulation of the DNA methylation machinery.	Cholecalciferol	131-141	H3 histone pseudogene 16	Homo sapiens	91-94
21801466-5	2012	Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression.	Cholecalciferol	0-10	phosphatase and tensin homolog	Homo sapiens	82-86
21801466-5	2012	Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression.	Cholecalciferol	0-10	phosphatase and tensin homolog	Homo sapiens	197-201
21801466-5	2012	Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression.	Cholecalciferol	0-10	phosphatase and tensin homolog	Homo sapiens	197-201
21801466-5	2012	Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression.	Cholecalciferol	152-162	phosphatase and tensin homolog	Homo sapiens	197-201
21801466-5	2012	Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression.	Cholecalciferol	152-162	phosphatase and tensin homolog	Homo sapiens	197-201
21801466-6	2012	In contrast, in highly invasive MDA-MB-231 cells, only vitamin D3 reduced PTEN methylation and induced its expression without notable effects in combined treatments.	Cholecalciferol	55-65	phosphatase and tensin homolog	Homo sapiens	74-78
21994003-3	2012	Our results demonstrated that vitamin D3-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE.	Cholecalciferol	30-40	G protein-coupled estrogen receptor 1	Mus musculus	156-161
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	G protein-coupled estrogen receptor 1	Mus musculus	53-56
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	interleukin 10	Mus musculus	96-101
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	interleukin 6	Mus musculus	106-110
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	myelin oligodendrocyte glycoprotein	Mus musculus	123-126
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	chemokine (C-C motif) ligand 5	Mus musculus	184-188
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	chemokine (C-C motif) receptor 1	Mus musculus	190-194
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	chemokine (C-C motif) receptor 3	Mus musculus	201-205
21994003-5	2012	These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D3-mediated protection in EAE.	Cholecalciferol	110-120	G protein-coupled estrogen receptor 1	Mus musculus	54-57
22251138-0	2012	Effects of vitamin D3 on the expression of growth-related oncogene-alpha in THP-1 cells and human primary monocytes.	Cholecalciferol	11-21	GLI family zinc finger 2	Homo sapiens	76-81
22251138-10	2012	Moreover, vitamin D3 may have potentiality in treating GRO-alpha-related chronic inflammatory diseases, like asthma and autoimmune diseases.	Cholecalciferol	10-20	C-X-C motif chemokine ligand 1	Homo sapiens	55-64
25520983-5	2012	Vitamin D3 increased the gene expressions of pro-inflammatory cytokines and peroxisome proliferator-activated receptor gamma, but decreased interleukin-15 in adipose tissue through nuclear vitamin D receptor and uncoupling protein-2 signals.	Cholecalciferol	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	76-124
25520983-5	2012	Vitamin D3 increased the gene expressions of pro-inflammatory cytokines and peroxisome proliferator-activated receptor gamma, but decreased interleukin-15 in adipose tissue through nuclear vitamin D receptor and uncoupling protein-2 signals.	Cholecalciferol	0-10	interleukin 15	Mus musculus	140-154
25520983-8	2012	Vitamin D3 amplified muscle u- and m-calpain protein content and suppressed muscle calpastatin protein content.	Cholecalciferol	0-10	calpain 2	Mus musculus	35-44
22293363-10	2012	CONCLUSIONS: Among HIV-infected individuals with vitamin D deficiency, supplementation with 4,000 IU vitamin D3 daily for 12 weeks modestly improved vitamin D status and cholesterol but worsened insulin resistance without change in endothelial function.	Cholecalciferol	101-111	insulin	Homo sapiens	195-202
22992568-8	2012	Overall, both cancerous and N-thy cell lines express CYP27A1 and CYP2R1 in addition to CYP27B1, establishing the potential to metabolize D(3) to 1,25(OH)(2)D(3).	Cholecalciferol	137-141	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	53-60
22283867-1	2012	INTRODUCTION: Therapy with vitamin D3 analogs suppress the parathyroid hormone (PTH) secretion in chronic kidney disease (CKD) patients suffering from secondary hyperparathyroidism (sHPT).	Cholecalciferol	27-37	parathyroid hormone	Homo sapiens	59-78
26069623-0	2012	Influence of Tumor Necrosis Factor alpha, Parathyroid Hormone, and Vitamin D3 on Modulation of the RANKL2 Isoform: A Pilot Study.	Cholecalciferol	67-77	TNF superfamily member 11	Homo sapiens	99-105
26069623-3	2012	Here, we investigated through a mechanistic model, human 293 cells stably transfected with the RANKL2cDNA, the production and modulation of RANKL2 protein stability upon treatment with TNF-alpha, vitamin D3, and PTH.	Cholecalciferol	196-206	TNF superfamily member 11	Homo sapiens	140-146
21966879-8	2012	Cultures treated with Dex (100 nM), Vit-D3 (10/50 nM), and BMP-2 (500 ng/mL) demonstrated maximal calcification and up-regulation of ALP and bone sialoprotein expression.	Cholecalciferol	36-42	alkaline phosphatase, placental	Homo sapiens	133-136
21930443-5	2012	Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets.	Cholecalciferol	61-71	interferon gamma	Homo sapiens	149-158
21930443-5	2012	Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets.	Cholecalciferol	61-71	tumor necrosis factor	Homo sapiens	163-172
21930443-5	2012	Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets.	Cholecalciferol	61-71	CD4 molecule	Homo sapiens	256-259
21930443-5	2012	Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets.	Cholecalciferol	61-71	CD4 molecule	Homo sapiens	261-264
22992568-8	2012	Overall, both cancerous and N-thy cell lines express CYP27A1 and CYP2R1 in addition to CYP27B1, establishing the potential to metabolize D(3) to 1,25(OH)(2)D(3).	Cholecalciferol	137-141	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	65-71
22992568-8	2012	Overall, both cancerous and N-thy cell lines express CYP27A1 and CYP2R1 in addition to CYP27B1, establishing the potential to metabolize D(3) to 1,25(OH)(2)D(3).	Cholecalciferol	137-141	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	87-94
23152895-1	2012	The vitamin D3 system imposes immunosuppressive effects on monocytic cells, in part, by inhibiting NF-kappaB-dependent expression of proinflammatory mediators.	Cholecalciferol	4-14	nuclear factor kappa B subunit 1	Homo sapiens	99-108
23152895-4	2012	We examined the influence of vitamin D3 signaling on LPS-induced expression of CD55 in human monocytic THP-1 cells using quantitative PCR, immunoblot, immunohistochemistry, and NF-kappaB activation pathway inhibitors.	Cholecalciferol	29-39	CD55 molecule (Cromer blood group)	Homo sapiens	79-83
23152895-8	2012	Our results unexpectedly suggest that vitamin D3 signaling may promote an anti-inflammatory response through an NF-kappaB-dependent increase in CD55 expression.	Cholecalciferol	38-48	nuclear factor kappa B subunit 1	Homo sapiens	112-121
23152895-8	2012	Our results unexpectedly suggest that vitamin D3 signaling may promote an anti-inflammatory response through an NF-kappaB-dependent increase in CD55 expression.	Cholecalciferol	38-48	CD55 molecule (Cromer blood group)	Homo sapiens	144-148
22095230-0	2011	High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives.	Cholecalciferol	107-117	nuclear factor kappa B subunit 1	Homo sapiens	11-20
21977923-11	2012	CONCLUSIONS: A single injection of 300,000 IU of vitamin D3 achieves a 3-month serum 25-hydroxyvitamin D range of 50-80 nmol/l and is an efficient, effective and safe procedure for improving the vitamin status and indices of insulin resistance in mothers with gestational diabetes after delivery.	Cholecalciferol	49-59	insulin	Homo sapiens	225-232
22242193-1	2012	1,25-dihydroxyvitamin D3 (1,25D3) was reported to induce premature organismal aging in fibroblast growth factor-23 (Fgf23) and klotho deficient mice, which is of main interest as 1,25D3 supplementation of its precursor cholecalciferol is used in basic osteoporosis treatment.	Cholecalciferol	219-234	fibroblast growth factor 23	Mus musculus	87-114
22095230-7	2011	Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm.	Cholecalciferol	37-47	nuclear factor kappa B subunit 1	Homo sapiens	70-79
22095230-7	2011	Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm.	Cholecalciferol	37-47	nuclear factor kappa B subunit 1	Homo sapiens	96-105
22095230-7	2011	Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm.	Cholecalciferol	37-47	RELA proto-oncogene, NF-kB subunit	Homo sapiens	187-190
22095230-7	2011	Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm.	Cholecalciferol	37-47	nuclear factor kappa B subunit 1	Homo sapiens	96-105
22095230-9	2011	CONCLUSION: Classical 1,25(OH)(2)D(3) and novel 20(OH)D(3) hydroxyderivatives of vitamin D3 can target NF-kappaB and regulate melanoma progression in nonpigmented melanoma cells.	Cholecalciferol	81-91	nuclear factor kappa B subunit 1	Homo sapiens	103-112
21843606-4	2011	Using PET analysis, reduction in [18F]2-fluoro-2-deoxy-d-glucose (FDG) uptake or tumor volume in tumors chemopreventively treated with vitamin D3 were detected in MNU-induced tumors, vitamin D3 reduced expression of 25-hydroxylase (25OHase) (p&lt;0.01) and 24-hydroxylase (24OHase) (p&lt;0.01) and Seocalcitol 24OHase.	Cholecalciferol	135-145	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	273-280
22085420-4	2011	PTH levels were restored to normal by the fourth postoperative week, allowing us to wean the patients off calcium and vitamin D3 supplementation, which was attributed to full autograft function.	Cholecalciferol	118-128	parathyroid hormone	Homo sapiens	0-3
21964212-1	2011	TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3.	Cholecalciferol	89-99	thioredoxin interacting protein	Homo sapiens	0-5
21964212-1	2011	TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3.	Cholecalciferol	89-99	thioredoxin interacting protein	Homo sapiens	21-27
21964212-1	2011	TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3.	Cholecalciferol	89-99	TATA-box binding protein like 2	Homo sapiens	31-36
21843606-4	2011	Using PET analysis, reduction in [18F]2-fluoro-2-deoxy-d-glucose (FDG) uptake or tumor volume in tumors chemopreventively treated with vitamin D3 were detected in MNU-induced tumors, vitamin D3 reduced expression of 25-hydroxylase (25OHase) (p&lt;0.01) and 24-hydroxylase (24OHase) (p&lt;0.01) and Seocalcitol 24OHase.	Cholecalciferol	135-145	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	310-317
21843606-5	2011	Positive regulation of 25OHase mRNA level after the treatment with vitamin D3 was observed in liver, while in kidney, vitamin D3 and Seocalcitol induced expression of 24OHase was significant.	Cholecalciferol	118-128	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	167-174
20462603-8	2011	RESULTS: Compared with the saline + sham group, there was a significant increase in plasma IL-6 level in both saline + I/R and vitamin D3 + I/R groups and muscle, lung wet/dry weight ratio in the saline + I/R group (P &lt; 0.05).	Cholecalciferol	127-137	interleukin 6	Rattus norvegicus	91-95
20462603-10	2011	Compared with the vitamin D3 + sham group, there was a significant increase in plasma IL-6 levels in the vitamin D3 + I/R group, and leukocyte HO-1 expression in vitamin D3 + sham group (P &lt; 0.05).	Cholecalciferol	105-115	interleukin 6	Rattus norvegicus	86-90
20462603-10	2011	Compared with the vitamin D3 + sham group, there was a significant increase in plasma IL-6 levels in the vitamin D3 + I/R group, and leukocyte HO-1 expression in vitamin D3 + sham group (P &lt; 0.05).	Cholecalciferol	105-115	interleukin 6	Rattus norvegicus	86-90
20462603-12	2011	CONCLUSIONS: Pretreatment of vitamin D3 ameliorates the systemic IL-6 levels, lung and muscle injury induced by ischemia followed by reperfusion of bilateral occluded vessels in a rat model.	Cholecalciferol	29-39	interleukin 6	Rattus norvegicus	65-69
22118750-9	2011	Human studies evaluating the relationship between vitamin D3 and apo A-I and HDLc have yielded conflicting results, but most suggest a positive link between increasing vitamin D3 levels and plasma apo A-I and HDLc.	Cholecalciferol	50-60	apolipoprotein A1	Homo sapiens	65-72
21878656-2	2011	Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo).	Cholecalciferol	64-76	patched 1	Homo sapiens	36-40
21878656-2	2011	Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo).	Cholecalciferol	64-76	patched 1	Homo sapiens	219-223
21878656-2	2011	Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo).	Cholecalciferol	64-76	smoothened, frizzled class receptor	Homo sapiens	225-235
21878656-2	2011	Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo).	Cholecalciferol	64-76	smoothened, frizzled class receptor	Homo sapiens	225-228
22118750-9	2011	Human studies evaluating the relationship between vitamin D3 and apo A-I and HDLc have yielded conflicting results, but most suggest a positive link between increasing vitamin D3 levels and plasma apo A-I and HDLc.	Cholecalciferol	168-178	apolipoprotein A1	Homo sapiens	197-204
21896008-2	2011	Vitamin D3 inhibits parathyroid hormone secretion, adaptive immunity and cell proliferation, and at the same time promotes insulin secretion, innate immunity and stimulates cellular differentiation.	Cholecalciferol	0-10	insulin	Homo sapiens	123-130
21640145-7	2011	Liposome uptake by THP-1 vitamin D3 stimulated macrophage-like cells did not show a liposome size-dependent pattern of uptake.	Cholecalciferol	25-35	GLI family zinc finger 2	Homo sapiens	19-24
21617846-6	2011	Compared with the control group, ghrelin mRNA expression was up-regulated and the myocardium calcium content was significantly increased in vitamin D3 and nicotine-treated rats.	Cholecalciferol	140-150	ghrelin and obestatin prepropeptide	Rattus norvegicus	33-40
21617846-11	2011	These results indicate that exogenous administration with ghrelin attenuates myocardial calcification induced by nicotine and vitamin D3, and that the possible mechanism is via the ghrelin-induced increase in the OPN mRNA levels and decrease in the ET-1 mRNA expression in the myocardium.	Cholecalciferol	126-136	ghrelin and obestatin prepropeptide	Rattus norvegicus	58-65
21617846-11	2011	These results indicate that exogenous administration with ghrelin attenuates myocardial calcification induced by nicotine and vitamin D3, and that the possible mechanism is via the ghrelin-induced increase in the OPN mRNA levels and decrease in the ET-1 mRNA expression in the myocardium.	Cholecalciferol	126-136	ghrelin and obestatin prepropeptide	Rattus norvegicus	181-188
21832985-0	2011	Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.	Cholecalciferol	5-20	transforming growth factor beta 1	Homo sapiens	55-64
21832985-0	2011	Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.	Cholecalciferol	5-20	renin	Homo sapiens	125-130
21832985-8	2011	Thus, in the short term, dietary vitamin D repletion with cholecalciferol had a beneficial effect in delaying the progression of diabetic nephropathy above that due to established renin-angiotensin-aldosterone system inhibition.	Cholecalciferol	58-73	renin	Homo sapiens	180-185
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	0-10	patched 1	Homo sapiens	63-71
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	0-10	GLI family zinc finger 1	Homo sapiens	73-77
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	0-10	cyclin D1	Homo sapiens	79-88
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	0-10	BCL2 apoptosis regulator	Homo sapiens	94-98
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	132-142	patched 1	Homo sapiens	63-71
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	132-142	GLI family zinc finger 1	Homo sapiens	73-77
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	132-142	cyclin D1	Homo sapiens	79-88
22025972-6	2011	Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling.	Cholecalciferol	132-142	BCL2 apoptosis regulator	Homo sapiens	94-98
21677063-0	2011	Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells.	Cholecalciferol	40-50	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	54-72
21677063-0	2011	Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells.	Cholecalciferol	40-50	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	74-81
21382175-0	2011	The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	57-60
20671418-1	2011	OBJECTIVE: The aim of the study was to evaluate whether vitamin D [25-(OH) D3] status affects serum IGFI concentrations in healthy subjects.	Cholecalciferol	75-77	insulin like growth factor 1	Homo sapiens	100-104
21382175-0	2011	The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance.	Cholecalciferol	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
21653679-3	2011	Microarray analyses of control- and vitamin D(3)-treated PrP/SCs revealed global gene expression signatures consistent with induction of differentiation.	Cholecalciferol	36-48	complement component 4 binding protein alpha	Homo sapiens	57-60
21766921-6	2011	The C-C and C-S stretching mode of 1599 cm(-1) and the C-S-C and C-C-S bending mode of 472 cm(-1) strongly couple to the b(3)u highest occupied molecular orbital (HOMO) in TTF molecule.	Cholecalciferol	65-70	ras homolog family member H	Homo sapiens	172-175
21635154-1	2011	OBJECTIVE: The objective of this study is to investigate the effect of a newly developed calcium carbonate-vitamin D3 chewable tablet formulation (600 mg of calcium + 400 IU of vitamin D3) on serum/urine calcium and serum parathyroid hormone (PTH) as measures of intestinal calcium absorption compared to a placebo.	Cholecalciferol	107-117	parathyroid hormone	Homo sapiens	222-241
21635154-1	2011	OBJECTIVE: The objective of this study is to investigate the effect of a newly developed calcium carbonate-vitamin D3 chewable tablet formulation (600 mg of calcium + 400 IU of vitamin D3) on serum/urine calcium and serum parathyroid hormone (PTH) as measures of intestinal calcium absorption compared to a placebo.	Cholecalciferol	107-117	parathyroid hormone	Homo sapiens	243-246
21455565-6	2011	In MCF-7 cells, silencing of the icb-1 gene inhibited the ATRA- and the vitamin D3-induced up-regulation of lactoferrin and estrogen receptor beta expression.	Cholecalciferol	72-82	thymocyte selection associated family member 2	Homo sapiens	33-38
21455565-6	2011	In MCF-7 cells, silencing of the icb-1 gene inhibited the ATRA- and the vitamin D3-induced up-regulation of lactoferrin and estrogen receptor beta expression.	Cholecalciferol	72-82	estrogen receptor 2	Homo sapiens	124-146
21455565-0	2011	Silencing of the icb-1 gene inhibits the induction of differentiation-associated genes by vitamin D3 and all-trans retinoic acid in gynecological cancer cells.	Cholecalciferol	90-100	thymocyte selection associated family member 2	Homo sapiens	17-22
21455565-3	2011	Knockdown of icb-1 inhibited the vitamin D3-induced up-regulation of E-cadherin expression in both MCF-7 and HEC-1B cells.	Cholecalciferol	33-43	thymocyte selection associated family member 2	Homo sapiens	13-18
21455565-7	2011	The data of our knockdown study suggest that icb-1 may act as a mediator of differentiation signals in breast cancer cells induced by ATRA or vitamin D3.	Cholecalciferol	142-152	thymocyte selection associated family member 2	Homo sapiens	45-50
21455565-3	2011	Knockdown of icb-1 inhibited the vitamin D3-induced up-regulation of E-cadherin expression in both MCF-7 and HEC-1B cells.	Cholecalciferol	33-43	cadherin 1	Homo sapiens	69-79
21498585-4	2011	Stimulating the expression of mCD14 with vitamin D3 enhanced the response to ExoS and LPS.	Cholecalciferol	41-51	CD14 antigen	Mus musculus	30-35
21458526-0	2011	A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation.	Cholecalciferol	121-131	insulin like growth factor binding protein 6	Homo sapiens	28-72
21397016-0	2011	A human vitamin D receptor mutant activated by cholecalciferol.	Cholecalciferol	47-62	vitamin D receptor	Homo sapiens	8-26
21397016-6	2011	Furthermore, via random mutagenesis, a hVDR mutant, H305F/H397Y, was discovered to bind a novel small molecule, cholecalciferol, a precursor in the 1alpha,25-dihydroxyvitamin D(3) biosynthetic pathway, which does not activate wild-type hVDR.	Cholecalciferol	112-127	vitamin D receptor	Homo sapiens	39-43
21397016-6	2011	Furthermore, via random mutagenesis, a hVDR mutant, H305F/H397Y, was discovered to bind a novel small molecule, cholecalciferol, a precursor in the 1alpha,25-dihydroxyvitamin D(3) biosynthetic pathway, which does not activate wild-type hVDR.	Cholecalciferol	112-127	vitamin D receptor	Homo sapiens	236-240
21397016-8	2011	In silico docking analysis of the variant displays a dramatic conformational shift of cholecalciferol in the ligand binding pocket in comparison to the docked analysis of cholecalciferol with wild-type hVDR.	Cholecalciferol	86-101	vitamin D receptor	Homo sapiens	202-206
21397016-8	2011	In silico docking analysis of the variant displays a dramatic conformational shift of cholecalciferol in the ligand binding pocket in comparison to the docked analysis of cholecalciferol with wild-type hVDR.	Cholecalciferol	171-186	vitamin D receptor	Homo sapiens	202-206
21696575-0	2011	Efficacy of vitamin D3-fortified-yogurt drink on anthropometric, metabolic, inflammatory and oxidative stress biomarkers according to vitamin D receptor gene polymorphisms in type 2 diabetic patients: a study protocol for a randomized controlled clinical trial.	Cholecalciferol	12-22	vitamin D receptor	Homo sapiens	134-152
21459125-0	2011	PKC and PTPalpha participate in Src activation by 1alpha,25OH2 vitamin D3 in C2C12 skeletal muscle cells.	Cholecalciferol	63-73	protein phosphatase 2 protein activator	Mus musculus	8-16
21459125-0	2011	PKC and PTPalpha participate in Src activation by 1alpha,25OH2 vitamin D3 in C2C12 skeletal muscle cells.	Cholecalciferol	63-73	Rous sarcoma oncogene	Mus musculus	32-35
21539305-0	2011	New C15-substituted active vitamin D3.	Cholecalciferol	27-37	placenta associated 8	Homo sapiens	4-7
21458526-0	2011	A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation.	Cholecalciferol	121-131	vitamin D receptor	Homo sapiens	81-99
21458410-4	2011	NCX activity was decreased by -D diet, returning to normal values after 50 IU daily of cholecalciferol/10 days or a dose of 1mug calcitriol/kg of b.w.	Cholecalciferol	87-102	T cell leukemia homeobox 2	Homo sapiens	0-3
21280209-6	2011	Moreover Block Lipid Transport-1 (SR-BI inhibitor) and ezetimibe glucuronide (Niemann-Pick C1 Like 1 inhibitor) significantly decreased cholecalciferol transport.	Cholecalciferol	136-151	scavenger receptor class B, member 1	Mus musculus	34-39
20655720-0	2011	Vitamin D3 restores altered cholinergic and insulin receptor expression in the cerebral cortex and muscarinic M3 receptor expression in pancreatic islets of streptozotocin induced diabetic rats.	Cholecalciferol	0-10	insulin receptor	Rattus norvegicus	44-60
21436386-4	2011	We find that indeed in BCC cells, vitamin D3 blocks both proliferation and HH signaling as assessed by mRNA expression of the HH target gene Gli1.	Cholecalciferol	34-44	GLI-Kruppel family member GLI1	Mus musculus	141-145
21436386-5	2011	These effects of vitamin D3 on Gli1 expression and on BCC cell proliferation are comparable to the effects of cyclopamine, a known inhibitor of the HH pathway.	Cholecalciferol	17-27	GLI-Kruppel family member GLI1	Mus musculus	31-35
21436386-6	2011	These results are specific for vitamin D3, because the precursor 7-dehydrocholesterol and the downstream products 25-hydroxy vitamin D3 [25(OH)D] and 1,25-dihydroxy vitamin D3 [1,25(OH)(2)D] are considerably less effective in reducing either Gli1 mRNA or cellular proliferation.	Cholecalciferol	31-41	GLI-Kruppel family member GLI1	Mus musculus	242-246
21436386-8	2011	Finally, topical vitamin D3 treatment of existing murine BCC tumors significantly decreases Gli1 and Ki67 staining.	Cholecalciferol	17-27	GLI-Kruppel family member GLI1	Mus musculus	92-96
21436386-8	2011	Finally, topical vitamin D3 treatment of existing murine BCC tumors significantly decreases Gli1 and Ki67 staining.	Cholecalciferol	17-27	antigen identified by monoclonal antibody Ki 67	Mus musculus	101-105
21722813-9	2011	However, hBD-2 concentrations were below the limit of detection in NL fluids at baseline and after the administration of cholecalciferol or the sham-challenge.	Cholecalciferol	121-136	defensin beta 4A	Homo sapiens	9-14
21300513-1	2011	A reliable, accurate and reproducible method to quantify vitamin D3 (Vit.	Cholecalciferol	57-67	vitrin	Homo sapiens	69-72
21483824-1	2011	BACKGROUND: The 1alpha,25-dihydroxy-3-epi-vitamin-D3 (1alpha,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator.	Cholecalciferol	121-131	vitamin D receptor	Homo sapiens	195-221
21483824-1	2011	BACKGROUND: The 1alpha,25-dihydroxy-3-epi-vitamin-D3 (1alpha,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator.	Cholecalciferol	121-131	vitamin D receptor	Homo sapiens	223-226
21091766-0	2011	Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells.	Cholecalciferol	14-24	AKT serine/threonine kinase 1	Homo sapiens	55-58
21280209-9	2011	In vivo, cholecalciferol uptake in proximal intestinal fragments was 60% higher in mice overexpressing SR-BI than in wild-type mice (p&lt;0.05), while ezetimibe effect remained non-significant.	Cholecalciferol	9-24	scavenger receptor class B, member 1	Mus musculus	103-108
21091766-0	2011	Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells.	Cholecalciferol	14-24	MDM2 proto-oncogene	Homo sapiens	63-67
21091766-0	2011	Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells.	Cholecalciferol	14-24	transforming growth factor beta 1	Homo sapiens	79-88
21352586-0	2011	Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation.	Cholecalciferol	47-57	interleukin 6	Mus musculus	84-88
21352586-4	2011	We examined the effects of vitamin D3 and vitamin E supplementation on levels of IL-6 and IL-10 (as a marker of anti-inflammatory cytokines since, a balance between pro- and anti-inflammatory cytokines is maintained) protein expression in adipose tissue of mice provided with an HFD.	Cholecalciferol	27-37	interleukin 6	Mus musculus	81-85
21352586-4	2011	We examined the effects of vitamin D3 and vitamin E supplementation on levels of IL-6 and IL-10 (as a marker of anti-inflammatory cytokines since, a balance between pro- and anti-inflammatory cytokines is maintained) protein expression in adipose tissue of mice provided with an HFD.	Cholecalciferol	27-37	interleukin 10	Mus musculus	90-95
21352586-5	2011	Additionally, we measured the effects of vitamin E and vitamin D3 treatment on LPS-stimulated 3T3-L1 adipocytes IL-6 and IL-10 secretion.	Cholecalciferol	55-65	interleukin 6	Mus musculus	112-116
21352586-5	2011	Additionally, we measured the effects of vitamin E and vitamin D3 treatment on LPS-stimulated 3T3-L1 adipocytes IL-6 and IL-10 secretion.	Cholecalciferol	55-65	interleukin 10	Mus musculus	121-126
21352586-7	2011	A 24-hour treatment of vitamin D3 and vitamin E significantly reduced the IL-6 levels in the adipocytes culture medium without affecting IL-10 levels.	Cholecalciferol	23-33	interleukin 6	Mus musculus	74-78
21352586-8	2011	CONCLUSIONS: Vitamin D3 and vitamin E supplementation in an HFD had an anti-inflammatory effect by decreasing IL-6 production in epididymal adipose tissue in mice and in 3T3-L1 adipocytes stimulated with LPS.	Cholecalciferol	13-23	interleukin 6	Mus musculus	110-114
21167785-0	2011	1alpha,25-dihydroxyvitamin D3 (vitamin D3) catalyzes suppressive activity on human natural regulatory T cells, uniquely modulates cell cycle progression, and augments FOXP3.	Cholecalciferol	19-29	forkhead box P3	Homo sapiens	167-172
21134350-1	2011	CYP27A1, an enzyme with several important roles in cholesterol homeostasis and vitamin D3 metabolism, has been ascribed anti-atherogenic properties.	Cholecalciferol	79-89	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-7
21347289-0	2011	TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth.	Cholecalciferol	31-41	transient receptor potential cation channel subfamily V member 6	Homo sapiens	0-5
21115105-0	2011	Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia?	Cholecalciferol	73-83	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	64-69
21115105-2	2011	In the current paper we propose a possible mechanism of VPA-induced osteomalacia involving accelerated catabolism of 1alpha,25(OH)(2)-vitamin D3 (VD3) due to increased expression of CYP24.	Cholecalciferol	134-144	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	182-187
21167785-7	2011	The enhanced suppressive capacity is likely due to vitamin D3"s ability to uniquely modulate cell cycle progression and elevate FOXP3 expression.	Cholecalciferol	51-61	forkhead box P3	Homo sapiens	128-133
20490785-7	2011	Serum 1,25 (OH)(2) vitamin D3 was associated with higher urinary excretion of calcium and phosphorus in ASF patients.	Cholecalciferol	19-29	arylsulfatase F	Homo sapiens	104-107
20490785-5	2011	Serum 1,25 (OH)(2) vitamin D3 levels in the ASF and control groups were 127 +- 40 and 93 +- 35 pmol/l (p &lt; 0.001).	Cholecalciferol	19-29	arylsulfatase F	Homo sapiens	44-47
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	128-138
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	146-165
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	167-170
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	nuclear receptor subfamily 1 group I member 3	Homo sapiens	173-205
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	nuclear receptor subfamily 1 group I member 3	Homo sapiens	207-210
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	155-165
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	nuclear receptor subfamily 1 group H member 4	Homo sapiens	235-238
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	vitamin D receptor	Homo sapiens	244-262
21395540-3	2011	These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR).	Cholecalciferol	43-53	vitamin D receptor	Homo sapiens	264-267
21041166-3	2011	RESULTS: A 48-year-old woman with a history of postsurgical hypoparathyroidism who was taking calcium carbonate, 1500 mg 3 times daily, and cholecalciferol, 1200 IU daily, presented with a generalized seizure in the setting of hypocalcemia 12 days after initiating therapy with the proton pump inhibitor lansoprazole.	Cholecalciferol	140-155	ATPase H+/K+ transporting non-gastric alpha2 subunit	Homo sapiens	282-293
21084270-7	2011	In the vitamin D3-supplemented group, CaR expression increased 39% (P=0.01) and CYP27B1 expression increased 159% (P=0.06).	Cholecalciferol	7-17	calcium sensing receptor	Homo sapiens	38-41
21084270-7	2011	In the vitamin D3-supplemented group, CaR expression increased 39% (P=0.01) and CYP27B1 expression increased 159% (P=0.06).	Cholecalciferol	7-17	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	80-87
21084270-8	2011	In patients supplemented with both calcium and vitamin D3, VDR expression increased 19% (P=0.13) and CaR expression increased 24% (P=0.05).	Cholecalciferol	47-57	vitamin D receptor	Homo sapiens	59-62
21084270-8	2011	In patients supplemented with both calcium and vitamin D3, VDR expression increased 19% (P=0.13) and CaR expression increased 24% (P=0.05).	Cholecalciferol	47-57	calcium sensing receptor	Homo sapiens	101-104
21307571-5	2011	We have identified the 1alpha(OH)ase gene, which uses a novel expression cloning method derived from VDR deficient mice that have excess amounts of active vitamin D3 in the serum.	Cholecalciferol	155-165	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	23-36
21307571-5	2011	We have identified the 1alpha(OH)ase gene, which uses a novel expression cloning method derived from VDR deficient mice that have excess amounts of active vitamin D3 in the serum.	Cholecalciferol	155-165	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	101-104
21307571-6	2011	Identification of 1alpha(OH)ase gene had lead us to understand not only the biological significance of active vitamin D3 synthesis, but also a novel mechanism of VDR-mediated transcriptional regulation.	Cholecalciferol	110-120	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	18-31
21307571-7	2011	The gene expression of 1alpha(OH)ase is positively and negatively regulated by parathyroid hormone (PTH) and active vitamin D3 respectively.	Cholecalciferol	116-126	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	23-36
21422528-6	2011	The results obtained indicate that a vitamin D3-enriched diet correlates with a decrease in the number of amyloid plaques, a decrease in Abeta peptides, a decrease in inflammation, and an increase in NGF in the brains of AbetaPP mice.	Cholecalciferol	37-47	nerve growth factor	Mus musculus	200-203
21253537-12	2011	Normal PTH levels were more frequently found in case of calcium and vitamin D3 use (RR 14.3, CI 3.6-56.5, P &lt; .001).	Cholecalciferol	68-78	parathyroid hormone	Homo sapiens	7-10
21253537-14	2011	This study demonstrates interrelationships between semi-quantified fecal scores, PTH levels, and the compliance of taking calcium/vitamin D3 suppletion.	Cholecalciferol	130-140	parathyroid hormone	Homo sapiens	81-84
22180837-1	2011	Derivatives of vitamin D(3) containing a second side-chain emanating at C-20 are known as gemini and act as vitamin D receptor agonists.	Cholecalciferol	15-27	vitamin D receptor	Homo sapiens	108-126
20714323-3	2011	In this study, we show that 1,25 vitamin D3 and its analogues EB1089 and KH1060 potently inhibit CEACAM1 expression in cancer cells.	Cholecalciferol	33-43	CEA cell adhesion molecule 1	Homo sapiens	97-104
21041072-0	2011	Expression and vitamin D3 regulation of long-chain fatty-acid-CoA ligase 3 in human prostate cancer cells.	Cholecalciferol	15-25	acyl-CoA synthetase long chain family member 3	Homo sapiens	40-74
20872152-10	2010	High-dose cholecalciferol is safe and effective in correcting vitamin D insufficiency and results in a significant reduction in PTH levels in vitamin D-insufficient children.	Cholecalciferol	10-25	parathyroid hormone	Homo sapiens	128-131
20654640-2	2010	The aim of this study was to determine whether mitogen-activated protein kinase (MAPK) pathways are associated with 1,25-D(3)-induced cell death in breast cancer.	Cholecalciferol	121-125	mitogen-activated protein kinase 3	Homo sapiens	81-85
21050239-0	2010	Vitamin D3 treatment of Crohn"s disease patients increases stimulated T cell IL-6 production and proliferation.	Cholecalciferol	0-10	interleukin 6	Homo sapiens	77-81
21050239-1	2010	BACKGROUND: Vitamin D3 has shown immune-modulating effects in CD4+ T cells from Crohn"s disease patients in vitro.	Cholecalciferol	12-22	CD4 molecule	Homo sapiens	62-65
21050239-6	2010	Vitamin D3 treatment increased interleukin-6 production (delta = 188 pg/mL, range: -444 to 4071) compared with a decrease in the placebo group (delta = -896 pg/mL, range: -3841 to 1323) (P &lt; 0.02, Wilcoxon rank sum test).	Cholecalciferol	0-10	interleukin 6	Homo sapiens	31-44
21050239-7	2010	Interestingly, vitamin D3 increased the amount of proliferating stimulated CD4+ T cells from median 41% (range: 10-75%) to 56% (range: 26-77%) (P = 0.02, Wilcoxon rank sum test).	Cholecalciferol	15-25	CD4 molecule	Homo sapiens	75-78
21050239-8	2010	CONCLUSIONS: Vitamin D3 treatment of Crohn"s disease patients increased the IL-6 levels.	Cholecalciferol	13-23	interleukin 6	Homo sapiens	76-80
21050239-9	2010	Interestingly, vitamin D3 treatment enhanced the CD4+ T cell proliferation.	Cholecalciferol	15-25	CD4 molecule	Homo sapiens	49-52
20971925-4	2010	Treatment with a Cox-2 selective inhibitor (SC-58125) or Cox-2 small interfering RNA attenuated hBD2 and hBD3 production in NHEKs when stimulated with macrophage-activating lipopeptide-2, polyinosinic-polycytidylic acid, or UVB (15 mJ/cm(2)), but it did not attenuate vitamin D3-induced cathelicidin.	Cholecalciferol	268-278	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
21067953-3	2010	Immune cells that produce calcitriol also express the vitamin D receptor (VDR) and the enzymes needed to metabolize vitamin D3 (1alpha-, 25-, and 24-hydroxylases).	Cholecalciferol	116-126	vitamin D receptor	Homo sapiens	54-72
21067953-3	2010	Immune cells that produce calcitriol also express the vitamin D receptor (VDR) and the enzymes needed to metabolize vitamin D3 (1alpha-, 25-, and 24-hydroxylases).	Cholecalciferol	116-126	vitamin D receptor	Homo sapiens	74-77
20667458-2	2010	The dopamine receptor DRD3 gene is a strong candidate in genetic studies of SCZ because of the dopamine hypothesis of SCZ and the selective expression of D(3) in areas of the limbic system implicated in the disease.	Cholecalciferol	154-158	dopamine receptor D3	Homo sapiens	22-26
20560977-1	2010	In human monocytes, Toll-like receptor (TLR) 2/1 activation leads to vitamin D3-dependent antimycobacterial activities, but the molecular mechanisms by which TLR2/1 stimulation induces antimicrobial activities against mycobacteria remain unclear.	Cholecalciferol	69-79	toll like receptor 1	Homo sapiens	40-43
20560977-1	2010	In human monocytes, Toll-like receptor (TLR) 2/1 activation leads to vitamin D3-dependent antimycobacterial activities, but the molecular mechanisms by which TLR2/1 stimulation induces antimicrobial activities against mycobacteria remain unclear.	Cholecalciferol	69-79	toll like receptor 2	Homo sapiens	158-164
20660032-12	2010	CONCLUSIONS: A single oral dose of 600,000 IU of cholecalciferol rapidly enhances 25(OH)D and reduces PTH in young people with vitamin D deficiency.	Cholecalciferol	49-64	parathyroid hormone	Homo sapiens	102-105
21105150-0	2010	A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D3.	Cholecalciferol	143-153	bone gamma-carboxyglutamate protein	Homo sapiens	59-70
20642435-1	2010	Vitamin-D-receptor (VDR) mediates immunomodulatory effects of vitamin-D3 (VD3).	Cholecalciferol	62-72	vitamin D receptor	Homo sapiens	0-18
20149622-7	2010	Data showed that either vitamin D (cholecalciferol or calcitriol) or a low Ca(2+) diet increases mMDH activity.	Cholecalciferol	35-50	malate dehydrogenase 2, NAD (mitochondrial)	Mus musculus	97-101
20642435-1	2010	Vitamin-D-receptor (VDR) mediates immunomodulatory effects of vitamin-D3 (VD3).	Cholecalciferol	62-72	vitamin D receptor	Homo sapiens	20-23
20664979-4	2010	The NDRG1/Cap43 expression in MG63 and U2OS was significantly enhanced by vitamin D3, which also induced the production of osteocalcin, a differentiation marker of osteoblasts.	Cholecalciferol	74-84	N-myc downstream regulated 1	Homo sapiens	4-9
20664979-4	2010	The NDRG1/Cap43 expression in MG63 and U2OS was significantly enhanced by vitamin D3, which also induced the production of osteocalcin, a differentiation marker of osteoblasts.	Cholecalciferol	74-84	N-myc downstream regulated 1	Homo sapiens	10-15
20664979-4	2010	The NDRG1/Cap43 expression in MG63 and U2OS was significantly enhanced by vitamin D3, which also induced the production of osteocalcin, a differentiation marker of osteoblasts.	Cholecalciferol	74-84	bone gamma-carboxyglutamate protein	Homo sapiens	123-134
20635334-3	2010	Patched 1 regulates the activity of Smoothened (1) via Vitamin D3, which inhibits Smoothened in the absence of hedgehog ligand or (2) via oxysterols, which activate Smoothened in the presence of hedgehog ligand.	Cholecalciferol	55-65	smoothened	Drosophila melanogaster	36-46
20557314-3	2010	Vitamin D3 contributes to host immune responses against Mycobacterium tuberculosis through LL-37/hCAP-18, which is the only cathelicidin identified to date in humans.	Cholecalciferol	0-10	cathelicidin antimicrobial peptide	Homo sapiens	97-104
20635334-3	2010	Patched 1 regulates the activity of Smoothened (1) via Vitamin D3, which inhibits Smoothened in the absence of hedgehog ligand or (2) via oxysterols, which activate Smoothened in the presence of hedgehog ligand.	Cholecalciferol	55-65	smoothened	Drosophila melanogaster	82-92
20635334-3	2010	Patched 1 regulates the activity of Smoothened (1) via Vitamin D3, which inhibits Smoothened in the absence of hedgehog ligand or (2) via oxysterols, which activate Smoothened in the presence of hedgehog ligand.	Cholecalciferol	55-65	smoothened	Drosophila melanogaster	82-92
20398751-1	2010	25-hydroxyvitamin D3 24-hydroxylase (CYP24A1), the catabolizing enzyme of the active vitamin D3, is often overexpressed in solid tumors.	Cholecalciferol	10-20	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	37-44
20722932-0	2010	Effects of vitamin D3 on expression of tumor necrosis factor-alpha and chemokines by monocytes.	Cholecalciferol	11-21	tumor necrosis factor	Homo sapiens	39-66
20495364-4	2010	Vitamin D3 was found to inhibit cell growth specifically through inactivation of Smo and the downstream Hh pathway, rather than activation of the vitamin D3 receptor.	Cholecalciferol	0-10	smoothened, frizzled class receptor	Mus musculus	81-84
20171278-7	2010	Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription.	Cholecalciferol	306-316	vitamin D receptor	Homo sapiens	52-55
20171278-7	2010	Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription.	Cholecalciferol	306-316	retinoid X receptor alpha	Homo sapiens	56-59
20171278-7	2010	Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription.	Cholecalciferol	306-316	vitamin D receptor	Homo sapiens	97-100
20171278-7	2010	Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription.	Cholecalciferol	306-316	retinoid X receptor alpha	Homo sapiens	101-104
20171278-7	2010	Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription.	Cholecalciferol	306-316	vitamin D receptor	Homo sapiens	97-100
20574005-3	2010	We studied the role of TNF in the induction of Ag-specific regulatory T cells (Tregs) by tolerogenic vitamin D3-modulated human dendritic cells (VD3-DCs), which previously were shown to release high amounts of soluble TNF (sTNF) upon maturation with LPS.	Cholecalciferol	101-111	tumor necrosis factor	Homo sapiens	23-26
20574005-3	2010	We studied the role of TNF in the induction of Ag-specific regulatory T cells (Tregs) by tolerogenic vitamin D3-modulated human dendritic cells (VD3-DCs), which previously were shown to release high amounts of soluble TNF (sTNF) upon maturation with LPS.	Cholecalciferol	101-111	tumor necrosis factor	Homo sapiens	218-221
20040518-2	2010	Ectopic expression of BRAP2 in transfected African green monkey kidney COS-7 cells was found to significantly reduce nuclear localization signal (NLS)-dependent nuclear accumulation of either simian virus SV40 large-tumor antigen (T-ag) or human cytomegalovirus DNA polymerase processivity factor ppUL44; this was also observed in HL-60 human promyelocytic leukemia cells on induction of BRAP2 expression by vitamin D3 treatment.	Cholecalciferol	408-418	BRCA1 associated protein	Homo sapiens	22-27
19603526-2	2010	In fact, vitamin D3 regulates vitamin D receptor and nerve growth factor expression, modulates brain development, and reverses experimental autoimmune encephalomyelitis.	Cholecalciferol	9-19	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	30-48
19603526-6	2010	We found that the translocation of vitamin D3 from cytoplasm to the nucleus is transient, as the maximal nuclear concentration is reached after 10 h of incubation with (3)H-vitamin D3 and decreases to control values by 12 h. The appearance of differentiation markers such as Bcl2, NGF, STAT3, and the decrease of proliferation markers such as cyclin-1 and PCNA are late events.	Cholecalciferol	35-45	B cell leukemia/lymphoma 2	Mus musculus	275-279
19603526-6	2010	We found that the translocation of vitamin D3 from cytoplasm to the nucleus is transient, as the maximal nuclear concentration is reached after 10 h of incubation with (3)H-vitamin D3 and decreases to control values by 12 h. The appearance of differentiation markers such as Bcl2, NGF, STAT3, and the decrease of proliferation markers such as cyclin-1 and PCNA are late events.	Cholecalciferol	35-45	signal transducer and activator of transcription 3	Mus musculus	286-291
19603526-6	2010	We found that the translocation of vitamin D3 from cytoplasm to the nucleus is transient, as the maximal nuclear concentration is reached after 10 h of incubation with (3)H-vitamin D3 and decreases to control values by 12 h. The appearance of differentiation markers such as Bcl2, NGF, STAT3, and the decrease of proliferation markers such as cyclin-1 and PCNA are late events.	Cholecalciferol	35-45	proliferating cell nuclear antigen	Mus musculus	356-360
20096724-9	2010	Our study showed Vitamin D3 functional regulation through dopaminergic, cholinergic and insulin receptors and glucose transport mechanism through GLUT3 in the cerebellum of diabetic rats which play a major role in neuroprotection in diabetes which has clinical application.	Cholecalciferol	17-27	solute carrier family 2 member 3	Rattus norvegicus	146-151
20435648-0	2010	Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes.	Cholecalciferol	0-10	toll like receptor 9	Homo sapiens	40-60
20435648-0	2010	Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes.	Cholecalciferol	0-10	toll like receptor 9	Homo sapiens	76-96
20435648-0	2010	Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes.	Cholecalciferol	0-10	interleukin 6	Homo sapiens	105-109
20193763-1	2010	CYP27B1 catalyzes the 1alpha-hydroxylation of 25-hydroxyvitamin D3 to 1alpha,25-dihydroxyvitamin D3, the hormonally active form of vitamin D3.	Cholecalciferol	56-66	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	0-7
20096724-1	2010	The study was to find out the effect of Vitamin D3 supplementation on preventing the altered gene expression of cholinergic, dopaminergic, insulin receptors and GLUT3 gene expression in cerebellum of diabetic rats.	Cholecalciferol	40-50	solute carrier family 2 member 3	Rattus norvegicus	161-166
20360850-0	2010	Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity.	Cholecalciferol	12-22	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	61-79
19878298-9	2010	We have shown that exposure to UVB, sufficient to produce vitamin D(3), upregulates hCAP18 in human skin in vivo.	Cholecalciferol	58-70	cathelicidin antimicrobial peptide	Homo sapiens	84-90
19878298-12	2010	Our results further support the role of vitamin D(3) as a key physiologic regulator of hCAP18/LL-37 in human skin.	Cholecalciferol	40-52	cathelicidin antimicrobial peptide	Homo sapiens	87-93
19878298-12	2010	Our results further support the role of vitamin D(3) as a key physiologic regulator of hCAP18/LL-37 in human skin.	Cholecalciferol	40-52	cathelicidin antimicrobial peptide	Homo sapiens	94-99
20360850-1	2010	BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1alpha,20-dihydroxyvitamin D3 (1,20(OH)(2)D3).	Cholecalciferol	51-53	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	12-30
20360850-1	2010	BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1alpha,20-dihydroxyvitamin D3 (1,20(OH)(2)D3).	Cholecalciferol	43-53	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	12-30
20684247-2	2010	Activity of vitamin D3 25-hydroxylase enzymes of hepatocytes is regulated by cholecalciferol and alpha-tocopherol.	Cholecalciferol	77-92	cytochrome P450, family 27, subfamily a, polypeptide 1	Rattus norvegicus	12-37
20227041-0	2010	Modulation of the vitamin D3 response by cancer-associated mutant p53.	Cholecalciferol	18-28	tumor protein p53	Homo sapiens	66-69
20089776-6	2010	Endpoint serum PTH was lower (P &lt; 0.05) in the 3 cholecalciferol-supplemented groups compared with that in the placebo group in &gt; or = 64-y olds, but cholecalciferol supplementation did not affect other markers in either cohort and there was no significant interaction with VDR genotype.	Cholecalciferol	52-67	vitamin D receptor	Homo sapiens	280-283
19885846-5	2010	Here, we demonstrate that in osteoblastic cells, the VDR binds to the nuclear matrix in a vitamin D(3)-dependent manner.	Cholecalciferol	90-102	vitamin D receptor	Homo sapiens	53-56
20056760-0	2010	A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.	Cholecalciferol	22-37	parathyroid hormone	Homo sapiens	74-93
20007751-3	2010	Cholecalciferol therapy increased serum 25(OH)D levels four-fold, monocyte vitamin D receptor expression three-fold, and 24-hydroxylase expression; therapy decreased monocyte 1alpha-hydroxylase levels.	Cholecalciferol	0-15	vitamin D receptor	Homo sapiens	75-93
20007751-4	2010	The CD16(+) "inflammatory" monocyte subset responded to 25(OH)D repletion the most, demonstrating the greatest increase in vitamin D receptor expression after cholecalciferol.	Cholecalciferol	159-174	Fc gamma receptor IIIa	Homo sapiens	4-8
20007751-5	2010	Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF.	Cholecalciferol	0-15	C-X-C motif chemokine ligand 8	Homo sapiens	88-92
20007751-5	2010	Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF.	Cholecalciferol	0-15	interleukin 6	Homo sapiens	94-98
19809375-3	2010	Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism.	Cholecalciferol	61-71	thioredoxin interacting protein	Mus musculus	0-29
19809375-3	2010	Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism.	Cholecalciferol	61-71	thioredoxin interacting protein	Mus musculus	31-36
19809375-3	2010	Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism.	Cholecalciferol	61-71	thioredoxin interacting protein	Mus musculus	94-99
19809375-3	2010	Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism.	Cholecalciferol	61-71	thioredoxin interacting protein	Mus musculus	138-143
19766150-3	2010	In this study, we investigated in rats whether CST inhibits vascular calcification induced by vitamin D3 and nicotine treatment in vivo and calcification of cultured rat vascular smooth muscular cells (VSMCs) induced by beta-glycerophosphate in vitro and the underlying mechanism.	Cholecalciferol	94-104	cortistatin	Rattus norvegicus	47-50
20510731-5	2010	Type-1 T regulatory (Tr1) cells, CD46-stimulated IL-10-secreting T cells, and IL-10-secreting T cells induced by vitamin D3 (VitD3) and dexamethasone (Dex) are induced populations with significant regulatory activities.	Cholecalciferol	113-123	interleukin 10	Homo sapiens	78-83
19415373-10	2010	To address the question whether a normalization of calcium homeostasis improves BMD in NF1 patients, we treated four patients with cholecalciferol for 1 year, which resulted in a significant increase of BMD.	Cholecalciferol	131-146	neurofibromin 1	Homo sapiens	87-90
19666701-0	2009	Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter.	Cholecalciferol	0-10	solute carrier family 46 member 1	Homo sapiens	86-119
19647104-8	2009	RESULTS: After one year, VDR gene polymorphisms using Bsm1 and TaqI restriction enzymes were associated with percent changes in bone area, BMC and BMD at multiple skeletal sites in the Vitamin D3 group but not in the placebo group.	Cholecalciferol	185-195	vitamin D receptor	Homo sapiens	25-28
20097959-0	2009	Vitamin D3 affects expression of thyroid hormone receptor alpha and deiodinase activity in liver of MNU-treated Sprague-Dawley rats.	Cholecalciferol	0-10	thyroid hormone receptor alpha	Rattus norvegicus	33-63
19721012-10	2009	Moreover, ectopic GATA-1 expression stabilizes the moDC phenotype under monocyte-promoting conditions in the presence of vitamin D3 (VD3).	Cholecalciferol	121-131	GATA binding protein 1	Homo sapiens	18-24
19733911-3	2009	The secondary bile acid lithocholic acid (LCA) is a ligand of the vitamin D receptor (VDR) and can carry out in vivo functions of vitamin D3.	Cholecalciferol	130-140	vitamin D receptor	Homo sapiens	66-84
19660988-1	2009	Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3.	Cholecalciferol	122-132	nuclear receptor subfamily 4 group A member 3	Homo sapiens	17-22
19660988-1	2009	Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3.	Cholecalciferol	122-132	vitamin D receptor	Homo sapiens	59-77
19660988-1	2009	Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3.	Cholecalciferol	122-132	vitamin D receptor	Homo sapiens	79-82
19667150-2	2009	From research on the synthesis of 1,25(OH)2D3 analogs with the goal of separating these biological activities, we have already reported two characteristic analogs of active vitamin D3, namely 1alpha,25-dihydroxy-22-oxavitamin D3 (OCT) and 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71).	Cholecalciferol	173-183	plexin A2	Homo sapiens	230-233
19538496-9	2009	Existing therapies including corticosteroids and allergen immunotherapy act on Tregs, in part to increase IL-10 production, while vitamin D3 and long-acting beta-agonists enhance IL-10 Treg function.	Cholecalciferol	130-140	interleukin 10	Homo sapiens	179-184
19733911-3	2009	The secondary bile acid lithocholic acid (LCA) is a ligand of the vitamin D receptor (VDR) and can carry out in vivo functions of vitamin D3.	Cholecalciferol	130-140	vitamin D receptor	Homo sapiens	86-89
19382910-0	2009	Vitamin D3 signalling in the brain enhances the function of phosphoprotein enriched in astrocytes--15 kD (PEA-15).	Cholecalciferol	0-10	proliferation and apoptosis adaptor protein 15	Homo sapiens	106-112
19282837-5	2009	Bcl-3 silencing enhanced vitamin D3 (1,25D3)-induced gene expression of cathelicidin AMP in keratinocytes, suggesting a negative regulatory function on cathelicidin transcription.	Cholecalciferol	25-35	BCL3 transcription coactivator	Homo sapiens	0-5
19390510-7	2009	The stimulatory effect of D(3) on ETB receptor mRNA and protein expression was also blocked by nicardipine.	Cholecalciferol	26-30	endothelin receptor type B	Rattus norvegicus	34-37
19701245-0	2009	Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3.	Cholecalciferol	114-124	interleukin 1 beta	Homo sapiens	19-27
19701245-6	2009	Vitamin D3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells.	Cholecalciferol	0-10	signal transducer and activator of transcription 1	Homo sapiens	118-123
19701245-6	2009	Vitamin D3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells.	Cholecalciferol	0-10	interleukin 1 beta	Homo sapiens	146-154
19701245-6	2009	Vitamin D3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	190-208
20387647-7	2009	The mechanism of vitaminE participation in the vitamin D3 metabolism under D-hypovitaminosis and D-hypervitaminosis may be its influence on the activity of different vitamin D3 25-hydroxylase systems of hepatocytes.	Cholecalciferol	47-57	cytochrome P450, family 27, subfamily a, polypeptide 1	Rattus norvegicus	166-191
19018785-7	2009	Serum 25OHD significantly increased at 4 and 8 weeks in both treatment groups (P &lt; 0.001), whereas PTH(1-84) declined significantly in subjects treated with cholecalciferol (P &lt; 0.007) and tended to decrease following ergocalciferol (P &lt; 0.09).	Cholecalciferol	160-175	parathyroid hormone	Homo sapiens	102-105
19644632-1	2009	INTRODUCTION: This study aims to compare Ki-67 antigen expression and K-ras mutation in lung tumours induced by the interfering effects of urethane followed by sodium nitrite, sodium chloride and vitamin D3.	Cholecalciferol	196-206	antigen identified by monoclonal antibody Ki 67	Mus musculus	41-46
19538461-1	2009	Genetic or vitamin D3-induced overexpression of thymic stromal lymphopoietin (TSLP) by keratinocytes results in an atopic dermatitis (AD)-like inflammatory phenotype in mice echoing the discovery of high TSLP expression in epidermis from AD patients.	Cholecalciferol	11-21	thymic stromal lymphopoietin	Mus musculus	78-82
19538461-1	2009	Genetic or vitamin D3-induced overexpression of thymic stromal lymphopoietin (TSLP) by keratinocytes results in an atopic dermatitis (AD)-like inflammatory phenotype in mice echoing the discovery of high TSLP expression in epidermis from AD patients.	Cholecalciferol	11-21	thymic stromal lymphopoietin	Mus musculus	204-208
19543524-0	2009	20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes.	Cholecalciferol	38-48	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	66-73
19543524-1	2009	The side chain of vitamin D3 is hydroxylated in a sequential manner by cytochrome P450scc (CYP11A1) to form 20-hydroxycholecalciferol, which can induce growth arrest and differentiation of both primary and immortalized epidermal keratinocytes.	Cholecalciferol	18-28	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	82-89
19543524-1	2009	The side chain of vitamin D3 is hydroxylated in a sequential manner by cytochrome P450scc (CYP11A1) to form 20-hydroxycholecalciferol, which can induce growth arrest and differentiation of both primary and immortalized epidermal keratinocytes.	Cholecalciferol	18-28	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	91-98
19644632-1	2009	INTRODUCTION: This study aims to compare Ki-67 antigen expression and K-ras mutation in lung tumours induced by the interfering effects of urethane followed by sodium nitrite, sodium chloride and vitamin D3.	Cholecalciferol	196-206	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	70-75
19244278-0	2009	The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages.	Cholecalciferol	64-74	aryl hydrocarbon receptor	Homo sapiens	4-29
19517319-1	2009	Elocalcitol, which had been under development by BioXell SpA, is a synthetic derivative of vitamin D3 that regulates cell proliferation and apoptosis via its binding to the vitamin D receptor.	Cholecalciferol	91-101	surfactant protein A1	Homo sapiens	57-60
19517319-1	2009	Elocalcitol, which had been under development by BioXell SpA, is a synthetic derivative of vitamin D3 that regulates cell proliferation and apoptosis via its binding to the vitamin D receptor.	Cholecalciferol	91-101	vitamin D receptor	Homo sapiens	173-191
19539561-10	2009	UV-induced regulatory T cells are expanded by UV-exposed cutaneous LC and recently, epidermal expression of vitamin D3 or RANKL (CD254) has been shown to connect the environment to the immune system via expansion of CD4(+)CD25(+) regulatory T cells.	Cholecalciferol	108-118	CD4 molecule	Homo sapiens	216-219
19244278-2	2009	1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], a potent ligand for the nuclear receptor vitamin D receptor (VDR), has been shown to decrease the risk of osteoporosis, some types of cancer and cardiovascular disease, suggesting an opposing effect of vitamin D3 to cigarette smoking.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	101-104
19244278-11	2009	Thus, AhR activation by BaP stimulates vitamin D3 catabolism.	Cholecalciferol	39-49	aryl hydrocarbon receptor	Homo sapiens	6-9
19102726-0	2009	Lysine-specific gingipain promotes lipopolysaccharide- and active-vitamin D3-induced osteoclast differentiation by degrading osteoprotegerin.	Cholecalciferol	66-76	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	125-140
19075641-4	2008	Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2).	Cholecalciferol	91-101	thioredoxin 1	Mus musculus	35-40
19056929-0	2009	PPARdelta is a ligand-dependent negative regulator of vitamin D3-induced monocyte differentiation.	Cholecalciferol	54-64	peroxisome proliferator activated receptor delta	Homo sapiens	0-9
18971286-4	2009	Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19.	Cholecalciferol	95-105	interferon regulatory factor 6	Homo sapiens	166-169
18971286-4	2009	Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19.	Cholecalciferol	95-105	interferon regulatory factor 6	Homo sapiens	171-180
18971286-4	2009	Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19.	Cholecalciferol	95-105	C-C motif chemokine receptor 7	Homo sapiens	278-282
18971286-4	2009	Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19.	Cholecalciferol	95-105	C-C motif chemokine ligand 19	Homo sapiens	290-295
18683889-6	2009	Vitamin D(3) was also shown to induce the expression of the osteoblast-specific markers, alkaline phosphatase and osteocalcin, in a dose-dependent manner in human dermal fibroblasts.	Cholecalciferol	0-12	bone gamma-carboxyglutamate protein	Homo sapiens	114-125
18981260-0	2009	Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation.	Cholecalciferol	174-184	nuclear receptor subfamily 1, group I, member 2	Mus musculus	28-47
18981260-0	2009	Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation.	Cholecalciferol	174-184	nuclear receptor co-repressor 2	Mus musculus	129-133
18981260-0	2009	Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation.	Cholecalciferol	174-184	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	144-151
20429425-8	2009	Activation and expansion ofantigen-specific CD4+CD25+ Tregs in vivo using adjuvants such as IL-10 or pharmacological agents such as low dose steroids or vitamin D3 could represent novel approaches to induce antigen-specific tolerance in immune-mediated conditions such as allergic asthma, autoimmune disease and the rejection of transplanted organs in man.	Cholecalciferol	153-163	CD4 molecule	Homo sapiens	44-47
19012883-4	2009	In addition, 18 h after sensitisation, the lymph node populations in the vitamin D3-deficient and normal male mice showed similar proliferation and IFN-gamma production.	Cholecalciferol	73-83	interferon gamma	Mus musculus	148-157
19068548-4	2009	RECENT FINDINGS: Recent studies advanced our understanding of the mechanisms controlling LL-37 expression, demonstrating the key involvement of the vitamin D3 and the hypoxia response pathways, and the impacts of commensal and pathogenic microorganisms on its production.	Cholecalciferol	148-158	cathelicidin antimicrobial peptide	Homo sapiens	89-94
19225217-0	2009	Osteocalcin attenuates T3- and increases vitamin D3-induced expression of MMP-13 in mouse osteoblasts.	Cholecalciferol	41-51	bone gamma-carboxyglutamate protein 2	Mus musculus	0-11
19225217-0	2009	Osteocalcin attenuates T3- and increases vitamin D3-induced expression of MMP-13 in mouse osteoblasts.	Cholecalciferol	41-51	matrix metallopeptidase 13	Mus musculus	74-80
19185400-0	2009	The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.	Cholecalciferol	35-45	parathyroid hormone	Homo sapiens	78-97
19034928-0	2009	Butyrate and vitamin D3 induce transcriptional attenuation at the cyclin D1 locus in colonic carcinoma cells.	Cholecalciferol	13-23	cyclin D1	Homo sapiens	66-75
18991184-17	2009	Vitamin D3 had greater potency than equimolar vitamin D2, with a higher, sustained serum 25(OH)D response and efficacious PTH suppression.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	122-125
19188585-3	2009	In the present study, we show that induced expression of thymic stromal lymphopoietin (TSLP) in mouse epidermal keratinocytes upon topical application of MC903 (a low calcemic analogue of vitamin D3) not only triggers AD as we previously reported but also aggravates experimental allergic asthma induced by ovalbumin sensitization and challenge.	Cholecalciferol	188-198	thymic stromal lymphopoietin	Mus musculus	57-85
19188585-3	2009	In the present study, we show that induced expression of thymic stromal lymphopoietin (TSLP) in mouse epidermal keratinocytes upon topical application of MC903 (a low calcemic analogue of vitamin D3) not only triggers AD as we previously reported but also aggravates experimental allergic asthma induced by ovalbumin sensitization and challenge.	Cholecalciferol	188-198	thymic stromal lymphopoietin	Mus musculus	87-91
19058874-0	2009	Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.	Cholecalciferol	14-24	AKT serine/threonine kinase 1	Homo sapiens	0-3
19058874-0	2009	Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.	Cholecalciferol	14-24	zinc fingers and homeoboxes 2	Homo sapiens	78-81
19058874-0	2009	Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.	Cholecalciferol	14-24	mitogen-activated protein kinase kinase 7	Homo sapiens	82-85
19058874-0	2009	Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.	Cholecalciferol	14-24	mitogen-activated protein kinase 1	Homo sapiens	86-89
19058874-0	2009	Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.	Cholecalciferol	14-24	mitogen-activated protein kinase 1	Homo sapiens	90-94
19058874-2	2009	Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling.	Cholecalciferol	19-29	AKT serine/threonine kinase 1	Homo sapiens	68-71
19058874-2	2009	Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling.	Cholecalciferol	19-29	zinc fingers and homeoboxes 2	Homo sapiens	80-83
19058874-2	2009	Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling.	Cholecalciferol	19-29	mitogen-activated protein kinase kinase 7	Homo sapiens	84-87
19058874-2	2009	Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling.	Cholecalciferol	19-29	mitogen-activated protein kinase 1	Homo sapiens	88-91
19058874-2	2009	Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling.	Cholecalciferol	19-29	mitogen-activated protein kinase 1	Homo sapiens	92-96
19058874-3	2009	Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway.	Cholecalciferol	0-10	AKT serine/threonine kinase 1	Homo sapiens	25-28
19058874-3	2009	Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway.	Cholecalciferol	0-10	AKT serine/threonine kinase 1	Homo sapiens	39-42
19058874-3	2009	Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway.	Cholecalciferol	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	43-47
19058874-3	2009	Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway.	Cholecalciferol	0-10	zinc fingers and homeoboxes 2	Homo sapiens	43-46
19058874-3	2009	Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway.	Cholecalciferol	0-10	mitogen-activated protein kinase kinase 7	Homo sapiens	96-99
19058874-3	2009	Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway.	Cholecalciferol	0-10	mitogen-activated protein kinase 1	Homo sapiens	100-103
19058874-3	2009	Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway.	Cholecalciferol	0-10	mitogen-activated protein kinase 1	Homo sapiens	104-108
19058874-4	2009	Pharmacological inhibition of MEK/ERK crippled differentiation in response to vitamin D3.	Cholecalciferol	78-88	mitogen-activated protein kinase kinase 7	Homo sapiens	30-33
19058874-4	2009	Pharmacological inhibition of MEK/ERK crippled differentiation in response to vitamin D3.	Cholecalciferol	78-88	mitogen-activated protein kinase 1	Homo sapiens	34-37
19058874-5	2009	Ectopic overexpression of Akt inhibited MAPK signaling, downregulated cyclin-dependent kinase (CDK) inhibitors p21(Wip1/Cip1) and p27(Kip1) and blunted differentiation in response to vitamin D3 while knockdown of Akt by RNA interference gave reverse effects.	Cholecalciferol	183-193	AKT serine/threonine kinase 1	Homo sapiens	26-29
19058874-7	2009	Vitamin D3-induced MAPK signaling mediated upregulation of the CDK inhibitors and Rb, disassociation of Raf1 and Rb, and dephosphorylation of Rb, resulting in Rb binding to transcription factor E2F1 and subsequent differentiation.	Cholecalciferol	0-10	mitogen-activated protein kinase 1	Homo sapiens	19-23
19058874-7	2009	Vitamin D3-induced MAPK signaling mediated upregulation of the CDK inhibitors and Rb, disassociation of Raf1 and Rb, and dephosphorylation of Rb, resulting in Rb binding to transcription factor E2F1 and subsequent differentiation.	Cholecalciferol	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	104-108
19058874-7	2009	Vitamin D3-induced MAPK signaling mediated upregulation of the CDK inhibitors and Rb, disassociation of Raf1 and Rb, and dephosphorylation of Rb, resulting in Rb binding to transcription factor E2F1 and subsequent differentiation.	Cholecalciferol	0-10	E2F transcription factor 1	Homo sapiens	194-198
19058874-10	2009	Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding.	Cholecalciferol	38-48	AKT serine/threonine kinase 1	Homo sapiens	136-139
19058874-10	2009	Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding.	Cholecalciferol	38-48	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	164-168
19058874-10	2009	Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding.	Cholecalciferol	38-48	mitogen-activated protein kinase 1	Homo sapiens	183-187
19058874-10	2009	Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding.	Cholecalciferol	38-48	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	237-241
19058874-10	2009	Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding.	Cholecalciferol	38-48	E2F transcription factor 1	Homo sapiens	321-325
19125756-0	2009	A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men.	Cholecalciferol	81-91	insulin	Homo sapiens	111-118
19125756-8	2009	CONCLUSION: The trial indicates that vitamin D(3) supplementation improves postprandial insulin sensitivity (OGIS) in apparently healthy men likely to have insulin resistance (centrally obese but non-diabetic).	Cholecalciferol	37-49	insulin	Homo sapiens	88-95
19125756-8	2009	CONCLUSION: The trial indicates that vitamin D(3) supplementation improves postprandial insulin sensitivity (OGIS) in apparently healthy men likely to have insulin resistance (centrally obese but non-diabetic).	Cholecalciferol	37-49	insulin	Homo sapiens	156-163
18839328-11	2009	PTH and vitamin D3 were independent predictors of FGF23 in the study group.	Cholecalciferol	8-18	fibroblast growth factor 23	Homo sapiens	50-55
19050268-0	2008	IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes.	Cholecalciferol	16-26	interleukin 17A	Homo sapiens	0-6
19050268-0	2008	IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes.	Cholecalciferol	16-26	cathelicidin antimicrobial peptide	Homo sapiens	49-83
19075641-4	2008	Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2).	Cholecalciferol	91-101	thioredoxin interacting protein	Mus musculus	123-129
19075641-4	2008	Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2).	Cholecalciferol	91-101	thioredoxin interacting protein	Mus musculus	144-149
19075641-4	2008	Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2).	Cholecalciferol	91-101	thioredoxin interacting protein	Mus musculus	191-196
19075641-4	2008	Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2).	Cholecalciferol	91-101	thioredoxin 1	Mus musculus	35-38
19000766-1	2008	Cytochrome P450scc (CYP11A1) metabolizes vitamin D3 to 20-hydroxyvitamin D3 as the major product, with subsequent production of dihydroxy and trihydroxy derivatives.	Cholecalciferol	41-51	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	0-18
19075789-8	2008	Activation and expansion of antigen-specific CD4(+)CD25(+) T(Regs) in vivo using adjuvants or pharmacological agents such as low dose steroids or vitamin D3 could represent novel approaches to induce antigen-specific tolerance in human diseases including allergic asthma, autoimmune disease and the rejection of transplanted organs.	Cholecalciferol	146-156	CD4 molecule	Homo sapiens	45-48
18814144-0	2008	Modulation of mouse RANKL gene expression by Runx2 and vitamin D3.	Cholecalciferol	55-65	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	20-25
19000766-1	2008	Cytochrome P450scc (CYP11A1) metabolizes vitamin D3 to 20-hydroxyvitamin D3 as the major product, with subsequent production of dihydroxy and trihydroxy derivatives.	Cholecalciferol	41-51	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	20-27
19000766-5	2008	The Km for 1alpha-hydroxyvitamin D3 determined for P450scc incorporated into phospholipid vesicles was 1.4 mol substrate/mol phospholipid, half that observed for vitamin D3.	Cholecalciferol	25-35	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	51-58
19000766-6	2008	The kcat was 3.0 mol/min/mol P450scc, 6-fold lower than that for vitamin D3.	Cholecalciferol	65-75	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	29-36
19112416-3	2008	MDB entails the use of anti-proliferative molecules such as somatostatine, prolactin, and estrogen inhibitors, along with differentiating and apoptotic molecules such as melatonin, retinoids, vitamins C, D3, and E, calcium, and amino-sugars, combined with minimal doses of chemotherapy.	Cholecalciferol	204-206	ABR activator of RhoGEF and GTPase	Homo sapiens	0-3
18997319-0	2008	Structure of the ligand-binding domain of rat VDR in complex with the nonsecosteroidal vitamin D3 analogue YR301.	Cholecalciferol	87-97	vitamin D receptor	Rattus norvegicus	46-49
18616960-4	2008	A recently described analog of vitamin D3, 2-methylene-19-nor-20(S)-1alpha-hydroxy-bishomopregnacalciferol [20(S)-2MbisP], suppresses PTH levels, but is unable to stimulate intestinal calcium absorption or bone resorption in rats.	Cholecalciferol	31-41	parathyroid hormone	Rattus norvegicus	134-137
19094444-1	2008	Catalase (antioxidant enzyme) activity in erythrocytes and serum levels of trace elements (copper, iron, zinc), heavy metals (cadmium, cobalt) and vitamins A (retinol), D (cholecalciferol) and E (alpha-tocopherol) were measured in 145 subjects comprising 47 pre-eclamptic pregnant women (PE), 48 healthy pregnant women (HP) and 50 healthy non-pregnant controls (NP).	Cholecalciferol	172-187	catalase	Homo sapiens	0-8
18940664-0	2008	Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor.	Cholecalciferol	27-37	vitamin D receptor a	Danio rerio	72-90
18754805-5	2008	RESULTS: After 24 weeks, cholecalciferol supplementation significantly increased 25(OH)D3 and 1,25(OH)2D3 levels and decreased PTH and insulin sensitivity.	Cholecalciferol	25-40	parathyroid hormone	Homo sapiens	127-130
18754805-5	2008	RESULTS: After 24 weeks, cholecalciferol supplementation significantly increased 25(OH)D3 and 1,25(OH)2D3 levels and decreased PTH and insulin sensitivity.	Cholecalciferol	25-40	insulin	Homo sapiens	135-142
18754805-9	2008	Cholecalciferol dosages of &gt; or =2000 IU are necessary to achieve 1,25(OH)2D3 levels that significantly decrease PTH, but also negatively affect insulin sensitivity.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	116-119
18754805-9	2008	Cholecalciferol dosages of &gt; or =2000 IU are necessary to achieve 1,25(OH)2D3 levels that significantly decrease PTH, but also negatively affect insulin sensitivity.	Cholecalciferol	0-15	insulin	Homo sapiens	148-155
18768889-1	2008	The epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) is sufficient to induce asthma or atopic dermatitis-like phenotypes when selectively overexpressed in transgenic mice, or when driven by topical application of vitamin D3 or low-calcemic analogues.	Cholecalciferol	228-238	thymic stromal lymphopoietin	Mus musculus	32-60
18754805-0	2008	The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients.	Cholecalciferol	14-29	insulin	Homo sapiens	70-77
18716166-0	2008	Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli1638N/+ mice.	Cholecalciferol	20-35	cyclin D1	Mus musculus	45-54
18716166-9	2008	Importantly, Apc(1638N/+) mice fed the WD/Ca/VitD3 diet did not develop colonic tumors, further indicating that dietary calcium and cholecalciferol have a key role in the chemoprevention of colorectal neoplasia in this mouse model of human colon cancer.	Cholecalciferol	132-147	APC, WNT signaling pathway regulator	Mus musculus	13-16
18628207-6	2008	Vitamin D3 up-regulates Beclin1, which binds to class III phosphatidylinositol 3-kinase to trigger autophagy.	Cholecalciferol	0-10	beclin 1	Homo sapiens	24-31
18628207-7	2008	Vitamin D3 phosphorylates Bad in its BH3 domain, resulting in disassociation of the apoptotic Bad-Bcl-xL complex and association of Bcl-xL with Beclin1 and ultimate suppression of apoptotic signaling.	Cholecalciferol	0-10	BCL2 like 1	Homo sapiens	98-104
18628207-7	2008	Vitamin D3 phosphorylates Bad in its BH3 domain, resulting in disassociation of the apoptotic Bad-Bcl-xL complex and association of Bcl-xL with Beclin1 and ultimate suppression of apoptotic signaling.	Cholecalciferol	0-10	BCL2 like 1	Homo sapiens	132-138
18628207-7	2008	Vitamin D3 phosphorylates Bad in its BH3 domain, resulting in disassociation of the apoptotic Bad-Bcl-xL complex and association of Bcl-xL with Beclin1 and ultimate suppression of apoptotic signaling.	Cholecalciferol	0-10	beclin 1	Homo sapiens	144-151
18628207-8	2008	Knockdown of Beclin1 eliminates vitamin D3-induced autophagy and inhibits differentiation but activates apoptosis, suggesting that Beclin1 is required for both autophagy and differentiation, and autophagy cooperates with differentiation but excludes apoptosis, in which Beclin1 acts as an interface for these three different cascades.	Cholecalciferol	32-42	beclin 1	Homo sapiens	13-20
18628207-8	2008	Knockdown of Beclin1 eliminates vitamin D3-induced autophagy and inhibits differentiation but activates apoptosis, suggesting that Beclin1 is required for both autophagy and differentiation, and autophagy cooperates with differentiation but excludes apoptosis, in which Beclin1 acts as an interface for these three different cascades.	Cholecalciferol	32-42	beclin 1	Homo sapiens	131-138
18628207-8	2008	Knockdown of Beclin1 eliminates vitamin D3-induced autophagy and inhibits differentiation but activates apoptosis, suggesting that Beclin1 is required for both autophagy and differentiation, and autophagy cooperates with differentiation but excludes apoptosis, in which Beclin1 acts as an interface for these three different cascades.	Cholecalciferol	32-42	beclin 1	Homo sapiens	131-138
18252022-11	2008	Thus, with 8 weeks of cholecalciferol supplementation in Asian Indians with chronic hypovitaminosis D, mean serum 25(OH)D levels would be normalized and serum PTH value would be reduced to half.	Cholecalciferol	22-37	parathyroid hormone	Homo sapiens	159-162
18768889-1	2008	The epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) is sufficient to induce asthma or atopic dermatitis-like phenotypes when selectively overexpressed in transgenic mice, or when driven by topical application of vitamin D3 or low-calcemic analogues.	Cholecalciferol	228-238	thymic stromal lymphopoietin	Mus musculus	62-66
18489902-0	2008	Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts.	Cholecalciferol	6-16	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	112-117
18492750-10	2008	At 60 d, the form of vitamin (cholecalciferol) significantly lowers PTH levels (P = 0.037).	Cholecalciferol	30-45	parathyroid hormone	Homo sapiens	68-71
18511070-0	2008	Structural analysis of CYP2R1 in complex with vitamin D3.	Cholecalciferol	46-56	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	23-29
18410337-3	2008	In recent years, vitamin D3 analogs and a new formulation containing 8% clobetasol-17-propionate in a colourless nail lacquer vehicle have produced good results for the control of nail psoriasis.	Cholecalciferol	17-27	CD244 molecule	Homo sapiens	180-184
18511070-4	2008	To understand the narrow substrate specificity of CYP2R1 we obtained the hemeprotein in a highly purified state, confirmed the enzyme as a vitamin D 25-hydroxylase, and solved the crystal structure of CYP2R1 in complex with vitamin D3.	Cholecalciferol	224-234	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	50-56
18511070-4	2008	To understand the narrow substrate specificity of CYP2R1 we obtained the hemeprotein in a highly purified state, confirmed the enzyme as a vitamin D 25-hydroxylase, and solved the crystal structure of CYP2R1 in complex with vitamin D3.	Cholecalciferol	224-234	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	139-163
18511070-4	2008	To understand the narrow substrate specificity of CYP2R1 we obtained the hemeprotein in a highly purified state, confirmed the enzyme as a vitamin D 25-hydroxylase, and solved the crystal structure of CYP2R1 in complex with vitamin D3.	Cholecalciferol	224-234	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	201-207
18226257-8	2008	Previously reviewed mechanisms include that 1) low vitamin D3, may impair insulin action, glucose metabolism and various other metabolic processes in adipose and lean tissue 2) fat soluble-vitamin D3 is sequestered in the large adipose compartment, and low in serum, 3) obese people may be sensitive about their body shape, minimising their skin exposure to view and sunlight (not tested).	Cholecalciferol	51-61	insulin	Homo sapiens	74-81
18410379-0	2008	Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc.	Cholecalciferol	44-54	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	58-76
18410379-1	2008	Cytochrome P450scc (CYP11A1) can hydroxylate vitamin D3 to produce 20-hydroxyvitamin D3 and other poorly characterized hydroxylated products.	Cholecalciferol	45-55	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	0-18
18410379-1	2008	Cytochrome P450scc (CYP11A1) can hydroxylate vitamin D3 to produce 20-hydroxyvitamin D3 and other poorly characterized hydroxylated products.	Cholecalciferol	45-55	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	20-27
18410379-2	2008	The present study aimed to identify all the products of vitamin D3 metabolism by P450scc, as well as the pathways leading to their formation.	Cholecalciferol	56-66	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	81-88
18410379-9	2008	We conclude that the major pathway of vitamin D3 metabolism by P450scc is: vitamin D3 --&gt; 20-hydroxyvitamin D3 --&gt; 20,23-dihydroxyvitamin D3 --&gt; 17alpha,20,23-trihydroxyvitamin D3.	Cholecalciferol	38-48	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	63-70
18410379-9	2008	We conclude that the major pathway of vitamin D3 metabolism by P450scc is: vitamin D3 --&gt; 20-hydroxyvitamin D3 --&gt; 20,23-dihydroxyvitamin D3 --&gt; 17alpha,20,23-trihydroxyvitamin D3.	Cholecalciferol	75-85	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	63-70
18410379-11	2008	Our new identification of the major dihydroxyvitamin D3 product as 20,23-dihydroxyvitamin D3, rather than 20,22-dihydroxyvitamin D3, explains why there is no cleavage of the vitamin D3 side chain, unlike the metabolism of cholesterol by P450scc.	Cholecalciferol	45-55	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	237-244
18358842-2	2008	Overexpression of Tob2 in stromal cells repressed vitamin D(3)-induced osteoclasts formation.	Cholecalciferol	50-62	transducer of ERBB2, 2	Mus musculus	18-22
18591157-0	2008	Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin D3.	Cholecalciferol	108-118	vitamin D receptor	Rattus norvegicus	18-36
18591157-0	2008	Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin D3.	Cholecalciferol	108-118	small proline-rich protein 1B	Rattus norvegicus	41-54
18424365-12	2008	Lowered exocrine pancreatic function with lowered fecal elastase 1 seems to be relevant as a reason for reduced levels of circulating vitamin D3 metabolites being an appropriate additional cause for predominant osteoporosis.	Cholecalciferol	134-144	chymotrypsin like elastase 3B	Homo sapiens	50-66
18178294-2	2008	Herein, we report that murine DCs exposed to TLR3/TLR4 ligands upregulate their expression of 1 alpha-hydroxylase, the enzyme that converts circulating 25(OH)D3 to calcitriol, the active form of vitamin D3.	Cholecalciferol	195-205	toll-like receptor 3	Mus musculus	45-49
18178294-2	2008	Herein, we report that murine DCs exposed to TLR3/TLR4 ligands upregulate their expression of 1 alpha-hydroxylase, the enzyme that converts circulating 25(OH)D3 to calcitriol, the active form of vitamin D3.	Cholecalciferol	195-205	toll-like receptor 4	Mus musculus	50-54
18411844-4	2008	The N,S-heterodisubstituted o-carborane containing a mercapto group, 1-(2"-pyridyl)-2-SH-1,2-closo-C2B10H10, 1, is one of the two examples of a rigid bidentate chelating (pyridine)N-C-C-C-S(H) motif having been structurally fully characterized.	Cholecalciferol	184-189	secretoglobin family 2B member 3, pseudogene	Homo sapiens	99-110
18368131-0	2008	20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation.	Cholecalciferol	10-20	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	74-81
18368131-1	2008	It has been shown that mammalian cytochrome P450scc can metabolize vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,22(OH)2D3.	Cholecalciferol	67-77	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	44-51
18368131-1	2008	It has been shown that mammalian cytochrome P450scc can metabolize vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,22(OH)2D3.	Cholecalciferol	67-77	MIA SH3 domain ER export factor 3	Homo sapiens	99-111
18368131-12	2008	These data imply that the previously unreported pathway of vitamin D3 metabolism by P450scc may have wider biological implications depending, for example, on the extent of adrenal gland or cutaneous metabolism.	Cholecalciferol	59-69	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	84-91
18547426-3	2008	METHODS: Over 12-months, 136 women out of 184 randomized (T-score spine &lt; -1.5) completed the study and received, daily, 1000 mg Ca and 20 microg cholecalciferol (Vit D3) and three different ch-OSA doses (3, 6 and 12 mg Si) or placebo.	Cholecalciferol	149-164	vitrin	Homo sapiens	166-169
18537536-2	2008	Starting in 1999 when the orphan nuclear receptor FXR was shown to be specifically activated by bile acids, these compounds became part of the arsenal of ligands of the steroid hormone superfamily of nuclear receptors, including receptors of Vitamin D3, retinoids (RAR, RXR), and thyroid hormone.	Cholecalciferol	242-252	nuclear receptor subfamily 1 group H member 4	Homo sapiens	50-53
18487663-0	2008	Blood mineral, hormone, and osteocalcin responses of multiparous Jersey cows to an oral dose of 25-hydroxyvitamin D3 or vitamin D3 before parturition.	Cholecalciferol	106-116	bone gamma-carboxyglutamate protein	Bos taurus	28-39
18411217-9	2008	TNF-alpha synthesis was also decreased upon TLR ligand stimulation in vitamin D(3)-treated monocytes.	Cholecalciferol	70-82	tumor necrosis factor	Homo sapiens	0-9
18004750-0	2008	Crystal structure of a secondary vitamin D3 binding site of milk beta-lactoglobulin.	Cholecalciferol	33-43	beta-lactoglobulin	Bos taurus	65-83
18004750-13	2008	Atomic coordinates for the crystal structure of beta-LG-vitamin D(3) complex described in this work have been deposited in the PDB (access code 2GJ5).	Cholecalciferol	56-68	beta-lactoglobulin	Bos taurus	48-55
18483314-0	2008	Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57.	Cholecalciferol	0-10	cyclin dependent kinase inhibitor 1C	Homo sapiens	102-105
17881271-0	2008	Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues.	Cholecalciferol	0-10	growth hormone	Mus musculus	44-58
17881271-0	2008	Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues.	Cholecalciferol	0-10	growth hormone	Mus musculus	60-62
17881271-0	2008	Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues.	Cholecalciferol	0-10	signal transducer and activator of transcription 5A	Mus musculus	72-77
17881271-5	2008	Vitamin D3 has been shown to inhibit GH-induced expression of CIS and SOCS-3 and therefore prolong GH signaling in osteoblast-like cells.	Cholecalciferol	0-10	growth hormone	Mus musculus	37-39
17881271-5	2008	Vitamin D3 has been shown to inhibit GH-induced expression of CIS and SOCS-3 and therefore prolong GH signaling in osteoblast-like cells.	Cholecalciferol	0-10	suppressor of cytokine signaling 3	Mus musculus	70-76
17881271-5	2008	Vitamin D3 has been shown to inhibit GH-induced expression of CIS and SOCS-3 and therefore prolong GH signaling in osteoblast-like cells.	Cholecalciferol	0-10	growth hormone	Mus musculus	99-101
17881271-6	2008	The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals.	Cholecalciferol	52-62	growth hormone	Mus musculus	97-99
17881271-6	2008	The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals.	Cholecalciferol	52-62	growth hormone	Mus musculus	144-146
17881271-6	2008	The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals.	Cholecalciferol	52-62	Janus kinase 2	Mus musculus	147-151
17881271-6	2008	The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals.	Cholecalciferol	52-62	signal transducer and activator of transcription 5A	Mus musculus	152-157
17881271-6	2008	The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals.	Cholecalciferol	52-62	growth hormone	Mus musculus	144-146
18248997-0	2008	The 2alpha-(3-hydroxypropyl) group as an active motif in vitamin D3 analogues as agonists of the mutant vitamin D receptor (Arg274Leu).	Cholecalciferol	57-67	vitamin D receptor	Homo sapiens	104-122
18178824-6	2008	PHA and IL-2 stimulation as well as vitamin D3/dexamethasone and anti-CD2/CD16 mAbs are demonstrated to induce IL-10 expression in NK cells.	Cholecalciferol	36-46	interleukin 10	Homo sapiens	111-116
18175915-0	2008	Differential regulation of extracellular signal-related kinase phosphorylation by vitamin D3 analogs.	Cholecalciferol	82-92	mitogen-activated protein kinase 1	Homo sapiens	27-62
18238736-1	2008	OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD).	Cholecalciferol	42-57	parathyroid hormone	Homo sapiens	139-158
18238736-1	2008	OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD).	Cholecalciferol	42-57	parathyroid hormone	Homo sapiens	160-163
18238736-1	2008	OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD).	Cholecalciferol	59-69	parathyroid hormone	Homo sapiens	139-158
18238736-1	2008	OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD).	Cholecalciferol	59-69	parathyroid hormone	Homo sapiens	160-163
18238736-11	2008	As-treated analysis indicated a trend toward lower PTH levels among cholecalciferol-treated participants (P = .07).	Cholecalciferol	68-83	parathyroid hormone	Homo sapiens	51-54
17949889-1	2008	OBJECTIVE: The roles of phosphatidylinositol 3 (PI3K) and mitogen-activated protein kinases (MAPK) have been widely studied in terms of the differentiation process induced by several drugs (phorbol ester, vitamin D-3, retinoic acid, etc.	Cholecalciferol	205-216	mitogen-activated protein kinase 1	Homo sapiens	93-97
18573681-0	2008	Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin.	Cholecalciferol	12-22	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	48-55
18573681-0	2008	Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin.	Cholecalciferol	12-22	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	57-64
18573681-1	2008	Vitamin D3 can be hydroxylated sequentially by cytochrome P450scc (CYP11A1) producing 20-hydroxyvitamin D3, 20,23-dihydroxyvitamin D3 and 17,20,23-trihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	58-65
18573681-1	2008	Vitamin D3 can be hydroxylated sequentially by cytochrome P450scc (CYP11A1) producing 20-hydroxyvitamin D3, 20,23-dihydroxyvitamin D3 and 17,20,23-trihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	67-74
18573681-2	2008	The aim of this study was to characterize the ability of vitamin D3 to associate with phospholipid vesicles and to determine the kinetics of metabolism of vitamin D3 by P450scc in vesicles and in 2-hydroxypropyl-beta-cyclodextrin (cyclodextrin).	Cholecalciferol	155-165	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	169-176
18573681-5	2008	The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane.	Cholecalciferol	22-32	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	10-17
18573681-5	2008	The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane.	Cholecalciferol	57-67	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	10-17
18573681-5	2008	The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane.	Cholecalciferol	57-67	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	10-17
18573681-5	2008	The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane.	Cholecalciferol	57-67	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	10-17
18573681-5	2008	The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane.	Cholecalciferol	57-67	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	10-17
18573681-6	2008	20-Hydroxyvitamin D3 was further hydroxylated by P450scc in vesicles, producing primarily 20,23-dihydroxyvitamin D3, with Km and kcat values 22- and 6-fold lower than those for vitamin D3, respectively.	Cholecalciferol	10-20	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	49-56
18573681-9	2008	This study shows that vitamin D3 quantitatively associates with phospholipid vesicles, can exchange between membranes, and can be hydroxylated by membrane-associated P450scc but with lower efficiency than for cholesterol hydroxylation.	Cholecalciferol	22-32	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	166-173
17910894-3	2008	Vitamin A (retinoic acid [RA]) and the active form of vitamin D3 (1,25 dihydroxyvitamin D3 [1,25D(3)]) have been used to treat certain T cell-mediated inflammatory skin diseases, as well as cutaneous T-cell lymphomas; however, their effect on CLA expression has not been studied.	Cholecalciferol	54-64	selectin P ligand	Homo sapiens	243-246
18979160-0	2008	The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit.	Cholecalciferol	51-66	parathyroid hormone	Homo sapiens	110-129
18387750-6	2008	The central nervous system converts vitamin D3 into 1,25-dihydroxyvitamin D3 (1,25-(OH)2 D3), a biologically active hormone with anti-inflammatory and neuro-protective functions that depend on IL-10-producing regulatory lymphocytes.	Cholecalciferol	36-46	interleukin 10	Homo sapiens	193-198
18387750-9	2008	We hypothesize that vIL-10 may induce a dysfunction of IL-10-producing regulatory lymphocytes, thereby undermining the protective functions of sunlight, vitamin D3, and 1,25-(OH)2 D3.	Cholecalciferol	153-163	interleukin 10	Homo sapiens	21-26
17621647-5	2007	The data indicate that dexamethasone and vitamin D3 ameliorated the age-related increase in IFNgamma and suggest that IFNgamma may be the trigger leading to microglial activation, since it increases MHCII mRNA and IL-1beta release from cultured glia.	Cholecalciferol	41-51	interleukin 18	Rattus norvegicus	92-100
17607662-2	2007	CYP2R1, a cytochrome P450 enzyme, catalyzes the formation of vitamin D3 to 25-hydroxyvitamin D3 (25(OH)D3), the main circulating vitamin D metabolite.	Cholecalciferol	61-71	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	0-6
17707062-1	2007	PURPOSE: The active form of vitamin D3, that is 1alpha,25-dihydroxyvitamin D3, binds with vitamin D receptor, which forms a complex with retinoid X receptors alpha, beta and gamma to manifest antitumor effects.	Cholecalciferol	28-38	vitamin D receptor	Homo sapiens	90-108
17621647-5	2007	The data indicate that dexamethasone and vitamin D3 ameliorated the age-related increase in IFNgamma and suggest that IFNgamma may be the trigger leading to microglial activation, since it increases MHCII mRNA and IL-1beta release from cultured glia.	Cholecalciferol	41-51	interleukin 18	Rattus norvegicus	118-126
17621647-5	2007	The data indicate that dexamethasone and vitamin D3 ameliorated the age-related increase in IFNgamma and suggest that IFNgamma may be the trigger leading to microglial activation, since it increases MHCII mRNA and IL-1beta release from cultured glia.	Cholecalciferol	41-51	interleukin 1 beta	Rattus norvegicus	214-222
17621647-6	2007	In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3.	Cholecalciferol	137-147	interleukin 1 beta	Rattus norvegicus	204-212
17621647-6	2007	In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3.	Cholecalciferol	137-147	interleukin 1 beta	Rattus norvegicus	238-246
17621647-6	2007	In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3.	Cholecalciferol	137-147	mitogen-activated protein kinase 8	Rattus norvegicus	282-285
17621647-6	2007	In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3.	Cholecalciferol	137-147	caspase 3	Rattus norvegicus	290-299
17699781-1	2007	Here, we show that the platelet-derived growth factor receptor (PDGFR) regulates myeloid and monocytic differentiation of HL-60 myeloblastic leukemia cells in response to retinoic acid (RA) and vitamin D3 (D3), respectively.	Cholecalciferol	194-204	platelet derived growth factor receptor beta	Homo sapiens	23-62
17699781-1	2007	Here, we show that the platelet-derived growth factor receptor (PDGFR) regulates myeloid and monocytic differentiation of HL-60 myeloblastic leukemia cells in response to retinoic acid (RA) and vitamin D3 (D3), respectively.	Cholecalciferol	194-204	platelet derived growth factor receptor beta	Homo sapiens	64-69
17259988-3	2007	We show here that 1,25(OH)(2)D(3), the active form of vitamin D3, signaled T cells to express CC chemokine receptor 10, which enabled them to migrate to the skin-specific chemokine CCL27 secreted by keratinocytes of the epidermis.	Cholecalciferol	54-64	C-C motif chemokine receptor 10	Homo sapiens	94-118
17956020-3	2007	In the bones treated with vitamin D3 plus vitamin K2, osteocalcin production and the ratio of the mineralization of osteoblasts were increased.	Cholecalciferol	26-36	bone gamma-carboxyglutamate protein	Homo sapiens	54-65
17433303-0	2007	Mechanism of vitamin D3-induced transcription of phospholipase D1 in HaCat human keratinocytes.	Cholecalciferol	13-23	phospholipase D1	Homo sapiens	49-65
17352718-5	2007	Thus, results from our study indicate that IPL-RF irradiation in combination with topical application of vitamin D(3) ointment would be useful as new modalities, especially for treatment of numerous small pigmented lesions in patients with NF1.	Cholecalciferol	105-117	neurofibromin 1	Homo sapiens	240-243
17440494-3	2007	In this study, we examined the ability of 1,25 dihydroxyvitamin D3 (1,25(OH)(2)D3) to regulate the expression of the vasculoprotective natriuretic peptide receptor-A gene in these cells in culture.	Cholecalciferol	64-66	natriuretic peptide receptor 1	Homo sapiens	135-165
17487855-8	2007	Treatment with 1,25(OH)(2)D(3), an active metabolite of vitamin D3, in the CCA cell lines with high expression of VDR significantly reduced cell proliferation in a dose-dependent manner.	Cholecalciferol	56-66	vitamin D receptor	Homo sapiens	114-117
17325131-0	2007	Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	91-109
17290304-5	2007	How 1,25D3 could participate in the injury response was explained by findings that the levels of CYP27B1, which converts 25OH vitamin D3 (25D3) to active 1,25D3, were increased in wounds and induced in keratinocytes in response to TGF-beta1.	Cholecalciferol	126-136	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	97-104
17290304-5	2007	How 1,25D3 could participate in the injury response was explained by findings that the levels of CYP27B1, which converts 25OH vitamin D3 (25D3) to active 1,25D3, were increased in wounds and induced in keratinocytes in response to TGF-beta1.	Cholecalciferol	126-136	transforming growth factor beta 1	Homo sapiens	231-240
17259988-3	2007	We show here that 1,25(OH)(2)D(3), the active form of vitamin D3, signaled T cells to express CC chemokine receptor 10, which enabled them to migrate to the skin-specific chemokine CCL27 secreted by keratinocytes of the epidermis.	Cholecalciferol	54-64	C-C motif chemokine ligand 27	Homo sapiens	181-186
17283131-6	2007	The silencing was manifested in an inability to activate the normal expression of INK4b RNA as shown in vitamin D3-treated U937 cells expressing CBFbeta-SMMHC.	Cholecalciferol	104-114	core-binding factor subunit beta	Homo sapiens	145-152
17203216-11	2007	In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity.	Cholecalciferol	42-52	integrin subunit alpha M	Homo sapiens	63-68
17203216-11	2007	In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity.	Cholecalciferol	42-52	CD14 molecule	Homo sapiens	73-77
17203216-11	2007	In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity.	Cholecalciferol	42-52	Spi-1 proto-oncogene	Homo sapiens	110-114
17203216-11	2007	In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity.	Cholecalciferol	42-52	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	115-120
17326835-4	2007	Osteoblasts were incubated in the presence of vitamin D3 (50 nM), which is an inducer of osteocalcin, encoded by an osteoblast terminal differentiation gene.	Cholecalciferol	46-56	bone gamma-carboxyglutamate protein	Homo sapiens	89-100
17326835-11	2007	The vitamin D3 induced osteocalcin was strongly inhibited in a dose-dependent manner in the presence of gal-3, at both the mRNA and protein levels.	Cholecalciferol	4-14	bone gamma-carboxyglutamate protein	Homo sapiens	23-34
17326835-11	2007	The vitamin D3 induced osteocalcin was strongly inhibited in a dose-dependent manner in the presence of gal-3, at both the mRNA and protein levels.	Cholecalciferol	4-14	galectin 3	Homo sapiens	104-109
17996099-6	2007	Interestingly, OPG expression and production under basal conditions or vitamin D3 treatment were upregulated by CS and by both CS and GS incubated together.	Cholecalciferol	71-81	TNF receptor superfamily member 11b	Homo sapiens	15-18
17156784-2	2007	The vitamin D3 action is mediated by the vitamin D3 receptor (VDR).	Cholecalciferol	4-14	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	41-60
17156784-2	2007	The vitamin D3 action is mediated by the vitamin D3 receptor (VDR).	Cholecalciferol	4-14	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	62-65
17156784-10	2007	The differential VDR expression in the epididymal region segments reveals that several extratesticular ducts may be target for vitamin D3 action and suggests that vitamin D3 may have a regional-specific function, such as calcium transport, that is modulated through VDR activity.	Cholecalciferol	127-137	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	17-20
17156784-10	2007	The differential VDR expression in the epididymal region segments reveals that several extratesticular ducts may be target for vitamin D3 action and suggests that vitamin D3 may have a regional-specific function, such as calcium transport, that is modulated through VDR activity.	Cholecalciferol	163-173	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	17-20
17156784-10	2007	The differential VDR expression in the epididymal region segments reveals that several extratesticular ducts may be target for vitamin D3 action and suggests that vitamin D3 may have a regional-specific function, such as calcium transport, that is modulated through VDR activity.	Cholecalciferol	163-173	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	266-269
17217059-5	2007	First, TRPV5 gene expression is regulated by calciotropic hormones such as vitamin D3 and parathyroid hormone.	Cholecalciferol	75-85	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	7-12
17217059-10	2007	Inactivation of TRPV5 in mice leads to severe hypercalciuria, which is compensated by increased intestinal Ca2+ absorption due to augmented vitamin D3 levels.	Cholecalciferol	140-150	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	16-21
17217060-2	2007	Transcriptional regulation of TRPV6 messenger RNA (mRNA) is controlled by 1,25-dihydroxyvitamin D, which is the active hormonal form of vitamin D3, and by additional calcium-dependent and vitamin D3-independent mechanisms.	Cholecalciferol	136-146	transient receptor potential cation channel subfamily V member 6	Homo sapiens	30-35
17217060-2	2007	Transcriptional regulation of TRPV6 messenger RNA (mRNA) is controlled by 1,25-dihydroxyvitamin D, which is the active hormonal form of vitamin D3, and by additional calcium-dependent and vitamin D3-independent mechanisms.	Cholecalciferol	188-198	transient receptor potential cation channel subfamily V member 6	Homo sapiens	30-35
17261502-3	2007	CD33 expression in the Liu01 cell line, a subclone of U266 cells, and in vitamin D3-treated ILKM3 cells, correlated with a monocytoid morphology featuring convoluted nuclei and with increased C/EBPalpha expression.	Cholecalciferol	73-83	CD33 molecule	Homo sapiens	0-4
17261502-3	2007	CD33 expression in the Liu01 cell line, a subclone of U266 cells, and in vitamin D3-treated ILKM3 cells, correlated with a monocytoid morphology featuring convoluted nuclei and with increased C/EBPalpha expression.	Cholecalciferol	73-83	CCAAT enhancer binding protein alpha	Homo sapiens	192-202
17721071-4	2007	NPT2 is crucial for the Pi reabsorption and is modulated by several hormones (PTH and vitamin D3, phosphatonins) and non-hormonal factors.	Cholecalciferol	86-96	solute carrier family 34 member 1	Homo sapiens	0-4
16902422-2	2007	In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR.	Cholecalciferol	132-142	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	212-219
16902422-2	2007	In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR.	Cholecalciferol	132-142	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	256-263
16902422-2	2007	In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR.	Cholecalciferol	132-142	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	270-309
16902422-2	2007	In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR.	Cholecalciferol	132-142	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	311-318
17426122-1	2007	The human 25-hydroxyvitamin D3 (25(OH)D3) 1alpha-hydroxylase, which is encoded by the CYP27B1 gene, catalyzes the metabolic activation of the 25(OH)D3 into 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the most biologically potent vitamin D3 metabolite.	Cholecalciferol	20-30	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	86-93
16824767-5	2006	Nevertheless, dermal fibroblasts produce inactive vitamin D3 metabolites that can be activated by epidermal keratinocytes as CYP24 mRNA is induced in epidermal keratinocytes but not in dermal fibroblasts after transfer of medium or cellular suspensions from BM15766-pretreated, UVB-irradiated fibroblasts.	Cholecalciferol	50-60	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	125-130
17996099-8	2007	Under vitamin D3, these drugs also showed a decrease in RANKL level, which, however, did not reach statistical significance.	Cholecalciferol	6-16	TNF superfamily member 11	Homo sapiens	56-61
16879968-1	2006	The synthesis of a new class of vitamin D3 analogues in which two units of 1alpha,25-dihydroxyvitamin D3 are linked at the C-3 position by a dicarbamate functionality of variable length is described.	Cholecalciferol	32-42	complement C3	Homo sapiens	123-126
16930540-1	2006	CYP27A1 catalyses hydroxylations in the biosynthesis of bile acids and the bioactivation of vitamin D3.	Cholecalciferol	92-102	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-7
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Cholecalciferol	106-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Cholecalciferol	176-186	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Cholecalciferol	176-186	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	156-162
16842832-10	2006	CYP2J2 and CYP2J3 exhibit distinct preferences toward vitamin D3 and D2.	Cholecalciferol	54-64	cytochrome P450, family 2, subfamily j, polypeptide 4	Rattus norvegicus	0-6
16842832-10	2006	CYP2J2 and CYP2J3 exhibit distinct preferences toward vitamin D3 and D2.	Cholecalciferol	54-64	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	11-17
16598763-3	2006	THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction.	Cholecalciferol	217-227	GLI family zinc finger 2	Homo sapiens	0-5
16598763-3	2006	THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction.	Cholecalciferol	217-227	vitamin D receptor	Homo sapiens	60-78
16598763-3	2006	THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction.	Cholecalciferol	217-227	vitamin D receptor	Homo sapiens	80-83
16518840-1	2006	Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter.	Cholecalciferol	36-46	vitamin D receptor	Homo sapiens	70-89
16924108-3	2006	We report that OX40 ligand (OX40L) completely inhibited the generation of IL-10-producing Tr1 cells from naive and memory CD4(+) T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3.	Cholecalciferol	194-204	TNF superfamily member 4	Homo sapiens	15-26
16924108-3	2006	We report that OX40 ligand (OX40L) completely inhibited the generation of IL-10-producing Tr1 cells from naive and memory CD4(+) T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3.	Cholecalciferol	194-204	TNF superfamily member 4	Homo sapiens	28-33
16924108-3	2006	We report that OX40 ligand (OX40L) completely inhibited the generation of IL-10-producing Tr1 cells from naive and memory CD4(+) T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3.	Cholecalciferol	194-204	interleukin 10	Homo sapiens	74-79
16518840-1	2006	Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter.	Cholecalciferol	36-46	vitamin D receptor	Homo sapiens	91-94
16518840-1	2006	Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter.	Cholecalciferol	36-46	cyclin dependent kinase inhibitor 1B	Homo sapiens	139-146
16518840-3	2006	To address this issue, we constructed the AF-2 deletion mutant of VDR and tested the effect of vitamin D3 on p27Kip1 expression.	Cholecalciferol	95-105	cyclin dependent kinase inhibitor 1B	Homo sapiens	109-116
16518840-4	2006	In consistent with our previous results, we found that expression of wild-type VDR in SW620 colon cancer cells, which expressed very low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity and protein expression.	Cholecalciferol	172-182	vitamin D receptor	Homo sapiens	79-82
16518840-4	2006	In consistent with our previous results, we found that expression of wild-type VDR in SW620 colon cancer cells, which expressed very low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity and protein expression.	Cholecalciferol	172-182	cyclin dependent kinase inhibitor 1B	Homo sapiens	194-201
16518840-6	2006	DNA affinity precipitation assay (DAPA) showed that both wild-type and deletion mutant of VDR bound to the DNA probe corresponding to the Sp1 binding site in the p27Kip1 promoter in a vitamin D3-dependent manner indicating deletion of AF-2 domain does not affect the interaction between VDR and Sp1.	Cholecalciferol	184-194	vitamin D receptor	Homo sapiens	90-93
16518840-6	2006	DNA affinity precipitation assay (DAPA) showed that both wild-type and deletion mutant of VDR bound to the DNA probe corresponding to the Sp1 binding site in the p27Kip1 promoter in a vitamin D3-dependent manner indicating deletion of AF-2 domain does not affect the interaction between VDR and Sp1.	Cholecalciferol	184-194	cyclin dependent kinase inhibitor 1B	Homo sapiens	162-169
16772287-2	2006	Two nuclease-hypersensitive sites span the key regulatory elements that control basal tissue-specific and vitamin D3-enhanced OC gene transcription.	Cholecalciferol	106-116	bone gamma-carboxyglutamate protein	Homo sapiens	126-128
16772287-5	2006	This interaction results in inhibition of both basal and vitamin D3-enhanced OC gene transcription and a marked decrease in nuclease hypersensitivity.	Cholecalciferol	57-67	bone gamma-carboxyglutamate protein	Homo sapiens	77-79
16777406-0	2006	Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway.	Cholecalciferol	13-23	AKT serine/threonine kinase 1	Homo sapiens	76-79
16777406-0	2006	Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway.	Cholecalciferol	13-23	mechanistic target of rapamycin kinase	Homo sapiens	80-84
16886665-6	2006	Vitamin D3 up-regulated 25(OH)D-24R-hydroxylase and IGFBP3, two 1alpha,25(OH)2D-responsive genes, in prostate cells.	Cholecalciferol	0-10	insulin like growth factor binding protein 3	Homo sapiens	52-58
16880407-0	2006	Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis.	Cholecalciferol	8-18	thymic stromal lymphopoietin	Mus musculus	51-79
16886688-3	2006	MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations.	Cholecalciferol	128-138	vitamin D receptor	Homo sapiens	23-41
16886688-3	2006	MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations.	Cholecalciferol	128-138	vitamin D receptor	Homo sapiens	43-46
16777406-8	2006	Inhibition of the Akt-mTOR pathway represents a novel mechanism by which vitamin D3 analogs may modulate the expression and activity of proteins involved in cancer cell proliferation.	Cholecalciferol	73-83	AKT serine/threonine kinase 1	Homo sapiens	18-21
16777406-8	2006	Inhibition of the Akt-mTOR pathway represents a novel mechanism by which vitamin D3 analogs may modulate the expression and activity of proteins involved in cancer cell proliferation.	Cholecalciferol	73-83	mechanistic target of rapamycin kinase	Homo sapiens	22-26
16614077-2	2006	The increase in OPG mRNA noted with dexamethasone was in contrast to 1,25(OH)(2)-vitamin D3 (D3) treatment, which decreased OPG expression.	Cholecalciferol	81-91	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	124-127
16672909-0	2006	Kidney-specific upregulation of vitamin D3 target genes in ClC-5 KO mice.	Cholecalciferol	32-42	chloride channel, voltage-sensitive 5	Mus musculus	59-64
16205781-2	2006	In the present study, we investigated the effects of the novel D(3)-selective antagonist NGB 2904 (N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-3-fluorenylcarboxamide) on cocaine self-administration, cocaine-enhanced brain stimulation reward (BSR), and cocaine-triggered reinstatement of drug-seeking behavior in male Long-Evans rats.	Cholecalciferol	63-67	neuroglobin	Rattus norvegicus	89-92
16205781-5	2006	Overall, these data show that the novel D(3)-selective antagonist NGB 2904 attenuates cocaine"s rewarding effects as assessed by PR self-administration, BSR, and cocaine-triggered reinstatement of cocaine-seeking behavior.	Cholecalciferol	40-44	neuroglobin	Rattus norvegicus	66-69
16895439-0	2006	Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion.	Cholecalciferol	52-62	smoothened, frizzled class receptor	Danio rerio	14-24
16895439-7	2006	Vitamin D3 bound to Smo with high affinity in a cyclopamine-sensitive manner.	Cholecalciferol	0-10	smoothened, frizzled class receptor	Danio rerio	20-23
16895439-8	2006	Treating zebrafish embryos with vitamin D3 mimicked the smo(-/-) phenotype, confirming the inhibitory action in vivo.	Cholecalciferol	32-42	smoothened, frizzled class receptor	Danio rerio	56-59
16690021-6	2006	The data suggest that VDR-mediated inhibition of 25-hydroxylase(s) by vitamin D3 metabolites at the transcriptional level may play an important role in the regulation of 25-hydroxyvitamin D3 production in liver and other tissues.	Cholecalciferol	70-80	vitamin D receptor	Homo sapiens	22-25
16696936-0	2006	Regulation of cholesterol 25-hydroxylase expression by vitamin D3 metabolites in human prostate stromal cells.	Cholecalciferol	55-65	cholesterol 25-hydroxylase	Homo sapiens	14-40
16696936-10	2006	Our data suggest that ch25h could be a vitamin D3 target gene and may partly mediate anti-proliferative action of vitamin D3 in human primary prostate stromal cells.	Cholecalciferol	39-49	cholesterol 25-hydroxylase	Homo sapiens	22-27
16696936-10	2006	Our data suggest that ch25h could be a vitamin D3 target gene and may partly mediate anti-proliferative action of vitamin D3 in human primary prostate stromal cells.	Cholecalciferol	114-124	cholesterol 25-hydroxylase	Homo sapiens	22-27
16800739-9	2006	In some breast cancer cell lines, KLK6 expression could be restored by the vitamin D3 analog EB1089.	Cholecalciferol	75-85	kallikrein related peptidase 6	Homo sapiens	34-38
16508948-0	2006	Vitamin D3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8.	Cholecalciferol	0-10	fibroblast growth factor 8	Homo sapiens	124-150
16508948-5	2006	Importantly, fgf8 was markedly repressed in response to vitamin D3.	Cholecalciferol	56-66	fibroblast growth factor 8	Homo sapiens	13-17
16508948-6	2006	The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition.	Cholecalciferol	66-76	fibroblast growth factor 8	Homo sapiens	26-30
16508948-6	2006	The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition.	Cholecalciferol	66-76	fibroblast growth factor 8	Homo sapiens	126-130
16508948-6	2006	The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition.	Cholecalciferol	159-169	fibroblast growth factor 8	Homo sapiens	26-30
16508948-6	2006	The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition.	Cholecalciferol	159-169	fibroblast growth factor 8	Homo sapiens	126-130
16508948-10	2006	All these findings strongly suggest that vitamin D3 serves as a negative regulator for both androgen-related and fgf8 transcriptions.	Cholecalciferol	41-51	fibroblast growth factor 8	Homo sapiens	113-117
16521124-0	2006	Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons.	Cholecalciferol	8-18	vitamin D receptor	Rattus norvegicus	109-127
16521124-1	2006	The vitamin D receptor (VDR) is believed to mediate different biologic actions of vitamin D3, an active metabolite of vitamin D, through regulation of gene expression after binding to specific DNA-response element (VDRE) on target genes.	Cholecalciferol	82-92	vitamin D receptor	Rattus norvegicus	4-22
16521124-1	2006	The vitamin D receptor (VDR) is believed to mediate different biologic actions of vitamin D3, an active metabolite of vitamin D, through regulation of gene expression after binding to specific DNA-response element (VDRE) on target genes.	Cholecalciferol	82-92	vitamin D receptor	Rattus norvegicus	24-27
16521124-5	2006	Chronic treatment of vitamin D3 increased the expression of microtubule-associated protein-2, growth-associated protein-43 and synapsin-1 in cultured rat cortical neurons, suggesting a trophic role of vitamin D3 in differentiation and maturation of neurons.	Cholecalciferol	21-31	microtubule-associated protein 2	Rattus norvegicus	60-92
16521124-5	2006	Chronic treatment of vitamin D3 increased the expression of microtubule-associated protein-2, growth-associated protein-43 and synapsin-1 in cultured rat cortical neurons, suggesting a trophic role of vitamin D3 in differentiation and maturation of neurons.	Cholecalciferol	21-31	growth associated protein 43	Rattus norvegicus	94-122
16521124-5	2006	Chronic treatment of vitamin D3 increased the expression of microtubule-associated protein-2, growth-associated protein-43 and synapsin-1 in cultured rat cortical neurons, suggesting a trophic role of vitamin D3 in differentiation and maturation of neurons.	Cholecalciferol	21-31	synapsin I	Rattus norvegicus	127-137
16521124-7	2006	Parallel studies showed that VDR mRNA was significantly upregulated 12-24 hr after brief glutamate exposure in cultured neurons chronically treated with vitamin D3, but not in those with vehicle alone.	Cholecalciferol	153-163	vitamin D receptor	Rattus norvegicus	29-32
16521124-8	2006	Our results suggest that vitamin D3 may play a role in mechanisms relevant to protective properties against the neurotoxicity of glutamate through upregulation of VDR expression in cultured rat cortical neurons.	Cholecalciferol	25-35	vitamin D receptor	Rattus norvegicus	163-166
16651407-6	2006	Among them, we focused on the vitamin D receptor (VDR) gene because vitamin D3 has recently been used for chemoprevention of human tumors.	Cholecalciferol	68-78	vitamin D receptor	Homo sapiens	30-48
16651407-6	2006	Among them, we focused on the vitamin D receptor (VDR) gene because vitamin D3 has recently been used for chemoprevention of human tumors.	Cholecalciferol	68-78	vitamin D receptor	Homo sapiens	50-53
16651407-9	2006	In addition, p53 induced VDR target genes in a vitamin D3-dependent manner.	Cholecalciferol	47-57	tumor protein p53	Homo sapiens	13-16
16651407-9	2006	In addition, p53 induced VDR target genes in a vitamin D3-dependent manner.	Cholecalciferol	47-57	vitamin D receptor	Homo sapiens	25-28
16549446-5	2006	Furthermore, HMEC cultures were dose dependently growth inhibited by physiological concentrations of 25(OH)D3, suggesting that CYP27B1 converts this precursor cholecalciferol metabolite to 1alpha,25(OH)2D3, the ligand for the vitamin D receptor (VDR).	Cholecalciferol	159-174	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	127-134
16555680-1	2006	Vitamin D3 is modified by vitamin D3 25-hydroxylase in the liver, and by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in the kidney, to form the active metabolite 1alpha,25-dihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	26-51
16555680-1	2006	Vitamin D3 is modified by vitamin D3 25-hydroxylase in the liver, and by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in the kidney, to form the active metabolite 1alpha,25-dihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	73-112
16555680-1	2006	Vitamin D3 is modified by vitamin D3 25-hydroxylase in the liver, and by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in the kidney, to form the active metabolite 1alpha,25-dihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	114-121
16483768-0	2006	Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	45-48
16234363-3	2006	In addition, forced expression of TEL2 but not TEL blocks vitamin D3-induced differentiation of U937 and HL60 myeloid cells.	Cholecalciferol	58-68	ETS variant transcription factor 7	Homo sapiens	34-38
16234363-3	2006	In addition, forced expression of TEL2 but not TEL blocks vitamin D3-induced differentiation of U937 and HL60 myeloid cells.	Cholecalciferol	58-68	ETS variant transcription factor 6	Homo sapiens	34-37
16269462-0	2006	Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling.	Cholecalciferol	73-83	thioredoxin	Homo sapiens	0-11
16402404-3	2006	We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion.	Cholecalciferol	20-30	toll like receptor 2	Homo sapiens	112-116
16402404-3	2006	We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion.	Cholecalciferol	20-30	toll like receptor 4	Homo sapiens	121-125
16402404-3	2006	We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion.	Cholecalciferol	78-81	toll like receptor 2	Homo sapiens	112-116
16402404-3	2006	We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion.	Cholecalciferol	78-81	toll like receptor 4	Homo sapiens	121-125
16502013-4	2006	The aim of this study was to examine whether the biologically active vitamin D3-metabolite 1alpha,25-dihydroxyvitamin D3 (1,25-D3), influences the expression of inducible cyclooxygenase-2 in photothrombotically lesioned brain or is part of an independent neuroprotective mechanism.	Cholecalciferol	69-79	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	171-187
16491287-1	2006	UNLABELLED: In this 2-year randomized controlled study of 167 men &gt;50 years of age, supplementation with calcium-vitamin D3-fortified milk providing an additional 1000 mg of calcium and 800 IU of vitamin D3 per day was effective for suppressing PTH and stopping or slowing bone loss at several clinically important skeletal sites at risk for fracture.	Cholecalciferol	116-126	parathyroid hormone	Homo sapiens	248-251
16316664-8	2006	Skin of the vitamin D3 pretreated group demonstrated stronger immunoreactivity for VDR compared to irradiation alone group.	Cholecalciferol	12-22	vitamin D receptor	Rattus norvegicus	83-86
16251181-11	2006	In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D3 were reversed by IL-4 and IL-13.	Cholecalciferol	122-132	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	89-92
16251181-11	2006	In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D3 were reversed by IL-4 and IL-13.	Cholecalciferol	122-132	interleukin 4	Mus musculus	150-154
16251181-11	2006	In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D3 were reversed by IL-4 and IL-13.	Cholecalciferol	122-132	interleukin 13	Mus musculus	159-164
16269462-0	2006	Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling.	Cholecalciferol	73-83	peroxisome proliferator activated receptor gamma	Homo sapiens	180-189
16380433-7	2006	Finally, BSPRY expression in kidney was increased in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice, suggesting an inverse regulation by vitamin D3.	Cholecalciferol	63-73	B-box and SPRY domain containing	Mus musculus	9-14
16355272-1	2006	UNLABELLED: Monocytes express 1alpha-hydroxylase, the enzyme responsible for final hydroxylation of vitamin D3, in response to IFNgamma and CD14/TLR4 activation.	Cholecalciferol	100-110	interferon gamma	Homo sapiens	127-135
16355272-1	2006	UNLABELLED: Monocytes express 1alpha-hydroxylase, the enzyme responsible for final hydroxylation of vitamin D3, in response to IFNgamma and CD14/TLR4 activation.	Cholecalciferol	100-110	CD14 molecule	Homo sapiens	140-144
17163485-10	2006	hCAR inhibited hVDR-mediated vitamin D3 induction of hSULT2A1 but not methotrexate induction of hSULT2A1.	Cholecalciferol	29-39	CXADR Ig-like cell adhesion molecule	Homo sapiens	0-4
16355272-1	2006	UNLABELLED: Monocytes express 1alpha-hydroxylase, the enzyme responsible for final hydroxylation of vitamin D3, in response to IFNgamma and CD14/TLR4 activation.	Cholecalciferol	100-110	toll like receptor 4	Homo sapiens	145-149
17163485-10	2006	hCAR inhibited hVDR-mediated vitamin D3 induction of hSULT2A1 but not methotrexate induction of hSULT2A1.	Cholecalciferol	29-39	vitamin D receptor	Homo sapiens	15-19
16341266-1	2006	We previously reported that human CD4+ Tregs secrete high levels of IL-10 when stimulated in the presence of dexamethasone and calcitriol (vitamin D3).	Cholecalciferol	139-149	CD4 molecule	Homo sapiens	34-37
17163485-10	2006	hCAR inhibited hVDR-mediated vitamin D3 induction of hSULT2A1 but not methotrexate induction of hSULT2A1.	Cholecalciferol	29-39	sulfotransferase family 2A member 1	Homo sapiens	53-61
16341266-1	2006	We previously reported that human CD4+ Tregs secrete high levels of IL-10 when stimulated in the presence of dexamethasone and calcitriol (vitamin D3).	Cholecalciferol	139-149	interleukin 10	Homo sapiens	68-73
16341266-5	2006	Addition of vitamin D3 with dexamethasone to cultures of SR CD4+ T cells enhanced IL-10 synthesis to levels observed in cells from glucocorticoid-sensitive patients cultured with dexamethasone alone.	Cholecalciferol	12-22	CD4 molecule	Homo sapiens	60-63
16341266-5	2006	Addition of vitamin D3 with dexamethasone to cultures of SR CD4+ T cells enhanced IL-10 synthesis to levels observed in cells from glucocorticoid-sensitive patients cultured with dexamethasone alone.	Cholecalciferol	12-22	interleukin 10	Homo sapiens	82-87
16336217-4	2006	Interestingly, pre-treating HIB5 with vitamin D3 significantly reduced these effects of Dex and, in addition, lowered the transactivational function of the glucocorticoid receptor (GR) in transient reporter gene assays.	Cholecalciferol	38-48	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	156-179
16336217-4	2006	Interestingly, pre-treating HIB5 with vitamin D3 significantly reduced these effects of Dex and, in addition, lowered the transactivational function of the glucocorticoid receptor (GR) in transient reporter gene assays.	Cholecalciferol	38-48	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	181-183
16336217-5	2006	A further impact of vitamin D3 on glucocorticoid effects was observed in a rat primary hippocampal culture known to be particularly sensitive to prolonged GR activation.	Cholecalciferol	20-30	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	155-157
16844314-8	2006	We present an example from our own studies by showing that vitamin D3 has the potential to de-methylate the osteocalcin-promoter in MG63 osteosarcoma cells.	Cholecalciferol	59-69	bone gamma-carboxyglutamate protein	Homo sapiens	108-119
16502129-6	2006	However, recent evidence indicates that bone matrix proteins such as osteopontin, matrix Gla protein (MGP), and osteocalcin are expressed in calcified atherosclerotic lesions, and that calcium-regulating hormones such as vitamin D3 and parathyroid hormone-related protein regulate vascular calcification in in vitro vascular calcification models based on cultured aortic smooth muscle cells.	Cholecalciferol	221-231	parathyroid hormone like hormone	Homo sapiens	236-271
16341266-7	2006	Vitamin D3 significantly overcame the inhibition of glucocorticoid-receptor expression by dexamethasone while IL-10 upregulated glucocorticoid-receptor expression by CD4+ T cells, suggesting potential mechanisms whereby these treatments may overcome poor glucocorticoid responsiveness.	Cholecalciferol	0-10	nuclear receptor subfamily 3 group C member 1	Homo sapiens	52-75
16341266-8	2006	We show here that administration of vitamin D3 to healthy individuals and SR asthmatic patients enhanced subsequent responsiveness to dexamethasone for induction of IL-10.	Cholecalciferol	36-46	interleukin 10	Homo sapiens	165-170
19079903-4	2005	It is suggested that the relationship between vitamin D and low-intensity chronic inflammation and insulin resistance in T2DM can be mediated in part by the immune-modulating properties of the active form of vitamin D (1-alpha,25-dihydroxyvitamin D3; 1,25(OH)2D3), which is able to down regulate the production of pro-inflammatory cytokines - particularly TNF-alpha, and IL-6.	Cholecalciferol	247-249	insulin	Homo sapiens	99-106
15904991-3	2005	Here, we present results of the effect of PRP on Vitamin D3-induced phenotypic (CD11b and CD14) and functional (phagocytic) differentiation/maturation of monocytes/macrophages using the premonocytic HL-60 cell line as a model.	Cholecalciferol	49-59	integrin subunit alpha M	Homo sapiens	80-85
16172800-8	2005	Furthermore, serum levels of 1.25 vitamin D3 and PTH were negatively correlated with disease activity and TNFalpha.	Cholecalciferol	34-44	tumor necrosis factor	Homo sapiens	106-114
15904991-3	2005	Here, we present results of the effect of PRP on Vitamin D3-induced phenotypic (CD11b and CD14) and functional (phagocytic) differentiation/maturation of monocytes/macrophages using the premonocytic HL-60 cell line as a model.	Cholecalciferol	49-59	CD14 molecule	Homo sapiens	90-94
16239345-6	2005	Association of HDAC3 and HDAC1 with the relB VDR-binding site was observed, but only HDAC3 was reciprocally modulated by D(3) analog and LPS.	Cholecalciferol	121-125	histone deacetylase 3	Mus musculus	85-90
16239345-8	2005	Depletion of HDAC3 attenuated relB suppression by D(3) analog.	Cholecalciferol	50-54	histone deacetylase 3	Mus musculus	13-18
16239345-8	2005	Depletion of HDAC3 attenuated relB suppression by D(3) analog.	Cholecalciferol	50-54	avian reticuloendotheliosis viral (v-rel) oncogene related B	Mus musculus	30-34
15988048-5	2005	Amplifying CD11b, CD11c, and CD14 mRNAs, as specific markers of differentiation, by the real-time RT-PCR assay we could detect both retinoic acid (RA) and vitamin D3 and human transforming growth factor beta1 (VitD3/TGFbeta1) induced cellular maturation more precociously than the canonical flow-cytofluorimetric assay.	Cholecalciferol	155-165	integrin subunit alpha M	Homo sapiens	11-16
16284441-3	2005	Despite the severity of her condition, oral administration of vitamin D3 (alphacalcido) has stalled both the tumor growth and further increases of serum thyroglobulin (Tg) level, and has led to a good preservation of quality of life for the last two years.	Cholecalciferol	62-72	thyroglobulin	Homo sapiens	153-166
16284441-3	2005	Despite the severity of her condition, oral administration of vitamin D3 (alphacalcido) has stalled both the tumor growth and further increases of serum thyroglobulin (Tg) level, and has led to a good preservation of quality of life for the last two years.	Cholecalciferol	62-72	thyroglobulin	Homo sapiens	168-170
16148162-6	2005	Correlating with reduced EAE, the intact, vitamin D(3)-fed female mice had significantly more 1,25-dihydroxyvitamin D(3) and fewer CYP24A1 transcripts, encoding the 1,25-dihydroxyvitamin D(3)-inactivating enzyme, in the spinal cord than the other groups of mice.	Cholecalciferol	42-54	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	131-138
16091841-3	2005	Osteocalcin production was evaluated by cultured cells in neridronate 10(-4) M and 10(-6) M, both under basal conditions and after vitamin D3 stimulation.	Cholecalciferol	131-141	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
16091841-4	2005	In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively.	Cholecalciferol	31-41	bone gamma-carboxyglutamate protein	Homo sapiens	52-63
16091841-4	2005	In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively.	Cholecalciferol	31-41	bone gamma-carboxyglutamate protein	Homo sapiens	203-214
16091841-4	2005	In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively.	Cholecalciferol	31-41	bone gamma-carboxyglutamate protein	Homo sapiens	203-214
16042547-4	2005	In this paper, we provide evidence to suggest that vitamin D3 acts as an anti-inflammatory agent and reverses the age-related increase in microglial activation and the accompanying increase in IL-1beta (interleukin-1beta) concentration.	Cholecalciferol	51-61	interleukin 1 beta	Rattus norvegicus	193-201
16042547-4	2005	In this paper, we provide evidence to suggest that vitamin D3 acts as an anti-inflammatory agent and reverses the age-related increase in microglial activation and the accompanying increase in IL-1beta (interleukin-1beta) concentration.	Cholecalciferol	51-61	interleukin 1 beta	Rattus norvegicus	203-220
16922635-6	2005	However, Caco-2 cells may be induced to express higher levels of CYP3A4 by treatment with vitamin D3.	Cholecalciferol	90-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
16098191-0	2005	The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism.	Cholecalciferol	60-70	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	4-22
16098191-1	2005	We show that cytochrome P450scc (CYP11A1) in either a reconstituted system or in isolated adrenal mitochondria can metabolize vitamin D3.	Cholecalciferol	126-136	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	13-31
16098191-1	2005	We show that cytochrome P450scc (CYP11A1) in either a reconstituted system or in isolated adrenal mitochondria can metabolize vitamin D3.	Cholecalciferol	126-136	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	33-40
16098191-4	2005	Based on NMR analysis and known properties of P450scc we propose that hydroxylation of vitamin D3 by P450scc occurs sequentially and stereospecifically with initial formation of 20(S)-hydroxyvitamin D3.	Cholecalciferol	87-97	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	46-53
16098191-4	2005	Based on NMR analysis and known properties of P450scc we propose that hydroxylation of vitamin D3 by P450scc occurs sequentially and stereospecifically with initial formation of 20(S)-hydroxyvitamin D3.	Cholecalciferol	87-97	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	101-108
16098191-8	2005	It therefore appears that non-P450scc enzymes present in the adrenal cortex to some extent contribute to metabolism of vitamin D3.	Cholecalciferol	119-129	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	30-37
16098191-9	2005	We conclude that purified P450scc in a reconstituted system or P450scc in adrenal mitochondria can add one hydroxyl group to vitamin D3 with subsequent hydroxylation being observed for reconstituted enzyme but not for adrenal mitochondria.	Cholecalciferol	125-135	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	26-33
16098191-9	2005	We conclude that purified P450scc in a reconstituted system or P450scc in adrenal mitochondria can add one hydroxyl group to vitamin D3 with subsequent hydroxylation being observed for reconstituted enzyme but not for adrenal mitochondria.	Cholecalciferol	125-135	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	63-70
15988048-5	2005	Amplifying CD11b, CD11c, and CD14 mRNAs, as specific markers of differentiation, by the real-time RT-PCR assay we could detect both retinoic acid (RA) and vitamin D3 and human transforming growth factor beta1 (VitD3/TGFbeta1) induced cellular maturation more precociously than the canonical flow-cytofluorimetric assay.	Cholecalciferol	155-165	CD14 molecule	Homo sapiens	29-33
16158969-0	2005	Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics.	Cholecalciferol	69-79	vitamin D receptor	Homo sapiens	20-23
15809060-6	2005	Furthermore, the expression of CD14 in U937 cells expressing the DeltaC-C mutant in response to vitamin D3 was markedly higher than in cells expressing PML-RARalpha.	Cholecalciferol	96-106	CD14 molecule	Homo sapiens	31-35
15864137-0	2005	Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis.	Cholecalciferol	113-123	vitamin D receptor	Homo sapiens	0-18
15863722-0	2005	Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter.	Cholecalciferol	51-61	cyclin C	Homo sapiens	24-32
15585593-4	2005	CYP2C11 had the greatest activity with these substrates, except vitamin D3, which had the same activity as four of the other enzymes.	Cholecalciferol	64-74	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	0-7
15585593-5	2005	The descending order of 25-hydroxylation by CYP2C11 was 1alphaOHD3 &gt; 1alphaOHD2 &gt; vitamin D2 &gt; vitamin D3.	Cholecalciferol	104-114	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	44-51
15585593-15	2005	It is concluded that CYP2C11 is a male-specific hepatic microsomal vitamin D 25-hydroxylase that hydroxylates vitamin D2, vitamin D3, 1alphaOHD2, and 1alphaOHD3.	Cholecalciferol	122-132	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	21-28
15585593-15	2005	It is concluded that CYP2C11 is a male-specific hepatic microsomal vitamin D 25-hydroxylase that hydroxylates vitamin D2, vitamin D3, 1alphaOHD2, and 1alphaOHD3.	Cholecalciferol	122-132	cytochrome P450, family 2, subfamily r, polypeptide 1	Rattus norvegicus	67-91
15752725-0	2005	Measurement and characterization of C-3 epimerization activity toward vitamin D3.	Cholecalciferol	70-80	complement C3	Homo sapiens	36-39
15746971-0	2005	Influence of mechanical and biological signals on gene expression in human MG-63 cells: evidence for a complex interplay between hydrostatic compression and vitamin D3 or TGF-beta1 on MMP-1 and MMP-3 mRNA levels.	Cholecalciferol	157-167	matrix metallopeptidase 1	Homo sapiens	184-189
15746971-0	2005	Influence of mechanical and biological signals on gene expression in human MG-63 cells: evidence for a complex interplay between hydrostatic compression and vitamin D3 or TGF-beta1 on MMP-1 and MMP-3 mRNA levels.	Cholecalciferol	157-167	matrix metallopeptidase 3	Homo sapiens	194-199
15785827-6	2005	RANKL expression can be upregulated by bone-resorbing factors such as glucocorticoids, vitamin D3, interleukin 1 (IL-1), IL-6, IL-11, IL-17, tumor necrosis factor-alpha, prostaglandin E2, or parathyroid hormone-related peptide.	Cholecalciferol	87-97	TNF superfamily member 11	Homo sapiens	0-5
15707954-0	2005	Negative regulation of human parathyroid hormone gene promoter by vitamin D3 through nuclear factor Y.	Cholecalciferol	66-76	parathyroid hormone	Homo sapiens	29-48
15707954-1	2005	The negative regulation of the human parathyroid hormone (PTH) gene by biologically active vitamin D3 (1,25-dihydroxyvitamin D3; 1,25(OH)2D3) was studied in rat pituitary GH4C1 cells, which express factors needed for the negative regulation.	Cholecalciferol	91-101	parathyroid hormone	Homo sapiens	37-56
15707954-1	2005	The negative regulation of the human parathyroid hormone (PTH) gene by biologically active vitamin D3 (1,25-dihydroxyvitamin D3; 1,25(OH)2D3) was studied in rat pituitary GH4C1 cells, which express factors needed for the negative regulation.	Cholecalciferol	91-101	parathyroid hormone	Homo sapiens	58-61
15816500-1	2005	Vitamin D3 is modified by vitamin D3-25-hydroxylase in the liver, and 25-hydroxyvitamin D3-1alpha-hydroxylase in the kidney, to form the active metabolite, 1,25-dihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	26-51
15766397-0	2005	[Expression of CD14 protein in U937 cells induced by vitamin D3].	Cholecalciferol	53-63	CD14 molecule	Homo sapiens	15-19
16158255-7	2005	Cholecalciferol has effects similar to those of calcitriol on growth, MMP activity, and VDR.	Cholecalciferol	0-15	matrix metallopeptidase 2	Homo sapiens	70-73
15638502-5	2005	The same phenomenon demonstrating massive denaturation and aggregation was observed for a greater than 500-fold excess of D(3) with respect to Fbg after 20 h of incubation.	Cholecalciferol	122-126	fibrinogen beta chain	Homo sapiens	143-146
15574355-3	2005	Upon analyses of the metabolites of vitamin D3 by the reconstituted system, CYP27A1 surprisingly produced at least seven forms of minor metabolites including 1alpha,25(OH)2D3 in addition to the major metabolite 25(OH)D3.	Cholecalciferol	36-46	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	76-83
15574355-4	2005	These results indicated that human CYP27A1 catalyzes multiple reactions involved in the vitamin D3 metabolism.	Cholecalciferol	88-98	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	35-42
15574355-6	2005	Enzymatic studies on substrate specificity of CYP27B1 suggest that the 1alpha-hydroxylase activity of CYP27B1 requires the presence of 25-hydroxyl group of vitamin D3 and is enhanced by 24-hydroxyl group while the presence of 23-hydroxyl group greatly reduced the activity.	Cholecalciferol	156-166	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	46-53
15574355-6	2005	Enzymatic studies on substrate specificity of CYP27B1 suggest that the 1alpha-hydroxylase activity of CYP27B1 requires the presence of 25-hydroxyl group of vitamin D3 and is enhanced by 24-hydroxyl group while the presence of 23-hydroxyl group greatly reduced the activity.	Cholecalciferol	156-166	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	102-109
15601870-3	2005	The CCAAT box on the ODF gene is required for its transcriptional induction by vitamin D3, suggesting that NF-Y coregulates this promoter along with VDR.	Cholecalciferol	79-89	TNF superfamily member 11	Homo sapiens	21-24
15601870-3	2005	The CCAAT box on the ODF gene is required for its transcriptional induction by vitamin D3, suggesting that NF-Y coregulates this promoter along with VDR.	Cholecalciferol	79-89	vitamin D receptor	Homo sapiens	149-152
15601870-5	2005	Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner.	Cholecalciferol	17-27	vitamin D receptor	Homo sapiens	59-62
15601870-5	2005	Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner.	Cholecalciferol	17-27	E1A binding protein p300	Homo sapiens	67-71
15601870-5	2005	Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner.	Cholecalciferol	17-27	TNF superfamily member 11	Homo sapiens	81-84
15749627-0	2005	Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.	Cholecalciferol	42-57	kallikrein related peptidase 3	Homo sapiens	76-79
15749627-3	2005	We investigated the effect of the nutrient vitamin D (cholecalciferol), a biochemical precursor of calcitriol, on PSA levels and the rate of rise of PSA in these patients.	Cholecalciferol	54-69	kallikrein related peptidase 3	Homo sapiens	114-117
15749627-5	2005	In 9 patients, PSA levels decreased or remained unchanged after the commencement of cholecalciferol.	Cholecalciferol	84-99	kallikrein related peptidase 3	Homo sapiens	15-18
15749627-7	2005	Also, there was a statistically significant decrease in the rate of PSA rise after administration of cholecalciferol (P = 0.005) compared with that before cholecalciferol.	Cholecalciferol	101-116	kallikrein related peptidase 3	Homo sapiens	68-71
15749627-8	2005	The median PSA doubling time increased from 14.3 mo prior to commencing cholecalciferol to 25 mo after commencing cholecalciferol.	Cholecalciferol	72-87	kallikrein related peptidase 3	Homo sapiens	11-14
15749627-8	2005	The median PSA doubling time increased from 14.3 mo prior to commencing cholecalciferol to 25 mo after commencing cholecalciferol.	Cholecalciferol	114-129	kallikrein related peptidase 3	Homo sapiens	11-14
15749627-9	2005	Fourteen of 15 patients had a prolongation of PSA doubling time after commencing cholecalciferol.	Cholecalciferol	81-96	kallikrein related peptidase 3	Homo sapiens	46-49
16152990-8	2005	On grouping patients according to their mean OPG levels, we observed significantly lower serum IGF-1, vitamin D3 concentrations, and lumbar spine and hip bone mineral density in the high OPG groups.	Cholecalciferol	102-112	TNF receptor superfamily member 11b	Homo sapiens	45-48
16152990-8	2005	On grouping patients according to their mean OPG levels, we observed significantly lower serum IGF-1, vitamin D3 concentrations, and lumbar spine and hip bone mineral density in the high OPG groups.	Cholecalciferol	102-112	TNF receptor superfamily member 11b	Homo sapiens	187-190
15801068-0	2004	Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation.	Cholecalciferol	85-95	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
16158254-0	2005	Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.	Cholecalciferol	38-53	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	55-82
16158254-0	2005	Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.	Cholecalciferol	38-53	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	84-91
16158254-6	2005	Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR).	Cholecalciferol	18-33	vitamin D receptor	Homo sapiens	204-222
16158254-6	2005	Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR).	Cholecalciferol	18-33	vitamin D receptor	Homo sapiens	224-227
16158254-6	2005	Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR).	Cholecalciferol	18-33	androgen receptor	Homo sapiens	263-280
16158254-6	2005	Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR).	Cholecalciferol	18-33	androgen receptor	Homo sapiens	282-284
16158254-7	2005	Furthermore, we discovered that human prostate epithelial cells constitutively express appreciable levels of 25-hydroxylase CYP27A1 protein, the enzyme which catalyzes the conversion of cholecalciferol to 25(OH)D(3), and that CYP27A1 is up-regulated by cholecalciferol.	Cholecalciferol	186-201	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	124-131
16158254-7	2005	Furthermore, we discovered that human prostate epithelial cells constitutively express appreciable levels of 25-hydroxylase CYP27A1 protein, the enzyme which catalyzes the conversion of cholecalciferol to 25(OH)D(3), and that CYP27A1 is up-regulated by cholecalciferol.	Cholecalciferol	186-201	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	226-233
16158254-7	2005	Furthermore, we discovered that human prostate epithelial cells constitutively express appreciable levels of 25-hydroxylase CYP27A1 protein, the enzyme which catalyzes the conversion of cholecalciferol to 25(OH)D(3), and that CYP27A1 is up-regulated by cholecalciferol.	Cholecalciferol	253-268	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	124-131
16158255-0	2005	Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.	Cholecalciferol	0-15	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	113-120
16158255-0	2005	Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.	Cholecalciferol	17-27	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	113-120
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	vimentin	Homo sapiens	144-152
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	matrix metallopeptidase 9	Homo sapiens	232-237
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	matrix metallopeptidase 2	Homo sapiens	242-247
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	vitamin D receptor	Homo sapiens	342-360
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	vitamin D receptor	Homo sapiens	362-365
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	retinoid X receptor alpha	Homo sapiens	368-393
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	retinoid X receptor alpha	Homo sapiens	395-404
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	androgen receptor	Homo sapiens	411-428
16158255-4	2005	Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner.	Cholecalciferol	0-15	androgen receptor	Homo sapiens	430-432
16158255-6	2005	Clin Exp Metast 2005; 22: 265-73), constitutively express the enzyme 25-hydroxylase CYP27A1 which is markedly up-regulated by cholecalciferol.	Cholecalciferol	126-141	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	84-91
15319350-0	2004	Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer.	Cholecalciferol	0-10	dynactin 6	Mus musculus	42-45
16158255-7	2005	Cholecalciferol has effects similar to those of calcitriol on growth, MMP activity, and VDR.	Cholecalciferol	0-15	vitamin D receptor	Homo sapiens	88-91
16158255-8	2005	The ability of CYP27A1 to catalyze the conversion of cholecalciferol to 25(OH)D(3) and of 25(OH)D(3) to calcitriol has been reported.	Cholecalciferol	53-68	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	15-22
15801068-3	2004	In this study we correlated osteocalcin production from human osteoblasts isolated from healthy and osteoarthritic subjects to the degree of cartilage damage, before and after stimulation with 1,25(OH)2-vitamin D3, the active metabolite of vitamin D3.	Cholecalciferol	203-213	bone gamma-carboxyglutamate protein	Homo sapiens	28-39
15801068-5	2004	We determined the osteocalcin production in normal and osteoarthritic osteoblasts from maximal and minimal cartilage damage areas both under basal conditions and after vitamin D3 stimulation.	Cholecalciferol	168-178	bone gamma-carboxyglutamate protein	Homo sapiens	18-29
15801068-8	2004	The response of osteoblasts to vitamin D3 stimulation appeared to be proportional to the degree of joint damage, as the vitamin D3-induced increase in osteocalcin is proportionally greater in maximally damaged osteoblasts compared to minimally damaged ones.	Cholecalciferol	31-41	bone gamma-carboxyglutamate protein	Homo sapiens	151-162
15801068-8	2004	The response of osteoblasts to vitamin D3 stimulation appeared to be proportional to the degree of joint damage, as the vitamin D3-induced increase in osteocalcin is proportionally greater in maximally damaged osteoblasts compared to minimally damaged ones.	Cholecalciferol	120-130	bone gamma-carboxyglutamate protein	Homo sapiens	151-162
15801068-9	2004	Thus, after vitamin D3 stimulation, a significant increase in osteocalcin production by maximally damaged osteoblasts compared to the minimally damaged ones was observed.	Cholecalciferol	12-22	bone gamma-carboxyglutamate protein	Homo sapiens	62-73
15876428-5	2004	The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction.	Cholecalciferol	32-42	vitamin D receptor	Homo sapiens	178-181
15556626-2	2004	In our previous studies, we found that FAS and FACL3 genes were vitamin D3-regulated and involved in the antiproliferative effect of 1alpha,25(OH)2D3 in the human prostate cancer LNCaP cells.	Cholecalciferol	72-74	acyl-CoA synthetase long chain family member 3	Homo sapiens	47-52
15556626-6	2004	This suggests that the downregulation of FAS expression by vitamin D3 is mediated by vitamin D3 upregulation of FACL3 expression.	Cholecalciferol	59-69	acyl-CoA synthetase long chain family member 3	Homo sapiens	112-117
15556626-6	2004	This suggests that the downregulation of FAS expression by vitamin D3 is mediated by vitamin D3 upregulation of FACL3 expression.	Cholecalciferol	85-95	acyl-CoA synthetase long chain family member 3	Homo sapiens	112-117
15556626-7	2004	Myristic acid, one of the substrates preferential for FACL3, enhanced the repression of FAS expression by vitamin D3.	Cholecalciferol	106-116	acyl-CoA synthetase long chain family member 3	Homo sapiens	54-59
15556626-8	2004	The action of myristic acid was abrogated by inhibition of FACL3 activity, suggesting that the enhancement in the downregulation of FAS expression by vitamin D3 is due to the formation of myristoyl-CoA.	Cholecalciferol	150-160	acyl-CoA synthetase long chain family member 3	Homo sapiens	59-64
15556626-9	2004	The data suggest that vitamin D3-repression of FAS mRNA expression is the consequence of feedback inhibition of FAS expression by long chain fatty acyl-CoAs, which are formed by FACL3 during its upregulation by vitamin D3 in human prostate cancer LNCaP cells.	Cholecalciferol	22-32	acyl-CoA synthetase long chain family member 3	Homo sapiens	178-183
15556626-9	2004	The data suggest that vitamin D3-repression of FAS mRNA expression is the consequence of feedback inhibition of FAS expression by long chain fatty acyl-CoAs, which are formed by FACL3 during its upregulation by vitamin D3 in human prostate cancer LNCaP cells.	Cholecalciferol	211-221	acyl-CoA synthetase long chain family member 3	Homo sapiens	178-183
15488475-2	2004	It remains to be determined whether CYP24A1 has the ability to hydroxylate vitamin D3 compounds at C-25.	Cholecalciferol	75-85	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	36-43
15521896-1	2004	AIMS: This study was undertaken to evaluate removal of 22-oxacalcitriol (OCT), an active and intravenously used vitamin D3 analogue with less calcaemic activity, by polysulphone haemodialyser in vivo and in vitro.	Cholecalciferol	112-122	plexin A2	Homo sapiens	73-76
15876428-2	2004	Vitamin D receptor (VDR) belongs to a nuclear receptor super-family that mediates the genomic actions of vitamin D3 and regulates gene expression by binding with vitamin D response elements in the promoter region of the cognate gene.	Cholecalciferol	105-115	vitamin D receptor	Homo sapiens	0-18
15876428-2	2004	Vitamin D receptor (VDR) belongs to a nuclear receptor super-family that mediates the genomic actions of vitamin D3 and regulates gene expression by binding with vitamin D response elements in the promoter region of the cognate gene.	Cholecalciferol	105-115	vitamin D receptor	Homo sapiens	20-23
15876428-5	2004	The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction.	Cholecalciferol	32-42	vitamin D receptor	Homo sapiens	98-101
15556626-0	2004	Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells.	Cholecalciferol	0-10	fatty acid synthase	Homo sapiens	20-39
15556626-0	2004	Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells.	Cholecalciferol	0-10	acyl-CoA synthetase long chain family member 3	Homo sapiens	84-118
15511223-3	2004	Moreover, purified mammalian P450scc enzyme and, most importantly, mitochondria isolated from placenta and adrenals produced robust transformation of 7-dehydrocholesterol (7-DHC; precursor to cholesterol and vitamin D3) to 7-dehydropregnenolone (7-DHP).	Cholecalciferol	208-218	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	29-36
15511223-7	2004	In the skin, 5,7-steroidal dienes (7-DHP and its hydroxy derivatives), whether synthesized locally or delivered by the circulation, may undergo UVB-induced intramolecular rearrangements to vitamin D3-like derivatives.	Cholecalciferol	189-199	dihydropyrimidinase	Homo sapiens	37-40
15369780-2	2004	To reveal the enzymatic properties of CYP27B1, we measured its hydroxylation activity toward vitamin D3 and 1alpha-hydroxyvitamin D3 (1alpha(OH)D3) in addition to the physiological substrate 25(OH)D3.	Cholecalciferol	93-103	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	38-45
15369780-3	2004	Surprisingly, CYP27B1 converted vitamin D3 to 1alpha,25(OH)D3.	Cholecalciferol	32-42	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	14-21
15369780-7	2004	Based on these results and the fact that human CYP27A1 and Streptomyces CYP105A1 also convert vitamin D3 to 1alpha,25(OH)D3, 1alpha-hydroxylation, and 25-hydroxylation of vitamin D3 appear to be closely linked together.	Cholecalciferol	94-104	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	47-54
15369780-7	2004	Based on these results and the fact that human CYP27A1 and Streptomyces CYP105A1 also convert vitamin D3 to 1alpha,25(OH)D3, 1alpha-hydroxylation, and 25-hydroxylation of vitamin D3 appear to be closely linked together.	Cholecalciferol	171-181	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	47-54
15876428-5	2004	The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction.	Cholecalciferol	32-42	GLI family zinc finger 2	Homo sapiens	105-110
15375610-9	2004	The complete human Osteocalcin promoter and the bone-sialoprotein promoter were partially induced by vitamin D3 or C respectively while the pAd.3r-luc activity could be shut down by doxycyclin.	Cholecalciferol	101-111	bone gamma-carboxyglutamate protein	Homo sapiens	19-30
15368355-2	2004	Vitamin D3 (VD3) exerts its biological actions by binding within cells to VDR.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	74-77
15357841-12	2004	From the results, it has become evident that Vitamin D3 induces EDNRB expression by NCCmelb4 cells.	Cholecalciferol	45-55	endothelin receptor type B	Mus musculus	64-69
15331408-0	2004	Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures.	Cholecalciferol	0-10	caspase 14	Homo sapiens	19-29
15342392-6	2004	Overexpression of TEL2 in U937 cells inhibited differentiation induced by vitamin D3.	Cholecalciferol	74-84	ETS variant transcription factor 7	Homo sapiens	18-22
15331408-0	2004	Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures.	Cholecalciferol	0-10	caspase 14	Homo sapiens	75-85
15331408-4	2004	Topical treatment of psoriatic lesions with a vitamin D3 analogue resulted in a decrease of the psoriatic phenotype and an increase in caspase-14 expression in the parakeratotic plugs.	Cholecalciferol	46-56	caspase 14	Homo sapiens	135-145
15331408-6	2004	1alpha,25-Dihydroxycholecalciferol, the biologically active form of vitamin D3, increased caspase-14 expression, whereas retinoic acid inhibited it.	Cholecalciferol	68-78	caspase 14	Homo sapiens	90-100
15331408-7	2004	Moreover, retinoic acid repressed the vitamin D3-induced caspase-14 expression level.	Cholecalciferol	38-48	caspase 14	Homo sapiens	57-67
15450141-9	2004	A possible explanation is mentioned in the literature by an increase in PGP level and multi-drug resistance, so we suggest that it may play a role in impaired Tc-99m MIBI uptake in the thyroid phase and recommend cessation of vitamin D3 metabolites before performing parathyroid scintigraphy.	Cholecalciferol	226-236	phosphoglycolate phosphatase	Homo sapiens	72-75
15503649-4	2004	Vitamin D3 exerts its effects through the vitamin D3 receptor (VDR), a ligand-activated nuclear receptor expressed in a wide array of tissue and cell types.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	42-61
15503649-4	2004	Vitamin D3 exerts its effects through the vitamin D3 receptor (VDR), a ligand-activated nuclear receptor expressed in a wide array of tissue and cell types.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	63-66
15207715-4	2004	As mammalian mitochondrial CYP27A1 catalyzes a similar two-step hydroxylation towards vitamin D3, the enzymatic properties of CYP105A1 were compared with those of human CYP27A1.	Cholecalciferol	86-96	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	27-34
15371984-9	2004	Moreover, intrinsic clearance of CYP3A4-mediated verapamil metabolism in homogenates of simultaneously collected shed enterocytes correlated with in vivo E GI of d0-verapamil 15 min /d3-verapamil 240 min (r = 0.62, P =.03).	Cholecalciferol	183-185	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
15232218-2	2004	In the present study we showed that expression of RANK was strongly induced by phorbol-12-myristate-13-acetate (PMA) during monocyte differentiation of U937 cells, and was enhanced by concomitant treatment with vitamin D3.	Cholecalciferol	211-221	TNF receptor superfamily member 11a	Homo sapiens	50-54
15149692-0	2004	Design and synthesis of dysidiolide analogs from vitamin D3: novel class of Cdc25A inhibitors.	Cholecalciferol	49-59	cell division cycle 25A	Homo sapiens	76-82
15064717-0	2004	Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3.	Cholecalciferol	87-97	vitamin D receptor	Homo sapiens	0-19
15064717-0	2004	Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3.	Cholecalciferol	87-97	cyclin dependent kinase inhibitor 1B	Homo sapiens	65-72
15064717-1	2004	1alpha,25-dihydroxyvitamin D3 (vitamin D3) has been shown to upregulate p27Kip1 expression via Sp1 and NF-Y binding sites in the p27Kip1 promoter.	Cholecalciferol	19-29	cyclin dependent kinase inhibitor 1B	Homo sapiens	72-79
15064717-1	2004	1alpha,25-dihydroxyvitamin D3 (vitamin D3) has been shown to upregulate p27Kip1 expression via Sp1 and NF-Y binding sites in the p27Kip1 promoter.	Cholecalciferol	19-29	cyclin dependent kinase inhibitor 1B	Homo sapiens	129-136
15064717-3	2004	In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity.	Cholecalciferol	125-135	vitamin D receptor	Homo sapiens	50-53
15064717-3	2004	In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity.	Cholecalciferol	125-135	vitamin D receptor	Homo sapiens	110-113
15064717-3	2004	In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity.	Cholecalciferol	125-135	cyclin dependent kinase inhibitor 1B	Homo sapiens	147-154
15064717-4	2004	On the contrary, suppression of Sp1 expression by small interference RNA reduced the stimulation of p27Kip1 promoter activity by vitamin D3 in LNCaP cells.	Cholecalciferol	129-139	cyclin dependent kinase inhibitor 1B	Homo sapiens	100-107
15064717-7	2004	Collectively, our results suggest that VDR is involved in the induction of p27Kip1 by vitamin D3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters.	Cholecalciferol	86-96	vitamin D receptor	Homo sapiens	39-42
15064717-7	2004	Collectively, our results suggest that VDR is involved in the induction of p27Kip1 by vitamin D3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters.	Cholecalciferol	86-96	cyclin dependent kinase inhibitor 1B	Homo sapiens	75-82
15173382-4	2004	Here, we show that Alien and Sin3A reside together in vivo with the vitamin D3 receptor on the human 24-hydroxylase (CYP24) promoter containing vitamin D3 response elements by chromatin immunoprecipitation.	Cholecalciferol	68-78	COP9 signalosome subunit 2	Homo sapiens	19-24
15328373-8	2004	Mad1-expression, however, neither enforced spontaneous differentiation nor enhanced differentiation induced by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, retinoic acid (RA), or vitamin D3 but rather led to delayed RA-stimulated differentiation.	Cholecalciferol	190-200	MAX dimerization protein 1	Homo sapiens	0-4
15173382-4	2004	Here, we show that Alien and Sin3A reside together in vivo with the vitamin D3 receptor on the human 24-hydroxylase (CYP24) promoter containing vitamin D3 response elements by chromatin immunoprecipitation.	Cholecalciferol	68-78	SIN3 transcription regulator family member A	Homo sapiens	29-34
15173382-4	2004	Here, we show that Alien and Sin3A reside together in vivo with the vitamin D3 receptor on the human 24-hydroxylase (CYP24) promoter containing vitamin D3 response elements by chromatin immunoprecipitation.	Cholecalciferol	68-78	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	117-122
15026419-10	2004	Purified recombinant CYP2J3 showed strong 25-hydroxylation activities toward vitamin D3 and 1alpha-hydroxyvitamin D3 with turnover numbers of 3.3 and 22, respectively, which were markedly higher than those of P450s previously characterized as 25-hydroxylases.	Cholecalciferol	77-87	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	21-27
15026419-12	2004	These results strongly suggest that CYP2J3 is the principal P450 responsible for vitamin D3 25-hydroxylation in rat liver.	Cholecalciferol	81-91	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	36-42
15225755-0	2004	Model of three-dimensional structure of VDR bound with Vitamin D3 analogs substituted at carbon-2.	Cholecalciferol	55-65	vitamin D receptor	Homo sapiens	40-43
15225839-5	2004	In addition, we found that TNF-alpha potently increases the conversion rate of Vitamin D(3) (cholecalciferol) to calcitriol in this cell system.	Cholecalciferol	79-91	tumor necrosis factor	Homo sapiens	27-36
15225839-5	2004	In addition, we found that TNF-alpha potently increases the conversion rate of Vitamin D(3) (cholecalciferol) to calcitriol in this cell system.	Cholecalciferol	93-108	tumor necrosis factor	Homo sapiens	27-36
14757768-0	2004	C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation.	Cholecalciferol	21-31	complement C3	Sus scrofa	0-3
14757768-2	2004	We now report the isolation and structural assignment of 3-epi-25-hydroxyvitamin D3 (3-epi-25(OH)D3 as a major metabolite of 25-hydroxyvitamin D3 (25(OH)D3) and the further metabolism of C-3 epimers of vitamin D3 metabolites.	Cholecalciferol	73-83	complement C3	Sus scrofa	187-190
14757768-10	2004	These results indicate that C-3 epimerization may be a common metabolic pathway for the major metabolites of vitamin D3.	Cholecalciferol	109-119	complement C3	Sus scrofa	28-31
15165715-2	2004	Our work was aimed to explore the production of ADM, changes and pathophysiological significance of ADM mRNA and ADM receptor components--calcitonin receptor like receptor (CRLR) and receptor activity modifying proteins (RAMPs) mRNA in calcified myocardium and aorta of rats induced by Vitamin D3 plus nicotine.	Cholecalciferol	286-296	adrenomedullin	Rattus norvegicus	48-51
15225744-0	2004	Cell specificity and properties of the C-3 epimerization of Vitamin D3 metabolites.	Cholecalciferol	60-70	complement C3	Homo sapiens	39-42
15225744-2	2004	We investigated the C-3 epimerization of Vitamin D3 metabolites in various cultured cells and basic properties of the enzyme responsible for the C-3 epimerization.	Cholecalciferol	41-51	complement C3	Rattus norvegicus	20-23
15225744-7	2004	Based on these results, the enzyme responsible for the C-3 epimerization of Vitamin D3 are thought to be different from already-known cytochrome P450-related Vitamin D metabolic enzymes and HSE.	Cholecalciferol	76-86	complement C3	Homo sapiens	55-58
15225744-7	2004	Based on these results, the enzyme responsible for the C-3 epimerization of Vitamin D3 are thought to be different from already-known cytochrome P450-related Vitamin D metabolic enzymes and HSE.	Cholecalciferol	76-86	hydroxysteroid 17-beta dehydrogenase 6	Homo sapiens	190-193
15225746-0	2004	Different effects of physiologically and pharmacologically increased growth hormone levels on cholecalciferol metabolism at prepubertal age.	Cholecalciferol	94-109	somatotropin	Canis lupus familiaris	69-83
15225746-1	2004	The aim of the study was to investigate the influence of physiologically and pharmacologically increased plasma growth hormone (GH) levels on cholecalciferol metabolism at prepubertal age.	Cholecalciferol	142-157	somatotropin	Canis lupus familiaris	112-126
15178414-0	2004	The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth.	Cholecalciferol	50-60	acyl-CoA synthetase long chain family member 3	Homo sapiens	12-46
15165715-2	2004	Our work was aimed to explore the production of ADM, changes and pathophysiological significance of ADM mRNA and ADM receptor components--calcitonin receptor like receptor (CRLR) and receptor activity modifying proteins (RAMPs) mRNA in calcified myocardium and aorta of rats induced by Vitamin D3 plus nicotine.	Cholecalciferol	286-296	adrenomedullin	Rattus norvegicus	100-103
15165715-2	2004	Our work was aimed to explore the production of ADM, changes and pathophysiological significance of ADM mRNA and ADM receptor components--calcitonin receptor like receptor (CRLR) and receptor activity modifying proteins (RAMPs) mRNA in calcified myocardium and aorta of rats induced by Vitamin D3 plus nicotine.	Cholecalciferol	286-296	adrenomedullin	Rattus norvegicus	100-103
15214747-0	2004	The effect of vitamin D3 on CD34 progenitor cells in vitamin D deficiency rickets.	Cholecalciferol	14-24	CD34 molecule	Homo sapiens	28-32
15005856-11	2004	CYP3A4 25-hydroxylase activity was four times higher with 1alpha(OH)D2 than with 1alpha(OH)D3 as substrate, was much less with vitamin D2, and was not detected with vitamin D3.	Cholecalciferol	165-175	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15083599-1	2004	Vitamin D3 is modified by vitamin D3-25-hydroxylase in the liver and 25-hydroxyvitamin D3-1 alpha-hydroxylase in the kidney to form the active metabolite 1 alpha,25-dihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	26-51
15083599-1	2004	Vitamin D3 is modified by vitamin D3-25-hydroxylase in the liver and 25-hydroxyvitamin D3-1 alpha-hydroxylase in the kidney to form the active metabolite 1 alpha,25-dihydroxyvitamin D3.	Cholecalciferol	0-10	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	69-109
14672955-9	2004	However, although adherence induced in response to D(3) was sensitive to silencing of p110alpha, LPS-induced adherence was not.	Cholecalciferol	51-55	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	86-95
14583431-3	2004	Vitamin D3 (VitD) is known to increase PMCA expression and activity in Ca2+-transporting tissues such as the intestine, as well as in osteoblasts and Madin-Darby bovine kidney epithelial cells.	Cholecalciferol	0-10	ATPase plasma membrane Ca2+ transporting 1	Bos taurus	39-43
14507914-2	2003	In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR).	Cholecalciferol	95-105	RELB proto-oncogene, NF-kB subunit	Homo sapiens	29-33
14696037-2	2004	Studies on the function of the hormonal form of vitamin D3, 1alpha,25-dihydroxyvitamin D3, have been greatly accelerated by the molecular cloning and structural analysis of the vitamin D3 receptor, which is a ligand-activated regulator of gene transcription.	Cholecalciferol	48-58	vitamin D receptor	Homo sapiens	177-196
14657394-0	2003	A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1).	Cholecalciferol	32-42	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	125-132
14507914-2	2003	In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR).	Cholecalciferol	95-105	vitamin D receptor	Homo sapiens	203-221
14507914-2	2003	In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR).	Cholecalciferol	95-105	vitamin D receptor	Homo sapiens	223-226
12893883-3	2003	Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription.	Cholecalciferol	110-120	retinoid X receptor alpha	Homo sapiens	51-54
12893883-3	2003	Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription.	Cholecalciferol	110-120	vitamin D receptor	Homo sapiens	55-58
12893883-3	2003	Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription.	Cholecalciferol	110-120	retinoid X receptor alpha	Homo sapiens	81-84
12893883-7	2003	These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription.	Cholecalciferol	208-218	retinoid X receptor alpha	Homo sapiens	75-78
12893883-7	2003	These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription.	Cholecalciferol	208-218	vitamin D receptor	Homo sapiens	111-114
12893883-7	2003	These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription.	Cholecalciferol	208-218	retinoid X receptor alpha	Homo sapiens	173-176
14550285-0	2003	Vitamin D3-dependent pathway regulates TACO gene transcription.	Cholecalciferol	0-10	coronin 1A	Homo sapiens	39-43
14531785-2	2003	The condition of vitamin D insufficiency is defined as the level of serum 25(OH)vitamin D at which vitamin D2 or D3 supplementation leads to a reduction of levels of parathyroid hormone (PTH).	Cholecalciferol	113-115	parathyroid hormone	Homo sapiens	166-185
14531785-2	2003	The condition of vitamin D insufficiency is defined as the level of serum 25(OH)vitamin D at which vitamin D2 or D3 supplementation leads to a reduction of levels of parathyroid hormone (PTH).	Cholecalciferol	113-115	parathyroid hormone	Homo sapiens	187-190
14753364-3	2004	A trend existed for pigs receiving the highest concentration of vitamin D3 supplementation to have a lower (P = 0.08) ADG (0.77 kg/d) compared with pigs fed either the 40-diet (0.88 kg/d) or control (0.92 kg/d).	Cholecalciferol	64-74	ADG	Sus scrofa	118-121
12842807-5	2003	Vitamin D3-differentiated THP-1 cells and peripheral blood mononuclear cells were stimulated in vitro with several concentrations of SP-A for different incubation times.	Cholecalciferol	0-10	surfactant protein A1	Homo sapiens	133-137
12972373-1	2003	The aim of the study was to investigate the influence of growth hormone (GH) on Vitamin D3 metabolism and the subsequent effects on calcium (Ca) homeostasis and skeletal growth in growing dogs.	Cholecalciferol	80-90	somatotropin	Canis lupus familiaris	73-75
12867411-7	2003	Co-expression of CYP2R1 with vitamin D 1alpha-hydroxylase (CYP27B1) elicited additive activation of vitamin D3, whereas co-expression with vitamin D 24-hydroxylase (CYP24A1) caused inactivation.	Cholecalciferol	100-110	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	17-23
12867411-7	2003	Co-expression of CYP2R1 with vitamin D 1alpha-hydroxylase (CYP27B1) elicited additive activation of vitamin D3, whereas co-expression with vitamin D 24-hydroxylase (CYP24A1) caused inactivation.	Cholecalciferol	100-110	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	59-66
12907249-0	2003	Inhibition of MG-63 cell cycle progression by synthetic vitamin D3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein.	Cholecalciferol	56-66	interferon alpha inducible protein 27	Homo sapiens	87-90
12907249-0	2003	Inhibition of MG-63 cell cycle progression by synthetic vitamin D3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein.	Cholecalciferol	56-66	cyclin dependent kinase 2	Homo sapiens	92-96
12916707-0	2003	IL-1beta induces and TGF-beta reduces vitamin D3-induced bone resorption in mouse calvarial bone cells.	Cholecalciferol	38-48	transforming growth factor, beta 1	Mus musculus	21-29
12916707-6	2003	TGF-beta reduced basal bone resorption and inhibited vitamin D3 [1,25(OH)2D3]-induced bone resorption in rat long bone cells.	Cholecalciferol	53-63	transforming growth factor, beta 1	Rattus norvegicus	0-8
14505649-3	2003	Therefore, 6-deoxy-5a-carba-beta-D-galactopyranosylamine (D-3) might be a promising lead compound for further design of new carba sugar-type beta-galactosidase inhibitors.	Cholecalciferol	58-61	galactosidase beta 1	Homo sapiens	141-159
12858342-0	2003	Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter.	Cholecalciferol	0-10	TNF superfamily member 11	Homo sapiens	90-95
12892157-3	2003	This study aimed to determine whether supplementation with vitamin D3 to healthy children during the winter affects bone turnover in healthy children measured by serum osteocalcin, PICP, PINP or ICTP.	Cholecalciferol	59-69	bone gamma-carboxyglutamate protein	Homo sapiens	168-179
12890894-0	2003	Selective inhibition of mammalian DNA polymerase alpha by vitamin D2 and D3.	Cholecalciferol	73-75	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	34-54
12736715-4	2003	Our results indicate that cells with endogenous or transfected exogenous c-myc overexpression (SW613-12A1 and -2G1mycP2Tu1 cell lines, respectively), activate the apoptotic machinery in response to the treatment with etoposide, doxorubicin and vitamin D3, which induce apoptosis through the death receptor Fas.	Cholecalciferol	244-254	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-78
12727200-7	2003	We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR.	Cholecalciferol	159-169	vitamin D receptor	Homo sapiens	55-58
12972373-0	2003	Growth hormone modulates cholecalciferol metabolism with moderate effects on intestinal mineral absorption and specific effects on bone formation in growing dogs raised on balanced food.	Cholecalciferol	25-40	somatotropin	Canis lupus familiaris	0-14
12972373-1	2003	The aim of the study was to investigate the influence of growth hormone (GH) on Vitamin D3 metabolism and the subsequent effects on calcium (Ca) homeostasis and skeletal growth in growing dogs.	Cholecalciferol	80-90	somatotropin	Canis lupus familiaris	57-71
12727200-7	2003	We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR.	Cholecalciferol	159-169	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	99-107
12727200-7	2003	We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR.	Cholecalciferol	159-169	vitamin D receptor	Homo sapiens	176-179
12759887-7	2003	Furthermore, fecal elastase 1 of patients correlated the same way with both D(3)-vitamins (P &lt;.01), as well as with parameters of BMD (P &lt;.01).	Cholecalciferol	76-89	chymotrypsin like elastase 3B	Homo sapiens	13-29
12800453-0	2003	The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients.	Cholecalciferol	14-24	insulin	Homo sapiens	28-35
12800453-1	2003	The aim of this study was to evaluate the effect of vitamin D3 supplementation on insulin secretion and insulin resistance.	Cholecalciferol	52-62	insulin	Homo sapiens	82-89
12800453-14	2003	Bearing in mind that the main defects in type 2 diabetes mellitus are reduced FPIS and insulin resistance, and the favourable effect vitamin D3 had on them, we suggest vitamin D3 deficiency may at least partly contribute to the impairment of insulin secretion and probably of insulin action.	Cholecalciferol	168-178	insulin	Homo sapiens	87-94
12800453-14	2003	Bearing in mind that the main defects in type 2 diabetes mellitus are reduced FPIS and insulin resistance, and the favourable effect vitamin D3 had on them, we suggest vitamin D3 deficiency may at least partly contribute to the impairment of insulin secretion and probably of insulin action.	Cholecalciferol	168-178	insulin	Homo sapiens	242-249
12697832-4	2003	Therefore, we addressed p300 control of basal and vitamin D(3)-enhanced activity of the OC promoter.	Cholecalciferol	50-62	E1A binding protein p300	Homo sapiens	24-28
12697832-4	2003	Therefore, we addressed p300 control of basal and vitamin D(3)-enhanced activity of the OC promoter.	Cholecalciferol	50-62	bone gamma-carboxyglutamate protein	Homo sapiens	88-90
12697832-5	2003	We find that transient overexpression of p300 results in a significant dose-dependent increase of both basal and vitamin D(3)-stimulated OC gene activity.	Cholecalciferol	113-125	E1A binding protein p300	Homo sapiens	41-45
12697832-5	2003	We find that transient overexpression of p300 results in a significant dose-dependent increase of both basal and vitamin D(3)-stimulated OC gene activity.	Cholecalciferol	113-125	bone gamma-carboxyglutamate protein	Homo sapiens	137-139
12757166-10	2003	Therefore, ERCP and fecal elastase 1 verify the severity grade of a chronic pancreatitis, and thus show a vitamin D3 deficiency, depending on the progress of the disease.	Cholecalciferol	106-116	chymotrypsin like elastase 3B	Homo sapiens	20-36
12446453-0	2003	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.	Cholecalciferol	4-14	tumor protein p53	Homo sapiens	53-56
12446453-0	2003	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.	Cholecalciferol	4-14	mitogen-activated protein kinase 14	Homo sapiens	89-92
12446453-0	2003	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.	Cholecalciferol	4-14	mitogen-activated protein kinase 1	Homo sapiens	134-137
12788662-0	2003	Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures.	Cholecalciferol	14-24	transforming growth factor, beta 1	Mus musculus	34-43
12399436-1	2002	The active form of vitamin D3 can regulate epidermal keratinization by inducing terminal differentiation; and mice lacking the vitamin D receptor display defects leading to postnatal alopecia.	Cholecalciferol	19-29	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	127-145
15758368-10	2003	Our data suggest that long-term treatment with calcium and 1,25(OH)(2) vitamin D3 supplements in hypoPTH patients on suppressive LT4 therapy results in increased BMD when compared with patients with normal PTH levels.	Cholecalciferol	71-81	parathyroid hormone	Homo sapiens	101-104
12711004-0	2003	Induction of apoptosis by 1,25-dihydroxyvitamin D3 in MCF-7 Vitamin D3-resistant variant can be sensitized by TPA.	Cholecalciferol	60-70	plasminogen activator, tissue type	Homo sapiens	110-113
12711004-6	2003	TPA pretreatment greatly enhances 1,25-(OH)(2)D(3) stimulated 24-hydroxylase luciferase activity and VDR protein expression, although transactivation is lower in the MCF-7(D(3)Res) cells compared to the parental cell line.	Cholecalciferol	46-49	plasminogen activator, tissue type	Homo sapiens	0-3
12711004-6	2003	TPA pretreatment greatly enhances 1,25-(OH)(2)D(3) stimulated 24-hydroxylase luciferase activity and VDR protein expression, although transactivation is lower in the MCF-7(D(3)Res) cells compared to the parental cell line.	Cholecalciferol	46-49	vitamin D receptor	Homo sapiens	101-104
12649563-0	2003	Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number.	Cholecalciferol	65-75	vitamin D receptor	Homo sapiens	0-18
12573816-0	2002	Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue.	Cholecalciferol	79-89	insulin like growth factor 1	Homo sapiens	10-15
12371967-0	2002	Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism.	Cholecalciferol	78-88	low density lipoprotein receptor-related protein 2	Mus musculus	61-68
12577313-5	2003	The 1,25(OH)(2)D(3)-induced phosphorylation was abolished by GF109203X, a general PKC inhibitor, in both cell types, confirming that the secosteroid induced PKC activity.	Cholecalciferol	15-19	protein kinase C, alpha	Mus musculus	82-85
12577313-5	2003	The 1,25(OH)(2)D(3)-induced phosphorylation was abolished by GF109203X, a general PKC inhibitor, in both cell types, confirming that the secosteroid induced PKC activity.	Cholecalciferol	15-19	protein kinase C, alpha	Mus musculus	157-160
12520525-0	2003	Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3.	Cholecalciferol	121-131	vitamin D receptor	Homo sapiens	63-81
12899518-1	2003	Calcitriol (1alpha,25(OH)2D3), the hormonally active form of vitamin D3 (D3) is produced by a cascade of reactions, including photochemical D3 synthesis in the skin and subsequent hydroxylation at the C-25 atom in the liver and finally at C-1alpha position in the kidney.	Cholecalciferol	61-71	endogenous retrovirus group K member 1	Homo sapiens	239-247
12599478-0	2002	Rational design of vitamin D3 analogues which selectively restore activity to a vitamin D receptor mutant associated with rickets.	Cholecalciferol	19-29	vitamin D receptor	Homo sapiens	80-98
12599478-1	2002	[formula: see text] Vitamin D3-resistant rickets (VDRR) is associated with mutations to the Vitamin D receptor (VDR) which effect ligand-dependent transactivation.	Cholecalciferol	20-30	vitamin D receptor	Homo sapiens	92-110
12599478-1	2002	[formula: see text] Vitamin D3-resistant rickets (VDRR) is associated with mutations to the Vitamin D receptor (VDR) which effect ligand-dependent transactivation.	Cholecalciferol	20-30	vitamin D receptor	Homo sapiens	50-53
12400159-0	2002	[Analysis of molecular mechanism of cancer cell differentiation and apoptosis induced by vitamin D3 analogs on the basis of molecular recognition of vitamin D receptor ligand binding domain].	Cholecalciferol	89-99	vitamin D receptor	Homo sapiens	149-167
12064463-0	2002	Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5,6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways.	Cholecalciferol	72-82	vitamin D receptor	Homo sapiens	140-158
12174089-11	2002	The lines of evidence for an effect of vitamin D3 in systemic cancer are the laboratory demonstration of relevant effects on cellular growth, differentiation, apoptosis, malignant cell invasion and metastasis; epidemiological findings of an association of the occurrence and outcome of cancers with derangements of vitamin D3/1,25(OH)2D3 and the association of functional polymorphisms of the VDR with the occurrence of certain cancers.	Cholecalciferol	39-49	vitamin D receptor	Homo sapiens	393-396
12363040-6	2002	The appearance of CD10 on the cell surface was blocked by preincubation of the cells with the monocytic/macrophage-differentiating agents vitamin D3 and phorbol 12-myristate 13-acetate, but not by the granulocytic differentiating agents retinoic acid or dimethyl sulfoxide.	Cholecalciferol	138-148	membrane metalloendopeptidase	Homo sapiens	18-22
12064463-0	2002	Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5,6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways.	Cholecalciferol	111-121	vitamin D receptor	Homo sapiens	140-158
11814331-5	2002	Treatment of ROS cells with Go6976, an inhibitor of PKC alpha and beta isozymes, produced similar effects as lead on vitamin D3-dependent osteocalcin production, while activation of PKC by phorbol-12-myristate-13-acetate (TPA) did not reverse or mimic this effect of lead.	Cholecalciferol	117-127	bone gamma-carboxyglutamate protein	Homo sapiens	138-149
12018917-8	2002	These findings indicate that vitamin D3 regulates Na+/H+ exchange activity in rat ileum by influencing the mRNA levels of NHE3, the predominant luminal membrane isoform involved in vectorial Na+ transport.	Cholecalciferol	29-39	solute carrier family 9 member A3	Rattus norvegicus	122-126
11811942-3	2002	In the present study, we investigated whether vitamin D3 induces vascular endothelial growth factor (VEGF) release in aortic smooth muscle A10 cells.	Cholecalciferol	46-56	vascular endothelial growth factor A	Homo sapiens	65-99
11811942-3	2002	In the present study, we investigated whether vitamin D3 induces vascular endothelial growth factor (VEGF) release in aortic smooth muscle A10 cells.	Cholecalciferol	46-56	vascular endothelial growth factor A	Homo sapiens	101-105
11811942-4	2002	1,25-Dihydroxyvitamin D3 (1,25(OH)2VD3), an active form of vitamin D3, stimulated the VEGF release while 24,25-dihydroxyvitamin D3 (24,25(OH)2VD3), an inactive form of vitamin D3, had little effect on the release.	Cholecalciferol	14-24	vascular endothelial growth factor A	Homo sapiens	86-90
11811942-4	2002	1,25-Dihydroxyvitamin D3 (1,25(OH)2VD3), an active form of vitamin D3, stimulated the VEGF release while 24,25-dihydroxyvitamin D3 (24,25(OH)2VD3), an inactive form of vitamin D3, had little effect on the release.	Cholecalciferol	59-69	vascular endothelial growth factor A	Homo sapiens	86-90
12022443-2	2002	In human osteoblasts, we showed that vitamin D3 analogue, 1,25(OH)2D3, had a stimulatory effect on ALP activity after 3 days, compared with control.	Cholecalciferol	37-47	ATHS	Homo sapiens	99-102
12022443-6	2002	These results also show that the vitamin D3 analogue stimulates ERK1 activation in primary human osteoblasts.	Cholecalciferol	33-43	mitogen-activated protein kinase 3	Homo sapiens	64-68
11801650-0	2002	Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.	Cholecalciferol	54-64	Fas cell surface death receptor	Homo sapiens	23-27
11755212-1	2001	We have recently shown that the hormonal form of vitamin D3, 1,25(OH)2-vitamin D3 (1,25(OH)2D3), stimulates the enzymatic activity of the non-receptor protein tyrosine kinase c-Src in skeletal muscle cells.	Cholecalciferol	49-59	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	175-180
11875645-0	2002	Effect of vitamin D3 on the increased expression of Bcl-xL in psoriasis.	Cholecalciferol	10-20	BCL2 like 1	Homo sapiens	52-58
11799400-1	2002	The human serum vitamin D-binding protein (DBP) has many physiologically important functions, ranging from transporting vitamin D3 metabolites, binding and sequestering globular actin and binding fatty acids to functioning in the immune system.	Cholecalciferol	120-130	GC vitamin D binding protein	Homo sapiens	16-41
11799400-1	2002	The human serum vitamin D-binding protein (DBP) has many physiologically important functions, ranging from transporting vitamin D3 metabolites, binding and sequestering globular actin and binding fatty acids to functioning in the immune system.	Cholecalciferol	120-130	D-box binding PAR bZIP transcription factor	Homo sapiens	43-46
11799400-2	2002	Here we report the 2.3 A crystal structure of DBP in complex with 25-hydroxyvitamin D3, a vitamin D3 metabolite, which reveals the vitamin D-binding site in the N-terminal part of domain I.	Cholecalciferol	76-86	D-box binding PAR bZIP transcription factor	Homo sapiens	46-49
11799400-3	2002	To more explicitly explore this, we also studied the structure of DBP in complex with a vitamin D3 analog.	Cholecalciferol	88-98	D-box binding PAR bZIP transcription factor	Homo sapiens	66-69
11799400-5	2002	These observed structural differences explain the unique vitamin D3-binding property of DBP.	Cholecalciferol	57-67	D-box binding PAR bZIP transcription factor	Homo sapiens	88-91
11814331-2	2002	To explain this clinical observation, we investigated the mechanism of action of lead on vitamin D3-dependent osteocalcin production.	Cholecalciferol	89-99	bone gamma-carboxyglutamate protein	Homo sapiens	110-121
11814331-3	2002	Lead (5-20 microM) blocked the stimulating effects of vitamin D3 on osteocalcin production in cultured rat osteosarcoma cells (ROS 17/2.8).	Cholecalciferol	54-64	bone gamma-carboxyglutamate protein	Rattus norvegicus	68-79
12362981-2	2002	PRI-1906, an analog of vitamin D2, and PRI-2191, an analog of vitamin D3 bind nuclear vitamin D receptor (nVDR) with substantially lower affinity than 1,25-dihydroxyvitamin D3 (1,25-D3), but have higher differentiation-inducing activity as estimated in HL-60 leukemia cellmodel.	Cholecalciferol	62-72	vitamin D receptor	Homo sapiens	86-104
12112004-0	2002	Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts.	Cholecalciferol	74-84	RUNX family transcription factor 2	Homo sapiens	27-32
12112004-0	2002	Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts.	Cholecalciferol	74-84	RUNX family transcription factor 2	Homo sapiens	33-38
12112004-0	2002	Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts.	Cholecalciferol	74-84	bone gamma-carboxyglutamate protein	Homo sapiens	43-54
12112009-8	2002	These studies, together with our previous findings of auto-suppression of the Runx2 promoter and negative regulation by 1,25(OH)(2) Vitamin D3, suggest that physiological control of Runx2 gene expression is mediated by a series of intricate regulatory mechanisms.	Cholecalciferol	132-142	RUNX family transcription factor 2	Rattus norvegicus	182-187
12903199-2	2002	The osteoblastic ROS17/2.8 cells abundantly express VDR and have been used for the promoter analysis of many of vitamin D3 target genes.	Cholecalciferol	112-122	vitamin D receptor	Rattus norvegicus	52-55
11748459-3	2002	The microarray showed that the most strongly up-regulated gene by 5-FU was vitamin D3 up-regulated protein 1 (VDUP1), an interesting stress response gene, which was originally reported as a vitamin D3 inducible gene in HL-60.	Cholecalciferol	75-85	thioredoxin interacting protein	Homo sapiens	110-115
11805636-13	2002	CONCLUSIONS: Posterior longitudinal ligament cells from the three North American white patients with ossification of the posterior longitudinal ligament, when cultured in vitro, synthesized osteocalcin on vitamin D3 priming, confirming their osteoblastic phenotype, whereas posterior longitudinal ligament cells from four white patients with isolated spondylosis did not.	Cholecalciferol	205-215	bone gamma-carboxyglutamate protein	Homo sapiens	190-201
11850224-1	2001	We investigated the effects of a nuclear receptor system constituted by retinoid X receptor (RXR) and its heterodimer partner on the aromatase activity in a cultured MCF-7 human breast cancer cell line and also in human ovarian granulosa cells, using each selective ligand for retinoic acid receptor, RAR (TTNPB), retinoid X receptor, RXR (LG100268), PPARgamma (troglitazone), and vitamin D3 receptor (cholecalciferol).	Cholecalciferol	402-417	retinoid X receptor alpha	Homo sapiens	93-96
11745731-3	2001	Surprisingly, only transformed cell lines were induced by 1alpha,25-dihydroxy vitamin D3 (D3) to express high amounts of CYP3A4.	Cholecalciferol	86-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
11562285-9	2001	The discovery of novel vitamin D3 analogs along with an increased understanding of the biological functions and mechanisms of action of VDR are likely to result in improved treatments for responsive indications.	Cholecalciferol	23-33	vitamin D receptor	Homo sapiens	136-139
11602520-8	2001	The retinoic acid receptor ligand all-trans-retinoic acid augmented the 1,25-(OH)(2)-D(3)-mediated induction of CYP3A4 catalytic activity up to 2-fold in Caco-2 cells, while having no demonstrable effect on levels of CYP3A4 mRNA or protein.	Cholecalciferol	85-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
11602520-8	2001	The retinoic acid receptor ligand all-trans-retinoic acid augmented the 1,25-(OH)(2)-D(3)-mediated induction of CYP3A4 catalytic activity up to 2-fold in Caco-2 cells, while having no demonstrable effect on levels of CYP3A4 mRNA or protein.	Cholecalciferol	85-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	217-223
11473365-0	2001	Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells.	Cholecalciferol	37-47	transforming growth factor beta 1	Homo sapiens	10-17
11473365-1	2001	In this study, we address whether TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in nonmalignant and malignant breast cells.	Cholecalciferol	61-71	transforming growth factor beta 1	Homo sapiens	34-41
11473365-4	2001	Thus, the sensitivity to the vitamin D3 analogs correlated with the sensitivity to TGFbeta.	Cholecalciferol	29-39	transforming growth factor beta 1	Homo sapiens	83-90
11473365-7	2001	These results are consistent with the idea that autocrine TGFbeta signaling mediates the anti-proliferative effects of the vitamin D3 analogs in these cells.	Cholecalciferol	123-133	transforming growth factor beta 1	Homo sapiens	58-65
11473365-8	2001	The expression of TGFbeta isoforms and/or TGFbeta receptors was induced by the analogs in the vitamin D3 and TGFbeta sensitive cells.	Cholecalciferol	94-104	transforming growth factor beta 1	Homo sapiens	18-25
11473365-8	2001	The expression of TGFbeta isoforms and/or TGFbeta receptors was induced by the analogs in the vitamin D3 and TGFbeta sensitive cells.	Cholecalciferol	94-104	transforming growth factor beta 1	Homo sapiens	42-49
11473365-8	2001	The expression of TGFbeta isoforms and/or TGFbeta receptors was induced by the analogs in the vitamin D3 and TGFbeta sensitive cells.	Cholecalciferol	94-104	transforming growth factor beta 1	Homo sapiens	42-49
11473365-14	2001	These results indicate that Smad3 coactivates VDR to further enhance TGFbeta signaling and vitamin D3 signaling in the sensitive 184A1 cells.	Cholecalciferol	91-101	SMAD family member 3	Homo sapiens	28-33
11473365-14	2001	These results indicate that Smad3 coactivates VDR to further enhance TGFbeta signaling and vitamin D3 signaling in the sensitive 184A1 cells.	Cholecalciferol	91-101	vitamin D receptor	Homo sapiens	46-49
11315990-0	2001	Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.	Cholecalciferol	31-41	vitamin D receptor	Homo sapiens	55-74
11493580-10	2001	Vitamin D3 supplementation causes a decrease of the serum PTH concentration, a decrease of bone turnover, and an increase of bone mineral density.	Cholecalciferol	0-10	parathyroid hormone	Homo sapiens	58-61
11516412-2	2001	Recent studies have shown that 1,25-dihydroxyvitamin D(3) (D3) enhances endogenous GDNF expression in vitro and in vivo.	Cholecalciferol	59-61	glial cell derived neurotrophic factor	Rattus norvegicus	83-87
11376942-1	2001	VDUP1 encodes a vitamin D3-inducible gene product that has been shown to be down-regulated in chemically-induced mammary tumors in rats.	Cholecalciferol	16-26	thioredoxin interacting protein	Rattus norvegicus	0-5
11339831-5	2001	Cells treated with D(3) or ATRA start to express CD11b after 9--14 h, before completing the first maturation division.	Cholecalciferol	19-23	integrin subunit alpha M	Homo sapiens	49-54
11464105-0	2001	Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes.	Cholecalciferol	22-32	nerve growth factor	Homo sapiens	42-61
11464105-5	2001	These results suggest that active vitamin D3 could treat peripheral neuropathy by inducing NGF production in the skin.	Cholecalciferol	34-44	nerve growth factor	Homo sapiens	91-94
11572331-0	2001	Stathmin levels in growth plate chondrocytes are modulated by vitamin D3 metabolites and transforming growth factor-beta1 and are associated with proliferation.	Cholecalciferol	62-72	stathmin 1	Homo sapiens	0-8
11572331-14	2001	Inhibition of PKC with chelerythrine had no effect on the response of RC cells to 1alpha,25-(OH)2D3 but it blocked the effect of rhTGF-beta1, indicating that decreases in stathmin by vitamin D3 metabolites may not be modulated by PKC, whereas increases in stathmin via rhTGF-beta1 may be regulated via a PKC-dependent mechanism.	Cholecalciferol	183-193	stathmin 1	Homo sapiens	171-179
11315990-0	2001	Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.	Cholecalciferol	31-41	retinoid X receptor alpha	Homo sapiens	75-94
11089522-0	2000	A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1.	Cholecalciferol	2-12	cyclin dependent kinase 2	Homo sapiens	76-80
11332696-1	2001	In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression.	Cholecalciferol	24-34	calcitonin-related polypeptide alpha	Rattus norvegicus	104-114
11332696-1	2001	In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression.	Cholecalciferol	24-34	calcitonin-related polypeptide alpha	Rattus norvegicus	116-118
11332696-1	2001	In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression.	Cholecalciferol	24-34	parathyroid hormone	Rattus norvegicus	124-143
11332696-1	2001	In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression.	Cholecalciferol	24-34	parathyroid hormone	Rattus norvegicus	145-148
11332696-8	2001	Our results show, that, in rats, long term administration of vitamin D3 results in a decrease in hormone biosynthetic activities of both PTH and CT-producing cells, albeit at different magnitudes.	Cholecalciferol	61-71	parathyroid hormone	Rattus norvegicus	137-140
11332696-8	2001	Our results show, that, in rats, long term administration of vitamin D3 results in a decrease in hormone biosynthetic activities of both PTH and CT-producing cells, albeit at different magnitudes.	Cholecalciferol	61-71	calcitonin-related polypeptide alpha	Rattus norvegicus	145-147
11270487-11	2001	Our results demonstrate that the biologically active form of vitamin D3 directly regulates the expression of p21 and p27, inducing a G0/G1 phase arrest: one mechanism by which 1,25(OH)2D3 controls cell proliferation inSCCHN.	Cholecalciferol	61-71	H3 histone pseudogene 16	Homo sapiens	109-112
11270487-11	2001	Our results demonstrate that the biologically active form of vitamin D3 directly regulates the expression of p21 and p27, inducing a G0/G1 phase arrest: one mechanism by which 1,25(OH)2D3 controls cell proliferation inSCCHN.	Cholecalciferol	61-71	interferon alpha inducible protein 27	Homo sapiens	117-120
11686044-1	2001	The key enzymes of vitamin D3 metabolism, renal 25-hydroxyvitamin D3 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24) were expressed in Escherichia coli, and their enzymatic properties were revealed.	Cholecalciferol	19-29	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	119-124
11686044-4	2001	Enzymatic studies on substrate specificity of CYP27B1 revealed that 25-hydroxyl group of vitamin D3 was essential for the 1 alpha-hydroxylase activity, and 24-hydroxyl group enhanced the activity, but, 23-hydroxyl group greatly reduced the activity.	Cholecalciferol	89-99	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	46-53
11702003-6	2001	In conclusion, stanniocalcin 1 was expressed in the apical membrane of distal nephron segments and enhanced by vitamin D3.	Cholecalciferol	111-121	stanniocalcin 1	Rattus norvegicus	15-30
11374031-3	2001	We found that MGP transcription is downregulated by retinoic acid and transforming growth factor beta (TGF beta) whereas it is upregulated by vitamin D3 and cyclic AMP.	Cholecalciferol	142-152	matrix Gla protein	Rattus norvegicus	14-17
11122013-3	2000	Objectives Here we report the response of the TGF-beta regulation system to 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3], an active vitamin D3 analogue Patients/methods We studied two types of fibroblasts derived from normal and psoriatic lesional skin, using an enzyme-linked immunosorbent assay and Northern blotting techniques.	Cholecalciferol	95-105	transforming growth factor beta 1	Homo sapiens	46-54
11140269-6	2000	The conversion of vitamin D3 generated after UVB irradiation to calcitriol is inhibited by ketoconazole indicating the involvement of P450 mixed function oxidases in this chemical reaction.	Cholecalciferol	18-28	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	134-138
11332745-0	2001	Nongenomic vitamin D3 analogs activating ERK2 in HL-60 cells show that retinoic acid-induced differentiation and cell cycle arrest require early concurrent MAPK and RAR and RXR activation.	Cholecalciferol	11-21	mitogen-activated protein kinase 1	Homo sapiens	41-45
11332745-0	2001	Nongenomic vitamin D3 analogs activating ERK2 in HL-60 cells show that retinoic acid-induced differentiation and cell cycle arrest require early concurrent MAPK and RAR and RXR activation.	Cholecalciferol	11-21	RAB40B, member RAS oncogene family	Homo sapiens	165-168
11332745-0	2001	Nongenomic vitamin D3 analogs activating ERK2 in HL-60 cells show that retinoic acid-induced differentiation and cell cycle arrest require early concurrent MAPK and RAR and RXR activation.	Cholecalciferol	11-21	retinoid X receptor alpha	Homo sapiens	173-176
11246549-1	2001	1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes.	Cholecalciferol	19-29	coagulation factor III, tissue factor	Rattus norvegicus	155-168
11246549-1	2001	1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes.	Cholecalciferol	19-29	coagulation factor III, tissue factor	Rattus norvegicus	170-172
11246549-1	2001	1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes.	Cholecalciferol	46-56	coagulation factor III, tissue factor	Rattus norvegicus	155-168
11246549-1	2001	1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes.	Cholecalciferol	46-56	coagulation factor III, tissue factor	Rattus norvegicus	170-172
11089522-0	2000	A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1.	Cholecalciferol	2-12	cyclin dependent kinase 6	Homo sapiens	85-89
11089522-0	2000	A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1.	Cholecalciferol	2-12	cyclin dependent kinase inhibitor 1B	Homo sapiens	123-130
11046111-6	2000	Two markers of monocyte differentiation, Mac-1 expression and nitroblue tetrazolium reduction, are increased in arsenite-exposed, D(3)-costimulated cells.	Cholecalciferol	130-134	integrin subunit alpha M	Homo sapiens	41-46
10886207-0	2000	Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase.	Cholecalciferol	26-36	caspase 3	Homo sapiens	97-106
11702003-0	2001	Distribution of stanniocalcin 1 in rat kidney and its regulation by vitamin D3.	Cholecalciferol	68-78	stanniocalcin 1	Rattus norvegicus	16-31
10951230-4	2000	We also studied the regulation of Fas and Fas ligand in skin cells by retinoic acid, vitamin D3, and dexamethasone as well as various cytokines.	Cholecalciferol	85-95	Fas ligand	Homo sapiens	42-52
12903442-0	2000	[The regulation of vitamin D3 and 9-cis-retinoic acid and their receptors on human hsp90 beta gene].	Cholecalciferol	19-29	heat shock protein 90 alpha family class B member 1	Homo sapiens	83-93
12903442-1	2000	OBJECTIVE: To study the effects of vitamin D3(VD3), 9-cis-retinoic acid (9-cis-RA) and their receptors on the regulation of human hsp90 beta gene.	Cholecalciferol	35-45	heat shock protein 90 alpha family class B member 1	Homo sapiens	130-140
12903442-8	2000	In addition, EMSA results showed that unliganded VDR and RXR simultaneously bound to the vitamin D3 response element (VDRE) of hsp90 beta gene.	Cholecalciferol	89-99	vitamin D receptor	Homo sapiens	49-52
12903442-8	2000	In addition, EMSA results showed that unliganded VDR and RXR simultaneously bound to the vitamin D3 response element (VDRE) of hsp90 beta gene.	Cholecalciferol	89-99	retinoid X receptor alpha	Homo sapiens	57-60
12903442-8	2000	In addition, EMSA results showed that unliganded VDR and RXR simultaneously bound to the vitamin D3 response element (VDRE) of hsp90 beta gene.	Cholecalciferol	89-99	heat shock protein 90 alpha family class B member 1	Homo sapiens	127-137
11080586-2	2000	As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3.	Cholecalciferol	278-288	protein tyrosine phosphatase, receptor type, U	Mus musculus	26-54
11080586-2	2000	As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3.	Cholecalciferol	278-288	protein tyrosine phosphatase, receptor type, U	Mus musculus	56-59
11080586-2	2000	As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3.	Cholecalciferol	278-288	protein tyrosine phosphatase, receptor type, U	Mus musculus	90-93
11080586-2	2000	As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3.	Cholecalciferol	278-288	protein tyrosine phosphatase, receptor type, V	Mus musculus	95-102
10944439-4	2000	The 5"-flanking region of ECAC1 contains four putative vitamin D(3)-responsive elements.	Cholecalciferol	55-67	transient receptor potential cation channel subfamily V member 5	Homo sapiens	26-31
10886207-0	2000	Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase.	Cholecalciferol	26-36	mitogen-activated protein kinase 14	Homo sapiens	111-114
10876100-0	2000	An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3.	Cholecalciferol	102-112	vitamin D receptor	Homo sapiens	43-61
11778232-0	2000	[Modulating effect of vitamin D3 in vitro on EGFR mRNA expression of human breast cancer cell lines].	Cholecalciferol	22-32	epidermal growth factor receptor	Homo sapiens	45-49
10777696-4	2000	VIP, PACAP-27, and PACAP-38, at concentrations of 10(-6) M, all significantly inhibited formation of tartrate-resistant acid phosphatase-positive multinuclear cells (TRAP + MNC) in mouse bone marrow cultures stimulated by 1, 25(OH)(2)-vitamin D3 (D3; 10(-8) M).	Cholecalciferol	235-245	vasoactive intestinal polypeptide	Mus musculus	0-3
10777696-4	2000	VIP, PACAP-27, and PACAP-38, at concentrations of 10(-6) M, all significantly inhibited formation of tartrate-resistant acid phosphatase-positive multinuclear cells (TRAP + MNC) in mouse bone marrow cultures stimulated by 1, 25(OH)(2)-vitamin D3 (D3; 10(-8) M).	Cholecalciferol	235-245	adenylate cyclase activating polypeptide 1	Mus musculus	19-24
11778232-1	2000	OBJECTIVE: To assess the modulating effects of vitamin D3, combined with or without tamoxifen, on cell proliferation and EGFR mRNA level of human breast cancer.	Cholecalciferol	47-57	epidermal growth factor receptor	Homo sapiens	121-125
11778232-5	2000	The growth inhibitory effect on the 2 cell lines could be augmented and accompanied by a decrease in EGFR mRNA level after combined treatment with IC50 dose of tamoxifen and 10(-10)-10(-9) mol/L vitamin D3.	Cholecalciferol	195-205	epidermal growth factor receptor	Homo sapiens	101-105
10702588-0	2000	Improved cholecalciferol nutrition in rats is noncalcemic, suppresses parathyroid hormone and increases responsiveness to 1, 25-dihydroxycholecalciferol.	Cholecalciferol	9-24	parathyroid hormone	Rattus norvegicus	70-89
10762037-0	2000	Synthesis of a novel class of cdc25A inhibitors from vitamin D3.	Cholecalciferol	53-63	cell division cycle 25A	Homo sapiens	30-36
10712807-4	2000	At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells.	Cholecalciferol	40-55	alkaline phosphatase, biomineralization associated	Canis lupus familiaris	64-67
10712807-4	2000	At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells.	Cholecalciferol	40-55	prolactin induced protein	Canis lupus familiaris	163-166
10712807-4	2000	At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells.	Cholecalciferol	139-154	alkaline phosphatase, biomineralization associated	Canis lupus familiaris	64-67
10712807-4	2000	At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells.	Cholecalciferol	139-154	prolactin induced protein	Canis lupus familiaris	163-166
10623885-7	2000	A low concentration of D(3) synergistically stimulated IL-4-induced TRAP-positive MGC formation, whereas a high concentration of D(3) inhibited it.	Cholecalciferol	23-27	interleukin 4	Homo sapiens	55-59
10706136-0	2000	SN-1, a novel leukemic cell line with t(11;16)(q23;p13): myeloid characteristics and resistance to retinoids and vitamin D3.	Cholecalciferol	113-123	solute carrier family 38 member 3	Homo sapiens	0-4
10676652-8	2000	In agreement with the recent identification of nuclear receptors for bile acids, our data suggest that functional interactions between nuclear bile acid signaling pathways, PKC, and nuclear receptors for retinoic acid and vitamin D3 are involved in the down-regulation of the myeloblastin gene and the induction of cell differentiation in human leukemic cells.	Cholecalciferol	222-232	proteinase 3	Homo sapiens	276-288
10721822-1	2000	Retinoic acid, vitamin D3 and triiodothyronine regulate keratinocyte proliferation and differentiation--processes that are disturbed in psoriatic skin--via binding to nuclear receptors for retinoic acid (RAR-alpha,-gamma), vitamin D3 (VDR), thyroid hormone (TR-alpha,-beta) plus the common heterodimer partners, the 9-cis-retinoic acid receptors (RXR-alpha,-beta).	Cholecalciferol	15-25	retinoic acid receptor alpha	Homo sapiens	204-256
10721822-1	2000	Retinoic acid, vitamin D3 and triiodothyronine regulate keratinocyte proliferation and differentiation--processes that are disturbed in psoriatic skin--via binding to nuclear receptors for retinoic acid (RAR-alpha,-gamma), vitamin D3 (VDR), thyroid hormone (TR-alpha,-beta) plus the common heterodimer partners, the 9-cis-retinoic acid receptors (RXR-alpha,-beta).	Cholecalciferol	15-25	T cell receptor alpha locus	Homo sapiens	258-266
10721822-1	2000	Retinoic acid, vitamin D3 and triiodothyronine regulate keratinocyte proliferation and differentiation--processes that are disturbed in psoriatic skin--via binding to nuclear receptors for retinoic acid (RAR-alpha,-gamma), vitamin D3 (VDR), thyroid hormone (TR-alpha,-beta) plus the common heterodimer partners, the 9-cis-retinoic acid receptors (RXR-alpha,-beta).	Cholecalciferol	15-25	retinoid X receptor alpha	Homo sapiens	347-356
11322510-4	2000	We also report on the permissive effects of Vitamin D3 and the Vitamin D3 analog EB 1089 in the promotion of apoptosis in p53-wild-type cells.	Cholecalciferol	44-54	tumor protein p53	Homo sapiens	122-125
11322510-4	2000	We also report on the permissive effects of Vitamin D3 and the Vitamin D3 analog EB 1089 in the promotion of apoptosis in p53-wild-type cells.	Cholecalciferol	63-73	tumor protein p53	Homo sapiens	122-125
10687144-0	2000	Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy.	Cholecalciferol	0-10	CD34 antigen	Mus musculus	66-70
10687144-2	2000	Using a metastatic Lewis lung carcinoma (LLC-LN7) tumor model, these CD34+ NS cells were shown to be present within the s.c. primary tumor tissue, but their levels declined after treatment with the inducer of myeloid cell differentiation, vitamin D3.	Cholecalciferol	239-249	CD34 antigen	Mus musculus	69-73
10687144-3	2000	Therefore, studies determined whether vitamin D3 treatment to diminish the CD34+ NS cell levels in LLC-LN7-bearing mice would enhance (a) intratumoral immune reactivity and (b) the antitumor activity of adoptive therapy consisting of tumor-reactive lymph node cells.	Cholecalciferol	38-48	CD34 antigen	Mus musculus	75-79
10687144-4	2000	The results showed that vitamin D3 treatment alone increased the intratumoral CD8+ cell content and the activity of the intratumoral infiltrate, as detected by production of interferon-gamma and expression of the p55 IL-2 receptor.	Cholecalciferol	24-34	interferon gamma	Mus musculus	174-190
10687144-7	2000	These studies demonstrate that vitamin D3 treatment increases intratumoral T-cell immune reactivity, and that coupling vitamin D3 treatment to diminish levels of CD34+ NS cells with adoptive immunotherapy enhances the effectiveness of the adoptively transferred tumor-reactive lymph node cells at limiting both metastasis and locoregional tumor recurrence.	Cholecalciferol	119-129	CD34 antigen	Mus musculus	162-166
10674883-10	1999	Northern analysis demonstrated that RAR-alpha was down-regulated by dexamethasone, ICI, and TPA, whereas vitamin D3 and E2 up-regulated RAR-alpha.	Cholecalciferol	105-115	retinoic acid receptor alpha	Homo sapiens	136-145
10587349-4	1999	Furthermore, induction of CD14 expression in response to D(3) was abrogated by (a) the PI 3-kinase inhibitors LY294002 and wortmannin; (b) antisense oligonucleotides to mRNA for the p110 catalytic subunit of PI 3-kinase; and (c) a dominant negative mutant of PI 3-kinase.	Cholecalciferol	57-61	CD14 molecule	Homo sapiens	26-30
10587349-5	1999	In THP-1 cells, induction of CD11b expression by D(3) was also abrogated by LY294002 and wortmannin.	Cholecalciferol	49-53	integrin subunit alpha M	Homo sapiens	29-34
10587349-6	1999	Similarly, LY294002 and wortmannin inhibited D(3)-induced expression of both CD14 and CD11b in peripheral blood monocytes.	Cholecalciferol	45-49	CD14 molecule	Homo sapiens	77-81
10587349-6	1999	Similarly, LY294002 and wortmannin inhibited D(3)-induced expression of both CD14 and CD11b in peripheral blood monocytes.	Cholecalciferol	45-49	integrin subunit alpha M	Homo sapiens	86-91
10552213-5	1999	The augmented expression of CD86 induced by NiCl(2) and DNCB was significantly suppressed by DEX at concentrations in the range 10(-8) to 10(-5) M, which include concentrations less than its therapeutically effective concentration of 10(-7) M. Vit D3 also significantly suppressed NiCl(2)- and DNCB-induced augmented expression of CD86, at concentrations in the ranges 10(-9) to 10(-7) M and 10(-10) to 10(-7) M, respectively.	Cholecalciferol	244-250	CD86 molecule	Homo sapiens	28-32
10554525-5	1999	The cytosolic GPx isoenzyme (cGPx) and thioredoxin reductase alpha (TrxR alpha) are upregulated during the process of differentiation and under the influence of 1.25 (OH)2 vitamin D3.	Cholecalciferol	172-182	thioredoxin	Homo sapiens	39-50
10552213-8	1999	Only DEX suppressed HLA-DR antigen expression at 10(-5) M. TNFalpha secretion by stimulated DCs was suppressed by DEX and Vit D3, although their effects were not statistically significant.	Cholecalciferol	122-128	tumor necrosis factor	Homo sapiens	59-67
10509435-7	1999	These results indicate that 25-OH-D3 is safe for use in laying hen feed as a source of vitamin D3 at 82.5 micrograms/kg feed (1x), with a margin of safety of approximately 5x between the proposed 1x level and the 5x level (412.5 micrograms/kg feed) that constitutes threshold toxicity in layers.	Cholecalciferol	87-97	dopamine receptor D3	Gallus gallus	28-36
10541881-0	1999	Expression of vitamin D3 25-hydroxylase (CYP27) mRNA after induction by vitamin D3 or UVB radiation in keratinocytes of human skin equivalents--a preliminary study.	Cholecalciferol	14-24	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	41-46
10541881-5	1999	CYP27 mRNA in keratinocytes is not constitutively expressed but is inducible both by vitamin D3 (780 nM) and by UVB radiation (300 nm, 30 mJ/cm2).	Cholecalciferol	85-95	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-5
10362505-4	1999	PLC gamma2 nuclear translocation increased progressively until 96 hours of vitamin D3 administration.	Cholecalciferol	75-85	phospholipase C gamma 2	Homo sapiens	0-10
10438943-2	1999	B. burgdorferi induced secretion of IL-8 by vitamin D3-matured THP-1 cells, which was inhibited by a CD14-specific mAb known to block cellular activation by LPS and the prototypic spirochetal lipoprotein, outer surface protein A.	Cholecalciferol	44-54	CD14 molecule	Homo sapiens	101-105
10373554-1	1999	Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells.	Cholecalciferol	259-269	TATA-box binding protein	Homo sapiens	26-46
10373554-1	1999	Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells.	Cholecalciferol	259-269	TATA-box binding protein	Homo sapiens	48-51
10373554-1	1999	Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells.	Cholecalciferol	259-269	TATA-box binding protein associated factor 11	Homo sapiens	75-83
10373554-1	1999	Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells.	Cholecalciferol	259-269	TATA-box binding protein	Homo sapiens	121-124
10359826-4	1999	By using luciferase reporter gene constructs of truncated forms of the 1alpha-OHase promoter transfected into a modified pig kidney cell line, AOK-B50, we identified regulatory regions of the 1.4-kb 1alpha-OHase promoter for parathyroid hormone 1-34 [PTH(1-34)], forskolin, and 1,25-hydroxyvitamin D3 [1,25(OH)2D3].	Cholecalciferol	298-300	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	71-83
10359826-4	1999	By using luciferase reporter gene constructs of truncated forms of the 1alpha-OHase promoter transfected into a modified pig kidney cell line, AOK-B50, we identified regulatory regions of the 1.4-kb 1alpha-OHase promoter for parathyroid hormone 1-34 [PTH(1-34)], forskolin, and 1,25-hydroxyvitamin D3 [1,25(OH)2D3].	Cholecalciferol	298-300	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	199-211
10362505-5	1999	A fourth PLC isozyme, beta2, present in the cytoplasm of untreated cells, translocates to the cytoplasm after vitamin D3 addition and reaches the highest concentration at the end of monocytic differentiation.	Cholecalciferol	110-120	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-27
10330159-0	1999	A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun.	Cholecalciferol	24-34	colony stimulating factor 2	Homo sapiens	78-126
10347174-0	1999	Differential regulation of direct repeat 3 vitamin D3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor.	Cholecalciferol	43-53	nuclear receptor subfamily 2 group C member 2	Homo sapiens	122-125
10347174-1	1999	In situ hybridization analysis demonstrated that abundant testicular orphan receptor (TR4) transcripts were detected in kidney, intestine, and bone, which are vitamin D3 target organs.	Cholecalciferol	159-169	nuclear receptor subfamily 2 group C member 2	Homo sapiens	86-89
10347174-2	1999	Cell transfection studies also demonstrated that the expression of the vitamin D3 target gene, 25-hydroxyvitamin D3 24-hydroxylase, can be repressed by TR4 through high affinity binding (Kd = 1.32 nM) to the direct repeat 3 vitamin D3 receptor response element (DR3VDRE).	Cholecalciferol	71-81	nuclear receptor subfamily 2 group C member 2	Homo sapiens	152-155
10380891-3	1999	Furthermore, TRANCE is expressed on osteoblasts stimulated with vitamin D3, dexamethasone, and parathyroid hormone.	Cholecalciferol	64-74	TNF superfamily member 11	Homo sapiens	13-19
10426559-0	1999	In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels.	Cholecalciferol	95-105	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	144-169
10517670-4	1999	In human skin nuclear extracts, VDR exclusively bound to DNA containing vitamin D3 response elements as heterodimers with retinoid X receptors.	Cholecalciferol	72-82	vitamin D receptor	Homo sapiens	32-35
10365915-5	1999	We chose two conditions under which osteocalcin expression is known to be upregulated: exposure of osteoblastic cells to differentiation-promoting medium and to vitamin D3.	Cholecalciferol	161-171	bone gamma-carboxyglutamate protein	Rattus norvegicus	36-47
10365915-7	1999	Vitamin D3 treatment resulted in upregulation of osteocalcin activity without a corresponding change in p53 transactivation activity or expression.	Cholecalciferol	0-10	bone gamma-carboxyglutamate protein	Rattus norvegicus	49-60
10330159-0	1999	A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun.	Cholecalciferol	24-34	vitamin D receptor	Homo sapiens	133-151
10330159-0	1999	A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun.	Cholecalciferol	24-34	nuclear factor of activated T cells 2	Homo sapiens	182-187
10330159-0	1999	A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun.	Cholecalciferol	24-34	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	203-208
10231362-1	1999	Previously we expressed rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) cDNA in Escherichia coli JM109 and showed that CYP24 catalyses three-step monooxygenation towards 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3 [Akiyoshi-Shibata, M., Sakaki, T., Ohyama, Y., Noshiro, M., Okuda, K. &amp; Yabusaki, Y.	Cholecalciferol	46-48	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	65-70
10383375-0	1999	Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D3.	Cholecalciferol	89-99	erb-b2 receptor tyrosine kinase 4	Homo sapiens	23-27
10470102-5	1999	1,25(OH)2D3 mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 response elements (VDRE) in genes modulated by 1,25(OH)2D3.	Cholecalciferol	79-89	vitamin D receptor	Homo sapiens	100-103
10470102-7	1999	To clarify the mechanism by which nine of these vitamin D3 analogs mediate their remarkably potent biological activities, we have investigated their abilities in PC-3 prostate cancer cells to transactivate a chroramphenicol acetyl transferase (CAT) reporter gene containing a VDRE from the human osteocalcin gene attached to a thymidine kinase minimal promoter.	Cholecalciferol	48-58	chromobox 8	Homo sapiens	162-166
10470102-11	1999	In summary, this is the first report of a potent series of 20-cyclopropyl-cholecalciferol vitamin D3 analogs with the ability to inhibit proliferation of LNCaP, PC-3, DU-145, MCF-7 and HL-60 cell lines.	Cholecalciferol	90-100	chromobox 8	Homo sapiens	161-165
10203416-6	1999	The time course study, in the presence of 10(-8) M vitamin D3 (vit D3) showed a marked increase (fourfold) in ALP activity with a peak at day 3.	Cholecalciferol	51-61	alkaline phosphatase, placental	Homo sapiens	110-113
10203416-6	1999	The time course study, in the presence of 10(-8) M vitamin D3 (vit D3) showed a marked increase (fourfold) in ALP activity with a peak at day 3.	Cholecalciferol	63-69	alkaline phosphatase, placental	Homo sapiens	110-113
10203416-10	1999	In contrast, treatment with vit D3 induced a marked increase of ALP and OC transcripts.	Cholecalciferol	28-34	alkaline phosphatase, placental	Homo sapiens	64-67
10203416-10	1999	In contrast, treatment with vit D3 induced a marked increase of ALP and OC transcripts.	Cholecalciferol	28-34	bone gamma-carboxyglutamate protein	Homo sapiens	72-74
10231362-1	1999	Previously we expressed rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) cDNA in Escherichia coli JM109 and showed that CYP24 catalyses three-step monooxygenation towards 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3 [Akiyoshi-Shibata, M., Sakaki, T., Ohyama, Y., Noshiro, M., Okuda, K. &amp; Yabusaki, Y.	Cholecalciferol	46-48	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	119-124
10232681-3	1999	In the present study, porcine CYP27B cDNA was cloned, and the effects of cAMP and vitamin D3 on the regulation of CYP27B1 mRNA expression in LLC-PK1 cells were examined.	Cholecalciferol	82-92	cytochrome P450 family 27 subfamily B member 1	Sus scrofa	114-121
10223184-13	1999	Thus the loss of the growth inhibitory effect of vitamin D3 in HBL100 cells may be caused by the expression of the large T antigen in the cells, and provide further evidence that VDR is required for efficient growth inhibition by vitamin D3.	Cholecalciferol	230-240	vitamin D receptor	Homo sapiens	179-182
10090931-5	1999	The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines.	Cholecalciferol	65-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	44-47
10090931-5	1999	The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines.	Cholecalciferol	65-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	48-57
10090931-5	1999	The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines.	Cholecalciferol	65-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	162-165
10090931-5	1999	The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines.	Cholecalciferol	65-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	48-52
10090931-5	1999	The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines.	Cholecalciferol	65-75	cyclin dependent kinase inhibitor 1A	Homo sapiens	53-57
10200351-8	1999	The results of these experiments show that the newly developed 19-nor synthetic vitamin D3 analog, Ro 25-6760, as well as 1, 25-dihydroxyvitamin D3, induced the expression of p21waf1, resulted in a significant G1/G0 cell cycle arrest leading to impressive growth inhibition and induction of apoptosis associated with proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) showing a possible involvement of apoptosis-specific activation of the ICE/CED-3 proteolitic pathway.	Cholecalciferol	80-90	poly(ADP-ribose) polymerase 1	Homo sapiens	341-368
10200351-8	1999	The results of these experiments show that the newly developed 19-nor synthetic vitamin D3 analog, Ro 25-6760, as well as 1, 25-dihydroxyvitamin D3, induced the expression of p21waf1, resulted in a significant G1/G0 cell cycle arrest leading to impressive growth inhibition and induction of apoptosis associated with proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) showing a possible involvement of apoptosis-specific activation of the ICE/CED-3 proteolitic pathway.	Cholecalciferol	80-90	poly(ADP-ribose) polymerase 1	Homo sapiens	370-374
10399884-1	1999	In this article, we describe the development of a general synthetic strategy to functionalize the C-6 position of vitamin D3 and its biologically important metabolites, i.e. 25-hydroxyvitamin D3 (25-OH-D3) and 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3].	Cholecalciferol	114-124	complement C6	Homo sapiens	98-101
10460008-1	1999	To examine whether synthetic vitamin D3 analog, 22-oxa-1,25(OH)2D3 (OCT) has an inhibitory effect on the growth of thyroid carcinoma, we tested the in vitro and in vivo effects of OCT on the growth of a well-differentiated thyroid cancer cell line, NPA.	Cholecalciferol	29-39	plexin A2	Homo sapiens	68-71
10399884-2	1999	We employed Mazur"s cyclovitamin D method to synthesize vitamin D3 analogs with several functionalities at the C-6 position.	Cholecalciferol	56-66	complement C6	Homo sapiens	111-114
10424403-2	1999	In our study, HC-11 cells exhibited specific vitamin D3 receptors (VDR) determined by Northern analysis or flow cytometry and responded to 10 nM vitamin D3 treatment displaying strong growth inhibition, arrest in G0/G1 phase without evidence of apoptosis, and VDR mRNA reduction, although the percentage of cells expressing VDR protein remained unchanged.	Cholecalciferol	45-55	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	67-70
9952315-0	1999	Greater synergism of retinoic acid receptor (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonists with regard to growth inhibition and differentiation induction in monoblastic leukemia cells.	Cholecalciferol	64-74	retinoic acid receptor alpha	Homo sapiens	21-43
9952315-0	1999	Greater synergism of retinoic acid receptor (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonists with regard to growth inhibition and differentiation induction in monoblastic leukemia cells.	Cholecalciferol	64-74	retinoic acid receptor alpha	Homo sapiens	45-48
10424403-4	1999	A down-regulation of VDR expression was observed after Ha-ras transformation of HC-11 cells which desensitized the cells to the growth inhibitory effects of vitamin D3.	Cholecalciferol	157-167	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	21-24
10424403-4	1999	A down-regulation of VDR expression was observed after Ha-ras transformation of HC-11 cells which desensitized the cells to the growth inhibitory effects of vitamin D3.	Cholecalciferol	157-167	Harvey rat sarcoma virus oncogene	Mus musculus	55-61
10064589-3	1999	Here, we report a novel cytoplasmic localization of p21(Cip1/WAF1) in peripheral blood monocytes (PBMs) and in U937 cells undergoing monocytic differentiation by in vitro treatment with vitamin D3 or ectopic expression of p21(Cip1/WAF1), and analyze the biological consequences of this cytoplasmic expression.	Cholecalciferol	186-196	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-55
10064589-3	1999	Here, we report a novel cytoplasmic localization of p21(Cip1/WAF1) in peripheral blood monocytes (PBMs) and in U937 cells undergoing monocytic differentiation by in vitro treatment with vitamin D3 or ectopic expression of p21(Cip1/WAF1), and analyze the biological consequences of this cytoplasmic expression.	Cholecalciferol	186-196	cyclin dependent kinase inhibitor 1A	Homo sapiens	56-60
10064589-3	1999	Here, we report a novel cytoplasmic localization of p21(Cip1/WAF1) in peripheral blood monocytes (PBMs) and in U937 cells undergoing monocytic differentiation by in vitro treatment with vitamin D3 or ectopic expression of p21(Cip1/WAF1), and analyze the biological consequences of this cytoplasmic expression.	Cholecalciferol	186-196	cyclin dependent kinase inhibitor 1A	Homo sapiens	61-65
9927498-0	1999	Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage.	Cholecalciferol	0-10	parathyroid hormone 1 receptor	Mus musculus	36-100
10450176-3	1999	Immunohistochemistry using the specific monoclonal antibody 9A7 gamma directed against the nuclear vitamin D receptor was used to identify receptors for the active metabolite of vitamin D3 (1,25-dihydroxyvitamin D3).	Cholecalciferol	178-188	vitamin D receptor	Homo sapiens	99-117
10450176-7	1999	CONCLUSIONS: Colorectal cancer tissue expresses the nuclear vitamin D receptor and this could act as a potential therapeutic target for synthetic vitamin D3 differentiating agents.	Cholecalciferol	146-156	vitamin D receptor	Homo sapiens	60-78
10231710-1	1999	The solution structure of a biologically active modified linear endothelin-1 analogue, ET1-21[Cys(Acm)1,15, Aib3,11, Leu7], has been determined for the first time by two-dimensional nuclear magnetic resonance spectroscopy in a methanol-d3/water solvent mixture.	Cholecalciferol	236-238	endothelin 1	Homo sapiens	64-76
10231710-1	1999	The solution structure of a biologically active modified linear endothelin-1 analogue, ET1-21[Cys(Acm)1,15, Aib3,11, Leu7], has been determined for the first time by two-dimensional nuclear magnetic resonance spectroscopy in a methanol-d3/water solvent mixture.	Cholecalciferol	236-238	endothelin 1	Homo sapiens	87-90
10219964-2	1999	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by 12 recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes have been investigated.	Cholecalciferol	72-87	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	147-175
10219964-7	1999	Retinol, retinoic acid and cholecalciferol were strong inhibitors for xenobiotic oxidations catalysed by recombinant CYP1A1, 2C8 and 2C19.	Cholecalciferol	27-42	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	117-123
10219964-9	1999	Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism.	Cholecalciferol	219-234	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	30-36
10219964-9	1999	Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism.	Cholecalciferol	219-234	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	115-121
10219964-9	1999	Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism.	Cholecalciferol	219-234	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	115-121
10343528-1	1999	OBJECTIVES: The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 (1,25D3), through its interaction with vitamin D receptors (VDR), is reported to effect a variety of anabolic and catabolic events, especially in bone and cartilage tissues.	Cholecalciferol	31-41	vitamin D receptor	Homo sapiens	113-132
10343528-1	1999	OBJECTIVES: The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 (1,25D3), through its interaction with vitamin D receptors (VDR), is reported to effect a variety of anabolic and catabolic events, especially in bone and cartilage tissues.	Cholecalciferol	31-41	vitamin D receptor	Homo sapiens	134-137
9933476-11	1999	In situ hybridization using mouse cRNA probes revealed that the increased BSP expression and decreased OPN expression in the vitamin D3-deficient mice was primarily in osteoblastic cells on the surface of calvariae and endosteal spaces of alveolar bone, on newly formed epiphyseal bone, and in cementoblasts and in hypertrophic chondrocytes.	Cholecalciferol	125-135	secreted phosphoprotein 1	Mus musculus	103-106
9933476-12	1999	These studies are the first to show that BSP and OPN are differentially regulated by vitamin D3 in vivo, reflecting the diverse roles of these protein in bone remodeling.	Cholecalciferol	85-95	black spleen	Mus musculus	41-44
9933476-12	1999	These studies are the first to show that BSP and OPN are differentially regulated by vitamin D3 in vivo, reflecting the diverse roles of these protein in bone remodeling.	Cholecalciferol	85-95	secreted phosphoprotein 1	Mus musculus	49-52
9933476-13	1999	Moreover, the increased expression of the BSP transgene in the rachitic mice demonstrates that vitamin D3 regulation of BSP expression is mediated, in part, by element(s) within the 2.7 kb promoter region.	Cholecalciferol	95-105	black spleen	Mus musculus	42-45
9933476-13	1999	Moreover, the increased expression of the BSP transgene in the rachitic mice demonstrates that vitamin D3 regulation of BSP expression is mediated, in part, by element(s) within the 2.7 kb promoter region.	Cholecalciferol	95-105	black spleen	Mus musculus	120-123
10025676-0	1999	Vitamin D3 metabolites regulate LTBP1 and latent TGF-beta1 expression and latent TGF-beta1 incorporation in the extracellular matrix of chondrocytes.	Cholecalciferol	0-10	latent transforming growth factor beta binding protein 1	Rattus norvegicus	32-37
11056661-1	1999	INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects.	Cholecalciferol	107-117	vitamin D receptor	Homo sapiens	149-167
11056661-1	1999	INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects.	Cholecalciferol	107-117	vitamin D receptor	Homo sapiens	169-172
9886497-0	1999	Transforming growth factor-beta1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids.	Cholecalciferol	116-126	transforming growth factor beta 1	Homo sapiens	0-32
10025676-0	1999	Vitamin D3 metabolites regulate LTBP1 and latent TGF-beta1 expression and latent TGF-beta1 incorporation in the extracellular matrix of chondrocytes.	Cholecalciferol	0-10	transforming growth factor, beta 1	Rattus norvegicus	49-58
10025676-18	1999	Thus, vitamin D3 metabolites may play a role in regulating the availability of TGF-beta1 by modulating LTBP1 production.	Cholecalciferol	6-16	transforming growth factor, beta 1	Rattus norvegicus	79-88
10025676-18	1999	Thus, vitamin D3 metabolites may play a role in regulating the availability of TGF-beta1 by modulating LTBP1 production.	Cholecalciferol	6-16	latent transforming growth factor beta binding protein 1	Rattus norvegicus	103-108
9568710-1	1998	The ligand for osteoprotegerin has been identified, and it is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in the coculture model of in vitro osteoclastogenesis.	Cholecalciferol	134-144	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	15-30
9870260-3	1998	The affinity of these three vitamin D3 derivatives to the vitamin D receptor (VDR) and was determined.	Cholecalciferol	28-38	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	58-76
9870260-3	1998	The affinity of these three vitamin D3 derivatives to the vitamin D receptor (VDR) and was determined.	Cholecalciferol	28-38	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	78-81
9795371-17	1998	Furthermore, biochemical markers indicating bone loss (ICTP) and increased bone turnover (PTH, OSC) correlated positively with IGFBP-1 and IGFBP-4 but negatively with IGF-I, IGFBP-3 and IGFBP-5, while the opposite was observed with bone formation markers (PICP, B-ALP) and vitamin D3 metabolites.	Cholecalciferol	273-283	lanosterol synthase	Homo sapiens	95-98
9808170-0	1998	Vitamin D3: a transcriptional modulator of the interferon-gamma gene.	Cholecalciferol	0-10	interferon gamma	Homo sapiens	47-63
9764845-4	1998	Although cPLA2 mRNA and protein were constitutively expressed in untreated HaCaT cells, expression levels did not increase in response to cholecalciferol treatment; however, unlike COX-1 and cPLA2 expression, COX-2 mRNA and COX-2 protein expression increased in response to cholecalciferol treatment.	Cholecalciferol	274-289	phospholipase A2 group IVA	Homo sapiens	9-14
9764845-5	1998	Calphostin C, a potent protein kinase C inhibitor, significantly reduced cholecalciferol-induced PGE2 production by inhibiting cholecalciferol-enhanced COX-2 mRNA and protein expression.	Cholecalciferol	73-88	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	152-157
9764845-5	1998	Calphostin C, a potent protein kinase C inhibitor, significantly reduced cholecalciferol-induced PGE2 production by inhibiting cholecalciferol-enhanced COX-2 mRNA and protein expression.	Cholecalciferol	127-142	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	152-157
9764845-6	1998	These results indicate that (i) 1alpha,25(OH)2D3 does not induce PGE2 biosynthesis in keratinocytes, (ii) cholecalciferol-induced PGE2 production is primarily COX-2 dependent, and (iii) cholecalciferol enhances both COX-2 mRNA and protein expression, via a protein kinase C-dependent mechanism in human keratinocytes.	Cholecalciferol	106-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	159-164
9764845-6	1998	These results indicate that (i) 1alpha,25(OH)2D3 does not induce PGE2 biosynthesis in keratinocytes, (ii) cholecalciferol-induced PGE2 production is primarily COX-2 dependent, and (iii) cholecalciferol enhances both COX-2 mRNA and protein expression, via a protein kinase C-dependent mechanism in human keratinocytes.	Cholecalciferol	106-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	216-221
9733889-3	1998	Vitamin D3 did not induce NF-kappaB activation but selectively upregulated CXCR4 expression in minus clones.	Cholecalciferol	0-10	C-X-C motif chemokine receptor 4	Homo sapiens	75-80
9733889-4	1998	The CXCR4 ligand stromal-cell derived factor-1 induced Ca2+ fluxes and inhibited both constitutive and vitamin D3-enhanced HIV replication in minus clones.	Cholecalciferol	103-113	C-X-C motif chemokine receptor 4	Homo sapiens	4-9
9733889-4	1998	The CXCR4 ligand stromal-cell derived factor-1 induced Ca2+ fluxes and inhibited both constitutive and vitamin D3-enhanced HIV replication in minus clones.	Cholecalciferol	103-113	C-X-C motif chemokine ligand 12	Homo sapiens	17-46
9801993-0	1998	Vitamin D3 inhibits proliferation and increases c-myc expression in fibroblasts from psoriatic patients.	Cholecalciferol	0-10	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	48-53
9723955-0	1998	Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol).	Cholecalciferol	86-96	C-C motif chemokine ligand 5	Homo sapiens	14-20
9723955-0	1998	Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol).	Cholecalciferol	86-96	C-X-C motif chemokine ligand 8	Homo sapiens	25-29
9723955-11	1998	Three active vitamin D3 compounds, tacalcitol, 1alpha,25-dihydroxyvitamin D3 and MC903 (calcipotriol), inhibited the production of RANTES and IL-8, with very similar potencies.	Cholecalciferol	13-23	C-C motif chemokine ligand 5	Homo sapiens	131-137
9723955-11	1998	Three active vitamin D3 compounds, tacalcitol, 1alpha,25-dihydroxyvitamin D3 and MC903 (calcipotriol), inhibited the production of RANTES and IL-8, with very similar potencies.	Cholecalciferol	13-23	C-X-C motif chemokine ligand 8	Homo sapiens	142-146
11327011-5	1998	The vitamin D3 in products was extracted with chloroform and separated with mu-Bondapak C18 column(300 mm x 3.9 mm i.d.)	Cholecalciferol	4-14	Bardet-Biedl syndrome 9	Homo sapiens	88-91
10205176-3	1999	PSU1 interacts in a ligand-dependent manner with the LBD of several NRs, including retinoic acid (RARalpha), retinoid X (RXRalpha), thyroid hormone (TRalpha), vitamin D3 (VDR) and oestrogen (ERalpha) receptors.	Cholecalciferol	159-169	decapping enzyme complex catalytic subunit	Saccharomyces cerevisiae S288C	0-4
9874511-4	1998	Northern analysis showed modulation of the expression of BMP-2 and BMP-4 mRNAs in two human osteosarcoma cell lines, MG63 and Saos-2, by prostaglandin E2 (PGE2), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interferon-alpha (IFN-alpha), retinoic acid and 1,25(OH)2 vitamin D3.	Cholecalciferol	280-282	bone morphogenetic protein 2	Homo sapiens	57-62
9874511-4	1998	Northern analysis showed modulation of the expression of BMP-2 and BMP-4 mRNAs in two human osteosarcoma cell lines, MG63 and Saos-2, by prostaglandin E2 (PGE2), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interferon-alpha (IFN-alpha), retinoic acid and 1,25(OH)2 vitamin D3.	Cholecalciferol	280-282	bone morphogenetic protein 4	Homo sapiens	67-72
9874511-10	1998	In Saos-2 cells only 1,25(OH)2 vitamin D3 had any great effect on BMP-2 expression, which was down-regulated to approximately 60% of control values.	Cholecalciferol	31-41	bone morphogenetic protein 2	Homo sapiens	66-71
9753201-1	1998	The vitamin D receptor (VDR) is a nuclear receptor that mediates the effect of the active metabolite of vitamin D3, the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3).	Cholecalciferol	104-114	vitamin D receptor	Rattus norvegicus	4-22
9753201-1	1998	The vitamin D receptor (VDR) is a nuclear receptor that mediates the effect of the active metabolite of vitamin D3, the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3).	Cholecalciferol	104-114	vitamin D receptor	Rattus norvegicus	24-27
9703220-4	1998	The vitamin D3 metabolite increased ALP activity in these cells, whereas no effect of the hormone was observed on gamma-glutamyltranspeptidase and acid phosphatase activities.	Cholecalciferol	4-14	ALPA	Sus scrofa	36-39
9677345-7	1998	Moreover, vitamin D3 enhanced calbindin-D28K synthesis as well as OC synthesis and alkaline phosphatase activity.	Cholecalciferol	10-20	bone gamma-carboxyglutamate protein	Homo sapiens	66-68
9680096-2	1998	Progressive decreases in the steady-state levels of the mRNAs for thymidylate synthase, topoisomerase II, and hypoxanthine guanine phosphoribosyltransferase occurred following exposure to TPA or vitamin D3.	Cholecalciferol	195-205	thymidylate synthetase	Homo sapiens	66-86
9680096-2	1998	Progressive decreases in the steady-state levels of the mRNAs for thymidylate synthase, topoisomerase II, and hypoxanthine guanine phosphoribosyltransferase occurred following exposure to TPA or vitamin D3.	Cholecalciferol	195-205	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	110-156
9680096-3	1998	In contrast, the steady-state levels of the mRNAs for thymidine kinase, topoisomerase I, and DNA polymerase-alpha did not decrease until days 3-5 of treatment with vitamin D3 and then progressively declined thereafter.	Cholecalciferol	164-174	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	93-113
9714336-0	1998	p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3.	Cholecalciferol	90-100	tumor protein p53	Homo sapiens	0-3
9714336-0	1998	p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3.	Cholecalciferol	90-100	cyclin dependent kinase inhibitor 1A	Homo sapiens	29-33
9714336-0	1998	p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3.	Cholecalciferol	90-100	cyclin dependent kinase inhibitor 1A	Homo sapiens	34-38
9773502-1	1998	In contrast to vitamin D3-dependent gene expression of calbindin (CaBP-D28k) in intestine and kidney, the cerebellar mRNA expression seems independent of vitamin D3.	Cholecalciferol	15-25	calbindin 1	Gallus gallus	55-64
9678721-7	1998	CD14+ cell numbers were maintained, or recovered, in cultures supplemented with vitamin D3 (59% at day 7), and CD15+ cell numbers, too, remained unchanged in the presence of retinoic acid (67%) or vitamin D3 (66%).	Cholecalciferol	80-90	CD14 molecule	Homo sapiens	0-4
9568645-0	1998	Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.	Cholecalciferol	128-138	CD34 antigen	Mus musculus	161-165
9568645-6	1998	Similarly, treatment of LLC-LN7-bearing mice with vitamin D3 alone diminished the levels of CD34+ NS cells within regional lymph nodes, spleens and tumors.	Cholecalciferol	50-60	CD34 antigen	Mus musculus	92-96
9568645-10	1998	The results of this study show that treatment of tumor bearers with vitamin D3 to eliminate CD34+ NS cells improves the anti-tumor effectiveness of adoptively transferred tumor-reactive lymph node cells.	Cholecalciferol	68-78	CD34 antigen	Mus musculus	92-96
9551426-9	1998	Active vitamin D3 and platelet activating factor inhibit Pgp transport and are possible endogenous substrates in proximal tubule and mesangial cells, respectively.	Cholecalciferol	7-17	phosphoglycolate phosphatase	Homo sapiens	57-60
9528762-0	1998	A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells.	Cholecalciferol	90-100	homeobox A10	Homo sapiens	68-74
9586948-9	1998	It is therefore possible that RXR-specific ligands may counteract certain biological actions of vitamin D3.	Cholecalciferol	96-106	retinoid X receptor alpha	Homo sapiens	30-33
9566710-0	1998	Enhancement by antisense oligonucleotides to NF-kappaB of the differentiation of HL-60 promyelocytic leukemia cells induced by vitamin D3.	Cholecalciferol	127-137	nuclear factor kappa B subunit 1	Homo sapiens	45-54
9566710-2	1998	We have also shown that a variety of agents which inhibit NF-kappaB, including vitamin E and related antioxidants, curcumin and several non-steroidal anti-inflammatory agents, significantly enhanced the differentiation of HL-60 leukemia cells when combined with low levels of 1,25-dihydroxyvitamin D3 (vitamin D3).	Cholecalciferol	290-300	nuclear factor kappa B subunit 1	Homo sapiens	58-67
9566710-3	1998	To provide further evidence that interference with the activation of NF-kappaB affects the maturation of HL-60 leukemia cells by creating an environment conducive to terminal differentiation, we measured the effects of phosphorothioate antisense oligonucleotides to the various subunits of NF-kappaB on the differentiation of HL-60 cells produced by low levels of vitamin D3.	Cholecalciferol	364-374	nuclear factor kappa B subunit 1	Homo sapiens	69-78
9566710-5	1998	However, the antisense oligomer to the Rel A subunit of NF-kappaB markedly increased the extent of differentiation produced by low levels of vitamin D3.	Cholecalciferol	141-151	RELA proto-oncogene, NF-kB subunit	Homo sapiens	39-44
9566710-5	1998	However, the antisense oligomer to the Rel A subunit of NF-kappaB markedly increased the extent of differentiation produced by low levels of vitamin D3.	Cholecalciferol	141-151	nuclear factor kappa B subunit 1	Homo sapiens	56-65
9566710-6	1998	An enhancement of the differentiation of HL-60 cells induced by vitamin D3 was also obtained by several transcription factor decoys designed to mimic the consensus sequences of genes activated by Rel A.	Cholecalciferol	64-74	RELA proto-oncogene, NF-kB subunit	Homo sapiens	196-201
9504637-1	1998	The effect of differentiating doses of all-trans retinoic acid (ATRA, 10(-6) M) and vitamin D3 (10(-7) M) was investigated on the nuclear levels of endogenous ceramide and protein kinase C-zeta (PKC-zeta) catalytic activity in HL-60 myeloid cells.	Cholecalciferol	84-94	protein kinase C zeta	Homo sapiens	172-193
9504637-1	1998	The effect of differentiating doses of all-trans retinoic acid (ATRA, 10(-6) M) and vitamin D3 (10(-7) M) was investigated on the nuclear levels of endogenous ceramide and protein kinase C-zeta (PKC-zeta) catalytic activity in HL-60 myeloid cells.	Cholecalciferol	84-94	protein kinase C zeta	Homo sapiens	195-203
9504637-3	1998	On the other hand, vitamin D3 increased the levels of nuclear ceramide and PKC-zeta activity to a lesser extent and with a delayed kinetics compared to ATRA (peak at 96 h).	Cholecalciferol	19-29	protein kinase C zeta	Homo sapiens	75-83
9492037-5	1998	All three vitamin D3 compounds decreased both basal and serum- and EGF-induced steady state PTHrP messenger RNA and secreted peptide levels.	Cholecalciferol	10-20	epidermal growth factor	Homo sapiens	67-70
9492037-5	1998	All three vitamin D3 compounds decreased both basal and serum- and EGF-induced steady state PTHrP messenger RNA and secreted peptide levels.	Cholecalciferol	10-20	parathyroid hormone like hormone	Homo sapiens	92-97
9602865-2	1998	The effects of vitamin D3 are mediated through the vitamin D3 receptor (VDR).	Cholecalciferol	15-25	vitamin D receptor	Homo sapiens	51-70
9673393-6	1998	Vitamin D3 analogs (10 nM) significantly counteracted the growth stimulation induced by TGF-a and IGF-I as well as the paracrine stimulation observed in co-cultures.	Cholecalciferol	0-10	transforming growth factor alpha	Homo sapiens	88-93
9673393-6	1998	Vitamin D3 analogs (10 nM) significantly counteracted the growth stimulation induced by TGF-a and IGF-I as well as the paracrine stimulation observed in co-cultures.	Cholecalciferol	0-10	insulin like growth factor 1	Homo sapiens	98-103
9484784-5	1998	Although U937 cells expressing WT1 were hampered in their ability to differentiate on incubation with retinoic acid and vitamin D3, the induced G1/G0-accumulation was similar to differentiating control cells treated with inducers.	Cholecalciferol	120-130	WT1 transcription factor	Homo sapiens	31-34
9437041-1	1998	The ratio of baseline level/maximum level of serum parathyroid hormone (PTH) is high in PTH-deficient hypoparathyroidism and it decreases after vitamin D3 treatment.	Cholecalciferol	144-154	parathyroid hormone	Homo sapiens	51-70
9602865-2	1998	The effects of vitamin D3 are mediated through the vitamin D3 receptor (VDR).	Cholecalciferol	15-25	vitamin D receptor	Homo sapiens	72-75
9602865-4	1998	In the present study the levels of VDR and RXR in involved and uninvolved psoriatic skin were determined by immunoblotting, and the binding of the VDR-RXR complex to a vitamin D3 response element (VDRE) consisting of two hexanucleotides spaced by three nucleotides (DR-3) by the electrophoretic mobility shift assay.	Cholecalciferol	168-178	vitamin D receptor	Homo sapiens	147-150
9602865-4	1998	In the present study the levels of VDR and RXR in involved and uninvolved psoriatic skin were determined by immunoblotting, and the binding of the VDR-RXR complex to a vitamin D3 response element (VDRE) consisting of two hexanucleotides spaced by three nucleotides (DR-3) by the electrophoretic mobility shift assay.	Cholecalciferol	168-178	retinoid X receptor alpha	Homo sapiens	151-154
9625456-4	1998	Based on the fact that PTH requires vitamin D3 to take effect on calcium mobilization from bone, it is possible that VDR polymorphism may influence the PTH action on bone.	Cholecalciferol	36-46	parathyroid hormone	Homo sapiens	23-26
9625456-4	1998	Based on the fact that PTH requires vitamin D3 to take effect on calcium mobilization from bone, it is possible that VDR polymorphism may influence the PTH action on bone.	Cholecalciferol	36-46	vitamin D receptor	Homo sapiens	117-120
9578149-0	1998	Effect of vitamin D3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts.	Cholecalciferol	10-20	interleukin 6	Mus musculus	24-37
9457545-7	1998	As indicated by increased alkaline phosphatase-specific activity, increased cell-surface and matrix-associated protein, and 1.25 (OH2) vitamin D3-stimulated osteocalcin production, a more differentiated osteoblast-like phenotype was observed on the sintered HA surfaces compared to the as-received HA and calcined HA surfaces.	Cholecalciferol	135-145	bone gamma-carboxyglutamate protein	Homo sapiens	157-168
9570559-7	1998	Similarly, pretreatment of cells with either alphaIR3 or an IGF-binding protein, IGFBP-3, led to a 75% inhibition of CD11b expression when cells were cultured with vitamin D3 in serum-containing medium.	Cholecalciferol	164-174	insulin like growth factor binding protein 3	Homo sapiens	81-88
9570559-7	1998	Similarly, pretreatment of cells with either alphaIR3 or an IGF-binding protein, IGFBP-3, led to a 75% inhibition of CD11b expression when cells were cultured with vitamin D3 in serum-containing medium.	Cholecalciferol	164-174	integrin subunit alpha M	Homo sapiens	117-122
9578149-2	1998	In the present study, we investigated the effect of vitamin D3 on IL-6 synthesis in MC3T3-E1 cells.	Cholecalciferol	52-62	interleukin 6	Mus musculus	66-70
9578149-3	1998	1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), an active form of vitamin D3, inhibited the IL-6 synthesis induced by PGF2alpha or PGE1.	Cholecalciferol	14-24	interleukin 6	Mus musculus	85-89
9578149-7	1998	These results strongly suggest that 1,25-(OH)2D3, an active form of vitamin D3, inhibits IL-6 synthesis at both the protein kinase C pathway and the protein kinase A pathway in osteoblasts.	Cholecalciferol	68-78	interleukin 6	Mus musculus	89-93
9417865-4	1997	Consistent with macrophage specificity, HC gp-39 expression is also induced upon selective stimulation of the pluripotent promyelocytic leukemia cell line HL-60 toward the monocyte/macrophage lineage with vitamin D3 or phorbol 12-myristate 13-acetate (PMA), while treatments stimulating granulocyte and eosinophilic pathways do not induce expression.	Cholecalciferol	205-215	chitinase 3 like 1	Homo sapiens	40-48
9781285-2	1998	In this paper we show that Cholecalciferol, a poor ligand of the vitamin D receptor, also induces cell death of HU197 human glioblastoma cell line and early passages cultures derived from a recurrent human glioblastoma.	Cholecalciferol	27-42	vitamin D receptor	Homo sapiens	65-83
9781285-5	1998	We determined the levels of sphingomyelin ceramide and ganglioside GD3 in Hu197 cells after treatment with cholecalciferol.	Cholecalciferol	107-122	GRDX	Homo sapiens	67-70
9536224-0	1998	RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol).	Cholecalciferol	128-138	C-C motif chemokine ligand 5	Homo sapiens	55-61
9536224-0	1998	RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol).	Cholecalciferol	128-138	C-X-C motif chemokine ligand 8	Homo sapiens	66-70
9536224-13	1998	Tacalcitol (1 alpha,24(R)-dihydroxyvitamin D3), an active vitamin D3 analogue, inhibited RANTES and IL-8 production in cultured normal epidermal keratinocytes.	Cholecalciferol	35-45	C-C motif chemokine ligand 5	Homo sapiens	89-95
9536224-13	1998	Tacalcitol (1 alpha,24(R)-dihydroxyvitamin D3), an active vitamin D3 analogue, inhibited RANTES and IL-8 production in cultured normal epidermal keratinocytes.	Cholecalciferol	35-45	C-X-C motif chemokine ligand 8	Homo sapiens	100-104
9503046-0	1998	Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3.	Cholecalciferol	109-119	parathyroid hormone	Homo sapiens	9-12
9705080-4	1998	The integrity of OLCs was confirmed by their ability to produce alkaline phosphatase and osteocalcin in response to vitamin D3 and also by their ability to deposit mineral.	Cholecalciferol	116-126	bone gamma-carboxyglutamate protein	Homo sapiens	89-100
9541257-2	1998	Expression of BSP is suppressed by the osteotropic hormone, 1,25-dihydroxyvitamin D3 (vitamin D3), which regulates bone remodelling.	Cholecalciferol	74-84	integrin-binding sialoprotein	Rattus norvegicus	14-17
9541257-9	1998	These studies demonstrate that subtle differences in the nucleotide sequence of VDREs affect VDR binding, which mediates the vitamin D3 response.	Cholecalciferol	125-135	vitamin D receptor	Rattus norvegicus	80-83
9437792-7	1998	The elucidation of the structure-function relationships at the DBP-binding-sites could have major impact on the development of new vitamin D3 derivatives with extended serum half-life.	Cholecalciferol	131-141	D site albumin promoter binding protein	Mus musculus	63-66
9425298-5	1997	Transfection of the vitamin D3 25-hydroxylase cDNA into simian COS cells resulted in the synthesis of an enzyme that was recognized by a monoclonal antibody raised against purified vitamin D3 25-hydroxylase and catalyzed 25-hydroxylation in the bioactivation of vitamin D3.	Cholecalciferol	20-30	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	181-206
9390178-0	1997	Identification of the subdomain in the nuclear receptor for the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3, vitamin D receptor, that is covalently modified by an affinity labeling reagent.	Cholecalciferol	81-91	vitamin D receptor	Homo sapiens	125-143
9390178-1	1997	Multiple physiological actions of the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), are mediated by a genomic pathway which is initiated by the highly specific recognition and binding by its cognate receptor (vitamin D receptor, VDR) in the target cells.	Cholecalciferol	55-65	vitamin D receptor	Homo sapiens	238-256
9390178-1	1997	Multiple physiological actions of the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), are mediated by a genomic pathway which is initiated by the highly specific recognition and binding by its cognate receptor (vitamin D receptor, VDR) in the target cells.	Cholecalciferol	55-65	vitamin D receptor	Homo sapiens	258-261
9417865-5	1997	Furthermore, HC gp-39 expression levels correlate with the degree of morphological differentiation induced by PMA and vitamin D3 treatments.	Cholecalciferol	118-128	chitinase 3 like 1	Homo sapiens	13-21
9467970-1	1997	To understand the structural requirements for the biological activity of endothelin peptides and to develop receptor selective endothelin analogues further, the solution structure of the bicyclic 21 amino acid residue vasoactive peptide, endothelin-1, has been determined in methanol-d3/water using high-resolution 1H-NMR spectroscopy.	Cholecalciferol	284-286	endothelin 1	Homo sapiens	238-250
21528312-3	1997	Addition of 10 nM and 100 nM vitamin D-3 to HL-60 cells cultured in the serum-free, chemically defined medium of insulin/transferrin/selenium (ITS) effected cell growth differently than cells maintained in a fetal bovine serum-supplemented medium.	Cholecalciferol	29-40	insulin	Homo sapiens	113-120
21528312-3	1997	Addition of 10 nM and 100 nM vitamin D-3 to HL-60 cells cultured in the serum-free, chemically defined medium of insulin/transferrin/selenium (ITS) effected cell growth differently than cells maintained in a fetal bovine serum-supplemented medium.	Cholecalciferol	29-40	transferrin	Homo sapiens	121-132
9326225-9	1997	Similarly, Western blot analysis showed that expression of C/EBP epsilon protein was either unchanged or decreased slightly as the promyelocytic cell line NB4 differentiated down the macrophage-like pathway after treatment with a potent vitamin D3 analog (KH1060).	Cholecalciferol	237-247	CCAAT enhancer binding protein epsilon	Homo sapiens	59-72
9333117-6	1997	To investigate further the mechanism for the apparent species difference in vitamin D3 induction of mouse and human osteocalcin, we examined the effect of 1,25(OH)2D3 in an MC3T3-E1 cell line (MC4) containing a stably integrated 3900 bp osteocalcin promoter-luciferase construct.	Cholecalciferol	76-86	bone gamma-carboxyglutamate protein	Homo sapiens	116-127
9380407-2	1997	EB1089 treatment of the breast cancer cell lines MCF-7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of Cdk2 activity was observed in the vitamin D3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines.	Cholecalciferol	278-288	cyclin dependent kinase 2	Homo sapiens	129-133
9344190-5	1997	RESULTS: The vitamin D receptor has been detected in most skin cells, which means that keratinization, hair growth, melanogenesis, fibrogenesis, angiogenesis, and immune-mediated processes are potential targets for vitamin D3.	Cholecalciferol	215-225	vitamin D receptor	Homo sapiens	13-31
9302649-3	1997	The present study was conducted to determine whether a new vitamin D3 analogue, 22-oxacalcitriol, could be effective in inhibiting the proliferation and IL-8 secretion of normal human epidermal keratinocytes.	Cholecalciferol	59-69	C-X-C motif chemokine ligand 8	Homo sapiens	153-157
9302649-9	1997	The inhibition of IL-8 secretion from keratinocytes by vitamin D3 could modulate the behaviour of immunocompetent cells infiltrating in the skin.	Cholecalciferol	55-65	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
9430985-0	1997	[Serum bone Gla-protein increases following short-term oral administration of active vitamin D3 in the elderly with vitamin D deficiency].	Cholecalciferol	85-95	bone gamma-carboxyglutamate protein	Homo sapiens	7-23
9430985-2	1997	It is well known that serum BGP levels increase after oral administration of active vitamin D3 in postmenopausal women and patients with chronic renal failure before dialysis.	Cholecalciferol	84-94	bone gamma-carboxyglutamate protein	Homo sapiens	28-31
9430985-3	1997	These findings indicate that active vitamin D3 increases the BGP production by osteoblasts.	Cholecalciferol	36-46	bone gamma-carboxyglutamate protein	Homo sapiens	61-64
9260973-7	1997	This discussion presents the hypothesis that reduced epidermal vitamin D3 photosynthesis associated with high skin melanin content and/or decreased UV light intensity at distances from the equator, alone or when coupled with decreased dietary calcium and vitamin D, may be associated with reduced vitamin D stores and increased parathyroid hormone secretion.	Cholecalciferol	63-73	parathyroid hormone	Homo sapiens	328-347
9258754-2	1997	In this study, we examined the effect of vitamin D3 supplementation on BMD at the femoral neck in relation to VDR genotype.	Cholecalciferol	41-51	vitamin D receptor	Homo sapiens	110-113
9278857-1	1997	We have synthesized and studied the ability of a series of seven novel 1 alpha,25(OH)2 vitamin D3 analogues to inhibit clonal growth of prostate cancer cells (LNCaP, PC-3 and DU-145).	Cholecalciferol	87-97	chromobox 8	Homo sapiens	166-170
9207192-6	1997	Both biochemical and immunohistochemical analyses show proportionately greater increased presence of AR in the nucleus, accompanied by relatively reduced AR in the cytosol, following treatment of LNCaP cells with vitamin D3.	Cholecalciferol	213-223	androgen receptor	Homo sapiens	101-103
9207192-6	1997	Both biochemical and immunohistochemical analyses show proportionately greater increased presence of AR in the nucleus, accompanied by relatively reduced AR in the cytosol, following treatment of LNCaP cells with vitamin D3.	Cholecalciferol	213-223	androgen receptor	Homo sapiens	154-156
9207192-8	1997	These results suggest that vitamin D3 promotes the translocation of AR from the cytosol to the nucleus.	Cholecalciferol	27-37	androgen receptor	Homo sapiens	68-70
9192867-0	1997	Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells.	Cholecalciferol	91-101	TATA-box binding protein associated factor 4	Homo sapiens	6-16
9148917-1	1997	A subset of nuclear receptors, including those for thyroid hormone (TR), retinoic acid, vitamin D3, and eicosanoids, can form heterodimers with the retinoid X receptor (RXR) on DNA regulatory elements in the absence of their cognate ligands.	Cholecalciferol	88-98	retinoid X receptor alpha	Homo sapiens	148-167
9196026-4	1997	While the expression of the TGM1 gene is markedly affected by the calcium concentration of the medium, all trans retinoic acid, vitamin D3, and TPA treatment, the expression of the RABGGTA gene was unaffected by these reagents.	Cholecalciferol	128-138	transglutaminase 1	Homo sapiens	28-32
9184230-4	1997	Moreover, DR3 and DR4 elements which mediate vitamin D3 and thyroid hormone responses, respectively, in other contexts, are converted to exclusive RAR response elements when placed in the RARbeta2 promoter and EC cell context.	Cholecalciferol	45-55	TNF receptor superfamily member 25	Homo sapiens	10-13
9184230-4	1997	Moreover, DR3 and DR4 elements which mediate vitamin D3 and thyroid hormone responses, respectively, in other contexts, are converted to exclusive RAR response elements when placed in the RARbeta2 promoter and EC cell context.	Cholecalciferol	45-55	retinoic acid receptor alpha	Homo sapiens	147-150
9182762-5	1997	Osf2/Cbfa1 expression is initiated in the mesenchymal condensations of the developing skeleton, is strictly restricted to cells of the osteoblast lineage thereafter, and is regulated by BMP7 and vitamin D3.	Cholecalciferol	195-205	RUNX family transcription factor 2	Homo sapiens	0-4
9182762-5	1997	Osf2/Cbfa1 expression is initiated in the mesenchymal condensations of the developing skeleton, is strictly restricted to cells of the osteoblast lineage thereafter, and is regulated by BMP7 and vitamin D3.	Cholecalciferol	195-205	RUNX family transcription factor 2	Homo sapiens	5-10
9148917-1	1997	A subset of nuclear receptors, including those for thyroid hormone (TR), retinoic acid, vitamin D3, and eicosanoids, can form heterodimers with the retinoid X receptor (RXR) on DNA regulatory elements in the absence of their cognate ligands.	Cholecalciferol	88-98	retinoid X receptor alpha	Homo sapiens	169-172
9125573-4	1997	Whereas tumor necrosis factor alpha, gamma interferon, bufalin, or granulocyte-macrophage colony-stimulating factor only marginally increased the ability of monocytic MonoMac-6 and myelomonocytic JOSK-M cells to interact with the bacteria, retinoic acid and vitamin D3 treatment for 2 to 4 days led to highly phagocytic cells that internalized gonococci in an Opa protein-specific manner.	Cholecalciferol	258-268	colony stimulating factor 2	Homo sapiens	37-115
9209684-2	1997	The actions of 1,25(OH)2D3 are mediated through the intracellular vitamin D receptor (VDR), and the level of VDR is believed to determine the cellular responsiveness to vitamin D3.	Cholecalciferol	169-179	vitamin D receptor	Homo sapiens	109-112
9176036-2	1997	The active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3, controls calcium absorption in the human duodenum, an effect that is mediated by mucosal vitamin D receptor expression.	Cholecalciferol	25-35	vitamin D receptor	Homo sapiens	152-170
9108352-6	1997	The vitamin D3 suppression of HES-1 mRNA level was blocked by actinomycin D as well as cycloheximide, suggesting the involvement of transcriptional control, which requires new protein synthesis.	Cholecalciferol	4-14	hes family bHLH transcription factor 1	Rattus norvegicus	30-35
9108352-11	1997	These results indicate that HES-1 is expressed in osteoblastic cells and is involved in vitamin D3 regulation of osteoblastic gene expression.	Cholecalciferol	88-98	hes family bHLH transcription factor 1	Rattus norvegicus	28-33
9130647-0	1997	Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid.	Cholecalciferol	153-163	C-X-C motif chemokine ligand 8	Homo sapiens	30-43
9130647-0	1997	Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid.	Cholecalciferol	153-163	complement C5a receptor 1	Homo sapiens	48-51
9130647-9	1997	Vitamin D3 (250 ng/ml, 7 days), which has been shown to induce differentiation of AML-193 and HL-60 cells into the monocytic phenotype, led to an up-regulation of IL-8RB and C5aR in both cell lines in the absence of any expression of IL-8RA.	Cholecalciferol	0-10	C-X-C motif chemokine receptor 2	Homo sapiens	163-169
9130647-9	1997	Vitamin D3 (250 ng/ml, 7 days), which has been shown to induce differentiation of AML-193 and HL-60 cells into the monocytic phenotype, led to an up-regulation of IL-8RB and C5aR in both cell lines in the absence of any expression of IL-8RA.	Cholecalciferol	0-10	complement C5a receptor 1	Homo sapiens	174-178
9130647-9	1997	Vitamin D3 (250 ng/ml, 7 days), which has been shown to induce differentiation of AML-193 and HL-60 cells into the monocytic phenotype, led to an up-regulation of IL-8RB and C5aR in both cell lines in the absence of any expression of IL-8RA.	Cholecalciferol	0-10	C-X-C motif chemokine receptor 1	Homo sapiens	234-240
9126352-4	1997	The efficient concentration ranges of other vitamin D3 metabolites suggest a mediation through the VD nuclear receptor (VDR).	Cholecalciferol	44-54	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	99-118
9126352-4	1997	The efficient concentration ranges of other vitamin D3 metabolites suggest a mediation through the VD nuclear receptor (VDR).	Cholecalciferol	44-54	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	120-123
9073553-0	1997	Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus.	Cholecalciferol	25-35	alpha-N-acetylgalactosaminidase	Homo sapiens	55-86
9081214-0	1997	Paxillin increases as retinoic acid or vitamin D3 induce HL-60 cell differentiation.	Cholecalciferol	39-49	paxillin	Homo sapiens	0-8
9426846-11	1997	In our study, treatment with intravenous vitamin D3 led to significant suppression of PTH secretion.	Cholecalciferol	41-51	parathyroid hormone	Homo sapiens	86-89
9192071-2	1997	We previously reported that 24 h treatment with 1 alpha, 25-dihydroxyvitamin D3 (1,25-D3), the active form of vitamin D3, induces calbindin-D28K and activates protein kinase C (PKC) in MDBK (Madin-Darby bovine kidney) cells.	Cholecalciferol	69-79	protein kinase C alpha	Bos taurus	177-180
8931118-2	1996	We have previously shown that interleukin 1 beta (IL-1 beta) induces PGE2 production in synovial fibroblast cultures and that this effect is suppressed by the active metabolite of vitamin D3, 1,25-(OH)2D3.	Cholecalciferol	180-190	interleukin 1 beta	Homo sapiens	30-48
9077482-2	1997	In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR).	Cholecalciferol	87-97	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	18-21
8977425-8	1997	Similarly, the alpha IR-3 mAb abrogated vitamin D3-induced differentiation of the HL-60 cells into macrophages in serum-free medium, as assessed by expression of the leucam surface protein, CD11b.	Cholecalciferol	40-50	integrin subunit alpha M	Homo sapiens	190-195
8978456-0	1996	Regulation of rat interstitial collagenase gene expression in growth cartilage and chondrocytes by vitamin D3, interleukin-1 beta, and okadaic acid.	Cholecalciferol	99-109	matrix metallopeptidase 13	Rattus norvegicus	18-42
8839845-3	1996	M-CSF was found to induce substantial bone resorption and osteoclast formation in a dose-responsive and time-dependent manner above that induced by 1,25 dihydroxyvitamin D3 (1,25 vitamin D3) in cultures of human bone marrow (BM) stromal cells sedimented onto devitalized bone.	Cholecalciferol	162-172	colony stimulating factor 1	Homo sapiens	0-5
8877104-0	1996	Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	101-120
8816911-0	1996	Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Matrix metalloproteinases (MMPs) are a group of enzymes with the potential to degrade extracellular matrix proteins.	Cholecalciferol	0-10	matrix metallopeptidase 3	Rattus norvegicus	25-38
8816911-0	1996	Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Matrix metalloproteinases (MMPs) are a group of enzymes with the potential to degrade extracellular matrix proteins.	Cholecalciferol	0-10	matrix metallopeptidase 3	Rattus norvegicus	40-45
8816911-0	1996	Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Matrix metalloproteinases (MMPs) are a group of enzymes with the potential to degrade extracellular matrix proteins.	Cholecalciferol	0-10	matrix metallopeptidase 3	Homo sapiens	131-135
8947586-8	1996	This mutation in the retinoic acid receptor alpha of the HL-60/RA cells may be responsible for drug resistance to ATRA and 9-cis-retinoic acid and increased sensitivity to vitamin D3 analogs.	Cholecalciferol	172-182	retinoic acid receptor alpha	Homo sapiens	21-49
8841046-1	1996	In order to assess the effect of vitamin D receptor (VDR) gene polymorphisms on vitamin D3 therapy for postmenopausal bone loss.	Cholecalciferol	80-90	vitamin D receptor	Homo sapiens	33-51
8841046-1	1996	In order to assess the effect of vitamin D receptor (VDR) gene polymorphisms on vitamin D3 therapy for postmenopausal bone loss.	Cholecalciferol	80-90	vitamin D receptor	Homo sapiens	53-56
9077482-2	1997	In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR).	Cholecalciferol	87-97	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	72-75
9077482-2	1997	In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR).	Cholecalciferol	87-97	tumor necrosis factor receptor superfamily, member 25	Mus musculus	118-121
9077482-2	1997	In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR).	Cholecalciferol	87-97	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	72-75
8980292-8	1997	These results suggest that EGF-treated HaCaT keratinocytes could serve for further studies of the vitamin D3 pathway and its relationship to proliferation and differentiation, but differences in calcitriol synthesis and catabolism from those in cultured primary keratinocytes or other cell lines must be considered.	Cholecalciferol	98-108	epidermal growth factor	Homo sapiens	27-30
9112257-2	1997	Synergistic induction of differentiation as measured by the above markers was observed when 1-10 muM curcumin was combined with 10-100 nM all-trans retinoic acid (RA) or with 100 nM 1 alpha, 25-dihydroxyvitamin D3 (vitamin D3).	Cholecalciferol	203-213	latexin	Homo sapiens	97-100
9018097-0	1996	Vitamin D3 reduces the apoptotic effect of IFN-gamma but does not facilitate HLA class II inducibility in RB-defective cells.	Cholecalciferol	0-10	interferon gamma	Homo sapiens	43-52
9018097-6	1996	Our results indicated that cotreating the RB-defective S4 cells with IFN-gamma and Vitamin D3 decreased the number of cells containing subdiploid DNA compared to cells treated with IFN-gamma alone, suggesting that Vitamin D3 reduced IFN-gamma-mediated apoptosis.	Cholecalciferol	214-224	interferon gamma	Homo sapiens	69-78
9018097-6	1996	Our results indicated that cotreating the RB-defective S4 cells with IFN-gamma and Vitamin D3 decreased the number of cells containing subdiploid DNA compared to cells treated with IFN-gamma alone, suggesting that Vitamin D3 reduced IFN-gamma-mediated apoptosis.	Cholecalciferol	214-224	interferon gamma	Homo sapiens	181-190
9018097-6	1996	Our results indicated that cotreating the RB-defective S4 cells with IFN-gamma and Vitamin D3 decreased the number of cells containing subdiploid DNA compared to cells treated with IFN-gamma alone, suggesting that Vitamin D3 reduced IFN-gamma-mediated apoptosis.	Cholecalciferol	214-224	interferon gamma	Homo sapiens	181-190
9018097-7	1996	S4 cells cotreated with Vitamin D3 and IFN-gamma also had decreased cell detachment, further indicating that Vitamin D3 decreased IFN-gamma induced apoptosis.	Cholecalciferol	24-34	interferon gamma	Homo sapiens	130-139
9018097-7	1996	S4 cells cotreated with Vitamin D3 and IFN-gamma also had decreased cell detachment, further indicating that Vitamin D3 decreased IFN-gamma induced apoptosis.	Cholecalciferol	109-119	interferon gamma	Homo sapiens	39-48
9018097-7	1996	S4 cells cotreated with Vitamin D3 and IFN-gamma also had decreased cell detachment, further indicating that Vitamin D3 decreased IFN-gamma induced apoptosis.	Cholecalciferol	109-119	interferon gamma	Homo sapiens	130-139
8977259-0	1996	Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.	Cholecalciferol	98-108	interleukin 6	Homo sapiens	43-56
8940196-2	1996	We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev.	Cholecalciferol	96-106	cyclin dependent kinase inhibitor 1A	Homo sapiens	162-165
8940196-2	1996	We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev.	Cholecalciferol	96-106	cyclin dependent kinase inhibitor 1A	Homo sapiens	166-175
8940196-2	1996	We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev.	Cholecalciferol	96-106	vitamin D receptor	Homo sapiens	189-208
9027335-5	1996	Elements allowing regulation by vitamin D3, pituitary-specific factors and Pit-1-dependent response to retinoic acid are well conserved.	Cholecalciferol	32-42	POU class 1 homeobox 1	Rattus norvegicus	75-80
8906031-1	1996	OBJECTIVE: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in beta-luteinizing hormone-Tag (LH beta-Tag) transgenic mice with heritable retinoblastoma.	Cholecalciferol	107-117	temporal alpha-galactosidase	Mus musculus	155-158
8906031-1	1996	OBJECTIVE: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in beta-luteinizing hormone-Tag (LH beta-Tag) transgenic mice with heritable retinoblastoma.	Cholecalciferol	107-117	luteinizing hormone beta	Mus musculus	160-167
9167334-9	1996	Although many other topical treatments for psoriasis (occlusive therapy and vitamin D3 analogues) result in a prominent reduction in the amount of transglutaminase and involucrin positive cell layers, the effect of dithranol on these markers is minimal.	Cholecalciferol	76-86	involucrin	Homo sapiens	168-178
8895322-10	1996	Vitamin D3 also increased osteocalcin secretion in a dose-dependent manner when the clone was maintained at 34 C (approximately 6-fold), and this stimulation was enhanced &gt; 5 fold at 40 C. In contrast to the low expression of alkaline phosphatase, the cells secreted high amounts of osteocalcin in response to vitamin D3 (approximately 15 ng/mg cell protein); this biochemical profile also resembled that of preosteocytes.	Cholecalciferol	0-10	bone gamma-carboxyglutamate protein	Homo sapiens	26-37
8895322-10	1996	Vitamin D3 also increased osteocalcin secretion in a dose-dependent manner when the clone was maintained at 34 C (approximately 6-fold), and this stimulation was enhanced &gt; 5 fold at 40 C. In contrast to the low expression of alkaline phosphatase, the cells secreted high amounts of osteocalcin in response to vitamin D3 (approximately 15 ng/mg cell protein); this biochemical profile also resembled that of preosteocytes.	Cholecalciferol	0-10	bone gamma-carboxyglutamate protein	Homo sapiens	286-297
8806764-1	1996	Vitamin D binding protein (DBP) plays an essential role in the vitamin D hormone endocrine system in sequestering vitamin D3 and its metabolites with high affinity, and transporting them to various target organs and tissues.	Cholecalciferol	114-124	GC, vitamin D binding protein	Rattus norvegicus	0-25
8806764-1	1996	Vitamin D binding protein (DBP) plays an essential role in the vitamin D hormone endocrine system in sequestering vitamin D3 and its metabolites with high affinity, and transporting them to various target organs and tissues.	Cholecalciferol	114-124	D-box binding PAR bZIP transcription factor	Rattus norvegicus	27-30
8931118-2	1996	We have previously shown that interleukin 1 beta (IL-1 beta) induces PGE2 production in synovial fibroblast cultures and that this effect is suppressed by the active metabolite of vitamin D3, 1,25-(OH)2D3.	Cholecalciferol	180-190	interleukin 1 beta	Homo sapiens	50-59
8806877-4	1996	We have demonstrated marked stimulation of chromaffin cell proliferation by vitamin D3, a potent stimulus to Ca2+ absorption not previously associated with adrenal medullary toxicity.	Cholecalciferol	76-86	carbonic anhydrase 2	Rattus norvegicus	109-112
8761475-0	1996	Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene.	Cholecalciferol	20-30	integrin-binding sialoprotein	Rattus norvegicus	100-117
8694856-5	1996	A gel mobility-shift assay demonstrated that the 1,25-(OH)2D3-induced alteration of hsp28 gene expression was associated with decreased binding activity to the vitamin D3 receptor-vitamin D3 response element (VDR-VDRE), whereas binding to the heat shock transcription factor-heat shock element (HSF-HSE) was not altered.	Cholecalciferol	160-170	heat shock protein family B (small) member 1	Homo sapiens	84-89
8665483-4	1996	Thus, vitamin D3 treatment can stimulate the immune competence of tumor bearers when treatment is targeted to coincide with a heightened presence of GM-CSF-induced suppressor cells.	Cholecalciferol	6-16	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	149-155
8663213-1	1996	Parathyroid hormone-related peptide (PTHRP) gene transcription is suppressed by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D3.	Cholecalciferol	94-104	parathyroid hormone-like hormone	Rattus norvegicus	0-35
8663213-1	1996	Parathyroid hormone-related peptide (PTHRP) gene transcription is suppressed by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D3.	Cholecalciferol	94-104	parathyroid hormone-like hormone	Rattus norvegicus	37-42
8869697-0	1996	Climatotherapy at the Dead Sea stimulates vitamin D3 metabolism.	Cholecalciferol	42-52	S13 erythroblastosis (avian) oncogene homolog	Homo sapiens	27-30
8928773-0	1996	Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells.	Cholecalciferol	44-54	parathyroid hormone	Rattus norvegicus	22-25
8947586-0	1996	Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs.	Cholecalciferol	159-169	retinoic acid receptor alpha	Homo sapiens	45-73
8687373-1	1996	The biologically active metabolite of vitamin D (cholecalciferol), i.e. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is a secosteroid hormone whose mode of action involves stereospecific interaction with an intracellular receptor protein (vitamin D receptor; VDR).	Cholecalciferol	49-64	vitamin D receptor	Homo sapiens	234-252
8687373-1	1996	The biologically active metabolite of vitamin D (cholecalciferol), i.e. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is a secosteroid hormone whose mode of action involves stereospecific interaction with an intracellular receptor protein (vitamin D receptor; VDR).	Cholecalciferol	49-64	vitamin D receptor	Homo sapiens	254-257
8665568-5	1996	In mice that were first treated with vitamin D3 and then also with IL-12, there was stimulation of splenic T cell proliferation in response to immobilized anti-CD3 plus IL-2.	Cholecalciferol	37-47	interleukin 2	Mus musculus	169-173
8612541-0	1996	Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements.	Cholecalciferol	59-69	bone gamma-carboxyglutamate protein	Rattus norvegicus	85-96
8612541-0	1996	Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements.	Cholecalciferol	59-69	secreted phosphoprotein 1	Rattus norvegicus	101-112
8676558-4	1996	BGP measurement is a clinically useful method to detect osteoblastic function after active vitamin D3 treatment.	Cholecalciferol	91-101	CEA cell adhesion molecule 1	Homo sapiens	0-3
8676558-9	1996	These findings suggest that B-ALP is a more sensitive and stable marker than BGP in evaluating bone formation, although both markers have significant correlations with each other, and BGP is useful to detect the active vitamin D3 effect on osteoblastic function.	Cholecalciferol	219-229	CEA cell adhesion molecule 1	Homo sapiens	184-187
8698190-0	1996	Protein kinase C isoforms in the chemopreventive effects of a novel vitamin D3 analogue in rat colonic tumorigenesis.	Cholecalciferol	68-78	protein kinase C, gamma	Rattus norvegicus	0-16
8966142-1	1996	Active vitamin D3 pulse therapy effectively suppresses parathormone (PTH) synthesis in uremic hyperparathyroidism but high serum levels of calcitriol achieved can induce direct osteoclastic resorption and block bone formation.	Cholecalciferol	7-17	parathyroid hormone	Homo sapiens	69-72
8672545-1	1996	We found that vitamin D3 up-regulates the expression of cytidine deaminase (CDD) gene in some human solid tumor cell lines as well as the monocytic leukemia cell lines.	Cholecalciferol	14-24	cytidine deaminase	Homo sapiens	56-74
8672545-1	1996	We found that vitamin D3 up-regulates the expression of cytidine deaminase (CDD) gene in some human solid tumor cell lines as well as the monocytic leukemia cell lines.	Cholecalciferol	14-24	cytidine deaminase	Homo sapiens	76-79
8672545-7	1996	Three of five gastric carcinoma cell lines and five of eight colorectal cancer lines had increased levels of CDD mRNA following 24 h treatment with vitamin D3.	Cholecalciferol	148-158	cytidine deaminase	Homo sapiens	109-112
8672545-9	1996	Our results demonstrate that CDD can be up-regulated by vitamin D3 in some solid tumor cell lines.	Cholecalciferol	56-66	cytidine deaminase	Homo sapiens	29-32
8660360-4	1996	The vitamin D3-elicited PSA increases were preceded by an induction of androgen receptor (AR) expression, as measured by Western blot analysis and by binding assays using [3H]R1881 as the ligand.	Cholecalciferol	4-14	androgen receptor	Homo sapiens	71-88
8660360-4	1996	The vitamin D3-elicited PSA increases were preceded by an induction of androgen receptor (AR) expression, as measured by Western blot analysis and by binding assays using [3H]R1881 as the ligand.	Cholecalciferol	4-14	androgen receptor	Homo sapiens	90-92
8660360-5	1996	These results are consistent with the hypothesis that the growth inhibitory effects of vitamin D3 is partially mediated through its ability to modulate PCNA expression.	Cholecalciferol	87-97	proliferating cell nuclear antigen	Homo sapiens	152-156
8809353-0	1996	Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome.	Cholecalciferol	119-129	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	40-64
8809353-0	1996	Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome.	Cholecalciferol	119-129	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	69-88
8809353-1	1996	Purified liver microsomal vitamin D 25-hydroxylase, a cytochrome P450, catalyzes 25-hydroxylation of vitamin D3 in the absence of NADPH and NADPH-cytochrome P450 reductase by using t-butyl hydroperoxide as electron donors.	Cholecalciferol	101-111	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	26-50
11866799-6	1996	We also evaluated the in vitro inhibitory effects of macrolides on IL---8 production by vitamin D3-induced human monocytic cell line THP-1 cells when stimulated with lipopolysaccharide and serum.	Cholecalciferol	88-98	C-X-C motif chemokine ligand 8	Homo sapiens	67-73
8776727-5	1996	One of these motifs resembles the negative VDRE (nVDRE) from the PTH gene, which is also down-regulated by vitamin D3.	Cholecalciferol	107-117	parathyroid hormone	Rattus norvegicus	65-68
9081364-0	1996	Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.	Cholecalciferol	120-130	insulin	Homo sapiens	14-21
9081364-0	1996	Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.	Cholecalciferol	120-130	insulin	Homo sapiens	27-34
9081364-2	1996	The purpose of the present study was to investigate a possible interaction of 1,25-(OH)2D3 and the vitamin D3 analogue EB1089 with the insulin-IGF-I regulatory system.	Cholecalciferol	99-109	insulin	Homo sapiens	135-142
9081364-2	1996	The purpose of the present study was to investigate a possible interaction of 1,25-(OH)2D3 and the vitamin D3 analogue EB1089 with the insulin-IGF-I regulatory system.	Cholecalciferol	99-109	insulin like growth factor 1	Homo sapiens	143-148
9081364-12	1996	Together, the present study demonstrates that vitamin D3 compounds can block the mitogenic activity of insulin and IGF-I, which may contribute to their tumour suppressive activity observed in vivo.	Cholecalciferol	46-56	insulin	Homo sapiens	103-110
9081364-12	1996	Together, the present study demonstrates that vitamin D3 compounds can block the mitogenic activity of insulin and IGF-I, which may contribute to their tumour suppressive activity observed in vivo.	Cholecalciferol	46-56	insulin like growth factor 1	Homo sapiens	115-120
9627702-1	1996	Vitamin D3 derivative 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) exerts various biological effects in cells that possess vitamin D3 receptor (VDR), including enhancement of cell differentiation and inhibition of cell proliferation.	Cholecalciferol	0-10	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	117-136
9627688-2	1996	The vitamin D receptor (VDR) mediates most, if not all, the effects of vitamin D3.	Cholecalciferol	71-81	vitamin D receptor	Homo sapiens	4-22
9627688-2	1996	The vitamin D receptor (VDR) mediates most, if not all, the effects of vitamin D3.	Cholecalciferol	71-81	vitamin D receptor	Homo sapiens	24-27
9627689-0	1996	Vitamin D3 regulation of transforming growth factor-beta system in epithelial and fibroblastic cells--relationships to plasminogen activation.	Cholecalciferol	0-10	transforming growth factor beta 1	Homo sapiens	25-56
9627689-2	1996	A mechanism of action of vitamin D3 and other steroid hormones is to enhance the secretion of transforming growth factor-beta (TGF-beta) in target cells.	Cholecalciferol	25-35	transforming growth factor beta 1	Homo sapiens	94-125
9627689-2	1996	A mechanism of action of vitamin D3 and other steroid hormones is to enhance the secretion of transforming growth factor-beta (TGF-beta) in target cells.	Cholecalciferol	25-35	transforming growth factor beta 1	Homo sapiens	127-135
9627689-3	1996	In epidermal keratinocytes, vitamin D3 induced the expression of both TGF-beta 1 and TGF-beta 2 with minor changes in mRNA levels, while in BT-20 breast carcinoma cells the increase in TGF-beta activity was preceded by an induction of mRNA.	Cholecalciferol	28-38	transforming growth factor beta 1	Homo sapiens	70-80
9627689-3	1996	In epidermal keratinocytes, vitamin D3 induced the expression of both TGF-beta 1 and TGF-beta 2 with minor changes in mRNA levels, while in BT-20 breast carcinoma cells the increase in TGF-beta activity was preceded by an induction of mRNA.	Cholecalciferol	28-38	transforming growth factor beta 2	Homo sapiens	85-95
9627689-3	1996	In epidermal keratinocytes, vitamin D3 induced the expression of both TGF-beta 1 and TGF-beta 2 with minor changes in mRNA levels, while in BT-20 breast carcinoma cells the increase in TGF-beta activity was preceded by an induction of mRNA.	Cholecalciferol	28-38	transforming growth factor beta 1	Homo sapiens	70-78
9627689-5	1996	A concomitant enhancement of secretion of the latent TGF-beta-binding protein by vitamin D3 was observed in BT-20 cells.	Cholecalciferol	81-91	transforming growth factor beta 1	Homo sapiens	53-61
9627689-6	1996	Retinoic acid, which is known to interfere with vitamin D3 signaling, slightly decreased the levels of secreted TGF-beta 1 protein in BT-20 cells, but did not significantly affect the vitamin D3-induced increase.	Cholecalciferol	48-58	transforming growth factor beta 1	Homo sapiens	112-122
9627689-12	1996	Our results indicate that vitamin D3 and its analogs are potent regulators of the TGF-beta and plasminogen activator systems in cells of epithelial and mesenchymal origin.	Cholecalciferol	26-36	transforming growth factor beta 1	Homo sapiens	82-90
9627692-3	1996	Because 9-cis-retinoic acid receptors (RXRs) form heterodimers both with RARs and the vitamin D3 receptor (VDR), it is plausible that vitamin D3 may affect retinol metabolism if altered transcription is involved in the regulation of vitamin A-metabolizing enzymes.	Cholecalciferol	86-96	vitamin D receptor	Homo sapiens	107-110
8867808-0	1996	Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer.	Cholecalciferol	20-30	fibronectin 1	Homo sapiens	55-66
8867808-2	1996	Regulation of FN occurs at the transcriptional level by the active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3).	Cholecalciferol	81-91	fibronectin 1	Homo sapiens	14-16
8593782-12	1996	Gel shift analyses indicate that nuclear extracts from MCF-7WT and MCF-7D3Res cells bind equally well to the DR3 consensus vitamin D3 response element.	Cholecalciferol	123-133	TNF receptor superfamily member 25	Homo sapiens	109-112
8628015-2	1996	To ascertain whether the NM23 genes are involved in the differentiation processes of human cell lines, the NM23.H1 and NM23.H2 expression level has been determined during the monocyte-macrophage differentiation of HL-60 and U-937 cell lines induced by vitamin D3.	Cholecalciferol	252-262	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	25-29
8628015-3	1996	In both lines, vitamin D3 produced induction of differentiative markers, inhibition of cell proliferation and a decrease of the NM23.H1, NM23.H2 and c-myc genes, behaving both as a differentiative and an antiproliferative agent.	Cholecalciferol	15-25	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	128-135
8628015-3	1996	In both lines, vitamin D3 produced induction of differentiative markers, inhibition of cell proliferation and a decrease of the NM23.H1, NM23.H2 and c-myc genes, behaving both as a differentiative and an antiproliferative agent.	Cholecalciferol	15-25	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	128-132
8628015-3	1996	In both lines, vitamin D3 produced induction of differentiative markers, inhibition of cell proliferation and a decrease of the NM23.H1, NM23.H2 and c-myc genes, behaving both as a differentiative and an antiproliferative agent.	Cholecalciferol	15-25	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	149-154
8628015-4	1996	The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2.	Cholecalciferol	187-197	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	47-50
8628015-4	1996	The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2.	Cholecalciferol	187-197	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	71-75
8628015-4	1996	The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2.	Cholecalciferol	187-197	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	93-97
8628015-4	1996	The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2.	Cholecalciferol	187-197	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	201-206
8628015-4	1996	The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2.	Cholecalciferol	187-197	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	93-97
8615881-3	1996	On the other hand, KCA-098 had no effect on the basal synthesis of osteocalcin but reduced the 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)(2)D3)-induced increase in osteocalcin synthesized by ROS 17/2.8 cells.	Cholecalciferol	123-125	bone gamma-carboxyglutamate protein	Rattus norvegicus	168-179
8566748-0	1996	Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.	Cholecalciferol	55-65	H3 histone pseudogene 16	Homo sapiens	48-51
8598193-2	1996	mSUG1 also efficiently interacts with other nuclear receptors, including oestrogen (ER), thyroid hormone (TR), Vitamin D3 (VDR) and retinoid X (RXR) receptors.	Cholecalciferol	111-121	protease (prosome, macropain) 26S subunit, ATPase 5	Mus musculus	0-5
9084640-6	1996	The TATA box is overlapped by a vitamin D3 response element (VDRE) which appears to mediate vitamin D suppression of BSP gene transcription by competing with the TATA-binding protein (TBP) for occupancy of the site of the pre-initiation complex formation.	Cholecalciferol	32-42	integrin binding sialoprotein	Homo sapiens	117-120
9084640-6	1996	The TATA box is overlapped by a vitamin D3 response element (VDRE) which appears to mediate vitamin D suppression of BSP gene transcription by competing with the TATA-binding protein (TBP) for occupancy of the site of the pre-initiation complex formation.	Cholecalciferol	32-42	TATA-box binding protein	Homo sapiens	184-187
9084648-3	1996	The present study determined whether there is an additive or synergistic effect of vitamin D3 metabolites and TGF beta on alkaline phosphatase and PKC specific activities and whether this effect is cell maturation-dependent.	Cholecalciferol	83-93	protein kinase C, gamma	Rattus norvegicus	147-150
9084648-6	1996	The addition of 24,25-(OH)2D3 with TGF beta to RC cells caused a synergistic effect on alkaline phosphatase activity; this result was not found if the vitamin D3 metabolite was replaced by 1,25-(OH)2D3.	Cholecalciferol	151-161	transforming growth factor, beta 1	Rattus norvegicus	35-43
8672415-0	1996	Changes in vitamin-D metabolites and parathyroid hormone in plasma following cholecalciferol administration to pre- and postmenopausal women in the Netherlands in early spring and to postmenopausal women in Curacao.	Cholecalciferol	77-92	parathyroid hormone	Homo sapiens	37-56
8672415-5	1996	Cholecalciferol administration increased 25(OH)D in all groups, 1,25(OH)2D in postmenopausal Curacao women and PTH in postmenopausal Curacao women and premenopausal Dutch women.	Cholecalciferol	0-15	parathyroid hormone	Homo sapiens	111-114
8622645-7	1996	Conversely, when VDR is overexpressed, vitamin D3 attenuates 9-cis RA induction from an RXR-responsive element.	Cholecalciferol	39-49	vitamin D receptor	Homo sapiens	17-20
8622645-7	1996	Conversely, when VDR is overexpressed, vitamin D3 attenuates 9-cis RA induction from an RXR-responsive element.	Cholecalciferol	39-49	retinoid X receptor alpha	Homo sapiens	88-91
9627702-1	1996	Vitamin D3 derivative 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) exerts various biological effects in cells that possess vitamin D3 receptor (VDR), including enhancement of cell differentiation and inhibition of cell proliferation.	Cholecalciferol	0-10	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	138-141
8698545-8	1996	Vitamin D3 treatment also caused 25% increase in glucose 6-phosphate dehydrogenase (G6PD) activity.	Cholecalciferol	0-10	glucose-6-phosphate dehydrogenase	Rattus norvegicus	49-82
8698545-8	1996	Vitamin D3 treatment also caused 25% increase in glucose 6-phosphate dehydrogenase (G6PD) activity.	Cholecalciferol	0-10	glucose-6-phosphate dehydrogenase	Rattus norvegicus	84-88
8711172-14	1996	During treatment with vitamin D3 hypercalcemia tends to develop, serum alkaline phosphatase normalizes, elevated PTH serum level decreases.	Cholecalciferol	22-32	parathyroid hormone	Homo sapiens	113-116
9371227-0	1996	Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A.	Cholecalciferol	0-10	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	120-134
9371227-4	1996	The cellular PP-2A activity could be stimulated by addition of C2-ceramide to LLC-LN7 lysates, or by incubating cells with either C2-ceramide or with a noncalcemic analog of vitamin D3, which has previously been shown to stimulate the release of ceramide.	Cholecalciferol	174-184	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	13-18
9371227-7	1996	Invasion by these cells was further reduced by additionally increasing PP-2A activity by incubation with C2-ceramide or the vitamin D3 analog.	Cholecalciferol	124-134	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	71-76
9371227-8	1996	These results suggest a role of a vitamin D3/ceramide/PP-2A pathway in limiting the invasiveness of tumor cells through select ECM components.	Cholecalciferol	34-44	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	54-59
7489414-3	1995	Active vitamin D3 acts via its receptor (VDR), and binding of the ligand-receptor complex to specific promoter regions of the PTH gene inhibits transcription.	Cholecalciferol	7-17	vitamin D receptor	Homo sapiens	41-44
8755104-3	1996	It is concluded that the lowering of the level of absorption of vitamin D3 by hepatocytes and its transportation to these cells from reticulocytes as well as the inhibition of vitamin D3-25-hydroxylase liver systems can be the most probable cause of these disturbances.	Cholecalciferol	64-74	cytochrome P450, family 27, subfamily a, polypeptide 1	Rattus norvegicus	176-201
8614417-0	1995	Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3.	Cholecalciferol	0-10	retinoid X receptor alpha	Homo sapiens	11-30
7489414-3	1995	Active vitamin D3 acts via its receptor (VDR), and binding of the ligand-receptor complex to specific promoter regions of the PTH gene inhibits transcription.	Cholecalciferol	7-17	parathyroid hormone	Homo sapiens	126-129
7489414-4	1995	Active vitamin D3 constitutes a principal regulator of parathyroid cell growth, and polymorphism in the VDR gene has recently been related to bone mineral density and suggested as predisposing to osteoporosis.	Cholecalciferol	7-17	vitamin D receptor	Homo sapiens	104-107
7583583-5	1995	OP mRNA expression was not detected by Northern blot analysis of total RNA from subconfluent or confluent cultures of human VSMCs of any passage maintained in normal growth medium or after stimulation with TGF beta 1 (20 ng/mL), angiotensin II (1 mumol/L), or basic fibroblast growth factor (10 mg/mL) but was just detectable after stimulation with activation vitamin D3 (1 mumol/L).	Cholecalciferol	360-370	secreted phosphoprotein 1	Homo sapiens	0-2
7578252-0	1995	Molecular cloning of 25-hydroxyvitamin D-3 24-hydroxylase (Cyp-24) from mouse kidney: its inducibility by vitamin D-3.	Cholecalciferol	31-42	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	59-65
7583386-9	1995	CONCLUSION: Vitamin D3 decreases N-myc expression in LA-N-5 human neuroblastoma cells, with extended treatment causing growth inhibition and differentiation.	Cholecalciferol	12-22	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	33-38
8643162-4	1995	The most potent vitamin D3 metabolite 1,25(OH)2 D3 (Vit D3) shares certain immunomodulatory properties with CsA.	Cholecalciferol	16-26	vitrin	Rattus norvegicus	52-55
7585485-5	1995	The association of 9-cis-retinoic acid, the ligand of RXR, with vitamin D3 derivatives modified the demonstrated effects, indicating in our model, a preferential effect of vitamin D3 derivatives via the heterodimeric form of the receptor.	Cholecalciferol	64-74	retinoid X receptor alpha	Homo sapiens	54-57
8590308-0	1995	Inhibition of vitamin D3-induced cell differentiation by interferon-gamma in HL-60 cells determined by a nitroblue tetrazolium reduction test.	Cholecalciferol	14-24	interferon gamma	Homo sapiens	57-73
7664636-1	1995	1 alpha, 25-Dihydroxyvitamin D3 [1 alpha, 25-(OH)2D3], the hormonal form of vitamin D3, is further metabolized in the kidney and intestine through the carbon 24 (C-24) oxidation pathway initiated by C-24 hydroxylation, and the carbon 23 (C-23) oxidation pathway initiated by C-23 hydroxylation.	Cholecalciferol	21-31	nucleolin	Homo sapiens	238-242
7585485-5	1995	The association of 9-cis-retinoic acid, the ligand of RXR, with vitamin D3 derivatives modified the demonstrated effects, indicating in our model, a preferential effect of vitamin D3 derivatives via the heterodimeric form of the receptor.	Cholecalciferol	172-182	retinoid X receptor alpha	Homo sapiens	54-57
7664636-1	1995	1 alpha, 25-Dihydroxyvitamin D3 [1 alpha, 25-(OH)2D3], the hormonal form of vitamin D3, is further metabolized in the kidney and intestine through the carbon 24 (C-24) oxidation pathway initiated by C-24 hydroxylation, and the carbon 23 (C-23) oxidation pathway initiated by C-23 hydroxylation.	Cholecalciferol	21-31	nucleolin	Homo sapiens	275-279
7565732-0	1995	Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor.	Cholecalciferol	56-66	interleukin 2	Homo sapiens	34-47
7565732-0	1995	Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor.	Cholecalciferol	56-66	nuclear factor of activated T cells 2	Homo sapiens	89-94
7565732-1	1995	T-lymphocyte proliferation is suppressed by 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the active metabolite of vitamin D3, and is associated with a decrease in interleukin 2 (IL-2), gamma interferon, and granulocyte-macrophage colony-stimulating factor mRNA levels.	Cholecalciferol	58-68	interleukin 2	Homo sapiens	173-177
7565732-3	1995	We therefore examined vitamin D3-mediated repression of activated IL-2 expression by cotransfecting Jurkat cells with IL-2 promoter/reporter constructs and a VDR overexpression vector and by DNA binding.	Cholecalciferol	22-32	interleukin 2	Homo sapiens	66-70
7565732-3	1995	We therefore examined vitamin D3-mediated repression of activated IL-2 expression by cotransfecting Jurkat cells with IL-2 promoter/reporter constructs and a VDR overexpression vector and by DNA binding.	Cholecalciferol	22-32	interleukin 2	Homo sapiens	118-122
7565732-3	1995	We therefore examined vitamin D3-mediated repression of activated IL-2 expression by cotransfecting Jurkat cells with IL-2 promoter/reporter constructs and a VDR overexpression vector and by DNA binding.	Cholecalciferol	22-32	vitamin D receptor	Homo sapiens	158-161
7641218-3	1995	Treatment of mice having LLC-LN7 tumors with vitamin D3 reduced tumor production of GM-CSF and the frequency of myeloid progenitor cells.	Cholecalciferol	45-55	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	84-90
7673731-8	1995	Treatment of monocytes with another combination of cytokines, IFN-gamma+ TNF-alpha + vitamin D3, markedly reduced bacterial viability, although this appeared to be due to decreased phagocytosis leading to extracellular death of the bacteria.	Cholecalciferol	85-95	tumor necrosis factor	Homo sapiens	73-82
7667104-0	1995	Calreticulin inhibits vitamin D3 signal transduction.	Cholecalciferol	22-32	calreticulin	Rattus norvegicus	0-12
7639762-3	1995	Western blot analysis showed that vitamin D3 deficiency also resulted in increased c-myc protein levels in the hearts of vitamin D3-deficient rats.	Cholecalciferol	34-44	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	83-88
7639762-3	1995	Western blot analysis showed that vitamin D3 deficiency also resulted in increased c-myc protein levels in the hearts of vitamin D3-deficient rats.	Cholecalciferol	121-131	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	83-88
7639762-5	1995	Our data suggest a possible relationship between myocyte hyperplasia and increased c-myc levels in the vitamin D3-deficient rat heart.	Cholecalciferol	103-113	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	83-88
8524170-3	1995	There is in vitro evidence that vitamin D3 (1,25 dihydrocholecalciferol) inhibits the production of elastin by smooth muscle cells.	Cholecalciferol	32-42	elastin	Homo sapiens	100-107
7484280-3	1995	1,25-dihydroxyvitamin D3 (1,25[OH]2D3), an active form of vitamin D3, stimulated OC secretion from the human osteosarcoma cell line MG-63 in a dose-dependent manner.	Cholecalciferol	14-24	bone gamma-carboxyglutamate protein	Homo sapiens	81-83
7566512-0	1995	Vitamin D3 effects on basal and cAMP modulated expression of cholecystokinin and somatostatin genes in a rat medullary thyroid carcinoma cell line [CA-77].	Cholecalciferol	0-10	cholecystokinin	Rattus norvegicus	61-76
7566512-0	1995	Vitamin D3 effects on basal and cAMP modulated expression of cholecystokinin and somatostatin genes in a rat medullary thyroid carcinoma cell line [CA-77].	Cholecalciferol	0-10	somatostatin	Rattus norvegicus	81-93
7786034-1	1995	Vitamin D-binding protein (DBP) is primarily involved in the binding and transportation of vitamin D3 and its various metabolites to target organs and tissues.	Cholecalciferol	91-101	D-box binding PAR bZIP transcription factor	Homo sapiens	27-30
7797563-10	1995	Vitamin D3-induced monocytic differentiation resulted in an increased carboxypeptidase M expression in all three cell lines.	Cholecalciferol	0-10	carboxypeptidase M	Homo sapiens	70-88
7625727-2	1995	Receptors for retinoids, thyroid hormone, vitamin D3 and fatty acids/peroxisome proliferators bind their response elements as heterodimers with the retinoid X receptor.	Cholecalciferol	42-52	retinoid X receptor alpha	Homo sapiens	148-167
7786034-1	1995	Vitamin D-binding protein (DBP) is primarily involved in the binding and transportation of vitamin D3 and its various metabolites to target organs and tissues.	Cholecalciferol	91-101	GC vitamin D binding protein	Homo sapiens	0-25
7671162-0	1995	Resetting of parathyroid hormone secretion after vitamin D3 treatment in hypoparathyroidism and after parathyroid adenectomy in primary hyperparathyroidism.	Cholecalciferol	49-59	parathyroid hormone	Homo sapiens	13-32
7662562-7	1995	Our findings provide the first evidence that a strong vitamin D3 analogue triggers synthesis of skin connective tissue, possibly via vitamin D receptor activation and the paracrine action of epidermis-derived TGF-beta 1.	Cholecalciferol	54-64	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	133-151
7579039-9	1995	Hence, other factors like ambient Ca2+ may be responsible for the perturbed secretory patterns of ALP and PRL seen in vitamin D3 treated rats.	Cholecalciferol	118-128	PDZ and LIM domain 3	Rattus norvegicus	98-101
7579039-9	1995	Hence, other factors like ambient Ca2+ may be responsible for the perturbed secretory patterns of ALP and PRL seen in vitamin D3 treated rats.	Cholecalciferol	118-128	prolactin	Rattus norvegicus	106-109
7662562-7	1995	Our findings provide the first evidence that a strong vitamin D3 analogue triggers synthesis of skin connective tissue, possibly via vitamin D receptor activation and the paracrine action of epidermis-derived TGF-beta 1.	Cholecalciferol	54-64	transforming growth factor, beta 1	Mus musculus	209-219
7782931-8	1995	These actions of the vitamin D3 compounds suggest that it may have potential therapeutic applications in Th1-mediated clinical situations such as autoimmunity and transplantation.	Cholecalciferol	21-31	negative elongation factor complex member C/D	Homo sapiens	105-108
7670562-4	1995	The cell growth of mEHE/CH1-5 cell lines was independent of TSH but was inhibited by c-AMP and vitamin D3.	Cholecalciferol	95-105	immediate early response 2	Mus musculus	24-27
7670562-5	1995	c-Myc proto-oncogene expression was also suppressed by vitamin D3 treatment.	Cholecalciferol	55-65	myelocytomatosis oncogene	Mus musculus	0-20
7738187-3	1995	In addition, our laboratory has demonstrated that the major active metabolite of vitamin D3, 1,25(OH)2D3, also rapidly (seconds-minutes) activated PKC and increased intracellular calcium in isolated rat colonocytes.	Cholecalciferol	81-91	protein kinase C, alpha	Rattus norvegicus	147-150
7785896-6	1995	Expression of OPN mRNA is upregulated by growth and differentiation factors (PDGF, EGF, TGF-beta and BMP-7/OP-1) and by mechanical stress, which promote bone formation, as well as by osteotropic hormones (retinoic acid and vitamin D3), which can promote bone resorption and remodelling.	Cholecalciferol	223-233	secreted phosphoprotein 1	Rattus norvegicus	14-17
7786034-2	1995	This is manifested by the ability of DBP to bind vitamin D3 and its metabolites with high affinity.	Cholecalciferol	49-59	D-box binding PAR bZIP transcription factor	Homo sapiens	37-40
7786039-0	1995	The role of dietary calcium in the physiology of vitamin D toxicity: excess dietary vitamin D3 blunts parathyroid hormone induction of kidney 1-hydroxylase.	Cholecalciferol	84-94	parathyroid hormone	Rattus norvegicus	102-121
7786039-9	1995	Also, the metabolic clearance rate for 1,25(OH)2D3 was enhanced by feeding excess vitamin D3, which was likely a result of the substantial elevations in intestinal (25-fold) and renal (46-fold) 24-OHase activities in the LCT and NCT groups, respectively.	Cholecalciferol	82-92	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	194-202
7882362-5	1995	Vitamin D3 is growth inhibitory for the estrogen receptor-negative breast cancer cell line BT-20 and regulates TGF-beta expression in cultured keratinocytes.	Cholecalciferol	0-10	transforming growth factor beta 1	Homo sapiens	111-119
7882362-6	1995	We studied here the effects of vitamin D3 and its analogues on TGF-beta expression and activity in BT-20 cells.	Cholecalciferol	31-41	transforming growth factor beta 1	Homo sapiens	63-71
7882362-7	1995	It was found that vitamin D3 enhanced both TGF-beta 1 mRNA and secretion of the protein in a time- and dose-dependent manner.	Cholecalciferol	18-28	transforming growth factor beta 1	Homo sapiens	43-53
7882362-8	1995	Analyses of the vitamin D3 responses in the presence of cycloheximide or actinomycin D indicated that the TGF-beta 1 mRNA induction was dependent on both protein and RNA synthesis.	Cholecalciferol	16-26	transforming growth factor beta 1	Homo sapiens	106-116
7882362-10	1995	The amounts of active TGF-beta were enhanced in vitamin D3-treated cultures as well, suggesting autocrine or paracrine functions for the secreted growth factor.	Cholecalciferol	48-58	transforming growth factor beta 1	Homo sapiens	22-30
7882362-11	1995	Some analogues of vitamin D3 (EB 1089, MC 903, and KH 1060) that are known to be potent inhibitors of breast cancer cell growth both in vitro and in vivo had similar or more pronounced inducing effects on TGF-beta 1 mRNA levels.	Cholecalciferol	18-28	transforming growth factor beta 1	Homo sapiens	205-215
7882362-12	1995	The present results indicate that vitamin D3 and its analogues are potent inducers of both active and latent forms of TGF-beta 1 in BT-20 breast carcinoma cells and provide evidence for coordinated regulation of latent TGF-beta binding protein and TGF-beta 1.	Cholecalciferol	34-44	transforming growth factor beta 1	Homo sapiens	118-128
7882362-12	1995	The present results indicate that vitamin D3 and its analogues are potent inducers of both active and latent forms of TGF-beta 1 in BT-20 breast carcinoma cells and provide evidence for coordinated regulation of latent TGF-beta binding protein and TGF-beta 1.	Cholecalciferol	34-44	transforming growth factor beta 1	Homo sapiens	118-126
7882362-12	1995	The present results indicate that vitamin D3 and its analogues are potent inducers of both active and latent forms of TGF-beta 1 in BT-20 breast carcinoma cells and provide evidence for coordinated regulation of latent TGF-beta binding protein and TGF-beta 1.	Cholecalciferol	34-44	transforming growth factor beta 1	Homo sapiens	248-258
7720709-3	1995	Using AP1 reporter cells, we also show that glucocorticoids or vitamin D3, together with either RA or these "dissociating" synthetic retinoids, can synergistically repress phorbol ester-induced AP1 activity.	Cholecalciferol	63-73	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	6-9
7714065-8	1995	Supplementation with 400 IU vitamin D3 daily in elderly women slightly decreases PTH secretion and increases bone mineral density at the femoral neck.	Cholecalciferol	28-38	parathyroid hormone	Homo sapiens	81-84
7536865-4	1995	In HL-60 cells, lacking constitutive TGF-alpha mRNA, vitamin D3 caused expression of the TGF-alpha gene and protein as demonstrated by Northern blot analysis and enzyme-linked immunoabsorbant assay (ELISA).	Cholecalciferol	53-63	transforming growth factor alpha	Homo sapiens	89-98
7606167-1	1995	During the course of our studies to probe the vitamin D ligand-binding domains of vitamin D-binding protein and vitamin D receptor, we developed a synthetic procedure to modify the 3 beta-hydroxyl group of vitamin D3 and its 25-hydroxy- and 1,25-dihydroxy metabolites with a 3"-aminopropylether group.	Cholecalciferol	206-216	GC vitamin D binding protein	Homo sapiens	82-107
7606167-1	1995	During the course of our studies to probe the vitamin D ligand-binding domains of vitamin D-binding protein and vitamin D receptor, we developed a synthetic procedure to modify the 3 beta-hydroxyl group of vitamin D3 and its 25-hydroxy- and 1,25-dihydroxy metabolites with a 3"-aminopropylether group.	Cholecalciferol	206-216	vitamin D receptor	Homo sapiens	112-130
7720709-3	1995	Using AP1 reporter cells, we also show that glucocorticoids or vitamin D3, together with either RA or these "dissociating" synthetic retinoids, can synergistically repress phorbol ester-induced AP1 activity.	Cholecalciferol	63-73	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	194-197
7530503-4	1995	Induction of monocytic differentiation in HL-60 cells by vitamin D3 resulted in rapid expression of HOX B7 mRNA, but stimulation with phorbol ester or dimethyl sulfoxide (DMSO) did not.	Cholecalciferol	57-67	homeobox B7	Homo sapiens	100-106
7887976-5	1995	Our study shows that vitamin D3 compounds that bind to the vitamin D receptor stimulate epidermal proliferation in mice.	Cholecalciferol	21-31	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	59-77
7700077-1	1995	1,25 dihydroxyvitamin D3 [1,25(OH)2D3] mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 responsive elements (VDRE) in genes modulated by 1,25(OH)2D3.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	106-125
7700077-1	1995	1,25 dihydroxyvitamin D3 [1,25(OH)2D3] mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 responsive elements (VDRE) in genes modulated by 1,25(OH)2D3.	Cholecalciferol	14-24	vitamin D receptor	Homo sapiens	127-130
7700077-10	1995	In contrast, biologically active vitamin D3 compounds (Cmpds HM, C, V) in a dose-dependent fashion enhanced the VDR/RXR (retinoid X receptor)-VDRE retarded band.	Cholecalciferol	33-43	vitamin D receptor	Homo sapiens	112-115
7700077-10	1995	In contrast, biologically active vitamin D3 compounds (Cmpds HM, C, V) in a dose-dependent fashion enhanced the VDR/RXR (retinoid X receptor)-VDRE retarded band.	Cholecalciferol	33-43	retinoid X receptor alpha	Homo sapiens	116-119
7700077-10	1995	In contrast, biologically active vitamin D3 compounds (Cmpds HM, C, V) in a dose-dependent fashion enhanced the VDR/RXR (retinoid X receptor)-VDRE retarded band.	Cholecalciferol	33-43	retinoid X receptor alpha	Homo sapiens	121-140
7862109-0	1995	Natural vitamin D3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation.	Cholecalciferol	8-18	retinoid X receptor alpha	Homo sapiens	129-148
7834638-4	1995	We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO.	Cholecalciferol	189-199	tumor protein p53	Homo sapiens	13-16
7834638-4	1995	We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO.	Cholecalciferol	189-199	cyclin dependent kinase inhibitor 1A	Homo sapiens	42-46
7834638-4	1995	We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO.	Cholecalciferol	189-199	cyclin dependent kinase inhibitor 1A	Homo sapiens	47-51
7834638-4	1995	We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO.	Cholecalciferol	189-199	interferon gamma	Homo sapiens	151-160
7554919-4	1995	In contrast, however, vitamin D3 suppresses bone formation and abrogates the expression of BSP.	Cholecalciferol	22-32	integrin binding sialoprotein	Homo sapiens	91-94
7554919-7	1995	The promoters are characterized by a highly conserved region (BSP box) encompassing the immediate promoter region, which includes a unique inverted TATA box overlapped by a putative (DR3) vitamin D3 response element (VDRE).	Cholecalciferol	188-198	integrin binding sialoprotein	Homo sapiens	62-65
7811238-0	1994	On the induction of 5-lipoxygenase expression and activity in HL-60 cells: effects of vitamin D3, retinoic acid, DMSO and TGF beta.	Cholecalciferol	86-96	arachidonate 5-lipoxygenase	Homo sapiens	20-34
7539760-9	1995	When CD14 expression is induced on the myelomonocytic cell line U937 by treatment with vitamin D3 the cells concomittently acquire the capacity to bind bacteria.	Cholecalciferol	87-97	CD14 molecule	Homo sapiens	5-9
7811384-0	1994	Identification and characterization of a vitamin D3 response element of chicken carbonic anhydrase-II.	Cholecalciferol	41-51	carbonic anhydrase 2	Gallus gallus	80-101
7519122-0	1994	PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.	Cholecalciferol	112-122	PML nuclear body scaffold	Homo sapiens	0-13
7876686-1	1994	The effects of a new derivative of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3 (OCT), on rheumatoid arthritis was investigated using collagen-induced arthritis in rat, as an experimental model of the disease.	Cholecalciferol	35-45	plexin A2	Homo sapiens	86-89
7798277-1	1994	The present study was undertaken to clarify the pharmacokinetics of 22-oxa-1,25-dihydroxyvitamin D3 (22-oxa-1,25-(OH)2D3, OCT), a vitamin D3 analogue with little calcemic activity, and its effect on the transcription of parathyroid hormone-related peptide (PTHRP) gene in nude mice bearing a human carcinoma (FA-6) associated with humoral hypercalcemia.	Cholecalciferol	89-99	parathyroid hormone-like peptide	Mus musculus	220-255
7798277-1	1994	The present study was undertaken to clarify the pharmacokinetics of 22-oxa-1,25-dihydroxyvitamin D3 (22-oxa-1,25-(OH)2D3, OCT), a vitamin D3 analogue with little calcemic activity, and its effect on the transcription of parathyroid hormone-related peptide (PTHRP) gene in nude mice bearing a human carcinoma (FA-6) associated with humoral hypercalcemia.	Cholecalciferol	89-99	parathyroid hormone-like peptide	Mus musculus	257-262
7855310-5	1994	AM from vitamin D3-deficient rats demonstrated reduced 5-LO metabolism of AA and a parallel reduction in FLAP expression compared to control rats.	Cholecalciferol	8-18	arachidonate 5-lipoxygenase activating protein	Rattus norvegicus	105-109
8049143-0	1994	Vitamin D receptor binding and biological effects of cholecalciferol analogues in rat thyroid cells.	Cholecalciferol	53-68	vitamin D receptor	Rattus norvegicus	0-18
7888303-0	1994	Potentiation by cholesterol and vitamin D3 oxygenated derivatives of arachidonic acid release and prostaglandin E2 synthesis induced by the epidermal growth factor in NRK 49F cells: the role of protein kinase C. We have previously demonstrated that oxysterols and calcitriol potentiate arachidonic acid (AA) release and prostaglandin (PG) synthesis when NRK cells (fibroblastic clone 49F) are activated by foetal calf serum.	Cholecalciferol	32-42	epidermal growth factor like 1	Rattus norvegicus	140-163
8049143-8	1994	In conclusion, the biological effects of these cholecalciferol analogues in rat thyroid FRTL-5 cells seem to be mainly determined by their binding affinity for the VDR, although non-genomic effects can not be excluded.	Cholecalciferol	47-62	vitamin D receptor	Rattus norvegicus	164-167
8076440-2	1994	injection of vitamin D3 has a well known suppressive effect on the release of parathyroid hormone.	Cholecalciferol	13-23	parathyroid hormone	Homo sapiens	78-97
8172088-0	1994	Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial.	Cholecalciferol	12-27	parathyroid hormone	Homo sapiens	62-81
7959906-6	1994	The protective effect observed against IL-1 beta-induced beta-cell dysfunction might be related to a beneficial action of vitamin D3 on the mitochondrial calcium metabolism of the beta-cells.	Cholecalciferol	122-132	interleukin 1 beta	Rattus norvegicus	39-48
8188744-3	1994	Vitamin D3 and thyroid hormone T3, that activate retinoic acid receptor (RAR) cognates, forming heterodimers with retinoid X receptor (RXR), do not affect the potency of immunotoxins.	Cholecalciferol	0-10	retinoic acid receptor alpha	Homo sapiens	73-76
8033198-9	1994	Vitamin D3 also decreased the conduction velocity and increased CaBP of the vagus nerve and, by lipid analysis, was shown to increase and decrease its phosphatidylcholine and phosphatidylethanolamine content, respectively, and to decrease its phospholipid/cholesterol ratio.	Cholecalciferol	0-10	S100 calcium binding protein G	Homo sapiens	64-68
8188744-3	1994	Vitamin D3 and thyroid hormone T3, that activate retinoic acid receptor (RAR) cognates, forming heterodimers with retinoid X receptor (RXR), do not affect the potency of immunotoxins.	Cholecalciferol	0-10	retinoid X receptor alpha	Homo sapiens	114-133
8142654-5	1994	The wt1 transcripts were also downregulated in HL60 cells during differentiation to monocytes by vitamin D3 or 12-o-tetradecanoyl-phorbol-13-acetate.	Cholecalciferol	97-107	WT1 transcription factor	Homo sapiens	4-7
8028822-2	1994	Evaluation of the gene coding for the vitamin D receptor (VDR) for the hormonally active form of vitamin D3, 1 alpha, 25(OH)2-vitamin D3, indicates the presence of two allelic variants.	Cholecalciferol	97-107	vitamin D receptor	Homo sapiens	38-56
8028822-2	1994	Evaluation of the gene coding for the vitamin D receptor (VDR) for the hormonally active form of vitamin D3, 1 alpha, 25(OH)2-vitamin D3, indicates the presence of two allelic variants.	Cholecalciferol	97-107	vitamin D receptor	Homo sapiens	58-61
7510956-1	1994	Pretreatment (4h) of human HL 60 leukemia cells with the topoisomerase I-inhibitor camptothecin (7-28 x 10(-9) Mol/l, single dose) enhanced vitamin D3-responsive CD 14 expression (10(-11)-10(-8) Mol/l vitamin D3) up to twofold, as measured by fluorescence activated flow cytometry after 1-3 days.	Cholecalciferol	140-150	CD14 molecule	Homo sapiens	162-167
8134128-6	1994	In contrast to these two genes the expression of mad was induced upon differentiation in the three cell lines by TPA, retinoic acid, vitamin D3, dimethyl sulfoxide, and interferon-gamma and remained elevated for at least 3 days.	Cholecalciferol	133-143	MAX dimerization protein 1	Homo sapiens	49-52
7510956-5	1994	We conclude that inhibition of topoisomerase I enhances vitamin D3-stimulated CD 14 expression.	Cholecalciferol	56-66	CD14 molecule	Homo sapiens	78-83
8164209-1	1993	OBJECTIVE: To investigate the effects of vitamin D3 [1,25-(OH)2D3] metabolites on interleukin 1 beta (IL-1 beta) stimulated secretory activities and on the proliferation of human synovial fibroblasts in culture.	Cholecalciferol	41-51	interleukin 1 beta	Homo sapiens	82-100
7509804-11	1994	Furthermore, vitamin D3 completely dissociates the production of 92-kDa gelatinase and interstitial collagenase in human mononuclear phagocytes.	Cholecalciferol	13-23	matrix metallopeptidase 1	Homo sapiens	87-111
8193081-0	1994	Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1).	Cholecalciferol	36-46	interleukin 1 alpha	Homo sapiens	122-132
8193081-0	1994	Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1).	Cholecalciferol	36-46	C-X-C motif chemokine ligand 8	Homo sapiens	138-142
10465025-8	1994	These findings indicate that vitamin D3 analogues regulate cell proliferation by control of the transition of G1 and G2+M phases, reminiscent of the cdc2/CDK2 type of cell cycle control.	Cholecalciferol	29-39	cyclin dependent kinase 1	Homo sapiens	149-153
10465025-8	1994	These findings indicate that vitamin D3 analogues regulate cell proliferation by control of the transition of G1 and G2+M phases, reminiscent of the cdc2/CDK2 type of cell cycle control.	Cholecalciferol	29-39	cyclin dependent kinase 2	Homo sapiens	154-158
8190177-2	1994	PBMC from HD patients without prior therapy with hydroxylated vitamin D3 analogs and from normal controls produced similar amounts of TNF-alpha, either spontaneously or after stimulation with lipopolysaccharide (LPS).	Cholecalciferol	62-72	tumor necrosis factor	Homo sapiens	134-143
8190177-7	1994	These results suggest that therapy with 1 alpha-hydroxylated vitamin D3 analogs normally given to HD patients for the management of renal osteodystrophy may also regulate the in vivo activity of TNF-alpha.	Cholecalciferol	61-71	tumor necrosis factor	Homo sapiens	195-204
8227160-0	1993	Maturation-dependent regulation of protein kinase C activity by vitamin D3 metabolites in chondrocyte cultures.	Cholecalciferol	64-74	protein kinase C, gamma	Rattus norvegicus	35-51
8227160-7	1993	The specificity of PKC stimulation by the vitamin D3 metabolites was verified using a specific pseudosubstrate region peptide inhibitor, which reduced PKC activity when included in the reaction mixture.	Cholecalciferol	42-52	protein kinase C, gamma	Rattus norvegicus	19-22
8227160-7	1993	The specificity of PKC stimulation by the vitamin D3 metabolites was verified using a specific pseudosubstrate region peptide inhibitor, which reduced PKC activity when included in the reaction mixture.	Cholecalciferol	42-52	protein kinase C, gamma	Rattus norvegicus	151-154
8228332-7	1993	A decrease was observed also in extracellular matrix and membrane-associated u-PA activity of vitamin D3 and calcipotriol treated cells.	Cholecalciferol	94-104	plasminogen activator, urokinase	Homo sapiens	77-81
8227185-6	1993	While parathyroid hormone (PTH) exposure did not influence IL-4R levels, vitamin D3 treatment augmented MC3T3 125I-IL-4 binding, in a time-dependent manner, up to threefold after a 24 h exposure with a metabolite specificity indicating the involvement of the vitamin D receptor.	Cholecalciferol	73-83	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	259-277
7508534-6	1994	CD14 expression was significantly (p = 0.035) enhanced with the combination of bryostatin 5 and vitamin D3.	Cholecalciferol	96-106	CD14 molecule	Homo sapiens	0-4
7508534-8	1994	A loss of CD34 expression occurred during cell culture; this loss was enhanced by vitamin D3, but prevented partly by bryostatin 5.	Cholecalciferol	82-92	CD34 molecule	Homo sapiens	10-14
7505123-8	1993	Vitamin D3, which increases the functional capacity of beta-glucan receptors, increased IL-1Ra production induced by particulate beta-glucan, whereas dexamethasone suppressed IL-1Ra synthesis.	Cholecalciferol	0-10	interleukin 1 receptor antagonist	Homo sapiens	88-94
8253854-3	1993	Similar to controls, OI bone cells produced predominantly collagen type I with traces of collagen types III and V. The 1,25(OH)2 vitamin D3-stimulated synthesis of osteocalcin, a specific osteoblastic marker protein, was similar in OI bone cells and age-matched controls.	Cholecalciferol	129-139	bone gamma-carboxyglutamate protein	Homo sapiens	164-175
8164209-1	1993	OBJECTIVE: To investigate the effects of vitamin D3 [1,25-(OH)2D3] metabolites on interleukin 1 beta (IL-1 beta) stimulated secretory activities and on the proliferation of human synovial fibroblasts in culture.	Cholecalciferol	41-51	interleukin 1 beta	Homo sapiens	102-111
8103274-1	1993	The induction of epidermal ornithine decarboxylase (ODC) can be partially blocked by corticosteroids, retinoic acid or active vitamin D3.	Cholecalciferol	126-136	ornithine decarboxylase 1	Homo sapiens	27-50
8227185-11	1993	Taken together, these findings raise the possibility that IL-4"s influence on mineral metabolism could be mediated by osteoblasts and that the effectiveness of this cytokine may be influenced by vitamin D3"s impact on IL-4R expression.	Cholecalciferol	195-205	interleukin 4 receptor, alpha	Mus musculus	218-223
8393784-6	1993	Accordingly, we show that PMLRAR can both prevent the binding of the vitamin D3 receptor (VDR) to a target sequence in vitro and inhibit vitamin D3-dependent activation of a VDR-responsive reporter gene in transfected cells.	Cholecalciferol	69-79	PML-RARA regulated adaptor molecule 1	Homo sapiens	26-32
8393784-6	1993	Accordingly, we show that PMLRAR can both prevent the binding of the vitamin D3 receptor (VDR) to a target sequence in vitro and inhibit vitamin D3-dependent activation of a VDR-responsive reporter gene in transfected cells.	Cholecalciferol	69-79	vitamin D receptor	Homo sapiens	90-93
8224758-0	1993	Effect of estrogen in relation to dietary vitamin D3 and calcium on activity of intestinal alkaline phosphatase and Ca-ATPase in immature chicks.	Cholecalciferol	42-52	alkaline phosphatase, intestinal	Homo sapiens	80-111
8224760-9	1993	Vitamin D3 supplementation resulted in VDR upregulation in the intestine and kidney and induced renal 24-OHase but had no effects on VDRs in Harderian glands.	Cholecalciferol	0-10	vitamin D3 receptor	Heterocephalus glaber	39-42
8366134-5	1993	The biologically less potent metabolite of vitamin D3, 25 (OH) D3, also augmented 125I-interleukin 1 alpha binding but at steroid levels 2-3 log orders greater than 1,25 (OH)2 D3.	Cholecalciferol	43-53	interleukin 1 alpha	Mus musculus	87-106
8390483-1	1993	Transport of vitamin D3 from its sites of cutaneous synthesis into the circulation has been assumed to be via the plasma vitamin D binding protein (DBP).	Cholecalciferol	13-23	GC vitamin D binding protein	Homo sapiens	121-146
8390483-1	1993	Transport of vitamin D3 from its sites of cutaneous synthesis into the circulation has been assumed to be via the plasma vitamin D binding protein (DBP).	Cholecalciferol	13-23	D-box binding PAR bZIP transcription factor	Homo sapiens	148-151
8390483-10	1993	These findings indicate that endogenously synthesized vitamin D3 travels in plasma almost exclusively on DBP, providing for a slower hepatic delivery of the vitamin D and the more sustained increase in plasma 25-hydroxycholecalciferol observed after depot, parenteral administration of vitamin D.	Cholecalciferol	54-64	D-box binding PAR bZIP transcription factor	Homo sapiens	105-108
8360493-0	1993	Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.	Cholecalciferol	14-24	vitamin D binding protein	Mus musculus	42-66
8360493-0	1993	Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.	Cholecalciferol	14-24	galactosidase, beta 1	Mus musculus	128-146
8368339-0	1993	Vitamin D3 accelerates PTH-dependent calcium transport in distal convoluted tubule cells.	Cholecalciferol	0-10	parathyroid hormone	Mus musculus	23-26
8390565-6	1993	Our results indicate that insulin treatment of neuronal cells in primary culture increases PtdIns 3-kinase activity and the formation of the unique D-3-phosphorylated phosphoinositides, suggesting that growth factor-mediated neuronal growth may include the formation of novel phosphoinositide 3-phosphate phospholipids.	Cholecalciferol	148-151	myotrophin	Rattus norvegicus	202-215
8103274-1	1993	The induction of epidermal ornithine decarboxylase (ODC) can be partially blocked by corticosteroids, retinoic acid or active vitamin D3.	Cholecalciferol	126-136	ornithine decarboxylase 1	Homo sapiens	52-55
8470912-4	1993	The heterodimer formation between RXR and RAR or other members of the steroid/thyroid hormone receptor superfamily gave us a new aspect of hormonal gene control including retinoids, thyroid hormone, vitamin D3 and others.	Cholecalciferol	199-209	retinoid X receptor alpha	Homo sapiens	34-37
8470912-4	1993	The heterodimer formation between RXR and RAR or other members of the steroid/thyroid hormone receptor superfamily gave us a new aspect of hormonal gene control including retinoids, thyroid hormone, vitamin D3 and others.	Cholecalciferol	199-209	retinoic acid receptor alpha	Homo sapiens	42-45
8386190-4	1993	Despite development of a macrophage morphology, &lt; 5% of cytokine-stimulated U937 cells were adherent at 24 h. Addition of 1-10 nM urokinase-type plasminogen activator (uPA) induced adherence in the presence of transforming growth factor type beta-1, 1,25-(OH)2 vitamin D3, granulocyte macrophage colony-stimulating factor, or tumor necrosis factor alpha.	Cholecalciferol	264-274	plasminogen activator, urokinase	Homo sapiens	133-169
8473513-5	1993	Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels.	Cholecalciferol	0-10	interleukin 1 complex	Mus musculus	21-25
7682243-0	1993	Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells.	Cholecalciferol	30-40	CD14 molecule	Homo sapiens	80-84
7682243-0	1993	Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells.	Cholecalciferol	30-40	Fc epsilon receptor II	Homo sapiens	89-93
8410379-1	1993	Messenger ribonucleic acid (mRNA) levels and activities of renal 25-hydroxyvitamin D3-24-hydroxylase (24-OHase) were determined in 3 groups of rats: vitamin D-deficient, normal, and 1 alpha-hydroxyvitamin D3 (1 alpha OHD3)-administered rats.	Cholecalciferol	83-85	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	102-110
8483269-4	1993	The complex of VDR and 1 alpha,25(OH)2D3 binds to vitamin D3-responsive elements (VDRE) present in the promoter region of target genes of 1 alpha,25(OH)2D3.	Cholecalciferol	50-60	vitamin D receptor	Homo sapiens	15-30
8473513-5	1993	Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels.	Cholecalciferol	0-10	interleukin 6	Mus musculus	166-170
8473513-5	1993	Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels.	Cholecalciferol	0-10	interleukin 1 complex	Mus musculus	137-141
8383719-0	1993	Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines.	Cholecalciferol	44-54	transforming growth factor beta 1	Homo sapiens	0-31
8516267-0	1993	Relationship between circulating vitamin D3 metabolites and prolactin or growth hormone levels in rat.	Cholecalciferol	33-43	prolactin	Rattus norvegicus	60-69
8516267-0	1993	Relationship between circulating vitamin D3 metabolites and prolactin or growth hormone levels in rat.	Cholecalciferol	33-43	gonadotropin releasing hormone receptor	Rattus norvegicus	73-87
8502602-0	1993	[Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism.	Cholecalciferol	36-46	parathyroid hormone	Homo sapiens	83-102
8428788-8	1993	The results suggest that the enhanced pressor responses to norepinephrine and Ang II could be attributed to the direct effect of active vitamin D3 on vasculature rather than to hypercalcemia.	Cholecalciferol	136-146	angiotensinogen	Rattus norvegicus	78-84
8466756-0	1993	Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-beta 1 and -beta 2 in cultured murine keratinocytes.	Cholecalciferol	0-10	transforming growth factor, beta 1	Mus musculus	53-98
8105940-0	1993	Intermittent minibolus oral vitamin D3 in CAPD patients with resistant parathyroid hormone values.	Cholecalciferol	28-38	parathyroid hormone	Homo sapiens	71-90
8443002-1	1993	We have tested two new vitamin D3 derivatives, 22-oxa-1 alpha, 25-dihydroxyvitamin D3 (OCT) and 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3 (ED-71), for their effects on bone metabolism compared with 1 alpha, 25-dihydroxyvitamin D3 (1,25(OH)2D3) in two organ-culture systems.	Cholecalciferol	23-33	plexin A2	Mus musculus	87-90
8466756-2	1993	Since TGF beta s are very potent inhibitors of keratinocyte growth we studied the effects of vitamin D3 and calcipotriol on the secretion of TGF beta in cultured murine keratinocytes.	Cholecalciferol	93-103	transforming growth factor, beta 1	Mus musculus	141-149
8466756-6	1993	Heat treatment of the conditioned medium, which activates latent forms of TGF beta, revealed higher levels of growth inhibitory activity in the medium from vitamin D3 and calcipotriol treated than from control cultures indicating that a fraction of TGF beta was in a latent form.	Cholecalciferol	156-166	transforming growth factor, beta 1	Mus musculus	74-82
8466756-6	1993	Heat treatment of the conditioned medium, which activates latent forms of TGF beta, revealed higher levels of growth inhibitory activity in the medium from vitamin D3 and calcipotriol treated than from control cultures indicating that a fraction of TGF beta was in a latent form.	Cholecalciferol	156-166	transforming growth factor, beta 1	Mus musculus	249-257
8466756-7	1993	Active TGF beta was, however, detected considerably more in vitamin D3 and calcipotriol treated cultures than in control cultures.	Cholecalciferol	60-70	transforming growth factor, beta 1	Mus musculus	7-15
8466756-9	1993	These results indicate that enhanced TGF beta 1 and TGF beta 2 secretion and activity is associated with vitamin D3-mediated growth inhibition of cultured keratinocytes.	Cholecalciferol	105-115	transforming growth factor, beta 1	Mus musculus	37-47
8466756-9	1993	These results indicate that enhanced TGF beta 1 and TGF beta 2 secretion and activity is associated with vitamin D3-mediated growth inhibition of cultured keratinocytes.	Cholecalciferol	105-115	transforming growth factor, beta 2	Mus musculus	52-62
8399644-9	1993	In group 2, in order to avoid the further rise of serum PTH, the low-Ca PDS was supplemented with 2 micrograms/day of 1,25(OH)2D3 (vitamin D3); this was followed by a reduction in serum PTH with no increase in Ca2+ and PO4.	Cholecalciferol	131-141	parathyroid hormone	Homo sapiens	186-189
8381250-3	1993	Gallium nitrate reduced both constitutive and vitamin D3-stimulated osteocalcin protein levels in culture medium by one-half and osteocalcin mRNA levels to one-third to one-tenth of control.	Cholecalciferol	46-56	bone gamma-carboxyglutamate protein	Rattus norvegicus	68-79
8381250-4	1993	Gallium nitrate also inhibited vitamin D3 stimulation of osteocalcin and osteopontin mRNA levels but did not affect constitutive osteopontin mRNA levels.	Cholecalciferol	31-41	bone gamma-carboxyglutamate protein	Rattus norvegicus	57-68
8381250-4	1993	Gallium nitrate also inhibited vitamin D3 stimulation of osteocalcin and osteopontin mRNA levels but did not affect constitutive osteopontin mRNA levels.	Cholecalciferol	31-41	secreted phosphoprotein 1	Rattus norvegicus	73-84
8396209-1	1993	The treatment of X-linked hypophosphatemia (XLH) consists of phosphate and vitamin D3 derivatives.	Cholecalciferol	75-85	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	17-42
1337336-2	1992	GM-CSF or vitamin D3 enhanced the synthesis of the third component of complement (C3) by U937 cells, but had no stimulatory effect on the synthesis of the fourth component of complement (C4).	Cholecalciferol	10-20	complement C3	Homo sapiens	70-84
8394607-8	1993	Simultaneous influence of ecdysterone and vitamin D3 leads to the partial normalization of the biochemical indices studied (except for those which characterize LPO reactions) mainly in the active chromatin fraction.	Cholecalciferol	42-52	lactoperoxidase	Rattus norvegicus	160-163
1337336-5	1992	Vitamin D3 enhanced IFN-gamma-induced C4 synthesis by U937 cells.	Cholecalciferol	0-10	interferon gamma	Homo sapiens	20-29
1445236-1	1992	A cytochrome P-450 which catalyses 25-hydroxylation of vitamin D3 has been purified to apparent homogeneity from pig liver microsomes.	Cholecalciferol	55-65	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	2-18
1445236-8	1992	The vitamin D3 25-hydroxylase in pig liver microsomes exhibited a turnover and an apparent Km for 25-hydroxylation of vitamin D3 which were of the same order of magnitude as those of a well-characterized male-specific 25-hydroxylating cytochrome P-450 in rat liver microsomes.	Cholecalciferol	4-14	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	235-251
1459360-2	1992	Small amounts of calbindin mRNA detected in vitamin D3 deficient (D-deficient) chick intestine increased rapidly to maximal values 8 h after hormone injection.	Cholecalciferol	44-54	calbindin 1	Gallus gallus	17-26
1331703-1	1992	The mechanism for the transfer of fat-soluble vitamin D3 from the avascular basal cellular layers of the epidermis to dermal capillaries and peripheral circulation is unknown, although vitamin D-binding protein (DBP) is thought to mediate this process.	Cholecalciferol	46-56	D-box binding PAR bZIP transcription factor	Homo sapiens	212-215
1331703-6	1992	We conclude that vitamin D3 egress from the skin is not affected by elevated circulating vitamin D concentrations; thus, the cutaneous release of vitamin D is probably mediated by a protein such as DBP with a high carrying capacity for the vitamin.	Cholecalciferol	17-27	D-box binding PAR bZIP transcription factor	Homo sapiens	198-201
1669973-0	1991	Possible role of the hormonal form of vitamin D3 in the granuloma-associated angiotensin-converting enzyme activity.	Cholecalciferol	38-48	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	77-106
1472030-0	1992	The effect of active vitamin D3 analogs and dexamethasone on the expression of osteocalcin gene in rat tibiae in vivo.	Cholecalciferol	21-31	bone gamma-carboxyglutamate protein	Rattus norvegicus	79-90
1643114-10	1992	These results suggest that at least part of the direct effect of vitamin D3 metabolites on cell membranes may be related to changes in PA2 activity.	Cholecalciferol	65-75	phospholipase A2 group IB	Homo sapiens	135-138
1320642-4	1992	In this study, neutrophils activated with C5a exhibited two distinct G protein-dependent signal pathways involving different phosphoinositides: 1) [32P]PI(4,5)P2 hydrolysis and [32P]PA production, and 2) the transient formation of D-3-phosphorylated phosphoinositides, [32P]PIP3 and [32P]PI(3,4)P2.	Cholecalciferol	231-234	complement C5a receptor 1	Homo sapiens	42-45
1336906-1	1992	Dihydrotachysterol3, a reduced (or hydrogenated) analog of vitamin D3 in which the A ring has been rotate through 180 degrees , is, after hepatic 25-hydroxylation, converted in vivo to a dihydroxylated metabolite, termed peak H, which is at present unidentified but with good affinity for the vitamin D receptor.	Cholecalciferol	59-69	vitamin D receptor	Rattus norvegicus	293-311
1584219-1	1992	The high affinity calcium-binding protein calbindin-D28K is one of the known proteins transcriptionally up-regulated by the hormonally active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3].	Cholecalciferol	150-160	calbindin 1	Homo sapiens	42-51
1310351-0	1992	Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling.	Cholecalciferol	91-101	retinoid X receptor alpha	Homo sapiens	0-19
1310351-4	1992	RXR also interacts directly with and enhances the binding of nuclear receptors conferring responsiveness to vitamin D3 and thyroid hormone T3; the DNA-binding activities of these receptors are also stimulated by the presence of nuclear extracts.	Cholecalciferol	108-118	retinoid X receptor alpha	Homo sapiens	0-3
1350411-4	1992	Psoriatic lesions improving after 1-2 weeks" treatment with betamethasone or vitamin D3 analogue revealed PTH-rp reactivity just above the granular layer.	Cholecalciferol	77-87	parathyroid hormone like hormone	Homo sapiens	106-112
1309487-6	1992	The anti-p68 antibody synergizes with the active metabolite of vitamin D3, 1,25-dehydroxyvitamin D3, to induce monocyte to macrophage maturation and enhances the function of mature granulocytes stimulated with the granulocyte-macrophage colony-stimulating factor in vitro.	Cholecalciferol	63-73	KH RNA binding domain containing, signal transduction associated 1	Homo sapiens	9-12
1667458-1	1991	We have developed an assay to measure the affinity of serum vitamin D binding protein for 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, and vitamin D3, using uniform diameter (6.4 microns) polystyrene beads coated with phosphatidylcholine and vitamin D metabolites as the vitamin D donor.	Cholecalciferol	100-110	GC vitamin D binding protein	Homo sapiens	60-85
1723613-2	1991	One of the nutrients implicated as having an interaction with boron is cholecalciferol (Vit D3).	Cholecalciferol	71-86	vitrin	Gallus gallus	88-91
1800316-0	1991	The weak calcemic vitamin D3 analogue 22-oxacalcitriol suppresses the production of tumor necrosis factor-alpha by peripheral mononuclear cells.	Cholecalciferol	18-28	tumor necrosis factor	Homo sapiens	84-111
1843267-2	1991	The administration of active vitamin D3 gradually increased the serum BGP to more than 3 times the original level by the 8th week.	Cholecalciferol	29-39	bone gamma-carboxyglutamate protein	Homo sapiens	70-73
1843267-3	1991	At the 12th week after starting the active vitamin D3 therapy, mean BGP was about twice the original level, which was about half the maximum level at the 8th week.	Cholecalciferol	43-53	bone gamma-carboxyglutamate protein	Homo sapiens	68-71
1843267-7	1991	These data suggest that BGP was increased through direct stimulation of osteoblasts by the active vitamin D3, and the increase was not due to deterioration of secondary hyperparathyroidism.	Cholecalciferol	98-108	bone gamma-carboxyglutamate protein	Homo sapiens	24-27
1843267-8	1991	The reduction of the increase in the BGP level at the 12th week with insignificant biochemical changes suggest that activation of osteoblasts by vitamin D3 may be transient.	Cholecalciferol	145-155	bone gamma-carboxyglutamate protein	Homo sapiens	37-40
1843267-9	1991	In conclusion, intermittent active vitamin D3 increases serum BGP, without deterioration of major biochemical changes even in patients with moderate to severe secondary hyperparathyroidism, although the increase may be transient.	Cholecalciferol	35-45	bone gamma-carboxyglutamate protein	Homo sapiens	62-65
1843267-10	1991	These facts suggest that the serum BGP of hemodialysis patients is controlled at least in part by active vitamin D3.	Cholecalciferol	105-115	bone gamma-carboxyglutamate protein	Homo sapiens	35-38
1361453-5	1992	Tumor necrosis factor and vitamin D3, which also induced ICAM-1 expression, increased HL-60 sensitivity to LAK lysis.	Cholecalciferol	26-36	intercellular adhesion molecule 1	Homo sapiens	57-63
1328275-2	1992	Since UV-B mediates the cutaneous formation of vitamin D3, we examined the attenuation of that photosynthetic reaction by the commonly used fabrics cotton, wool, and polyester in black and white colors.	Cholecalciferol	47-57	uncharacterized protein LOC107958776	Gossypium hirsutum	6-10
1328275-6	1992	Regular (seasonal) street clothing also prevented an elevation of the vitamin D3 in response to UV-B radiation.	Cholecalciferol	70-80	uncharacterized protein LOC107958776	Gossypium hirsutum	96-100
1328275-7	1992	We conclude that clothing prevents or significantly impairs the formation of vitamin D3 after photostimulation with up to six MEDs of UV-B.	Cholecalciferol	77-87	uncharacterized protein LOC107958776	Gossypium hirsutum	134-138
1395167-0	1992	Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.	Cholecalciferol	64-74	parathyroid hormone	Homo sapiens	95-114
1324161-6	1992	Binding of [3H]1,25(OH)2 vitamin D3 was increased to 130% of control in cytosolic extracts of UMR 106-06 cells pretreated for 3 days with 1 ng/ml TGF beta.	Cholecalciferol	25-35	transforming growth factor, beta 1	Rattus norvegicus	146-154
1320952-3	1992	In the U937 cell line, recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) inhibits cell proliferation, 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits proliferation and induces the early differentiation antigen CD11b, and vitamin D3 inhibits proliferation and induces both CD11b and the late differentiation antigen CD14.	Cholecalciferol	253-263	colony stimulating factor 2	Homo sapiens	41-89
1584805-9	1992	These results suggest that activation of the CAII gene occurs early in the differentiation events triggered by vitamin D3 in myelomonocytic cells.	Cholecalciferol	111-121	carbonic anhydrase 2	Gallus gallus	45-49
1654998-1	1991	The effects of two anticonvulsant drugs, phenytoin and sodium valproate, on the bioactivation of vitamin D3 have been studied with respect to the microsomal and mitochondrial cytochrome P-450-linked monooxygenase systems that contribute to 25-hydroxylation of vitamin D3 in rabbit liver, and the mitochondrial cytochrome P-450-linked monooxygenase system that catalyzes 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in rabbit kidney.	Cholecalciferol	97-107	cytochrome P-450	Oryctolagus cuniculus	310-326
1654998-4	1991	It is possible that the inhibition of bioactivation of vitamin D3 by these anticonvulsant drugs causes rickets and osteomalacia, and the site of inhibition is expected to be the cytochrome P-450 mediated reactions in liver mitochondria.	Cholecalciferol	55-65	cytochrome P-450	Oryctolagus cuniculus	178-194
1714931-0	1991	Expression of beta 4 integrins in human skin: comparison of epidermal distribution with beta 1-integrin epitopes, and modulation by calcium and vitamin D3 in cultured keratinocytes.	Cholecalciferol	144-154	tubulin beta 3 class III	Homo sapiens	14-20
1714931-7	1991	This Ca(++)-induced redistribution of beta 4 integrin epitopes could be counteracted by 10(-7) M vitamin D3.	Cholecalciferol	97-107	tubulin beta 3 class III	Homo sapiens	38-44
1855478-0	1991	A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.	Cholecalciferol	8-18	OXA1L mitochondrial inner membrane protein	Homo sapiens	30-35
1855478-2	1991	We have recently developed a novel vitamin D3 analog, 22-oxa-1,25-(OH)2D3 (OCT), that is capable of promoting differentiation and inhibiting proliferation without inducing hypercalcemia.	Cholecalciferol	35-45	OXA1L mitochondrial inner membrane protein	Homo sapiens	57-62
1873206-0	1991	The induction of epidermal ornithine decarboxylase following tape stripping is inhibited by a topical vitamin D3 analogue (MC903).	Cholecalciferol	102-112	ornithine decarboxylase 1	Homo sapiens	27-50
1669973-1	1991	We studied effects of the hormonal form of vitamin D3 on the angiotensin-converting enzyme (ACE) activity of hepatic granulomas in mice infected with Schistosoma mansoni.	Cholecalciferol	43-53	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	61-90
1669973-1	1991	We studied effects of the hormonal form of vitamin D3 on the angiotensin-converting enzyme (ACE) activity of hepatic granulomas in mice infected with Schistosoma mansoni.	Cholecalciferol	43-53	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	92-95
1669973-6	1991	The present observation may have relevance to sarcoid granulomas characterized by an increased tissue ACE activity, since macrophages from patients with sarcoidosis synthesize a biologically active hormonal form of vitamin D3.	Cholecalciferol	215-225	angiotensin I converting enzyme	Homo sapiens	102-105
1669973-7	1991	Namely hormonal form of vitamin D3 locally produced by macrophages is involved not only in systemic Ca++ metabolism but also in the stimulation of macrophages themselves to produce ACE in the granulomas.	Cholecalciferol	24-34	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	181-184
1835718-1	1991	Fibronectin release from cultured macrophages, derived from human blood monocytes, was measured during incubation of the cells with increasing concentrations of vitamin D3 metabolites or of aminobutane bisphosphonate (AHButBP) or dichloromethylene bisphosphonate (Cl2MBP), two powerful inhibitors of bone resorption.	Cholecalciferol	161-171	fibronectin 1	Homo sapiens	0-11
1659121-1	1991	This study used the ionophore, A23187, to examine the hypothesis that the regulation of alkaline phosphatase and phospholipase A2 activity by vitamin D3 metabolites in cartilage cells is mediated by changes in calcium influx.	Cholecalciferol	142-152	phospholipase A2 group IB	Homo sapiens	113-129
2049072-17	1991	The N-terminal amino acid sequence of cytochrome P-450(26) in kidney mitochondria resembled that of pig kidney microsomal 25-hydroxylase active in 25-hydroxylation of vitamin D3 and C27 steroids, whereas the sequence of pig liver mitochondrial cytochrome P-450(26) differed from those of rabbit and rat liver mitochondrial 26-hydroxylases as well as from those of other hitherto isolated mammalian cytochromes P-450.	Cholecalciferol	167-177	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	38-54
1709200-11	1991	IFN gamma treatment increased this binding by four-fold, PMA treatment resulted in a 50% increase in the number of IgG immune complexes bound, whereas vitamin D3 treated THP-1 cells bound half as many IgG immune complexes as control cells.	Cholecalciferol	151-161	interferon gamma	Homo sapiens	0-9
1709200-11	1991	IFN gamma treatment increased this binding by four-fold, PMA treatment resulted in a 50% increase in the number of IgG immune complexes bound, whereas vitamin D3 treated THP-1 cells bound half as many IgG immune complexes as control cells.	Cholecalciferol	151-161	GLI family zinc finger 2	Homo sapiens	170-175
1709200-13	1991	Treatment of THP-1 cells with IFN gamma, TNF alpha, PMA, or vitamin D3 had no effect on Fc gamma RII expression.	Cholecalciferol	60-70	GLI family zinc finger 2	Homo sapiens	13-18
1709200-16	1991	Fc gamma R expression may not be linked to differentiation of THP-1 cells since only 1,25 vitamin D3 was able to induce the expression of CD14, a marker of mature monocytic phenotype.	Cholecalciferol	90-100	CD14 molecule	Homo sapiens	138-142
1656244-5	1991	Nuclear extracts from cells infected with the hVDR-expressing adenoviruses contain an activity that specifically binds an oligonucleotide with sequences from the rat osteocalcin vitamin D3 response element, as determined by gel mobility shift.	Cholecalciferol	178-188	vitamin D receptor	Homo sapiens	46-50
1656244-5	1991	Nuclear extracts from cells infected with the hVDR-expressing adenoviruses contain an activity that specifically binds an oligonucleotide with sequences from the rat osteocalcin vitamin D3 response element, as determined by gel mobility shift.	Cholecalciferol	178-188	bone gamma-carboxyglutamate protein	Rattus norvegicus	166-177
2026586-1	1991	A cytochrome P-450 that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3 (P-450cc24: P-450cholecalciferol24) was purified to electrophoretic homogeneity from the kidney mitochondria of female rats treated with vitamin D3 (Ohyama, Y., Hayashi, S., and Okuda, K. (1989) FEBS Lett.	Cholecalciferol	68-78	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	2-18
2026586-1	1991	A cytochrome P-450 that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3 (P-450cc24: P-450cholecalciferol24) was purified to electrophoretic homogeneity from the kidney mitochondria of female rats treated with vitamin D3 (Ohyama, Y., Hayashi, S., and Okuda, K. (1989) FEBS Lett.	Cholecalciferol	68-78	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	80-89
2015403-0	1991	Two-step differentiation of AML-193 leukemic line: terminal maturation is induced by positive interaction of retinoic acid with granulocyte colony-stimulating factor (CSF) and vitamin D3 with monocyte CSF.	Cholecalciferol	176-186	colony stimulating factor 2	Homo sapiens	201-204
1769236-8	1991	These results suggest that vitamin D3 may be an important modulator of elastin expression.	Cholecalciferol	27-37	elastin	Bos taurus	71-78
1835629-7	1991	However, differences in the binding sites could be distinguished by competition experiments where vitamin D3, vitamin D2 or 7-dehydrocholesterol competed for the specific binding of 1.25-dihydroxyvitamin D3 to a greater extent by B700 than by vitamin D binding protein.	Cholecalciferol	98-108	vitamin D binding protein	Mus musculus	243-268
1855478-2	1991	We have recently developed a novel vitamin D3 analog, 22-oxa-1,25-(OH)2D3 (OCT), that is capable of promoting differentiation and inhibiting proliferation without inducing hypercalcemia.	Cholecalciferol	35-45	plexin A2	Homo sapiens	75-78
1835718-3	1991	Opposite results were observed when the cells were incubated with vitamin D3 metabolites: the stimulation of fibronectin release was specific for 1,25-dihydroxyvitamin D3 relative to other vitamin D3 metabolites (1,25-dihydroxyvitamin D3 greater than 25-hydroxyvitamin D3 greater than 24,25-dihydroxyvitamin D3).	Cholecalciferol	66-76	fibronectin 1	Homo sapiens	109-120
1835718-3	1991	Opposite results were observed when the cells were incubated with vitamin D3 metabolites: the stimulation of fibronectin release was specific for 1,25-dihydroxyvitamin D3 relative to other vitamin D3 metabolites (1,25-dihydroxyvitamin D3 greater than 25-hydroxyvitamin D3 greater than 24,25-dihydroxyvitamin D3).	Cholecalciferol	160-170	fibronectin 1	Homo sapiens	109-120
1895752-0	1991	Inhibition by vitamin D3 of erythroid differentiation of human leukemia line cells induced by transforming growth factor beta or erythroid differentiation factor (activin A).	Cholecalciferol	14-24	transforming growth factor beta 1	Homo sapiens	94-125
1895752-0	1991	Inhibition by vitamin D3 of erythroid differentiation of human leukemia line cells induced by transforming growth factor beta or erythroid differentiation factor (activin A).	Cholecalciferol	14-24	inhibin subunit beta A	Homo sapiens	129-161
1700829-8	1990	In contrast, both IFN-alpha and IFN-beta exerted some inhibitory effect on HIV production, which was more marked in vitamin D3-treated cultures than in untreated cultures.	Cholecalciferol	116-126	interferon alpha 1	Homo sapiens	18-21
27458673-2	1991	The present results show that stimulation of U-937 cells to macrophage differentiation by a phorbol ester or vitamin D3 induced a continuous high level expression of c-jun mRNA and protein.	Cholecalciferol	109-119	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	166-171
1700829-8	1990	In contrast, both IFN-alpha and IFN-beta exerted some inhibitory effect on HIV production, which was more marked in vitamin D3-treated cultures than in untreated cultures.	Cholecalciferol	116-126	interferon alpha 1	Homo sapiens	32-35
1700829-9	1990	HIV production was significantly increased by antibodies to IFN-alpha in both untreated and vitamin D3-treated cultures.	Cholecalciferol	92-102	interferon alpha 1	Homo sapiens	60-63
1700829-10	1990	Anti-IFN-beta antibody increased HIV production only in vitamin D3-treated cells.	Cholecalciferol	56-66	interferon alpha 1	Homo sapiens	5-8
1700829-12	1990	Vitamin D3 treatment resulted in a higher expression of TNF receptors in differentiating cells than in control HIV-infected cells.	Cholecalciferol	0-10	tumor necrosis factor	Homo sapiens	56-59
1700829-13	1990	These data demonstrate a strong correlation between HIV production and macrophagelike differentiation in chronically infected U937 cells and suggest that endogenous IFN and TNF exert opposite effects in the regulation of virus production in both undifferentiated and vitamin D3-treated cell cultures.	Cholecalciferol	267-277	interferon alpha 1	Homo sapiens	165-168
1700829-13	1990	These data demonstrate a strong correlation between HIV production and macrophagelike differentiation in chronically infected U937 cells and suggest that endogenous IFN and TNF exert opposite effects in the regulation of virus production in both undifferentiated and vitamin D3-treated cell cultures.	Cholecalciferol	267-277	tumor necrosis factor	Homo sapiens	173-176
2175918-9	1990	These results indicate that this 24-bp sequence containing two 9-bp motifs binds to the vitamin D receptor and mediates the vitamin D3 enhancement of murine Spp-1 gene expression.	Cholecalciferol	124-134	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	88-106
2175918-9	1990	These results indicate that this 24-bp sequence containing two 9-bp motifs binds to the vitamin D receptor and mediates the vitamin D3 enhancement of murine Spp-1 gene expression.	Cholecalciferol	124-134	secreted phosphoprotein 1	Mus musculus	157-162
2171663-1	1990	The rate of non-specific lipid transfer protein (nsLTP)-mediated exchange is independent of structure for dissimilar sterols: cholesterol, lanosterol, sitosterol and vitamin D-3.	Cholecalciferol	166-177	sterol carrier protein 2	Homo sapiens	12-47
2241170-5	1990	Following acute administration of vitamin D3, calbindin-D mRNA levels increased somewhat more rapidly than calbindin-D protein, but overall, the correlation was excellent.	Cholecalciferol	34-44	calbindin 1	Gallus gallus	46-55
2241170-5	1990	Following acute administration of vitamin D3, calbindin-D mRNA levels increased somewhat more rapidly than calbindin-D protein, but overall, the correlation was excellent.	Cholecalciferol	34-44	calbindin 1	Gallus gallus	107-116
2177986-3	1990	Other vitamin D3 metabolites had similar but weaker effects in increasing transferrin synthesis.	Cholecalciferol	6-16	transferrin	Rattus norvegicus	74-85
2171663-1	1990	The rate of non-specific lipid transfer protein (nsLTP)-mediated exchange is independent of structure for dissimilar sterols: cholesterol, lanosterol, sitosterol and vitamin D-3.	Cholecalciferol	166-177	sterol carrier protein 2	Homo sapiens	49-54
2173501-2	1990	The vitamin D3 metabolism in 35 patients with primary Sjogren"s syndrome was investigated by measuring blood concentrations of 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25-(OH)2D3) and 25-hydroxyvitamin D3 (25-OHD3), as well as phenotypes and blood concentrations of Gc globulin, the main vitamin D3 binding protein in the blood.	Cholecalciferol	4-14	GC vitamin D binding protein	Homo sapiens	265-276
2169238-8	1990	After coupling to Sepharose, the antibody was able to bind to cytochrome P-450(25) from kidney as well as from pig liver microsomes, and to immunoprecipitate the activity for 25-hydroxylation of vitamin D3 and 5 beta-cholestane-3 alpha,7 alpha-diol when assayed in a reconstituted system.	Cholecalciferol	195-205	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	62-78
2169238-0	1990	Characterization of pig kidney microsomal cytochrome P-450 catalysing 25-hydroxylation of vitamin D3 and C27 steroids.	Cholecalciferol	90-100	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	42-58
2119787-2	1990	In this study we investigated the effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the most active metabolite of vitamin D3, on the IFN-gamma-induced expression of MHC class II antigens on HEp-2 cells.	Cholecalciferol	58-68	interferon gamma	Homo sapiens	133-142
2117528-2	1990	1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3], a seco-steroid derived from vitamin D3, has previously been reported to enhance such expression alone or together with IFN gamma on a number of monocyte/macrophage tumorigenic lines.	Cholecalciferol	14-24	interferon gamma	Rattus norvegicus	160-169
2169238-11	1990	These results indicate a similar or the same species of cytochrome P-450 in pig kidney and liver microsomes catalysing 25-hydroxylation of vitamin D3 and C27 steroids.	Cholecalciferol	139-149	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	56-72
2169238-1	1990	The cytochrome P-450 enzyme which catalyses 25-hydroxylation of vitamin D3 (cytochrome P-450(25] from pig kidney microsomes [Postlind &amp; Wikvall (1988) Biochem.	Cholecalciferol	64-74	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	4-20
2169238-1	1990	The cytochrome P-450 enzyme which catalyses 25-hydroxylation of vitamin D3 (cytochrome P-450(25] from pig kidney microsomes [Postlind &amp; Wikvall (1988) Biochem.	Cholecalciferol	64-74	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	76-92
2375769-7	1990	In competition studies, MC 969 was able to inhibit 25-hydroxylation of tritiated vitamin D3 more effectively than 1 alpha-OH-D3 itself, indicating that the vitamin D3-25-hydroxylase may be responsible for generation of one or more of the metabolites observed.	Cholecalciferol	81-91	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	156-181
2169238-5	1990	The 25-hydroxylase activity towards vitamin D3 was 124 pmol.min-1.nmol of cytochrome P-450-1 and towards 1 alpha-hydroxyvitamin D3 it was 1375 pmol.min-1.nmol-1.	Cholecalciferol	36-46	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	74-90
2177015-0	1990	Modulation of chick intestinal and renal calbindin gene expression by dietary vitamin D3, 1,25-dihydroxyvitamin D3, calcium and phosphorus.	Cholecalciferol	78-88	calbindin 1	Gallus gallus	41-50
2177015-4	1990	Renal calbindin and its mRNA were lower in the vitamin D-deficient than in vitamin D3- or 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)-fed chicks.	Cholecalciferol	75-85	calbindin 1	Gallus gallus	6-15
2177015-9	1990	The results suggest that: (a) most of the changes in renal and intestinal calbindin could be attributed to the changes in the mRNA; (b) the adaptation to dietary Ca and P alterations requires vitamin D metabolites; (c) high dietary Ca affects intestinal and renal calbindin-mRNA and calbindin via mechanisms independent of kidney 1-hydroxylase; and (d) plasma Ca and renal calbindin or its mRNA tend to change together in vitamin D-deficient or vitamin D3-fed, but not in 1,25(OH)2D3-fed chicks.	Cholecalciferol	445-455	calbindin 1	Gallus gallus	74-83
1693772-3	1990	In support of this hypothesis is the fact that the synthesis of osteopontin is stimulated by calcitriol (1,25-dihydroxy-vitamin(D3), a substance that induces bone resorption.	Cholecalciferol	128-130	secreted phosphoprotein 1	Homo sapiens	64-75
2158960-1	1990	Calcitonin was used in conjunction with saline diuresis, furosemide, and prednisone in treatment of a dog that consumed a rodenticide that contained cholecalciferol and has been touted as safe for nontarget species.	Cholecalciferol	149-164	calcitonin	Canis lupus familiaris	0-10
2159384-5	1990	Unexpectedly, cotransfection of Jun and Fos expression vectors suppresses basal level transcription of the osteocalcin gene and suppresses induction by both retinoic acid and vitamin D3.	Cholecalciferol	175-185	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	40-43
1972874-4	1990	Peripheral lymphocyte subsets CD4/CD8 were higher in patients with senile osteoporosis than in the age-matched controls, and returned to normal after 1 month of 1 alpha(OH)vitamin D3 treatment.	Cholecalciferol	172-182	CD4 molecule	Homo sapiens	30-33
2407190-0	1990	Novel vitamin D3 derivatives, 26-homo-delta 22-dehydro-1 alpha,25(S)-dihydroxyvitamin D3 and 26-homo-delta 22-dehydro-1 alpha,25(R)-dihydroxyvitamin D3: preferential activity in c-myc mRNA production and in induction of phenotypic differentiation of HL-60 cells.	Cholecalciferol	6-16	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	178-183
2407190-1	1990	Novel vitamin D3 derivatives, 26-homo-delta 22-1 alpha,25(S)-dihydroxyvitamin D3 and 26-homo-delta 22-1 alpha,25(R)-dihydroxyvitamin D3 were compared with the native hormone, 1,25-dihydroxyvitamin D3, and with other vitamin D3 derivatives, in inhibition of cell growth, induction of phenotypic differentiation, and c-myc mRNA reduction of HL-60 cells.	Cholecalciferol	6-16	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	315-320
2407190-7	1990	These results suggest that the novel vitamin D3 derivatives, 26-homo-delta 22-1 alpha,25(S)-(OH)2D3 and 26-homo-delta 22-1 alpha,25(R)-(OH)2D3, have preferential activity in inducing phenotypic differentiation and in inducing cell proliferation related c-myc mRNA activity.	Cholecalciferol	37-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	253-258
1972874-4	1990	Peripheral lymphocyte subsets CD4/CD8 were higher in patients with senile osteoporosis than in the age-matched controls, and returned to normal after 1 month of 1 alpha(OH)vitamin D3 treatment.	Cholecalciferol	172-182	CD8a molecule	Homo sapiens	34-37
33806248-3	2021	The expression of Foxp3 in Tregs is regulated by the transcription factor GATA binding-protein 3 (GATA3) and vitamin D3.	Cholecalciferol	109-119	forkhead box P3	Homo sapiens	18-23
2252808-7	1990	Controls showed a nearly linear secretion rate of osteocalcin, reaching 8-9 ng/10(6) cells by 8 h. Vitamin D3 (2.6 nM) maximally stimulated secretion nearly two-fold after 24 or 48 h of pretreatment in comparison to controls.	Cholecalciferol	99-109	bone gamma-carboxyglutamate protein	Rattus norvegicus	50-61
2298449-11	1990	Competition assays with vitamin D3 and Gc in enzyme-linked immunosorbent assay indicate that the epitope of hDBP-1 on the Gc molecule may be related to the vitamin-D3-binding site.	Cholecalciferol	24-34	DEAH-box helicase 15	Homo sapiens	108-114
2298449-11	1990	Competition assays with vitamin D3 and Gc in enzyme-linked immunosorbent assay indicate that the epitope of hDBP-1 on the Gc molecule may be related to the vitamin-D3-binding site.	Cholecalciferol	156-166	DEAH-box helicase 15	Homo sapiens	108-114
14236372-0	1963	[3 CASES OF LEPROMATOUS LEPROSY TREATED WITH LYSOZYME ASSOCIATED WITH CALCIFEROL (VITAMINS D2 AND D3)].	Cholecalciferol	98-100	lysozyme	Homo sapiens	45-53
33774074-17	2021	Another small trial showed that supplementation with cholecalciferol, 60,000 IU/d, decreased fibrinogen levels, but did not have an effect on D-dimer, procalcitonin and CRP levels, compared to placebo.	Cholecalciferol	53-68	fibrinogen beta chain	Homo sapiens	93-103
33939911-2	2021	We aimed in this study to investigate the safety and efficacy of ASCs + daily cholecalciferol (VIT D) for 6 months in patients with recent-onset T1D.	Cholecalciferol	78-93	vitrin	Homo sapiens	95-98
33775819-10	2021	Finally, energy intake influenced the vitamin D 25-hydroxylase through the 25-hydroxyvitamin D3/vitamin D3 ratio, which regulates the synthesis of the circulating form.	Cholecalciferol	85-95	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	38-62
33817577-0	2021	Vitamin D3 induces mesenchymal-to-endothelial transition and promotes a proangiogenic niche through IGF-1 signaling.	Cholecalciferol	0-10	insulin like growth factor 1	Homo sapiens	100-105
33806248-4	2021	The aim of this retrospective case-control study was to investigate the potential association between FOXP3 and GATA3 genetic variants, Vitamin D3, and MS risk.	Cholecalciferol	136-146	forkhead box P3	Homo sapiens	102-107
34710370-0	2021	Cholecalciferol and metformin protect against lipopolysaccharide-induced endothelial dysfunction and senescence by modulating sirtuin-1 and protein arginine methyltransferase-1.	Cholecalciferol	0-15	sirtuin 1	Homo sapiens	126-135
32795167-8	2022	The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group.	Cholecalciferol	68-78	insulin	Homo sapiens	42-49
34802735-18	2022	Haptoglobin concentrations were significantly increased on 5 DIM in cows injected once with 12 x 106 IU of cholecalciferol.	Cholecalciferol	107-122	haptoglobin	Bos taurus	0-11
34844141-0	2022	Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma.	Cholecalciferol	44-54	heat shock protein 1B	Mus musculus	60-81
34757179-0	2022	Vitamin D3 protects against nitrogen mustard-induced apoptosis of the bronchial epithelial cells via activating the VDR/Nrf2/Sirt3 pathway.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	116-119
34757179-0	2022	Vitamin D3 protects against nitrogen mustard-induced apoptosis of the bronchial epithelial cells via activating the VDR/Nrf2/Sirt3 pathway.	Cholecalciferol	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	120-124
34757179-0	2022	Vitamin D3 protects against nitrogen mustard-induced apoptosis of the bronchial epithelial cells via activating the VDR/Nrf2/Sirt3 pathway.	Cholecalciferol	0-10	sirtuin 3	Homo sapiens	125-130
34757179-9	2022	Inhibition of Nrf2 or Sirt3 could decrease the protective effects of vitamin D3 and enhance mitochondrial ROS production via modulating mitochondrial redox balance.	Cholecalciferol	69-79	NFE2 like bZIP transcription factor 2	Homo sapiens	14-18
34757179-9	2022	Inhibition of Nrf2 or Sirt3 could decrease the protective effects of vitamin D3 and enhance mitochondrial ROS production via modulating mitochondrial redox balance.	Cholecalciferol	69-79	sirtuin 3	Homo sapiens	22-27
34757179-10	2022	In conclusion, impaired VDR/Nrf2/Sirt3 axis contributed to NM-induced apoptosis, while vitamin D3 supplementation provides protective effects via the activation of VDR and the improvement of mitochondrial functions.	Cholecalciferol	87-97	vitamin D receptor	Homo sapiens	164-167
34919352-8	2022	RESULTS: Vitamin D3 injection significantly affected the amounts of 25(OH) vitamin D, urea, insulin and insulin resistance index (p <= 0.05).	Cholecalciferol	9-19	insulin	Bos taurus	92-99
34919352-8	2022	RESULTS: Vitamin D3 injection significantly affected the amounts of 25(OH) vitamin D, urea, insulin and insulin resistance index (p <= 0.05).	Cholecalciferol	9-19	insulin	Bos taurus	104-111
34919352-12	2022	CONCLUSION: It seems that injection of vitamin D3 in close up period influenced lipolysis potentially modifying energy metabolism and resulted in reducing insulin resistance.	Cholecalciferol	39-49	insulin	Bos taurus	155-162
28398098-8	2018	RESULTS: ASC mineralization in dexamethasone or vitamin D3-induced ASCs correlated with both increased ERK1/2 and JNK1/2 activation.	Cholecalciferol	48-58	mitogen-activated protein kinase 3	Homo sapiens	103-109
28398098-8	2018	RESULTS: ASC mineralization in dexamethasone or vitamin D3-induced ASCs correlated with both increased ERK1/2 and JNK1/2 activation.	Cholecalciferol	48-58	mitogen-activated protein kinase 8	Homo sapiens	114-118
34894076-7	2022	Short-term vitamin D3 supplementation prevented Lipopolysaccharide-induced ALI by preventing pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha.	Cholecalciferol	11-21	interleukin 1 alpha	Mus musculus	130-138
34894076-7	2022	Short-term vitamin D3 supplementation prevented Lipopolysaccharide-induced ALI by preventing pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha.	Cholecalciferol	11-21	interleukin 6	Mus musculus	140-144
34894076-7	2022	Short-term vitamin D3 supplementation prevented Lipopolysaccharide-induced ALI by preventing pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha.	Cholecalciferol	11-21	tumor necrosis factor	Mus musculus	150-159
34894076-9	2022	Short-term vitamin D3, but not long-term pretreatment significantly reduced the phosphorylation of STAT3 and SOCS3, but upregulated the phosphorylation of IkappaBalpha.	Cholecalciferol	11-21	signal transducer and activator of transcription 3	Mus musculus	99-104
34894076-9	2022	Short-term vitamin D3, but not long-term pretreatment significantly reduced the phosphorylation of STAT3 and SOCS3, but upregulated the phosphorylation of IkappaBalpha.	Cholecalciferol	11-21	suppressor of cytokine signaling 3	Mus musculus	109-114
34894076-9	2022	Short-term vitamin D3, but not long-term pretreatment significantly reduced the phosphorylation of STAT3 and SOCS3, but upregulated the phosphorylation of IkappaBalpha.	Cholecalciferol	11-21	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	155-167
34657267-3	2022	We hypothesized that vitamin D3 supplementation affects OPG and RANKL activity in the aorta.	Cholecalciferol	21-31	TNF receptor superfamily member 11B	Rattus norvegicus	56-59
34657267-3	2022	We hypothesized that vitamin D3 supplementation affects OPG and RANKL activity in the aorta.	Cholecalciferol	21-31	TNF superfamily member 11	Rattus norvegicus	64-69
34657267-7	2022	RESULTS: Opg and Il-1b expression levels were significantly associated with both diabetes and vitamin D3 supplementation in the aortas of the study groups (p <= 0.05).	Cholecalciferol	94-104	TNF receptor superfamily member 11B	Rattus norvegicus	9-12
34657267-7	2022	RESULTS: Opg and Il-1b expression levels were significantly associated with both diabetes and vitamin D3 supplementation in the aortas of the study groups (p <= 0.05).	Cholecalciferol	94-104	interleukin 1 beta	Rattus norvegicus	17-22
34657267-10	2022	CONCLUSIONS: It is concluded that vitamin D3 supplementation has a modulatory effect on OPG/RANKL activity in the vessel wall by ameliorating endothelial damage in diabetes.	Cholecalciferol	34-44	TNF receptor superfamily member 11B	Rattus norvegicus	88-91
34657267-10	2022	CONCLUSIONS: It is concluded that vitamin D3 supplementation has a modulatory effect on OPG/RANKL activity in the vessel wall by ameliorating endothelial damage in diabetes.	Cholecalciferol	34-44	TNF superfamily member 11	Rattus norvegicus	92-97
34368951-9	2022	Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification.	Cholecalciferol	37-47	klotho	Mus musculus	0-6
34368951-9	2022	Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification.	Cholecalciferol	37-47	bone morphogenetic protein 2	Mus musculus	32-36
34368951-9	2022	Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification.	Cholecalciferol	37-47	solute carrier family 20, member 2	Mus musculus	78-82
34368951-9	2022	Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification.	Cholecalciferol	37-47	runt related transcription factor 2	Mus musculus	87-92
34368951-9	2022	Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification.	Cholecalciferol	37-47	SMAD family member 1	Mus musculus	113-122
34368951-9	2022	Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification.	Cholecalciferol	37-47	SMAD family member 2	Mus musculus	127-134
34368951-10	2022	Interestingly, treatments with recombinant Klotho protein abolished BMP2/vitamin D3-induced osteoblastic transition and morphogenesis and calcification.	Cholecalciferol	73-83	klotho	Mus musculus	43-49
34368951-10	2022	Interestingly, treatments with recombinant Klotho protein abolished BMP2/vitamin D3-induced osteoblastic transition and morphogenesis and calcification.	Cholecalciferol	73-83	bone morphogenetic protein 2	Mus musculus	68-72
34504311-4	2022	Interestingly, the increased IgE responses correlated with stimulation of the vitamin D3-metabolizing enzymes CYP27B1 and CYP24A1 in the gut and increased luminal levels of oxidized vitamin D3 metabolites that are not ligands of the vitamin D receptor.	Cholecalciferol	78-88	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	110-117
34504311-4	2022	Interestingly, the increased IgE responses correlated with stimulation of the vitamin D3-metabolizing enzymes CYP27B1 and CYP24A1 in the gut and increased luminal levels of oxidized vitamin D3 metabolites that are not ligands of the vitamin D receptor.	Cholecalciferol	78-88	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	122-129
34710370-0	2021	Cholecalciferol and metformin protect against lipopolysaccharide-induced endothelial dysfunction and senescence by modulating sirtuin-1 and protein arginine methyltransferase-1.	Cholecalciferol	0-15	protein arginine methyltransferase 1	Homo sapiens	140-176
34710370-3	2021	In this study, we observed that a combination treatment with metformin (MET) and cholecalciferol (VD) blocked the LPS-induced S-adenosylmethionine (SAM)-dependent methyltransferase (SDM) activity in Eahy926 cells.	Cholecalciferol	81-96	THUMP domain containing 2	Homo sapiens	126-180
34472641-0	2021	Sulindac and vitamin D3 synergically inhibit proliferation of MCF-7 breast cancer cell through AMPK/Akt/beta-catenin axis in vitro.	Cholecalciferol	13-23	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	95-99
34472641-0	2021	Sulindac and vitamin D3 synergically inhibit proliferation of MCF-7 breast cancer cell through AMPK/Akt/beta-catenin axis in vitro.	Cholecalciferol	13-23	AKT serine/threonine kinase 1	Homo sapiens	100-103
34472641-0	2021	Sulindac and vitamin D3 synergically inhibit proliferation of MCF-7 breast cancer cell through AMPK/Akt/beta-catenin axis in vitro.	Cholecalciferol	13-23	catenin beta 1	Homo sapiens	104-116
34853015-9	2021	CONCLUSION: The results of our study show that the patients supplemented with a microencapsulated form of vitamin D3 achieved faster compensation of 25(OH)D levels, which in turn, under equal conditions, led to significant improvement in the metabolic profile, in particular insulin sensitivity.	Cholecalciferol	106-116	insulin	Homo sapiens	275-282
34656907-0	2021	Vitamin D3 alleviates pulmonary fibrosis by regulating the MAPK pathway via targeting PSAT1 expression in vivo and in vitro.	Cholecalciferol	0-10	phosphoserine aminotransferase 1	Homo sapiens	86-91
34849546-9	2022	With baseline 25(OH)D >=30 ng/mL as the reference, 25(OH)D <20 ng/mL was associated with a larger decline in PTH with vitamin D3 supplementation (-10 (95% CI: -15, -6) pg/mL) whereas 25(OH)D 20-30 ng/mL was not (-2 (95% CI: -6, 1) pg/mL).	Cholecalciferol	118-128	parathyroid hormone	Homo sapiens	109-112
34919352-0	2022	Effects of vitamin D3 injection in close-up period on insulin resistance and energy balance in transition dairy cows.	Cholecalciferol	11-21	insulin	Bos taurus	54-61
34324049-0	2021	Increased integrity of cell-cell junctions accompanied by increased expression of claudin 4 in keratinocytes stimulated with vitamin D3.	Cholecalciferol	125-135	claudin 4	Homo sapiens	82-91
34873873-5	2021	We previously identified a unique and specific transport mechanism for skin-generated vitamin D3 which requires vitamin D binding protein (DBP); a mechanism that differs from absorption and transport of oral vitamin D3 .	Cholecalciferol	86-96	GC vitamin D binding protein	Homo sapiens	112-137
34873873-5	2021	We previously identified a unique and specific transport mechanism for skin-generated vitamin D3 which requires vitamin D binding protein (DBP); a mechanism that differs from absorption and transport of oral vitamin D3 .	Cholecalciferol	86-96	D-box binding PAR bZIP transcription factor	Homo sapiens	139-142
34873873-8	2021	By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D.	Cholecalciferol	43-53	D-box binding PAR bZIP transcription factor	Homo sapiens	87-90
34873873-8	2021	By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D.	Cholecalciferol	43-53	D-box binding PAR bZIP transcription factor	Homo sapiens	209-212
34873873-8	2021	By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D.	Cholecalciferol	147-157	D-box binding PAR bZIP transcription factor	Homo sapiens	87-90
34873873-8	2021	By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D.	Cholecalciferol	147-157	D-box binding PAR bZIP transcription factor	Homo sapiens	209-212
34873873-9	2021	Thus, removal of vitamin D3 from the skin by the natural DBP system markedly improves biological activity compared to that given orally.	Cholecalciferol	17-27	D-box binding PAR bZIP transcription factor	Homo sapiens	57-60
34959623-0	2021	Vitamin D3 Prevents the Deleterious Effects of Testicular Torsion on Testis by Targeting miRNA-145 and ADAM17: In Silico and In Vivo Study.	Cholecalciferol	0-10	microRNA 145	Homo sapiens	89-98
34950832-1	2021	1,25(OH)2D3, the biologically active form of vitamin D3, is a major regulator of mineral and bone homeostasis and exerts its actions through binding to the vitamin D receptor (VDR), a ligand-activated transcription factor that can directly modulate gene expression in vitamin D-target tissues such as the intestine, kidney, and bone.	Cholecalciferol	45-55	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	156-174
34950832-1	2021	1,25(OH)2D3, the biologically active form of vitamin D3, is a major regulator of mineral and bone homeostasis and exerts its actions through binding to the vitamin D receptor (VDR), a ligand-activated transcription factor that can directly modulate gene expression in vitamin D-target tissues such as the intestine, kidney, and bone.	Cholecalciferol	45-55	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	176-179
34867333-4	2021	Based on a network pharmacological analysis, N-acetyltransferase 2 (NAT2) was identified as a potential target of vitamin D3 against CRC.	Cholecalciferol	114-124	N-acetyltransferase 2	Homo sapiens	45-66
34867333-4	2021	Based on a network pharmacological analysis, N-acetyltransferase 2 (NAT2) was identified as a potential target of vitamin D3 against CRC.	Cholecalciferol	114-124	N-acetyltransferase 2	Homo sapiens	68-72
34867333-8	2021	These findings expand the potential uses of vitamin D3 against CRC and introduce VDR signaling via the enzyme NAT2 as a potential diagnostic and therapeutic target for CRC.	Cholecalciferol	44-54	vitamin D receptor	Homo sapiens	81-84
34959623-0	2021	Vitamin D3 Prevents the Deleterious Effects of Testicular Torsion on Testis by Targeting miRNA-145 and ADAM17: In Silico and In Vivo Study.	Cholecalciferol	0-10	ADAM metallopeptidase domain 17	Homo sapiens	103-109
34959623-8	2021	Our results revealed that the protective effect of vitamin D3 treatment could be attributed to target miRNA145 and ADAM17 protein.	Cholecalciferol	51-61	microRNA 145	Homo sapiens	102-110
34959623-8	2021	Our results revealed that the protective effect of vitamin D3 treatment could be attributed to target miRNA145 and ADAM17 protein.	Cholecalciferol	51-61	ADAM metallopeptidase domain 17	Homo sapiens	115-121
34959623-9	2021	To further investigate these findings, we performed a detailed molecular modelling study in order to explore the binding affinity of vitamin D3 toward ADAM17 protein.	Cholecalciferol	133-143	ADAM metallopeptidase domain 17	Homo sapiens	151-157
34959623-10	2021	Our results revealed that vitamin D3 has the ability to bind to the active site of ADAM17 protein via a set of hydrophobic and hydrophilic interactions with high docking score.	Cholecalciferol	26-36	ADAM metallopeptidase domain 17	Homo sapiens	83-89
34959623-11	2021	In conclusion, this study highlights the protective pharmacological application of vitamin D3 to ameliorate the damages of testicular T/D on the testicular tissues via targeting miRNA145 and ADAM17 protein.	Cholecalciferol	83-93	microRNA 145	Homo sapiens	178-186
34959623-11	2021	In conclusion, this study highlights the protective pharmacological application of vitamin D3 to ameliorate the damages of testicular T/D on the testicular tissues via targeting miRNA145 and ADAM17 protein.	Cholecalciferol	83-93	ADAM metallopeptidase domain 17	Homo sapiens	191-197
34959778-1	2021	Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes.	Cholecalciferol	70-80	vitamin D receptor	Homo sapiens	145-163
34959778-1	2021	Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes.	Cholecalciferol	70-80	vitamin D receptor	Homo sapiens	165-168
34836354-1	2021	Vitamin D3 is an essential micronutrient mediating pleiotropic effects in multiple tissues and cell types via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), which activates the transcription factor vitamin D receptor.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	211-229
34824670-0	2021	Vitamin D3 Protects Mice from Diquat-Induced Oxidative Stress through the NF-kappaB/Nrf2/HO-1 Signaling Pathway.	Cholecalciferol	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	74-83
34824670-0	2021	Vitamin D3 Protects Mice from Diquat-Induced Oxidative Stress through the NF-kappaB/Nrf2/HO-1 Signaling Pathway.	Cholecalciferol	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	84-88
34824670-0	2021	Vitamin D3 Protects Mice from Diquat-Induced Oxidative Stress through the NF-kappaB/Nrf2/HO-1 Signaling Pathway.	Cholecalciferol	0-10	heme oxygenase 1	Mus musculus	89-93
34824670-3	2021	The results showed that oral gavage of vitamin D3 daily significantly improved the body weight gain and immune organ index and significantly reverted the abnormal changes of ALT, AST, SOD, GSH-Px, T-AOC, and MDA in the serum and jejunum induced by diquat.	Cholecalciferol	39-49	glutamic pyruvic transaminase, soluble	Mus musculus	174-177
34824670-4	2021	The addition of vitamin D3 also significantly reduced the concentration of DAO, D-LA, and certain proinflammatory cytokines in serum.	Cholecalciferol	16-26	D-amino acid oxidase	Mus musculus	75-78
34824670-7	2021	In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group.	Cholecalciferol	40-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-116
34824670-7	2021	In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group.	Cholecalciferol	40-50	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	118-121
34824670-7	2021	In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group.	Cholecalciferol	40-50	nuclear factor, erythroid derived 2, like 2	Mus musculus	153-157
34824670-7	2021	In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group.	Cholecalciferol	40-50	heme oxygenase 1	Mus musculus	162-166
34824670-8	2021	This study suggested that oral administration of vitamin D3 can protect mice against oxidative damage by inhibiting the phosphorylation level of NF-kappaB (p65) and activating Nrf2-related signaling pathways.	Cholecalciferol	49-59	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	145-154
34824670-8	2021	This study suggested that oral administration of vitamin D3 can protect mice against oxidative damage by inhibiting the phosphorylation level of NF-kappaB (p65) and activating Nrf2-related signaling pathways.	Cholecalciferol	49-59	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	156-159
34824670-8	2021	This study suggested that oral administration of vitamin D3 can protect mice against oxidative damage by inhibiting the phosphorylation level of NF-kappaB (p65) and activating Nrf2-related signaling pathways.	Cholecalciferol	49-59	nuclear factor, erythroid derived 2, like 2	Mus musculus	176-180
34782657-7	2021	All patients were fulfilling both old and new criteria of fibromyalgia syndrome, and not fulfilling any RA criteria, and had vitamin D3 deficiency or insufficiency.	Cholecalciferol	125-135	3-hydroxyanthranilate 3,4-dioxygenase	Homo sapiens	121-124
34297067-7	2021	CTX at 14 and 34 weeks" gestation were correlated in both placebo (r = 0.31) and cholecalciferol (r = 0.45) groups (P < 0.0001).	Cholecalciferol	81-96	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	0-3
34297067-8	2021	Median CTX(mug/mmol creatinine) increased from 14 to 34 weeks" gestation in both groups (n = 372 total) (placebo (n = 188) 223.6 to 449.7; cholecalciferol (n = 184) 222.3 to 419.3; P = 0.03 for placebo vs cholecalciferol difference in CTX at 34 weeks" gestation).	Cholecalciferol	205-220	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	235-238
34297067-9	2021	The conditional increase in CTX(SD) from early to late pregnancy was greater in the placebo group (n = 188) than in the cholecalciferol group (n = 184) (placebo, mean(SD) 0.16(0.92); cholecalciferol, -0.16(1.06); p difference < 0.01).	Cholecalciferol	120-135	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	28-31
34297067-9	2021	The conditional increase in CTX(SD) from early to late pregnancy was greater in the placebo group (n = 188) than in the cholecalciferol group (n = 184) (placebo, mean(SD) 0.16(0.92); cholecalciferol, -0.16(1.06); p difference < 0.01).	Cholecalciferol	183-198	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	28-31
34297067-11	2021	CONCLUSIONS: Maternal urinary CTX, a bone resorption marker, rises through pregnancy, though to a lesser degree with gestational cholecalciferol supplementation, and is inversely associated with maternal bone mass post-partum.Clinical Trial Registry number and website: ISRCTN:82927713; EUDRACT:2007-001716-23.	Cholecalciferol	129-144	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	30-33
34747516-7	2022	Compared with placebo, cholecalciferol significantly reduced whole PTH concentrations (between-group difference of -15% (95% confidence interval (CI), -25 to -3)), with greater treatment effects in subgroups with lower 25(OH)D, lower serum calcium, or higher estimated glomerular filtration rate (Pint  < 0.05).	Cholecalciferol	23-38	parathyroid hormone	Homo sapiens	67-70
34747516-12	2022	In conclusion, 4000 IU/day cholecalciferol significantly reduced PTH levels and attenuated LS BMD loss after KTx.	Cholecalciferol	27-42	parathyroid hormone	Homo sapiens	65-68
34831233-3	2021	These ALP(+)-HUCPVCs were created from HUCPVCs in this study by culturing in the presence of activated vitamin D3, an inhibitor of bone morphogenetic protein signaling and transforming growth factor-beta1 (TGF-beta1).	Cholecalciferol	103-113	alkaline phosphatase, placental	Homo sapiens	6-9
34669255-12	2021	Pharmacological profile revealed that the treatment of DO and D3 inhibited the production of pro-inflammatory cytokines (TNF-alpha, IL-6) induced by lipopolysaccharide (LPS) in primary macrophages without any cytotoxic effect after administration of their effective concentrations.	Cholecalciferol	62-64	tumor necrosis factor	Homo sapiens	121-130
34669255-12	2021	Pharmacological profile revealed that the treatment of DO and D3 inhibited the production of pro-inflammatory cytokines (TNF-alpha, IL-6) induced by lipopolysaccharide (LPS) in primary macrophages without any cytotoxic effect after administration of their effective concentrations.	Cholecalciferol	62-64	interleukin 6	Homo sapiens	132-136
34849546-7	2022	Mean (SD) change in PTH was -3 (16) pg/mL with vitamin D3 vs 2 (18) pg/mL with placebo (estimated mean difference, -5 (95% CI: -8, -2) pg/mL).	Cholecalciferol	47-57	parathyroid hormone	Homo sapiens	20-23
34849546-8	2022	Within the vitamin D3 group, lower baseline 25(OH)D was associated with a larger decline in PTH in a non-linear fashion.	Cholecalciferol	11-21	parathyroid hormone	Homo sapiens	92-95
34831233-3	2021	These ALP(+)-HUCPVCs were created from HUCPVCs in this study by culturing in the presence of activated vitamin D3, an inhibitor of bone morphogenetic protein signaling and transforming growth factor-beta1 (TGF-beta1).	Cholecalciferol	103-113	transforming growth factor beta 1	Homo sapiens	206-215
34684328-3	2021	The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density.	Cholecalciferol	93-108	parathyroid hormone	Homo sapiens	218-229
34492244-0	2021	Vitamin D3/vitamin K2/magnesium-loaded polylactic acid/tricalcium phosphate/polycaprolactone composite nanofibers demonstrated osteoinductive effect by increasing Runx2 via Wnt/B-catenin pathway.	Cholecalciferol	0-10	RUNX family transcription factor 2	Homo sapiens	163-168
34492244-0	2021	Vitamin D3/vitamin K2/magnesium-loaded polylactic acid/tricalcium phosphate/polycaprolactone composite nanofibers demonstrated osteoinductive effect by increasing Runx2 via Wnt/B-catenin pathway.	Cholecalciferol	0-10	catenin beta 1	Homo sapiens	177-186
34492244-4	2021	Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9.	Cholecalciferol	0-10	RUNX family transcription factor 2	Homo sapiens	133-138
34492244-4	2021	Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9.	Cholecalciferol	0-10	bone morphogenetic protein 2	Homo sapiens	140-144
34492244-4	2021	Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9.	Cholecalciferol	0-10	secreted phosphoprotein 1	Homo sapiens	150-161
34492244-4	2021	Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9.	Cholecalciferol	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	178-188
34492244-4	2021	Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9.	Cholecalciferol	0-10	SRY-box transcription factor 9	Homo sapiens	193-197
34461573-0	2021	Vitamin D3 and estradiol alter PAD2 expression and activity levels in C6 glioma cells.	Cholecalciferol	0-10	peptidyl arginine deiminase 2	Homo sapiens	31-35
34461573-3	2021	The aim of this study was to investigate the effects of vitamin D (25-hydroxy cholecalciferol (D3)) and estradiol on PAD2 gene expression level and its catalytic activity in rat C6 glioma cells.	Cholecalciferol	95-97	peptidyl arginine deiminase 2	Homo sapiens	117-121
34827108-1	2021	The purpose of this study was to elucidate the effects of static electric field (SEF) treatment on vitamin D3 (Vit D3)-induced hypercalcemia and renal calcification in mice.	Cholecalciferol	99-109	vitrin	Mus musculus	111-114
34669728-1	2021	Vitamin D3 (VD3) induces intestinal CYP3A that metabolizes orally administered anti-leukemic chemotherapeutic substrates dexamethasone (DEX) and dasatinib potentially causing a vitamin-drug interaction.	Cholecalciferol	0-10	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	36-41
34656640-9	2022	Serum 25-OH Vit D concentration increased by a mean of 17.2 nmol/L (standard deviation: 30.8 nmol/L) in the cholecalciferol group and declined by 8.2 nmol/L (+-24.3 nmol/L) in the placebo group (between group difference: 28.3 nmol/L (95% confidence interval 17.2, 39.4); p<0.001).	Cholecalciferol	108-123	vitrin	Homo sapiens	12-15
34684596-0	2021	COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis.	Cholecalciferol	50-60	adaptor-related protein complex 2, alpha 2 subunit	Mus musculus	145-156
34255034-11	2021	CONCLUSIONS: Moderate supplementation of 15 ug/d cholecalciferol, in accordance with current recommendations, supports an adequate vitamin D status in adult women, irrespective of latitude, and might concomitantly prevent an increase in parathyroid hormone.	Cholecalciferol	49-64	parathyroid hormone	Homo sapiens	237-256
34650431-11	2021	Our data further demonstrated that geniposide could inhibit the activation of p38 MAPK and then restrict the vitamin D receptor signaling stimulated by vitamin D3.	Cholecalciferol	152-162	mitogen-activated protein kinase 14	Mus musculus	78-86
34650431-11	2021	Our data further demonstrated that geniposide could inhibit the activation of p38 MAPK and then restrict the vitamin D receptor signaling stimulated by vitamin D3.	Cholecalciferol	152-162	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	109-127
34570900-8	2021	However, MCs may use molecular mechanisms to exert immunosuppressive activity including releasing complement C3, lower expression of CD40L, and overexpression of enzymes with vitamin D3 metabolizing activity including CYP27A1 and CYP27B1.	Cholecalciferol	175-185	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	218-225
34339814-2	2021	In this light, vitamin D3 (vit.D3)-coated micelles were fabricated to encapsulate the cytotoxic drug; etoposide (ETP).	Cholecalciferol	15-25	vitrin	Homo sapiens	27-30
34758235-8	2021	CONCLUSIONS: Some biological parameters such as low albumin, thrombocytosis, increased CRP, elevated levels of 25 OH vitamin D3, elevated levels of FGF23, elevated D-dimers, and elevated ferritin could be considered as laboratory negative predictive factors for CAL.	Cholecalciferol	117-127	filamin binding LIM protein 1	Homo sapiens	262-265
34721760-14	2021	The decreased ability of neutrophils to generate NETs, which can be achieved by vitamin D3/omega-3 PUFA supplementation, could have a positive effect on wound healing in T2DM patients and reduce the incidence and severity of complications.	Cholecalciferol	80-90	pumilio RNA binding family member 3	Homo sapiens	99-103
34682898-9	2021	Serum calcium and 25-hydroxy vitamin D3 increased only in the DPP-4 inhibitor group, while other glycemic parameters did not show significant differences between the two groups.	Cholecalciferol	29-39	dipeptidyl peptidase 4	Homo sapiens	62-67
34250710-0	2021	Chemical synthesis of side-chain-hydroxylated vitamin D3 derivatives and their metabolism by CYP27B1.	Cholecalciferol	46-56	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	93-100
34250710-1	2021	1alpha,25-Dihydroxyvitamin D 3  (abbreviated here as 1,25D 3 ; other hydroxylated compounds are designated similarly) is a hormonally active form of vitamin D 3  (D 3 ), and is produced from D 3  by CYP27A1-mediated hydroxylation at C25, followed by CYP27B1-mediated hydroxylation at C1.	Cholecalciferol	149-160	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	199-206
34250710-1	2021	1alpha,25-Dihydroxyvitamin D 3  (abbreviated here as 1,25D 3 ; other hydroxylated compounds are designated similarly) is a hormonally active form of vitamin D 3  (D 3 ), and is produced from D 3  by CYP27A1-mediated hydroxylation at C25, followed by CYP27B1-mediated hydroxylation at C1.	Cholecalciferol	149-160	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	250-257
34684328-3	2021	The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density.	Cholecalciferol	93-108	parathyroid hormone	Homo sapiens	231-234
34684328-3	2021	The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density.	Cholecalciferol	110-120	parathyroid hormone	Homo sapiens	218-229
34684328-3	2021	The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density.	Cholecalciferol	110-120	parathyroid hormone	Homo sapiens	231-234
34684328-9	2021	The quantitative analysis suggested higher efficacy of cholecalciferol than ergocalciferol in improving total 25(OH)D (mean difference: 15.69, 95%CI: 9.46 to 21.93 nmol/L) and reducing PTH levels, consistently across variable participant demographics, dosage and vehicle of supplementation.	Cholecalciferol	55-70	parathyroid hormone	Homo sapiens	185-188
34684328-12	2021	CONCLUSIONS: Compared to ergocalciferol, cholecalciferol intervention was more efficacious in improving vitamin D status (serum levels of total 25(OH)D and 25(OH)D3) and regulating PTH levels, irrespective of the participant demographics, dosage and vehicle of supplementation.	Cholecalciferol	41-56	parathyroid hormone	Homo sapiens	181-184
34558256-8	2021	An increase in TGF-beta levels was noted among patients using vitamin D supplementation, which may suggest a mechanism by which cholecalciferol may improve MS prognosis.	Cholecalciferol	128-143	transforming growth factor alpha	Homo sapiens	15-23
34506728-4	2022	Intriguingly, the interaction of lactone-vitamin D3 with HADHA does not affect the HADHA enzymatic activity but instead limits biosynthesis of carnitine, an endogenous metabolite required for the transport of fatty acids into the mitochondria for beta-oxidation.	Cholecalciferol	41-51	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha	Homo sapiens	57-62
34506728-5	2022	Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis.	Cholecalciferol	8-18	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha	Homo sapiens	66-71
34506728-5	2022	Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis.	Cholecalciferol	8-18	trimethyllysine hydroxylase, epsilon	Homo sapiens	77-104
34506728-5	2022	Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis.	Cholecalciferol	8-18	trimethyllysine hydroxylase, epsilon	Homo sapiens	106-110
34506728-5	2022	Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis.	Cholecalciferol	8-18	trimethyllysine hydroxylase, epsilon	Homo sapiens	135-139
34628889-8	2021	Following the addition of vitamin D3 treatment, serum Ca2+, FT3, FT4, and TRAb levels were significantly decreased relative to the ATD group, while the thyroid-stimulating hormone (TSH), PTH, and 25-OHVit D levels were normalized.	Cholecalciferol	26-36	parathyroid hormone	Homo sapiens	187-190
34587698-13	2021	After adjustments for triglycerides, BMI, uric acid, HbA1C, 25-OH vitamin D3, alcohol consumption, and anemia, the multiple logistic regression revealed that participants with low TTR levels had a significantly increased risk of BPPV (OR: 5.5; 95% CI, 2.55-11.9; p<0.001).	Cholecalciferol	66-76	transthyretin	Homo sapiens	180-183
34484626-15	2021	Conclusions: We found that vit D insufficient patients can be rapidly supplemented on the morning of surgery with a large dose of oral cholecalciferol 600,000 IU, and the effect was consistent over 2 weeks after surgery.	Cholecalciferol	135-150	vitrin	Homo sapiens	27-30
34780049-1	2021	As the active form of vitamin D3, 1alpha,25-(OH)2-D3 promotes receptor activator for nuclear factor-kappaB ligand (RANKL)-induced autophagy in osteoclast precursors (OCPs).	Cholecalciferol	22-32	TNF superfamily member 11	Homo sapiens	115-120
34302132-6	2021	RESULTS: Median C-reactive protein level was 10.8 mg/dL in the vitamin D3 group and 10.6 mg/dL in the control group (p = 0.465).	Cholecalciferol	63-73	C-reactive protein	Homo sapiens	16-34
34502192-7	2021	Vitamin D3 was identified as responsible for the vitamin D receptor loss, for the increase in neutral sphingomyelinase content and sphingomyelin changes.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	49-67
34242778-20	2021	The proportion of women with the lowest cholecalciferol concentrations increased at V2 compared to the V1 (36.1 to 42.8 %; p = 0.02).	Cholecalciferol	40-55	nibrin	Homo sapiens	81-86
34147475-9	2021	Vitamin D3 also downregulated the expression of vimentin, collagen I and alpha-smooth muscle actin and attenuated renal fibrosis and epithelial to mesenchymal transition in the kidney.	Cholecalciferol	0-10	vimentin	Rattus norvegicus	48-56
34147475-9	2021	Vitamin D3 also downregulated the expression of vimentin, collagen I and alpha-smooth muscle actin and attenuated renal fibrosis and epithelial to mesenchymal transition in the kidney.	Cholecalciferol	0-10	actin gamma 2, smooth muscle	Rattus norvegicus	73-98
34147475-10	2021	Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease.	Cholecalciferol	13-23	vitamin D receptor	Rattus norvegicus	66-84
34147475-10	2021	Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease.	Cholecalciferol	13-23	transforming growth factor, beta 1	Rattus norvegicus	99-131
34147475-10	2021	Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease.	Cholecalciferol	13-23	transforming growth factor, beta 1	Rattus norvegicus	133-142
34147475-10	2021	Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease.	Cholecalciferol	13-23	SMAD family member 3	Rattus norvegicus	144-149
34147475-11	2021	Mechanistically, the upregulation of TGF-beta1 and phosphorylation of Smad3 induced by vitamin D3 was reversed by activation of the vitamin D receptor.	Cholecalciferol	87-97	transforming growth factor, beta 1	Rattus norvegicus	37-46
34147475-11	2021	Mechanistically, the upregulation of TGF-beta1 and phosphorylation of Smad3 induced by vitamin D3 was reversed by activation of the vitamin D receptor.	Cholecalciferol	87-97	SMAD family member 3	Rattus norvegicus	70-75
34147475-11	2021	Mechanistically, the upregulation of TGF-beta1 and phosphorylation of Smad3 induced by vitamin D3 was reversed by activation of the vitamin D receptor.	Cholecalciferol	87-97	vitamin D receptor	Rattus norvegicus	132-150
34502192-7	2021	Vitamin D3 was identified as responsible for the vitamin D receptor loss, for the increase in neutral sphingomyelinase content and sphingomyelin changes.	Cholecalciferol	0-10	sphingomyelin phosphodiesterase 2	Homo sapiens	94-118
34502192-9	2021	Incubation of the cells with neutral sphingomyelinase, or the same concentration of ceramide produced in exosomes was necessary and sufficient to stimulate embryonic hippocampal cell differentiation, as vitamin D3.	Cholecalciferol	203-213	sphingomyelin phosphodiesterase 2	Homo sapiens	29-53
34576700-0	2021	The Cooperation of Bifidobacterium longum and Active Vitamin D3 on Innate Immunity in Salmonella Colitis Mice via Vitamin D Receptor.	Cholecalciferol	53-63	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	114-132
34576700-8	2021	The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group.	Cholecalciferol	94-104	interleukin 6	Mus musculus	248-253
34576700-8	2021	The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group.	Cholecalciferol	94-104	chemokine (C-X-C motif) ligand 15	Mus musculus	255-260
34576700-8	2021	The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group.	Cholecalciferol	94-104	tumor necrosis factor	Mus musculus	262-272
34576700-8	2021	The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group.	Cholecalciferol	94-104	interleukin 1 alpha	Mus musculus	277-286
34415218-2	2021	In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions.	Cholecalciferol	148-158	transmembrane serine protease 2	Homo sapiens	189-196
34147475-12	2021	Our findings indicated that vitamin D3 is a potential antifibrotic drug in chronic kidney disease via the vitmin D receptor and inhibiting TGF-beta1/Smad3 signaling pathway.	Cholecalciferol	28-38	transforming growth factor, beta 1	Rattus norvegicus	139-148
34147475-12	2021	Our findings indicated that vitamin D3 is a potential antifibrotic drug in chronic kidney disease via the vitmin D receptor and inhibiting TGF-beta1/Smad3 signaling pathway.	Cholecalciferol	28-38	SMAD family member 3	Rattus norvegicus	149-154
34445803-5	2021	Therefore, active forms of vitamin D3 including its canonical (1,25(OH)2D3) and noncanonical (CYP11A1-intitated) D3 derivatives as well as L3 derivatives are promising agents for the prevention, attenuation, or treatment of premature skin aging.	Cholecalciferol	27-37	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	94-101
34418235-5	2022	RESULTS: Ultraviolet radiation (UVR) and pigmentation genes interact to modify blood vitamin levels; Light skin IRF4-TT genotype has greatest folate loss while light skin HERC2-GG genotype has greatest vitamin D3 synthesis (reflected in both TOMS and seasonal data).	Cholecalciferol	202-212	HECT and RLD domain containing E3 ubiquitin protein ligase 2	Homo sapiens	171-176
34418235-7	2022	Significant vitamin D3 photosynthesis only occurs within light skin HERC2-GG genotype, and is maximal at 305 nm.	Cholecalciferol	12-22	HECT and RLD domain containing E3 ubiquitin protein ligase 2	Homo sapiens	68-73
34418235-11	2022	Lightest IRF4-TT/darkest HERC2-AA genotype combination (greatest folate loss/lowest vitamin D3 synthesis) has 0% occurrence.	Cholecalciferol	84-94	HECT and RLD domain containing E3 ubiquitin protein ligase 2	Homo sapiens	25-30
34418235-12	2022	The opposing, commonest (39%) compound genotype (darkest IRF4-CC/lightest HERC2-GG) permits least folate loss and greatest synthesis of vitamin D3 .	Cholecalciferol	136-146	interferon regulatory factor 4	Homo sapiens	57-61
34418235-12	2022	The opposing, commonest (39%) compound genotype (darkest IRF4-CC/lightest HERC2-GG) permits least folate loss and greatest synthesis of vitamin D3 .	Cholecalciferol	136-146	HECT and RLD domain containing E3 ubiquitin protein ligase 2	Homo sapiens	74-79
34381124-1	2021	The present study aimed to investigate the effects of vitamin D3 (Vit D) administration on memory function, hippocampal level of amyloid-beta (Abeta), brain-derived neurotrophic factor (BDNF) and oxidative stress status in a rat model of unpredictable chronic mild stress (UCMS).	Cholecalciferol	54-64	vitrin	Rattus norvegicus	66-69
34512638-4	2021	We therefore aimed to investigate the effect of vitamin D3 treatment on viral-induced TLR3 responses in Bronchial Smooth Muscle Cells (BSMCs) as a mechanism contributing to pulmonary fibrosis in asthma and COPD.	Cholecalciferol	48-58	toll like receptor 3	Homo sapiens	86-90
34512638-11	2021	Our findings suggest that vitamin D3 attenuates TLR3 agonist-induced inflammatory and fibrotic responses in BSMCs and support the clinical relevance of vitamin D3 supplementation in patients with viral infections having chronic respiratory diseases, such as asthma and COPD.	Cholecalciferol	26-36	toll like receptor 3	Homo sapiens	48-52
34445803-5	2021	Therefore, active forms of vitamin D3 including its canonical (1,25(OH)2D3) and noncanonical (CYP11A1-intitated) D3 derivatives as well as L3 derivatives are promising agents for the prevention, attenuation, or treatment of premature skin aging.	Cholecalciferol	113-115	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	94-101
34174395-11	2021	Finally, Cel treatment reduced Vitamin D3-induced aortic calcification in mice and this effect was blocked by HMOX-1 inhibitor ZnPP9.	Cholecalciferol	31-41	heme oxygenase 1	Mus musculus	110-116
34368851-9	2022	Daily consumption of soft plain cheese fortified with 2.5 microg of vitamin D3 and 302 mg of calcium for 4 weeks resulted in a mean increase of 0.8 ng/mL in 25(OH)D and 15.9 ng/mL in P1NP levels compared with baseline, and decreased CTX, TRAP5b, and PTH values.	Cholecalciferol	68-78	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	233-236
34368851-9	2022	Daily consumption of soft plain cheese fortified with 2.5 microg of vitamin D3 and 302 mg of calcium for 4 weeks resulted in a mean increase of 0.8 ng/mL in 25(OH)D and 15.9 ng/mL in P1NP levels compared with baseline, and decreased CTX, TRAP5b, and PTH values.	Cholecalciferol	68-78	parathyroid hormone	Homo sapiens	250-253
34368851-11	2022	Yogurt fortified with 10 microg of vitamin D3 and 800 mg of calcium did not change P1NP values after 8 weeks of intervention, but was associated with decreases of 0.0286 ng/mL and 1.06 U/L in PTH and TRAP5b, respectively.	Cholecalciferol	35-45	parathyroid hormone	Homo sapiens	192-195
34408754-7	2021	We show that in addition to the transcription factors AhR and RORgammat, the active form of vitamin D3 (1,25(OH)2D3) regulates IL-22 production in these cells.	Cholecalciferol	92-102	interleukin 22	Homo sapiens	127-132
34358825-0	2021	Effect of supplementation with calcitriol versus cholecalciferol on insulin resistance in patients with nonalcoholic fatty liver disease: Several issues of concern.	Cholecalciferol	49-64	insulin	Homo sapiens	68-75
34415218-2	2021	In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions.	Cholecalciferol	148-158	angiotensin converting enzyme 2	Homo sapiens	278-309
34415218-2	2021	In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions.	Cholecalciferol	148-158	angiotensin converting enzyme 2	Homo sapiens	311-315
34415218-2	2021	In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions.	Cholecalciferol	148-158	angiotensin converting enzyme 2	Homo sapiens	407-411
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	22-32	transmembrane serine protease 2	Homo sapiens	97-104
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	22-32	angiotensin converting enzyme 2	Homo sapiens	137-141
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	22-32	transmembrane serine protease 2	Homo sapiens	252-259
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	22-32	angiotensin converting enzyme 2	Homo sapiens	286-290
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	181-191	transmembrane serine protease 2	Homo sapiens	97-104
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	181-191	angiotensin converting enzyme 2	Homo sapiens	137-141
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	181-191	transmembrane serine protease 2	Homo sapiens	252-259
34415218-3	2021	The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry.	Cholecalciferol	181-191	angiotensin converting enzyme 2	Homo sapiens	286-290
34143299-4	2021	The GH/IGF-1 system regulates glomerular hemodynamics, renal gluconeogenesis, tubular sodium and water, phosphate, and calcium handling, as well as renal synthesis of 1,25 (OH)2 vitamin D3 and the antiaging hormone Klotho.	Cholecalciferol	178-188	insulin like growth factor 1	Homo sapiens	7-12
34272637-2	2021	Tyrosine kinase inhibitor such as imatinib is reported to interfere with the activation of vitamin D3 by inhibiting CYP27B1 enzyme.	Cholecalciferol	91-101	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	116-123
34132891-8	2021	There were positive significant correlations between levels of vitamin D3 and acute-phase reactants in serum, such as C-reactive protein (P = 0.0292).	Cholecalciferol	63-73	C-reactive protein	Homo sapiens	118-136
34268906-12	2021	Inhibition of SQLE reduced the levels of calcitriol (active form of vitamin D3) and CYP24A1, followed by an increase in intracellular Ca2+ concentration.	Cholecalciferol	68-78	squalene epoxidase	Homo sapiens	14-18
34362518-5	2021	Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05).	Cholecalciferol	149-159	integrin alpha 2b	Mus musculus	77-81
34362518-5	2021	Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05).	Cholecalciferol	149-159	integrin beta 3	Mus musculus	83-87
34362518-5	2021	Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05).	Cholecalciferol	149-159	integrin alpha 2b	Mus musculus	93-97
34362518-5	2021	Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05).	Cholecalciferol	149-159	selectin, platelet	Mus musculus	99-104
34362518-5	2021	Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05).	Cholecalciferol	149-159	platelet/endothelial cell adhesion molecule 1	Mus musculus	118-125
34362518-5	2021	Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05).	Cholecalciferol	149-159	advanced glycosylation end product-specific receptor	Mus musculus	130-134
34298790-3	2021	GBM incidence has been negatively correlated with the serum levels of 25-hydroxy-vitamin D3, while the low pH within tumors has been shown to promote the expression of the vitamin D3-degrading enzyme 24-hydroxylase, encoded by the CYP24A1 gene.	Cholecalciferol	172-182	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	231-238
34531993-10	2021	Moreover, vitamin D3 treatment has increased the phosphorylation of cAMP-response element-binding protein and the expression of brain-derived neurotrophic factor and vitamin D receptor.	Cholecalciferol	10-20	brain derived neurotrophic factor	Mus musculus	128-161
34531993-10	2021	Moreover, vitamin D3 treatment has increased the phosphorylation of cAMP-response element-binding protein and the expression of brain-derived neurotrophic factor and vitamin D receptor.	Cholecalciferol	10-20	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	166-184
34294550-2	2022	This study aimed to assess the effects of cholecalciferol supplementation on FGF23 and alpha-klotho in patients with hypovitaminosis D requiring hemodialysis.	Cholecalciferol	42-57	fibroblast growth factor 23	Homo sapiens	77-82
34294550-8	2022	However, the before-after differences between cholecalciferol supplement and placebo were significant only for alpha-klotho (P = .035).	Cholecalciferol	46-61	klotho	Homo sapiens	117-123
34294550-10	2022	CONCLUSION: Cholecalciferol supplementation of 50,000 IU for 12 weeks increases alpha-klotho levels in the serum of kidney failure patients undergoing hemodialysis.	Cholecalciferol	12-27	klotho	Homo sapiens	86-92
34316406-17	2021	In addition, in THP-1 cells undergoing the combined stimulation, the gene expression patterns were influenced by vitamin D3, which also ablated the effect of the mechanical stimulus on PIEZO1 upregulation.	Cholecalciferol	113-123	piezo type mechanosensitive ion channel component 1	Homo sapiens	185-191
34255241-0	2021	Vitamin D3 decreases TNF-alpha-induced inflammation in lung epithelial cells through a reduction in mitochondrial fission and mitophagy.	Cholecalciferol	0-10	tumor necrosis factor	Homo sapiens	21-30
34255241-5	2021	The purpose of this study was to examine the effects and mechanisms of action of vitamin D3 (Vit.	Cholecalciferol	81-91	vitrin	Homo sapiens	93-96
34238191-5	2022	They were stable (particle size and distribution) for 15 days when stored in a refrigerator and for 30 days at room temperature and 32  C. The nanoparticles decreased the drug cytotoxicity against fibroblasts, as shown by IC50 (nanoparticle: 32.48 mug mL-1; vitamin D3: 16.73 mug mL-1).	Cholecalciferol	258-268	L1 cell adhesion molecule	Mus musculus	280-284
34262557-0	2021	Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-gamma: Results From the D-SIRe2 Randomized Controlled Trial.	Cholecalciferol	9-19	interferon gamma	Homo sapiens	140-149
34163023-10	2022	Administration of BK channel activator BMS191011 (10 mg  kg-1  d-1) in high-dosage vitamin D3-treated mice significantly ameliorated calcification.	Cholecalciferol	83-93	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	18-28
34206371-0	2021	Knocking out the Vitamin D Receptor Enhances Malignancy and Decreases Responsiveness to Vitamin D3 Hydroxyderivatives in Human Melanoma Cells.	Cholecalciferol	88-98	vitamin D receptor	Homo sapiens	17-35
34178387-0	2021	Vitamin D3 reduces hippocampal NR2A and anxiety in nicotine withdrawal mice.	Cholecalciferol	0-10	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	31-35
34178387-6	2021	Moreover, vitamin D3 supplementation attenuated the hippocampal NR2A expression on both protein and mRNA levels in nicotine and vitamin D3-treated mice.	Cholecalciferol	10-20	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	64-68
34178387-6	2021	Moreover, vitamin D3 supplementation attenuated the hippocampal NR2A expression on both protein and mRNA levels in nicotine and vitamin D3-treated mice.	Cholecalciferol	128-138	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	64-68
34178387-7	2021	Our data showed that dietary supplementation with vitamin D3 ameliorated nicotine withdrawal-induced anxiety, which may be related to downregulation of NR2A expression in hippocampus.	Cholecalciferol	50-60	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	152-156
34101754-0	2021	Vitamin D3 attenuates doxorubicin-induced senescence of human aortic endothelial cells by upregulation of IL-10 via the pAMPKalpha/Sirt1/Foxo3a signaling pathway.	Cholecalciferol	0-10	interleukin 10	Homo sapiens	106-111
34101754-0	2021	Vitamin D3 attenuates doxorubicin-induced senescence of human aortic endothelial cells by upregulation of IL-10 via the pAMPKalpha/Sirt1/Foxo3a signaling pathway.	Cholecalciferol	0-10	sirtuin 1	Homo sapiens	131-136
34101754-0	2021	Vitamin D3 attenuates doxorubicin-induced senescence of human aortic endothelial cells by upregulation of IL-10 via the pAMPKalpha/Sirt1/Foxo3a signaling pathway.	Cholecalciferol	0-10	forkhead box O3	Homo sapiens	137-143
34101754-4	2021	We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity.	Cholecalciferol	42-52	interleukin 10	Homo sapiens	89-94
34101754-4	2021	We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity.	Cholecalciferol	42-52	forkhead box O3	Homo sapiens	99-105
34101754-4	2021	We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity.	Cholecalciferol	42-52	sirtuin 1	Homo sapiens	155-160
34101754-4	2021	We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity.	Cholecalciferol	42-52	forkhead box O3	Homo sapiens	161-167
34071156-6	2021	The yield of milk (0.05 < p < 0.10), energy-corrected milk (p < 0.05), 3.5% fat-corrected milk (p < 0.05), and milk protein (p < 0.05) were significantly higher in 25-hydroxyvitamin D3-treated groups within 3 weeks of lactation than in vitamin D3-treated cows.	Cholecalciferol	236-246	casein kappa	Bos taurus	111-123
34071156-8	2021	Feeding 25-hydroxyvitamin D3 also showed a lower concentration of malondialdehyde (p < 0.05), interleukin 6 (p < 0.05), and tumor necrosis factor-alpha (TNF-alpha) (p < 0.05), as well as a higher concentration of alkaline phosphatase (p < 0.05), total antioxidant capacity (p < 0.05), and immunoglobulin G (p < 0.05) than vitamin D3.	Cholecalciferol	322-332	interleukin 6	Bos taurus	94-107
34071156-8	2021	Feeding 25-hydroxyvitamin D3 also showed a lower concentration of malondialdehyde (p < 0.05), interleukin 6 (p < 0.05), and tumor necrosis factor-alpha (TNF-alpha) (p < 0.05), as well as a higher concentration of alkaline phosphatase (p < 0.05), total antioxidant capacity (p < 0.05), and immunoglobulin G (p < 0.05) than vitamin D3.	Cholecalciferol	322-332	tumor necrosis factor	Bos taurus	124-151
34109109-8	2021	Moreover, increased vitamin D3 levels by calcitriol supplementation or induction by UVB-radiation was associated with inhibited IL-6 signaling and increased the response to irradiation observed in animal models.	Cholecalciferol	20-30	interleukin 6	Homo sapiens	128-132
34063823-8	2021	Possible molecular mechanisms of neuroprotective action of vitamin D3 can be associated with the increased expression level of transcription factor HIF-1alpha and maintaining the relationship between the levels of BDNF and TrkB expression in cells of primary neuronal cultures.	Cholecalciferol	59-69	hypoxia inducible factor 1 subunit alpha	Homo sapiens	148-158
34063823-8	2021	Possible molecular mechanisms of neuroprotective action of vitamin D3 can be associated with the increased expression level of transcription factor HIF-1alpha and maintaining the relationship between the levels of BDNF and TrkB expression in cells of primary neuronal cultures.	Cholecalciferol	59-69	brain derived neurotrophic factor	Homo sapiens	214-218
34063823-8	2021	Possible molecular mechanisms of neuroprotective action of vitamin D3 can be associated with the increased expression level of transcription factor HIF-1alpha and maintaining the relationship between the levels of BDNF and TrkB expression in cells of primary neuronal cultures.	Cholecalciferol	59-69	neurotrophic receptor tyrosine kinase 2	Homo sapiens	223-227
34178862-8	2021	Vitamin D3 was applied via oral gavage once daily to the STZ + vit-D3 group for a total period of 14 days, starting from the 7th day of the experiment.	Cholecalciferol	0-10	vitrin	Rattus norvegicus	63-66
34909713-4	2021	Furthermore, our results show that afatinib may interfere with vitamin D3 metabolism, acting via CYP27A1 and CYP24A1 to regulate calcium concentration through the phosphatidylinositol 3-kinase/protein kinase B pathway.	Cholecalciferol	63-73	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	97-104
34909713-4	2021	Furthermore, our results show that afatinib may interfere with vitamin D3 metabolism, acting via CYP27A1 and CYP24A1 to regulate calcium concentration through the phosphatidylinositol 3-kinase/protein kinase B pathway.	Cholecalciferol	63-73	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	109-116
34909713-4	2021	Furthermore, our results show that afatinib may interfere with vitamin D3 metabolism, acting via CYP27A1 and CYP24A1 to regulate calcium concentration through the phosphatidylinositol 3-kinase/protein kinase B pathway.	Cholecalciferol	63-73	protein tyrosine kinase 2 beta	Homo sapiens	193-209
34099581-5	2021	Noteworthy, recent studies suggested that supplementation with vitamin D3 may be an alternative therapy increasing insulin sensitivity and thereby improving reproductive parameters in PCOS women.	Cholecalciferol	63-73	insulin	Homo sapiens	115-122
34515192-7	2021	The mRNA and protein expression of CYP2R1 of hydroxylated vitamin D3 was significantly reduced; CYP11A1 and CYP11A2, which synthesize testosterone, were significantly reduced.	Cholecalciferol	58-68	cytochrome P450, family 2, subfamily r, polypeptide 1	Mus musculus	35-41
34725288-7	2021	The women, who received the course of the preventive therapy with metformin, vitamin D3 and corvitin, showed a decrease in the concentration of pro-inflammatory cytokines and an increase in anti-inflammatory cytokine IL-10, normalization of the balance between iNOS and arginase activity, and the normalization of the M1 / M2 macrophages ratio.	Cholecalciferol	77-87	inositol-3-phosphate synthase 1	Homo sapiens	261-265
35364123-3	2022	Vitamin D3 is considered as a strong modulator of a number of transcription factors, including NF-kappaB.	Cholecalciferol	0-10	nuclear factor kappa B subunit 1	Homo sapiens	95-104
35364123-13	2022	GENERAL SIGNIFICANCE: Vitamin D3 supplementation counteracts diabetes-induced kidney damage, most likely through VDR-mediated inhibition of NF-kappaB activation.	Cholecalciferol	22-32	vitamin D receptor	Homo sapiens	113-116
35364123-13	2022	GENERAL SIGNIFICANCE: Vitamin D3 supplementation counteracts diabetes-induced kidney damage, most likely through VDR-mediated inhibition of NF-kappaB activation.	Cholecalciferol	22-32	nuclear factor kappa B subunit 1	Homo sapiens	140-149
35533917-0	2022	Vitamin D3 reverses the transcriptional profile of offspring CD4+ T lymphocytes exposed to intrauterine inflammation.	Cholecalciferol	0-10	CD4 antigen	Mus musculus	61-64
35531910-6	2022	Our research provides the first evidence that exogenous FGF21 treatment can alleviate the vitamin D3 plus nicotine-induced VC at least in part via suppressing ATF4 mediated apoptosis and osteogenic transformation in rats.	Cholecalciferol	90-100	fibroblast growth factor 21	Rattus norvegicus	56-61
35421413-0	2022	Molecular and structural basis of interactions of vitamin D3 hydroxyderivatives with aryl hydrocarbon receptor (AhR): An integrated experimental and computational study.	Cholecalciferol	50-60	aryl hydrocarbon receptor	Homo sapiens	85-110
35421413-0	2022	Molecular and structural basis of interactions of vitamin D3 hydroxyderivatives with aryl hydrocarbon receptor (AhR): An integrated experimental and computational study.	Cholecalciferol	50-60	aryl hydrocarbon receptor	Homo sapiens	112-115
35421413-1	2022	To better understand the molecular and structural basis underlying the interaction of vitamin D3 hydroxyderivatives with AhR, molecular simulation was used to probe the binding of 1,20(OH)2D3, 1,25(OH)2D3, 20,23(OH)2D3 and 20(OH)D3 to AhR.	Cholecalciferol	86-96	aryl hydrocarbon receptor	Homo sapiens	121-124
35421413-2	2022	qPCR showed that vitamin D3 derivatives stimulate expression of cyp1A1 and cyp1B1 genes that are downstream targets of AhR signaling.	Cholecalciferol	17-27	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	64-70
35421413-2	2022	qPCR showed that vitamin D3 derivatives stimulate expression of cyp1A1 and cyp1B1 genes that are downstream targets of AhR signaling.	Cholecalciferol	17-27	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	75-81
35421413-2	2022	qPCR showed that vitamin D3 derivatives stimulate expression of cyp1A1 and cyp1B1 genes that are downstream targets of AhR signaling.	Cholecalciferol	17-27	aryl hydrocarbon receptor	Homo sapiens	119-122
35421413-4	2022	Molecular dynamics simulations were used to model the binding of vitamin D3 derivatives to AhR to examine their influence on the structure, conformation and dynamics of the AhR ligand binding domain (LBD).	Cholecalciferol	65-75	aryl hydrocarbon receptor	Homo sapiens	91-94
35334282-0	2022	Cholecalciferol pretreatment ameliorates ischemia/reperfusion-induced acute kidney injury through inhibiting ROS production, NF-kappaB pathway and pyroptosis.	Cholecalciferol	0-15	nuclear factor kappa B subunit 1	Homo sapiens	125-134
35334282-7	2022	Cholecalciferol reduced ROS production, suppressed activated NF-kappaB signaling, and inhibited gasdermin D (GSDMD, a pyroptosis execution protein)-mediated pyroptosis.	Cholecalciferol	0-15	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	61-70
35334282-7	2022	Cholecalciferol reduced ROS production, suppressed activated NF-kappaB signaling, and inhibited gasdermin D (GSDMD, a pyroptosis execution protein)-mediated pyroptosis.	Cholecalciferol	0-15	gasdermin D	Homo sapiens	96-107
35334282-7	2022	Cholecalciferol reduced ROS production, suppressed activated NF-kappaB signaling, and inhibited gasdermin D (GSDMD, a pyroptosis execution protein)-mediated pyroptosis.	Cholecalciferol	0-15	gasdermin D	Homo sapiens	109-114
35334282-8	2022	Cholecalciferol therefore has potential, as a clinical drug, to protect renal function in I/R-induced AKI through reducing ROS production, NF-kappaB activation and GSDMD-mediated pyroptosis.	Cholecalciferol	0-15	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	139-148
35334282-8	2022	Cholecalciferol therefore has potential, as a clinical drug, to protect renal function in I/R-induced AKI through reducing ROS production, NF-kappaB activation and GSDMD-mediated pyroptosis.	Cholecalciferol	0-15	gasdermin D	Homo sapiens	164-169
34251424-8	2021	The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF.	Cholecalciferol	69-79	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	99-106
34251424-8	2021	The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF.	Cholecalciferol	69-79	Src homology 2 domain containing E	Homo sapiens	108-111
34251424-8	2021	The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF.	Cholecalciferol	69-79	keratin 16	Homo sapiens	113-118
34251424-8	2021	The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF.	Cholecalciferol	69-79	cartilage intermediate layer protein	Homo sapiens	134-138
34725288-7	2021	The women, who received the course of the preventive therapy with metformin, vitamin D3 and corvitin, showed a decrease in the concentration of pro-inflammatory cytokines and an increase in anti-inflammatory cytokine IL-10, normalization of the balance between iNOS and arginase activity, and the normalization of the M1 / M2 macrophages ratio.	Cholecalciferol	77-87	interleukin 10	Homo sapiens	217-222
35183964-0	2022	pH-driven-assembled soy peptide nanoparticles as particulate emulsifier for oil-in-water Pickering emulsion and their potential for encapsulation of vitamin D3.	Cholecalciferol	149-159	phenylalanine hydroxylase	Homo sapiens	0-2
35485195-6	2022	RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05).	Cholecalciferol	30-40	interferon gamma	Homo sapiens	63-72
35485195-6	2022	RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05).	Cholecalciferol	30-40	interleukin 4	Homo sapiens	74-78
35485195-6	2022	RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05).	Cholecalciferol	30-40	interleukin 5	Homo sapiens	80-84
35485195-6	2022	RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05).	Cholecalciferol	30-40	interleukin 10	Homo sapiens	90-95
35485195-6	2022	RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05).	Cholecalciferol	30-40	interleukin 2	Homo sapiens	154-158
35560516-2	2022	Vitamin D3 (VD3 ) through its receptor (VDR) plays an important immunomodulatory role in autoimmune misbalance, being capable of modulating immune responses.	Cholecalciferol	0-10	vitamin D receptor	Homo sapiens	40-43
35257869-7	2022	Although no difference in serum levels of 25(OH)D3, calcium or zonulin was observed in cholecalciferol-treated mice vs. healthy controls, a significant improvement in intestinal mucosa pathological features in mice administered cholecalciferol was observed by histological analysis.	Cholecalciferol	87-102	haptoglobin	Mus musculus	63-70
35257869-7	2022	Although no difference in serum levels of 25(OH)D3, calcium or zonulin was observed in cholecalciferol-treated mice vs. healthy controls, a significant improvement in intestinal mucosa pathological features in mice administered cholecalciferol was observed by histological analysis.	Cholecalciferol	228-243	haptoglobin	Mus musculus	63-70
35257869-9	2022	Immunohistochemical staining revealed increased expression of CD3 and ZO-1 in celiac mice compared to mice receiving high dose (130 mug/kg) cholecalciferol.	Cholecalciferol	140-155	CD247 antigen	Mus musculus	62-65
35257869-9	2022	Immunohistochemical staining revealed increased expression of CD3 and ZO-1 in celiac mice compared to mice receiving high dose (130 mug/kg) cholecalciferol.	Cholecalciferol	140-155	tight junction protein 1	Mus musculus	70-74
35603161-7	2022	We also observed epigenetic and genetic modulation of several of these T1D susceptibility genes in dendritic cells (DCs) treated with vitamin D3 and dexamethasone to acquire tolerogenic properties as compared to immune activating DCs (mDC) illustrating the interaction between genes and environment that collectively determines risk for T1D.	Cholecalciferol	134-144	decorin	Mus musculus	235-238
35547357-4	2022	By conducting this study, we wanted to emphasize the role of vitamin D3 in reducing the oxidative stress load on patients undergoing peritoneal dialysis (PD) via serum TRX level measurement.	Cholecalciferol	61-71	thioredoxin	Homo sapiens	168-171
35547357-10	2022	The serum TRX level was significantly higher (211,62 U/l +- 314,46) in the group receiving vitamin D3 compared to the group which is not using Vitamin D3 (101,63 U/l +- 215,03) (p < 0,006).	Cholecalciferol	91-101	thioredoxin	Homo sapiens	10-13
35547357-10	2022	The serum TRX level was significantly higher (211,62 U/l +- 314,46) in the group receiving vitamin D3 compared to the group which is not using Vitamin D3 (101,63 U/l +- 215,03) (p < 0,006).	Cholecalciferol	143-153	thioredoxin	Homo sapiens	10-13
35493433-0	2022	Vitamin D3 alleviates cigarette smoke extract-mediated epithelial-mesenchymal transition and fibrogenesis by upregulating CC16 expression in bronchial epithelial cells.	Cholecalciferol	0-10	secretoglobin family 1A member 1	Homo sapiens	122-126
35138562-8	2022	The acromegaly group showed an increase in DBP levels after cholecalciferol intake as opposed to the control group (p < 0.05) and had lower increase in free 25(OH)D levels (p < 0.05).	Cholecalciferol	60-75	D-box binding PAR bZIP transcription factor	Homo sapiens	43-46
34995387-4	2022	However, it can be associated with the disturbances in transmembrane glycoprotein-LRP2/megalin, which is implicated in vitamin D3 transport to the cell, and defects in vitamin D-signalling through the nuclear receptors.	Cholecalciferol	119-129	LDL receptor related protein 2	Homo sapiens	82-86
34995387-4	2022	However, it can be associated with the disturbances in transmembrane glycoprotein-LRP2/megalin, which is implicated in vitamin D3 transport to the cell, and defects in vitamin D-signalling through the nuclear receptors.	Cholecalciferol	119-129	LDL receptor related protein 2	Homo sapiens	87-94
35493433-10	2022	The results of the present study found that vitamin D3 could increase the protein expression level of CC16 to inhibit the activation of the TGF-beta1/SMAD3 signaling pathway; thereby reducing the 20% increase in CSE-induced EMT- and fibrogenesis-related protein expression levels.	Cholecalciferol	44-54	secretoglobin family 1A member 1	Homo sapiens	102-106
35493433-10	2022	The results of the present study found that vitamin D3 could increase the protein expression level of CC16 to inhibit the activation of the TGF-beta1/SMAD3 signaling pathway; thereby reducing the 20% increase in CSE-induced EMT- and fibrogenesis-related protein expression levels.	Cholecalciferol	44-54	transforming growth factor beta 1	Homo sapiens	140-149
35493433-10	2022	The results of the present study found that vitamin D3 could increase the protein expression level of CC16 to inhibit the activation of the TGF-beta1/SMAD3 signaling pathway; thereby reducing the 20% increase in CSE-induced EMT- and fibrogenesis-related protein expression levels.	Cholecalciferol	44-54	SMAD family member 3	Homo sapiens	150-155
35493433-11	2022	Following CC16 knockdown, the inhibitory effects of vitamin D3 on EMT- and fibrogenesis-related protein expression were partially reversed.	Cholecalciferol	52-62	secretoglobin family 1A member 1	Homo sapiens	10-14
35493433-12	2022	To conclude, these results suggest that vitamin D3 can inhibit the protein expression levels of EMT- and fibrogenesis-related proteins induced by CSE, at least partially through the function of CC16.	Cholecalciferol	40-50	secretoglobin family 1A member 1	Homo sapiens	194-198
35245520-0	2022	Enhanced in vitro tumoricidal effects of 5-Fluorouracil, thymoquinone, and active vitamin D3 triple therapy against colon cancer cells by attenuating the PI3K/AKT/mTOR pathway.	Cholecalciferol	82-92	AKT serine/threonine kinase 1	Homo sapiens	159-162
35245520-0	2022	Enhanced in vitro tumoricidal effects of 5-Fluorouracil, thymoquinone, and active vitamin D3 triple therapy against colon cancer cells by attenuating the PI3K/AKT/mTOR pathway.	Cholecalciferol	82-92	mechanistic target of rapamycin kinase	Homo sapiens	163-167
35488267-0	2022	Cholecalciferol supplementation lowers leptin and TMAO but increases NO and VEGF-A levels in obese vitamin D deficient patients: Is it one of the potential cardioprotective mechanisms of vitamin D?	Cholecalciferol	0-15	leptin	Homo sapiens	39-45
35183675-12	2022	Mechanistically, our results demonstrated that vitamin D3 can activate AMPK, inhibiting the mTOR pathway, thus inhibiting NLRP3 inflammasome activation and alleviating pyroptosis in beta-cell dysfunction.	Cholecalciferol	47-57	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	71-75
35183675-12	2022	Mechanistically, our results demonstrated that vitamin D3 can activate AMPK, inhibiting the mTOR pathway, thus inhibiting NLRP3 inflammasome activation and alleviating pyroptosis in beta-cell dysfunction.	Cholecalciferol	47-57	mechanistic target of rapamycin kinase	Rattus norvegicus	92-96
35183675-12	2022	Mechanistically, our results demonstrated that vitamin D3 can activate AMPK, inhibiting the mTOR pathway, thus inhibiting NLRP3 inflammasome activation and alleviating pyroptosis in beta-cell dysfunction.	Cholecalciferol	47-57	NLR family, pyrin domain containing 3	Rattus norvegicus	122-127
35436103-1	2022	Overexpression of the vitamin D3-inactivating enzyme CYP24A1 (cytochrome P450 family 24 subfamily and hereafter referred to as CYP24) can cause chronic kidney diseases, osteoporosis, and several types of cancers.	Cholecalciferol	22-32	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	53-60
35436103-1	2022	Overexpression of the vitamin D3-inactivating enzyme CYP24A1 (cytochrome P450 family 24 subfamily and hereafter referred to as CYP24) can cause chronic kidney diseases, osteoporosis, and several types of cancers.	Cholecalciferol	22-32	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	127-132
35436103-4	2022	We have identified a novel 70-nt DNA aptamer-based inhibitor of CYP24 by utilizing the competition-based aptamer selection strategy, taking CYP24 as the positive target protein and CYP27B1 (the enzyme catalyzing active vitamin D3 production) as the countertarget protein.	Cholecalciferol	219-229	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	64-69
35436103-4	2022	We have identified a novel 70-nt DNA aptamer-based inhibitor of CYP24 by utilizing the competition-based aptamer selection strategy, taking CYP24 as the positive target protein and CYP27B1 (the enzyme catalyzing active vitamin D3 production) as the countertarget protein.	Cholecalciferol	219-229	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	140-145
35436103-4	2022	We have identified a novel 70-nt DNA aptamer-based inhibitor of CYP24 by utilizing the competition-based aptamer selection strategy, taking CYP24 as the positive target protein and CYP27B1 (the enzyme catalyzing active vitamin D3 production) as the countertarget protein.	Cholecalciferol	219-229	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	181-188
35488267-0	2022	Cholecalciferol supplementation lowers leptin and TMAO but increases NO and VEGF-A levels in obese vitamin D deficient patients: Is it one of the potential cardioprotective mechanisms of vitamin D?	Cholecalciferol	0-15	vascular endothelial growth factor A	Homo sapiens	76-82
35445563-4	2022	We consider the likely biological determinants of cancer outcome, the reported effects of vitamin D3 on these in both cancerous and non-cancerous settings, and how the effect of vitamin D3 might change depending on the integrity of tumour vitamin D receptor (VDR) signalling.	Cholecalciferol	178-188	vitamin D receptor	Homo sapiens	239-257
35445563-6	2022	In animal models, having defective VDR signalling, vitamin D3 administration decreased survival and increased metastases.	Cholecalciferol	51-61	vitamin D receptor	Homo sapiens	35-38
35063658-0	2022	Vitamin D3 and zinc synergistically induce regulatory T cells and suppress interferon-gamma production in mixed lymphocyte culture.	Cholecalciferol	0-10	interferon gamma	Homo sapiens	75-91
35443806-9	2022	Conclusions: Study findings supported that CBD interacts with CYP2R1, CYP27B1, CYP24A1, and vitamin D receptors, resulting in increased vitamin D3 metabolites, which improved memory, pain tolerance, reduced inflammation, and aging through modulating antioxidative enzymes, cytokines, and neurotransmitters in VDD-induced rats.	Cholecalciferol	136-146	cytochrome P450, family 2, subfamily r, polypeptide 1	Rattus norvegicus	62-68
35443806-9	2022	Conclusions: Study findings supported that CBD interacts with CYP2R1, CYP27B1, CYP24A1, and vitamin D receptors, resulting in increased vitamin D3 metabolites, which improved memory, pain tolerance, reduced inflammation, and aging through modulating antioxidative enzymes, cytokines, and neurotransmitters in VDD-induced rats.	Cholecalciferol	136-146	cytochrome P450, family 27, subfamily b, polypeptide 1	Rattus norvegicus	70-77
35443806-9	2022	Conclusions: Study findings supported that CBD interacts with CYP2R1, CYP27B1, CYP24A1, and vitamin D receptors, resulting in increased vitamin D3 metabolites, which improved memory, pain tolerance, reduced inflammation, and aging through modulating antioxidative enzymes, cytokines, and neurotransmitters in VDD-induced rats.	Cholecalciferol	136-146	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	79-86
35157949-10	2022	In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus.	Cholecalciferol	13-23	glial fibrillary acidic protein	Mus musculus	119-123
35157949-10	2022	In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus.	Cholecalciferol	13-23	brain derived neurotrophic factor	Mus musculus	206-239
35157949-10	2022	In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus.	Cholecalciferol	13-23	brain derived neurotrophic factor	Mus musculus	241-245
35157949-10	2022	In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus.	Cholecalciferol	13-23	carbonic anhydrase 1	Mus musculus	278-281
35157949-10	2022	In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus.	Cholecalciferol	13-23	carbonic anhydrase 3	Mus musculus	286-289
35409330-2	2022	This study aimed to examine vitamin D3 metabolic enzymes, i.e., CYP27B1 and CYP24A1, mRNA transcript and protein abundance, and protein localization in the uterus of pigs on days 2-5, 10-12, 15-16 and 18-20 of the estrous cycle.	Cholecalciferol	28-38	cytochrome P450 family 27 subfamily B member 1	Sus scrofa	64-71
35063658-2	2022	This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg).	Cholecalciferol	71-81	forkhead box P3	Homo sapiens	200-205
35063658-2	2022	This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg).	Cholecalciferol	71-81	CD4 molecule	Homo sapiens	206-209
35063658-2	2022	This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg).	Cholecalciferol	141-151	forkhead box P3	Homo sapiens	200-205
35063658-2	2022	This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg).	Cholecalciferol	141-151	CD4 molecule	Homo sapiens	206-209
35063658-3	2022	Vitamin D3 alone reduced the percentage of CD4+T-bet+ T cells (TH1).	Cholecalciferol	0-10	CD4 molecule	Homo sapiens	43-46
35063658-3	2022	Vitamin D3 alone reduced the percentage of CD4+T-bet+ T cells (TH1).	Cholecalciferol	0-10	T-box transcription factor 21	Homo sapiens	47-52
35063658-4	2022	In mixed lymphocyte culture (MLC), therapeutic concentrations of vitamin D3 and zinc in combination suppressed interferon-gamma (IFN-gamma) secretion more strongly than the single agent treatment.	Cholecalciferol	65-75	interferon gamma	Homo sapiens	111-127
35063658-4	2022	In mixed lymphocyte culture (MLC), therapeutic concentrations of vitamin D3 and zinc in combination suppressed interferon-gamma (IFN-gamma) secretion more strongly than the single agent treatment.	Cholecalciferol	65-75	interferon gamma	Homo sapiens	129-138
35063658-9	2022	In summary, this study shows, for the first time, a vitamin D3-induced upregulation of CD4+Foxp3+ T cells in MLC.	Cholecalciferol	52-62	CD4 molecule	Homo sapiens	87-90
35063658-9	2022	In summary, this study shows, for the first time, a vitamin D3-induced upregulation of CD4+Foxp3+ T cells in MLC.	Cholecalciferol	52-62	forkhead box P3	Homo sapiens	91-96
34997087-0	2022	Association between vitamin D3 levels and insulin resistance: a large sample cross-sectional study.	Cholecalciferol	20-30	insulin	Homo sapiens	42-49
35338345-8	2022	We identified the Vitamin D response element (VDRE) binding sites in a reporter system showed that VDRE in the Claudin-5 promoter is required for vitamin D3-induced Claudin-5 expression.	Cholecalciferol	146-156	claudin 5	Mus musculus	111-120
35338345-8	2022	We identified the Vitamin D response element (VDRE) binding sites in a reporter system showed that VDRE in the Claudin-5 promoter is required for vitamin D3-induced Claudin-5 expression.	Cholecalciferol	146-156	claudin 5	Mus musculus	165-174
35326689-0	2022	In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network.	Cholecalciferol	71-81	AKT serine/threonine kinase 1	Homo sapiens	161-164
35326689-0	2022	In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network.	Cholecalciferol	71-81	phosphatase and tensin homolog	Homo sapiens	165-169
35326689-0	2022	In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network.	Cholecalciferol	71-81	mechanistic target of rapamycin kinase	Homo sapiens	170-174
35359726-0	2022	Vitamin D3 Suppresses Human Cytomegalovirus-Induced Vascular Endothelial Apoptosis via Rectification of Paradoxical m6A Modification of Mitochondrial Calcium Uniporter mRNA, Which Is Regulated by METTL3 and YTHDF3.	Cholecalciferol	0-10	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	196-202
35359726-0	2022	Vitamin D3 Suppresses Human Cytomegalovirus-Induced Vascular Endothelial Apoptosis via Rectification of Paradoxical m6A Modification of Mitochondrial Calcium Uniporter mRNA, Which Is Regulated by METTL3 and YTHDF3.	Cholecalciferol	0-10	YTH N6-methyladenosine RNA binding protein 3	Homo sapiens	207-213
35359726-7	2022	Conversely, vitamin D3 downregulated the METTL3 by inhibiting the activation of AMPK, thereby inhibiting the m6A modification of MCU and cell apoptosis.	Cholecalciferol	12-22	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	41-47
35359726-7	2022	Conversely, vitamin D3 downregulated the METTL3 by inhibiting the activation of AMPK, thereby inhibiting the m6A modification of MCU and cell apoptosis.	Cholecalciferol	12-22	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	80-84
35359726-7	2022	Conversely, vitamin D3 downregulated the METTL3 by inhibiting the activation of AMPK, thereby inhibiting the m6A modification of MCU and cell apoptosis.	Cholecalciferol	12-22	mitochondrial calcium uniporter	Homo sapiens	129-132
35126351-5	2021	Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR).	Cholecalciferol	111-121	toll like receptor 1	Homo sapiens	171-175
35126351-5	2021	Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR).	Cholecalciferol	111-121	toll like receptor 2	Homo sapiens	177-181
35126351-5	2021	Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR).	Cholecalciferol	111-121	toll like receptor 4	Homo sapiens	183-187
35126351-5	2021	Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR).	Cholecalciferol	111-121	vitamin D receptor	Homo sapiens	193-196
35221151-0	2022	Epidermal CD8+CD103+ skin resident memory T cells in psoriasis plaques are reduced in number but remain in the basement membrane zone after topical application of corticosteroid and vitamin D3.	Cholecalciferol	182-192	CD8a molecule	Homo sapiens	10-13
35221151-0	2022	Epidermal CD8+CD103+ skin resident memory T cells in psoriasis plaques are reduced in number but remain in the basement membrane zone after topical application of corticosteroid and vitamin D3.	Cholecalciferol	182-192	integrin subunit alpha E	Homo sapiens	14-19
35220479-11	2022	Highest AMH concentrations were found between August and October and this quartile was associated with highest D3 concentrations.	Cholecalciferol	111-113	anti-Mullerian hormone	Homo sapiens	8-11
35196318-4	2022	The current study investigated the effect of TGF-beta1 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in stromal cells induced by 1alpha,25(OH)2D3 (D3) and dexamethasone (Dex).	Cholecalciferol	175-177	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	58-109
35196318-4	2022	The current study investigated the effect of TGF-beta1 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in stromal cells induced by 1alpha,25(OH)2D3 (D3) and dexamethasone (Dex).	Cholecalciferol	175-177	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	111-116
35196318-5	2022	TGF-beta1 downregulated the expression of RANKL induced by D3 and Dex in mouse bone marrow stromal lineage, ST2 cells.	Cholecalciferol	59-61	transforming growth factor, beta 1	Mus musculus	0-9
35196318-5	2022	TGF-beta1 downregulated the expression of RANKL induced by D3 and Dex in mouse bone marrow stromal lineage, ST2 cells.	Cholecalciferol	59-61	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	42-47
35196318-11	2022	These results indicated that TGF-beta1 downregulates RANKL expression and the osteoclast-supporting activity of osteoblasts/stromal cells induced by D3 and Dex through the degradation of the RXR-alpha protein mediated by ubiquitin-proteasome system.	Cholecalciferol	149-151	transforming growth factor, beta 1	Mus musculus	29-38
35196318-11	2022	These results indicated that TGF-beta1 downregulates RANKL expression and the osteoclast-supporting activity of osteoblasts/stromal cells induced by D3 and Dex through the degradation of the RXR-alpha protein mediated by ubiquitin-proteasome system.	Cholecalciferol	149-151	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	53-58
35196318-11	2022	These results indicated that TGF-beta1 downregulates RANKL expression and the osteoclast-supporting activity of osteoblasts/stromal cells induced by D3 and Dex through the degradation of the RXR-alpha protein mediated by ubiquitin-proteasome system.	Cholecalciferol	149-151	retinoid X receptor alpha	Mus musculus	191-200
35204824-0	2022	Vitamin D3 Stimulates Proliferation Capacity, Expression of Pluripotency Markers, and Osteogenesis of Human Bone Marrow Mesenchymal Stromal/Stem Cells, Partly through SIRT1 Signaling.	Cholecalciferol	0-10	sirtuin 1	Homo sapiens	167-172
35083032-2	2022	We evaluated the effect of a high dose of vitamin D3 on the Neuron-Specific Enolase (NSE) level, National Institute of Health Stroke Scale (NIHSS), and Barthel Index (BI) scoring system in moderate ischemic stroke patients.	Cholecalciferol	42-52	enolase 2	Homo sapiens	60-83
35083032-2	2022	We evaluated the effect of a high dose of vitamin D3 on the Neuron-Specific Enolase (NSE) level, National Institute of Health Stroke Scale (NIHSS), and Barthel Index (BI) scoring system in moderate ischemic stroke patients.	Cholecalciferol	42-52	enolase 2	Homo sapiens	85-88
35083032-12	2022	Conclusions: Administration of a single 600000 IU of vitamin D3 could have neuroprotective effects in patients with moderate ischemic stroke, according to its significantly positive effects on functional clinical outcomes (NIHSS and BI), but this effect on the biomarker related to neural damage (NSE) was not significant.	Cholecalciferol	53-63	enolase 2	Homo sapiens	297-300
35053278-1	2022	1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3, 1) is an active form of vitamin D3 and regulates various biological phenomena, including calcium and phosphate homeostasis, bone metabolism, and immune response via binding to and activation of vitamin D receptor (VDR).	Cholecalciferol	73-83	vitamin D receptor	Homo sapiens	263-266
35053549-1	2022	The active forms of vitamin D3 (calcitriol and tacalcitol) coupled to the vitamin D receptor (VDR) are known to exhibit anti-cancer properties.	Cholecalciferol	20-30	vitamin D receptor	Homo sapiens	74-92
35053549-1	2022	The active forms of vitamin D3 (calcitriol and tacalcitol) coupled to the vitamin D receptor (VDR) are known to exhibit anti-cancer properties.	Cholecalciferol	20-30	vitamin D receptor	Homo sapiens	94-97
34997087-1	2022	Previous studies have shown that vitamin D3 may be a potential factor in insulin resistance, but the relationship between vitamin D3 and insulin resistance still remains controversial.	Cholecalciferol	33-43	insulin	Homo sapiens	73-80
34997087-1	2022	Previous studies have shown that vitamin D3 may be a potential factor in insulin resistance, but the relationship between vitamin D3 and insulin resistance still remains controversial.	Cholecalciferol	122-132	insulin	Homo sapiens	137-144
34997087-2	2022	At present, more research is needed to explore the relationship between vitamin D3 and insulin resistance.	Cholecalciferol	72-82	insulin	Homo sapiens	87-94
34997087-5	2022	Finally, 9298 participants were selected through strict inclusion and exclusion criteria, Multivariate logistic regression analysis and curve fitting were conducted to explore the relationship between vitamin D3 level and insulin resistance.	Cholecalciferol	201-211	insulin	Homo sapiens	222-229
34997087-7	2022	The results revealed that there was a strong association between vitamin D3 and insulin resistance (OR 0.82, 95% CI 0.72-0.93).	Cholecalciferol	65-75	insulin	Homo sapiens	80-87
34997087-9	2022	There was a negative correlation between vitamin D3 level and insulin resistance, which provides a new proof for exploring the influencing factors of insulin resistance.	Cholecalciferol	41-51	insulin	Homo sapiens	62-69
34997087-9	2022	There was a negative correlation between vitamin D3 level and insulin resistance, which provides a new proof for exploring the influencing factors of insulin resistance.	Cholecalciferol	41-51	insulin	Homo sapiens	150-157
34989311-13	2022	Vitamin D3 and carbamazepine protect against CDI by restoring MITF expression and lysosomal function in mice.	Cholecalciferol	0-10	melanogenesis associated transcription factor	Mus musculus	62-66
35181615-8	2022	CONCLUSION: By targeting the Sirt1, EZH2 and CXCR4 pathways using relatively non-toxic adjuvant therapeutic agents such as metformin, melatonin, curcumin, sulforaphane, vitamin D3 and plerixafor, we should be able to target the biology of DLBCL.	Cholecalciferol	169-179	sirtuin 1	Homo sapiens	29-34
35181615-8	2022	CONCLUSION: By targeting the Sirt1, EZH2 and CXCR4 pathways using relatively non-toxic adjuvant therapeutic agents such as metformin, melatonin, curcumin, sulforaphane, vitamin D3 and plerixafor, we should be able to target the biology of DLBCL.	Cholecalciferol	169-179	C-X-C motif chemokine receptor 4	Homo sapiens	45-50
35145896-1	2022	Objective: The purpose of this study was to evaluate the effects of ATRA (all trans retinoic acid), vitamin D3, and their combination on circulating levels of miR (MicroRNA) -125a-5p, miR-126, and miR-34ain diabetic rats.	Cholecalciferol	100-110	microRNA 126b	Rattus norvegicus	184-191
35145896-8	2022	In addition, vitamin D3+ATRA supplementation increased miR-126 expression (p=0.014).	Cholecalciferol	13-23	microRNA 126b	Rattus norvegicus	55-62
35145896-11	2022	Also, vitamin D3+ATRA can be considered a new therapeutic agent that can elevate miR-126 expression and prevent diabetes-related cardiovascular complications.	Cholecalciferol	6-16	microRNA 126b	Rattus norvegicus	81-88
35475214-6	2022	The computational analysis demonstrated that vitamin B12 resulted in depicting suitable significant binding with furin, RNA dependent RNA polymerase (RdRp), Main proteases (Mpro), ORF3a and ORF7a and Vitamin D3 with spike protein and vitamin B9 with non structural protein 3 (NSP3).	Cholecalciferol	200-210	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	216-221
34975341-4	2022	The present study found PolGD257A/D257A mice presented more severe calcification of aortas than wild type (WT) mice with vitamin D3 (Vit D3) treatment, and this phenomenon was also confirmed in vitro.	Cholecalciferol	121-131	vitrin	Mus musculus	133-136
34473295-2	2022	OBJECTIVE: To investigate the effects of vitamin D3 supplementation on insulin sensitivity and beta-cell function.	Cholecalciferol	41-51	insulin	Homo sapiens	71-78
35053278-1	2022	1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3, 1) is an active form of vitamin D3 and regulates various biological phenomena, including calcium and phosphate homeostasis, bone metabolism, and immune response via binding to and activation of vitamin D receptor (VDR).	Cholecalciferol	73-83	vitamin D receptor	Homo sapiens	243-261